data_1u39_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1u39 _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 14.4 p . . . . . 0 N--CA 1.456 -0.154 0 CA-C-O 120.769 0.318 . . . . 0.0 111.179 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.3 m -103.66 141.49 35.97 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.8 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 5.1 m -105.63 111.3 23.93 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.149 179.191 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.426 ' HB ' ' HG2' ' A' ' 153' ' ' MET . 48.5 t -82.66 106.14 13.2 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.65 -179.418 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . 0.405 ' HA ' ' O ' ' A' ' 151' ' ' ILE . 0.8 OUTLIER -105.55 84.04 2.03 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 178.456 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.462 HG12 ' HA ' ' A' ' 113' ' ' ALA . 4.0 mt -81.53 151.28 4.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.582 -178.671 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.428 ' CG ' ' CG2' ' A' ' 112' ' ' ILE . 0.0 OUTLIER -110.07 114.85 28.7 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.712 -0.677 . . . . 0.0 110.451 -179.789 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -120.56 100.91 46.63 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.058 -179.728 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' PRO . . . . . 0.419 ' HG2' ' CD2' ' A' ' 93' ' ' TYR . 71.5 Cg_endo -74.54 -26.73 11.61 Favored 'Trans proline' 0 C--N 1.346 0.414 0 C-N-CA 122.585 2.19 . . . . 0.0 112.448 179.874 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -141.39 -166.01 2.1 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.087 -179.866 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 2.6 mt -102.59 -19.74 14.72 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.43 -179.823 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -95.08 21.81 7.35 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.48 -0.327 . . . . 0.0 111.291 -179.775 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . 0.419 ' CD2' ' HG2' ' A' ' 89' ' ' PRO . 7.4 m-85 -112.31 98.67 7.45 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.768 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 1.2 pm0 -57.97 146.76 31.35 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.136 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . 0.404 ' N ' ' CD1' ' A' ' 95' ' ' LEU . 6.7 mp -71.78 -52.5 17.31 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.758 -179.919 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 124.85 36.82 0.57 Allowed Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.579 -0.82 . . . . 0.0 113.023 179.576 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . 0.413 ' CE2' HG22 ' A' ' 118' ' ' VAL . 31.8 p90 -177.36 169.24 2.24 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.839 0.352 . . . . 0.0 111.197 179.787 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -120.66 148.2 44.24 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.745 179.735 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.469 HG22 ' CG2' ' A' ' 140' ' ' ILE . 8.6 p -115.3 142.82 26.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.427 -179.878 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' GLN . . . . . 0.407 ' O ' ' N ' ' A' ' 102' ' ' GLY . 22.8 tt0 -132.14 88.42 2.55 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.905 -0.588 . . . . 0.0 110.233 179.049 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 65.36 -68.51 0.11 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.151 -179.838 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . 0.431 ' O ' ' HA ' ' A' ' 123' ' ' ARG . . . -142.9 -2.24 1.05 Allowed Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.387 -0.911 . . . . 0.0 113.4 -179.758 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.4 HD13 ' CB ' ' A' ' 158' ' ' ALA . 42.2 mm -122.86 151.36 26.99 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.128 0 CA-C-N 117.13 0.465 . . . . 0.0 111.529 -179.716 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.416 ' CD1' ' N ' ' A' ' 104' ' ' ILE . 2.8 mp -86.46 158.33 3.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.499 179.605 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 1.6 m -109.59 -71.68 0.75 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.475 -179.595 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 8.3 m -125.23 173.56 8.7 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.93 0.395 . . . . 0.0 111.17 -179.543 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -148.48 140.63 24.05 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.779 179.901 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 2.0 mtm -106.22 114.21 28.2 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.868 -179.883 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -63.58 82.74 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.708 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 167.02 -31.36 0.19 Allowed Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.938 -0.648 . . . . 0.0 112.002 -179.858 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . 0.405 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -64.34 172.48 17.46 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.132 179.651 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . 0.428 ' CG2' ' CG ' ' A' ' 87' ' ' ARG . 0.5 OUTLIER -78.65 -16.66 13.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 120.744 0.306 . . . . 0.0 111.474 -179.952 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 113' ' ' ALA . . . . . 0.462 ' HA ' HG12 ' A' ' 86' ' ' ILE . . . -58.0 -30.35 66.0 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.002 0.429 . . . . 0.0 110.671 179.744 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 114' ' ' GLU . . . . . 0.405 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 19.7 pt-20 -60.03 -46.63 88.86 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.876 179.67 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 23.3 mtt180 -65.0 -46.19 82.45 Favored 'General case' 0 N--CA 1.453 -0.301 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.21 -179.572 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -51.1 -73.57 0.37 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.557 -0.83 . . . . 0.0 112.641 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 170.54 -20.11 0.07 OUTLIER Glycine 0 CA--C 1.518 0.271 0 C-N-CA 121.032 -0.604 . . . . 0.0 112.662 -179.773 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.418 ' N ' ' CG2' ' A' ' 84' ' ' VAL . 0.9 OUTLIER -37.59 114.92 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.323 0 CA-C-O 120.937 0.399 . . . . 0.0 111.652 -179.819 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -117.46 100.95 8.0 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.577 179.799 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 10.1 p -48.11 101.76 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 121.057 0.456 . . . . 0.0 111.106 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 133.38 -10.19 5.01 Favored Glycine 0 N--CA 1.451 -0.36 0 CA-C-N 115.831 -0.622 . . . . 0.0 112.231 -179.318 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 35.7 m170 -86.1 -161.62 0.66 Allowed 'General case' 0 C--N 1.331 -0.231 0 N-CA-C 110.322 -0.251 . . . . 0.0 110.322 179.802 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . 0.459 ' N ' ' O ' ' A' ' 156' ' ' MET . 10.1 ttm-85 -139.35 90.4 2.41 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.679 0.276 . . . . 0.0 110.802 -179.866 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . 0.475 HG23 ' CG2' ' A' ' 132' ' ' VAL . 15.4 mt -55.99 157.13 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.251 179.225 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 125' ' ' ILE . . . . . 0.459 ' CG1' ' H ' ' A' ' 126' ' ' GLU . 0.7 OUTLIER -151.54 -84.51 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.451 -0.383 0 N-CA-C 112.374 0.509 . . . . 0.0 112.374 -179.538 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . 0.459 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 13.5 mt-10 -79.99 88.24 5.36 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 112.498 0.555 . . . . 0.0 112.498 -178.793 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.503 ' HA ' ' CB ' ' A' ' 153' ' ' MET . 1.3 mt -92.44 103.05 14.22 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.185 0 CA-C-O 121.101 0.477 . . . . 0.0 111.344 179.281 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . 0.409 ' HA ' ' CD2' ' A' ' 152' ' ' HIS . 20.2 m-80 59.84 18.64 7.57 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.857 -0.61 . . . . 0.0 111.369 179.847 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 116.6 -17.18 13.88 Favored Glycine 0 C--N 1.333 0.372 0 C-N-CA 120.517 -0.849 . . . . 0.0 113.179 179.627 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 1.2 pt20 -97.88 119.56 36.71 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 117.029 0.414 . . . . 0.0 110.963 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 2.5 m -79.06 93.15 5.09 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.119 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . 0.475 ' CG2' HG23 ' A' ' 124' ' ' ILE . 27.2 m -72.56 -5.38 6.22 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.298 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.978 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 8.3 p -45.36 -38.46 2.22 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.135 0 CA-C-O 120.818 0.342 . . . . 0.0 111.487 -179.807 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -120.08 28.22 8.2 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.748 179.465 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 135' ' ' THR . . . . . 0.429 ' HB ' ' HA ' ' A' ' 132' ' ' VAL . 36.0 m -110.73 143.15 27.63 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.181 -179.929 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 136' ' ' PRO . . . . . 0.402 ' HD2' ' CG2' ' A' ' 135' ' ' THR . 50.1 Cg_exo -53.41 164.21 2.14 Favored 'Trans proline' 0 C--N 1.347 0.456 0 C-N-CA 122.526 2.151 . . . . 0.0 112.119 179.704 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 9.3 p80 -74.05 -46.95 40.04 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.224 -179.798 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -54.16 -35.14 61.95 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.173 -179.786 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 139' ' ' LYS . . . . . 0.446 ' O ' ' CD1' ' A' ' 143' ' ' ILE . 0.0 OUTLIER -65.96 -48.87 69.86 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.943 -179.931 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . 0.469 ' CG2' HG22 ' A' ' 99' ' ' VAL . 8.7 mt -59.47 -46.41 92.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 121.033 0.444 . . . . 0.0 110.319 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 55.6 t -59.54 -32.53 49.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 115.711 -0.677 . . . . 0.0 109.93 179.074 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -61.47 -54.22 46.27 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.009 -0.542 . . . . 0.0 110.835 179.808 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . 0.539 ' O ' ' HB2' ' A' ' 147' ' ' ALA . 4.3 mp -53.39 -57.86 4.23 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.424 0 CA-C-O 121.015 0.436 . . . . 0.0 110.135 179.487 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.474 HD21 HG12 ' A' ' 151' ' ' ILE . 15.1 mt -60.39 -30.14 69.4 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.408 179.402 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 23.4 t -69.38 -28.55 66.28 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.219 -0.446 . . . . 0.0 109.934 178.811 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 4.9 m-80 -128.17 34.48 4.57 Favored 'General case' 0 C--N 1.333 -0.112 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.908 179.666 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 147' ' ' ALA . . . . . 0.539 ' HB2' ' O ' ' A' ' 143' ' ' ILE . . . -103.62 79.21 1.65 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.207 -179.929 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 5.7 m -77.32 146.18 8.92 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.338 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.149 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 105.43 -104.68 2.35 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.525 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 53.4 mt-10 -145.58 114.73 7.03 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.79 0.328 . . . . 0.0 110.847 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . 0.474 HG12 HD21 ' A' ' 144' ' ' LEU . 1.8 mp -81.93 128.13 39.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 121.047 0.451 . . . . 0.0 110.628 179.854 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . 0.409 ' CD2' ' HA ' ' A' ' 128' ' ' ASN . 21.6 p-80 -125.47 115.77 20.77 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.361 179.819 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 153' ' ' MET . . . . . 0.503 ' CB ' ' HA ' ' A' ' 127' ' ' ILE . 0.0 OUTLIER -141.21 174.99 10.01 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.164 0.507 . . . . 0.0 111.619 -179.379 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -121.41 147.83 45.2 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.589 -0.732 . . . . 0.0 109.912 179.22 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 12.1 p -140.7 140.49 34.92 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.04 0.448 . . . . 0.0 111.175 -179.665 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 156' ' ' MET . . . . . 0.459 ' O ' ' N ' ' A' ' 123' ' ' ARG . 0.0 OUTLIER -108.7 178.86 0.95 Allowed Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 115.791 -0.64 . . . . 0.0 110.56 179.854 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 157' ' ' PRO . . . . . 0.413 ' CD ' ' CB ' ' A' ' 156' ' ' MET . 94.6 Cg_endo -89.85 111.01 0.46 Allowed 'Trans proline' 0 N--CA 1.458 -0.559 0 C-N-CA 122.532 2.154 . . . . 0.0 112.504 -179.776 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 158' ' ' ALA . . . . . 0.4 ' CB ' HD13 ' A' ' 103' ' ' ILE . . . . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.283 -0.865 . . . . 0.0 110.962 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 10.2 p . . . . . 0 C--O 1.231 0.112 0 CA-C-O 120.823 0.344 . . . . 0.0 111.015 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.9 m -126.52 140.99 52.03 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.984 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 6.6 m -99.86 111.18 23.51 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.147 179.272 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.548 HG13 HG13 ' A' ' 86' ' ' ILE . 47.2 t -82.66 108.57 15.64 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 CA-C-N 116.015 -0.539 . . . . 0.0 112.268 -179.112 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 6.7 tt -103.12 85.01 2.43 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.876 -0.602 . . . . 0.0 109.436 178.345 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.548 HG13 HG13 ' A' ' 84' ' ' VAL . 5.6 mt -82.81 118.81 31.17 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.251 0 CA-C-O 121.293 0.568 . . . . 0.0 111.893 -178.715 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -73.13 153.06 40.92 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.089 -0.959 . . . . 0.0 109.99 179.21 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -152.92 124.32 3.68 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 120.618 0.247 . . . . 0.0 111.11 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 92.0 Cg_endo -83.47 -42.45 0.08 OUTLIER 'Trans proline' 0 C--N 1.347 0.465 0 C-N-CA 122.613 2.209 . . . . 0.0 112.584 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 57.4 p30 -156.78 -167.54 2.4 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.203 -179.781 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 7.3 mt -96.19 30.87 2.33 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.43 -179.519 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -138.9 32.06 2.21 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.886 0.374 . . . . 0.0 110.982 179.914 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 2.1 m-85 -136.84 104.06 5.37 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.832 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 3.0 mp0 -65.51 145.07 56.56 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.03 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 8.3 mp -78.49 -24.62 45.77 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.94 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 72.27 68.81 1.51 Allowed Glycine 0 C--N 1.331 0.257 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.868 179.709 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . 0.422 ' CZ ' ' CD1' ' A' ' 144' ' ' LEU . 1.8 p90 -161.37 -171.83 3.15 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.918 0.39 . . . . 0.0 111.212 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.416 ' O ' ' HA ' ' A' ' 104' ' ' ILE . 1.2 t -149.67 126.24 10.95 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.408 179.71 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.44 ' CG1' ' CG2' ' A' ' 141' ' ' VAL . 11.8 p -111.97 140.16 32.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 121.163 0.506 . . . . 0.0 111.764 -179.284 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 3.6 mp0 -133.03 89.75 2.66 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.598 -0.728 . . . . 0.0 109.847 179.156 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 9.8 t-20 60.35 15.64 5.59 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.756 -178.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 127.31 -39.3 1.97 Allowed Glycine 0 N--CA 1.449 -0.474 0 C-N-CA 121.012 -0.613 . . . . 0.0 112.228 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.486 HG12 ' CB ' ' A' ' 158' ' ' ALA . 31.5 mt -77.27 138.67 20.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 121.007 0.432 . . . . 0.0 111.575 -179.587 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.416 ' HA ' ' O ' ' A' ' 98' ' ' SER . 4.1 mp -96.36 138.25 22.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.991 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -108.0 -65.62 1.1 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.653 179.878 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 9.5 p -94.22 155.06 17.23 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.614 179.724 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -163.92 121.71 1.81 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.942 -179.855 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 20.2 ttp -82.36 120.94 26.06 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.881 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -67.97 71.92 0.16 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.143 0.497 . . . . 0.0 110.602 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 175.36 -33.85 0.1 OUTLIER Glycine 0 N--CA 1.45 -0.39 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.966 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . 0.439 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -55.26 176.33 0.6 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.781 -0.724 . . . . 0.0 112.275 179.788 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 1.1 mp -78.7 -18.57 13.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 N-CA-C 111.848 0.314 . . . . 0.0 111.848 -179.734 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 113' ' ' ALA . . . . . . . . . . . . . . . -58.01 -30.54 66.19 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.895 0.378 . . . . 0.0 110.757 179.855 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 114' ' ' GLU . . . . . 0.439 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 13.2 pt-20 -61.64 -47.42 85.48 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.871 179.8 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 43.4 mtm180 -62.27 -41.98 98.93 Favored 'General case' 0 N--CA 1.453 -0.31 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.832 -179.631 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -53.79 -73.83 0.37 Allowed Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.296 -0.954 . . . . 0.0 112.394 179.854 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 164.57 -18.13 0.11 Allowed Glycine 0 CA--C 1.523 0.538 0 C-N-CA 121.249 -0.5 . . . . 0.0 112.74 -179.889 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.445 ' N ' ' CG2' ' A' ' 84' ' ' VAL . 2.0 t -29.58 -64.26 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 C-N-CA 123.212 0.605 . . . . 0.0 112.569 -179.54 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.401 ' N ' HG13 ' A' ' 118' ' ' VAL . 30.0 mmt180 61.71 178.7 0.12 Allowed 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.303 -0.408 . . . . 0.0 109.941 -178.872 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 11.8 t -111.18 101.12 12.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-O 120.917 0.389 . . . . 0.0 111.341 -179.86 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 126.17 42.34 0.3 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.894 -0.669 . . . . 0.0 112.417 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 15.3 m170 -129.87 -171.52 2.54 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.767 0.317 . . . . 0.0 110.963 -179.822 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . 0.504 ' N ' ' O ' ' A' ' 156' ' ' MET . 5.7 ttm-85 -142.08 89.39 2.17 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.874 -179.756 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . 0.447 HG23 ' CG2' ' A' ' 132' ' ' VAL . 14.6 mt -51.67 142.5 4.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.547 -0.297 . . . . 0.0 110.285 179.375 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 125' ' ' ILE . . . . . 0.437 ' CG1' ' H ' ' A' ' 126' ' ' GLU . 0.6 OUTLIER -137.18 -84.46 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 N-CA-C 112.668 0.618 . . . . 0.0 112.668 -179.05 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . 0.437 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 1.0 OUTLIER -80.52 83.73 6.26 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 112.421 0.526 . . . . 0.0 112.421 -178.538 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.447 ' CG2' ' HB3' ' A' ' 153' ' ' MET . 1.9 mt -86.26 104.37 13.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 120.97 0.414 . . . . 0.0 111.175 179.086 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 11.3 m-20 56.15 23.05 6.56 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.777 -0.647 . . . . 0.0 111.402 179.804 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 112.68 -14.21 24.71 Favored Glycine 0 C--N 1.332 0.318 0 C-N-CA 120.554 -0.831 . . . . 0.0 112.961 179.746 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 130' ' ' GLN . . . . . 0.4 ' O ' ' CG ' ' A' ' 130' ' ' GLN . 5.0 pt20 -96.16 122.07 38.61 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.742 0.306 . . . . 0.0 110.484 -179.888 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 21.3 p -83.75 90.02 7.26 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.892 0.377 . . . . 0.0 110.826 179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . 0.447 ' CG2' HG23 ' A' ' 124' ' ' ILE . 35.0 m -72.69 -3.81 4.45 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.351 0 CA-C-N 116.013 -0.54 . . . . 0.0 112.04 -179.845 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 7.9 p -47.27 -35.13 3.41 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.158 0 CA-C-O 120.894 0.378 . . . . 0.0 111.228 -179.889 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -121.01 27.84 8.24 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.684 179.4 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 135' ' ' THR . . . . . 0.411 ' CG2' ' HD2' ' A' ' 136' ' ' PRO . 25.8 m -114.08 140.64 25.16 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 115.664 -0.698 . . . . 0.0 111.02 -179.8 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 136' ' ' PRO . . . . . 0.411 ' HD2' ' CG2' ' A' ' 135' ' ' THR . 8.3 Cg_endo -50.11 163.97 0.52 Allowed 'Trans proline' 0 C--N 1.347 0.458 0 C-N-CA 122.676 2.251 . . . . 0.0 112.181 179.64 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 137' ' ' HIS . . . . . 0.404 ' CD2' ' N ' ' A' ' 138' ' ' GLU . 22.9 p-80 -74.45 -41.85 60.11 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.284 -0.417 . . . . 0.0 111.439 -179.642 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . 0.404 ' N ' ' CD2' ' A' ' 137' ' ' HIS . 53.8 mt-10 -54.15 -38.04 65.06 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.753 0.311 . . . . 0.0 111.42 -179.516 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 139' ' ' LYS . . . . . 0.417 ' O ' ' CD1' ' A' ' 143' ' ' ILE . 6.9 tttp -64.67 -48.86 73.2 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.11 -179.728 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 13.8 mt -59.26 -43.27 89.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.624 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . 0.44 ' CG2' ' CG1' ' A' ' 99' ' ' VAL . 86.6 t -62.29 -33.13 57.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.389 179.291 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -61.93 -56.46 18.98 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.07 -0.514 . . . . 0.0 111.104 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . 0.465 ' O ' ' N ' ' A' ' 147' ' ' ALA . 4.3 mp -52.9 -57.17 4.92 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.49 0 CA-C-O 121.095 0.474 . . . . 0.0 110.192 179.559 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.612 HD21 HG12 ' A' ' 151' ' ' ILE . 6.3 mt -59.83 -29.91 68.58 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.575 179.409 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 14.0 t -73.18 -28.25 62.1 Favored 'General case' 0 N--CA 1.456 -0.141 0 CA-C-N 116.361 -0.382 . . . . 0.0 110.219 178.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 3.1 m-80 -125.11 31.58 5.58 Favored 'General case' 0 C--O 1.232 0.152 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.189 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 147' ' ' ALA . . . . . 0.465 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . -107.02 97.06 6.88 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.243 179.942 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 6.3 m -79.96 179.86 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.357 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.983 -179.744 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 67.94 -116.04 7.38 Favored Glycine 0 N--CA 1.453 -0.223 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.599 179.924 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 11.5 mt-10 -134.97 110.7 9.27 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.606 0.241 . . . . 0.0 110.984 -179.815 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . 0.612 HG12 HD21 ' A' ' 144' ' ' LEU . 1.7 mp -68.16 124.02 22.77 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-O 120.915 0.388 . . . . 0.0 110.778 179.776 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -113.51 115.56 28.18 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.801 -0.636 . . . . 0.0 109.964 179.192 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 153' ' ' MET . . . . . 0.447 ' CG ' ' HB ' ' A' ' 84' ' ' VAL . 1.4 ptt? -147.2 164.77 32.1 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.217 0.532 . . . . 0.0 111.732 -178.97 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 2.2 mttm -110.9 152.33 26.86 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.524 -0.762 . . . . 0.0 109.851 179.182 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 155' ' ' THR . . . . . 0.41 HG23 ' CG1' ' A' ' 124' ' ' ILE . 37.4 p -136.88 142.59 42.78 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.163 0.506 . . . . 0.0 111.604 -179.547 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 156' ' ' MET . . . . . 0.504 ' O ' ' N ' ' A' ' 123' ' ' ARG . 0.0 OUTLIER -111.82 179.0 0.86 Allowed Pre-proline 0 C--N 1.327 -0.392 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.39 179.755 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 157' ' ' PRO . . . . . 0.412 ' CD ' ' CB ' ' A' ' 156' ' ' MET . 80.2 Cg_endo -92.96 103.41 0.17 Allowed 'Trans proline' 0 N--CA 1.456 -0.688 0 C-N-CA 122.786 2.324 . . . . 0.0 112.543 -179.752 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 158' ' ' ALA . . . . . 0.486 ' CB ' HG12 ' A' ' 103' ' ' ILE . . . . . . . . 0 C--O 1.25 1.085 0 CA-C-O 118.169 -0.92 . . . . 0.0 111.09 179.788 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.41 ' CG1' ' CG ' ' A' ' 154' ' ' LYS . 47.0 t . . . . . 0 C--O 1.231 0.101 0 CA-C-O 120.854 0.359 . . . . 0.0 111.04 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.7 m -118.61 134.25 55.25 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.848 179.849 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 6.9 m -95.25 111.52 23.36 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.178 179.324 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.435 HG11 ' CG2' ' A' ' 118' ' ' VAL . 58.3 t -82.56 105.73 12.7 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.547 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.742 -179.33 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . 0.45 ' CD1' ' CD2' ' A' ' 152' ' ' HIS . 4.6 tp -107.73 80.1 1.35 Allowed 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 178.348 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.412 HG13 HG13 ' A' ' 84' ' ' VAL . 1.2 mt -81.67 130.95 34.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 121.173 0.511 . . . . 0.0 111.729 -178.272 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -84.19 142.87 30.0 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.443 -0.799 . . . . 0.0 110.256 179.929 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 3.7 ttt180 -144.88 114.16 5.01 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.964 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -75.32 -45.24 0.27 Allowed 'Trans proline' 0 C--N 1.347 0.466 0 C-N-CA 122.463 2.109 . . . . 0.0 112.616 -179.895 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -135.1 -173.97 3.47 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.196 -179.753 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -86.96 -34.04 19.44 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.976 -179.928 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 3.2 ptm180 -73.07 -7.97 53.65 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.608 -179.842 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 10.9 m-85 -85.08 128.57 34.7 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.797 0.332 . . . . 0.0 110.876 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 4.0 mp0 -89.51 160.49 16.7 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.899 -179.895 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 59.3 mt -81.42 -69.21 0.63 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.903 179.917 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 135.9 40.96 0.13 Allowed Glycine 0 CA--C 1.518 0.277 0 C-N-CA 120.484 -0.865 . . . . 0.0 113.192 179.631 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . 0.436 ' CD1' ' HB1' ' A' ' 113' ' ' ALA . 33.1 p90 -175.12 174.67 2.4 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.879 0.371 . . . . 0.0 111.09 179.62 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -124.74 143.86 50.55 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.961 -179.814 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.404 ' CG1' ' CG2' ' A' ' 141' ' ' VAL . 10.6 p -111.54 139.48 35.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.026 179.907 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' GLN . . . . . 0.413 ' O ' ' N ' ' A' ' 102' ' ' GLY . 0.5 OUTLIER -130.53 89.01 2.71 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.806 179.758 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' ASN . . . . . 0.421 ' O ' ' CD1' ' A' ' 140' ' ' ILE . 7.3 m-80 64.34 -68.19 0.1 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.903 -0.59 . . . . 0.0 111.51 179.569 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . 0.413 ' N ' ' O ' ' A' ' 100' ' ' GLN . . . -143.83 1.1 1.27 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.238 -0.982 . . . . 0.0 113.414 -179.731 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.449 HD11 ' HB2' ' A' ' 158' ' ' ALA . 44.2 mm -126.46 155.08 36.64 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 117.232 0.516 . . . . 0.0 111.209 -179.886 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.414 ' CD1' ' N ' ' A' ' 104' ' ' ILE . 3.2 mp -97.26 145.11 9.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.735 179.817 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 1.6 m -106.46 -79.48 0.57 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.171 -179.704 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 1.5 m -90.91 168.83 11.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.375 -0.375 . . . . 0.0 111.141 -179.7 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 62.1 tp -174.16 101.86 0.1 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.698 179.897 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 8.0 mtp -73.93 122.05 21.94 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.081 -179.819 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.03 78.2 0.09 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.692 179.775 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 174.25 -33.62 0.11 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.986 -0.626 . . . . 0.0 112.04 -179.837 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . 0.426 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -57.46 174.62 2.0 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.142 179.741 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -78.5 -17.46 13.59 Favored 'Isoleucine or valine' 0 C--O 1.236 0.36 0 CA-C-O 120.829 0.347 . . . . 0.0 111.522 -179.845 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 113' ' ' ALA . . . . . 0.436 ' HB1' ' CD1' ' A' ' 97' ' ' PHE . . . -58.11 -30.62 66.43 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.911 0.386 . . . . 0.0 110.703 179.863 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 114' ' ' GLU . . . . . 0.426 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 17.4 pt-20 -60.48 -47.21 87.15 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.969 -0.559 . . . . 0.0 110.766 179.634 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 2.4 mmt85 -62.32 -44.78 95.71 Favored 'General case' 0 N--CA 1.452 -0.337 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.892 -179.556 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -53.25 -74.01 0.35 Allowed Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.245 -0.979 . . . . 0.0 112.519 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . 0.495 ' O ' ' C ' ' A' ' 118' ' ' VAL . . . 172.45 -24.94 0.08 OUTLIER Glycine 0 CA--C 1.518 0.249 0 C-N-CA 121.065 -0.588 . . . . 0.0 112.701 -179.951 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.495 ' C ' ' O ' ' A' ' 117' ' ' GLY . 18.0 t -15.11 -83.31 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.627 0 C-N-CA 123.235 0.614 . . . . 0.0 112.489 -179.835 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.411 ' N ' ' CG1' ' A' ' 118' ' ' VAL . 0.0 OUTLIER 62.56 143.19 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.725 -179.649 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 11.4 t -81.97 132.06 32.37 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 116.439 -0.346 . . . . 0.0 111.198 -179.704 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 101.63 24.63 8.6 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.886 -0.673 . . . . 0.0 112.57 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 10.4 m170 -112.72 -174.42 2.45 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.656 0.265 . . . . 0.0 110.706 179.869 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . 0.503 ' N ' ' O ' ' A' ' 156' ' ' MET . 0.0 OUTLIER -140.58 90.14 2.33 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.819 -179.783 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . 0.419 ' CG2' ' N ' ' A' ' 125' ' ' ILE . 5.9 mt -50.82 154.95 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.811 179.484 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 125' ' ' ILE . . . . . 0.464 ' CG1' ' H ' ' A' ' 126' ' ' GLU . 0.8 OUTLIER -157.79 -86.66 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 N-CA-C 112.481 0.549 . . . . 0.0 112.481 -179.88 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . 0.464 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 15.6 mt-10 -81.82 92.79 6.74 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 112.321 0.489 . . . . 0.0 112.321 -178.637 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.473 HG12 ' HG3' ' A' ' 153' ' ' MET . 1.5 mt -91.3 99.16 9.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.126 179.297 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 52.8 m-20 63.96 15.92 9.52 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.451 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 121.19 -18.94 8.82 Favored Glycine 0 C--N 1.332 0.31 0 C-N-CA 120.452 -0.88 . . . . 0.0 113.117 179.629 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 1.8 pt20 -98.63 117.1 32.32 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.93 0.395 . . . . 0.0 110.948 -179.916 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 1.4 m -77.18 93.41 3.93 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.182 -179.787 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . 0.41 ' HB ' HD13 ' A' ' 140' ' ' ILE . 35.6 m -77.08 0.31 2.64 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.324 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.801 179.67 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 8.5 p -46.82 -40.23 4.72 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.14 0 CA-C-O 120.805 0.336 . . . . 0.0 111.261 -179.826 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -113.13 29.54 7.9 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.687 179.452 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 135' ' ' THR . . . . . 0.432 ' CG2' ' HD2' ' A' ' 136' ' ' PRO . 91.0 m -116.97 143.03 30.8 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.852 -179.805 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 136' ' ' PRO . . . . . 0.432 ' HD2' ' CG2' ' A' ' 135' ' ' THR . 6.1 Cg_endo -47.92 164.09 0.18 Allowed 'Trans proline' 0 C--N 1.347 0.451 0 C-N-CA 122.805 2.337 . . . . 0.0 112.281 179.795 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 45.1 p-80 -76.11 -44.55 38.02 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.301 -179.606 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -54.08 -33.53 57.79 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.362 -179.607 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 139' ' ' LYS . . . . . 0.43 ' O ' ' CD1' ' A' ' 143' ' ' ILE . 0.0 OUTLIER -66.41 -50.12 64.49 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.873 0.368 . . . . 0.0 111.033 -179.923 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . 0.421 ' CD1' ' O ' ' A' ' 101' ' ' ASN . 8.5 mt -59.1 -46.18 92.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.421 179.827 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . 0.404 ' CG2' ' CG1' ' A' ' 99' ' ' VAL . 69.0 t -59.86 -32.38 49.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.906 -0.588 . . . . 0.0 109.885 178.73 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 2.1 t-160 -60.57 -52.97 62.89 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.492 179.604 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . 0.481 ' O ' ' HB2' ' A' ' 147' ' ' ALA . 4.5 mp -53.29 -57.78 4.28 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.394 0 CA-C-O 121.035 0.445 . . . . 0.0 110.108 179.202 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.566 HD22 HG12 ' A' ' 151' ' ' ILE . 9.7 mt -60.05 -30.19 69.04 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.627 -0.715 . . . . 0.0 110.231 179.389 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 38.9 t -70.81 -27.79 64.15 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.075 -0.511 . . . . 0.0 109.878 178.745 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 2.8 m-80 -124.85 31.47 5.65 Favored 'General case' 0 C--O 1.232 0.151 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.83 179.799 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 147' ' ' ALA . . . . . 0.481 ' HB2' ' O ' ' A' ' 143' ' ' ILE . . . -113.14 101.06 9.08 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.952 179.789 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 3.4 m -101.59 158.62 4.24 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.433 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.321 -179.79 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 95.0 -95.89 1.94 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.564 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 14.4 mt-10 -146.81 104.93 3.76 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.716 0.294 . . . . 0.0 110.715 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . 0.566 HG12 HD22 ' A' ' 144' ' ' LEU . 1.5 mp -72.41 117.52 16.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 121.149 0.5 . . . . 0.0 111.204 -179.756 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . 0.45 ' CD2' ' CD1' ' A' ' 85' ' ' LEU . 0.2 OUTLIER -101.37 121.84 42.64 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.585 -0.734 . . . . 0.0 109.295 178.724 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 153' ' ' MET . . . . . 0.473 ' HG3' HG12 ' A' ' 127' ' ' ILE . 8.6 tmm? -153.41 155.16 35.84 Favored 'General case' 0 C--N 1.327 -0.385 0 C-N-CA 120.754 -0.378 . . . . 0.0 111.678 -178.436 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 154' ' ' LYS . . . . . 0.41 ' CG ' ' CG1' ' A' ' 81' ' ' VAL . 0.0 OUTLIER -109.23 152.27 25.41 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.605 179.893 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 155' ' ' THR . . . . . 0.412 ' CG2' ' SD ' ' A' ' 153' ' ' MET . 30.3 p -142.13 150.05 40.61 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 121.159 0.504 . . . . 0.0 111.644 -179.919 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 156' ' ' MET . . . . . 0.503 ' O ' ' N ' ' A' ' 123' ' ' ARG . 10.7 mmm -115.82 178.93 0.87 Allowed Pre-proline 0 C--N 1.328 -0.369 0 CA-C-N 115.556 -0.747 . . . . 0.0 110.302 179.413 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 157' ' ' PRO . . . . . 0.426 ' CD ' ' HB3' ' A' ' 156' ' ' MET . 88.5 Cg_endo -91.33 114.82 0.4 Allowed 'Trans proline' 0 N--CA 1.457 -0.632 0 C-N-CA 122.61 2.207 . . . . 0.0 112.546 -179.685 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 158' ' ' ALA . . . . . 0.449 ' HB2' HD11 ' A' ' 103' ' ' ILE . . . . . . . . 0 C--O 1.249 1.035 0 CA-C-O 118.285 -0.864 . . . . 0.0 111.071 179.727 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 56.5 t . . . . . 0 C--O 1.231 0.129 0 CA-C-O 120.759 0.314 . . . . 0.0 110.884 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 1.8 m -120.5 143.01 48.78 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.868 179.75 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 35.9 m -107.09 111.33 23.73 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.267 179.289 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.427 HG12 ' HB ' ' A' ' 118' ' ' VAL . 53.6 t -86.21 106.33 15.49 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.423 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.107 -179.759 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 1.4 tt -110.09 81.93 1.51 Allowed 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.157 -0.474 . . . . 0.0 109.729 179.107 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.405 ' CD1' ' CG1' ' A' ' 84' ' ' VAL . 1.8 mp -81.83 134.17 27.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 121.106 0.479 . . . . 0.0 111.732 -178.965 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.461 ' CB ' HG21 ' A' ' 112' ' ' ILE . 0.0 OUTLIER -91.36 108.69 20.06 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.99 179.813 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . 0.454 ' HA ' ' NE ' ' A' ' 88' ' ' ARG . 1.0 OUTLIER -113.14 87.11 10.24 Favored Pre-proline 0 C--N 1.328 -0.365 0 CA-C-O 120.878 0.371 . . . . 0.0 111.676 -179.209 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' PRO . . . . . 0.405 ' HD2' ' NH2' ' A' ' 88' ' ' ARG . 96.4 Cg_endo -78.96 1.91 8.73 Favored 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.598 2.199 . . . . 0.0 112.952 179.776 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -154.5 -162.29 1.37 Allowed 'General case' 0 C--N 1.332 -0.17 0 CA-C-O 120.743 0.306 . . . . 0.0 111.36 -179.884 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -128.18 -40.58 1.64 Allowed 'General case' 0 C--N 1.332 -0.153 0 CA-C-O 120.925 0.393 . . . . 0.0 111.389 -179.622 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -53.44 -23.3 9.6 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.536 -179.524 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . 0.444 ' HB2' ' NH2' ' A' ' 88' ' ' ARG . 77.4 m-85 -95.65 148.89 22.06 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.828 179.824 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -97.03 175.6 6.26 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.155 -179.842 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . 0.42 ' N ' ' CD2' ' A' ' 95' ' ' LEU . 2.7 mm? -72.49 -51.68 19.06 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.661 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 121.74 31.74 1.09 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.9 179.784 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 47.8 p90 -175.55 145.14 0.71 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.832 0.349 . . . . 0.0 111.058 179.818 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.427 ' O ' ' HA ' ' A' ' 104' ' ' ILE . 14.8 m -91.76 148.44 22.24 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.747 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.404 ' CG1' ' CG2' ' A' ' 141' ' ' VAL . 5.1 p -118.82 137.02 54.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.366 -179.686 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -129.89 89.85 2.88 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.866 -0.607 . . . . 0.0 109.959 179.424 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 63.9 t30 60.6 17.38 7.39 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.627 -179.038 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 124.58 -39.31 2.15 Favored Glycine 0 N--CA 1.448 -0.566 0 C-N-CA 120.957 -0.639 . . . . 0.0 112.031 -179.808 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.449 HG12 ' CB ' ' A' ' 158' ' ' ALA . 23.2 mt -78.35 131.41 34.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-O 120.989 0.423 . . . . 0.0 111.432 -179.693 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.427 ' HA ' ' O ' ' A' ' 98' ' ' SER . 3.6 mp -85.54 139.34 17.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.841 179.743 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 12.0 t -94.97 -67.35 0.86 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.047 -179.648 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 3.3 m -112.64 146.92 37.8 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.79 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -133.24 100.89 4.99 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.662 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 2.7 tmm? -60.01 141.34 55.82 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.907 -179.888 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -93.4 44.14 1.13 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.09 0.471 . . . . 0.0 110.703 179.798 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -162.78 23.98 0.2 Allowed Glycine 0 N--CA 1.45 -0.375 0 CA-C-N 115.691 -0.686 . . . . 0.0 112.282 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . 0.5 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -112.77 175.46 16.8 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.851 -0.69 . . . . 0.0 111.952 179.798 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . 0.461 HG21 ' CB ' ' A' ' 87' ' ' ARG . 0.5 OUTLIER -79.27 -23.55 12.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-O 120.933 0.397 . . . . 0.0 111.578 -179.772 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 113' ' ' ALA . . . . . . . . . . . . . . . -57.92 -30.41 65.91 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.968 0.413 . . . . 0.0 110.604 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 114' ' ' GLU . . . . . 0.5 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 8.6 pt-20 -59.92 -45.2 93.33 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.722 179.467 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 88.5 mtt180 -64.78 -46.26 82.83 Favored 'General case' 0 N--CA 1.452 -0.358 0 CA-C-N 115.96 -0.564 . . . . 0.0 111.087 -179.441 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -49.75 -74.65 0.25 Allowed Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.413 -0.899 . . . . 0.0 112.591 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 175.21 -16.49 0.04 OUTLIER Glycine 0 CA--C 1.52 0.386 0 C-N-CA 120.77 -0.729 . . . . 0.0 113.112 179.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.427 ' HB ' HG12 ' A' ' 84' ' ' VAL . 5.0 p -34.13 148.8 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 N-CA-C 112.156 0.428 . . . . 0.0 112.156 -179.659 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 1.1 ttp85 -151.83 113.01 4.28 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.823 179.907 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 14.9 p -52.48 114.89 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.316 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 113.5 19.12 6.74 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.433 -179.809 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 3.2 m170 -120.86 139.79 52.69 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.803 0.335 . . . . 0.0 110.773 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . 0.45 ' HB2' ' CB ' ' A' ' 158' ' ' ALA . 10.7 ttt180 -83.65 90.65 7.31 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.384 -179.673 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . 0.419 HG13 ' CD1' ' A' ' 104' ' ' ILE . 71.4 mt -48.75 134.33 6.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 178.784 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 125' ' ' ILE . . . . . 0.465 ' CG1' ' H ' ' A' ' 126' ' ' GLU . 0.8 OUTLIER -128.29 -84.46 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 N-CA-C 113.175 0.806 . . . . 0.0 113.175 -178.398 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . 0.465 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 4.3 mt-10 -80.88 92.16 6.08 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 112.922 0.712 . . . . 0.0 112.922 -178.236 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.479 HG12 ' HG3' ' A' ' 153' ' ' MET . 1.3 mt -94.34 94.87 4.74 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.668 178.722 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . 0.454 ' N ' ' O ' ' A' ' 152' ' ' HIS . 55.5 m-80 62.3 26.35 15.77 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.882 -179.813 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 108.91 -19.37 30.44 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.733 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 5.5 tt0 -90.77 110.39 21.59 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.785 0.326 . . . . 0.0 110.878 179.903 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 1.4 m -76.2 93.32 3.36 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.077 -179.822 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . 0.428 ' CG2' HD13 ' A' ' 127' ' ' ILE . 25.9 m -73.48 -5.15 6.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.877 179.859 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 11.4 p -47.26 -36.65 4.1 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-O 120.857 0.361 . . . . 0.0 111.41 -179.713 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -117.28 28.65 8.35 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.628 179.501 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 135' ' ' THR . . . . . 0.405 ' CG2' ' HD2' ' A' ' 136' ' ' PRO . 67.4 m -116.37 140.81 27.0 Favored Pre-proline 0 C--N 1.328 -0.363 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.343 -179.734 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 136' ' ' PRO . . . . . 0.424 ' HG2' ' HB2' ' A' ' 139' ' ' LYS . 8.9 Cg_endo -50.99 164.36 0.63 Allowed 'Trans proline' 0 C--N 1.347 0.493 0 C-N-CA 122.759 2.306 . . . . 0.0 112.347 179.765 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 137' ' ' HIS . . . . . 0.412 ' CE1' ' HG3' ' A' ' 138' ' ' GLU . 20.9 p80 -70.91 -50.09 38.63 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.739 -179.42 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . 0.412 ' HG3' ' CE1' ' A' ' 137' ' ' HIS . 3.7 mt-10 -53.91 -33.79 57.66 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.607 -179.355 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 139' ' ' LYS . . . . . 0.463 ' O ' ' CD1' ' A' ' 143' ' ' ILE . 8.6 tptt -64.02 -48.05 77.86 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.369 -0.378 . . . . 0.0 111.098 -179.828 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . 0.44 HD13 HG23 ' A' ' 140' ' ' ILE . 13.9 mt -58.38 -46.15 89.38 Favored 'Isoleucine or valine' 0 C--O 1.235 0.318 0 CA-C-O 121.013 0.435 . . . . 0.0 110.669 -179.898 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . 0.404 ' CG2' ' CG1' ' A' ' 99' ' ' VAL . 58.9 t -60.05 -32.82 51.16 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.353 179.166 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 57.2 t-80 -62.77 -54.15 43.4 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.304 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . 0.463 ' CD1' ' O ' ' A' ' 139' ' ' LYS . 4.2 mp -52.96 -57.21 4.9 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.451 0 CA-C-O 121.018 0.437 . . . . 0.0 110.375 179.647 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.566 HD23 HG12 ' A' ' 151' ' ' ILE . 1.4 mt -62.41 -30.04 70.93 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.55 -0.75 . . . . 0.0 110.381 179.581 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 3.4 m -66.63 -26.57 67.14 Favored 'General case' 0 N--CA 1.452 -0.347 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 178.448 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 4.3 m-80 -132.86 35.86 3.53 Favored 'General case' 0 CA--C 1.529 0.145 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.377 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 147' ' ' ALA . . . . . 0.408 ' CB ' ' O ' ' A' ' 143' ' ' ILE . . . -118.06 52.59 1.0 Allowed 'General case' 0 C--N 1.332 -0.178 0 CA-C-O 120.776 0.322 . . . . 0.0 111.464 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 15.6 m -53.5 -178.48 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 120.877 0.37 . . . . 0.0 111.035 179.91 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 83.96 -108.47 3.08 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.424 -179.834 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 20.2 mt-10 -138.27 101.6 4.43 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.878 0.37 . . . . 0.0 110.454 179.787 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . 0.566 HG12 HD23 ' A' ' 144' ' ' LEU . 1.1 mt -76.15 111.72 13.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 121.051 0.453 . . . . 0.0 111.487 -179.516 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . 0.454 ' O ' ' N ' ' A' ' 128' ' ' ASN . 0.2 OUTLIER -99.72 124.23 44.76 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 178.356 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 153' ' ' MET . . . . . 0.479 ' HG3' HG12 ' A' ' 127' ' ' ILE . 11.5 tmm? -150.68 155.08 38.63 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.139 0.495 . . . . 0.0 112.25 -177.937 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -113.45 148.17 36.43 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.59 -0.732 . . . . 0.0 109.669 178.977 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 16.3 p -130.7 141.02 50.39 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.28 0.562 . . . . 0.0 111.836 -179.266 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 156' ' ' MET . . . . . 0.439 ' O ' ' CB ' ' A' ' 123' ' ' ARG . 0.0 OUTLIER -123.28 119.45 27.49 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 115.109 -0.951 . . . . 0.0 110.053 179.475 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 88.9 Cg_exo -42.24 110.63 0.16 Allowed 'Trans proline' 0 C--N 1.346 0.402 0 C-N-CA 122.56 2.173 . . . . 0.0 112.935 -179.756 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 158' ' ' ALA . . . . . 0.45 ' CB ' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.249 1.05 0 CA-C-O 118.23 -0.89 . . . . 0.0 111.043 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 12.5 p . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.795 0.331 . . . . 0.0 111.035 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 3.0 m -115.49 132.05 56.74 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.993 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 26.6 m -92.26 111.65 23.29 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.032 179.235 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.484 ' HB ' ' HG3' ' A' ' 153' ' ' MET . 94.5 t -83.89 105.41 13.34 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.566 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.68 -179.093 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . 0.402 ' HG ' ' CD2' ' A' ' 152' ' ' HIS . 5.2 tt -105.2 80.07 1.56 Allowed 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 109.176 -0.676 . . . . 0.0 109.176 178.466 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.445 HG13 HG11 ' A' ' 84' ' ' VAL . 4.5 mt -82.04 125.33 39.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 121.236 0.541 . . . . 0.0 111.874 -178.354 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.411 ' CB ' HG21 ' A' ' 112' ' ' ILE . 0.1 OUTLIER -76.94 147.86 36.7 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.289 -0.869 . . . . 0.0 110.061 179.467 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 6.0 mtp85 -141.84 96.13 6.81 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 120.686 0.279 . . . . 0.0 111.089 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_exo -56.38 -60.28 0.51 Allowed 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 122.562 2.175 . . . . 0.0 112.447 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -127.5 -169.17 2.0 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 121.03 0.443 . . . . 0.0 111.033 -179.692 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -89.11 -43.16 11.26 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.988 -0.551 . . . . 0.0 111.04 -179.942 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 16.5 mtt-85 -64.81 -13.66 56.44 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.639 -179.689 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 24.1 m-85 -88.68 117.57 27.75 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.456 -0.338 . . . . 0.0 110.976 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -85.21 169.42 13.84 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.999 -179.918 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . 0.432 HD11 ' CE2' ' A' ' 97' ' ' PHE . 76.9 mt -76.21 -69.4 0.51 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.779 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 128.23 54.13 0.12 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.457 -0.877 . . . . 0.0 113.1 179.531 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . 0.432 ' CE2' HD11 ' A' ' 95' ' ' LEU . 42.5 p90 -177.83 174.25 1.47 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.817 0.342 . . . . 0.0 111.053 179.635 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -116.52 150.3 38.17 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.866 179.869 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.442 ' CG1' ' CG2' ' A' ' 141' ' ' VAL . 9.3 p -125.6 136.36 61.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.314 -179.894 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' GLN . . . . . 0.404 ' HG3' ' HB ' ' A' ' 103' ' ' ILE . 1.6 pt20 -130.37 91.64 3.13 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.215 179.464 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER 60.74 13.83 4.64 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.175 -179.343 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . 0.422 ' O ' ' N ' ' A' ' 124' ' ' ILE . . . 129.67 -38.4 2.0 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.872 -0.68 . . . . 0.0 112.366 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.458 HG12 ' CB ' ' A' ' 158' ' ' ALA . 36.2 mt -77.13 136.86 23.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-O 121.105 0.479 . . . . 0.0 111.684 -179.559 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 4.0 mp -90.98 138.37 19.73 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.54 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 7.7 m -94.29 -84.28 0.32 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.509 -179.298 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 46.3 t -109.88 113.53 26.33 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.926 0.393 . . . . 0.0 111.203 -179.6 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 1.4 tm? -105.74 110.06 22.23 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.45 179.645 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 9.0 ttp -58.08 116.84 3.79 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.024 -179.762 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 7.1 mtt85 -63.89 80.79 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.001 0.429 . . . . 0.0 110.671 179.789 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 166.74 -30.88 0.2 Allowed Glycine 0 N--CA 1.45 -0.399 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.894 -179.754 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . 0.45 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -59.1 176.18 2.7 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.131 179.625 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . 0.411 HG21 ' CB ' ' A' ' 87' ' ' ARG . 1.2 mt -79.06 -19.53 12.88 Favored 'Isoleucine or valine' 0 C--O 1.236 0.343 0 CA-C-O 120.892 0.377 . . . . 0.0 111.729 -179.69 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 113' ' ' ALA . . . . . 0.432 ' CB ' ' CD2' ' A' ' 97' ' ' PHE . . . -57.77 -30.61 65.78 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.981 0.42 . . . . 0.0 110.74 179.909 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 114' ' ' GLU . . . . . 0.45 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 10.5 pt-20 -60.92 -46.46 90.59 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.746 179.703 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -62.23 -45.76 91.89 Favored 'General case' 0 N--CA 1.453 -0.304 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.946 -179.444 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -51.19 -74.35 0.3 Allowed Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.297 -0.954 . . . . 0.0 112.532 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . 0.483 ' O ' ' C ' ' A' ' 118' ' ' VAL . . . 174.29 -26.22 0.08 OUTLIER Glycine 0 CA--C 1.518 0.276 0 C-N-CA 121.116 -0.564 . . . . 0.0 112.61 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.483 ' C ' ' O ' ' A' ' 117' ' ' GLY . 13.5 t -15.72 -81.98 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.471 0.594 0 C-N-CA 123.259 0.624 . . . . 0.0 112.632 -179.824 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.4 ' N ' ' CG1' ' A' ' 118' ' ' VAL . 0.8 OUTLIER 63.84 129.05 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.748 0.309 . . . . 0.0 110.454 -179.43 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 22.2 t -63.29 130.88 28.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.314 -179.799 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 97.41 34.22 5.65 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.685 179.756 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 5.1 m170 -122.65 -174.54 2.94 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.933 0.396 . . . . 0.0 110.878 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . 0.53 ' N ' ' O ' ' A' ' 156' ' ' MET . 8.7 ttm-85 -144.23 89.43 2.02 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.87 -179.803 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . 0.438 HG22 ' CG2' ' A' ' 132' ' ' VAL . 78.3 mt -50.4 150.16 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 N-CA-C 110.208 -0.293 . . . . 0.0 110.208 179.246 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 125' ' ' ILE . . . . . 0.444 ' CG1' ' H ' ' A' ' 126' ' ' GLU . 0.6 OUTLIER -146.07 -84.5 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 N-CA-C 112.87 0.693 . . . . 0.0 112.87 -178.892 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . 0.444 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 40.0 mt-10 -83.2 89.12 6.92 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 112.532 0.568 . . . . 0.0 112.532 -178.499 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.55 ' HA ' ' HB3' ' A' ' 153' ' ' MET . 1.8 mt -89.03 102.0 12.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.005 179.221 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 22.6 m-20 53.75 24.85 4.64 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.121 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 111.83 -16.51 25.76 Favored Glycine 0 CA--C 1.519 0.317 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.725 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -93.16 108.94 20.45 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.782 0.325 . . . . 0.0 110.889 -179.88 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 83.1 p -74.83 89.47 2.33 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.096 -179.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . 0.438 ' CG2' HG22 ' A' ' 124' ' ' ILE . 27.7 m -74.99 -4.08 5.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.832 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 12.1 p -46.37 -40.95 4.35 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-O 120.928 0.394 . . . . 0.0 111.343 -179.854 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -113.91 29.48 7.97 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.673 179.395 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 135' ' ' THR . . . . . 0.417 ' CG2' ' HD2' ' A' ' 136' ' ' PRO . 84.0 m -114.04 143.26 29.32 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.047 -179.746 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 136' ' ' PRO . . . . . 0.417 ' HD2' ' CG2' ' A' ' 135' ' ' THR . 74.8 Cg_exo -49.72 156.97 2.73 Favored 'Trans proline' 0 C--N 1.347 0.494 0 C-N-CA 122.45 2.1 . . . . 0.0 112.245 179.851 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 137' ' ' HIS . . . . . 0.419 ' CE1' ' HG3' ' A' ' 138' ' ' GLU . 7.6 p80 -68.08 -46.47 70.93 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.266 -179.762 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . 0.419 ' HG3' ' CE1' ' A' ' 137' ' ' HIS . 18.1 mt-10 -55.56 -35.75 66.07 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.299 -179.791 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 139' ' ' LYS . . . . . 0.437 ' O ' ' CD1' ' A' ' 143' ' ' ILE . 5.4 tptt -62.78 -47.5 83.2 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.885 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . 0.445 HG23 HD12 ' A' ' 140' ' ' ILE . 16.4 mt -58.8 -43.04 87.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.584 179.951 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . 0.442 ' CG2' ' CG1' ' A' ' 99' ' ' VAL . 92.8 t -62.16 -32.72 55.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.177 179.051 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 2.0 t-80 -62.19 -54.48 40.36 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.907 179.901 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . 0.437 ' CD1' ' O ' ' A' ' 139' ' ' LYS . 4.4 mp -53.09 -56.94 5.67 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.408 0 CA-C-O 121.207 0.527 . . . . 0.0 110.214 179.391 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.575 HD21 HG12 ' A' ' 151' ' ' ILE . 4.5 mt -60.94 -30.12 70.04 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.327 -0.852 . . . . 0.0 110.288 179.619 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 28.5 t -69.37 -26.45 64.67 Favored 'General case' 0 N--CA 1.452 -0.356 0 CA-C-N 116.183 -0.462 . . . . 0.0 109.929 178.672 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -128.9 33.42 4.62 Favored 'General case' 0 C--O 1.232 0.138 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.104 179.85 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 147' ' ' ALA . . . . . 0.41 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . -115.81 46.17 1.58 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.859 0.361 . . . . 0.0 111.462 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 11.2 m -50.69 157.36 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.389 -179.864 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 102.68 -106.39 2.91 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.504 -179.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 30.1 mt-10 -139.14 94.44 2.8 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.805 0.336 . . . . 0.0 110.768 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . 0.575 HG12 HD21 ' A' ' 144' ' ' LEU . 1.0 OUTLIER -64.71 111.96 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.037 -179.867 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . 0.402 ' CD2' ' HG ' ' A' ' 85' ' ' LEU . 0.2 OUTLIER -99.43 115.94 30.42 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.046 -0.524 . . . . 0.0 109.962 179.135 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 153' ' ' MET . . . . . 0.55 ' HB3' ' HA ' ' A' ' 127' ' ' ILE . 0.1 OUTLIER -147.82 177.42 9.33 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.406 0.622 . . . . 0.0 111.58 -179.216 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 12.9 mttt -126.7 160.27 31.26 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 114.938 -1.028 . . . . 0.0 109.866 179.562 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 24.4 p -144.18 144.58 31.62 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.299 0.571 . . . . 0.0 111.814 -179.565 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 156' ' ' MET . . . . . 0.53 ' O ' ' N ' ' A' ' 123' ' ' ARG . 0.0 OUTLIER -115.87 177.51 1.19 Allowed Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 115.142 -0.936 . . . . 0.0 109.997 179.508 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 157' ' ' PRO . . . . . 0.4 ' HD2' ' HB3' ' A' ' 156' ' ' MET . 89.8 Cg_endo -92.4 102.07 0.19 Allowed 'Trans proline' 0 N--CA 1.455 -0.757 0 C-N-CA 122.585 2.19 . . . . 0.0 112.627 -179.684 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 158' ' ' ALA . . . . . 0.466 ' CB ' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.248 1.025 0 CA-C-O 118.168 -0.92 . . . . 0.0 111.054 179.739 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 37.1 t . . . . . 0 C--O 1.231 0.089 0 CA-C-O 120.765 0.316 . . . . 0.0 111.061 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.5 m -98.69 139.24 34.69 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.869 179.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 10.3 m -109.29 111.46 23.06 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.106 -0.497 . . . . 0.0 109.93 179.015 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.443 ' HB ' ' CG ' ' A' ' 153' ' ' MET . 66.2 t -81.72 106.38 12.68 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.638 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.506 -179.475 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . 0.41 ' HB2' ' CD2' ' A' ' 152' ' ' HIS . 16.8 tp -104.91 87.06 2.57 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.592 178.859 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.463 HG12 ' HA ' ' A' ' 113' ' ' ALA . 3.7 mt -81.56 146.82 6.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.229 -179.088 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.423 ' CB ' HG21 ' A' ' 112' ' ' ILE . 0.0 OUTLIER -115.7 108.97 17.06 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.486 -179.602 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 53.5 ttt180 -104.02 108.28 59.49 Favored Pre-proline 0 C--N 1.33 -0.257 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.847 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -68.45 -27.56 33.4 Favored 'Trans proline' 0 C--N 1.347 0.487 0 C-N-CA 122.36 2.04 . . . . 0.0 112.402 -179.942 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -165.22 168.98 16.52 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.993 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -66.86 -36.87 83.3 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.067 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.21 -14.15 59.96 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.086 -0.507 . . . . 0.0 111.492 -179.769 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 46.6 m-85 -99.39 113.11 25.26 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.42 -0.355 . . . . 0.0 110.889 179.881 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -73.98 165.93 24.27 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.007 -179.926 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . 0.405 HD13 ' CE1' ' A' ' 97' ' ' PHE . 26.0 mt -77.44 -67.43 0.72 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.835 179.965 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 132.51 40.6 0.2 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.566 -0.826 . . . . 0.0 112.956 179.624 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . 0.405 ' CE1' HD13 ' A' ' 95' ' ' LEU . 35.3 p90 -177.05 159.55 1.67 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.796 0.331 . . . . 0.0 110.968 179.68 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -112.94 144.67 42.12 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.963 -179.92 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.484 HG21 ' CG2' ' A' ' 140' ' ' ILE . 12.7 p -111.47 138.0 41.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.591 -179.861 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' GLN . . . . . 0.402 ' O ' ' N ' ' A' ' 102' ' ' GLY . 5.2 mm-40 -130.04 88.58 2.68 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.007 179.013 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 3.7 t30 64.69 -70.66 0.08 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.951 -179.662 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . 0.412 ' O ' ' HA ' ' A' ' 123' ' ' ARG . . . -141.86 -1.19 1.4 Allowed Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 120.445 -0.883 . . . . 0.0 113.024 179.928 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.481 HD13 ' HB2' ' A' ' 158' ' ' ALA . 25.5 mm -119.55 159.2 20.68 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.166 0 CA-C-O 120.969 0.414 . . . . 0.0 111.304 -179.712 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.503 HD11 HG13 ' A' ' 124' ' ' ILE . 3.3 mp -102.19 141.46 18.36 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.912 -179.762 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -83.51 -69.43 0.64 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.936 -179.845 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -142.9 168.98 18.42 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.941 -179.882 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.407 ' HB2' ' CG2' ' A' ' 120' ' ' VAL . 0.6 OUTLIER -123.1 167.46 13.63 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.912 179.926 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 4.5 ttt -122.62 97.76 5.6 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.648 179.705 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -55.21 91.0 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.86 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 152.94 -29.38 0.82 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.947 -0.644 . . . . 0.0 112.029 -179.69 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . 0.4 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -70.88 176.82 35.88 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.278 179.753 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . 0.423 HG21 ' CB ' ' A' ' 87' ' ' ARG . 0.6 OUTLIER -78.74 -16.6 13.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 120.711 0.291 . . . . 0.0 111.664 -179.769 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 113' ' ' ALA . . . . . 0.463 ' HA ' HG12 ' A' ' 86' ' ' ILE . . . -57.75 -30.53 65.66 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.013 0.435 . . . . 0.0 110.726 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 114' ' ' GLU . . . . . 0.4 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 10.5 pt-20 -60.34 -46.91 88.24 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.662 179.632 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -62.49 -47.8 82.39 Favored 'General case' 0 N--CA 1.452 -0.352 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.125 -179.684 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -49.91 -74.14 0.3 Allowed Glycine 0 CA--C 1.519 0.325 0 C-N-CA 120.454 -0.879 . . . . 0.0 112.452 179.866 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 173.99 -25.16 0.07 OUTLIER Glycine 0 CA--C 1.519 0.299 0 C-N-CA 121.141 -0.552 . . . . 0.0 112.366 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.423 ' N ' ' CG2' ' A' ' 84' ' ' VAL . 1.1 t -40.24 113.76 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.256 0 CA-C-O 120.981 0.419 . . . . 0.0 111.802 -179.709 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 2.3 ttt180 -132.3 110.26 10.47 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.117 179.462 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 120' ' ' VAL . . . . . 0.407 ' CG2' ' HB2' ' A' ' 107' ' ' LEU . 85.1 t -43.6 118.12 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.688 -179.451 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 118.5 28.13 2.21 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.845 -0.693 . . . . 0.0 112.932 179.73 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . 0.479 ' CD2' ' HB ' ' A' ' 155' ' ' THR . 20.2 p-80 -137.3 -170.29 2.7 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.619 0.247 . . . . 0.0 111.07 179.752 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . 0.412 ' HA ' ' O ' ' A' ' 102' ' ' GLY . 55.6 ttp85 -133.92 114.39 13.23 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-N 116.574 -0.285 . . . . 0.0 111.711 -179.555 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . 0.503 HG13 HD11 ' A' ' 104' ' ' ILE . 34.7 mt -73.16 158.58 6.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 178.59 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 125' ' ' ILE . . . . . 0.495 ' CG1' ' H ' ' A' ' 126' ' ' GLU . 0.8 OUTLIER -147.14 -83.02 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 N-CA-C 112.867 0.691 . . . . 0.0 112.867 -179.624 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . 0.495 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 5.4 mt-10 -87.41 87.7 7.48 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 112.44 0.533 . . . . 0.0 112.44 -178.477 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.469 ' HA ' ' CB ' ' A' ' 153' ' ' MET . 2.4 mt -87.06 103.83 13.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.29 179.197 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 7.5 m-20 53.01 25.32 3.96 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.905 -0.588 . . . . 0.0 111.193 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 110.08 -13.57 31.45 Favored Glycine 0 CA--C 1.519 0.3 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.846 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 11.6 tt0 -95.72 110.88 22.95 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.787 0.327 . . . . 0.0 110.772 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 131' ' ' SER . . . . . 0.401 ' HA ' ' O ' ' A' ' 125' ' ' ILE . 1.1 m -74.84 87.24 2.25 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.042 -179.901 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . 0.462 ' CG2' HG21 ' A' ' 124' ' ' ILE . 31.9 m -73.9 -5.3 6.53 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.369 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.956 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 9.8 p -46.31 -31.56 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-O 120.888 0.375 . . . . 0.0 111.566 -179.695 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -127.95 27.41 5.7 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.617 179.409 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 135' ' ' THR . . . . . 0.447 ' HB ' ' HA ' ' A' ' 132' ' ' VAL . 32.5 m -110.65 143.79 28.93 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 115.833 -0.621 . . . . 0.0 111.214 -179.736 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 136' ' ' PRO . . . . . 0.418 ' HD2' ' CG2' ' A' ' 135' ' ' THR . 50.5 Cg_exo -53.78 164.27 2.45 Favored 'Trans proline' 0 C--N 1.347 0.495 0 C-N-CA 122.545 2.163 . . . . 0.0 112.048 179.512 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 137' ' ' HIS . . . . . 0.405 ' CG ' ' N ' ' A' ' 138' ' ' GLU . 6.8 p80 -72.6 -46.83 52.27 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.517 -179.607 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . 0.405 ' N ' ' CG ' ' A' ' 137' ' ' HIS . 1.7 mm-40 -54.01 -39.13 65.85 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.472 -179.513 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 139' ' ' LYS . . . . . 0.454 ' O ' ' CD1' ' A' ' 143' ' ' ILE . 7.0 tttp -63.53 -45.97 88.18 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.225 -179.701 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . 0.484 ' CG2' HG21 ' A' ' 99' ' ' VAL . 9.7 mt -59.36 -46.08 92.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.983 0.421 . . . . 0.0 110.431 179.956 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 55.4 t -60.08 -32.37 50.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.039 179.034 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 4.6 t60 -61.08 -53.68 54.06 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.679 179.579 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . 0.454 ' CD1' ' O ' ' A' ' 139' ' ' LYS . 4.3 mp -53.16 -56.9 5.98 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.379 0 CA-C-O 121.276 0.56 . . . . 0.0 110.263 179.209 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.541 HD22 HG12 ' A' ' 151' ' ' ILE . 3.9 mt -61.24 -30.32 70.38 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.254 -0.884 . . . . 0.0 110.275 179.453 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 30.9 t -69.31 -26.38 64.69 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.123 -0.489 . . . . 0.0 109.925 178.676 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -127.43 32.2 5.06 Favored 'General case' 0 C--O 1.231 0.099 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.985 179.697 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . -114.03 41.62 2.21 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.352 -0.386 . . . . 0.0 111.296 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 18.5 m -51.72 138.76 8.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.447 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 120.88 -103.46 0.9 Allowed Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.442 -179.914 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 4.7 mt-10 -139.28 100.65 4.06 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.79 0.328 . . . . 0.0 110.877 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . 0.541 HG12 HD22 ' A' ' 144' ' ' LEU . 1.3 mt -78.86 111.78 16.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.942 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . 0.41 ' CD2' ' HB2' ' A' ' 85' ' ' LEU . 0.5 OUTLIER -106.97 115.55 30.37 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.141 179.325 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 153' ' ' MET . . . . . 0.469 ' CB ' ' HA ' ' A' ' 127' ' ' ILE . 1.7 ptm -136.64 161.98 34.43 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.071 0.463 . . . . 0.0 111.729 -179.318 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 3.5 mttt -104.53 150.3 24.73 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.712 -0.676 . . . . 0.0 109.778 179.121 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 155' ' ' THR . . . . . 0.479 ' HB ' ' CD2' ' A' ' 122' ' ' HIS . 21.8 p -146.14 150.44 35.89 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.295 0.569 . . . . 0.0 112.076 -179.086 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 156' ' ' MET . . . . . 0.401 ' CE ' HD12 ' A' ' 125' ' ' ILE . 0.0 OUTLIER -144.76 145.33 27.58 Favored Pre-proline 0 C--N 1.327 -0.406 0 CA-C-N 115.226 -0.897 . . . . 0.0 110.346 179.102 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_exo -50.92 109.38 0.3 Allowed 'Trans proline' 0 C--N 1.343 0.263 0 C-N-CA 122.512 2.141 . . . . 0.0 112.628 -179.759 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 158' ' ' ALA . . . . . 0.481 ' HB2' HD13 ' A' ' 103' ' ' ILE . . . . . . . . 0 C--O 1.25 1.084 0 CA-C-O 118.266 -0.873 . . . . 0.0 111.343 179.863 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 18.3 t . . . . . 0 C--O 1.232 0.179 0 CA-C-O 120.802 0.334 . . . . 0.0 111.104 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.1 m -114.42 132.14 56.35 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.926 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 56.5 m -95.58 111.19 23.16 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.947 179.119 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.473 HG13 HG13 ' A' ' 86' ' ' ILE . 86.3 t -88.39 105.38 15.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.58 -179.206 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . 0.439 ' O ' ' HA2' ' A' ' 116' ' ' GLY . 2.7 tp -100.01 84.27 2.84 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 178.588 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.473 HG13 HG13 ' A' ' 84' ' ' VAL . 22.0 mt -81.27 127.31 39.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-O 121.4 0.619 . . . . 0.0 111.928 -178.501 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.49 153.34 39.16 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.136 -0.938 . . . . 0.0 110.407 179.856 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 5.5 ttt-85 -152.15 91.71 3.62 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 120.682 0.277 . . . . 0.0 111.161 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -58.53 -63.48 0.14 Allowed 'Trans proline' 0 C--N 1.345 0.346 0 C-N-CA 122.583 2.189 . . . . 0.0 112.23 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 4.9 t0 -117.14 -173.68 2.45 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.169 -179.859 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . 0.403 ' CD1' ' CG1' ' A' ' 148' ' ' VAL . 0.1 OUTLIER -91.79 -21.95 20.41 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.311 -179.864 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -95.76 22.7 6.97 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.469 -0.332 . . . . 0.0 111.219 -179.779 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 17.7 m-85 -121.04 117.97 28.59 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.801 0.334 . . . . 0.0 110.835 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 3.4 mp0 -64.57 177.93 0.83 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.874 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . 0.4 ' CD1' ' CD1' ' A' ' 144' ' ' LEU . 42.5 mt -96.98 -61.35 1.42 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.932 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 132.05 53.91 0.09 OUTLIER Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.718 179.912 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -176.68 -171.96 0.41 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.904 0.383 . . . . 0.0 110.991 179.9 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 8.3 t -137.44 130.35 30.36 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.793 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.447 ' O ' ' CE1' ' A' ' 137' ' ' HIS . 10.4 p -109.97 114.35 46.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.06 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' GLN . . . . . 0.421 ' O ' ' N ' ' A' ' 102' ' ' GLY . 1.2 tt0 -110.31 89.0 2.9 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.817 0.341 . . . . 0.0 110.908 -180.0 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' ASN . . . . . 0.46 ' O ' ' CD1' ' A' ' 140' ' ' ILE . 1.6 t30 65.18 -64.64 0.17 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.51 179.702 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . 0.421 ' N ' ' O ' ' A' ' 100' ' ' GLN . . . -146.88 -4.49 0.42 Allowed Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.336 -0.935 . . . . 0.0 113.661 -179.623 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.403 HD12 ' CB ' ' A' ' 158' ' ' ALA . 31.5 mm -125.09 142.64 41.35 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 117.389 0.594 . . . . 0.0 111.307 -179.543 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 3.9 mp -84.44 142.58 13.16 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.788 179.712 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -105.42 -77.73 0.58 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.991 -179.829 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 62.6 p -90.64 146.98 23.6 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.944 0.402 . . . . 0.0 110.9 -179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -136.72 123.92 21.77 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.883 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 4.1 mtt -77.06 120.37 22.05 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.882 -179.949 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -81.33 105.59 12.63 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.765 179.893 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 101.66 26.63 7.52 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.394 -179.917 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . 0.476 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -111.76 -158.25 14.53 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.701 -0.762 . . . . 0.0 113.209 -179.761 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 16.3 mt -80.16 -41.92 21.35 Favored 'Isoleucine or valine' 0 C--O 1.238 0.463 0 CA-C-O 121.076 0.465 . . . . 0.0 111.766 -179.588 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 113' ' ' ALA . . . . . . . . . . . . . . . -57.7 -36.21 71.67 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.193 -179.394 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 114' ' ' GLU . . . . . 0.52 ' HG3' ' N ' ' A' ' 115' ' ' ARG . 8.3 pt-20 -66.9 -36.26 81.87 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.484 179.561 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.52 ' N ' ' HG3' ' A' ' 114' ' ' GLU . 0.0 OUTLIER -59.39 -46.55 88.35 Favored 'General case' 0 N--CA 1.452 -0.359 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.559 -179.905 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . 0.439 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -56.05 -71.31 0.75 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.205 -0.998 . . . . 0.0 112.539 179.635 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 174.32 -22.76 0.06 OUTLIER Glycine 0 CA--C 1.519 0.282 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.824 -179.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.452 ' N ' ' CG2' ' A' ' 84' ' ' VAL . 7.3 p -31.75 145.72 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 N-CA-C 112.265 0.469 . . . . 0.0 112.265 -179.621 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.423 ' HB3' ' CD2' ' A' ' 122' ' ' HIS . 0.1 OUTLIER -147.83 134.43 19.85 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.734 179.899 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 22.0 t -59.48 111.26 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.036 179.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 109.72 18.49 8.91 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.602 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . 0.423 ' CD2' ' HB3' ' A' ' 119' ' ' ARG . 1.7 m-70 -102.22 -173.02 2.24 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.682 0.277 . . . . 0.0 110.693 179.909 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . 0.441 ' N ' ' O ' ' A' ' 156' ' ' MET . 40.4 ttt180 -142.76 90.71 2.24 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.363 -0.38 . . . . 0.0 111.335 -179.647 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . 0.437 HG23 ' CG2' ' A' ' 132' ' ' VAL . 25.2 mt -51.48 157.07 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.307 179.112 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 125' ' ' ILE . . . . . 0.446 ' CG1' ' H ' ' A' ' 126' ' ' GLU . 0.6 OUTLIER -149.38 -82.99 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 N-CA-C 112.576 0.584 . . . . 0.0 112.576 -179.389 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . 0.446 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 72.7 mt-10 -89.29 89.4 7.89 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 112.353 0.501 . . . . 0.0 112.353 -178.62 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.486 ' HA ' ' CB ' ' A' ' 153' ' ' MET . 2.1 mt -88.89 106.87 17.24 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.181 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.573 179.43 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . 0.419 ' HA ' ' CE1' ' A' ' 152' ' ' HIS . 3.1 t-20 53.45 31.69 12.64 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.899 -0.591 . . . . 0.0 111.066 179.726 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 98.23 -7.26 62.06 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.754 -179.74 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 2.9 tt0 -99.92 106.23 18.02 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.836 0.351 . . . . 0.0 110.756 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 1.6 m -71.12 84.26 0.72 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.157 -179.773 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . 0.437 ' CG2' HG23 ' A' ' 124' ' ' ILE . 34.1 m -67.73 -10.03 11.67 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.759 179.867 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 9.3 p -51.06 117.85 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.925 0.393 . . . . 0.0 110.961 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . 75.1 21.2 1.98 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.754 -178.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 135' ' ' THR . . . . . 0.455 ' CG2' ' HD2' ' A' ' 136' ' ' PRO . 29.3 m -103.5 142.52 24.74 Favored Pre-proline 0 C--N 1.327 -0.402 0 CA-C-N 115.648 -0.706 . . . . 0.0 110.802 179.828 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 136' ' ' PRO . . . . . 0.455 ' HD2' ' CG2' ' A' ' 135' ' ' THR . 94.9 Cg_exo -42.77 164.2 0.04 OUTLIER 'Trans proline' 0 C--N 1.348 0.533 0 C-N-CA 122.849 2.366 . . . . 0.0 112.9 -179.869 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 137' ' ' HIS . . . . . 0.447 ' CE1' ' O ' ' A' ' 99' ' ' VAL . 3.1 t-160 -74.17 -59.35 2.76 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.558 -179.525 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -53.67 -27.17 26.07 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.901 -179.135 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 139' ' ' LYS . . . . . 0.459 ' O ' ' CD1' ' A' ' 143' ' ' ILE . 0.9 OUTLIER -67.52 -51.44 50.85 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.651 0.262 . . . . 0.0 111.172 -179.535 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . 0.488 HG21 HD11 ' A' ' 140' ' ' ILE . 17.4 mt -59.54 -46.35 93.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 121.026 0.441 . . . . 0.0 110.751 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 93.5 t -60.11 -32.44 50.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.227 179.237 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -61.75 -54.88 36.48 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.971 179.723 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . 0.459 ' CD1' ' O ' ' A' ' 139' ' ' LYS . 4.1 mp -52.88 -56.9 5.62 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.391 0 CA-C-O 121.232 0.539 . . . . 0.0 110.267 179.569 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.563 HD23 HG12 ' A' ' 151' ' ' ILE . 1.6 mt -61.75 -29.97 70.48 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.394 179.582 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 25.8 t -69.25 -26.56 64.84 Favored 'General case' 0 C--N 1.33 -0.242 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 178.523 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -126.91 31.61 5.26 Favored 'General case' 0 CA--C 1.53 0.181 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.093 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 147' ' ' ALA . . . . . 0.454 ' HB3' ' HA ' ' A' ' 144' ' ' LEU . . . -116.98 58.19 0.78 Allowed 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.356 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . 0.403 ' CG1' ' CD1' ' A' ' 91' ' ' LEU . 3.9 m -53.28 173.7 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.346 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 87.9 -113.38 4.01 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.468 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 -139.76 102.84 4.53 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.835 0.35 . . . . 0.0 110.778 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . 0.563 HG12 HD23 ' A' ' 144' ' ' LEU . 1.3 mt -73.99 111.67 9.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.098 -179.905 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . 0.419 ' CE1' ' HA ' ' A' ' 128' ' ' ASN . 8.7 p80 -104.58 115.58 30.59 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.136 -0.484 . . . . 0.0 109.733 178.84 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 153' ' ' MET . . . . . 0.486 ' CB ' ' HA ' ' A' ' 127' ' ' ILE . 0.8 OUTLIER -136.72 174.66 10.37 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.193 0.52 . . . . 0.0 111.874 -178.737 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -118.56 151.62 37.55 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.77 179.268 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 44.4 p -139.65 143.22 37.07 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.027 0.441 . . . . 0.0 111.479 -179.551 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 156' ' ' MET . . . . . 0.441 ' O ' ' N ' ' A' ' 123' ' ' ARG . 0.0 OUTLIER -110.77 176.63 1.45 Allowed Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 115.538 -0.755 . . . . 0.0 110.545 179.764 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 96.3 Cg_endo -90.12 118.75 0.74 Allowed 'Trans proline' 0 N--CA 1.457 -0.619 0 C-N-CA 122.735 2.29 . . . . 0.0 112.546 -179.856 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 158' ' ' ALA . . . . . 0.403 ' CB ' HD12 ' A' ' 103' ' ' ILE . . . . . . . . 0 C--O 1.249 1.071 0 CA-C-O 118.242 -0.885 . . . . 0.0 111.019 179.781 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 9.4 p . . . . . 0 N--CA 1.456 -0.129 0 CA-C-O 120.721 0.296 . . . . 0.0 111.048 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.6 m -111.1 121.28 44.92 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.871 179.764 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' THR . . . . . 0.419 ' HA ' ' O ' ' A' ' 153' ' ' MET . 8.9 m -92.65 110.82 22.26 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.039 179.046 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.597 HG11 ' H ' ' A' ' 118' ' ' VAL . 76.2 t -83.31 106.0 13.54 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.597 0 CA-C-N 116.298 -0.41 . . . . 0.0 112.059 -179.17 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 3.9 tt -102.97 81.11 1.94 Allowed 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 177.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.404 HG13 ' CG1' ' A' ' 84' ' ' VAL . 4.4 mt -81.49 123.88 38.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 121.281 0.562 . . . . 0.0 111.769 -178.328 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -70.43 142.62 51.98 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.307 -0.86 . . . . 0.0 110.496 179.761 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 10.2 mtp180 -141.93 98.73 6.22 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.891 179.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' PRO . . . . . 0.423 ' HG2' ' CG ' ' A' ' 93' ' ' TYR . 64.1 Cg_endo -73.61 -41.62 1.09 Allowed 'Trans proline' 0 C--N 1.346 0.403 0 C-N-CA 122.552 2.168 . . . . 0.0 112.561 -179.877 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -137.05 -168.09 2.22 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.149 -179.824 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 3.9 mt -95.08 -22.74 17.69 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.204 -179.861 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 4.5 ptt-85 -96.23 22.84 7.2 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.144 -179.834 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . 0.423 ' CG ' ' HG2' ' A' ' 89' ' ' PRO . 12.9 m-85 -106.05 96.63 6.61 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.922 0.391 . . . . 0.0 110.894 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 1.3 pp0? -50.58 159.21 0.54 Allowed 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.276 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . 0.42 HD21 ' CZ ' ' A' ' 97' ' ' PHE . 2.1 mp -88.05 -66.8 0.88 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.861 179.872 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 130.49 37.77 0.32 Allowed Glycine 0 CA--C 1.519 0.29 0 C-N-CA 120.562 -0.828 . . . . 0.0 112.885 179.661 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . 0.42 ' CZ ' HD21 ' A' ' 95' ' ' LEU . 50.2 p90 -176.93 178.06 1.21 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.707 0.289 . . . . 0.0 110.936 179.775 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.6 t -128.36 146.1 50.88 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.97 0.414 . . . . 0.0 111.06 -179.787 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 5.5 p -113.09 124.33 69.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.832 179.9 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' GLN . . . . . 0.417 ' O ' ' N ' ' A' ' 102' ' ' GLY . 1.9 tt0 -115.55 88.77 2.95 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.803 179.766 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' ASN . . . . . 0.453 ' O ' ' CD1' ' A' ' 140' ' ' ILE . 1.2 m-80 64.94 -67.16 0.12 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.87 -0.605 . . . . 0.0 111.424 179.685 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . 0.417 ' N ' ' O ' ' A' ' 100' ' ' GLN . . . -144.52 -3.7 0.7 Allowed Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.29 -0.957 . . . . 0.0 113.41 -179.629 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.422 HD13 ' HB3' ' A' ' 158' ' ' ALA . 39.2 mm -122.99 148.57 26.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 117.315 0.557 . . . . 0.0 111.406 -179.574 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.404 ' CD1' ' N ' ' A' ' 104' ' ' ILE . 2.8 mp -85.08 141.91 13.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.507 179.594 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 94.1 m -97.81 -80.11 0.45 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.125 -179.677 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 1.4 m -109.13 145.63 35.41 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.981 -179.872 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.408 ' CD1' ' CG1' ' A' ' 118' ' ' VAL . 1.2 tt -143.2 113.2 7.14 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.808 179.987 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -74.83 142.55 44.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.719 179.852 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.87 47.52 1.42 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.974 0.416 . . . . 0.0 110.808 -179.904 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -161.35 25.83 0.26 Allowed Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.39 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . 0.465 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -121.05 -174.63 14.98 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.331 179.867 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 1.2 mp -78.92 -22.56 12.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 120.785 0.326 . . . . 0.0 111.463 -179.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 113' ' ' ALA . . . . . 0.409 ' HB3' ' CE1' ' A' ' 97' ' ' PHE . . . -58.2 -30.57 66.56 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.894 0.378 . . . . 0.0 110.723 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 114' ' ' GLU . . . . . 0.465 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 12.4 pt-20 -61.26 -46.42 90.42 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.796 179.734 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 3.5 mtp85 -63.38 -44.13 95.62 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.908 -179.617 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -53.73 -73.97 0.35 Allowed Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.386 -0.911 . . . . 0.0 112.504 179.885 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . 0.401 ' O ' ' C ' ' A' ' 118' ' ' VAL . . . 174.98 -27.01 0.08 OUTLIER Glycine 0 CA--C 1.519 0.331 0 C-N-CA 120.922 -0.656 . . . . 0.0 112.65 -179.824 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.597 ' H ' HG11 ' A' ' 84' ' ' VAL . 94.3 t -31.87 116.56 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 CA-C-O 121.026 0.441 . . . . 0.0 111.709 -179.82 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 11.7 mtt-85 -128.62 112.64 14.49 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.294 179.583 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 32.2 t -46.99 108.42 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.239 -179.768 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 120.36 16.28 4.76 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 121.009 -0.615 . . . . 0.0 112.54 -179.721 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 3.9 m170 -110.35 -172.39 2.03 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.597 0.237 . . . . 0.0 110.562 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . 0.476 ' N ' ' O ' ' A' ' 156' ' ' MET . 4.1 ttt180 -139.88 92.87 2.59 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.682 0.277 . . . . 0.0 111.418 -179.657 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . 0.433 HG23 ' CG2' ' A' ' 132' ' ' VAL . 7.2 mt -52.76 147.65 1.91 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.077 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 125' ' ' ILE . . . . . 0.432 ' CG1' ' H ' ' A' ' 126' ' ' GLU . 0.6 OUTLIER -141.42 -84.79 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 N-CA-C 112.393 0.516 . . . . 0.0 112.393 -179.335 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . 0.432 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 8.5 mm-40 -86.39 90.06 8.08 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 112.316 0.488 . . . . 0.0 112.316 -178.719 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.496 ' HA ' ' CB ' ' A' ' 153' ' ' MET . 2.3 mt -85.45 105.72 14.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 121.24 0.543 . . . . 0.0 111.473 179.307 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . 0.444 ' N ' ' O ' ' A' ' 152' ' ' HIS . 0.6 OUTLIER 56.61 20.81 5.23 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.694 -0.684 . . . . 0.0 111.512 179.667 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 115.14 -12.8 19.54 Favored Glycine 0 C--N 1.331 0.301 0 C-N-CA 120.519 -0.848 . . . . 0.0 113.434 179.665 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 130' ' ' GLN . . . . . 0.408 ' HG3' ' O ' ' A' ' 130' ' ' GLN . 1.1 pt20 -103.17 117.54 34.78 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-O 120.958 0.408 . . . . 0.0 110.834 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 95.9 p -74.85 85.8 2.22 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.31 -179.643 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . 0.445 HG21 HG13 ' A' ' 127' ' ' ILE . 33.8 m -66.61 -10.89 12.39 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.315 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.535 179.537 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 8.9 p -49.69 117.73 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 120.915 0.388 . . . . 0.0 110.964 -179.952 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . 76.15 20.77 1.58 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.789 -179.141 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 135' ' ' THR . . . . . 0.449 ' CG2' ' HD2' ' A' ' 136' ' ' PRO . 36.9 m -104.21 143.21 26.2 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.691 179.637 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 136' ' ' PRO . . . . . 0.449 ' HD2' ' CG2' ' A' ' 135' ' ' THR . 1.9 Cg_endo -41.51 141.19 1.47 Allowed 'Trans proline' 0 C--N 1.347 0.499 0 C-N-CA 123.113 2.542 . . . . 0.0 112.631 179.898 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 38.0 p-80 -63.95 -48.49 76.3 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.024 -0.534 . . . . 0.0 111.464 -179.62 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -54.73 -36.58 64.92 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.301 -179.625 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 139' ' ' LYS . . . . . 0.456 ' O ' ' CD1' ' A' ' 143' ' ' ILE . 19.2 tttm -63.34 -48.81 76.41 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.83 -179.933 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . 0.453 ' CD1' ' O ' ' A' ' 101' ' ' ASN . 21.6 mt -58.47 -46.12 89.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.722 -179.861 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 99.3 t -59.34 -32.5 48.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.014 178.869 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 1.7 t60 -61.78 -52.01 65.96 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.71 179.628 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . 0.456 ' CD1' ' O ' ' A' ' 139' ' ' LYS . 4.3 mp -53.19 -57.23 5.14 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.414 0 CA-C-O 121.024 0.44 . . . . 0.0 110.222 179.416 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.553 ' CD2' HG12 ' A' ' 151' ' ' ILE . 3.4 mt -60.53 -30.15 69.57 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.562 -0.745 . . . . 0.0 110.23 179.574 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 1.1 m -69.33 -26.91 64.94 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-N 116.062 -0.517 . . . . 0.0 109.895 178.557 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 3.6 m-80 -129.82 34.61 4.27 Favored 'General case' 0 CA--C 1.528 0.114 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.216 179.837 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 147' ' ' ALA . . . . . 0.441 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . -116.82 56.39 0.8 Allowed 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.835 0.35 . . . . 0.0 111.325 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 27.7 m -54.21 -177.96 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.403 -179.922 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 81.67 -100.96 2.11 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.552 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 13.0 mt-10 -152.9 98.2 2.29 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.813 0.34 . . . . 0.0 110.707 -179.898 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . 0.553 HG12 ' CD2' ' A' ' 144' ' ' LEU . 1.2 mt -63.09 111.56 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.185 -179.718 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . 0.444 ' O ' ' N ' ' A' ' 128' ' ' ASN . 1.5 t-160 -107.1 115.64 30.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.983 -0.553 . . . . 0.0 109.805 179.121 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 153' ' ' MET . . . . . 0.496 ' CB ' ' HA ' ' A' ' 127' ' ' ILE . 1.0 OUTLIER -141.96 176.17 9.15 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.041 0.448 . . . . 0.0 111.82 -178.893 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 53.1 mttt -124.23 148.9 46.99 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.064 179.401 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 20.0 p -137.1 132.17 33.7 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.942 0.401 . . . . 0.0 111.466 -179.57 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 156' ' ' MET . . . . . 0.476 ' O ' ' N ' ' A' ' 123' ' ' ARG . 0.0 OUTLIER -104.78 154.43 38.58 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.266 179.51 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 17.1 Cg_exo -66.77 118.78 5.82 Favored 'Trans proline' 0 C--N 1.342 0.228 0 C-N-CA 122.359 2.04 . . . . 0.0 112.136 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 158' ' ' ALA . . . . . 0.422 ' HB3' HD13 ' A' ' 103' ' ' ILE . . . . . . . . 0 C--O 1.249 1.058 0 CA-C-O 118.262 -0.875 . . . . 0.0 111.107 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 41.7 t . . . . . 0 N--CA 1.457 -0.084 0 CA-C-O 120.781 0.324 . . . . 0.0 111.094 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.5 m -117.09 143.4 45.83 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.913 179.854 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 17.7 m -105.67 111.56 24.3 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.247 179.279 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.412 HG12 HG13 ' A' ' 86' ' ' ILE . 43.4 t -82.34 105.94 12.73 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.552 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.78 -179.359 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 6.3 tt -108.14 82.3 1.61 Allowed 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 109.122 -0.696 . . . . 0.0 109.122 178.574 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.428 HG12 ' HA ' ' A' ' 113' ' ' ALA . 5.1 mt -81.36 145.21 9.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.009 -0.541 . . . . 0.0 111.807 -178.165 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.411 ' CB ' HG22 ' A' ' 112' ' ' ILE . 0.1 OUTLIER -97.71 114.71 26.75 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.518 -179.831 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 2.3 ttt-85 -112.26 103.09 55.15 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.136 -179.714 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' PRO . . . . . 0.419 ' HB2' ' CD2' ' A' ' 93' ' ' TYR . 34.8 Cg_exo -57.63 -53.6 4.37 Favored 'Trans proline' 0 C--N 1.347 0.475 0 C-N-CA 122.498 2.132 . . . . 0.0 112.369 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -140.41 -167.07 2.25 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.986 -179.921 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 8.2 mt -84.01 -20.1 33.37 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.313 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -96.41 23.33 6.86 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.095 -179.808 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . 0.419 ' CD2' ' HB2' ' A' ' 89' ' ' PRO . 15.9 m-85 -115.04 122.04 44.96 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.951 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -79.58 162.11 25.53 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.818 -179.979 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . 0.413 ' CD1' ' CD1' ' A' ' 144' ' ' LEU . 53.9 mt -89.5 -69.94 0.69 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.837 179.964 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 138.54 43.66 0.08 OUTLIER Glycine 0 CA--C 1.518 0.234 0 C-N-CA 120.42 -0.895 . . . . 0.0 113.011 179.724 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 35.4 p90 -176.74 161.97 2.12 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.849 0.357 . . . . 0.0 111.07 179.65 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -115.63 139.16 50.37 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.761 179.876 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.455 HG23 ' CG2' ' A' ' 140' ' ' ILE . 12.3 p -109.88 131.7 60.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.487 -179.818 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' GLN . . . . . 0.412 ' O ' ' N ' ' A' ' 102' ' ' GLY . 10.0 mt-30 -122.58 88.57 2.95 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.13 179.224 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 2.0 m120 63.89 -73.94 0.05 OUTLIER 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.971 -179.725 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . 0.47 ' O ' HD11 ' A' ' 103' ' ' ILE . . . -137.82 0.67 2.74 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.299 -0.953 . . . . 0.0 113.05 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.524 HD12 ' HB1' ' A' ' 158' ' ' ALA . 38.1 mm -124.17 151.88 29.51 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.127 0 CA-C-O 121.014 0.435 . . . . 0.0 111.435 -179.617 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.419 ' CD1' ' N ' ' A' ' 104' ' ' ILE . 3.2 mp -93.32 152.15 3.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.739 179.858 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 96.3 m -105.59 -67.54 0.92 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.107 -179.8 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 78.8 p -123.98 154.24 40.1 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.387 -0.369 . . . . 0.0 111.167 -179.853 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 27.1 tp -139.55 103.42 4.69 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.619 179.861 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 6.8 ttm -60.89 110.91 1.46 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.006 -179.861 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 2.2 tmt_? -68.7 72.21 0.23 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.768 179.747 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 174.34 -34.12 0.11 Allowed Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.973 -0.632 . . . . 0.0 112.149 -179.853 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . 0.411 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -60.0 -176.73 1.31 Allowed Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.21 179.697 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . 0.411 HG22 ' CB ' ' A' ' 87' ' ' ARG . 0.8 OUTLIER -78.7 -17.09 13.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-O 120.822 0.344 . . . . 0.0 111.625 -179.89 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 113' ' ' ALA . . . . . 0.428 ' HA ' HG12 ' A' ' 86' ' ' ILE . . . -58.08 -30.46 66.25 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.937 0.398 . . . . 0.0 110.827 179.961 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 114' ' ' GLU . . . . . 0.411 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 14.5 pt-20 -61.56 -46.84 88.21 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.74 179.687 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 27.9 mtm-85 -62.1 -44.59 96.33 Favored 'General case' 0 N--CA 1.451 -0.406 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.082 -179.64 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -52.92 -73.75 0.37 Allowed Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.36 -0.924 . . . . 0.0 112.536 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 167.33 -19.31 0.09 OUTLIER Glycine 0 CA--C 1.52 0.377 0 C-N-CA 121.0 -0.619 . . . . 0.0 112.75 -179.702 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.411 ' N ' ' CG2' ' A' ' 84' ' ' VAL . 0.9 OUTLIER -38.5 129.47 0.36 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.244 0 CA-C-O 121.007 0.432 . . . . 0.0 111.607 -179.862 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -127.63 101.94 6.62 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.603 179.752 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 12.5 p -49.86 117.81 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.013 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 115.91 -14.56 16.77 Favored Glycine 0 CA--C 1.518 0.228 0 C-N-CA 120.854 -0.689 . . . . 0.0 112.333 -179.488 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . 0.409 ' CD2' ' HA ' ' A' ' 157' ' ' PRO . 0.1 OUTLIER -84.65 -165.6 1.23 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.64 0.257 . . . . 0.0 110.54 179.872 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . 0.435 ' N ' ' O ' ' A' ' 156' ' ' MET . 51.6 ttt85 -130.39 102.2 6.07 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.881 0.372 . . . . 0.0 111.445 -179.718 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . 0.439 ' CG2' ' N ' ' A' ' 125' ' ' ILE . 9.1 mt -60.63 157.95 2.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.092 178.86 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 125' ' ' ILE . . . . . 0.445 ' CG1' ' H ' ' A' ' 126' ' ' GLU . 0.7 OUTLIER -154.79 -85.04 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 N-CA-C 113.086 0.773 . . . . 0.0 113.086 -179.708 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . 0.445 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 3.3 mt-10 -84.28 91.21 7.7 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 112.932 0.716 . . . . 0.0 112.932 -178.117 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.434 HD12 ' CG1' ' A' ' 132' ' ' VAL . 1.7 mt -90.88 98.79 8.76 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.146 0 CA-C-N 116.374 -0.376 . . . . 0.0 110.878 178.628 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . 0.422 ' N ' ' O ' ' A' ' 152' ' ' HIS . 45.8 m-20 60.84 26.13 16.0 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.703 -179.848 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 106.98 -16.14 39.55 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.556 -179.841 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -92.35 108.17 19.76 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.909 0.385 . . . . 0.0 110.715 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 27.4 m -74.59 90.9 2.28 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.125 -179.772 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . 0.434 ' CG1' HD12 ' A' ' 127' ' ' ILE . 35.0 m -81.62 4.39 2.02 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.341 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.967 179.904 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 9.8 p -47.81 -32.42 3.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 120.914 0.388 . . . . 0.0 111.253 -179.857 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -124.68 27.69 6.78 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.601 179.313 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 135' ' ' THR . . . . . 0.429 ' CG2' ' HD2' ' A' ' 136' ' ' PRO . 90.6 m -109.5 143.69 28.31 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.982 -179.841 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 136' ' ' PRO . . . . . 0.429 ' HD2' ' CG2' ' A' ' 135' ' ' THR . 80.3 Cg_exo -48.27 164.16 0.21 Allowed 'Trans proline' 0 C--N 1.349 0.565 0 C-N-CA 122.496 2.13 . . . . 0.0 112.483 179.909 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 57.1 p-80 -76.23 -48.45 20.29 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.492 -179.606 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -55.53 -34.66 64.87 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.939 0.4 . . . . 0.0 111.197 -179.636 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 139' ' ' LYS . . . . . 0.456 ' O ' ' CD1' ' A' ' 143' ' ' ILE . 0.8 OUTLIER -64.43 -47.47 78.98 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.021 -179.831 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . 0.455 ' CG2' HG23 ' A' ' 99' ' ' VAL . 8.7 mt -59.18 -46.5 92.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 121.155 0.503 . . . . 0.0 110.553 -179.868 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 54.1 t -59.68 -32.45 49.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.057 179.013 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 5.6 t-160 -61.58 -53.44 56.31 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.909 179.738 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . 0.456 ' CD1' ' O ' ' A' ' 139' ' ' LYS . 4.2 mp -53.06 -56.95 5.62 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.468 0 CA-C-O 121.203 0.525 . . . . 0.0 110.455 179.494 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.599 HD21 HG12 ' A' ' 151' ' ' ILE . 1.6 mt -63.3 -29.82 71.07 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.414 -0.812 . . . . 0.0 110.455 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 4.0 m -69.66 -28.47 65.9 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 178.773 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 4.6 m-80 -129.67 35.42 4.19 Favored 'General case' 0 CA--C 1.528 0.128 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.227 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 147' ' ' ALA . . . . . 0.442 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . -101.05 -33.27 10.22 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.945 0.402 . . . . 0.0 111.28 -179.917 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . 0.425 ' CG2' ' O ' ' A' ' 147' ' ' ALA . 35.5 m 44.44 -173.63 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.527 -0.76 . . . . 0.0 111.849 -179.877 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 50.78 -148.67 7.42 Favored Glycine 0 C--N 1.332 0.341 0 C-N-CA 120.854 -0.689 . . . . 0.0 112.772 -179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 7.9 mt-10 -89.41 105.33 17.73 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.72 0.295 . . . . 0.0 110.845 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . 0.599 HG12 HD21 ' A' ' 144' ' ' LEU . 0.6 OUTLIER -78.25 111.58 15.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.387 -0.37 . . . . 0.0 111.12 -179.917 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . 0.422 ' O ' ' N ' ' A' ' 128' ' ' ASN . 0.0 OUTLIER -93.29 124.79 37.51 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 178.889 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 153' ' ' MET . . . . . 0.413 ' SD ' ' CG2' ' A' ' 155' ' ' THR . 5.2 tmm? -147.92 151.89 36.62 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.873 0.368 . . . . 0.0 111.79 -178.721 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -111.86 148.14 34.27 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.476 179.644 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 155' ' ' THR . . . . . 0.413 ' CG2' ' SD ' ' A' ' 153' ' ' MET . 37.6 p -145.23 151.32 38.21 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.086 0.47 . . . . 0.0 111.702 -179.755 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 156' ' ' MET . . . . . 0.435 ' O ' ' N ' ' A' ' 123' ' ' ARG . 5.0 ptp -139.43 156.3 71.65 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.295 179.061 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 157' ' ' PRO . . . . . 0.409 ' HA ' ' CD2' ' A' ' 122' ' ' HIS . 12.7 Cg_endo -56.43 120.44 8.31 Favored 'Trans proline' 0 C--N 1.342 0.229 0 C-N-CA 122.5 2.133 . . . . 0.0 112.609 -179.714 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 158' ' ' ALA . . . . . 0.524 ' HB1' HD12 ' A' ' 103' ' ' ILE . . . . . . . . 0 C--O 1.249 1.051 0 CA-C-O 118.308 -0.853 . . . . 0.0 110.995 179.845 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 11.6 p . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.72 0.295 . . . . 0.0 110.969 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 1.4 m -82.2 146.03 29.75 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.87 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 8.8 m -108.3 111.16 22.96 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.188 179.13 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.465 ' HB ' ' HB3' ' A' ' 153' ' ' MET . 49.9 t -90.29 106.13 16.97 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.448 0 CA-C-N 116.024 -0.534 . . . . 0.0 111.078 -179.708 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -107.01 81.55 1.56 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.02 179.134 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.44 HG13 HG11 ' A' ' 84' ' ' VAL . 1.7 mp -81.59 149.09 4.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 121.067 0.46 . . . . 0.0 111.047 -179.235 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.434 ' CB ' HG22 ' A' ' 112' ' ' ILE . 0.3 OUTLIER -109.43 108.8 19.45 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.761 -179.354 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -102.82 104.75 41.12 Favored Pre-proline 0 C--N 1.33 -0.257 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.812 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' PRO . . . . . 0.418 ' HG2' ' CG ' ' A' ' 93' ' ' TYR . 37.9 Cg_endo -66.46 -49.21 1.88 Allowed 'Trans proline' 0 C--N 1.347 0.479 0 C-N-CA 122.341 2.027 . . . . 0.0 112.546 -179.814 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -136.2 178.95 6.66 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.157 -179.86 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 25.5 mt -77.64 -19.89 54.74 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.194 -179.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 2.9 ptt180 -96.85 23.26 7.29 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.48 -0.327 . . . . 0.0 111.158 -179.895 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . 0.418 ' CG ' ' HG2' ' A' ' 89' ' ' PRO . 16.8 m-85 -120.15 92.3 3.74 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.942 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -59.49 165.92 2.63 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.049 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 2.4 mp -82.63 -37.46 24.91 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.709 179.836 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 96.11 50.85 1.84 Allowed Glycine 0 C--N 1.33 0.229 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.84 179.653 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 1.3 p90 -160.58 -172.92 3.72 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.905 0.383 . . . . 0.0 111.077 179.873 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.424 ' O ' ' HA ' ' A' ' 104' ' ' ILE . 6.4 t -135.71 128.64 31.34 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.458 179.757 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.43 ' CG1' ' CG2' ' A' ' 141' ' ' VAL . 9.9 p -109.79 131.59 60.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.918 0.389 . . . . 0.0 111.675 -179.525 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 13.0 mt-30 -123.33 88.32 2.9 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.908 -0.587 . . . . 0.0 109.527 178.842 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 4.6 m120 56.59 18.97 3.9 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.932 -178.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 128.68 -41.43 1.57 Allowed Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.854 -0.688 . . . . 0.0 112.572 179.835 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.528 HG12 ' CB ' ' A' ' 158' ' ' ALA . 21.0 mt -77.42 133.38 30.8 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-O 121.061 0.457 . . . . 0.0 111.678 -179.361 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.424 ' HA ' ' O ' ' A' ' 98' ' ' SER . 4.5 mp -93.14 137.57 22.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.609 179.487 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 53.5 t -108.89 -75.39 0.63 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.094 -179.576 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 2.7 m -90.6 124.3 34.93 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.052 -179.826 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.409 ' CD1' HG13 ' A' ' 118' ' ' VAL . 1.1 tt -130.91 110.06 11.0 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.646 179.857 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -64.63 150.12 47.62 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.786 -179.905 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -91.96 45.53 1.22 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.164 0.507 . . . . 0.0 110.619 179.79 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -153.2 -33.81 0.03 OUTLIER Glycine 0 N--CA 1.45 -0.419 0 CA-C-N 115.617 -0.72 . . . . 0.0 112.283 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . 0.45 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -49.39 166.53 0.31 Allowed Glycine 0 C--N 1.333 0.411 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.431 179.812 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . 0.434 HG22 ' CB ' ' A' ' 87' ' ' ARG . 0.8 OUTLIER -78.86 -19.44 13.04 Favored 'Isoleucine or valine' 0 C--O 1.237 0.404 0 CA-C-O 120.822 0.344 . . . . 0.0 111.835 -179.652 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 113' ' ' ALA . . . . . . . . . . . . . . . -58.12 -30.38 66.26 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.939 0.399 . . . . 0.0 110.529 179.796 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 114' ' ' GLU . . . . . 0.45 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 20.2 pt-20 -59.34 -44.98 92.58 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.682 179.525 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 7.9 mtm180 -64.55 -47.48 78.6 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.151 -179.48 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -49.04 -74.5 0.26 Allowed Glycine 0 CA--C 1.519 0.297 0 C-N-CA 120.296 -0.954 . . . . 0.0 112.744 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 175.45 -14.97 0.04 OUTLIER Glycine 0 CA--C 1.52 0.398 0 C-N-CA 120.863 -0.684 . . . . 0.0 113.116 -179.876 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.439 ' HB ' HG13 ' A' ' 84' ' ' VAL . 7.6 p -35.49 153.19 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.275 0 N-CA-C 112.132 0.419 . . . . 0.0 112.132 -179.727 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 9.5 mmt180 -139.73 138.86 36.29 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.881 179.924 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 19.4 t -71.22 81.5 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.154 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 132.1 41.02 0.2 Allowed Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.664 179.902 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 12.9 m170 -131.64 132.0 43.66 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.843 0.354 . . . . 0.0 110.766 179.856 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . 0.473 ' HB2' ' CB ' ' A' ' 158' ' ' ALA . 0.2 OUTLIER -81.3 92.39 6.37 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.391 -179.768 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . 0.468 HG22 ' CG2' ' A' ' 132' ' ' VAL . 9.0 mt -46.16 156.7 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.164 178.753 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 125' ' ' ILE . . . . . 0.437 ' CG1' ' H ' ' A' ' 126' ' ' GLU . 0.6 OUTLIER -153.89 -86.06 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 N-CA-C 112.48 0.548 . . . . 0.0 112.48 -179.497 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . 0.437 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 13.5 mt-10 -77.01 92.64 3.73 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 112.131 0.419 . . . . 0.0 112.131 -178.707 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.517 HD12 HG22 ' A' ' 127' ' ' ILE . 1.2 mt -91.52 98.77 8.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 121.008 0.432 . . . . 0.0 110.991 179.194 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . 0.423 ' N ' ' O ' ' A' ' 152' ' ' HIS . 19.3 p30 48.18 26.51 1.06 Allowed 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.651 -0.704 . . . . 0.0 112.133 179.752 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 125.2 -26.22 5.59 Favored Glycine 0 C--N 1.332 0.357 0 C-N-CA 120.239 -0.981 . . . . 0.0 113.878 178.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -100.03 114.02 27.02 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 117.27 0.535 . . . . 0.0 111.428 -179.497 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 12.0 t -78.33 101.99 7.48 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.047 179.847 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . 0.468 ' CG2' HG22 ' A' ' 124' ' ' ILE . 21.5 m -83.08 6.94 1.57 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.282 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.825 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 11.1 p -51.91 119.7 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.18 0 CA-C-O 120.958 0.409 . . . . 0.0 110.82 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . 68.45 22.84 7.67 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.751 -179.101 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 135' ' ' THR . . . . . 0.416 ' CG2' ' HD2' ' A' ' 136' ' ' PRO . 28.8 m -99.47 142.05 23.92 Favored Pre-proline 0 C--N 1.328 -0.364 0 CA-C-N 115.669 -0.696 . . . . 0.0 110.702 179.864 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 136' ' ' PRO . . . . . 0.416 ' HD2' ' CG2' ' A' ' 135' ' ' THR . 87.1 Cg_exo -44.97 142.65 5.15 Favored 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 122.628 2.219 . . . . 0.0 112.549 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 6.8 p80 -62.86 -48.05 80.71 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.468 -179.599 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 1.4 tt0 -55.23 -33.44 63.11 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.244 -179.726 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 139' ' ' LYS . . . . . 0.438 ' O ' ' CD1' ' A' ' 143' ' ' ILE . 1.6 tmtp? -66.14 -49.44 67.44 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.933 -179.928 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 8.0 mt -58.82 -45.14 91.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 121.102 0.477 . . . . 0.0 110.405 179.888 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . 0.43 ' CG2' ' CG1' ' A' ' 99' ' ' VAL . 93.3 t -60.78 -32.67 52.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.06 178.794 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 3.8 t-160 -59.9 -52.57 64.87 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.538 179.586 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . 0.438 ' CD1' ' O ' ' A' ' 139' ' ' LYS . 4.1 mp -53.15 -56.85 6.15 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.433 0 CA-C-O 121.197 0.522 . . . . 0.0 110.282 179.253 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.597 HD21 HG12 ' A' ' 151' ' ' ILE . 1.2 mt -61.9 -29.97 70.56 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.315 -0.857 . . . . 0.0 110.45 179.625 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 1.5 m -68.84 -26.73 65.3 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.124 -0.489 . . . . 0.0 109.939 178.549 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 3.8 m-80 -127.41 32.07 5.09 Favored 'General case' 0 C--O 1.232 0.152 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.173 179.796 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 147' ' ' ALA . . . . . 0.444 ' HB2' ' HA ' ' A' ' 144' ' ' LEU . . . -117.62 59.52 0.78 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.819 0.343 . . . . 0.0 111.16 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 28.1 m -54.74 175.7 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.37 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 79.3 -118.62 4.82 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.779 -0.725 . . . . 0.0 112.393 179.912 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -123.8 117.15 24.23 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.714 0.293 . . . . 0.0 110.582 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . 0.597 HG12 HD21 ' A' ' 144' ' ' LEU . 0.9 OUTLIER -89.32 111.87 23.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.365 -179.679 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . 0.423 ' O ' ' N ' ' A' ' 128' ' ' ASN . 6.4 m-70 -94.83 120.02 34.36 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 178.357 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 153' ' ' MET . . . . . 0.465 ' HB3' ' HB ' ' A' ' 84' ' ' VAL . 27.4 ttp -139.86 162.93 33.97 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 112.44 0.533 . . . . 0.0 112.44 -178.106 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 6.1 mttp -129.96 141.3 50.79 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.226 -0.897 . . . . 0.0 109.831 179.276 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 4.7 p -139.61 147.4 41.05 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.948 0.404 . . . . 0.0 111.726 -179.174 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 156' ' ' MET . . . . . 0.448 ' CB ' ' CD ' ' A' ' 157' ' ' PRO . 1.0 OUTLIER -113.75 -179.78 0.67 Allowed Pre-proline 0 C--N 1.328 -0.368 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.24 179.59 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 157' ' ' PRO . . . . . 0.448 ' CD ' ' CB ' ' A' ' 156' ' ' MET . 89.3 Cg_endo -85.11 112.09 1.41 Allowed 'Trans proline' 0 N--CA 1.462 -0.375 0 C-N-CA 122.493 2.128 . . . . 0.0 112.558 -179.883 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 158' ' ' ALA . . . . . 0.528 ' CB ' HG12 ' A' ' 103' ' ' ILE . . . . . . . . 0 C--O 1.249 1.074 0 CA-C-O 118.141 -0.933 . . . . 0.0 111.092 179.864 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 29.6 t . . . . . 0 C--O 1.232 0.137 0 CA-C-O 120.719 0.295 . . . . 0.0 111.062 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 1.6 m -104.64 145.79 29.84 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.994 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 91.7 m -107.05 111.09 23.39 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.049 -0.523 . . . . 0.0 109.917 178.92 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.469 HG11 ' CD1' ' A' ' 86' ' ' ILE . 33.5 t -93.15 105.94 17.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.696 -179.415 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 4.2 tt -102.77 83.28 2.23 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.21 -0.45 . . . . 0.0 109.823 179.047 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.52 HG12 ' HA ' ' A' ' 113' ' ' ALA . 2.0 mt -81.7 132.46 31.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-O 121.096 0.474 . . . . 0.0 111.389 -178.932 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.446 ' CB ' HG21 ' A' ' 112' ' ' ILE . 0.0 OUTLIER -89.45 114.01 25.44 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.692 -0.685 . . . . 0.0 110.531 -179.917 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 5.9 mmm180 -104.91 104.4 46.28 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.451 -0.341 . . . . 0.0 111.133 -179.733 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' PRO . . . . . 0.429 ' HG2' ' CE2' ' A' ' 93' ' ' TYR . 29.7 Cg_exo -61.96 -39.81 48.07 Favored 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.581 2.187 . . . . 0.0 112.427 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -153.61 -171.26 3.84 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.939 0.399 . . . . 0.0 111.303 -179.87 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . 0.411 ' CD2' ' CG1' ' A' ' 148' ' ' VAL . 6.0 mt -86.14 -19.23 30.43 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.491 -179.757 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -93.97 21.58 6.55 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.707 0.289 . . . . 0.0 111.344 -179.585 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . 0.429 ' CE2' ' HG2' ' A' ' 89' ' ' PRO . 15.8 m-85 -104.25 175.56 5.45 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.654 179.547 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -128.35 149.71 50.41 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.897 0.38 . . . . 0.0 111.131 -179.876 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . 0.419 ' HB3' ' CE2' ' A' ' 97' ' ' PHE . 4.6 mm? -67.59 -56.55 9.01 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.662 179.799 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 118.1 29.63 1.94 Allowed Glycine 0 C--N 1.333 0.401 0 C-N-CA 120.637 -0.792 . . . . 0.0 112.995 179.424 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . 0.419 ' CE2' ' HB3' ' A' ' 95' ' ' LEU . 47.8 p90 -166.81 165.23 16.36 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.852 0.358 . . . . 0.0 111.374 179.843 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -101.16 138.18 38.54 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.626 179.843 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.411 ' CG1' ' CG2' ' A' ' 141' ' ' VAL . 9.7 p -115.36 132.75 63.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.923 0.392 . . . . 0.0 111.591 -179.716 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 24.6 mt-30 -131.11 89.25 2.71 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.1 179.387 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 44.7 m-80 60.61 16.25 6.4 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.004 -179.436 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . 0.417 ' O ' ' HB ' ' A' ' 124' ' ' ILE . . . 124.87 -36.25 2.9 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.969 -0.634 . . . . 0.0 112.293 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.441 ' CG1' ' HG3' ' A' ' 123' ' ' ARG . 36.7 mt -77.77 134.97 27.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-O 121.067 0.461 . . . . 0.0 111.738 -179.639 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 4.4 mp -90.29 135.48 26.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.519 179.666 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -106.15 -72.18 0.72 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.208 -179.591 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 1.5 m -101.87 142.26 33.45 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.145 -179.691 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.405 ' CD1' HG11 ' A' ' 118' ' ' VAL . 1.2 tt -144.68 124.54 13.44 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.646 179.695 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 19.8 mtp -82.09 149.76 27.86 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.03 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 4.6 mtm-85 -93.25 44.47 1.14 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.213 0.53 . . . . 0.0 110.367 179.649 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -161.03 22.43 0.23 Allowed Glycine 0 N--CA 1.449 -0.447 0 CA-C-N 115.617 -0.72 . . . . 0.0 112.284 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . 0.522 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -110.35 174.2 17.17 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 120.934 -0.651 . . . . 0.0 111.901 179.743 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . 0.446 HG21 ' CB ' ' A' ' 87' ' ' ARG . 0.6 OUTLIER -79.22 -21.94 12.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-O 120.854 0.359 . . . . 0.0 111.585 -179.713 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 113' ' ' ALA . . . . . 0.52 ' HA ' HG12 ' A' ' 86' ' ' ILE . . . -58.35 -30.76 66.99 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.934 0.397 . . . . 0.0 110.549 179.775 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 114' ' ' GLU . . . . . 0.522 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 9.0 pt-20 -59.76 -44.59 93.79 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.753 179.672 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 85.1 mtt180 -65.36 -46.74 78.99 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.32 -179.468 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -48.94 -74.43 0.27 Allowed Glycine 0 CA--C 1.519 0.316 0 C-N-CA 120.302 -0.951 . . . . 0.0 112.709 -179.903 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . 0.433 ' O ' ' C ' ' A' ' 118' ' ' VAL . . . 175.59 -20.46 0.05 OUTLIER Glycine 0 CA--C 1.519 0.283 0 C-N-CA 121.013 -0.613 . . . . 0.0 112.72 -179.902 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.433 ' C ' ' O ' ' A' ' 117' ' ' GLY . 11.0 p -24.91 136.87 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.399 0 N-CA-C 112.575 0.583 . . . . 0.0 112.575 -179.847 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 3.3 ttt180 -134.33 110.69 9.64 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.855 179.902 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 21.0 t -57.11 100.21 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.083 -179.88 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 124.02 40.67 0.44 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.39 -179.83 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . 0.436 ' O ' ' HA ' ' A' ' 103' ' ' ILE . 0.1 OUTLIER -134.91 -167.22 1.95 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.664 0.269 . . . . 0.0 110.657 -179.917 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . 0.488 ' HB2' ' CB ' ' A' ' 158' ' ' ALA . 13.8 ttt180 -137.26 90.44 2.52 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.883 179.976 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . 0.439 HG23 ' CG2' ' A' ' 132' ' ' VAL . 9.4 mt -50.06 156.08 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 N-CA-C 110.158 -0.312 . . . . 0.0 110.158 179.199 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 125' ' ' ILE . . . . . 0.434 ' CG1' ' H ' ' A' ' 126' ' ' GLU . 0.6 OUTLIER -148.59 -84.71 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 N-CA-C 112.171 0.434 . . . . 0.0 112.171 -179.577 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . 0.434 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 12.2 mt-10 -80.34 86.16 5.74 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 112.164 0.431 . . . . 0.0 112.164 -178.999 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.52 HD12 HG23 ' A' ' 127' ' ' ILE . 1.4 mt -89.53 102.43 13.1 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 CA-C-O 120.899 0.381 . . . . 0.0 110.839 179.117 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . 0.449 ' HA ' ' CD2' ' A' ' 152' ' ' HIS . 0.9 OUTLIER 59.97 24.83 13.98 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.077 -0.511 . . . . 0.0 111.109 179.902 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 107.29 -13.43 40.07 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.919 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -97.62 113.07 24.72 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.789 0.328 . . . . 0.0 111.025 -179.878 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 1.2 p -77.44 94.68 4.3 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.019 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . 0.445 ' CG2' HD11 ' A' ' 127' ' ' ILE . 27.1 m -80.14 1.38 2.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.883 -179.879 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 9.2 p -46.79 -38.11 3.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-O 120.907 0.384 . . . . 0.0 111.619 -179.65 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -115.97 28.89 8.32 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.747 179.554 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 135' ' ' THR . . . . . 0.409 ' CG2' ' HD2' ' A' ' 136' ' ' PRO . 97.9 m -116.32 144.61 33.36 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 115.912 -0.585 . . . . 0.0 111.172 -179.834 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 136' ' ' PRO . . . . . 0.409 ' HD2' ' CG2' ' A' ' 135' ' ' THR . 48.9 Cg_exo -55.75 164.29 4.66 Favored 'Trans proline' 0 C--N 1.348 0.516 0 C-N-CA 122.528 2.152 . . . . 0.0 112.245 179.842 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 41.7 p-80 -67.18 -48.9 66.56 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.299 -179.837 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 6.0 tp10 -54.47 -36.66 64.36 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.388 -179.692 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 139' ' ' LYS . . . . . 0.44 ' O ' ' CD1' ' A' ' 143' ' ' ILE . 4.1 mmmt -61.63 -46.54 89.35 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.723 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . 0.452 HD11 HG23 ' A' ' 140' ' ' ILE . 16.8 mt -58.86 -46.03 91.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.581 -179.909 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . 0.411 ' CG2' ' CG1' ' A' ' 99' ' ' VAL . 93.7 t -59.8 -32.42 49.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.089 179.086 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -61.77 -54.0 48.33 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.834 179.764 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . 0.44 ' CD1' ' O ' ' A' ' 139' ' ' LYS . 4.3 mp -52.88 -56.44 7.56 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.454 0 CA-C-O 121.194 0.521 . . . . 0.0 110.312 179.413 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.685 HD21 HG12 ' A' ' 151' ' ' ILE . 2.2 mt -63.0 -29.92 71.2 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.294 -0.866 . . . . 0.0 110.361 179.83 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 15.5 t -69.83 -30.14 67.58 Favored 'General case' 0 N--CA 1.453 -0.289 0 CA-C-N 116.302 -0.408 . . . . 0.0 109.933 178.676 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 3.0 m-80 -125.65 34.66 4.86 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.864 179.722 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 147' ' ' ALA . . . . . 0.437 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . -100.3 -39.33 8.07 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.036 0.446 . . . . 0.0 111.585 -179.68 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . 0.416 ' CG2' ' O ' ' A' ' 147' ' ' ALA . 24.8 m 44.86 -171.38 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.488 -0.778 . . . . 0.0 111.662 -179.88 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 55.76 -135.35 48.88 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.569 -179.813 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 27.9 mt-10 -107.69 101.24 10.56 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.839 0.352 . . . . 0.0 110.761 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . 0.685 HG12 HD21 ' A' ' 144' ' ' LEU . 0.5 OUTLIER -76.07 111.76 12.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.189 -179.768 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . 0.449 ' CD2' ' HA ' ' A' ' 128' ' ' ASN . 0.8 OUTLIER -98.94 115.13 28.2 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 178.241 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 153' ' ' MET . . . . . 0.447 ' HB3' ' HB ' ' A' ' 84' ' ' VAL . 13.1 ttp -123.17 163.3 20.86 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.318 0.58 . . . . 0.0 112.139 -178.064 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -128.97 139.39 52.12 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.118 -0.946 . . . . 0.0 109.454 179.077 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 155' ' ' THR . . . . . 0.4 ' HA ' ' HA ' ' A' ' 124' ' ' ILE . 10.4 p -136.0 143.48 44.81 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.125 0.488 . . . . 0.0 111.738 -179.253 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 156' ' ' MET . . . . . 0.465 ' O ' ' CB ' ' A' ' 123' ' ' ARG . 8.9 mtp -132.64 149.66 73.65 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 115.28 -0.873 . . . . 0.0 110.298 179.646 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 77.2 Cg_exo -47.96 116.8 2.11 Favored 'Trans proline' 0 C--N 1.343 0.286 0 C-N-CA 122.37 2.047 . . . . 0.0 112.713 -179.834 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 158' ' ' ALA . . . . . 0.488 ' CB ' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.248 1.019 0 CA-C-O 118.317 -0.849 . . . . 0.0 110.958 179.837 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 35.0 t . . . . . 0 C--O 1.232 0.133 0 CA-C-O 120.71 0.29 . . . . 0.0 110.936 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.8 m -117.3 134.56 54.67 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.867 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 3.5 m -94.58 111.27 23.03 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.128 179.314 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.453 HG12 HG13 ' A' ' 86' ' ' ILE . 63.7 t -82.77 106.2 13.35 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.938 -179.249 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -106.83 80.81 1.48 Allowed 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 178.491 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.455 HG12 ' HA ' ' A' ' 113' ' ' ALA . 3.3 mt -81.53 136.02 23.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-O 121.252 0.549 . . . . 0.0 111.945 -178.195 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.45 148.44 22.77 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.368 -0.833 . . . . 0.0 110.194 179.685 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -155.05 102.91 2.27 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.595 -0.275 . . . . 0.0 110.96 -179.819 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 67.3 Cg_endo -74.06 -24.59 14.78 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.514 2.143 . . . . 0.0 112.494 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -149.59 -166.94 2.69 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.914 0.388 . . . . 0.0 111.236 -179.786 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 4.2 mt -96.54 -44.4 7.18 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.349 -179.598 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -58.06 -18.77 26.77 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.96 -0.564 . . . . 0.0 111.634 -179.436 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 38.4 m-85 -88.2 87.71 7.4 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.805 179.833 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -66.42 -177.83 0.6 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.079 -179.948 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 6.5 mp -94.74 -56.18 2.86 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.771 179.945 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 98.06 71.07 1.01 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.848 179.745 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 14.0 p90 -166.27 162.4 17.34 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.918 0.389 . . . . 0.0 111.01 179.916 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.418 ' O ' ' HA ' ' A' ' 104' ' ' ILE . 1.5 m -106.18 120.49 41.96 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.607 179.724 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.427 ' CG1' ' CG2' ' A' ' 141' ' ' VAL . 8.4 p -109.78 139.05 34.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.448 -179.697 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -135.87 89.15 2.46 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.309 179.491 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 27.2 m120 58.26 18.91 5.78 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.174 -179.529 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 126.73 -38.16 2.25 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.575 179.884 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.491 HG12 ' CB ' ' A' ' 158' ' ' ALA . 31.8 mt -76.88 141.9 15.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 121.034 0.445 . . . . 0.0 111.452 -179.611 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.418 ' HA ' ' O ' ' A' ' 98' ' ' SER . 5.2 mp -109.54 130.01 63.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.863 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 1.8 m -123.52 28.97 6.78 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.969 -179.872 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -178.19 141.24 0.24 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.772 179.988 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -159.09 107.63 1.86 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.844 -179.826 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 2.8 ttp -68.13 113.14 5.53 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.74 179.918 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 26.1 mtt180 -58.81 86.49 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.798 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 163.79 -33.97 0.29 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.913 -0.66 . . . . 0.0 112.012 -179.818 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . 0.415 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -61.13 171.43 7.8 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.193 179.693 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -78.64 -16.93 13.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 120.777 0.323 . . . . 0.0 111.477 -179.789 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 113' ' ' ALA . . . . . 0.455 ' HA ' HG12 ' A' ' 86' ' ' ILE . . . -58.12 -30.5 66.35 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.056 0.455 . . . . 0.0 110.707 179.882 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 114' ' ' GLU . . . . . 0.415 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 21.7 pt-20 -62.0 -46.51 88.9 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.768 -0.651 . . . . 0.0 111.105 179.823 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.4 ' N ' ' CG ' ' A' ' 114' ' ' GLU . 25.2 mtt-85 -62.75 -46.16 89.33 Favored 'General case' 0 N--CA 1.452 -0.347 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.142 -179.378 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -50.29 -74.05 0.31 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.338 -0.934 . . . . 0.0 112.578 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . 0.406 ' O ' ' C ' ' A' ' 118' ' ' VAL . . . 175.97 -27.4 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.736 -179.782 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.444 ' CG2' HG13 ' A' ' 84' ' ' VAL . 12.0 t -31.25 102.04 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 CA-C-O 120.993 0.425 . . . . 0.0 111.8 -179.722 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -104.13 123.89 48.09 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.643 179.765 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 21.4 t -53.76 99.99 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.188 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 120.7 14.67 5.15 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.934 -0.651 . . . . 0.0 112.79 -179.879 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 14.0 m170 -115.61 132.89 56.49 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.744 0.307 . . . . 0.0 110.626 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . 0.428 ' HB3' ' CB ' ' A' ' 158' ' ' ALA . 13.1 ptt180 -84.55 91.85 7.97 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.677 -179.734 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . 0.512 HG22 ' CG2' ' A' ' 132' ' ' VAL . 19.1 mt -48.09 157.85 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.333 -0.133 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 178.72 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 125' ' ' ILE . . . . . 0.423 ' CG1' ' H ' ' A' ' 126' ' ' GLU . 0.6 OUTLIER -150.73 -83.37 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 N-CA-C 113.064 0.765 . . . . 0.0 113.064 -179.008 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . 0.423 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 0.6 OUTLIER -75.62 81.85 2.62 Favored 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 112.695 0.628 . . . . 0.0 112.695 -178.247 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.475 ' HA ' ' HB3' ' A' ' 153' ' ' MET . 1.7 mt -91.02 95.25 5.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.931 0.395 . . . . 0.0 111.062 179.015 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . 0.442 ' N ' ' O ' ' A' ' 152' ' ' HIS . 33.0 m-20 57.76 39.93 26.72 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.934 179.966 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 91.51 -4.18 79.56 Favored Glycine 0 CA--C 1.519 0.329 0 C-N-CA 120.632 -0.794 . . . . 0.0 112.813 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 2.9 tt0 -104.08 107.51 18.44 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.824 0.345 . . . . 0.0 110.836 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 26.0 p -75.6 92.01 2.9 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.093 -179.824 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . 0.512 ' CG2' HG22 ' A' ' 124' ' ' ILE . 31.4 m -74.74 -3.67 4.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.724 179.838 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . 0.41 ' HB ' ' CG2' ' A' ' 125' ' ' ILE . 9.0 p -43.79 -44.6 1.87 Allowed 'Isoleucine or valine' 0 C--O 1.231 0.111 0 CA-C-O 120.806 0.336 . . . . 0.0 111.804 -179.775 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 134' ' ' ALA . . . . . 0.403 ' N ' ' CG1' ' A' ' 133' ' ' VAL . . . -113.37 30.24 7.36 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.958 179.906 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 91.6 m -115.15 140.47 25.71 Favored Pre-proline 0 C--N 1.33 -0.244 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.015 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 136' ' ' PRO . . . . . . . . . . . . . 7.6 Cg_endo -50.33 164.18 0.53 Allowed 'Trans proline' 0 C--N 1.347 0.494 0 C-N-CA 122.64 2.226 . . . . 0.0 112.244 179.841 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 137' ' ' HIS . . . . . 0.439 ' CD2' ' N ' ' A' ' 138' ' ' GLU . 32.9 p-80 -72.77 -46.69 52.03 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.606 -179.5 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . 0.439 ' N ' ' CD2' ' A' ' 137' ' ' HIS . 16.7 mt-10 -53.69 -36.69 62.46 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.396 -179.59 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 139' ' ' LYS . . . . . 0.456 ' O ' ' CD1' ' A' ' 143' ' ' ILE . 6.7 tmtm? -62.93 -47.02 85.04 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.927 -179.816 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 8.6 mt -58.41 -44.71 89.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.523 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . 0.427 ' CG2' ' CG1' ' A' ' 99' ' ' VAL . 93.1 t -60.78 -32.46 52.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.107 178.856 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -61.46 -52.32 65.01 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.641 179.558 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . 0.474 ' O ' ' N ' ' A' ' 147' ' ' ALA . 4.4 mp -53.23 -56.67 7.1 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.395 0 CA-C-O 121.098 0.475 . . . . 0.0 110.205 179.422 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.518 ' CD2' HG12 ' A' ' 151' ' ' ILE . 4.9 mt -62.31 -30.31 71.06 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.518 -0.764 . . . . 0.0 110.326 179.506 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 34.5 t -70.09 -28.31 65.31 Favored 'General case' 0 N--CA 1.453 -0.283 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.117 178.901 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 10.3 m120 -131.71 37.4 3.65 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.082 179.808 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 147' ' ' ALA . . . . . 0.474 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . -99.79 -44.71 5.99 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.094 0.473 . . . . 0.0 111.512 -179.68 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . 0.426 ' CG2' ' O ' ' A' ' 147' ' ' ALA . 32.4 m 45.96 -174.68 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 115.321 -0.854 . . . . 0.0 111.788 -179.684 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 59.64 -108.07 1.54 Allowed Glycine 0 N--CA 1.453 -0.214 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.361 -179.819 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 46.1 mt-10 -136.81 114.1 10.8 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.778 0.323 . . . . 0.0 110.856 179.892 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . 0.518 HG12 ' CD2' ' A' ' 144' ' ' LEU . 1.5 mt -82.84 112.0 19.96 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.139 -179.912 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . 0.442 ' O ' ' N ' ' A' ' 128' ' ' ASN . 0.1 OUTLIER -99.09 115.88 30.01 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.978 -0.556 . . . . 0.0 109.82 179.04 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 153' ' ' MET . . . . . 0.475 ' HB3' ' HA ' ' A' ' 127' ' ' ILE . 0.0 OUTLIER -144.64 177.83 8.41 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.548 0.69 . . . . 0.0 111.751 -179.048 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 14.4 mttp -139.43 152.66 47.23 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 114.633 -1.167 . . . . 0.0 109.977 179.546 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 155' ' ' THR . . . . . 0.437 HG21 HG23 ' A' ' 84' ' ' VAL . 2.0 p -142.99 150.4 39.59 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.195 0.522 . . . . 0.0 111.888 -179.488 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 156' ' ' MET . . . . . 0.423 ' CB ' ' CD ' ' A' ' 157' ' ' PRO . 2.3 mtp -118.69 178.93 0.94 Allowed Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 115.235 -0.893 . . . . 0.0 109.898 179.343 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 157' ' ' PRO . . . . . 0.423 ' CD ' ' CB ' ' A' ' 156' ' ' MET . 89.9 Cg_endo -86.45 106.16 0.75 Allowed 'Trans proline' 0 N--CA 1.459 -0.555 0 C-N-CA 122.44 2.094 . . . . 0.0 112.493 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 158' ' ' ALA . . . . . 0.491 ' CB ' HG12 ' A' ' 103' ' ' ILE . . . . . . . . 0 C--O 1.249 1.057 0 CA-C-O 118.253 -0.879 . . . . 0.0 111.052 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 11.2 p . . . . . 0 CA--C 1.527 0.094 0 CA-C-O 120.706 0.288 . . . . 0.0 110.77 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.5 m -104.26 146.09 29.29 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.925 0.393 . . . . 0.0 111.203 -179.709 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' THR . . . . . 0.431 HG22 ' CE1' ' A' ' 152' ' ' HIS . 11.6 m -110.17 111.09 22.21 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.002 178.972 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.504 HG11 HG13 ' A' ' 86' ' ' ILE . 72.6 t -86.23 106.5 15.66 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.896 -179.164 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . 0.413 ' HG ' ' CD2' ' A' ' 152' ' ' HIS . 4.2 tt -106.34 81.34 1.6 Allowed 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 178.497 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.527 HG12 ' HA ' ' A' ' 113' ' ' ALA . 1.2 mt -81.46 140.19 16.9 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 121.167 0.508 . . . . 0.0 111.674 -178.777 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.423 ' HG3' ' CG2' ' A' ' 112' ' ' ILE . 0.0 OUTLIER -99.01 145.9 26.6 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.551 -0.749 . . . . 0.0 110.27 179.873 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 3.8 mtt-85 -139.09 102.26 7.53 Favored Pre-proline 0 C--N 1.331 -0.232 0 CA-C-N 116.463 -0.335 . . . . 0.0 110.982 -179.782 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' PRO . . . . . 0.419 ' HB2' ' CE1' ' A' ' 93' ' ' TYR . 52.5 Cg_exo -55.09 -57.04 1.88 Allowed 'Trans proline' 0 C--N 1.347 0.478 0 C-N-CA 122.465 2.11 . . . . 0.0 112.35 -179.858 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.7 t0 -139.83 -168.67 2.55 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.869 0.366 . . . . 0.0 111.174 -179.86 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -83.32 -30.82 27.21 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.04 -179.924 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -68.13 -11.02 58.4 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.62 -179.694 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . 0.419 ' CE1' ' HB2' ' A' ' 89' ' ' PRO . 25.2 m-85 -82.88 178.17 8.3 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.507 -0.315 . . . . 0.0 110.784 179.839 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 8.3 mp0 -136.57 164.8 27.35 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.068 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -72.51 -60.21 2.34 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.781 179.847 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 121.4 14.0 5.06 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.657 -0.783 . . . . 0.0 113.174 179.797 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . 0.419 ' CD2' HG22 ' A' ' 104' ' ' ILE . 30.5 p90 -160.45 175.12 13.12 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.958 0.408 . . . . 0.0 111.197 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -118.42 141.19 48.79 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.009 -0.542 . . . . 0.0 110.771 179.86 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.433 ' CG1' ' CG2' ' A' ' 141' ' ' VAL . 6.3 p -109.98 136.0 47.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 121.1 0.476 . . . . 0.0 111.427 -179.858 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -126.92 89.78 3.04 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.048 179.457 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 2.5 m-20 62.27 12.2 5.01 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.814 -179.083 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 129.7 -37.65 2.13 Favored Glycine 0 N--CA 1.445 -0.716 0 C-N-CA 121.095 -0.574 . . . . 0.0 112.007 -179.871 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.456 HG12 ' CB ' ' A' ' 158' ' ' ALA . 41.8 mt -79.2 135.67 25.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-O 121.093 0.473 . . . . 0.0 111.801 -179.469 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.419 HG22 ' CD2' ' A' ' 97' ' ' PHE . 3.8 mp -91.54 141.27 14.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.825 179.799 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 36.9 m -116.82 -81.1 0.61 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.285 -179.556 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 4.6 m -77.13 139.16 39.88 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.991 -179.78 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 9.5 tt -156.38 120.75 4.5 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.636 179.867 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 19.2 mtm -90.75 129.0 36.87 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.985 -179.889 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 2.3 mpt_? -66.13 76.71 0.09 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.644 179.82 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 178.23 -34.8 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.927 -0.654 . . . . 0.0 112.126 -179.843 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . 0.408 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -55.31 171.54 1.46 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.286 179.697 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . 0.423 ' CG2' ' HG3' ' A' ' 87' ' ' ARG . 0.5 OUTLIER -78.66 -17.59 13.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-O 120.82 0.343 . . . . 0.0 111.505 -179.778 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 113' ' ' ALA . . . . . 0.527 ' HA ' HG12 ' A' ' 86' ' ' ILE . . . -58.4 -30.78 67.1 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.87 0.367 . . . . 0.0 110.633 179.804 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 114' ' ' GLU . . . . . 0.408 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 10.9 pt-20 -60.02 -45.72 91.88 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.691 179.579 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 1.6 mmm180 -62.93 -49.08 76.18 Favored 'General case' 0 N--CA 1.452 -0.359 0 CA-C-N 115.843 -0.617 . . . . 0.0 111.132 -179.473 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . 0.405 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -49.52 -74.33 0.28 Allowed Glycine 0 CA--C 1.519 0.318 0 C-N-CA 120.224 -0.989 . . . . 0.0 112.532 179.936 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . 0.42 ' O ' ' C ' ' A' ' 118' ' ' VAL . . . -179.81 -30.67 0.06 OUTLIER Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 121.124 -0.56 . . . . 0.0 112.181 179.864 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.463 ' N ' ' CG2' ' A' ' 84' ' ' VAL . 73.6 t -26.43 123.7 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.384 0 C-N-CA 122.956 0.503 . . . . 0.0 112.283 -179.771 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 14.1 mtt-85 -123.29 118.42 27.52 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.54 179.779 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 21.5 t -52.2 93.23 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.239 -179.919 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 122.78 37.9 0.6 Allowed Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.933 -0.651 . . . . 0.0 112.332 -179.861 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . 0.416 ' O ' ' HA ' ' A' ' 103' ' ' ILE . 10.3 m170 -138.77 169.25 18.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.753 0.311 . . . . 0.0 110.805 179.933 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . 0.462 ' HB2' ' CB ' ' A' ' 158' ' ' ALA . 1.4 ttm180 -108.42 143.89 36.75 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.201 -179.877 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . 0.498 HG21 ' CG2' ' A' ' 132' ' ' VAL . 26.8 mt -101.29 155.36 4.6 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 178.465 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 125' ' ' ILE . . . . . 0.454 ' CG1' ' H ' ' A' ' 126' ' ' GLU . 0.7 OUTLIER -147.45 -84.31 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 N-CA-C 113.208 0.818 . . . . 0.0 113.208 -178.561 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . 0.454 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 6.1 mt-10 -79.87 85.34 5.53 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 112.626 0.602 . . . . 0.0 112.626 -178.093 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.465 ' HA ' ' CB ' ' A' ' 153' ' ' MET . 1.7 mt -91.18 103.35 14.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 121.025 0.441 . . . . 0.0 111.17 179.094 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 33.4 m-80 55.65 25.4 8.08 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.106 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 107.65 -13.91 38.69 Favored Glycine 0 CA--C 1.518 0.273 0 C-N-CA 120.624 -0.798 . . . . 0.0 112.775 179.895 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 22.3 tt0 -95.95 113.94 25.61 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.849 0.357 . . . . 0.0 110.875 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -77.54 91.4 3.95 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.141 -179.902 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . 0.498 ' CG2' HG21 ' A' ' 124' ' ' ILE . 32.4 m -75.41 -2.57 4.11 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.257 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.818 179.891 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 8.2 p -46.24 -38.3 3.22 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.142 0 CA-C-O 120.858 0.361 . . . . 0.0 111.445 -179.758 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -117.6 28.57 8.36 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.787 179.401 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 135' ' ' THR . . . . . 0.427 ' CG2' ' HD2' ' A' ' 136' ' ' PRO . 86.0 m -111.48 141.88 25.41 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 115.777 -0.647 . . . . 0.0 111.105 -179.772 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 136' ' ' PRO . . . . . 0.427 ' HD2' ' CG2' ' A' ' 135' ' ' THR . 9.5 Cg_endo -51.87 164.23 1.13 Allowed 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.8 2.333 . . . . 0.0 112.215 179.742 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 12.4 p80 -70.47 -47.64 59.6 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.376 -179.785 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -55.6 -32.74 63.33 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.249 -179.707 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 139' ' ' LYS . . . . . 0.458 ' O ' ' CD1' ' A' ' 143' ' ' ILE . 0.4 OUTLIER -65.08 -50.27 66.78 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.833 -179.917 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 8.8 mt -58.68 -43.46 87.68 Favored 'Isoleucine or valine' 0 C--O 1.235 0.311 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.577 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . 0.433 ' CG2' ' CG1' ' A' ' 99' ' ' VAL . 61.8 t -61.42 -32.93 54.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.292 179.189 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 0.5 OUTLIER -62.66 -53.47 54.05 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.968 179.924 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . 0.458 ' CD1' ' O ' ' A' ' 139' ' ' LYS . 4.3 mp -53.04 -57.23 4.96 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.393 0 CA-C-O 121.162 0.506 . . . . 0.0 110.371 179.558 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.556 HD21 HG12 ' A' ' 151' ' ' ILE . 1.8 mt -62.16 -30.04 70.77 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.417 -0.81 . . . . 0.0 110.42 179.557 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 9.2 t -68.16 -26.7 65.89 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.179 -0.464 . . . . 0.0 109.872 178.567 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 4.1 m-80 -131.19 35.01 3.95 Favored 'General case' 0 CA--C 1.528 0.107 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.199 179.918 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 147' ' ' ALA . . . . . 0.408 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . -114.29 48.75 1.07 Allowed 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.855 0.36 . . . . 0.0 111.304 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 29.8 m -54.09 150.35 1.76 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.285 -179.953 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 108.68 -107.72 2.51 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.445 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 40.9 mt-10 -138.05 104.32 5.2 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.711 0.291 . . . . 0.0 110.889 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . 0.556 HG12 HD21 ' A' ' 144' ' ' LEU . 1.2 mt -78.64 111.7 15.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.065 -179.91 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . 0.431 ' CE1' HG22 ' A' ' 83' ' ' THR . 0.6 OUTLIER -103.82 115.66 30.88 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.999 -0.546 . . . . 0.0 109.828 179.129 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 153' ' ' MET . . . . . 0.465 ' CB ' ' HA ' ' A' ' 127' ' ' ILE . 1.9 ptt? -145.91 167.08 24.15 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.089 0.471 . . . . 0.0 111.876 -179.077 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -115.06 153.28 30.99 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.625 -0.716 . . . . 0.0 109.899 179.234 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 155' ' ' THR . . . . . 0.42 HG23 ' HA ' ' A' ' 124' ' ' ILE . 51.8 p -142.69 140.29 31.48 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.235 0.54 . . . . 0.0 111.829 -179.302 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 156' ' ' MET . . . . . 0.41 ' N ' ' O ' ' A' ' 123' ' ' ARG . 0.2 OUTLIER -126.46 152.45 74.23 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 115.329 -0.85 . . . . 0.0 109.947 179.309 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 12.6 Cg_endo -56.16 115.8 2.72 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.497 2.131 . . . . 0.0 112.496 -179.784 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 158' ' ' ALA . . . . . 0.462 ' CB ' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.248 0.992 0 CA-C-O 118.234 -0.889 . . . . 0.0 110.943 179.733 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 37.0 t . . . . . 0 C--O 1.232 0.135 0 CA-C-O 120.772 0.32 . . . . 0.0 110.995 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.3 m -111.12 138.4 47.6 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.85 179.934 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 9.5 m -98.63 111.14 23.6 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.166 179.266 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.501 ' HB ' ' HG2' ' A' ' 153' ' ' MET . 62.0 t -84.95 106.2 14.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.731 -179.432 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . 0.418 HD13 ' CD2' ' A' ' 152' ' ' HIS . 10.2 tt -104.36 83.8 2.11 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 178.431 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.465 HG12 ' HA ' ' A' ' 113' ' ' ALA . 7.3 mt -81.84 130.89 35.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.92 -178.342 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -92.18 124.41 36.24 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.388 -0.823 . . . . 0.0 110.447 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -126.48 120.26 23.29 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 116.451 -0.341 . . . . 0.0 110.874 -179.864 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 62.5 Cg_endo -73.41 -28.65 11.99 Favored 'Trans proline' 0 C--N 1.346 0.425 0 C-N-CA 122.465 2.11 . . . . 0.0 112.16 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -173.07 -169.38 0.54 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.959 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 1.9 mp -80.36 -5.56 56.59 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.556 -179.909 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 2.2 ptm85 -102.76 27.28 7.12 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.861 0.362 . . . . 0.0 111.153 -179.807 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 4.3 m-85 -138.37 81.53 1.86 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.914 179.858 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -60.97 161.85 7.78 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.98 -179.847 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . 0.4 ' CD1' ' HB3' ' A' ' 144' ' ' LEU . 0.5 OUTLIER -79.99 -65.31 1.02 Allowed 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.674 179.897 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 114.34 58.33 0.38 Allowed Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.916 179.512 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . 0.415 ' CE2' HG22 ' A' ' 99' ' ' VAL . 14.2 p90 -165.33 128.49 2.22 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.916 0.389 . . . . 0.0 111.106 179.698 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 6.4 t -71.98 144.09 48.99 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.832 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.45 ' CG1' ' HB ' ' A' ' 140' ' ' ILE . 48.9 t -111.9 136.9 46.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 121.032 0.444 . . . . 0.0 111.648 -179.705 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 4.1 mm-40 -135.72 88.06 2.37 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.722 -0.672 . . . . 0.0 109.507 178.563 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 85.6 m-20 53.57 21.65 2.63 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.985 -178.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . 0.422 ' N ' HD11 ' A' ' 140' ' ' ILE . . . 121.88 -32.83 4.46 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.922 -0.656 . . . . 0.0 112.374 179.902 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.448 HG12 ' CB ' ' A' ' 158' ' ' ALA . 31.2 mt -77.49 128.65 38.01 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 121.003 0.43 . . . . 0.0 111.781 -179.649 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.41 ' CD1' ' CD1' ' A' ' 124' ' ' ILE . 3.6 mp -84.42 144.81 9.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.146 179.296 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 55.9 m -126.51 -80.64 0.61 Allowed 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 112.009 0.374 . . . . 0.0 112.009 -179.205 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 40.3 m -79.17 66.18 4.55 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 112.027 0.38 . . . . 0.0 112.027 -178.797 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.413 ' HB3' ' CG2' ' A' ' 120' ' ' VAL . 14.0 tp -89.12 100.58 13.33 Favored 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 178.859 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 2.0 ptm -81.33 140.51 34.74 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.317 -179.472 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.51 166.74 9.9 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.596 179.697 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 92.79 -41.97 2.69 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.533 -0.842 . . . . 0.0 112.23 -179.732 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . 0.401 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -58.21 168.76 5.25 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.227 179.751 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -78.35 -16.23 13.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.733 0.301 . . . . 0.0 111.768 -179.797 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 113' ' ' ALA . . . . . 0.465 ' HA ' HG12 ' A' ' 86' ' ' ILE . . . -57.52 -30.34 65.07 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 121.015 0.436 . . . . 0.0 110.78 179.853 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 114' ' ' GLU . . . . . 0.401 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 15.3 pt-20 -60.15 -46.69 88.79 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.904 179.56 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 16.2 mtm180 -64.7 -46.38 82.62 Favored 'General case' 0 N--CA 1.453 -0.314 0 CA-C-N 116.009 -0.541 . . . . 0.0 111.127 -179.316 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -50.55 -73.41 0.37 Allowed Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.431 -0.89 . . . . 0.0 112.686 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 171.78 -21.27 0.07 OUTLIER Glycine 0 CA--C 1.519 0.284 0 C-N-CA 121.048 -0.596 . . . . 0.0 112.663 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.436 ' N ' ' CG2' ' A' ' 84' ' ' VAL . 1.2 t -37.95 135.9 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.261 0 CA-C-O 120.98 0.419 . . . . 0.0 111.638 -179.783 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 5.3 mtm180 -136.64 132.18 34.66 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.553 179.64 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 120' ' ' VAL . . . . . 0.413 ' CG2' ' HB3' ' A' ' 107' ' ' LEU . 15.4 t -57.11 89.45 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.852 0.358 . . . . 0.0 110.999 -179.866 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 131.98 -3.32 5.25 Favored Glycine 0 CA--C 1.52 0.375 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.861 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 1.6 m-70 -90.16 127.51 36.12 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-O 120.888 0.375 . . . . 0.0 110.73 179.899 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . 0.446 ' HB2' ' CB ' ' A' ' 158' ' ' ALA . 20.8 ttm180 -82.62 92.35 7.12 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.926 -179.373 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . 0.492 HG22 ' CG2' ' A' ' 132' ' ' VAL . 10.0 mt -50.39 157.56 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.05 178.544 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 125' ' ' ILE . . . . . 0.423 ' CG2' ' HB ' ' A' ' 133' ' ' VAL . 0.6 OUTLIER -150.77 -85.66 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 N-CA-C 112.38 0.511 . . . . 0.0 112.38 -179.349 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . 0.416 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 1.7 mt-10 -75.29 85.12 2.46 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 112.067 0.395 . . . . 0.0 112.067 -178.959 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.517 ' HA ' ' CB ' ' A' ' 153' ' ' MET . 1.3 mt -92.61 102.6 13.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 120.951 0.405 . . . . 0.0 111.312 179.47 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 1.3 m-20 61.83 15.52 7.15 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.596 179.745 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 119.88 -16.95 10.15 Favored Glycine 0 C--N 1.333 0.368 0 C-N-CA 120.401 -0.904 . . . . 0.0 113.338 179.634 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 8.2 pt20 -101.94 123.08 45.24 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 117.091 0.445 . . . . 0.0 111.104 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 48.1 t -81.05 101.68 9.73 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.347 -179.68 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . 0.492 ' CG2' HG22 ' A' ' 124' ' ' ILE . 27.2 m -81.68 2.7 2.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.68 179.691 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . 0.423 ' HB ' ' CG2' ' A' ' 125' ' ' ILE . 8.0 p -44.7 -45.18 2.64 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.133 0 CA-C-O 120.853 0.358 . . . . 0.0 111.697 -179.674 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -112.46 30.22 7.27 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.869 179.73 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 86.2 m -109.28 142.47 25.68 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.942 -179.788 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 136' ' ' PRO . . . . . . . . . . . . . 71.2 Cg_exo -50.73 164.01 0.64 Allowed 'Trans proline' 0 C--N 1.348 0.535 0 C-N-CA 122.583 2.189 . . . . 0.0 112.431 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 28.1 p-80 -72.02 -51.22 22.84 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.161 -179.814 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -55.25 -30.96 61.1 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.986 -179.899 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 139' ' ' LYS . . . . . 0.468 ' O ' ' CD1' ' A' ' 143' ' ' ILE . 0.2 OUTLIER -64.62 -48.65 74.07 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.94 179.998 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . 0.45 ' HB ' ' CG1' ' A' ' 99' ' ' VAL . 5.4 mt -58.76 -45.01 91.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-O 121.048 0.452 . . . . 0.0 110.438 179.973 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 48.4 t -61.21 -32.43 52.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.417 179.24 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 1.6 m-70 -62.19 -53.09 60.32 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.723 179.79 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . 0.468 ' CD1' ' O ' ' A' ' 139' ' ' LYS . 4.2 mp -53.28 -56.27 8.97 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.44 0 CA-C-O 121.207 0.527 . . . . 0.0 110.222 179.157 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.629 HD21 HG12 ' A' ' 151' ' ' ILE . 2.9 mt -62.95 -30.36 71.5 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.466 179.741 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 2.8 m -67.22 -29.9 69.69 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.17 -0.468 . . . . 0.0 109.743 178.738 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 4.4 m-80 -131.13 38.28 3.67 Favored 'General case' 0 C--N 1.333 -0.135 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.625 179.596 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 147' ' ' ALA . . . . . 0.466 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . -90.15 -51.91 5.21 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.246 0.546 . . . . 0.0 111.258 -179.545 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER 57.01 164.61 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-N 115.292 -0.867 . . . . 0.0 111.078 -179.932 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 73.18 -133.41 18.26 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.524 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 -114.39 99.71 7.78 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.788 0.328 . . . . 0.0 110.92 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . 0.629 HG12 HD21 ' A' ' 144' ' ' LEU . 0.6 OUTLIER -68.1 111.9 2.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.987 179.982 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . 0.418 ' CD2' HD13 ' A' ' 85' ' ' LEU . 0.7 OUTLIER -108.31 115.75 30.69 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.251 179.455 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 153' ' ' MET . . . . . 0.517 ' CB ' ' HA ' ' A' ' 127' ' ' ILE . 0.0 OUTLIER -143.62 176.05 9.5 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.208 0.528 . . . . 0.0 111.846 -179.356 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 9.7 mttp -122.76 151.99 41.07 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.416 -0.811 . . . . 0.0 109.487 178.919 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 6.6 p -141.57 141.39 33.5 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.031 0.443 . . . . 0.0 111.598 -179.345 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 156' ' ' MET . . . . . . . . . . . . . 9.6 mtp -125.8 133.52 24.98 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.588 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 82.5 Cg_exo -44.68 120.19 2.66 Favored 'Trans proline' 0 C--N 1.345 0.344 0 C-N-CA 122.558 2.172 . . . . 0.0 112.752 -179.888 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 158' ' ' ALA . . . . . 0.448 ' CB ' HG12 ' A' ' 103' ' ' ILE . . . . . . . . 0 C--O 1.249 1.061 0 CA-C-O 118.181 -0.914 . . . . 0.0 111.061 179.87 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 39.0 t . . . . . 0 C--O 1.232 0.142 0 CA-C-O 120.794 0.331 . . . . 0.0 110.9 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.0 m -123.18 140.93 52.51 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.01 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 20.0 m -97.34 111.37 23.65 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.059 179.134 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.454 HG12 HG13 ' A' ' 86' ' ' ILE . 78.9 t -88.98 105.73 16.15 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.42 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.792 -179.239 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . 0.465 ' O ' ' HA2' ' A' ' 116' ' ' GLY . 0.5 OUTLIER -103.21 83.87 2.26 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 178.395 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.454 HG13 HG12 ' A' ' 84' ' ' VAL . 19.8 mt -80.85 132.51 31.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 121.405 0.621 . . . . 0.0 111.862 -178.306 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.4 ' O ' ' CG2' ' A' ' 112' ' ' ILE . 2.9 mmt180 -79.38 149.01 31.8 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 114.957 -1.02 . . . . 0.0 111.137 -179.477 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . 0.519 ' HB3' ' HA ' ' A' ' 148' ' ' VAL . 2.7 mtt-85 -164.57 97.81 0.89 Allowed Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.846 179.689 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 70.3 Cg_endo -89.26 25.77 0.59 Allowed 'Trans proline' 0 N--CA 1.46 -0.483 0 C-N-CA 122.893 2.396 . . . . 0.0 113.414 -179.296 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 5.6 p-10 -179.03 177.74 0.79 Allowed 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.039 0.447 . . . . 0.0 111.741 179.922 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 6.0 mt -98.42 6.68 47.05 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.692 -0.686 . . . . 0.0 111.486 -179.89 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 8.6 ptt180 -129.18 42.06 3.37 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.853 0.359 . . . . 0.0 111.035 -179.78 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -120.52 126.04 49.37 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.748 179.828 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -86.02 136.6 33.18 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.963 -179.844 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . 0.427 ' CD1' ' HB3' ' A' ' 144' ' ' LEU . 2.2 mp -77.24 -28.28 53.59 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.804 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 75.08 73.17 0.98 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.835 -0.697 . . . . 0.0 112.782 179.622 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -176.14 156.75 1.72 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.806 0.336 . . . . 0.0 111.168 179.766 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.464 ' O ' ' HA ' ' A' ' 104' ' ' ILE . 3.3 t -106.15 133.81 50.27 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.422 179.559 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.417 ' CG1' ' CG2' ' A' ' 141' ' ' VAL . 9.7 p -118.49 134.84 60.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 121.026 0.441 . . . . 0.0 111.459 -179.581 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -131.75 89.24 2.67 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.23 179.405 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 12.1 m120 57.78 18.28 4.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.134 -179.468 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 128.18 -39.83 1.83 Allowed Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.531 179.858 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.421 HG12 ' CB ' ' A' ' 158' ' ' ALA . 26.6 mt -77.3 138.66 20.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 121.006 0.432 . . . . 0.0 111.531 -179.57 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.464 ' HA ' ' O ' ' A' ' 98' ' ' SER . 4.5 mp -99.07 137.83 25.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.911 179.917 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 43.4 t -105.0 -77.98 0.58 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.983 -179.781 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 77.0 p -90.63 119.24 30.71 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.707 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 25.7 tp -112.91 119.3 37.47 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.841 -179.938 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 9.3 mtp -68.13 98.26 0.77 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.975 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -60.86 117.59 5.61 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.826 -179.95 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 97.44 32.5 6.3 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.407 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . 0.491 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -118.61 -160.74 11.56 Favored Glycine 0 N--CA 1.453 -0.216 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.968 -179.789 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . 0.4 ' CG2' ' O ' ' A' ' 87' ' ' ARG . 7.9 mt -80.62 -39.9 18.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-O 121.094 0.473 . . . . 0.0 111.506 -179.924 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 113' ' ' ALA . . . . . 0.406 ' CB ' HG12 ' A' ' 118' ' ' VAL . . . -57.67 -39.29 76.72 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.12 -179.481 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 114' ' ' GLU . . . . . 0.491 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 15.3 pt-20 -62.83 -37.83 88.33 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.503 179.499 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.487 ' N ' ' HG3' ' A' ' 114' ' ' GLU . 54.8 mtt85 -59.2 -46.71 87.71 Favored 'General case' 0 N--CA 1.452 -0.361 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.644 -179.866 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . 0.465 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -56.33 -71.14 0.78 Allowed Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.343 -0.932 . . . . 0.0 112.501 179.719 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 175.04 -22.74 0.06 OUTLIER Glycine 0 CA--C 1.52 0.39 0 C-N-CA 120.788 -0.72 . . . . 0.0 113.064 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.45 ' N ' ' CG2' ' A' ' 84' ' ' VAL . 6.0 p -34.27 146.36 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 N-CA-C 112.128 0.418 . . . . 0.0 112.128 -179.604 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -140.95 153.84 45.81 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.917 -179.925 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 22.0 t -74.7 88.44 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.972 179.9 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 124.01 41.0 0.42 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.921 -0.657 . . . . 0.0 112.295 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 1.2 m170 -135.08 122.68 22.09 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.858 0.361 . . . . 0.0 110.764 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . 0.486 ' HB2' ' CB ' ' A' ' 158' ' ' ALA . 34.9 ttp180 -79.74 93.6 5.6 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.538 -179.731 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . 0.5 HG22 ' CG2' ' A' ' 132' ' ' VAL . 9.2 mt -49.98 158.21 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 178.715 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 125' ' ' ILE . . . . . 0.432 ' N ' ' CG2' ' A' ' 124' ' ' ILE . 0.6 OUTLIER -148.99 -82.7 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 N-CA-C 112.446 0.535 . . . . 0.0 112.446 -179.49 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . 0.427 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 7.1 mt-10 -74.64 80.72 2.01 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 112.361 0.504 . . . . 0.0 112.361 -178.758 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.458 ' CG2' ' CG ' ' A' ' 153' ' ' MET . 2.7 mt -84.55 92.04 3.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 121.05 0.452 . . . . 0.0 111.01 179.259 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . 0.414 ' N ' ' O ' ' A' ' 152' ' ' HIS . 56.9 m-80 58.65 25.26 13.06 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.995 -179.81 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 113.36 -16.96 21.81 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.716 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 6.0 tt0 -94.4 111.15 22.89 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.809 0.338 . . . . 0.0 110.814 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -75.98 93.29 3.24 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.084 -179.822 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . 0.5 ' CG2' HG22 ' A' ' 124' ' ' ILE . 30.6 m -76.39 -1.58 3.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.881 179.835 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 8.7 p -42.94 -44.23 1.22 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.121 0 CA-C-O 120.825 0.345 . . . . 0.0 111.611 -179.653 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -117.24 29.75 7.71 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.772 179.714 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 52.3 m -108.71 142.17 24.87 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.057 -0.519 . . . . 0.0 111.161 -179.844 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 136' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -52.37 164.11 1.45 Allowed 'Trans proline' 0 C--N 1.346 0.442 0 C-N-CA 122.56 2.173 . . . . 0.0 112.284 179.677 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 31.9 p-80 -70.95 -49.81 41.44 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.368 -179.855 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 5.8 tp10 -54.36 -34.79 61.88 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.332 -0.394 . . . . 0.0 111.393 -179.695 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 139' ' ' LYS . . . . . 0.456 ' O ' ' CD1' ' A' ' 143' ' ' ILE . 3.3 tttp -62.76 -47.34 83.94 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.881 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . 0.493 HD13 HG23 ' A' ' 140' ' ' ILE . 15.1 mt -58.59 -45.45 90.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.603 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . 0.417 ' CG2' ' CG1' ' A' ' 99' ' ' VAL . 87.9 t -60.27 -32.5 50.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.326 178.987 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 1.8 t-80 -62.06 -53.56 53.77 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.012 179.774 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . 0.456 ' CD1' ' O ' ' A' ' 139' ' ' LYS . 4.1 mp -52.94 -56.8 6.11 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.463 0 CA-C-O 121.227 0.537 . . . . 0.0 110.265 179.44 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.62 HD21 HG12 ' A' ' 151' ' ' ILE . 1.9 mt -62.44 -30.33 71.16 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.313 -0.858 . . . . 0.0 110.397 179.674 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 27.5 t -67.67 -27.8 67.15 Favored 'General case' 0 N--CA 1.453 -0.29 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.085 178.884 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 7.8 m-80 -133.81 37.34 3.26 Favored 'General case' 0 CA--C 1.529 0.163 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.164 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 147' ' ' ALA . . . . . 0.444 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . -101.46 -37.66 8.34 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.118 0.485 . . . . 0.0 111.301 -179.861 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . 0.519 ' HA ' ' HB3' ' A' ' 88' ' ' ARG . 32.0 m 44.56 -172.67 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.37 -0.832 . . . . 0.0 112.036 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 58.38 -135.14 52.13 Favored Glycine 0 C--N 1.332 0.309 0 C-N-CA 121.035 -0.602 . . . . 0.0 112.704 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 62.2 mm-40 -110.09 91.28 3.59 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.851 0.357 . . . . 0.0 110.449 179.836 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . 0.62 HG12 HD21 ' A' ' 144' ' ' LEU . 0.7 OUTLIER -61.03 111.62 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.49 -179.448 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . 0.414 ' O ' ' N ' ' A' ' 128' ' ' ASN . 4.2 t60 -90.03 115.78 27.57 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 109.168 -0.679 . . . . 0.0 109.168 178.573 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 153' ' ' MET . . . . . 0.458 ' CG ' ' CG2' ' A' ' 127' ' ' ILE . 26.9 mtp -133.62 162.14 32.73 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.422 0.629 . . . . 0.0 112.452 -178.431 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 17.7 mttt -134.04 140.39 46.64 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 114.881 -1.054 . . . . 0.0 108.905 178.673 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 155' ' ' THR . . . . . 0.417 ' CG2' ' CG1' ' A' ' 124' ' ' ILE . 1.6 p -140.32 149.44 42.76 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.241 0.543 . . . . 0.0 112.046 -178.871 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 156' ' ' MET . . . . . . . . . . . . . 4.8 ptp -132.23 156.38 80.17 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 115.207 -0.906 . . . . 0.0 110.139 179.146 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_endo -57.4 120.41 8.31 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.366 2.044 . . . . 0.0 112.639 -179.726 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 158' ' ' ALA . . . . . 0.486 ' CB ' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.249 1.029 0 CA-C-O 118.289 -0.862 . . . . 0.0 111.114 179.876 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 20.2 t . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.741 0.305 . . . . 0.0 111.01 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 1.9 m -115.2 139.03 50.28 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.951 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 8.4 m -95.79 111.31 23.31 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.014 179.091 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.486 HG12 HG13 ' A' ' 86' ' ' ILE . 67.3 t -90.63 105.76 16.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.757 -179.166 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . 0.441 ' O ' ' HA2' ' A' ' 116' ' ' GLY . 6.2 tt -103.0 84.36 2.35 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 178.633 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.486 HG13 HG12 ' A' ' 84' ' ' VAL . 3.6 mt -80.94 128.64 38.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 121.27 0.557 . . . . 0.0 111.864 -178.526 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.41 ' HB2' HG21 ' A' ' 112' ' ' ILE . 0.2 OUTLIER -74.81 153.01 38.94 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.459 179.962 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -148.33 100.1 3.61 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.109 179.845 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' PRO . . . . . 0.408 ' HG2' ' CD2' ' A' ' 93' ' ' TYR . 57.8 Cg_endo -71.21 -39.85 3.64 Favored 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.423 2.082 . . . . 0.0 112.497 -179.855 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -145.69 -169.24 3.18 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.167 -179.887 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -88.78 -53.27 4.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.057 -179.967 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.2 mpp_? -57.93 -20.06 34.65 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.522 -179.528 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . 0.408 ' CD2' ' HG2' ' A' ' 89' ' ' PRO . 12.7 m-85 -77.21 133.39 38.91 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.799 179.896 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 4.5 mp0 -89.58 177.48 6.53 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.986 -179.925 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . 0.415 ' HB2' ' CE1' ' A' ' 97' ' ' PHE . 2.3 mp -93.61 -67.62 0.85 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.858 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 134.8 52.53 0.07 OUTLIER Glycine 0 CA--C 1.519 0.332 0 C-N-CA 120.465 -0.874 . . . . 0.0 113.026 179.584 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . 0.459 ' CD2' ' HB2' ' A' ' 113' ' ' ALA . 0.0 OUTLIER 179.96 177.41 0.65 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.839 0.352 . . . . 0.0 111.402 179.663 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 71.0 m -125.73 137.09 53.8 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.762 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 7.1 p -109.74 135.26 49.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.453 -179.687 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 4.6 tt0 -131.58 89.4 2.7 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.068 179.359 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 61.05 15.85 6.55 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.016 -179.215 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 125.37 -37.01 2.64 Favored Glycine 0 N--CA 1.447 -0.569 0 C-N-CA 120.987 -0.625 . . . . 0.0 112.065 -179.924 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.428 HG12 ' CB ' ' A' ' 158' ' ' ALA . 44.8 mt -77.43 140.93 16.28 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-O 121.016 0.436 . . . . 0.0 111.574 -179.815 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.403 ' CD1' ' CD1' ' A' ' 124' ' ' ILE . 3.7 mp -98.53 141.21 16.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.985 -179.824 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 22.0 m -119.82 -48.45 2.36 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.936 -0.574 . . . . 0.0 111.003 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -96.81 151.66 19.44 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.871 -179.972 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -167.25 116.46 0.83 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.871 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 5.0 tmm? -85.49 116.31 23.72 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.939 -179.939 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -60.78 125.6 24.29 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.921 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 88.11 26.99 27.1 Favored Glycine 0 N--CA 1.453 -0.217 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.552 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . 0.472 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -108.36 -161.61 20.55 Favored Glycine 0 CA--C 1.518 0.249 0 C-N-CA 120.782 -0.723 . . . . 0.0 113.031 -179.704 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . 0.41 HG21 ' HB2' ' A' ' 87' ' ' ARG . 7.6 mt -80.46 -42.68 21.32 Favored 'Isoleucine or valine' 0 C--O 1.237 0.434 0 CA-C-O 121.181 0.515 . . . . 0.0 111.41 -179.829 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 113' ' ' ALA . . . . . 0.475 ' HA ' HG12 ' A' ' 86' ' ' ILE . . . -57.76 -34.72 69.85 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.283 -179.251 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 114' ' ' GLU . . . . . 0.511 ' HG3' ' N ' ' A' ' 115' ' ' ARG . 7.3 pt-20 -67.9 -35.72 78.97 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.725 179.568 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.511 ' N ' ' HG3' ' A' ' 114' ' ' GLU . 36.1 mmt180 -61.71 -47.35 85.7 Favored 'General case' 0 N--CA 1.452 -0.368 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.885 -179.626 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . 0.441 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -55.09 -72.58 0.53 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.225 -0.988 . . . . 0.0 112.615 179.894 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 175.49 -22.15 0.06 OUTLIER Glycine 0 CA--C 1.52 0.393 0 C-N-CA 120.936 -0.65 . . . . 0.0 112.857 -179.881 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.425 ' HB ' HG13 ' A' ' 84' ' ' VAL . 9.1 p -30.76 147.24 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 N-CA-C 112.637 0.606 . . . . 0.0 112.637 -179.723 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -142.79 130.47 21.42 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.653 179.748 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 26.0 t -62.0 95.75 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.209 -179.809 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 123.38 40.41 0.47 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.688 179.859 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -125.32 -165.98 1.48 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.656 0.265 . . . . 0.0 110.851 -179.982 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . 0.435 ' HB2' ' CB ' ' A' ' 158' ' ' ALA . 0.1 OUTLIER -145.76 90.75 2.02 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.376 -0.375 . . . . 0.0 110.813 179.952 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . 0.488 HG22 ' CG2' ' A' ' 132' ' ' VAL . 8.0 mt -53.36 157.04 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.582 179.496 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 125' ' ' ILE . . . . . 0.424 ' CG1' ' H ' ' A' ' 126' ' ' GLU . 0.6 OUTLIER -150.31 -84.48 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 N-CA-C 112.209 0.448 . . . . 0.0 112.209 -179.474 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . 0.424 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 21.9 mt-10 -79.75 85.84 5.39 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 112.176 0.436 . . . . 0.0 112.176 -178.964 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.471 ' HA ' ' CB ' ' A' ' 153' ' ' MET . 1.9 mt -89.83 108.3 19.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 116.396 -0.365 . . . . 0.0 111.377 179.475 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . 0.401 ' OD1' ' CD2' ' A' ' 152' ' ' HIS . 55.2 m-80 54.42 24.88 5.54 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.128 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 105.26 -10.22 46.76 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.665 -0.779 . . . . 0.0 112.794 -179.85 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 21.4 tt0 -98.85 112.19 24.36 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.85 0.357 . . . . 0.0 110.756 179.855 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 1.5 m -74.49 91.09 2.24 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.286 -179.595 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . 0.488 ' CG2' HG22 ' A' ' 124' ' ' ILE . 29.6 m -71.54 -5.6 6.18 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.312 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.547 179.43 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 10.3 p -48.63 121.63 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.254 0 CA-C-O 120.893 0.378 . . . . 0.0 111.133 -179.916 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . 68.15 22.38 8.3 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.034 -179.395 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 135' ' ' THR . . . . . 0.441 ' HB ' ' O ' ' A' ' 132' ' ' VAL . 50.8 m -106.16 141.53 22.94 Favored Pre-proline 0 C--N 1.326 -0.438 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.698 179.559 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 136' ' ' PRO . . . . . 0.408 ' HD2' ' CG2' ' A' ' 135' ' ' THR . 80.2 Cg_exo -45.38 146.92 2.84 Favored 'Trans proline' 0 C--N 1.345 0.359 0 C-N-CA 122.609 2.206 . . . . 0.0 112.565 -179.922 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 137' ' ' HIS . . . . . 0.413 ' CE1' ' HG2' ' A' ' 138' ' ' GLU . 7.0 p80 -65.21 -41.74 94.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.019 -179.929 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . 0.413 ' HG2' ' CE1' ' A' ' 137' ' ' HIS . 4.7 mm-40 -56.25 -37.21 69.44 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.947 -179.899 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 139' ' ' LYS . . . . . 0.46 ' O ' ' CD1' ' A' ' 143' ' ' ILE . 27.9 tttt -63.66 -48.96 75.09 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.903 179.942 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . 0.436 HD12 HG22 ' A' ' 140' ' ' ILE . 16.1 mt -58.62 -42.15 84.07 Favored 'Isoleucine or valine' 0 C--O 1.236 0.364 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.628 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 89.2 t -62.49 -33.03 57.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.194 178.972 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -61.85 -51.74 66.99 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.64 179.736 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . 0.46 ' CD1' ' O ' ' A' ' 139' ' ' LYS . 4.4 mp -53.24 -57.18 5.3 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.433 0 CA-C-O 121.079 0.466 . . . . 0.0 110.316 179.167 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.542 HD22 HG12 ' A' ' 151' ' ' ILE . 2.9 mt -61.71 -30.24 70.63 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.25 179.597 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 2.1 m -69.27 -25.96 64.52 Favored 'General case' 0 N--CA 1.453 -0.317 0 CA-C-N 116.097 -0.501 . . . . 0.0 109.965 178.529 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 4.9 m-80 -130.15 33.91 4.29 Favored 'General case' 0 CA--C 1.529 0.149 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.213 179.861 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 147' ' ' ALA . . . . . 0.418 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . -117.89 54.88 0.89 Allowed 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.192 179.908 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 8.1 m -50.78 177.61 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.447 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 81.75 -111.62 3.35 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.458 -179.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 58.9 mt-10 -138.4 105.64 5.49 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.877 0.37 . . . . 0.0 110.715 179.841 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . 0.542 HG12 HD22 ' A' ' 144' ' ' LEU . 1.1 mt -73.01 111.36 7.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.069 -179.802 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . 0.401 ' CD2' ' OD1' ' A' ' 128' ' ' ASN . 8.3 p80 -106.34 115.58 30.46 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 178.918 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 153' ' ' MET . . . . . 0.471 ' CB ' ' HA ' ' A' ' 127' ' ' ILE . 1.5 ptt? -140.35 176.13 9.03 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.324 0.583 . . . . 0.0 112.085 -178.663 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 17.6 mttm -126.94 147.69 50.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.194 -0.912 . . . . 0.0 109.812 179.153 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 4.7 p -142.73 145.27 33.16 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.977 0.418 . . . . 0.0 111.163 -179.515 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 156' ' ' MET . . . . . 0.424 ' O ' ' N ' ' A' ' 123' ' ' ARG . 6.6 ptp -133.12 156.65 79.75 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.631 179.647 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_exo -49.46 126.18 15.42 Favored 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.508 2.139 . . . . 0.0 112.623 -179.887 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 158' ' ' ALA . . . . . 0.435 ' CB ' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.249 1.034 0 CA-C-O 118.26 -0.876 . . . . 0.0 111.016 179.823 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 21.5 t . . . . . 0 C--O 1.23 0.051 0 CA-C-O 120.811 0.338 . . . . 0.0 111.011 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.2 m -101.8 134.91 44.23 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.786 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 20.2 m -95.71 111.78 23.65 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.186 179.235 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.485 ' HB ' ' HB2' ' A' ' 153' ' ' MET . 62.2 t -85.63 105.37 14.29 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.41 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.401 -179.408 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . 0.413 ' O ' ' HA2' ' A' ' 116' ' ' GLY . 1.0 OUTLIER -103.17 83.68 2.23 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.058 -0.519 . . . . 0.0 109.652 178.893 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.462 HG13 HG11 ' A' ' 84' ' ' VAL . 12.6 mt -81.77 123.72 38.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-O 121.368 0.604 . . . . 0.0 111.717 -178.756 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.403 ' CB ' HG21 ' A' ' 112' ' ' ILE . 0.0 OUTLIER -71.98 132.5 44.39 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.776 -179.901 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -130.14 90.43 42.11 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.705 179.969 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' PRO . . . . . 0.426 ' HG2' ' CD2' ' A' ' 93' ' ' TYR . 48.7 Cg_endo -68.87 -25.28 33.07 Favored 'Trans proline' 0 C--N 1.345 0.376 0 C-N-CA 122.552 2.168 . . . . 0.0 112.569 -179.912 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -155.02 -169.57 3.23 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.978 0.418 . . . . 0.0 111.238 -179.856 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -97.44 -46.65 5.98 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.121 -179.82 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -57.01 -20.5 24.42 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.906 -0.588 . . . . 0.0 111.538 -179.631 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . 0.426 ' CD2' ' HG2' ' A' ' 89' ' ' PRO . 8.2 m-85 -60.3 -177.44 0.07 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.688 179.765 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -151.28 161.46 42.67 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.173 -179.941 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . 0.405 HD12 ' CD1' ' A' ' 144' ' ' LEU . 1.4 mt -96.89 -50.34 4.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.698 179.898 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 88.78 72.0 1.27 Allowed Glycine 0 N--CA 1.452 -0.249 0 C-N-CA 120.797 -0.716 . . . . 0.0 113.096 179.456 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 15.9 p90 -175.66 158.33 2.17 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.827 0.346 . . . . 0.0 111.174 179.57 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -105.17 146.64 28.96 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.681 179.924 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.405 ' CG1' ' CG2' ' A' ' 141' ' ' VAL . 7.3 p -130.63 134.02 62.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.307 -179.688 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -127.04 89.41 2.97 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.351 179.493 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 6.5 m120 57.11 18.74 4.27 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.052 -179.432 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 129.79 -41.44 1.54 Allowed Glycine 0 N--CA 1.448 -0.506 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.515 179.871 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.516 HG12 ' CB ' ' A' ' 158' ' ' ALA . 22.7 mt -77.57 129.5 37.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 121.077 0.465 . . . . 0.0 111.576 -179.344 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.404 ' CD1' ' CD1' ' A' ' 124' ' ' ILE . 3.6 mp -85.75 140.84 15.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.771 179.684 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 64.6 m -106.44 -69.89 0.81 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.826 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -100.86 141.25 34.01 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.788 179.859 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 5.7 tp -143.6 113.72 7.29 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.695 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 21.9 mmm -76.28 116.7 17.23 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.86 -179.839 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.05 78.88 0.05 OUTLIER 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.675 179.809 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 173.91 -34.24 0.11 Allowed Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.937 -0.649 . . . . 0.0 112.207 -179.811 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . 0.421 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -57.85 174.63 2.31 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.258 179.853 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . 0.403 HG21 ' CB ' ' A' ' 87' ' ' ARG . 0.9 OUTLIER -78.53 -16.98 13.65 Favored 'Isoleucine or valine' 0 C--O 1.236 0.395 0 CA-C-O 120.91 0.386 . . . . 0.0 111.611 -179.886 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 113' ' ' ALA . . . . . 0.429 ' HA ' HG12 ' A' ' 86' ' ' ILE . . . -57.81 -30.68 65.91 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.997 0.427 . . . . 0.0 110.875 179.908 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 114' ' ' GLU . . . . . 0.421 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 17.0 pt-20 -63.96 -46.85 82.84 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.856 179.828 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.4 ' N ' ' CG ' ' A' ' 114' ' ' GLU . 8.8 mtt180 -58.91 -47.33 85.39 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.087 -179.557 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . 0.413 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -50.1 -72.67 0.45 Allowed Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.368 -0.92 . . . . 0.0 112.689 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 172.34 -21.69 0.07 OUTLIER Glycine 0 CA--C 1.519 0.293 0 C-N-CA 120.972 -0.632 . . . . 0.0 112.674 -179.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.444 ' N ' ' CG2' ' A' ' 84' ' ' VAL . 3.8 p -30.34 144.58 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.29 0 N-CA-C 112.327 0.492 . . . . 0.0 112.327 -179.78 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.413 ' HB3' ' CD2' ' A' ' 122' ' ' HIS . 0.0 OUTLIER -136.64 126.65 26.02 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.643 -179.992 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 19.5 t -56.05 90.79 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.184 179.899 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 121.25 11.21 6.29 Favored Glycine 0 CA--C 1.52 0.379 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.8 -179.904 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . 0.413 ' CD2' ' HB3' ' A' ' 119' ' ' ARG . 6.9 m170 -98.24 132.21 43.94 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.891 0.377 . . . . 0.0 110.739 179.889 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . 0.489 ' HB2' ' CB ' ' A' ' 158' ' ' ALA . 0.0 OUTLIER -79.41 90.78 5.04 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.586 -179.622 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . 0.453 HG23 ' CG2' ' A' ' 132' ' ' VAL . 7.7 mt -54.13 143.15 6.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 N-CA-C 109.709 -0.478 . . . . 0.0 109.709 178.577 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 125' ' ' ILE . . . . . 0.425 ' N ' HG22 ' A' ' 124' ' ' ILE . 0.5 OUTLIER -137.97 -82.84 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 N-CA-C 112.365 0.506 . . . . 0.0 112.365 -179.35 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . 0.417 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 11.6 mt-10 -73.92 81.35 1.66 Allowed 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 112.538 0.57 . . . . 0.0 112.538 -178.776 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.43 HD13 ' CG2' ' A' ' 132' ' ' VAL . 3.0 mt -82.61 92.44 2.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.95 179.045 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . 0.406 ' N ' ' O ' ' A' ' 152' ' ' HIS . 1.6 t-20 58.9 21.11 8.78 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.014 -179.915 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 119.08 -18.5 10.37 Favored Glycine 0 C--N 1.332 0.349 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.787 -179.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -94.72 112.02 23.77 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.837 0.351 . . . . 0.0 110.922 -179.842 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 3.6 p -76.22 96.4 3.91 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.0 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . 0.453 ' CG2' HG23 ' A' ' 124' ' ' ILE . 27.4 m -81.04 2.64 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.323 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.86 179.983 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . 0.418 ' HB ' ' CG2' ' A' ' 125' ' ' ILE . 9.0 p -44.43 -42.57 2.14 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.178 0 CA-C-O 120.922 0.392 . . . . 0.0 111.661 -179.761 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -116.55 29.73 7.77 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.843 179.587 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 85.4 m -111.92 140.17 23.11 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.089 -179.834 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 136' ' ' PRO . . . . . 0.412 ' HG2' ' HB2' ' A' ' 139' ' ' LYS . 10.6 Cg_endo -54.44 164.23 3.08 Favored 'Trans proline' 0 C--N 1.347 0.455 0 C-N-CA 122.646 2.23 . . . . 0.0 112.333 179.895 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 15.2 p80 -67.44 -46.65 72.47 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.603 -179.593 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -53.68 -35.21 60.83 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.387 -0.369 . . . . 0.0 111.468 -179.445 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 139' ' ' LYS . . . . . 0.456 ' O ' ' CD1' ' A' ' 143' ' ' ILE . 0.1 OUTLIER -65.36 -48.94 71.2 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.85 0.357 . . . . 0.0 111.079 -179.8 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 10.1 mt -58.58 -46.19 90.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.529 -179.925 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . 0.405 ' CG2' ' CG1' ' A' ' 99' ' ' VAL . 86.8 t -60.41 -32.29 50.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.058 178.797 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 1.9 t60 -60.65 -52.94 63.01 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.664 179.585 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . 0.456 ' CD1' ' O ' ' A' ' 139' ' ' LYS . 4.2 mp -53.25 -57.03 5.59 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.456 0 CA-C-O 121.151 0.5 . . . . 0.0 110.178 179.364 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.615 HD22 HG12 ' A' ' 151' ' ' ILE . 4.5 mt -60.96 -30.23 70.12 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.279 179.699 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 1.3 m -68.56 -27.0 65.69 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.13 -0.486 . . . . 0.0 109.887 178.572 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 9.0 m120 -127.82 32.59 4.93 Favored 'General case' 0 CA--C 1.528 0.109 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.124 179.813 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 147' ' ' ALA . . . . . 0.403 ' HB2' HG13 ' A' ' 151' ' ' ILE . . . -119.26 63.45 0.79 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.375 -0.375 . . . . 0.0 111.223 179.915 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . 0.443 ' CG2' ' H ' ' A' ' 149' ' ' GLY . 1.6 p -60.11 -157.28 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.983 -179.869 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . 0.443 ' H ' ' CG2' ' A' ' 148' ' ' VAL . . . 58.0 -109.94 2.15 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.867 -0.683 . . . . 0.0 112.438 -179.961 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 3.9 mm-40 -131.18 100.13 5.1 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.739 0.304 . . . . 0.0 110.526 179.791 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . 0.615 HG12 HD22 ' A' ' 144' ' ' LEU . 0.3 OUTLIER -63.04 111.73 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.982 0.42 . . . . 0.0 111.213 -179.751 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . 0.406 ' O ' ' N ' ' A' ' 128' ' ' ASN . 1.2 t-80 -95.56 121.32 37.13 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 178.943 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 153' ' ' MET . . . . . 0.485 ' HB2' ' HB ' ' A' ' 84' ' ' VAL . 29.3 mtp -137.74 166.43 23.98 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.386 0.612 . . . . 0.0 112.368 -178.525 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -143.34 132.19 22.74 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 114.852 -1.067 . . . . 0.0 108.811 178.762 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 155' ' ' THR . . . . . 0.423 ' CG2' ' CG1' ' A' ' 124' ' ' ILE . 1.3 p -138.57 161.25 37.56 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.333 0.587 . . . . 0.0 112.176 -178.53 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 156' ' ' MET . . . . . 0.42 ' O ' ' N ' ' A' ' 123' ' ' ARG . 5.1 ptp -135.58 160.03 69.28 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 115.133 -0.94 . . . . 0.0 109.953 179.174 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 21.6 Cg_endo -61.67 118.36 5.23 Favored 'Trans proline' 0 C--N 1.343 0.274 0 C-N-CA 122.366 2.044 . . . . 0.0 112.544 -179.675 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 158' ' ' ALA . . . . . 0.516 ' CB ' HG12 ' A' ' 103' ' ' ILE . . . . . . . . 0 C--O 1.25 1.092 0 CA-C-O 118.211 -0.9 . . . . 0.0 111.037 179.749 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 10.3 p . . . . . 0 C--O 1.231 0.1 0 CA-C-O 120.718 0.294 . . . . 0.0 110.864 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.8 m -121.35 142.94 49.49 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.013 -179.842 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 5.4 m -101.37 111.15 23.3 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.135 179.2 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.548 HG12 ' H ' ' A' ' 118' ' ' VAL . 41.4 t -82.85 105.95 13.18 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.562 0 CA-C-N 115.949 -0.569 . . . . 0.0 112.184 -179.215 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 7.1 tt -99.96 79.81 2.24 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 178.069 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.433 ' CD1' HG11 ' A' ' 84' ' ' VAL . 3.3 mt -82.66 104.95 11.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.767 -178.413 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.424 ' N ' HG21 ' A' ' 112' ' ' ILE . 0.0 OUTLIER -74.93 108.31 7.57 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.428 179.21 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 10.4 mtp180 -92.32 111.45 50.52 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.184 -179.646 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_exo -62.26 -63.9 0.09 OUTLIER 'Trans proline' 0 C--N 1.346 0.445 0 C-N-CA 122.572 2.181 . . . . 0.0 112.407 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 3.1 t0 -121.44 -173.36 2.61 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.919 0.39 . . . . 0.0 111.165 -179.71 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -94.82 -21.2 18.86 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.281 -179.905 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -96.7 23.28 7.14 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.81 0.338 . . . . 0.0 111.14 -179.877 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 2.0 m-85 -102.23 178.41 4.6 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.824 179.827 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -135.71 143.61 45.46 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.017 -179.918 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . 0.417 HD21 ' CE1' ' A' ' 97' ' ' PHE . 8.3 mp -72.57 -31.06 64.94 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.798 179.872 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 82.96 55.16 3.01 Favored Glycine 0 C--N 1.33 0.242 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.968 179.626 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . 0.417 ' CE1' HD21 ' A' ' 95' ' ' LEU . 0.1 OUTLIER -173.17 156.82 3.29 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.836 0.351 . . . . 0.0 111.144 179.82 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.2 m -99.28 155.92 17.25 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.677 179.804 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.43 ' CG1' ' CG2' ' A' ' 141' ' ' VAL . 8.5 p -133.0 132.15 58.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.927 0.394 . . . . 0.0 111.336 -179.86 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -128.97 89.27 2.85 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.27 179.509 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 3.3 m-80 58.25 17.25 4.52 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.126 -179.637 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 129.81 -40.09 1.73 Allowed Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.261 179.905 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.528 HG12 ' CB ' ' A' ' 158' ' ' ALA . 30.1 mt -77.24 130.19 36.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 121.098 0.475 . . . . 0.0 111.522 -179.677 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 3.8 mp -83.96 139.67 17.28 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.793 179.894 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -84.62 -75.62 0.34 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.328 -179.479 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -132.37 121.75 23.96 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.917 0.389 . . . . 0.0 111.114 -179.74 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 7.8 tp -105.57 116.2 31.53 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.463 179.761 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 36.2 mtm -69.27 132.94 47.26 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.056 -179.807 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -67.18 76.14 0.14 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.549 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 174.63 -34.22 0.1 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.285 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . 0.45 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -56.54 176.26 1.05 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.438 179.774 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . 0.424 HG21 ' N ' ' A' ' 87' ' ' ARG . 1.8 mt -78.61 -22.04 13.09 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-O 120.782 0.325 . . . . 0.0 111.615 -179.846 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 113' ' ' ALA . . . . . . . . . . . . . . . -57.82 -30.31 65.63 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.008 0.432 . . . . 0.0 110.702 179.828 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 114' ' ' GLU . . . . . 0.45 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 19.6 pt-20 -60.63 -47.19 87.32 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.89 -0.595 . . . . 0.0 111.197 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 3.8 mtm180 -66.59 -41.33 88.67 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.241 -179.294 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -56.19 -72.63 0.54 Allowed Glycine 0 N--CA 1.448 -0.539 0 C-N-CA 120.398 -0.906 . . . . 0.0 112.669 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 161.09 -10.67 0.13 Allowed Glycine 0 CA--C 1.522 0.47 0 C-N-CA 121.219 -0.515 . . . . 0.0 112.851 -179.879 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.548 ' H ' HG12 ' A' ' 84' ' ' VAL . 2.2 t -29.75 -71.46 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 C-N-CA 123.11 0.564 . . . . 0.0 112.306 -179.677 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.429 ' N ' ' CG1' ' A' ' 118' ' ' VAL . 0.0 OUTLIER 64.32 136.12 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.467 -179.486 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 20.2 t -69.73 116.98 11.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.447 -0.342 . . . . 0.0 111.427 -179.69 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 112.55 33.25 2.12 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.799 179.644 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 1.5 m-70 -135.71 132.96 37.55 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.831 0.348 . . . . 0.0 110.991 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . 0.461 ' HB2' ' CB ' ' A' ' 158' ' ' ALA . 72.3 ttt180 -88.76 95.29 10.22 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.65 -179.686 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . 0.488 HG21 ' CG2' ' A' ' 132' ' ' VAL . 11.7 mt -49.68 146.63 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 178.657 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 125' ' ' ILE . . . . . 0.42 ' CG1' ' H ' ' A' ' 126' ' ' GLU . 0.6 OUTLIER -137.11 -84.8 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 N-CA-C 112.772 0.656 . . . . 0.0 112.772 -178.924 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . 0.42 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 19.5 mt-10 -80.8 90.86 5.87 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 112.454 0.538 . . . . 0.0 112.454 -178.383 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.48 ' HA ' ' CB ' ' A' ' 153' ' ' MET . 1.8 mt -92.15 100.79 11.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.288 179.284 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . 0.404 ' N ' ' O ' ' A' ' 152' ' ' HIS . 52.7 m-80 57.82 17.87 4.52 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.622 179.815 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 121.69 -20.69 8.18 Favored Glycine 0 C--N 1.333 0.39 0 C-N-CA 120.348 -0.929 . . . . 0.0 113.381 179.406 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -98.22 120.96 39.53 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 117.256 0.528 . . . . 0.0 111.038 -179.727 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 67.4 p -79.25 94.62 5.47 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.362 -179.838 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . 0.488 ' CG2' HG21 ' A' ' 124' ' ' ILE . 31.0 m -74.62 -4.87 6.17 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.304 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.594 179.679 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . 0.412 ' HB ' ' CG2' ' A' ' 125' ' ' ILE . 6.6 p -46.5 -37.69 3.32 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.141 0 CA-C-O 120.895 0.379 . . . . 0.0 111.526 -179.683 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -116.99 29.66 7.79 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.719 179.602 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 135' ' ' THR . . . . . 0.421 ' CG2' ' HD2' ' A' ' 136' ' ' PRO . 87.9 m -117.24 141.94 29.37 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-N 115.881 -0.6 . . . . 0.0 111.033 -179.759 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 136' ' ' PRO . . . . . 0.421 ' HD2' ' CG2' ' A' ' 135' ' ' THR . 7.6 Cg_endo -49.65 164.04 0.41 Allowed 'Trans proline' 0 C--N 1.347 0.477 0 C-N-CA 122.77 2.313 . . . . 0.0 112.23 179.685 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 11.3 p80 -73.38 -45.95 51.84 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.539 -179.655 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -53.78 -36.94 62.95 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.373 -179.55 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 139' ' ' LYS . . . . . 0.44 ' O ' ' CD1' ' A' ' 143' ' ' ILE . 0.1 OUTLIER -63.26 -47.34 82.78 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.895 -179.857 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 8.6 mt -58.74 -41.79 83.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.965 0.412 . . . . 0.0 110.646 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . 0.43 ' CG2' ' CG1' ' A' ' 99' ' ' VAL . 90.1 t -63.51 -32.68 57.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.28 179.139 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 56.7 t60 -62.33 -54.57 38.54 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.828 179.943 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . 0.44 ' CD1' ' O ' ' A' ' 139' ' ' LYS . 4.3 mp -53.23 -56.83 6.36 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.395 0 CA-C-O 121.112 0.482 . . . . 0.0 110.138 179.373 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.566 ' CD2' HG12 ' A' ' 151' ' ' ILE . 5.1 mt -60.63 -30.28 69.77 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.47 -0.786 . . . . 0.0 110.313 179.409 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 2.3 m -67.65 -27.08 66.56 Favored 'General case' 0 N--CA 1.453 -0.323 0 CA-C-N 116.164 -0.471 . . . . 0.0 109.981 178.471 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 4.6 m-80 -130.28 34.73 4.16 Favored 'General case' 0 CA--C 1.527 0.087 0 CA-C-N 116.013 -0.54 . . . . 0.0 111.215 179.796 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 147' ' ' ALA . . . . . 0.411 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . -118.65 55.26 0.92 Allowed 'General case' 0 C--O 1.232 0.149 0 CA-C-O 120.864 0.364 . . . . 0.0 111.451 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 2.8 m -55.84 174.89 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.181 179.881 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 88.64 -101.69 2.77 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.813 -0.708 . . . . 0.0 112.606 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 29.8 mt-10 -148.95 94.49 2.26 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.786 0.327 . . . . 0.0 110.989 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . 0.566 HG12 ' CD2' ' A' ' 144' ' ' LEU . 1.2 mt -61.75 112.2 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.995 179.939 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . 0.404 ' O ' ' N ' ' A' ' 128' ' ' ASN . 0.3 OUTLIER -102.68 115.53 30.77 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.076 179.144 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 153' ' ' MET . . . . . 0.48 ' CB ' ' HA ' ' A' ' 127' ' ' ILE . 1.8 ptm -147.59 166.68 26.62 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.129 0.49 . . . . 0.0 111.875 -179.111 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 35.4 mttp -112.58 155.99 23.43 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.889 179.146 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 155' ' ' THR . . . . . 0.406 HG23 ' CG1' ' A' ' 124' ' ' ILE . 13.8 p -141.2 144.13 34.58 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.226 0.536 . . . . 0.0 111.915 -179.451 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 156' ' ' MET . . . . . 0.418 ' CB ' ' CD ' ' A' ' 157' ' ' PRO . 1.5 mtm -110.86 179.94 0.74 Allowed Pre-proline 0 C--N 1.33 -0.241 0 CA-C-N 115.257 -0.883 . . . . 0.0 110.072 179.593 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 157' ' ' PRO . . . . . 0.418 ' CD ' ' CB ' ' A' ' 156' ' ' MET . 90.2 Cg_endo -92.68 106.98 0.2 Allowed 'Trans proline' 0 N--CA 1.456 -0.725 0 C-N-CA 122.757 2.305 . . . . 0.0 112.511 -179.919 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 158' ' ' ALA . . . . . 0.528 ' CB ' HG12 ' A' ' 103' ' ' ILE . . . . . . . . 0 C--O 1.249 1.039 0 CA-C-O 118.186 -0.912 . . . . 0.0 111.036 179.801 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 44.7 t . . . . . 0 C--O 1.232 0.144 0 CA-C-O 120.819 0.342 . . . . 0.0 110.922 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.7 m -131.31 140.04 49.68 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.02 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 6.8 m -100.29 111.3 23.57 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.149 179.284 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.493 ' HB ' ' HG2' ' A' ' 153' ' ' MET . 49.5 t -83.68 106.57 14.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.929 -179.339 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 7.0 tt -105.88 81.57 1.67 Allowed 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 178.317 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.458 HG13 HG12 ' A' ' 84' ' ' VAL . 12.7 mt -81.52 152.26 4.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.549 -178.498 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.404 ' CG ' ' CG2' ' A' ' 112' ' ' ILE . 0.0 OUTLIER -111.68 141.39 45.35 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.797 -179.426 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 11.5 mtp85 -140.27 84.32 14.65 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.85 179.812 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 63.7 Cg_exo -51.66 -35.44 57.34 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.656 2.238 . . . . 0.0 112.516 -179.817 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -136.06 -169.64 2.47 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.942 0.401 . . . . 0.0 111.134 -179.777 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 3.9 mt -93.63 -43.17 8.8 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.783 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 2.3 mpp_? -63.27 -14.79 53.39 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.84 -0.618 . . . . 0.0 111.703 -179.595 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 7.5 m-85 -56.69 174.72 0.14 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.866 0.365 . . . . 0.0 110.915 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 9.0 mp0 -138.6 166.13 25.14 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.027 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 1.1 mt -97.66 -49.07 4.99 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.877 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 91.62 50.92 2.61 Favored Glycine 0 C--N 1.331 0.298 0 C-N-CA 120.728 -0.748 . . . . 0.0 113.108 179.5 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -168.95 162.97 11.39 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.795 0.331 . . . . 0.0 111.039 179.64 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -110.55 133.95 52.83 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.726 179.907 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.413 ' CG1' ' CG2' ' A' ' 141' ' ' VAL . 11.4 p -110.46 132.13 59.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.378 -179.813 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 3.6 mt-30 -129.08 89.51 2.88 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.222 179.485 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 2.4 m120 59.67 18.04 6.8 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.037 -0.528 . . . . 0.0 111.0 -179.406 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 124.9 -37.29 2.61 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.441 179.887 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.563 HG12 ' CB ' ' A' ' 158' ' ' ALA . 28.3 mt -77.28 140.29 17.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.97 0.414 . . . . 0.0 111.598 -179.603 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 4.5 mp -100.23 137.13 28.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.818 179.732 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -114.93 -64.31 1.33 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.876 -179.898 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 5.1 m -86.16 145.15 27.13 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.862 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 3.9 tt -162.26 116.54 1.83 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.705 179.81 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 3.6 tmm? -94.44 128.86 41.27 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.991 -179.774 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -65.44 79.5 0.06 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.64 179.744 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 176.89 -35.22 0.09 OUTLIER Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 120.927 -0.654 . . . . 0.0 111.956 -179.843 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . 0.412 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -59.18 167.86 7.16 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.017 179.613 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . 0.404 ' CG2' ' CG ' ' A' ' 87' ' ' ARG . 1.0 OUTLIER -78.36 -16.54 13.79 Favored 'Isoleucine or valine' 0 C--O 1.235 0.313 0 CA-C-O 120.872 0.367 . . . . 0.0 111.6 -179.837 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 113' ' ' ALA . . . . . . . . . . . . . . . -57.97 -30.44 66.02 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.969 0.414 . . . . 0.0 110.556 179.797 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 114' ' ' GLU . . . . . 0.412 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 16.4 pt-20 -60.42 -47.02 87.91 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.859 179.665 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -63.16 -47.32 83.16 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.049 -179.52 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -49.64 -73.8 0.33 Allowed Glycine 0 CA--C 1.52 0.379 0 C-N-CA 120.414 -0.898 . . . . 0.0 112.6 -179.862 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 169.8 -19.79 0.07 OUTLIER Glycine 0 CA--C 1.519 0.296 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.719 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.441 ' N ' ' CG2' ' A' ' 84' ' ' VAL . 1.2 t -40.46 108.21 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.529 0.149 0 CA-C-O 120.999 0.428 . . . . 0.0 111.494 -179.791 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 6.1 mtp180 -102.75 128.34 49.52 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.612 179.751 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 22.2 t -54.06 92.61 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 121.017 0.437 . . . . 0.0 111.1 -179.815 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 128.58 -0.08 6.28 Favored Glycine 0 CA--C 1.519 0.297 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.999 -179.944 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . 0.407 ' HB3' ' HB ' ' A' ' 155' ' ' THR . 1.4 m170 -93.82 133.1 37.57 Favored 'General case' 0 C--O 1.232 0.156 0 CA-C-O 120.876 0.37 . . . . 0.0 110.865 179.953 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . 0.436 ' HB2' ' CB ' ' A' ' 158' ' ' ALA . 0.2 OUTLIER -83.27 91.62 7.32 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.009 -0.541 . . . . 0.0 111.791 -179.509 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . 0.431 HG22 ' CG2' ' A' ' 132' ' ' VAL . 14.9 mt -51.03 142.93 3.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 N-CA-C 109.638 -0.504 . . . . 0.0 109.638 178.572 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 125' ' ' ILE . . . . . 0.432 ' CG1' ' H ' ' A' ' 126' ' ' GLU . 0.6 OUTLIER -136.65 -83.98 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 N-CA-C 112.995 0.739 . . . . 0.0 112.995 -178.581 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . 0.432 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 2.2 mt-10 -78.5 85.82 4.56 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 112.733 0.642 . . . . 0.0 112.733 -178.28 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.557 ' HA ' ' CB ' ' A' ' 153' ' ' MET . 1.4 mt -90.61 104.32 15.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-O 121.071 0.462 . . . . 0.0 110.897 178.872 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 59.1 m-20 53.19 24.35 3.62 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.202 -179.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 111.47 -16.42 26.7 Favored Glycine 0 CA--C 1.519 0.33 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.944 179.879 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 10.4 tt0 -94.09 113.12 25.02 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.865 0.365 . . . . 0.0 111.04 -179.855 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -77.52 93.96 4.24 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.087 -179.974 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . 0.431 ' CG2' HG22 ' A' ' 124' ' ' ILE . 28.2 m -75.88 -3.31 4.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.183 -0.462 . . . . 0.0 112.038 -179.977 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 7.2 p -45.16 -38.26 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 CA-C-O 120.856 0.36 . . . . 0.0 111.616 -179.596 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -121.14 28.16 8.0 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.765 179.508 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 135' ' ' THR . . . . . 0.412 ' HB ' ' HA ' ' A' ' 132' ' ' VAL . 43.3 m -109.48 140.52 22.18 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.999 -179.88 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 136' ' ' PRO . . . . . 0.407 ' HD2' ' CG2' ' A' ' 135' ' ' THR . 11.1 Cg_endo -54.26 151.02 30.54 Favored 'Trans proline' 0 C--N 1.346 0.403 0 C-N-CA 122.654 2.236 . . . . 0.0 112.1 179.694 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 3.8 p-80 -60.41 -33.69 72.86 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.51 -179.727 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -62.53 -39.3 93.14 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.815 0.34 . . . . 0.0 111.227 -179.661 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 139' ' ' LYS . . . . . 0.443 ' O ' ' CD1' ' A' ' 143' ' ' ILE . 1.7 tptp -62.84 -46.17 89.18 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.025 -179.72 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 7.5 mt -58.97 -46.13 91.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.697 -179.819 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . 0.413 ' CG2' ' CG1' ' A' ' 99' ' ' VAL . 89.1 t -60.87 -32.46 52.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.22 179.235 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -61.56 -54.95 36.26 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.966 179.888 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . 0.443 ' CD1' ' O ' ' A' ' 139' ' ' LYS . 3.9 mp -53.18 -57.42 4.8 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.476 0 CA-C-O 121.185 0.517 . . . . 0.0 110.229 179.463 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.736 HD21 HG12 ' A' ' 151' ' ' ILE . 2.6 mt -60.36 -30.06 69.31 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.219 -0.9 . . . . 0.0 110.445 179.571 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 2.2 m -67.23 -27.99 67.69 Favored 'General case' 0 N--CA 1.454 -0.251 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.024 178.825 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 10.8 m120 -134.35 37.73 3.14 Favored 'General case' 0 CA--C 1.527 0.095 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.192 179.83 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 147' ' ' ALA . . . . . 0.475 ' HB2' HG13 ' A' ' 151' ' ' ILE . . . -111.62 40.17 2.18 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.484 -0.326 . . . . 0.0 111.43 -179.848 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 4.3 m -48.27 143.52 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.818 0.342 . . . . 0.0 111.412 179.884 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 118.65 -109.55 1.77 Allowed Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.443 -179.829 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 70.4 mt-10 -137.86 90.17 2.47 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.758 0.313 . . . . 0.0 110.77 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . 0.736 HG12 HD21 ' A' ' 144' ' ' LEU . 1.2 mp -65.54 111.82 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-O 121.012 0.434 . . . . 0.0 110.804 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 4.0 t60 -109.64 115.8 30.56 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.358 179.559 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 153' ' ' MET . . . . . 0.557 ' CB ' ' HA ' ' A' ' 127' ' ' ILE . 0.0 OUTLIER -144.37 166.23 25.69 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.194 0.521 . . . . 0.0 112.033 -179.258 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -109.74 151.81 26.45 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.526 -0.761 . . . . 0.0 109.346 178.665 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 155' ' ' THR . . . . . 0.407 ' HB ' ' HB3' ' A' ' 122' ' ' HIS . 16.1 p -139.84 138.61 35.89 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.054 0.454 . . . . 0.0 111.697 -179.453 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 156' ' ' MET . . . . . 0.416 ' HB3' ' HD2' ' A' ' 157' ' ' PRO . 0.0 OUTLIER -101.72 178.68 1.16 Allowed Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 115.474 -0.784 . . . . 0.0 110.31 179.732 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 157' ' ' PRO . . . . . 0.416 ' HD2' ' HB3' ' A' ' 156' ' ' MET . 94.7 Cg_endo -91.99 96.19 0.19 Allowed 'Trans proline' 0 N--CA 1.456 -0.722 0 C-N-CA 122.765 2.31 . . . . 0.0 112.505 -179.773 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 158' ' ' ALA . . . . . 0.563 ' CB ' HG12 ' A' ' 103' ' ' ILE . . . . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.201 -0.904 . . . . 0.0 111.051 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 40.6 t . . . . . 0 C--O 1.23 0.049 0 CA-C-O 120.846 0.355 . . . . 0.0 110.932 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 1.8 m -124.62 142.65 51.21 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.931 179.842 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 4.1 m -101.73 111.44 23.69 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.22 179.267 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.447 ' HB ' ' HB2' ' A' ' 153' ' ' MET . 60.9 t -87.71 106.08 15.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.439 -179.461 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . 0.408 ' HG ' ' CD2' ' A' ' 152' ' ' HIS . 2.5 tt -104.33 85.55 2.38 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.094 -0.503 . . . . 0.0 109.827 178.778 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.47 HG12 ' HA ' ' A' ' 113' ' ' ALA . 3.5 mt -81.35 138.59 19.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 121.008 0.433 . . . . 0.0 111.306 -179.064 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.442 ' CB ' HG23 ' A' ' 112' ' ' ILE . 0.1 OUTLIER -98.77 108.83 21.61 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.507 -179.723 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 8.5 mmt180 -103.39 103.37 35.04 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.016 -179.84 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' PRO . . . . . 0.429 ' HG2' ' CG ' ' A' ' 93' ' ' TYR . 56.3 Cg_endo -70.49 -28.33 21.88 Favored 'Trans proline' 0 C--N 1.347 0.472 0 C-N-CA 122.385 2.056 . . . . 0.0 112.332 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . 0.42 ' HB2' ' CD1' ' A' ' 93' ' ' TYR . 2.9 m-20 -164.4 -175.49 3.93 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.876 0.37 . . . . 0.0 111.131 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 1.5 mp -80.32 -31.56 38.06 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.984 -179.884 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -73.84 -6.26 46.03 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.693 -179.708 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . 0.429 ' CG ' ' HG2' ' A' ' 89' ' ' PRO . 28.5 m-85 -104.7 110.37 22.66 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.803 0.335 . . . . 0.0 110.866 179.932 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 2.0 mp0 -80.29 179.34 7.72 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.981 -179.927 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -91.42 -66.67 0.91 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.749 179.902 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 118.83 63.51 0.29 Allowed Glycine 0 C--N 1.33 0.224 0 C-N-CA 120.566 -0.825 . . . . 0.0 112.959 179.57 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 19.5 p90 -176.82 161.64 2.04 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.807 0.337 . . . . 0.0 110.967 179.664 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 14.5 m -102.64 145.49 29.58 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.768 179.792 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.411 ' CG1' ' CG2' ' A' ' 141' ' ' VAL . 10.1 p -126.08 130.56 72.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.332 -179.809 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 4.3 mt-30 -129.83 89.5 2.83 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.253 179.625 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 85.7 m-20 60.22 18.22 7.68 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.858 -179.343 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 123.23 -36.95 2.91 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 120.934 -0.651 . . . . 0.0 112.409 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 26.6 mt -77.24 130.77 35.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 121.018 0.437 . . . . 0.0 111.506 -179.619 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 3.7 mp -82.32 139.52 17.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.87 179.787 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -100.52 -78.79 0.51 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.104 -179.793 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 18.4 m -108.43 135.57 49.51 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.91 -179.826 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -110.75 108.73 18.69 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.823 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 41.1 mtm -73.01 100.39 2.97 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.965 -179.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 25.0 mmt85 -56.97 122.09 11.48 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.78 179.888 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 129.44 -31.29 3.45 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.85 -0.691 . . . . 0.0 112.024 -179.683 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . 0.437 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -66.68 175.81 21.46 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.716 -0.755 . . . . 0.0 112.273 179.688 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . 0.442 HG23 ' CB ' ' A' ' 87' ' ' ARG . 0.8 OUTLIER -78.63 -18.18 13.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-O 120.88 0.372 . . . . 0.0 111.62 -179.842 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 113' ' ' ALA . . . . . 0.47 ' HA ' HG12 ' A' ' 86' ' ' ILE . . . -58.31 -30.25 66.51 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.95 0.405 . . . . 0.0 110.611 179.817 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 114' ' ' GLU . . . . . 0.437 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 15.2 pt-20 -59.87 -45.65 91.79 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.731 179.503 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -64.69 -46.96 80.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.2 -179.433 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . 0.403 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -51.05 -74.03 0.32 Allowed Glycine 0 CA--C 1.518 0.262 0 C-N-CA 120.355 -0.926 . . . . 0.0 112.59 -179.908 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 175.5 -20.91 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.938 -0.649 . . . . 0.0 112.808 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.43 ' HA ' HG23 ' A' ' 84' ' ' VAL . 0.3 OUTLIER -34.7 128.07 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.23 0 CA-C-O 120.912 0.387 . . . . 0.0 112.026 -179.801 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -136.66 144.85 44.21 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.847 -179.822 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 22.7 t -70.43 102.47 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.208 -179.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 119.7 49.11 0.32 Allowed Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.61 -0.805 . . . . 0.0 112.681 179.869 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 5.4 m170 -154.29 132.65 11.95 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.834 0.35 . . . . 0.0 110.857 179.849 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . 0.485 ' HB2' ' CB ' ' A' ' 158' ' ' ALA . 2.8 ttt180 -87.85 95.71 10.2 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.664 -179.532 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . 0.493 HG22 ' CG2' ' A' ' 132' ' ' VAL . 9.1 mt -49.71 159.14 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 178.771 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 125' ' ' ILE . . . . . 0.449 ' N ' ' CG2' ' A' ' 124' ' ' ILE . 0.6 OUTLIER -148.79 -82.23 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 N-CA-C 112.567 0.58 . . . . 0.0 112.567 -179.579 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . 0.444 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 13.7 mt-10 -76.88 80.84 3.45 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 112.44 0.533 . . . . 0.0 112.44 -178.69 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.427 ' CG2' ' HG2' ' A' ' 153' ' ' MET . 2.8 mt -82.99 90.8 2.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 121.05 0.452 . . . . 0.0 111.153 179.117 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . 0.452 ' N ' ' O ' ' A' ' 152' ' ' HIS . 1.2 m-20 56.99 29.84 17.11 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.9 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 109.34 -15.11 32.93 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.774 -0.726 . . . . 0.0 112.686 -179.892 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 20.7 tt0 -95.04 106.03 17.99 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.895 0.379 . . . . 0.0 110.846 -179.921 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 11.7 p -73.5 90.3 1.72 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.851 179.971 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . 0.493 ' CG2' HG22 ' A' ' 124' ' ' ILE . 27.2 m -75.2 -2.86 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.29 0 CA-C-N 116.31 -0.405 . . . . 0.0 112.013 -179.828 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 10.4 p -44.77 -42.1 2.29 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.148 0 CA-C-O 120.862 0.363 . . . . 0.0 111.558 -179.731 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -116.2 29.54 7.9 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.891 179.578 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 38.1 m -114.73 140.06 24.9 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.175 -179.839 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 136' ' ' PRO . . . . . . . . . . . . . 11.5 Cg_endo -55.32 164.06 4.23 Favored 'Trans proline' 0 C--N 1.348 0.512 0 C-N-CA 122.652 2.235 . . . . 0.0 112.121 179.766 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 18.8 p-80 -66.43 -45.79 78.67 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.749 -179.557 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -53.71 -39.78 65.49 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.562 -179.341 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 139' ' ' LYS . . . . . 0.453 ' O ' ' CD1' ' A' ' 143' ' ' ILE . 8.7 tttt -62.7 -46.71 86.89 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.467 -0.333 . . . . 0.0 111.131 -179.7 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . 0.41 HG21 HD13 ' A' ' 140' ' ' ILE . 9.0 mt -58.32 -45.92 89.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.735 -179.836 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . 0.411 ' CG2' ' CG1' ' A' ' 99' ' ' VAL . 82.6 t -60.87 -32.64 52.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.334 179.244 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -62.02 -55.19 31.76 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.012 179.908 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . 0.453 ' CD1' ' O ' ' A' ' 139' ' ' LYS . 4.2 mp -52.83 -56.9 5.54 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.489 0 CA-C-O 121.321 0.581 . . . . 0.0 110.248 179.459 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.568 HD21 HG12 ' A' ' 151' ' ' ILE . 3.0 mt -61.2 -30.11 70.22 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.305 -0.861 . . . . 0.0 110.398 179.579 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 3.0 m -68.78 -26.74 65.36 Favored 'General case' 0 N--CA 1.454 -0.226 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.022 178.691 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 3.6 m-80 -129.92 33.92 4.34 Favored 'General case' 0 CA--C 1.527 0.093 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.182 179.894 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 147' ' ' ALA . . . . . 0.409 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . -112.28 45.73 1.25 Allowed 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.887 0.375 . . . . 0.0 111.242 179.992 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 3.1 m -50.48 152.33 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.592 -179.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 108.74 -104.42 1.97 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.539 -179.944 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 53.2 mt-10 -141.63 98.39 3.34 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.81 0.338 . . . . 0.0 110.558 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . 0.568 HG12 HD21 ' A' ' 144' ' ' LEU . 1.2 mt -73.41 111.79 8.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.353 -179.65 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . 0.452 ' O ' ' N ' ' A' ' 128' ' ' ASN . 0.0 OUTLIER -98.17 115.47 28.39 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 178.436 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 153' ' ' MET . . . . . 0.447 ' HB2' ' HB ' ' A' ' 84' ' ' VAL . 24.4 mtp -128.63 168.17 16.14 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.614 0.721 . . . . 0.0 112.677 -178.311 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 17.1 mttm -134.6 140.15 45.87 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 114.723 -1.126 . . . . 0.0 108.759 178.502 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 155' ' ' THR . . . . . 0.428 ' HA ' ' HA ' ' A' ' 124' ' ' ILE . 3.1 p -136.66 140.31 42.66 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.137 0.494 . . . . 0.0 111.909 -178.79 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 156' ' ' MET . . . . . . . . . . . . . 3.8 ptp -132.37 145.75 58.62 Favored Pre-proline 0 C--N 1.328 -0.362 0 CA-C-N 115.318 -0.855 . . . . 0.0 110.44 179.291 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_exo -44.43 122.7 4.02 Favored 'Trans proline' 0 C--N 1.345 0.35 0 C-N-CA 122.597 2.198 . . . . 0.0 112.879 -179.704 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 158' ' ' ALA . . . . . 0.485 ' CB ' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.25 1.081 0 CA-C-O 118.259 -0.877 . . . . 0.0 111.051 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_endo . . . . . 0 N--CA 1.49 1.286 0 CA-C-O 120.798 0.249 . . . . 0.0 111.763 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo -78.4 55.67 5.52 Favored 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.684 2.256 . . . . 0.0 112.527 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 14.4 p -90.88 126.31 43.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.179 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.3 m -103.66 141.49 35.97 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.8 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 5.1 m -105.63 111.3 23.93 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.149 179.191 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.426 ' HB ' ' HG2' ' A' ' 153' ' ' MET . 48.5 t -82.66 106.14 13.2 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.65 -179.418 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . 0.405 ' HA ' ' O ' ' A' ' 151' ' ' ILE . 0.8 OUTLIER -105.55 84.04 2.03 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 178.456 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.462 HG12 ' HA ' ' A' ' 113' ' ' ALA . 4.0 mt -81.53 151.28 4.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.582 -178.671 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.428 ' CG ' ' CG2' ' A' ' 112' ' ' ILE . 0.0 OUTLIER -110.07 114.85 28.7 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.712 -0.677 . . . . 0.0 110.451 -179.789 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -120.56 100.91 46.63 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.058 -179.728 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . 0.419 ' HG2' ' CD2' ' A' ' 93' ' ' TYR . 71.5 Cg_endo -74.54 -26.73 11.61 Favored 'Trans proline' 0 C--N 1.346 0.414 0 C-N-CA 122.585 2.19 . . . . 0.0 112.448 179.874 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -141.39 -166.01 2.1 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.087 -179.866 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 2.6 mt -102.59 -19.74 14.72 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.43 -179.823 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -95.08 21.81 7.35 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.48 -0.327 . . . . 0.0 111.291 -179.775 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . 0.419 ' CD2' ' HG2' ' A' ' 89' ' ' PRO . 7.4 m-85 -112.31 98.67 7.45 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.768 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 1.2 pm0 -57.97 146.76 31.35 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.136 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . 0.404 ' N ' ' CD1' ' A' ' 95' ' ' LEU . 6.7 mp -71.78 -52.5 17.31 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.758 -179.919 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 124.85 36.82 0.57 Allowed Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.579 -0.82 . . . . 0.0 113.023 179.576 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . 0.413 ' CE2' HG22 ' A' ' 118' ' ' VAL . 31.8 p90 -177.36 169.24 2.24 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.839 0.352 . . . . 0.0 111.197 179.787 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -120.66 148.2 44.24 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.745 179.735 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.469 HG22 ' CG2' ' A' ' 140' ' ' ILE . 8.6 p -115.3 142.82 26.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.427 -179.878 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . 0.407 ' O ' ' N ' ' A' ' 102' ' ' GLY . 22.8 tt0 -132.14 88.42 2.55 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.905 -0.588 . . . . 0.0 110.233 179.049 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 65.36 -68.51 0.11 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.151 -179.838 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.431 ' O ' ' HA ' ' A' ' 123' ' ' ARG . . . -142.9 -2.24 1.05 Allowed Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.387 -0.911 . . . . 0.0 113.4 -179.758 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.4 HD13 ' CB ' ' A' ' 158' ' ' ALA . 42.2 mm -122.86 151.36 26.99 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.128 0 CA-C-N 117.13 0.465 . . . . 0.0 111.529 -179.716 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.416 ' CD1' ' N ' ' A' ' 104' ' ' ILE . 2.8 mp -86.46 158.33 3.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.499 179.605 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 1.6 m -109.59 -71.68 0.75 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.475 -179.595 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 8.3 m -125.23 173.56 8.7 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.93 0.395 . . . . 0.0 111.17 -179.543 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -148.48 140.63 24.05 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.779 179.901 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 2.0 mtm -106.22 114.21 28.2 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.868 -179.883 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -63.58 82.74 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.708 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 167.02 -31.36 0.19 Allowed Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.938 -0.648 . . . . 0.0 112.002 -179.858 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.405 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -64.34 172.48 17.46 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.132 179.651 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . 0.428 ' CG2' ' CG ' ' A' ' 87' ' ' ARG . 0.5 OUTLIER -78.65 -16.66 13.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 120.744 0.306 . . . . 0.0 111.474 -179.952 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' ALA . . . . . 0.462 ' HA ' HG12 ' A' ' 86' ' ' ILE . . . -58.0 -30.35 66.0 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.002 0.429 . . . . 0.0 110.671 179.744 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' GLU . . . . . 0.405 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 19.7 pt-20 -60.03 -46.63 88.86 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.876 179.67 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 23.3 mtt180 -65.0 -46.19 82.45 Favored 'General case' 0 N--CA 1.453 -0.301 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.21 -179.572 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -51.1 -73.57 0.37 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.557 -0.83 . . . . 0.0 112.641 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 170.54 -20.11 0.07 OUTLIER Glycine 0 CA--C 1.518 0.271 0 C-N-CA 121.032 -0.604 . . . . 0.0 112.662 -179.773 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.418 ' N ' ' CG2' ' A' ' 84' ' ' VAL . 0.9 OUTLIER -37.59 114.92 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.323 0 CA-C-O 120.937 0.399 . . . . 0.0 111.652 -179.819 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -117.46 100.95 8.0 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.577 179.799 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 10.1 p -48.11 101.76 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 121.057 0.456 . . . . 0.0 111.106 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 133.38 -10.19 5.01 Favored Glycine 0 N--CA 1.451 -0.36 0 CA-C-N 115.831 -0.622 . . . . 0.0 112.231 -179.318 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 35.7 m170 -86.1 -161.62 0.66 Allowed 'General case' 0 C--N 1.331 -0.231 0 N-CA-C 110.322 -0.251 . . . . 0.0 110.322 179.802 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.459 ' N ' ' O ' ' A' ' 156' ' ' MET . 10.1 ttm-85 -139.35 90.4 2.41 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.679 0.276 . . . . 0.0 110.802 -179.866 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . 0.475 HG23 ' CG2' ' A' ' 132' ' ' VAL . 15.4 mt -55.99 157.13 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.251 179.225 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' ILE . . . . . 0.459 ' CG1' ' H ' ' A' ' 126' ' ' GLU . 0.7 OUTLIER -151.54 -84.51 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.451 -0.383 0 N-CA-C 112.374 0.509 . . . . 0.0 112.374 -179.538 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . 0.459 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 13.5 mt-10 -79.99 88.24 5.36 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 112.498 0.555 . . . . 0.0 112.498 -178.793 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.503 ' HA ' ' CB ' ' A' ' 153' ' ' MET . 1.3 mt -92.44 103.05 14.22 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.185 0 CA-C-O 121.101 0.477 . . . . 0.0 111.344 179.281 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . 0.409 ' HA ' ' CD2' ' A' ' 152' ' ' HIS . 20.2 m-80 59.84 18.64 7.57 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.857 -0.61 . . . . 0.0 111.369 179.847 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 116.6 -17.18 13.88 Favored Glycine 0 C--N 1.333 0.372 0 C-N-CA 120.517 -0.849 . . . . 0.0 113.179 179.627 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 1.2 pt20 -97.88 119.56 36.71 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 117.029 0.414 . . . . 0.0 110.963 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 2.5 m -79.06 93.15 5.09 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.119 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . 0.475 ' CG2' HG23 ' A' ' 124' ' ' ILE . 27.2 m -72.56 -5.38 6.22 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.298 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.978 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 8.3 p -45.36 -38.46 2.22 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.135 0 CA-C-O 120.818 0.342 . . . . 0.0 111.487 -179.807 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -120.08 28.22 8.2 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.748 179.465 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' THR . . . . . 0.429 ' HB ' ' HA ' ' A' ' 132' ' ' VAL . 36.0 m -110.73 143.15 27.63 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.181 -179.929 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' PRO . . . . . 0.402 ' HD2' ' CG2' ' A' ' 135' ' ' THR . 50.1 Cg_exo -53.41 164.21 2.14 Favored 'Trans proline' 0 C--N 1.347 0.456 0 C-N-CA 122.526 2.151 . . . . 0.0 112.119 179.704 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 9.3 p80 -74.05 -46.95 40.04 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.224 -179.798 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -54.16 -35.14 61.95 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.173 -179.786 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 139' ' ' LYS . . . . . 0.446 ' O ' ' CD1' ' A' ' 143' ' ' ILE . 0.0 OUTLIER -65.96 -48.87 69.86 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.943 -179.931 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . 0.469 ' CG2' HG22 ' A' ' 99' ' ' VAL . 8.7 mt -59.47 -46.41 92.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 121.033 0.444 . . . . 0.0 110.319 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 55.6 t -59.54 -32.53 49.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 115.711 -0.677 . . . . 0.0 109.93 179.074 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -61.47 -54.22 46.27 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.009 -0.542 . . . . 0.0 110.835 179.808 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . 0.539 ' O ' ' HB2' ' A' ' 147' ' ' ALA . 4.3 mp -53.39 -57.86 4.23 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.424 0 CA-C-O 121.015 0.436 . . . . 0.0 110.135 179.487 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.474 HD21 HG12 ' A' ' 151' ' ' ILE . 15.1 mt -60.39 -30.14 69.4 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.408 179.402 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 23.4 t -69.38 -28.55 66.28 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.219 -0.446 . . . . 0.0 109.934 178.811 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 4.9 m-80 -128.17 34.48 4.57 Favored 'General case' 0 C--N 1.333 -0.112 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.908 179.666 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 147' ' ' ALA . . . . . 0.539 ' HB2' ' O ' ' A' ' 143' ' ' ILE . . . -103.62 79.21 1.65 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.207 -179.929 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 5.7 m -77.32 146.18 8.92 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.338 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.149 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 105.43 -104.68 2.35 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.525 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 53.4 mt-10 -145.58 114.73 7.03 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.79 0.328 . . . . 0.0 110.847 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . 0.474 HG12 HD21 ' A' ' 144' ' ' LEU . 1.8 mp -81.93 128.13 39.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 121.047 0.451 . . . . 0.0 110.628 179.854 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . 0.409 ' CD2' ' HA ' ' A' ' 128' ' ' ASN . 21.6 p-80 -125.47 115.77 20.77 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.361 179.819 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 153' ' ' MET . . . . . 0.503 ' CB ' ' HA ' ' A' ' 127' ' ' ILE . 0.0 OUTLIER -141.21 174.99 10.01 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.164 0.507 . . . . 0.0 111.619 -179.379 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -121.41 147.83 45.2 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.589 -0.732 . . . . 0.0 109.912 179.22 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 12.1 p -140.7 140.49 34.92 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.04 0.448 . . . . 0.0 111.175 -179.665 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 156' ' ' MET . . . . . 0.459 ' O ' ' N ' ' A' ' 123' ' ' ARG . 0.0 OUTLIER -108.7 178.86 0.95 Allowed Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 115.791 -0.64 . . . . 0.0 110.56 179.854 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . 0.413 ' CD ' ' CB ' ' A' ' 156' ' ' MET . 94.6 Cg_endo -89.85 111.01 0.46 Allowed 'Trans proline' 0 N--CA 1.458 -0.559 0 C-N-CA 122.532 2.154 . . . . 0.0 112.504 -179.776 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 158' ' ' ALA . . . . . 0.4 ' CB ' HD13 ' A' ' 103' ' ' ILE . . . . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.283 -0.865 . . . . 0.0 110.962 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_endo . . . . . 0 N--CA 1.489 1.24 0 CA-C-O 120.67 0.196 . . . . 0.0 111.736 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -72.3 99.52 1.03 Allowed 'Trans proline' 0 C--N 1.345 0.351 0 C-N-CA 122.524 2.15 . . . . 0.0 112.396 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 10.2 p -81.4 140.58 16.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.015 179.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.9 m -126.52 140.99 52.03 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.984 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 6.6 m -99.86 111.18 23.51 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.147 179.272 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.548 HG13 HG13 ' A' ' 86' ' ' ILE . 47.2 t -82.66 108.57 15.64 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 CA-C-N 116.015 -0.539 . . . . 0.0 112.268 -179.112 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 6.7 tt -103.12 85.01 2.43 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.876 -0.602 . . . . 0.0 109.436 178.345 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.548 HG13 HG13 ' A' ' 84' ' ' VAL . 5.6 mt -82.81 118.81 31.17 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.251 0 CA-C-O 121.293 0.568 . . . . 0.0 111.893 -178.715 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -73.13 153.06 40.92 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.089 -0.959 . . . . 0.0 109.99 179.21 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -152.92 124.32 3.68 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 120.618 0.247 . . . . 0.0 111.11 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 92.0 Cg_endo -83.47 -42.45 0.08 OUTLIER 'Trans proline' 0 C--N 1.347 0.465 0 C-N-CA 122.613 2.209 . . . . 0.0 112.584 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 57.4 p30 -156.78 -167.54 2.4 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.203 -179.781 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 7.3 mt -96.19 30.87 2.33 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.43 -179.519 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -138.9 32.06 2.21 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.886 0.374 . . . . 0.0 110.982 179.914 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 2.1 m-85 -136.84 104.06 5.37 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.832 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 3.0 mp0 -65.51 145.07 56.56 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.03 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 8.3 mp -78.49 -24.62 45.77 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.94 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 72.27 68.81 1.51 Allowed Glycine 0 C--N 1.331 0.257 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.868 179.709 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . 0.422 ' CZ ' ' CD1' ' A' ' 144' ' ' LEU . 1.8 p90 -161.37 -171.83 3.15 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.918 0.39 . . . . 0.0 111.212 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.416 ' O ' ' HA ' ' A' ' 104' ' ' ILE . 1.2 t -149.67 126.24 10.95 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.408 179.71 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.44 ' CG1' ' CG2' ' A' ' 141' ' ' VAL . 11.8 p -111.97 140.16 32.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 121.163 0.506 . . . . 0.0 111.764 -179.284 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 3.6 mp0 -133.03 89.75 2.66 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.598 -0.728 . . . . 0.0 109.847 179.156 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 9.8 t-20 60.35 15.64 5.59 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.756 -178.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 127.31 -39.3 1.97 Allowed Glycine 0 N--CA 1.449 -0.474 0 C-N-CA 121.012 -0.613 . . . . 0.0 112.228 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.486 HG12 ' CB ' ' A' ' 158' ' ' ALA . 31.5 mt -77.27 138.67 20.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 121.007 0.432 . . . . 0.0 111.575 -179.587 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.416 ' HA ' ' O ' ' A' ' 98' ' ' SER . 4.1 mp -96.36 138.25 22.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.991 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -108.0 -65.62 1.1 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.653 179.878 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 9.5 p -94.22 155.06 17.23 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.614 179.724 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -163.92 121.71 1.81 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.942 -179.855 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 20.2 ttp -82.36 120.94 26.06 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.881 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -67.97 71.92 0.16 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.143 0.497 . . . . 0.0 110.602 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 175.36 -33.85 0.1 OUTLIER Glycine 0 N--CA 1.45 -0.39 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.966 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.439 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -55.26 176.33 0.6 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.781 -0.724 . . . . 0.0 112.275 179.788 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 1.1 mp -78.7 -18.57 13.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 N-CA-C 111.848 0.314 . . . . 0.0 111.848 -179.734 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' ALA . . . . . . . . . . . . . . . -58.01 -30.54 66.19 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.895 0.378 . . . . 0.0 110.757 179.855 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' GLU . . . . . 0.439 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 13.2 pt-20 -61.64 -47.42 85.48 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.871 179.8 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 43.4 mtm180 -62.27 -41.98 98.93 Favored 'General case' 0 N--CA 1.453 -0.31 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.832 -179.631 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -53.79 -73.83 0.37 Allowed Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.296 -0.954 . . . . 0.0 112.394 179.854 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 164.57 -18.13 0.11 Allowed Glycine 0 CA--C 1.523 0.538 0 C-N-CA 121.249 -0.5 . . . . 0.0 112.74 -179.889 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.445 ' N ' ' CG2' ' A' ' 84' ' ' VAL . 2.0 t -29.58 -64.26 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 C-N-CA 123.212 0.605 . . . . 0.0 112.569 -179.54 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.401 ' N ' HG13 ' A' ' 118' ' ' VAL . 30.0 mmt180 61.71 178.7 0.12 Allowed 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.303 -0.408 . . . . 0.0 109.941 -178.872 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 11.8 t -111.18 101.12 12.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-O 120.917 0.389 . . . . 0.0 111.341 -179.86 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 126.17 42.34 0.3 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.894 -0.669 . . . . 0.0 112.417 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 15.3 m170 -129.87 -171.52 2.54 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.767 0.317 . . . . 0.0 110.963 -179.822 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.504 ' N ' ' O ' ' A' ' 156' ' ' MET . 5.7 ttm-85 -142.08 89.39 2.17 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.874 -179.756 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . 0.447 HG23 ' CG2' ' A' ' 132' ' ' VAL . 14.6 mt -51.67 142.5 4.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.547 -0.297 . . . . 0.0 110.285 179.375 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' ILE . . . . . 0.437 ' CG1' ' H ' ' A' ' 126' ' ' GLU . 0.6 OUTLIER -137.18 -84.46 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 N-CA-C 112.668 0.618 . . . . 0.0 112.668 -179.05 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . 0.437 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 1.0 OUTLIER -80.52 83.73 6.26 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 112.421 0.526 . . . . 0.0 112.421 -178.538 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.447 ' CG2' ' HB3' ' A' ' 153' ' ' MET . 1.9 mt -86.26 104.37 13.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 120.97 0.414 . . . . 0.0 111.175 179.086 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 11.3 m-20 56.15 23.05 6.56 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.777 -0.647 . . . . 0.0 111.402 179.804 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 112.68 -14.21 24.71 Favored Glycine 0 C--N 1.332 0.318 0 C-N-CA 120.554 -0.831 . . . . 0.0 112.961 179.746 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' GLN . . . . . 0.4 ' O ' ' CG ' ' A' ' 130' ' ' GLN . 5.0 pt20 -96.16 122.07 38.61 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.742 0.306 . . . . 0.0 110.484 -179.888 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 21.3 p -83.75 90.02 7.26 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.892 0.377 . . . . 0.0 110.826 179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . 0.447 ' CG2' HG23 ' A' ' 124' ' ' ILE . 35.0 m -72.69 -3.81 4.45 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.351 0 CA-C-N 116.013 -0.54 . . . . 0.0 112.04 -179.845 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 7.9 p -47.27 -35.13 3.41 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.158 0 CA-C-O 120.894 0.378 . . . . 0.0 111.228 -179.889 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -121.01 27.84 8.24 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.684 179.4 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 135' ' ' THR . . . . . 0.411 ' CG2' ' HD2' ' A' ' 136' ' ' PRO . 25.8 m -114.08 140.64 25.16 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 115.664 -0.698 . . . . 0.0 111.02 -179.8 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 136' ' ' PRO . . . . . 0.411 ' HD2' ' CG2' ' A' ' 135' ' ' THR . 8.3 Cg_endo -50.11 163.97 0.52 Allowed 'Trans proline' 0 C--N 1.347 0.458 0 C-N-CA 122.676 2.251 . . . . 0.0 112.181 179.64 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 137' ' ' HIS . . . . . 0.404 ' CD2' ' N ' ' A' ' 138' ' ' GLU . 22.9 p-80 -74.45 -41.85 60.11 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.284 -0.417 . . . . 0.0 111.439 -179.642 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . 0.404 ' N ' ' CD2' ' A' ' 137' ' ' HIS . 53.8 mt-10 -54.15 -38.04 65.06 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.753 0.311 . . . . 0.0 111.42 -179.516 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 139' ' ' LYS . . . . . 0.417 ' O ' ' CD1' ' A' ' 143' ' ' ILE . 6.9 tttp -64.67 -48.86 73.2 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.11 -179.728 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 13.8 mt -59.26 -43.27 89.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.624 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . 0.44 ' CG2' ' CG1' ' A' ' 99' ' ' VAL . 86.6 t -62.29 -33.13 57.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.389 179.291 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -61.93 -56.46 18.98 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.07 -0.514 . . . . 0.0 111.104 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . 0.465 ' O ' ' N ' ' A' ' 147' ' ' ALA . 4.3 mp -52.9 -57.17 4.92 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.49 0 CA-C-O 121.095 0.474 . . . . 0.0 110.192 179.559 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.612 HD21 HG12 ' A' ' 151' ' ' ILE . 6.3 mt -59.83 -29.91 68.58 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.575 179.409 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 14.0 t -73.18 -28.25 62.1 Favored 'General case' 0 N--CA 1.456 -0.141 0 CA-C-N 116.361 -0.382 . . . . 0.0 110.219 178.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 3.1 m-80 -125.11 31.58 5.58 Favored 'General case' 0 C--O 1.232 0.152 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.189 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 147' ' ' ALA . . . . . 0.465 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . -107.02 97.06 6.88 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.243 179.942 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 6.3 m -79.96 179.86 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.357 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.983 -179.744 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 67.94 -116.04 7.38 Favored Glycine 0 N--CA 1.453 -0.223 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.599 179.924 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 11.5 mt-10 -134.97 110.7 9.27 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.606 0.241 . . . . 0.0 110.984 -179.815 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . 0.612 HG12 HD21 ' A' ' 144' ' ' LEU . 1.7 mp -68.16 124.02 22.77 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-O 120.915 0.388 . . . . 0.0 110.778 179.776 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -113.51 115.56 28.18 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.801 -0.636 . . . . 0.0 109.964 179.192 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 153' ' ' MET . . . . . 0.447 ' CG ' ' HB ' ' A' ' 84' ' ' VAL . 1.4 ptt? -147.2 164.77 32.1 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.217 0.532 . . . . 0.0 111.732 -178.97 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 2.2 mttm -110.9 152.33 26.86 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.524 -0.762 . . . . 0.0 109.851 179.182 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 155' ' ' THR . . . . . 0.41 HG23 ' CG1' ' A' ' 124' ' ' ILE . 37.4 p -136.88 142.59 42.78 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.163 0.506 . . . . 0.0 111.604 -179.547 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 156' ' ' MET . . . . . 0.504 ' O ' ' N ' ' A' ' 123' ' ' ARG . 0.0 OUTLIER -111.82 179.0 0.86 Allowed Pre-proline 0 C--N 1.327 -0.392 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.39 179.755 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . 0.412 ' CD ' ' CB ' ' A' ' 156' ' ' MET . 80.2 Cg_endo -92.96 103.41 0.17 Allowed 'Trans proline' 0 N--CA 1.456 -0.688 0 C-N-CA 122.786 2.324 . . . . 0.0 112.543 -179.752 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 158' ' ' ALA . . . . . 0.486 ' CB ' HG12 ' A' ' 103' ' ' ILE . . . . . . . . 0 C--O 1.25 1.085 0 CA-C-O 118.169 -0.92 . . . . 0.0 111.09 179.788 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . 0.474 ' CB ' ' CD ' ' A' ' 80' ' ' PRO . 2.0 Cg_endo . . . . . 0 N--CA 1.484 0.944 0 CA-C-O 120.522 0.134 . . . . 0.0 112.155 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . 0.474 ' CD ' ' CB ' ' A' ' 79' ' ' PRO . 42.4 Cg_endo -67.93 165.58 27.57 Favored 'Trans proline' 0 C--N 1.343 0.284 0 C-N-CA 122.51 2.14 . . . . 0.0 112.355 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.41 ' CG1' ' CG ' ' A' ' 154' ' ' LYS . 47.0 t -81.16 140.93 15.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.04 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.7 m -118.61 134.25 55.25 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.848 179.849 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 6.9 m -95.25 111.52 23.36 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.178 179.324 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.435 HG11 ' CG2' ' A' ' 118' ' ' VAL . 58.3 t -82.56 105.73 12.7 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.547 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.742 -179.33 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . 0.45 ' CD1' ' CD2' ' A' ' 152' ' ' HIS . 4.6 tp -107.73 80.1 1.35 Allowed 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 178.348 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.412 HG13 HG13 ' A' ' 84' ' ' VAL . 1.2 mt -81.67 130.95 34.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 121.173 0.511 . . . . 0.0 111.729 -178.272 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -84.19 142.87 30.0 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.443 -0.799 . . . . 0.0 110.256 179.929 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 3.7 ttt180 -144.88 114.16 5.01 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.964 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -75.32 -45.24 0.27 Allowed 'Trans proline' 0 C--N 1.347 0.466 0 C-N-CA 122.463 2.109 . . . . 0.0 112.616 -179.895 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -135.1 -173.97 3.47 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.196 -179.753 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -86.96 -34.04 19.44 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.976 -179.928 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 3.2 ptm180 -73.07 -7.97 53.65 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.608 -179.842 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 10.9 m-85 -85.08 128.57 34.7 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.797 0.332 . . . . 0.0 110.876 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 4.0 mp0 -89.51 160.49 16.7 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.899 -179.895 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 59.3 mt -81.42 -69.21 0.63 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.903 179.917 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 135.9 40.96 0.13 Allowed Glycine 0 CA--C 1.518 0.277 0 C-N-CA 120.484 -0.865 . . . . 0.0 113.192 179.631 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . 0.436 ' CD1' ' HB1' ' A' ' 113' ' ' ALA . 33.1 p90 -175.12 174.67 2.4 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.879 0.371 . . . . 0.0 111.09 179.62 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -124.74 143.86 50.55 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.961 -179.814 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.404 ' CG1' ' CG2' ' A' ' 141' ' ' VAL . 10.6 p -111.54 139.48 35.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.026 179.907 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . 0.413 ' O ' ' N ' ' A' ' 102' ' ' GLY . 0.5 OUTLIER -130.53 89.01 2.71 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.806 179.758 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' ASN . . . . . 0.421 ' O ' ' CD1' ' A' ' 140' ' ' ILE . 7.3 m-80 64.34 -68.19 0.1 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.903 -0.59 . . . . 0.0 111.51 179.569 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.413 ' N ' ' O ' ' A' ' 100' ' ' GLN . . . -143.83 1.1 1.27 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.238 -0.982 . . . . 0.0 113.414 -179.731 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.449 HD11 ' HB2' ' A' ' 158' ' ' ALA . 44.2 mm -126.46 155.08 36.64 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 117.232 0.516 . . . . 0.0 111.209 -179.886 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.414 ' CD1' ' N ' ' A' ' 104' ' ' ILE . 3.2 mp -97.26 145.11 9.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.735 179.817 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 1.6 m -106.46 -79.48 0.57 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.171 -179.704 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 1.5 m -90.91 168.83 11.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.375 -0.375 . . . . 0.0 111.141 -179.7 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 62.1 tp -174.16 101.86 0.1 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.698 179.897 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 8.0 mtp -73.93 122.05 21.94 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.081 -179.819 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.03 78.2 0.09 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.692 179.775 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 174.25 -33.62 0.11 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.986 -0.626 . . . . 0.0 112.04 -179.837 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.426 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -57.46 174.62 2.0 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.142 179.741 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -78.5 -17.46 13.59 Favored 'Isoleucine or valine' 0 C--O 1.236 0.36 0 CA-C-O 120.829 0.347 . . . . 0.0 111.522 -179.845 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' ALA . . . . . 0.436 ' HB1' ' CD1' ' A' ' 97' ' ' PHE . . . -58.11 -30.62 66.43 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.911 0.386 . . . . 0.0 110.703 179.863 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' GLU . . . . . 0.426 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 17.4 pt-20 -60.48 -47.21 87.15 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.969 -0.559 . . . . 0.0 110.766 179.634 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 2.4 mmt85 -62.32 -44.78 95.71 Favored 'General case' 0 N--CA 1.452 -0.337 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.892 -179.556 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -53.25 -74.01 0.35 Allowed Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.245 -0.979 . . . . 0.0 112.519 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . 0.495 ' O ' ' C ' ' A' ' 118' ' ' VAL . . . 172.45 -24.94 0.08 OUTLIER Glycine 0 CA--C 1.518 0.249 0 C-N-CA 121.065 -0.588 . . . . 0.0 112.701 -179.951 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.495 ' C ' ' O ' ' A' ' 117' ' ' GLY . 18.0 t -15.11 -83.31 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.627 0 C-N-CA 123.235 0.614 . . . . 0.0 112.489 -179.835 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.411 ' N ' ' CG1' ' A' ' 118' ' ' VAL . 0.0 OUTLIER 62.56 143.19 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.725 -179.649 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 11.4 t -81.97 132.06 32.37 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 116.439 -0.346 . . . . 0.0 111.198 -179.704 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 101.63 24.63 8.6 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.886 -0.673 . . . . 0.0 112.57 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 10.4 m170 -112.72 -174.42 2.45 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.656 0.265 . . . . 0.0 110.706 179.869 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.503 ' N ' ' O ' ' A' ' 156' ' ' MET . 0.0 OUTLIER -140.58 90.14 2.33 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.819 -179.783 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . 0.419 ' CG2' ' N ' ' A' ' 125' ' ' ILE . 5.9 mt -50.82 154.95 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.811 179.484 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' ILE . . . . . 0.464 ' CG1' ' H ' ' A' ' 126' ' ' GLU . 0.8 OUTLIER -157.79 -86.66 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 N-CA-C 112.481 0.549 . . . . 0.0 112.481 -179.88 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . 0.464 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 15.6 mt-10 -81.82 92.79 6.74 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 112.321 0.489 . . . . 0.0 112.321 -178.637 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.473 HG12 ' HG3' ' A' ' 153' ' ' MET . 1.5 mt -91.3 99.16 9.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.126 179.297 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 52.8 m-20 63.96 15.92 9.52 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.451 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 121.19 -18.94 8.82 Favored Glycine 0 C--N 1.332 0.31 0 C-N-CA 120.452 -0.88 . . . . 0.0 113.117 179.629 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 1.8 pt20 -98.63 117.1 32.32 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.93 0.395 . . . . 0.0 110.948 -179.916 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 1.4 m -77.18 93.41 3.93 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.182 -179.787 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . 0.41 ' HB ' HD13 ' A' ' 140' ' ' ILE . 35.6 m -77.08 0.31 2.64 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.324 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.801 179.67 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 8.5 p -46.82 -40.23 4.72 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.14 0 CA-C-O 120.805 0.336 . . . . 0.0 111.261 -179.826 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -113.13 29.54 7.9 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.687 179.452 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 135' ' ' THR . . . . . 0.432 ' CG2' ' HD2' ' A' ' 136' ' ' PRO . 91.0 m -116.97 143.03 30.8 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.852 -179.805 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 136' ' ' PRO . . . . . 0.432 ' HD2' ' CG2' ' A' ' 135' ' ' THR . 6.1 Cg_endo -47.92 164.09 0.18 Allowed 'Trans proline' 0 C--N 1.347 0.451 0 C-N-CA 122.805 2.337 . . . . 0.0 112.281 179.795 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 45.1 p-80 -76.11 -44.55 38.02 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.301 -179.606 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -54.08 -33.53 57.79 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.362 -179.607 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 139' ' ' LYS . . . . . 0.43 ' O ' ' CD1' ' A' ' 143' ' ' ILE . 0.0 OUTLIER -66.41 -50.12 64.49 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.873 0.368 . . . . 0.0 111.033 -179.923 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . 0.421 ' CD1' ' O ' ' A' ' 101' ' ' ASN . 8.5 mt -59.1 -46.18 92.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.421 179.827 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . 0.404 ' CG2' ' CG1' ' A' ' 99' ' ' VAL . 69.0 t -59.86 -32.38 49.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.906 -0.588 . . . . 0.0 109.885 178.73 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 2.1 t-160 -60.57 -52.97 62.89 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.492 179.604 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . 0.481 ' O ' ' HB2' ' A' ' 147' ' ' ALA . 4.5 mp -53.29 -57.78 4.28 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.394 0 CA-C-O 121.035 0.445 . . . . 0.0 110.108 179.202 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.566 HD22 HG12 ' A' ' 151' ' ' ILE . 9.7 mt -60.05 -30.19 69.04 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.627 -0.715 . . . . 0.0 110.231 179.389 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 38.9 t -70.81 -27.79 64.15 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.075 -0.511 . . . . 0.0 109.878 178.745 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 2.8 m-80 -124.85 31.47 5.65 Favored 'General case' 0 C--O 1.232 0.151 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.83 179.799 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 147' ' ' ALA . . . . . 0.481 ' HB2' ' O ' ' A' ' 143' ' ' ILE . . . -113.14 101.06 9.08 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.952 179.789 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 3.4 m -101.59 158.62 4.24 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.433 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.321 -179.79 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 95.0 -95.89 1.94 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.564 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 14.4 mt-10 -146.81 104.93 3.76 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.716 0.294 . . . . 0.0 110.715 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . 0.566 HG12 HD22 ' A' ' 144' ' ' LEU . 1.5 mp -72.41 117.52 16.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 121.149 0.5 . . . . 0.0 111.204 -179.756 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . 0.45 ' CD2' ' CD1' ' A' ' 85' ' ' LEU . 0.2 OUTLIER -101.37 121.84 42.64 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.585 -0.734 . . . . 0.0 109.295 178.724 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 153' ' ' MET . . . . . 0.473 ' HG3' HG12 ' A' ' 127' ' ' ILE . 8.6 tmm? -153.41 155.16 35.84 Favored 'General case' 0 C--N 1.327 -0.385 0 C-N-CA 120.754 -0.378 . . . . 0.0 111.678 -178.436 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . 0.41 ' CG ' ' CG1' ' A' ' 81' ' ' VAL . 0.0 OUTLIER -109.23 152.27 25.41 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.605 179.893 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 155' ' ' THR . . . . . 0.412 ' CG2' ' SD ' ' A' ' 153' ' ' MET . 30.3 p -142.13 150.05 40.61 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 121.159 0.504 . . . . 0.0 111.644 -179.919 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 156' ' ' MET . . . . . 0.503 ' O ' ' N ' ' A' ' 123' ' ' ARG . 10.7 mmm -115.82 178.93 0.87 Allowed Pre-proline 0 C--N 1.328 -0.369 0 CA-C-N 115.556 -0.747 . . . . 0.0 110.302 179.413 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . 0.426 ' CD ' ' HB3' ' A' ' 156' ' ' MET . 88.5 Cg_endo -91.33 114.82 0.4 Allowed 'Trans proline' 0 N--CA 1.457 -0.632 0 C-N-CA 122.61 2.207 . . . . 0.0 112.546 -179.685 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 158' ' ' ALA . . . . . 0.449 ' HB2' HD11 ' A' ' 103' ' ' ILE . . . . . . . . 0 C--O 1.249 1.035 0 CA-C-O 118.285 -0.864 . . . . 0.0 111.071 179.727 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo . . . . . 0 N--CA 1.488 1.175 0 CA-C-O 120.671 0.196 . . . . 0.0 111.706 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -75.48 129.57 12.04 Favored 'Trans proline' 0 C--N 1.345 0.354 0 C-N-CA 122.616 2.211 . . . . 0.0 112.592 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 56.5 t -87.95 142.39 13.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.884 179.843 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 1.8 m -120.5 143.01 48.78 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.868 179.75 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 35.9 m -107.09 111.33 23.73 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.267 179.289 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.427 HG12 ' HB ' ' A' ' 118' ' ' VAL . 53.6 t -86.21 106.33 15.49 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.423 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.107 -179.759 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 1.4 tt -110.09 81.93 1.51 Allowed 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.157 -0.474 . . . . 0.0 109.729 179.107 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.405 ' CD1' ' CG1' ' A' ' 84' ' ' VAL . 1.8 mp -81.83 134.17 27.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 121.106 0.479 . . . . 0.0 111.732 -178.965 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.461 ' CB ' HG21 ' A' ' 112' ' ' ILE . 0.0 OUTLIER -91.36 108.69 20.06 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.99 179.813 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . 0.454 ' HA ' ' NE ' ' A' ' 88' ' ' ARG . 1.0 OUTLIER -113.14 87.11 10.24 Favored Pre-proline 0 C--N 1.328 -0.365 0 CA-C-O 120.878 0.371 . . . . 0.0 111.676 -179.209 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . 0.405 ' HD2' ' NH2' ' A' ' 88' ' ' ARG . 96.4 Cg_endo -78.96 1.91 8.73 Favored 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.598 2.199 . . . . 0.0 112.952 179.776 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -154.5 -162.29 1.37 Allowed 'General case' 0 C--N 1.332 -0.17 0 CA-C-O 120.743 0.306 . . . . 0.0 111.36 -179.884 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -128.18 -40.58 1.64 Allowed 'General case' 0 C--N 1.332 -0.153 0 CA-C-O 120.925 0.393 . . . . 0.0 111.389 -179.622 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -53.44 -23.3 9.6 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.536 -179.524 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . 0.444 ' HB2' ' NH2' ' A' ' 88' ' ' ARG . 77.4 m-85 -95.65 148.89 22.06 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.828 179.824 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -97.03 175.6 6.26 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.155 -179.842 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . 0.42 ' N ' ' CD2' ' A' ' 95' ' ' LEU . 2.7 mm? -72.49 -51.68 19.06 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.661 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 121.74 31.74 1.09 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.9 179.784 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 47.8 p90 -175.55 145.14 0.71 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.832 0.349 . . . . 0.0 111.058 179.818 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.427 ' O ' ' HA ' ' A' ' 104' ' ' ILE . 14.8 m -91.76 148.44 22.24 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.747 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.404 ' CG1' ' CG2' ' A' ' 141' ' ' VAL . 5.1 p -118.82 137.02 54.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.366 -179.686 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -129.89 89.85 2.88 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.866 -0.607 . . . . 0.0 109.959 179.424 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 63.9 t30 60.6 17.38 7.39 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.627 -179.038 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 124.58 -39.31 2.15 Favored Glycine 0 N--CA 1.448 -0.566 0 C-N-CA 120.957 -0.639 . . . . 0.0 112.031 -179.808 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.449 HG12 ' CB ' ' A' ' 158' ' ' ALA . 23.2 mt -78.35 131.41 34.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-O 120.989 0.423 . . . . 0.0 111.432 -179.693 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.427 ' HA ' ' O ' ' A' ' 98' ' ' SER . 3.6 mp -85.54 139.34 17.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.841 179.743 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 12.0 t -94.97 -67.35 0.86 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.047 -179.648 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 3.3 m -112.64 146.92 37.8 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.79 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -133.24 100.89 4.99 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.662 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 2.7 tmm? -60.01 141.34 55.82 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.907 -179.888 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -93.4 44.14 1.13 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.09 0.471 . . . . 0.0 110.703 179.798 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -162.78 23.98 0.2 Allowed Glycine 0 N--CA 1.45 -0.375 0 CA-C-N 115.691 -0.686 . . . . 0.0 112.282 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.5 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -112.77 175.46 16.8 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.851 -0.69 . . . . 0.0 111.952 179.798 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . 0.461 HG21 ' CB ' ' A' ' 87' ' ' ARG . 0.5 OUTLIER -79.27 -23.55 12.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-O 120.933 0.397 . . . . 0.0 111.578 -179.772 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' ALA . . . . . . . . . . . . . . . -57.92 -30.41 65.91 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.968 0.413 . . . . 0.0 110.604 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' GLU . . . . . 0.5 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 8.6 pt-20 -59.92 -45.2 93.33 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.722 179.467 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 88.5 mtt180 -64.78 -46.26 82.83 Favored 'General case' 0 N--CA 1.452 -0.358 0 CA-C-N 115.96 -0.564 . . . . 0.0 111.087 -179.441 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -49.75 -74.65 0.25 Allowed Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.413 -0.899 . . . . 0.0 112.591 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 175.21 -16.49 0.04 OUTLIER Glycine 0 CA--C 1.52 0.386 0 C-N-CA 120.77 -0.729 . . . . 0.0 113.112 179.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.427 ' HB ' HG12 ' A' ' 84' ' ' VAL . 5.0 p -34.13 148.8 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 N-CA-C 112.156 0.428 . . . . 0.0 112.156 -179.659 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 1.1 ttp85 -151.83 113.01 4.28 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.823 179.907 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 14.9 p -52.48 114.89 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.316 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 113.5 19.12 6.74 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.433 -179.809 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 3.2 m170 -120.86 139.79 52.69 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.803 0.335 . . . . 0.0 110.773 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.45 ' HB2' ' CB ' ' A' ' 158' ' ' ALA . 10.7 ttt180 -83.65 90.65 7.31 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.384 -179.673 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . 0.419 HG13 ' CD1' ' A' ' 104' ' ' ILE . 71.4 mt -48.75 134.33 6.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 178.784 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' ILE . . . . . 0.465 ' CG1' ' H ' ' A' ' 126' ' ' GLU . 0.8 OUTLIER -128.29 -84.46 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 N-CA-C 113.175 0.806 . . . . 0.0 113.175 -178.398 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . 0.465 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 4.3 mt-10 -80.88 92.16 6.08 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 112.922 0.712 . . . . 0.0 112.922 -178.236 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.479 HG12 ' HG3' ' A' ' 153' ' ' MET . 1.3 mt -94.34 94.87 4.74 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.668 178.722 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . 0.454 ' N ' ' O ' ' A' ' 152' ' ' HIS . 55.5 m-80 62.3 26.35 15.77 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.882 -179.813 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 108.91 -19.37 30.44 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.733 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 5.5 tt0 -90.77 110.39 21.59 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.785 0.326 . . . . 0.0 110.878 179.903 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 1.4 m -76.2 93.32 3.36 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.077 -179.822 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . 0.428 ' CG2' HD13 ' A' ' 127' ' ' ILE . 25.9 m -73.48 -5.15 6.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.877 179.859 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 11.4 p -47.26 -36.65 4.1 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-O 120.857 0.361 . . . . 0.0 111.41 -179.713 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -117.28 28.65 8.35 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.628 179.501 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 135' ' ' THR . . . . . 0.405 ' CG2' ' HD2' ' A' ' 136' ' ' PRO . 67.4 m -116.37 140.81 27.0 Favored Pre-proline 0 C--N 1.328 -0.363 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.343 -179.734 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 136' ' ' PRO . . . . . 0.424 ' HG2' ' HB2' ' A' ' 139' ' ' LYS . 8.9 Cg_endo -50.99 164.36 0.63 Allowed 'Trans proline' 0 C--N 1.347 0.493 0 C-N-CA 122.759 2.306 . . . . 0.0 112.347 179.765 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 137' ' ' HIS . . . . . 0.412 ' CE1' ' HG3' ' A' ' 138' ' ' GLU . 20.9 p80 -70.91 -50.09 38.63 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.739 -179.42 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . 0.412 ' HG3' ' CE1' ' A' ' 137' ' ' HIS . 3.7 mt-10 -53.91 -33.79 57.66 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.607 -179.355 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 139' ' ' LYS . . . . . 0.463 ' O ' ' CD1' ' A' ' 143' ' ' ILE . 8.6 tptt -64.02 -48.05 77.86 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.369 -0.378 . . . . 0.0 111.098 -179.828 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . 0.44 HD13 HG23 ' A' ' 140' ' ' ILE . 13.9 mt -58.38 -46.15 89.38 Favored 'Isoleucine or valine' 0 C--O 1.235 0.318 0 CA-C-O 121.013 0.435 . . . . 0.0 110.669 -179.898 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . 0.404 ' CG2' ' CG1' ' A' ' 99' ' ' VAL . 58.9 t -60.05 -32.82 51.16 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.353 179.166 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 57.2 t-80 -62.77 -54.15 43.4 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.304 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . 0.463 ' CD1' ' O ' ' A' ' 139' ' ' LYS . 4.2 mp -52.96 -57.21 4.9 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.451 0 CA-C-O 121.018 0.437 . . . . 0.0 110.375 179.647 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.566 HD23 HG12 ' A' ' 151' ' ' ILE . 1.4 mt -62.41 -30.04 70.93 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.55 -0.75 . . . . 0.0 110.381 179.581 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 3.4 m -66.63 -26.57 67.14 Favored 'General case' 0 N--CA 1.452 -0.347 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 178.448 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 4.3 m-80 -132.86 35.86 3.53 Favored 'General case' 0 CA--C 1.529 0.145 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.377 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 147' ' ' ALA . . . . . 0.408 ' CB ' ' O ' ' A' ' 143' ' ' ILE . . . -118.06 52.59 1.0 Allowed 'General case' 0 C--N 1.332 -0.178 0 CA-C-O 120.776 0.322 . . . . 0.0 111.464 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 15.6 m -53.5 -178.48 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 120.877 0.37 . . . . 0.0 111.035 179.91 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 83.96 -108.47 3.08 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.424 -179.834 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 20.2 mt-10 -138.27 101.6 4.43 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.878 0.37 . . . . 0.0 110.454 179.787 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . 0.566 HG12 HD23 ' A' ' 144' ' ' LEU . 1.1 mt -76.15 111.72 13.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 121.051 0.453 . . . . 0.0 111.487 -179.516 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . 0.454 ' O ' ' N ' ' A' ' 128' ' ' ASN . 0.2 OUTLIER -99.72 124.23 44.76 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 178.356 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 153' ' ' MET . . . . . 0.479 ' HG3' HG12 ' A' ' 127' ' ' ILE . 11.5 tmm? -150.68 155.08 38.63 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.139 0.495 . . . . 0.0 112.25 -177.937 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -113.45 148.17 36.43 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.59 -0.732 . . . . 0.0 109.669 178.977 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 16.3 p -130.7 141.02 50.39 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.28 0.562 . . . . 0.0 111.836 -179.266 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 156' ' ' MET . . . . . 0.439 ' O ' ' CB ' ' A' ' 123' ' ' ARG . 0.0 OUTLIER -123.28 119.45 27.49 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 115.109 -0.951 . . . . 0.0 110.053 179.475 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 88.9 Cg_exo -42.24 110.63 0.16 Allowed 'Trans proline' 0 C--N 1.346 0.402 0 C-N-CA 122.56 2.173 . . . . 0.0 112.935 -179.756 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 158' ' ' ALA . . . . . 0.45 ' CB ' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.249 1.05 0 CA-C-O 118.23 -0.89 . . . . 0.0 111.043 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_endo . . . . . 0 N--CA 1.488 1.196 0 CA-C-O 120.604 0.168 . . . . 0.0 111.753 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 55.1 Cg_exo -52.05 88.87 0.03 OUTLIER 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 122.519 2.146 . . . . 0.0 112.377 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 12.5 p -86.16 141.43 14.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.035 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 3.0 m -115.49 132.05 56.74 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.993 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 26.6 m -92.26 111.65 23.29 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.032 179.235 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.484 ' HB ' ' HG3' ' A' ' 153' ' ' MET . 94.5 t -83.89 105.41 13.34 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.566 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.68 -179.093 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . 0.402 ' HG ' ' CD2' ' A' ' 152' ' ' HIS . 5.2 tt -105.2 80.07 1.56 Allowed 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 109.176 -0.676 . . . . 0.0 109.176 178.466 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.445 HG13 HG11 ' A' ' 84' ' ' VAL . 4.5 mt -82.04 125.33 39.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 121.236 0.541 . . . . 0.0 111.874 -178.354 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.411 ' CB ' HG21 ' A' ' 112' ' ' ILE . 0.1 OUTLIER -76.94 147.86 36.7 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.289 -0.869 . . . . 0.0 110.061 179.467 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 6.0 mtp85 -141.84 96.13 6.81 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 120.686 0.279 . . . . 0.0 111.089 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_exo -56.38 -60.28 0.51 Allowed 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 122.562 2.175 . . . . 0.0 112.447 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -127.5 -169.17 2.0 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 121.03 0.443 . . . . 0.0 111.033 -179.692 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -89.11 -43.16 11.26 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.988 -0.551 . . . . 0.0 111.04 -179.942 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 16.5 mtt-85 -64.81 -13.66 56.44 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.639 -179.689 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 24.1 m-85 -88.68 117.57 27.75 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.456 -0.338 . . . . 0.0 110.976 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -85.21 169.42 13.84 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.999 -179.918 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . 0.432 HD11 ' CE2' ' A' ' 97' ' ' PHE . 76.9 mt -76.21 -69.4 0.51 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.779 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 128.23 54.13 0.12 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.457 -0.877 . . . . 0.0 113.1 179.531 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . 0.432 ' CE2' HD11 ' A' ' 95' ' ' LEU . 42.5 p90 -177.83 174.25 1.47 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.817 0.342 . . . . 0.0 111.053 179.635 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -116.52 150.3 38.17 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.866 179.869 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.442 ' CG1' ' CG2' ' A' ' 141' ' ' VAL . 9.3 p -125.6 136.36 61.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.314 -179.894 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . 0.404 ' HG3' ' HB ' ' A' ' 103' ' ' ILE . 1.6 pt20 -130.37 91.64 3.13 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.215 179.464 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER 60.74 13.83 4.64 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.175 -179.343 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.422 ' O ' ' N ' ' A' ' 124' ' ' ILE . . . 129.67 -38.4 2.0 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.872 -0.68 . . . . 0.0 112.366 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.458 HG12 ' CB ' ' A' ' 158' ' ' ALA . 36.2 mt -77.13 136.86 23.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-O 121.105 0.479 . . . . 0.0 111.684 -179.559 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 4.0 mp -90.98 138.37 19.73 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.54 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 7.7 m -94.29 -84.28 0.32 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.509 -179.298 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 46.3 t -109.88 113.53 26.33 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.926 0.393 . . . . 0.0 111.203 -179.6 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 1.4 tm? -105.74 110.06 22.23 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.45 179.645 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 9.0 ttp -58.08 116.84 3.79 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.024 -179.762 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 7.1 mtt85 -63.89 80.79 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.001 0.429 . . . . 0.0 110.671 179.789 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 166.74 -30.88 0.2 Allowed Glycine 0 N--CA 1.45 -0.399 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.894 -179.754 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.45 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -59.1 176.18 2.7 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.131 179.625 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . 0.411 HG21 ' CB ' ' A' ' 87' ' ' ARG . 1.2 mt -79.06 -19.53 12.88 Favored 'Isoleucine or valine' 0 C--O 1.236 0.343 0 CA-C-O 120.892 0.377 . . . . 0.0 111.729 -179.69 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' ALA . . . . . 0.432 ' CB ' ' CD2' ' A' ' 97' ' ' PHE . . . -57.77 -30.61 65.78 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.981 0.42 . . . . 0.0 110.74 179.909 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' GLU . . . . . 0.45 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 10.5 pt-20 -60.92 -46.46 90.59 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.746 179.703 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -62.23 -45.76 91.89 Favored 'General case' 0 N--CA 1.453 -0.304 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.946 -179.444 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -51.19 -74.35 0.3 Allowed Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.297 -0.954 . . . . 0.0 112.532 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . 0.483 ' O ' ' C ' ' A' ' 118' ' ' VAL . . . 174.29 -26.22 0.08 OUTLIER Glycine 0 CA--C 1.518 0.276 0 C-N-CA 121.116 -0.564 . . . . 0.0 112.61 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.483 ' C ' ' O ' ' A' ' 117' ' ' GLY . 13.5 t -15.72 -81.98 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.471 0.594 0 C-N-CA 123.259 0.624 . . . . 0.0 112.632 -179.824 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.4 ' N ' ' CG1' ' A' ' 118' ' ' VAL . 0.8 OUTLIER 63.84 129.05 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.748 0.309 . . . . 0.0 110.454 -179.43 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 22.2 t -63.29 130.88 28.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.314 -179.799 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 97.41 34.22 5.65 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.685 179.756 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 5.1 m170 -122.65 -174.54 2.94 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.933 0.396 . . . . 0.0 110.878 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.53 ' N ' ' O ' ' A' ' 156' ' ' MET . 8.7 ttm-85 -144.23 89.43 2.02 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.87 -179.803 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . 0.438 HG22 ' CG2' ' A' ' 132' ' ' VAL . 78.3 mt -50.4 150.16 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 N-CA-C 110.208 -0.293 . . . . 0.0 110.208 179.246 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' ILE . . . . . 0.444 ' CG1' ' H ' ' A' ' 126' ' ' GLU . 0.6 OUTLIER -146.07 -84.5 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 N-CA-C 112.87 0.693 . . . . 0.0 112.87 -178.892 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . 0.444 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 40.0 mt-10 -83.2 89.12 6.92 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 112.532 0.568 . . . . 0.0 112.532 -178.499 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.55 ' HA ' ' HB3' ' A' ' 153' ' ' MET . 1.8 mt -89.03 102.0 12.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.005 179.221 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 22.6 m-20 53.75 24.85 4.64 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.121 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 111.83 -16.51 25.76 Favored Glycine 0 CA--C 1.519 0.317 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.725 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -93.16 108.94 20.45 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.782 0.325 . . . . 0.0 110.889 -179.88 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 83.1 p -74.83 89.47 2.33 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.096 -179.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . 0.438 ' CG2' HG22 ' A' ' 124' ' ' ILE . 27.7 m -74.99 -4.08 5.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.832 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 12.1 p -46.37 -40.95 4.35 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-O 120.928 0.394 . . . . 0.0 111.343 -179.854 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -113.91 29.48 7.97 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.673 179.395 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 135' ' ' THR . . . . . 0.417 ' CG2' ' HD2' ' A' ' 136' ' ' PRO . 84.0 m -114.04 143.26 29.32 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.047 -179.746 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 136' ' ' PRO . . . . . 0.417 ' HD2' ' CG2' ' A' ' 135' ' ' THR . 74.8 Cg_exo -49.72 156.97 2.73 Favored 'Trans proline' 0 C--N 1.347 0.494 0 C-N-CA 122.45 2.1 . . . . 0.0 112.245 179.851 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 137' ' ' HIS . . . . . 0.419 ' CE1' ' HG3' ' A' ' 138' ' ' GLU . 7.6 p80 -68.08 -46.47 70.93 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.266 -179.762 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . 0.419 ' HG3' ' CE1' ' A' ' 137' ' ' HIS . 18.1 mt-10 -55.56 -35.75 66.07 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.299 -179.791 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 139' ' ' LYS . . . . . 0.437 ' O ' ' CD1' ' A' ' 143' ' ' ILE . 5.4 tptt -62.78 -47.5 83.2 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.885 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . 0.445 HG23 HD12 ' A' ' 140' ' ' ILE . 16.4 mt -58.8 -43.04 87.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.584 179.951 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . 0.442 ' CG2' ' CG1' ' A' ' 99' ' ' VAL . 92.8 t -62.16 -32.72 55.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.177 179.051 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 2.0 t-80 -62.19 -54.48 40.36 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.907 179.901 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . 0.437 ' CD1' ' O ' ' A' ' 139' ' ' LYS . 4.4 mp -53.09 -56.94 5.67 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.408 0 CA-C-O 121.207 0.527 . . . . 0.0 110.214 179.391 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.575 HD21 HG12 ' A' ' 151' ' ' ILE . 4.5 mt -60.94 -30.12 70.04 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.327 -0.852 . . . . 0.0 110.288 179.619 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 28.5 t -69.37 -26.45 64.67 Favored 'General case' 0 N--CA 1.452 -0.356 0 CA-C-N 116.183 -0.462 . . . . 0.0 109.929 178.672 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -128.9 33.42 4.62 Favored 'General case' 0 C--O 1.232 0.138 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.104 179.85 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 147' ' ' ALA . . . . . 0.41 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . -115.81 46.17 1.58 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.859 0.361 . . . . 0.0 111.462 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 11.2 m -50.69 157.36 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.389 -179.864 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 102.68 -106.39 2.91 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.504 -179.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 30.1 mt-10 -139.14 94.44 2.8 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.805 0.336 . . . . 0.0 110.768 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . 0.575 HG12 HD21 ' A' ' 144' ' ' LEU . 1.0 OUTLIER -64.71 111.96 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.037 -179.867 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . 0.402 ' CD2' ' HG ' ' A' ' 85' ' ' LEU . 0.2 OUTLIER -99.43 115.94 30.42 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.046 -0.524 . . . . 0.0 109.962 179.135 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 153' ' ' MET . . . . . 0.55 ' HB3' ' HA ' ' A' ' 127' ' ' ILE . 0.1 OUTLIER -147.82 177.42 9.33 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.406 0.622 . . . . 0.0 111.58 -179.216 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 12.9 mttt -126.7 160.27 31.26 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 114.938 -1.028 . . . . 0.0 109.866 179.562 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 24.4 p -144.18 144.58 31.62 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.299 0.571 . . . . 0.0 111.814 -179.565 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 156' ' ' MET . . . . . 0.53 ' O ' ' N ' ' A' ' 123' ' ' ARG . 0.0 OUTLIER -115.87 177.51 1.19 Allowed Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 115.142 -0.936 . . . . 0.0 109.997 179.508 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . 0.4 ' HD2' ' HB3' ' A' ' 156' ' ' MET . 89.8 Cg_endo -92.4 102.07 0.19 Allowed 'Trans proline' 0 N--CA 1.455 -0.757 0 C-N-CA 122.585 2.19 . . . . 0.0 112.627 -179.684 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 158' ' ' ALA . . . . . 0.466 ' CB ' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.248 1.025 0 CA-C-O 118.168 -0.92 . . . . 0.0 111.054 179.739 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_endo . . . . . 0 N--CA 1.489 1.25 0 CA-C-O 120.652 0.188 . . . . 0.0 111.772 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -72.08 65.46 3.4 Favored 'Trans proline' 0 C--N 1.343 0.248 0 C-N-CA 122.575 2.183 . . . . 0.0 112.37 -179.878 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 37.1 t -108.02 121.6 61.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.061 179.796 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.5 m -98.69 139.24 34.69 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.869 179.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 10.3 m -109.29 111.46 23.06 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.106 -0.497 . . . . 0.0 109.93 179.015 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.443 ' HB ' ' CG ' ' A' ' 153' ' ' MET . 66.2 t -81.72 106.38 12.68 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.638 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.506 -179.475 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . 0.41 ' HB2' ' CD2' ' A' ' 152' ' ' HIS . 16.8 tp -104.91 87.06 2.57 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.592 178.859 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.463 HG12 ' HA ' ' A' ' 113' ' ' ALA . 3.7 mt -81.56 146.82 6.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.229 -179.088 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.423 ' CB ' HG21 ' A' ' 112' ' ' ILE . 0.0 OUTLIER -115.7 108.97 17.06 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.486 -179.602 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 53.5 ttt180 -104.02 108.28 59.49 Favored Pre-proline 0 C--N 1.33 -0.257 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.847 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -68.45 -27.56 33.4 Favored 'Trans proline' 0 C--N 1.347 0.487 0 C-N-CA 122.36 2.04 . . . . 0.0 112.402 -179.942 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -165.22 168.98 16.52 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.993 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -66.86 -36.87 83.3 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.067 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.21 -14.15 59.96 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.086 -0.507 . . . . 0.0 111.492 -179.769 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 46.6 m-85 -99.39 113.11 25.26 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.42 -0.355 . . . . 0.0 110.889 179.881 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -73.98 165.93 24.27 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.007 -179.926 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . 0.405 HD13 ' CE1' ' A' ' 97' ' ' PHE . 26.0 mt -77.44 -67.43 0.72 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.835 179.965 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 132.51 40.6 0.2 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.566 -0.826 . . . . 0.0 112.956 179.624 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . 0.405 ' CE1' HD13 ' A' ' 95' ' ' LEU . 35.3 p90 -177.05 159.55 1.67 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.796 0.331 . . . . 0.0 110.968 179.68 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -112.94 144.67 42.12 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.963 -179.92 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.484 HG21 ' CG2' ' A' ' 140' ' ' ILE . 12.7 p -111.47 138.0 41.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.591 -179.861 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . 0.402 ' O ' ' N ' ' A' ' 102' ' ' GLY . 5.2 mm-40 -130.04 88.58 2.68 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.007 179.013 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 3.7 t30 64.69 -70.66 0.08 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.951 -179.662 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.412 ' O ' ' HA ' ' A' ' 123' ' ' ARG . . . -141.86 -1.19 1.4 Allowed Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 120.445 -0.883 . . . . 0.0 113.024 179.928 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.481 HD13 ' HB2' ' A' ' 158' ' ' ALA . 25.5 mm -119.55 159.2 20.68 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.166 0 CA-C-O 120.969 0.414 . . . . 0.0 111.304 -179.712 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.503 HD11 HG13 ' A' ' 124' ' ' ILE . 3.3 mp -102.19 141.46 18.36 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.912 -179.762 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -83.51 -69.43 0.64 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.936 -179.845 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -142.9 168.98 18.42 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.941 -179.882 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.407 ' HB2' ' CG2' ' A' ' 120' ' ' VAL . 0.6 OUTLIER -123.1 167.46 13.63 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.912 179.926 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 4.5 ttt -122.62 97.76 5.6 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.648 179.705 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -55.21 91.0 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.86 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 152.94 -29.38 0.82 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.947 -0.644 . . . . 0.0 112.029 -179.69 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.4 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -70.88 176.82 35.88 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.278 179.753 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . 0.423 HG21 ' CB ' ' A' ' 87' ' ' ARG . 0.6 OUTLIER -78.74 -16.6 13.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 120.711 0.291 . . . . 0.0 111.664 -179.769 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' ALA . . . . . 0.463 ' HA ' HG12 ' A' ' 86' ' ' ILE . . . -57.75 -30.53 65.66 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.013 0.435 . . . . 0.0 110.726 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' GLU . . . . . 0.4 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 10.5 pt-20 -60.34 -46.91 88.24 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.662 179.632 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -62.49 -47.8 82.39 Favored 'General case' 0 N--CA 1.452 -0.352 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.125 -179.684 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -49.91 -74.14 0.3 Allowed Glycine 0 CA--C 1.519 0.325 0 C-N-CA 120.454 -0.879 . . . . 0.0 112.452 179.866 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 173.99 -25.16 0.07 OUTLIER Glycine 0 CA--C 1.519 0.299 0 C-N-CA 121.141 -0.552 . . . . 0.0 112.366 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.423 ' N ' ' CG2' ' A' ' 84' ' ' VAL . 1.1 t -40.24 113.76 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.256 0 CA-C-O 120.981 0.419 . . . . 0.0 111.802 -179.709 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 2.3 ttt180 -132.3 110.26 10.47 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.117 179.462 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . 0.407 ' CG2' ' HB2' ' A' ' 107' ' ' LEU . 85.1 t -43.6 118.12 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.688 -179.451 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 118.5 28.13 2.21 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.845 -0.693 . . . . 0.0 112.932 179.73 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . 0.479 ' CD2' ' HB ' ' A' ' 155' ' ' THR . 20.2 p-80 -137.3 -170.29 2.7 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.619 0.247 . . . . 0.0 111.07 179.752 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.412 ' HA ' ' O ' ' A' ' 102' ' ' GLY . 55.6 ttp85 -133.92 114.39 13.23 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-N 116.574 -0.285 . . . . 0.0 111.711 -179.555 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . 0.503 HG13 HD11 ' A' ' 104' ' ' ILE . 34.7 mt -73.16 158.58 6.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 178.59 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' ILE . . . . . 0.495 ' CG1' ' H ' ' A' ' 126' ' ' GLU . 0.8 OUTLIER -147.14 -83.02 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 N-CA-C 112.867 0.691 . . . . 0.0 112.867 -179.624 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . 0.495 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 5.4 mt-10 -87.41 87.7 7.48 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 112.44 0.533 . . . . 0.0 112.44 -178.477 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.469 ' HA ' ' CB ' ' A' ' 153' ' ' MET . 2.4 mt -87.06 103.83 13.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.29 179.197 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 7.5 m-20 53.01 25.32 3.96 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.905 -0.588 . . . . 0.0 111.193 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 110.08 -13.57 31.45 Favored Glycine 0 CA--C 1.519 0.3 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.846 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 11.6 tt0 -95.72 110.88 22.95 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.787 0.327 . . . . 0.0 110.772 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' SER . . . . . 0.401 ' HA ' ' O ' ' A' ' 125' ' ' ILE . 1.1 m -74.84 87.24 2.25 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.042 -179.901 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . 0.462 ' CG2' HG21 ' A' ' 124' ' ' ILE . 31.9 m -73.9 -5.3 6.53 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.369 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.956 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 9.8 p -46.31 -31.56 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-O 120.888 0.375 . . . . 0.0 111.566 -179.695 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -127.95 27.41 5.7 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.617 179.409 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 135' ' ' THR . . . . . 0.447 ' HB ' ' HA ' ' A' ' 132' ' ' VAL . 32.5 m -110.65 143.79 28.93 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 115.833 -0.621 . . . . 0.0 111.214 -179.736 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 136' ' ' PRO . . . . . 0.418 ' HD2' ' CG2' ' A' ' 135' ' ' THR . 50.5 Cg_exo -53.78 164.27 2.45 Favored 'Trans proline' 0 C--N 1.347 0.495 0 C-N-CA 122.545 2.163 . . . . 0.0 112.048 179.512 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 137' ' ' HIS . . . . . 0.405 ' CG ' ' N ' ' A' ' 138' ' ' GLU . 6.8 p80 -72.6 -46.83 52.27 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.517 -179.607 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . 0.405 ' N ' ' CG ' ' A' ' 137' ' ' HIS . 1.7 mm-40 -54.01 -39.13 65.85 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.472 -179.513 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 139' ' ' LYS . . . . . 0.454 ' O ' ' CD1' ' A' ' 143' ' ' ILE . 7.0 tttp -63.53 -45.97 88.18 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.225 -179.701 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . 0.484 ' CG2' HG21 ' A' ' 99' ' ' VAL . 9.7 mt -59.36 -46.08 92.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.983 0.421 . . . . 0.0 110.431 179.956 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 55.4 t -60.08 -32.37 50.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.039 179.034 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 4.6 t60 -61.08 -53.68 54.06 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.679 179.579 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . 0.454 ' CD1' ' O ' ' A' ' 139' ' ' LYS . 4.3 mp -53.16 -56.9 5.98 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.379 0 CA-C-O 121.276 0.56 . . . . 0.0 110.263 179.209 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.541 HD22 HG12 ' A' ' 151' ' ' ILE . 3.9 mt -61.24 -30.32 70.38 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.254 -0.884 . . . . 0.0 110.275 179.453 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 30.9 t -69.31 -26.38 64.69 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.123 -0.489 . . . . 0.0 109.925 178.676 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -127.43 32.2 5.06 Favored 'General case' 0 C--O 1.231 0.099 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.985 179.697 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . -114.03 41.62 2.21 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.352 -0.386 . . . . 0.0 111.296 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 18.5 m -51.72 138.76 8.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.447 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 120.88 -103.46 0.9 Allowed Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.442 -179.914 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 4.7 mt-10 -139.28 100.65 4.06 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.79 0.328 . . . . 0.0 110.877 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . 0.541 HG12 HD22 ' A' ' 144' ' ' LEU . 1.3 mt -78.86 111.78 16.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.942 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . 0.41 ' CD2' ' HB2' ' A' ' 85' ' ' LEU . 0.5 OUTLIER -106.97 115.55 30.37 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.141 179.325 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 153' ' ' MET . . . . . 0.469 ' CB ' ' HA ' ' A' ' 127' ' ' ILE . 1.7 ptm -136.64 161.98 34.43 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.071 0.463 . . . . 0.0 111.729 -179.318 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 3.5 mttt -104.53 150.3 24.73 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.712 -0.676 . . . . 0.0 109.778 179.121 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 155' ' ' THR . . . . . 0.479 ' HB ' ' CD2' ' A' ' 122' ' ' HIS . 21.8 p -146.14 150.44 35.89 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.295 0.569 . . . . 0.0 112.076 -179.086 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 156' ' ' MET . . . . . 0.401 ' CE ' HD12 ' A' ' 125' ' ' ILE . 0.0 OUTLIER -144.76 145.33 27.58 Favored Pre-proline 0 C--N 1.327 -0.406 0 CA-C-N 115.226 -0.897 . . . . 0.0 110.346 179.102 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_exo -50.92 109.38 0.3 Allowed 'Trans proline' 0 C--N 1.343 0.263 0 C-N-CA 122.512 2.141 . . . . 0.0 112.628 -179.759 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 158' ' ' ALA . . . . . 0.481 ' HB2' HD13 ' A' ' 103' ' ' ILE . . . . . . . . 0 C--O 1.25 1.084 0 CA-C-O 118.266 -0.873 . . . . 0.0 111.343 179.863 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_exo . . . . . 0 N--CA 1.489 1.252 0 CA-C-O 120.716 0.215 . . . . 0.0 111.733 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -70.22 115.36 4.12 Favored 'Trans proline' 0 C--N 1.343 0.265 0 C-N-CA 122.515 2.143 . . . . 0.0 112.372 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 18.3 t -93.17 139.42 18.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.104 179.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.1 m -114.42 132.14 56.35 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.926 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 56.5 m -95.58 111.19 23.16 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.947 179.119 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.473 HG13 HG13 ' A' ' 86' ' ' ILE . 86.3 t -88.39 105.38 15.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.58 -179.206 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . 0.439 ' O ' ' HA2' ' A' ' 116' ' ' GLY . 2.7 tp -100.01 84.27 2.84 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 178.588 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.473 HG13 HG13 ' A' ' 84' ' ' VAL . 22.0 mt -81.27 127.31 39.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-O 121.4 0.619 . . . . 0.0 111.928 -178.501 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.49 153.34 39.16 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.136 -0.938 . . . . 0.0 110.407 179.856 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 5.5 ttt-85 -152.15 91.71 3.62 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 120.682 0.277 . . . . 0.0 111.161 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -58.53 -63.48 0.14 Allowed 'Trans proline' 0 C--N 1.345 0.346 0 C-N-CA 122.583 2.189 . . . . 0.0 112.23 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 4.9 t0 -117.14 -173.68 2.45 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.169 -179.859 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.403 ' CD1' ' CG1' ' A' ' 148' ' ' VAL . 0.1 OUTLIER -91.79 -21.95 20.41 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.311 -179.864 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -95.76 22.7 6.97 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.469 -0.332 . . . . 0.0 111.219 -179.779 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 17.7 m-85 -121.04 117.97 28.59 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.801 0.334 . . . . 0.0 110.835 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 3.4 mp0 -64.57 177.93 0.83 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.874 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . 0.4 ' CD1' ' CD1' ' A' ' 144' ' ' LEU . 42.5 mt -96.98 -61.35 1.42 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.932 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 132.05 53.91 0.09 OUTLIER Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.718 179.912 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -176.68 -171.96 0.41 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.904 0.383 . . . . 0.0 110.991 179.9 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 8.3 t -137.44 130.35 30.36 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.793 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.447 ' O ' ' CE1' ' A' ' 137' ' ' HIS . 10.4 p -109.97 114.35 46.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.06 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . 0.421 ' O ' ' N ' ' A' ' 102' ' ' GLY . 1.2 tt0 -110.31 89.0 2.9 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.817 0.341 . . . . 0.0 110.908 -180.0 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' ASN . . . . . 0.46 ' O ' ' CD1' ' A' ' 140' ' ' ILE . 1.6 t30 65.18 -64.64 0.17 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.51 179.702 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.421 ' N ' ' O ' ' A' ' 100' ' ' GLN . . . -146.88 -4.49 0.42 Allowed Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.336 -0.935 . . . . 0.0 113.661 -179.623 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.403 HD12 ' CB ' ' A' ' 158' ' ' ALA . 31.5 mm -125.09 142.64 41.35 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 117.389 0.594 . . . . 0.0 111.307 -179.543 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 3.9 mp -84.44 142.58 13.16 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.788 179.712 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -105.42 -77.73 0.58 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.991 -179.829 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 62.6 p -90.64 146.98 23.6 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.944 0.402 . . . . 0.0 110.9 -179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -136.72 123.92 21.77 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.883 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 4.1 mtt -77.06 120.37 22.05 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.882 -179.949 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -81.33 105.59 12.63 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.765 179.893 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 101.66 26.63 7.52 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.394 -179.917 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.476 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -111.76 -158.25 14.53 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.701 -0.762 . . . . 0.0 113.209 -179.761 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 16.3 mt -80.16 -41.92 21.35 Favored 'Isoleucine or valine' 0 C--O 1.238 0.463 0 CA-C-O 121.076 0.465 . . . . 0.0 111.766 -179.588 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' ALA . . . . . . . . . . . . . . . -57.7 -36.21 71.67 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.193 -179.394 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' GLU . . . . . 0.52 ' HG3' ' N ' ' A' ' 115' ' ' ARG . 8.3 pt-20 -66.9 -36.26 81.87 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.484 179.561 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.52 ' N ' ' HG3' ' A' ' 114' ' ' GLU . 0.0 OUTLIER -59.39 -46.55 88.35 Favored 'General case' 0 N--CA 1.452 -0.359 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.559 -179.905 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.439 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -56.05 -71.31 0.75 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.205 -0.998 . . . . 0.0 112.539 179.635 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 174.32 -22.76 0.06 OUTLIER Glycine 0 CA--C 1.519 0.282 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.824 -179.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.452 ' N ' ' CG2' ' A' ' 84' ' ' VAL . 7.3 p -31.75 145.72 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 N-CA-C 112.265 0.469 . . . . 0.0 112.265 -179.621 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.423 ' HB3' ' CD2' ' A' ' 122' ' ' HIS . 0.1 OUTLIER -147.83 134.43 19.85 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.734 179.899 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 22.0 t -59.48 111.26 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.036 179.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 109.72 18.49 8.91 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.602 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . 0.423 ' CD2' ' HB3' ' A' ' 119' ' ' ARG . 1.7 m-70 -102.22 -173.02 2.24 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.682 0.277 . . . . 0.0 110.693 179.909 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.441 ' N ' ' O ' ' A' ' 156' ' ' MET . 40.4 ttt180 -142.76 90.71 2.24 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.363 -0.38 . . . . 0.0 111.335 -179.647 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . 0.437 HG23 ' CG2' ' A' ' 132' ' ' VAL . 25.2 mt -51.48 157.07 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.307 179.112 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' ILE . . . . . 0.446 ' CG1' ' H ' ' A' ' 126' ' ' GLU . 0.6 OUTLIER -149.38 -82.99 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 N-CA-C 112.576 0.584 . . . . 0.0 112.576 -179.389 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . 0.446 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 72.7 mt-10 -89.29 89.4 7.89 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 112.353 0.501 . . . . 0.0 112.353 -178.62 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.486 ' HA ' ' CB ' ' A' ' 153' ' ' MET . 2.1 mt -88.89 106.87 17.24 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.181 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.573 179.43 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . 0.419 ' HA ' ' CE1' ' A' ' 152' ' ' HIS . 3.1 t-20 53.45 31.69 12.64 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.899 -0.591 . . . . 0.0 111.066 179.726 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 98.23 -7.26 62.06 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.754 -179.74 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 2.9 tt0 -99.92 106.23 18.02 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.836 0.351 . . . . 0.0 110.756 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 1.6 m -71.12 84.26 0.72 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.157 -179.773 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . 0.437 ' CG2' HG23 ' A' ' 124' ' ' ILE . 34.1 m -67.73 -10.03 11.67 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.759 179.867 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 9.3 p -51.06 117.85 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.925 0.393 . . . . 0.0 110.961 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . 75.1 21.2 1.98 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.754 -178.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 135' ' ' THR . . . . . 0.455 ' CG2' ' HD2' ' A' ' 136' ' ' PRO . 29.3 m -103.5 142.52 24.74 Favored Pre-proline 0 C--N 1.327 -0.402 0 CA-C-N 115.648 -0.706 . . . . 0.0 110.802 179.828 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 136' ' ' PRO . . . . . 0.455 ' HD2' ' CG2' ' A' ' 135' ' ' THR . 94.9 Cg_exo -42.77 164.2 0.04 OUTLIER 'Trans proline' 0 C--N 1.348 0.533 0 C-N-CA 122.849 2.366 . . . . 0.0 112.9 -179.869 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 137' ' ' HIS . . . . . 0.447 ' CE1' ' O ' ' A' ' 99' ' ' VAL . 3.1 t-160 -74.17 -59.35 2.76 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.558 -179.525 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -53.67 -27.17 26.07 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.901 -179.135 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 139' ' ' LYS . . . . . 0.459 ' O ' ' CD1' ' A' ' 143' ' ' ILE . 0.9 OUTLIER -67.52 -51.44 50.85 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.651 0.262 . . . . 0.0 111.172 -179.535 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . 0.488 HG21 HD11 ' A' ' 140' ' ' ILE . 17.4 mt -59.54 -46.35 93.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 121.026 0.441 . . . . 0.0 110.751 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 93.5 t -60.11 -32.44 50.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.227 179.237 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -61.75 -54.88 36.48 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.971 179.723 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . 0.459 ' CD1' ' O ' ' A' ' 139' ' ' LYS . 4.1 mp -52.88 -56.9 5.62 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.391 0 CA-C-O 121.232 0.539 . . . . 0.0 110.267 179.569 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.563 HD23 HG12 ' A' ' 151' ' ' ILE . 1.6 mt -61.75 -29.97 70.48 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.394 179.582 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 25.8 t -69.25 -26.56 64.84 Favored 'General case' 0 C--N 1.33 -0.242 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 178.523 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -126.91 31.61 5.26 Favored 'General case' 0 CA--C 1.53 0.181 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.093 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 147' ' ' ALA . . . . . 0.454 ' HB3' ' HA ' ' A' ' 144' ' ' LEU . . . -116.98 58.19 0.78 Allowed 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.356 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . 0.403 ' CG1' ' CD1' ' A' ' 91' ' ' LEU . 3.9 m -53.28 173.7 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.346 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 87.9 -113.38 4.01 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.468 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 -139.76 102.84 4.53 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.835 0.35 . . . . 0.0 110.778 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . 0.563 HG12 HD23 ' A' ' 144' ' ' LEU . 1.3 mt -73.99 111.67 9.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.098 -179.905 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . 0.419 ' CE1' ' HA ' ' A' ' 128' ' ' ASN . 8.7 p80 -104.58 115.58 30.59 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.136 -0.484 . . . . 0.0 109.733 178.84 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 153' ' ' MET . . . . . 0.486 ' CB ' ' HA ' ' A' ' 127' ' ' ILE . 0.8 OUTLIER -136.72 174.66 10.37 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.193 0.52 . . . . 0.0 111.874 -178.737 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -118.56 151.62 37.55 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.77 179.268 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 44.4 p -139.65 143.22 37.07 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.027 0.441 . . . . 0.0 111.479 -179.551 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 156' ' ' MET . . . . . 0.441 ' O ' ' N ' ' A' ' 123' ' ' ARG . 0.0 OUTLIER -110.77 176.63 1.45 Allowed Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 115.538 -0.755 . . . . 0.0 110.545 179.764 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 96.3 Cg_endo -90.12 118.75 0.74 Allowed 'Trans proline' 0 N--CA 1.457 -0.619 0 C-N-CA 122.735 2.29 . . . . 0.0 112.546 -179.856 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 158' ' ' ALA . . . . . 0.403 ' CB ' HD12 ' A' ' 103' ' ' ILE . . . . . . . . 0 C--O 1.249 1.071 0 CA-C-O 118.242 -0.885 . . . . 0.0 111.019 179.781 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_exo . . . . . 0 N--CA 1.488 1.178 0 N-CA-C 111.656 -0.171 . . . . 0.0 111.656 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_exo -66.64 62.57 0.56 Allowed 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.79 2.327 . . . . 0.0 112.351 -179.79 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 9.4 p -87.33 146.57 6.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.048 179.92 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.6 m -111.1 121.28 44.92 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.871 179.764 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' THR . . . . . 0.419 ' HA ' ' O ' ' A' ' 153' ' ' MET . 8.9 m -92.65 110.82 22.26 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.039 179.046 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.597 HG11 ' H ' ' A' ' 118' ' ' VAL . 76.2 t -83.31 106.0 13.54 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.597 0 CA-C-N 116.298 -0.41 . . . . 0.0 112.059 -179.17 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 3.9 tt -102.97 81.11 1.94 Allowed 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 177.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.404 HG13 ' CG1' ' A' ' 84' ' ' VAL . 4.4 mt -81.49 123.88 38.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 121.281 0.562 . . . . 0.0 111.769 -178.328 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -70.43 142.62 51.98 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.307 -0.86 . . . . 0.0 110.496 179.761 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 10.2 mtp180 -141.93 98.73 6.22 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.891 179.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . 0.423 ' HG2' ' CG ' ' A' ' 93' ' ' TYR . 64.1 Cg_endo -73.61 -41.62 1.09 Allowed 'Trans proline' 0 C--N 1.346 0.403 0 C-N-CA 122.552 2.168 . . . . 0.0 112.561 -179.877 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -137.05 -168.09 2.22 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.149 -179.824 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 3.9 mt -95.08 -22.74 17.69 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.204 -179.861 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 4.5 ptt-85 -96.23 22.84 7.2 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.144 -179.834 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . 0.423 ' CG ' ' HG2' ' A' ' 89' ' ' PRO . 12.9 m-85 -106.05 96.63 6.61 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.922 0.391 . . . . 0.0 110.894 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 1.3 pp0? -50.58 159.21 0.54 Allowed 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.276 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . 0.42 HD21 ' CZ ' ' A' ' 97' ' ' PHE . 2.1 mp -88.05 -66.8 0.88 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.861 179.872 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 130.49 37.77 0.32 Allowed Glycine 0 CA--C 1.519 0.29 0 C-N-CA 120.562 -0.828 . . . . 0.0 112.885 179.661 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . 0.42 ' CZ ' HD21 ' A' ' 95' ' ' LEU . 50.2 p90 -176.93 178.06 1.21 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.707 0.289 . . . . 0.0 110.936 179.775 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.6 t -128.36 146.1 50.88 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.97 0.414 . . . . 0.0 111.06 -179.787 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 5.5 p -113.09 124.33 69.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.832 179.9 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . 0.417 ' O ' ' N ' ' A' ' 102' ' ' GLY . 1.9 tt0 -115.55 88.77 2.95 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.803 179.766 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' ASN . . . . . 0.453 ' O ' ' CD1' ' A' ' 140' ' ' ILE . 1.2 m-80 64.94 -67.16 0.12 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.87 -0.605 . . . . 0.0 111.424 179.685 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.417 ' N ' ' O ' ' A' ' 100' ' ' GLN . . . -144.52 -3.7 0.7 Allowed Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.29 -0.957 . . . . 0.0 113.41 -179.629 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.422 HD13 ' HB3' ' A' ' 158' ' ' ALA . 39.2 mm -122.99 148.57 26.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 117.315 0.557 . . . . 0.0 111.406 -179.574 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.404 ' CD1' ' N ' ' A' ' 104' ' ' ILE . 2.8 mp -85.08 141.91 13.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.507 179.594 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 94.1 m -97.81 -80.11 0.45 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.125 -179.677 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 1.4 m -109.13 145.63 35.41 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.981 -179.872 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.408 ' CD1' ' CG1' ' A' ' 118' ' ' VAL . 1.2 tt -143.2 113.2 7.14 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.808 179.987 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -74.83 142.55 44.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.719 179.852 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.87 47.52 1.42 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.974 0.416 . . . . 0.0 110.808 -179.904 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -161.35 25.83 0.26 Allowed Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.39 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.465 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -121.05 -174.63 14.98 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.331 179.867 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 1.2 mp -78.92 -22.56 12.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 120.785 0.326 . . . . 0.0 111.463 -179.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' ALA . . . . . 0.409 ' HB3' ' CE1' ' A' ' 97' ' ' PHE . . . -58.2 -30.57 66.56 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.894 0.378 . . . . 0.0 110.723 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' GLU . . . . . 0.465 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 12.4 pt-20 -61.26 -46.42 90.42 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.796 179.734 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 3.5 mtp85 -63.38 -44.13 95.62 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.908 -179.617 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -53.73 -73.97 0.35 Allowed Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.386 -0.911 . . . . 0.0 112.504 179.885 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . 0.401 ' O ' ' C ' ' A' ' 118' ' ' VAL . . . 174.98 -27.01 0.08 OUTLIER Glycine 0 CA--C 1.519 0.331 0 C-N-CA 120.922 -0.656 . . . . 0.0 112.65 -179.824 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.597 ' H ' HG11 ' A' ' 84' ' ' VAL . 94.3 t -31.87 116.56 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 CA-C-O 121.026 0.441 . . . . 0.0 111.709 -179.82 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 11.7 mtt-85 -128.62 112.64 14.49 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.294 179.583 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 32.2 t -46.99 108.42 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.239 -179.768 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 120.36 16.28 4.76 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 121.009 -0.615 . . . . 0.0 112.54 -179.721 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 3.9 m170 -110.35 -172.39 2.03 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.597 0.237 . . . . 0.0 110.562 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.476 ' N ' ' O ' ' A' ' 156' ' ' MET . 4.1 ttt180 -139.88 92.87 2.59 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.682 0.277 . . . . 0.0 111.418 -179.657 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . 0.433 HG23 ' CG2' ' A' ' 132' ' ' VAL . 7.2 mt -52.76 147.65 1.91 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.077 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' ILE . . . . . 0.432 ' CG1' ' H ' ' A' ' 126' ' ' GLU . 0.6 OUTLIER -141.42 -84.79 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 N-CA-C 112.393 0.516 . . . . 0.0 112.393 -179.335 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . 0.432 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 8.5 mm-40 -86.39 90.06 8.08 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 112.316 0.488 . . . . 0.0 112.316 -178.719 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.496 ' HA ' ' CB ' ' A' ' 153' ' ' MET . 2.3 mt -85.45 105.72 14.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 121.24 0.543 . . . . 0.0 111.473 179.307 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . 0.444 ' N ' ' O ' ' A' ' 152' ' ' HIS . 0.6 OUTLIER 56.61 20.81 5.23 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.694 -0.684 . . . . 0.0 111.512 179.667 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 115.14 -12.8 19.54 Favored Glycine 0 C--N 1.331 0.301 0 C-N-CA 120.519 -0.848 . . . . 0.0 113.434 179.665 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' GLN . . . . . 0.408 ' HG3' ' O ' ' A' ' 130' ' ' GLN . 1.1 pt20 -103.17 117.54 34.78 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-O 120.958 0.408 . . . . 0.0 110.834 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 95.9 p -74.85 85.8 2.22 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.31 -179.643 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . 0.445 HG21 HG13 ' A' ' 127' ' ' ILE . 33.8 m -66.61 -10.89 12.39 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.315 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.535 179.537 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 8.9 p -49.69 117.73 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 120.915 0.388 . . . . 0.0 110.964 -179.952 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . 76.15 20.77 1.58 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.789 -179.141 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 135' ' ' THR . . . . . 0.449 ' CG2' ' HD2' ' A' ' 136' ' ' PRO . 36.9 m -104.21 143.21 26.2 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.691 179.637 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 136' ' ' PRO . . . . . 0.449 ' HD2' ' CG2' ' A' ' 135' ' ' THR . 1.9 Cg_endo -41.51 141.19 1.47 Allowed 'Trans proline' 0 C--N 1.347 0.499 0 C-N-CA 123.113 2.542 . . . . 0.0 112.631 179.898 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 38.0 p-80 -63.95 -48.49 76.3 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.024 -0.534 . . . . 0.0 111.464 -179.62 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -54.73 -36.58 64.92 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.301 -179.625 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 139' ' ' LYS . . . . . 0.456 ' O ' ' CD1' ' A' ' 143' ' ' ILE . 19.2 tttm -63.34 -48.81 76.41 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.83 -179.933 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . 0.453 ' CD1' ' O ' ' A' ' 101' ' ' ASN . 21.6 mt -58.47 -46.12 89.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.722 -179.861 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 99.3 t -59.34 -32.5 48.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.014 178.869 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 1.7 t60 -61.78 -52.01 65.96 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.71 179.628 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . 0.456 ' CD1' ' O ' ' A' ' 139' ' ' LYS . 4.3 mp -53.19 -57.23 5.14 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.414 0 CA-C-O 121.024 0.44 . . . . 0.0 110.222 179.416 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.553 ' CD2' HG12 ' A' ' 151' ' ' ILE . 3.4 mt -60.53 -30.15 69.57 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.562 -0.745 . . . . 0.0 110.23 179.574 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 1.1 m -69.33 -26.91 64.94 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-N 116.062 -0.517 . . . . 0.0 109.895 178.557 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 3.6 m-80 -129.82 34.61 4.27 Favored 'General case' 0 CA--C 1.528 0.114 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.216 179.837 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 147' ' ' ALA . . . . . 0.441 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . -116.82 56.39 0.8 Allowed 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.835 0.35 . . . . 0.0 111.325 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 27.7 m -54.21 -177.96 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.403 -179.922 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 81.67 -100.96 2.11 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.552 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 13.0 mt-10 -152.9 98.2 2.29 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.813 0.34 . . . . 0.0 110.707 -179.898 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . 0.553 HG12 ' CD2' ' A' ' 144' ' ' LEU . 1.2 mt -63.09 111.56 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.185 -179.718 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . 0.444 ' O ' ' N ' ' A' ' 128' ' ' ASN . 1.5 t-160 -107.1 115.64 30.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.983 -0.553 . . . . 0.0 109.805 179.121 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 153' ' ' MET . . . . . 0.496 ' CB ' ' HA ' ' A' ' 127' ' ' ILE . 1.0 OUTLIER -141.96 176.17 9.15 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.041 0.448 . . . . 0.0 111.82 -178.893 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 53.1 mttt -124.23 148.9 46.99 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.064 179.401 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 20.0 p -137.1 132.17 33.7 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.942 0.401 . . . . 0.0 111.466 -179.57 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 156' ' ' MET . . . . . 0.476 ' O ' ' N ' ' A' ' 123' ' ' ARG . 0.0 OUTLIER -104.78 154.43 38.58 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.266 179.51 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 17.1 Cg_exo -66.77 118.78 5.82 Favored 'Trans proline' 0 C--N 1.342 0.228 0 C-N-CA 122.359 2.04 . . . . 0.0 112.136 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 158' ' ' ALA . . . . . 0.422 ' HB3' HD13 ' A' ' 103' ' ' ILE . . . . . . . . 0 C--O 1.249 1.058 0 CA-C-O 118.262 -0.875 . . . . 0.0 111.107 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_exo . . . . . 0 N--CA 1.488 1.18 0 CA-C-O 120.772 0.238 . . . . 0.0 111.804 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 62.5 Cg_endo -73.81 -172.98 1.22 Allowed 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.507 2.138 . . . . 0.0 112.292 -179.835 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 41.7 t -87.65 141.19 14.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.094 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.5 m -117.09 143.4 45.83 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.913 179.854 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 17.7 m -105.67 111.56 24.3 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.247 179.279 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.412 HG12 HG13 ' A' ' 86' ' ' ILE . 43.4 t -82.34 105.94 12.73 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.552 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.78 -179.359 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 6.3 tt -108.14 82.3 1.61 Allowed 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 109.122 -0.696 . . . . 0.0 109.122 178.574 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.428 HG12 ' HA ' ' A' ' 113' ' ' ALA . 5.1 mt -81.36 145.21 9.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.009 -0.541 . . . . 0.0 111.807 -178.165 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.411 ' CB ' HG22 ' A' ' 112' ' ' ILE . 0.1 OUTLIER -97.71 114.71 26.75 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.518 -179.831 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 2.3 ttt-85 -112.26 103.09 55.15 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.136 -179.714 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . 0.419 ' HB2' ' CD2' ' A' ' 93' ' ' TYR . 34.8 Cg_exo -57.63 -53.6 4.37 Favored 'Trans proline' 0 C--N 1.347 0.475 0 C-N-CA 122.498 2.132 . . . . 0.0 112.369 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -140.41 -167.07 2.25 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.986 -179.921 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 8.2 mt -84.01 -20.1 33.37 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.313 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -96.41 23.33 6.86 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.095 -179.808 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . 0.419 ' CD2' ' HB2' ' A' ' 89' ' ' PRO . 15.9 m-85 -115.04 122.04 44.96 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.951 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -79.58 162.11 25.53 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.818 -179.979 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . 0.413 ' CD1' ' CD1' ' A' ' 144' ' ' LEU . 53.9 mt -89.5 -69.94 0.69 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.837 179.964 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 138.54 43.66 0.08 OUTLIER Glycine 0 CA--C 1.518 0.234 0 C-N-CA 120.42 -0.895 . . . . 0.0 113.011 179.724 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 35.4 p90 -176.74 161.97 2.12 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.849 0.357 . . . . 0.0 111.07 179.65 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -115.63 139.16 50.37 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.761 179.876 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.455 HG23 ' CG2' ' A' ' 140' ' ' ILE . 12.3 p -109.88 131.7 60.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.487 -179.818 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . 0.412 ' O ' ' N ' ' A' ' 102' ' ' GLY . 10.0 mt-30 -122.58 88.57 2.95 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.13 179.224 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 2.0 m120 63.89 -73.94 0.05 OUTLIER 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.971 -179.725 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.47 ' O ' HD11 ' A' ' 103' ' ' ILE . . . -137.82 0.67 2.74 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.299 -0.953 . . . . 0.0 113.05 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.524 HD12 ' HB1' ' A' ' 158' ' ' ALA . 38.1 mm -124.17 151.88 29.51 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.127 0 CA-C-O 121.014 0.435 . . . . 0.0 111.435 -179.617 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.419 ' CD1' ' N ' ' A' ' 104' ' ' ILE . 3.2 mp -93.32 152.15 3.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.739 179.858 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 96.3 m -105.59 -67.54 0.92 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.107 -179.8 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 78.8 p -123.98 154.24 40.1 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.387 -0.369 . . . . 0.0 111.167 -179.853 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 27.1 tp -139.55 103.42 4.69 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.619 179.861 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 6.8 ttm -60.89 110.91 1.46 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.006 -179.861 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 2.2 tmt_? -68.7 72.21 0.23 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.768 179.747 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 174.34 -34.12 0.11 Allowed Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.973 -0.632 . . . . 0.0 112.149 -179.853 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.411 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -60.0 -176.73 1.31 Allowed Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.21 179.697 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . 0.411 HG22 ' CB ' ' A' ' 87' ' ' ARG . 0.8 OUTLIER -78.7 -17.09 13.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-O 120.822 0.344 . . . . 0.0 111.625 -179.89 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' ALA . . . . . 0.428 ' HA ' HG12 ' A' ' 86' ' ' ILE . . . -58.08 -30.46 66.25 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.937 0.398 . . . . 0.0 110.827 179.961 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' GLU . . . . . 0.411 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 14.5 pt-20 -61.56 -46.84 88.21 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.74 179.687 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 27.9 mtm-85 -62.1 -44.59 96.33 Favored 'General case' 0 N--CA 1.451 -0.406 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.082 -179.64 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -52.92 -73.75 0.37 Allowed Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.36 -0.924 . . . . 0.0 112.536 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 167.33 -19.31 0.09 OUTLIER Glycine 0 CA--C 1.52 0.377 0 C-N-CA 121.0 -0.619 . . . . 0.0 112.75 -179.702 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.411 ' N ' ' CG2' ' A' ' 84' ' ' VAL . 0.9 OUTLIER -38.5 129.47 0.36 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.244 0 CA-C-O 121.007 0.432 . . . . 0.0 111.607 -179.862 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -127.63 101.94 6.62 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.603 179.752 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 12.5 p -49.86 117.81 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.013 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 115.91 -14.56 16.77 Favored Glycine 0 CA--C 1.518 0.228 0 C-N-CA 120.854 -0.689 . . . . 0.0 112.333 -179.488 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . 0.409 ' CD2' ' HA ' ' A' ' 157' ' ' PRO . 0.1 OUTLIER -84.65 -165.6 1.23 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.64 0.257 . . . . 0.0 110.54 179.872 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.435 ' N ' ' O ' ' A' ' 156' ' ' MET . 51.6 ttt85 -130.39 102.2 6.07 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.881 0.372 . . . . 0.0 111.445 -179.718 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . 0.439 ' CG2' ' N ' ' A' ' 125' ' ' ILE . 9.1 mt -60.63 157.95 2.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.092 178.86 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' ILE . . . . . 0.445 ' CG1' ' H ' ' A' ' 126' ' ' GLU . 0.7 OUTLIER -154.79 -85.04 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 N-CA-C 113.086 0.773 . . . . 0.0 113.086 -179.708 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . 0.445 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 3.3 mt-10 -84.28 91.21 7.7 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 112.932 0.716 . . . . 0.0 112.932 -178.117 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.434 HD12 ' CG1' ' A' ' 132' ' ' VAL . 1.7 mt -90.88 98.79 8.76 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.146 0 CA-C-N 116.374 -0.376 . . . . 0.0 110.878 178.628 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . 0.422 ' N ' ' O ' ' A' ' 152' ' ' HIS . 45.8 m-20 60.84 26.13 16.0 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.703 -179.848 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 106.98 -16.14 39.55 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.556 -179.841 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -92.35 108.17 19.76 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.909 0.385 . . . . 0.0 110.715 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 27.4 m -74.59 90.9 2.28 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.125 -179.772 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . 0.434 ' CG1' HD12 ' A' ' 127' ' ' ILE . 35.0 m -81.62 4.39 2.02 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.341 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.967 179.904 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 9.8 p -47.81 -32.42 3.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 120.914 0.388 . . . . 0.0 111.253 -179.857 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -124.68 27.69 6.78 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.601 179.313 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 135' ' ' THR . . . . . 0.429 ' CG2' ' HD2' ' A' ' 136' ' ' PRO . 90.6 m -109.5 143.69 28.31 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.982 -179.841 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 136' ' ' PRO . . . . . 0.429 ' HD2' ' CG2' ' A' ' 135' ' ' THR . 80.3 Cg_exo -48.27 164.16 0.21 Allowed 'Trans proline' 0 C--N 1.349 0.565 0 C-N-CA 122.496 2.13 . . . . 0.0 112.483 179.909 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 57.1 p-80 -76.23 -48.45 20.29 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.492 -179.606 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -55.53 -34.66 64.87 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.939 0.4 . . . . 0.0 111.197 -179.636 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 139' ' ' LYS . . . . . 0.456 ' O ' ' CD1' ' A' ' 143' ' ' ILE . 0.8 OUTLIER -64.43 -47.47 78.98 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.021 -179.831 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . 0.455 ' CG2' HG23 ' A' ' 99' ' ' VAL . 8.7 mt -59.18 -46.5 92.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 121.155 0.503 . . . . 0.0 110.553 -179.868 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 54.1 t -59.68 -32.45 49.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.057 179.013 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 5.6 t-160 -61.58 -53.44 56.31 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.909 179.738 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . 0.456 ' CD1' ' O ' ' A' ' 139' ' ' LYS . 4.2 mp -53.06 -56.95 5.62 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.468 0 CA-C-O 121.203 0.525 . . . . 0.0 110.455 179.494 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.599 HD21 HG12 ' A' ' 151' ' ' ILE . 1.6 mt -63.3 -29.82 71.07 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.414 -0.812 . . . . 0.0 110.455 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 4.0 m -69.66 -28.47 65.9 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 178.773 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 4.6 m-80 -129.67 35.42 4.19 Favored 'General case' 0 CA--C 1.528 0.128 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.227 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 147' ' ' ALA . . . . . 0.442 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . -101.05 -33.27 10.22 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.945 0.402 . . . . 0.0 111.28 -179.917 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . 0.425 ' CG2' ' O ' ' A' ' 147' ' ' ALA . 35.5 m 44.44 -173.63 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.527 -0.76 . . . . 0.0 111.849 -179.877 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 50.78 -148.67 7.42 Favored Glycine 0 C--N 1.332 0.341 0 C-N-CA 120.854 -0.689 . . . . 0.0 112.772 -179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 7.9 mt-10 -89.41 105.33 17.73 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.72 0.295 . . . . 0.0 110.845 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . 0.599 HG12 HD21 ' A' ' 144' ' ' LEU . 0.6 OUTLIER -78.25 111.58 15.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.387 -0.37 . . . . 0.0 111.12 -179.917 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . 0.422 ' O ' ' N ' ' A' ' 128' ' ' ASN . 0.0 OUTLIER -93.29 124.79 37.51 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 178.889 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 153' ' ' MET . . . . . 0.413 ' SD ' ' CG2' ' A' ' 155' ' ' THR . 5.2 tmm? -147.92 151.89 36.62 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.873 0.368 . . . . 0.0 111.79 -178.721 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -111.86 148.14 34.27 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.476 179.644 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 155' ' ' THR . . . . . 0.413 ' CG2' ' SD ' ' A' ' 153' ' ' MET . 37.6 p -145.23 151.32 38.21 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.086 0.47 . . . . 0.0 111.702 -179.755 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 156' ' ' MET . . . . . 0.435 ' O ' ' N ' ' A' ' 123' ' ' ARG . 5.0 ptp -139.43 156.3 71.65 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.295 179.061 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . 0.409 ' HA ' ' CD2' ' A' ' 122' ' ' HIS . 12.7 Cg_endo -56.43 120.44 8.31 Favored 'Trans proline' 0 C--N 1.342 0.229 0 C-N-CA 122.5 2.133 . . . . 0.0 112.609 -179.714 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 158' ' ' ALA . . . . . 0.524 ' HB1' HD12 ' A' ' 103' ' ' ILE . . . . . . . . 0 C--O 1.249 1.051 0 CA-C-O 118.308 -0.853 . . . . 0.0 110.995 179.845 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_endo . . . . . 0 N--CA 1.489 1.252 0 CA-C-O 120.831 0.263 . . . . 0.0 111.7 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -70.13 126.67 13.32 Favored 'Trans proline' 0 C--N 1.345 0.348 0 C-N-CA 122.566 2.178 . . . . 0.0 112.351 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 11.6 p -83.89 140.48 16.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.969 179.857 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 1.4 m -82.2 146.03 29.75 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.87 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 8.8 m -108.3 111.16 22.96 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.188 179.13 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.465 ' HB ' ' HB3' ' A' ' 153' ' ' MET . 49.9 t -90.29 106.13 16.97 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.448 0 CA-C-N 116.024 -0.534 . . . . 0.0 111.078 -179.708 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -107.01 81.55 1.56 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.02 179.134 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.44 HG13 HG11 ' A' ' 84' ' ' VAL . 1.7 mp -81.59 149.09 4.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 121.067 0.46 . . . . 0.0 111.047 -179.235 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.434 ' CB ' HG22 ' A' ' 112' ' ' ILE . 0.3 OUTLIER -109.43 108.8 19.45 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.761 -179.354 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -102.82 104.75 41.12 Favored Pre-proline 0 C--N 1.33 -0.257 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.812 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . 0.418 ' HG2' ' CG ' ' A' ' 93' ' ' TYR . 37.9 Cg_endo -66.46 -49.21 1.88 Allowed 'Trans proline' 0 C--N 1.347 0.479 0 C-N-CA 122.341 2.027 . . . . 0.0 112.546 -179.814 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -136.2 178.95 6.66 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.157 -179.86 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 25.5 mt -77.64 -19.89 54.74 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.194 -179.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 2.9 ptt180 -96.85 23.26 7.29 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.48 -0.327 . . . . 0.0 111.158 -179.895 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . 0.418 ' CG ' ' HG2' ' A' ' 89' ' ' PRO . 16.8 m-85 -120.15 92.3 3.74 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.942 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -59.49 165.92 2.63 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.049 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 2.4 mp -82.63 -37.46 24.91 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.709 179.836 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 96.11 50.85 1.84 Allowed Glycine 0 C--N 1.33 0.229 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.84 179.653 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 1.3 p90 -160.58 -172.92 3.72 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.905 0.383 . . . . 0.0 111.077 179.873 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.424 ' O ' ' HA ' ' A' ' 104' ' ' ILE . 6.4 t -135.71 128.64 31.34 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.458 179.757 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.43 ' CG1' ' CG2' ' A' ' 141' ' ' VAL . 9.9 p -109.79 131.59 60.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.918 0.389 . . . . 0.0 111.675 -179.525 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 13.0 mt-30 -123.33 88.32 2.9 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.908 -0.587 . . . . 0.0 109.527 178.842 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 4.6 m120 56.59 18.97 3.9 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.932 -178.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 128.68 -41.43 1.57 Allowed Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.854 -0.688 . . . . 0.0 112.572 179.835 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.528 HG12 ' CB ' ' A' ' 158' ' ' ALA . 21.0 mt -77.42 133.38 30.8 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-O 121.061 0.457 . . . . 0.0 111.678 -179.361 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.424 ' HA ' ' O ' ' A' ' 98' ' ' SER . 4.5 mp -93.14 137.57 22.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.609 179.487 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 53.5 t -108.89 -75.39 0.63 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.094 -179.576 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 2.7 m -90.6 124.3 34.93 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.052 -179.826 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.409 ' CD1' HG13 ' A' ' 118' ' ' VAL . 1.1 tt -130.91 110.06 11.0 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.646 179.857 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -64.63 150.12 47.62 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.786 -179.905 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -91.96 45.53 1.22 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.164 0.507 . . . . 0.0 110.619 179.79 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -153.2 -33.81 0.03 OUTLIER Glycine 0 N--CA 1.45 -0.419 0 CA-C-N 115.617 -0.72 . . . . 0.0 112.283 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.45 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -49.39 166.53 0.31 Allowed Glycine 0 C--N 1.333 0.411 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.431 179.812 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . 0.434 HG22 ' CB ' ' A' ' 87' ' ' ARG . 0.8 OUTLIER -78.86 -19.44 13.04 Favored 'Isoleucine or valine' 0 C--O 1.237 0.404 0 CA-C-O 120.822 0.344 . . . . 0.0 111.835 -179.652 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' ALA . . . . . . . . . . . . . . . -58.12 -30.38 66.26 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.939 0.399 . . . . 0.0 110.529 179.796 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' GLU . . . . . 0.45 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 20.2 pt-20 -59.34 -44.98 92.58 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.682 179.525 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 7.9 mtm180 -64.55 -47.48 78.6 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.151 -179.48 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -49.04 -74.5 0.26 Allowed Glycine 0 CA--C 1.519 0.297 0 C-N-CA 120.296 -0.954 . . . . 0.0 112.744 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 175.45 -14.97 0.04 OUTLIER Glycine 0 CA--C 1.52 0.398 0 C-N-CA 120.863 -0.684 . . . . 0.0 113.116 -179.876 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.439 ' HB ' HG13 ' A' ' 84' ' ' VAL . 7.6 p -35.49 153.19 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.275 0 N-CA-C 112.132 0.419 . . . . 0.0 112.132 -179.727 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 9.5 mmt180 -139.73 138.86 36.29 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.881 179.924 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 19.4 t -71.22 81.5 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.154 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 132.1 41.02 0.2 Allowed Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.664 179.902 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 12.9 m170 -131.64 132.0 43.66 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.843 0.354 . . . . 0.0 110.766 179.856 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.473 ' HB2' ' CB ' ' A' ' 158' ' ' ALA . 0.2 OUTLIER -81.3 92.39 6.37 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.391 -179.768 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . 0.468 HG22 ' CG2' ' A' ' 132' ' ' VAL . 9.0 mt -46.16 156.7 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.164 178.753 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' ILE . . . . . 0.437 ' CG1' ' H ' ' A' ' 126' ' ' GLU . 0.6 OUTLIER -153.89 -86.06 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 N-CA-C 112.48 0.548 . . . . 0.0 112.48 -179.497 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . 0.437 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 13.5 mt-10 -77.01 92.64 3.73 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 112.131 0.419 . . . . 0.0 112.131 -178.707 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.517 HD12 HG22 ' A' ' 127' ' ' ILE . 1.2 mt -91.52 98.77 8.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 121.008 0.432 . . . . 0.0 110.991 179.194 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . 0.423 ' N ' ' O ' ' A' ' 152' ' ' HIS . 19.3 p30 48.18 26.51 1.06 Allowed 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.651 -0.704 . . . . 0.0 112.133 179.752 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 125.2 -26.22 5.59 Favored Glycine 0 C--N 1.332 0.357 0 C-N-CA 120.239 -0.981 . . . . 0.0 113.878 178.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -100.03 114.02 27.02 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 117.27 0.535 . . . . 0.0 111.428 -179.497 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 12.0 t -78.33 101.99 7.48 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.047 179.847 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . 0.468 ' CG2' HG22 ' A' ' 124' ' ' ILE . 21.5 m -83.08 6.94 1.57 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.282 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.825 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 11.1 p -51.91 119.7 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.18 0 CA-C-O 120.958 0.409 . . . . 0.0 110.82 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . 68.45 22.84 7.67 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.751 -179.101 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 135' ' ' THR . . . . . 0.416 ' CG2' ' HD2' ' A' ' 136' ' ' PRO . 28.8 m -99.47 142.05 23.92 Favored Pre-proline 0 C--N 1.328 -0.364 0 CA-C-N 115.669 -0.696 . . . . 0.0 110.702 179.864 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 136' ' ' PRO . . . . . 0.416 ' HD2' ' CG2' ' A' ' 135' ' ' THR . 87.1 Cg_exo -44.97 142.65 5.15 Favored 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 122.628 2.219 . . . . 0.0 112.549 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 6.8 p80 -62.86 -48.05 80.71 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.468 -179.599 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 1.4 tt0 -55.23 -33.44 63.11 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.244 -179.726 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 139' ' ' LYS . . . . . 0.438 ' O ' ' CD1' ' A' ' 143' ' ' ILE . 1.6 tmtp? -66.14 -49.44 67.44 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.933 -179.928 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 8.0 mt -58.82 -45.14 91.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 121.102 0.477 . . . . 0.0 110.405 179.888 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . 0.43 ' CG2' ' CG1' ' A' ' 99' ' ' VAL . 93.3 t -60.78 -32.67 52.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.06 178.794 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 3.8 t-160 -59.9 -52.57 64.87 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.538 179.586 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . 0.438 ' CD1' ' O ' ' A' ' 139' ' ' LYS . 4.1 mp -53.15 -56.85 6.15 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.433 0 CA-C-O 121.197 0.522 . . . . 0.0 110.282 179.253 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.597 HD21 HG12 ' A' ' 151' ' ' ILE . 1.2 mt -61.9 -29.97 70.56 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.315 -0.857 . . . . 0.0 110.45 179.625 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 1.5 m -68.84 -26.73 65.3 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.124 -0.489 . . . . 0.0 109.939 178.549 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 3.8 m-80 -127.41 32.07 5.09 Favored 'General case' 0 C--O 1.232 0.152 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.173 179.796 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 147' ' ' ALA . . . . . 0.444 ' HB2' ' HA ' ' A' ' 144' ' ' LEU . . . -117.62 59.52 0.78 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.819 0.343 . . . . 0.0 111.16 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 28.1 m -54.74 175.7 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.37 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 79.3 -118.62 4.82 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.779 -0.725 . . . . 0.0 112.393 179.912 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -123.8 117.15 24.23 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.714 0.293 . . . . 0.0 110.582 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . 0.597 HG12 HD21 ' A' ' 144' ' ' LEU . 0.9 OUTLIER -89.32 111.87 23.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.365 -179.679 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . 0.423 ' O ' ' N ' ' A' ' 128' ' ' ASN . 6.4 m-70 -94.83 120.02 34.36 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 178.357 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 153' ' ' MET . . . . . 0.465 ' HB3' ' HB ' ' A' ' 84' ' ' VAL . 27.4 ttp -139.86 162.93 33.97 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 112.44 0.533 . . . . 0.0 112.44 -178.106 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 6.1 mttp -129.96 141.3 50.79 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.226 -0.897 . . . . 0.0 109.831 179.276 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 4.7 p -139.61 147.4 41.05 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.948 0.404 . . . . 0.0 111.726 -179.174 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 156' ' ' MET . . . . . 0.448 ' CB ' ' CD ' ' A' ' 157' ' ' PRO . 1.0 OUTLIER -113.75 -179.78 0.67 Allowed Pre-proline 0 C--N 1.328 -0.368 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.24 179.59 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . 0.448 ' CD ' ' CB ' ' A' ' 156' ' ' MET . 89.3 Cg_endo -85.11 112.09 1.41 Allowed 'Trans proline' 0 N--CA 1.462 -0.375 0 C-N-CA 122.493 2.128 . . . . 0.0 112.558 -179.883 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 158' ' ' ALA . . . . . 0.528 ' CB ' HG12 ' A' ' 103' ' ' ILE . . . . . . . . 0 C--O 1.249 1.074 0 CA-C-O 118.141 -0.933 . . . . 0.0 111.092 179.864 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_exo . . . . . 0 N--CA 1.488 1.194 0 CA-C-O 120.689 0.204 . . . . 0.0 111.671 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -74.55 94.76 0.93 Allowed 'Trans proline' 0 C--N 1.344 0.315 0 C-N-CA 122.64 2.227 . . . . 0.0 112.343 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 29.6 t -107.79 126.85 64.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.062 179.938 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 1.6 m -104.64 145.79 29.84 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.994 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 91.7 m -107.05 111.09 23.39 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.049 -0.523 . . . . 0.0 109.917 178.92 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.469 HG11 ' CD1' ' A' ' 86' ' ' ILE . 33.5 t -93.15 105.94 17.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.696 -179.415 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 4.2 tt -102.77 83.28 2.23 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.21 -0.45 . . . . 0.0 109.823 179.047 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.52 HG12 ' HA ' ' A' ' 113' ' ' ALA . 2.0 mt -81.7 132.46 31.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-O 121.096 0.474 . . . . 0.0 111.389 -178.932 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.446 ' CB ' HG21 ' A' ' 112' ' ' ILE . 0.0 OUTLIER -89.45 114.01 25.44 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.692 -0.685 . . . . 0.0 110.531 -179.917 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 5.9 mmm180 -104.91 104.4 46.28 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.451 -0.341 . . . . 0.0 111.133 -179.733 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . 0.429 ' HG2' ' CE2' ' A' ' 93' ' ' TYR . 29.7 Cg_exo -61.96 -39.81 48.07 Favored 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.581 2.187 . . . . 0.0 112.427 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -153.61 -171.26 3.84 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.939 0.399 . . . . 0.0 111.303 -179.87 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.411 ' CD2' ' CG1' ' A' ' 148' ' ' VAL . 6.0 mt -86.14 -19.23 30.43 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.491 -179.757 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -93.97 21.58 6.55 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.707 0.289 . . . . 0.0 111.344 -179.585 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . 0.429 ' CE2' ' HG2' ' A' ' 89' ' ' PRO . 15.8 m-85 -104.25 175.56 5.45 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.654 179.547 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -128.35 149.71 50.41 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.897 0.38 . . . . 0.0 111.131 -179.876 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . 0.419 ' HB3' ' CE2' ' A' ' 97' ' ' PHE . 4.6 mm? -67.59 -56.55 9.01 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.662 179.799 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 118.1 29.63 1.94 Allowed Glycine 0 C--N 1.333 0.401 0 C-N-CA 120.637 -0.792 . . . . 0.0 112.995 179.424 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . 0.419 ' CE2' ' HB3' ' A' ' 95' ' ' LEU . 47.8 p90 -166.81 165.23 16.36 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.852 0.358 . . . . 0.0 111.374 179.843 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -101.16 138.18 38.54 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.626 179.843 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.411 ' CG1' ' CG2' ' A' ' 141' ' ' VAL . 9.7 p -115.36 132.75 63.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.923 0.392 . . . . 0.0 111.591 -179.716 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 24.6 mt-30 -131.11 89.25 2.71 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.1 179.387 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 44.7 m-80 60.61 16.25 6.4 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.004 -179.436 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.417 ' O ' ' HB ' ' A' ' 124' ' ' ILE . . . 124.87 -36.25 2.9 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.969 -0.634 . . . . 0.0 112.293 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.441 ' CG1' ' HG3' ' A' ' 123' ' ' ARG . 36.7 mt -77.77 134.97 27.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-O 121.067 0.461 . . . . 0.0 111.738 -179.639 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 4.4 mp -90.29 135.48 26.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.519 179.666 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -106.15 -72.18 0.72 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.208 -179.591 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 1.5 m -101.87 142.26 33.45 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.145 -179.691 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.405 ' CD1' HG11 ' A' ' 118' ' ' VAL . 1.2 tt -144.68 124.54 13.44 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.646 179.695 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 19.8 mtp -82.09 149.76 27.86 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.03 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 4.6 mtm-85 -93.25 44.47 1.14 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.213 0.53 . . . . 0.0 110.367 179.649 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -161.03 22.43 0.23 Allowed Glycine 0 N--CA 1.449 -0.447 0 CA-C-N 115.617 -0.72 . . . . 0.0 112.284 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.522 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -110.35 174.2 17.17 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 120.934 -0.651 . . . . 0.0 111.901 179.743 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . 0.446 HG21 ' CB ' ' A' ' 87' ' ' ARG . 0.6 OUTLIER -79.22 -21.94 12.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-O 120.854 0.359 . . . . 0.0 111.585 -179.713 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' ALA . . . . . 0.52 ' HA ' HG12 ' A' ' 86' ' ' ILE . . . -58.35 -30.76 66.99 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.934 0.397 . . . . 0.0 110.549 179.775 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' GLU . . . . . 0.522 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 9.0 pt-20 -59.76 -44.59 93.79 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.753 179.672 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 85.1 mtt180 -65.36 -46.74 78.99 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.32 -179.468 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -48.94 -74.43 0.27 Allowed Glycine 0 CA--C 1.519 0.316 0 C-N-CA 120.302 -0.951 . . . . 0.0 112.709 -179.903 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . 0.433 ' O ' ' C ' ' A' ' 118' ' ' VAL . . . 175.59 -20.46 0.05 OUTLIER Glycine 0 CA--C 1.519 0.283 0 C-N-CA 121.013 -0.613 . . . . 0.0 112.72 -179.902 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.433 ' C ' ' O ' ' A' ' 117' ' ' GLY . 11.0 p -24.91 136.87 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.399 0 N-CA-C 112.575 0.583 . . . . 0.0 112.575 -179.847 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 3.3 ttt180 -134.33 110.69 9.64 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.855 179.902 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 21.0 t -57.11 100.21 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.083 -179.88 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 124.02 40.67 0.44 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.39 -179.83 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . 0.436 ' O ' ' HA ' ' A' ' 103' ' ' ILE . 0.1 OUTLIER -134.91 -167.22 1.95 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.664 0.269 . . . . 0.0 110.657 -179.917 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.488 ' HB2' ' CB ' ' A' ' 158' ' ' ALA . 13.8 ttt180 -137.26 90.44 2.52 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.883 179.976 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . 0.439 HG23 ' CG2' ' A' ' 132' ' ' VAL . 9.4 mt -50.06 156.08 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 N-CA-C 110.158 -0.312 . . . . 0.0 110.158 179.199 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 125' ' ' ILE . . . . . 0.434 ' CG1' ' H ' ' A' ' 126' ' ' GLU . 0.6 OUTLIER -148.59 -84.71 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 N-CA-C 112.171 0.434 . . . . 0.0 112.171 -179.577 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . 0.434 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 12.2 mt-10 -80.34 86.16 5.74 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 112.164 0.431 . . . . 0.0 112.164 -178.999 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.52 HD12 HG23 ' A' ' 127' ' ' ILE . 1.4 mt -89.53 102.43 13.1 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 CA-C-O 120.899 0.381 . . . . 0.0 110.839 179.117 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . 0.449 ' HA ' ' CD2' ' A' ' 152' ' ' HIS . 0.9 OUTLIER 59.97 24.83 13.98 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.077 -0.511 . . . . 0.0 111.109 179.902 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 107.29 -13.43 40.07 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.919 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -97.62 113.07 24.72 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.789 0.328 . . . . 0.0 111.025 -179.878 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 1.2 p -77.44 94.68 4.3 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.019 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . 0.445 ' CG2' HD11 ' A' ' 127' ' ' ILE . 27.1 m -80.14 1.38 2.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.883 -179.879 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 9.2 p -46.79 -38.11 3.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-O 120.907 0.384 . . . . 0.0 111.619 -179.65 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -115.97 28.89 8.32 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.747 179.554 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 135' ' ' THR . . . . . 0.409 ' CG2' ' HD2' ' A' ' 136' ' ' PRO . 97.9 m -116.32 144.61 33.36 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 115.912 -0.585 . . . . 0.0 111.172 -179.834 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 136' ' ' PRO . . . . . 0.409 ' HD2' ' CG2' ' A' ' 135' ' ' THR . 48.9 Cg_exo -55.75 164.29 4.66 Favored 'Trans proline' 0 C--N 1.348 0.516 0 C-N-CA 122.528 2.152 . . . . 0.0 112.245 179.842 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 41.7 p-80 -67.18 -48.9 66.56 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.299 -179.837 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 6.0 tp10 -54.47 -36.66 64.36 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.388 -179.692 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 139' ' ' LYS . . . . . 0.44 ' O ' ' CD1' ' A' ' 143' ' ' ILE . 4.1 mmmt -61.63 -46.54 89.35 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.723 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . 0.452 HD11 HG23 ' A' ' 140' ' ' ILE . 16.8 mt -58.86 -46.03 91.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.581 -179.909 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . 0.411 ' CG2' ' CG1' ' A' ' 99' ' ' VAL . 93.7 t -59.8 -32.42 49.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.089 179.086 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -61.77 -54.0 48.33 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.834 179.764 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . 0.44 ' CD1' ' O ' ' A' ' 139' ' ' LYS . 4.3 mp -52.88 -56.44 7.56 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.454 0 CA-C-O 121.194 0.521 . . . . 0.0 110.312 179.413 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.685 HD21 HG12 ' A' ' 151' ' ' ILE . 2.2 mt -63.0 -29.92 71.2 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.294 -0.866 . . . . 0.0 110.361 179.83 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 15.5 t -69.83 -30.14 67.58 Favored 'General case' 0 N--CA 1.453 -0.289 0 CA-C-N 116.302 -0.408 . . . . 0.0 109.933 178.676 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 3.0 m-80 -125.65 34.66 4.86 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.864 179.722 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 147' ' ' ALA . . . . . 0.437 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . -100.3 -39.33 8.07 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.036 0.446 . . . . 0.0 111.585 -179.68 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . 0.416 ' CG2' ' O ' ' A' ' 147' ' ' ALA . 24.8 m 44.86 -171.38 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.488 -0.778 . . . . 0.0 111.662 -179.88 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 55.76 -135.35 48.88 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.569 -179.813 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 27.9 mt-10 -107.69 101.24 10.56 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.839 0.352 . . . . 0.0 110.761 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . 0.685 HG12 HD21 ' A' ' 144' ' ' LEU . 0.5 OUTLIER -76.07 111.76 12.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.189 -179.768 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . 0.449 ' CD2' ' HA ' ' A' ' 128' ' ' ASN . 0.8 OUTLIER -98.94 115.13 28.2 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 178.241 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 153' ' ' MET . . . . . 0.447 ' HB3' ' HB ' ' A' ' 84' ' ' VAL . 13.1 ttp -123.17 163.3 20.86 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.318 0.58 . . . . 0.0 112.139 -178.064 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -128.97 139.39 52.12 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.118 -0.946 . . . . 0.0 109.454 179.077 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 155' ' ' THR . . . . . 0.4 ' HA ' ' HA ' ' A' ' 124' ' ' ILE . 10.4 p -136.0 143.48 44.81 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.125 0.488 . . . . 0.0 111.738 -179.253 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 156' ' ' MET . . . . . 0.465 ' O ' ' CB ' ' A' ' 123' ' ' ARG . 8.9 mtp -132.64 149.66 73.65 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 115.28 -0.873 . . . . 0.0 110.298 179.646 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 77.2 Cg_exo -47.96 116.8 2.11 Favored 'Trans proline' 0 C--N 1.343 0.286 0 C-N-CA 122.37 2.047 . . . . 0.0 112.713 -179.834 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 158' ' ' ALA . . . . . 0.488 ' CB ' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.248 1.019 0 CA-C-O 118.317 -0.849 . . . . 0.0 110.958 179.837 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_endo . . . . . 0 N--CA 1.488 1.154 0 CA-C-O 120.805 0.252 . . . . 0.0 111.792 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.54 169.41 18.69 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.444 2.096 . . . . 0.0 112.351 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 35.0 t -80.88 142.02 14.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.936 -179.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.8 m -117.3 134.56 54.67 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.867 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 3.5 m -94.58 111.27 23.03 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.128 179.314 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.453 HG12 HG13 ' A' ' 86' ' ' ILE . 63.7 t -82.77 106.2 13.35 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.938 -179.249 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -106.83 80.81 1.48 Allowed 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 178.491 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.455 HG12 ' HA ' ' A' ' 113' ' ' ALA . 3.3 mt -81.53 136.02 23.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-O 121.252 0.549 . . . . 0.0 111.945 -178.195 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.45 148.44 22.77 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.368 -0.833 . . . . 0.0 110.194 179.685 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -155.05 102.91 2.27 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.595 -0.275 . . . . 0.0 110.96 -179.819 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 67.3 Cg_endo -74.06 -24.59 14.78 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.514 2.143 . . . . 0.0 112.494 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -149.59 -166.94 2.69 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.914 0.388 . . . . 0.0 111.236 -179.786 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 4.2 mt -96.54 -44.4 7.18 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.349 -179.598 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -58.06 -18.77 26.77 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.96 -0.564 . . . . 0.0 111.634 -179.436 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 38.4 m-85 -88.2 87.71 7.4 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.805 179.833 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -66.42 -177.83 0.6 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.079 -179.948 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 6.5 mp -94.74 -56.18 2.86 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.771 179.945 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 98.06 71.07 1.01 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.848 179.745 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 14.0 p90 -166.27 162.4 17.34 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.918 0.389 . . . . 0.0 111.01 179.916 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.418 ' O ' ' HA ' ' A' ' 104' ' ' ILE . 1.5 m -106.18 120.49 41.96 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.607 179.724 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.427 ' CG1' ' CG2' ' A' ' 141' ' ' VAL . 8.4 p -109.78 139.05 34.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.448 -179.697 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -135.87 89.15 2.46 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.309 179.491 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 27.2 m120 58.26 18.91 5.78 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.174 -179.529 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 126.73 -38.16 2.25 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.575 179.884 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.491 HG12 ' CB ' ' A' ' 158' ' ' ALA . 31.8 mt -76.88 141.9 15.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 121.034 0.445 . . . . 0.0 111.452 -179.611 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.418 ' HA ' ' O ' ' A' ' 98' ' ' SER . 5.2 mp -109.54 130.01 63.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.863 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 1.8 m -123.52 28.97 6.78 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.969 -179.872 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -178.19 141.24 0.24 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.772 179.988 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -159.09 107.63 1.86 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.844 -179.826 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 2.8 ttp -68.13 113.14 5.53 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.74 179.918 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 26.1 mtt180 -58.81 86.49 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.798 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 163.79 -33.97 0.29 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.913 -0.66 . . . . 0.0 112.012 -179.818 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.415 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -61.13 171.43 7.8 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.193 179.693 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -78.64 -16.93 13.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 120.777 0.323 . . . . 0.0 111.477 -179.789 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' ALA . . . . . 0.455 ' HA ' HG12 ' A' ' 86' ' ' ILE . . . -58.12 -30.5 66.35 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.056 0.455 . . . . 0.0 110.707 179.882 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' GLU . . . . . 0.415 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 21.7 pt-20 -62.0 -46.51 88.9 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.768 -0.651 . . . . 0.0 111.105 179.823 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.4 ' N ' ' CG ' ' A' ' 114' ' ' GLU . 25.2 mtt-85 -62.75 -46.16 89.33 Favored 'General case' 0 N--CA 1.452 -0.347 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.142 -179.378 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -50.29 -74.05 0.31 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.338 -0.934 . . . . 0.0 112.578 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . 0.406 ' O ' ' C ' ' A' ' 118' ' ' VAL . . . 175.97 -27.4 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.736 -179.782 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.444 ' CG2' HG13 ' A' ' 84' ' ' VAL . 12.0 t -31.25 102.04 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 CA-C-O 120.993 0.425 . . . . 0.0 111.8 -179.722 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -104.13 123.89 48.09 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.643 179.765 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 21.4 t -53.76 99.99 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.188 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 120.7 14.67 5.15 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.934 -0.651 . . . . 0.0 112.79 -179.879 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 14.0 m170 -115.61 132.89 56.49 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.744 0.307 . . . . 0.0 110.626 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.428 ' HB3' ' CB ' ' A' ' 158' ' ' ALA . 13.1 ptt180 -84.55 91.85 7.97 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.677 -179.734 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . 0.512 HG22 ' CG2' ' A' ' 132' ' ' VAL . 19.1 mt -48.09 157.85 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.333 -0.133 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 178.72 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 125' ' ' ILE . . . . . 0.423 ' CG1' ' H ' ' A' ' 126' ' ' GLU . 0.6 OUTLIER -150.73 -83.37 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 N-CA-C 113.064 0.765 . . . . 0.0 113.064 -179.008 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . 0.423 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 0.6 OUTLIER -75.62 81.85 2.62 Favored 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 112.695 0.628 . . . . 0.0 112.695 -178.247 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.475 ' HA ' ' HB3' ' A' ' 153' ' ' MET . 1.7 mt -91.02 95.25 5.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.931 0.395 . . . . 0.0 111.062 179.015 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . 0.442 ' N ' ' O ' ' A' ' 152' ' ' HIS . 33.0 m-20 57.76 39.93 26.72 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.934 179.966 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 91.51 -4.18 79.56 Favored Glycine 0 CA--C 1.519 0.329 0 C-N-CA 120.632 -0.794 . . . . 0.0 112.813 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 2.9 tt0 -104.08 107.51 18.44 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.824 0.345 . . . . 0.0 110.836 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 26.0 p -75.6 92.01 2.9 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.093 -179.824 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . 0.512 ' CG2' HG22 ' A' ' 124' ' ' ILE . 31.4 m -74.74 -3.67 4.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.724 179.838 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . 0.41 ' HB ' ' CG2' ' A' ' 125' ' ' ILE . 9.0 p -43.79 -44.6 1.87 Allowed 'Isoleucine or valine' 0 C--O 1.231 0.111 0 CA-C-O 120.806 0.336 . . . . 0.0 111.804 -179.775 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . 0.403 ' N ' ' CG1' ' A' ' 133' ' ' VAL . . . -113.37 30.24 7.36 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.958 179.906 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 91.6 m -115.15 140.47 25.71 Favored Pre-proline 0 C--N 1.33 -0.244 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.015 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 136' ' ' PRO . . . . . . . . . . . . . 7.6 Cg_endo -50.33 164.18 0.53 Allowed 'Trans proline' 0 C--N 1.347 0.494 0 C-N-CA 122.64 2.226 . . . . 0.0 112.244 179.841 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 137' ' ' HIS . . . . . 0.439 ' CD2' ' N ' ' A' ' 138' ' ' GLU . 32.9 p-80 -72.77 -46.69 52.03 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.606 -179.5 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . 0.439 ' N ' ' CD2' ' A' ' 137' ' ' HIS . 16.7 mt-10 -53.69 -36.69 62.46 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.396 -179.59 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 139' ' ' LYS . . . . . 0.456 ' O ' ' CD1' ' A' ' 143' ' ' ILE . 6.7 tmtm? -62.93 -47.02 85.04 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.927 -179.816 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 8.6 mt -58.41 -44.71 89.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.523 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . 0.427 ' CG2' ' CG1' ' A' ' 99' ' ' VAL . 93.1 t -60.78 -32.46 52.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.107 178.856 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -61.46 -52.32 65.01 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.641 179.558 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . 0.474 ' O ' ' N ' ' A' ' 147' ' ' ALA . 4.4 mp -53.23 -56.67 7.1 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.395 0 CA-C-O 121.098 0.475 . . . . 0.0 110.205 179.422 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.518 ' CD2' HG12 ' A' ' 151' ' ' ILE . 4.9 mt -62.31 -30.31 71.06 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.518 -0.764 . . . . 0.0 110.326 179.506 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 34.5 t -70.09 -28.31 65.31 Favored 'General case' 0 N--CA 1.453 -0.283 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.117 178.901 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 10.3 m120 -131.71 37.4 3.65 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.082 179.808 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 147' ' ' ALA . . . . . 0.474 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . -99.79 -44.71 5.99 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.094 0.473 . . . . 0.0 111.512 -179.68 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . 0.426 ' CG2' ' O ' ' A' ' 147' ' ' ALA . 32.4 m 45.96 -174.68 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 115.321 -0.854 . . . . 0.0 111.788 -179.684 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 59.64 -108.07 1.54 Allowed Glycine 0 N--CA 1.453 -0.214 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.361 -179.819 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 46.1 mt-10 -136.81 114.1 10.8 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.778 0.323 . . . . 0.0 110.856 179.892 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . 0.518 HG12 ' CD2' ' A' ' 144' ' ' LEU . 1.5 mt -82.84 112.0 19.96 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.139 -179.912 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . 0.442 ' O ' ' N ' ' A' ' 128' ' ' ASN . 0.1 OUTLIER -99.09 115.88 30.01 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.978 -0.556 . . . . 0.0 109.82 179.04 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 153' ' ' MET . . . . . 0.475 ' HB3' ' HA ' ' A' ' 127' ' ' ILE . 0.0 OUTLIER -144.64 177.83 8.41 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.548 0.69 . . . . 0.0 111.751 -179.048 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 14.4 mttp -139.43 152.66 47.23 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 114.633 -1.167 . . . . 0.0 109.977 179.546 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 155' ' ' THR . . . . . 0.437 HG21 HG23 ' A' ' 84' ' ' VAL . 2.0 p -142.99 150.4 39.59 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.195 0.522 . . . . 0.0 111.888 -179.488 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 156' ' ' MET . . . . . 0.423 ' CB ' ' CD ' ' A' ' 157' ' ' PRO . 2.3 mtp -118.69 178.93 0.94 Allowed Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 115.235 -0.893 . . . . 0.0 109.898 179.343 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . 0.423 ' CD ' ' CB ' ' A' ' 156' ' ' MET . 89.9 Cg_endo -86.45 106.16 0.75 Allowed 'Trans proline' 0 N--CA 1.459 -0.555 0 C-N-CA 122.44 2.094 . . . . 0.0 112.493 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 158' ' ' ALA . . . . . 0.491 ' CB ' HG12 ' A' ' 103' ' ' ILE . . . . . . . . 0 C--O 1.249 1.057 0 CA-C-O 118.253 -0.879 . . . . 0.0 111.052 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 6.6 Cg_endo . . . . . 0 N--CA 1.49 1.319 0 CA-C-O 120.722 0.218 . . . . 0.0 111.744 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_exo -61.18 113.38 1.73 Allowed 'Trans proline' 0 C--N 1.346 0.412 0 C-N-CA 122.582 2.188 . . . . 0.0 112.295 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 11.2 p -81.4 145.49 8.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.77 179.816 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.5 m -104.26 146.09 29.29 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.925 0.393 . . . . 0.0 111.203 -179.709 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' THR . . . . . 0.431 HG22 ' CE1' ' A' ' 152' ' ' HIS . 11.6 m -110.17 111.09 22.21 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.002 178.972 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.504 HG11 HG13 ' A' ' 86' ' ' ILE . 72.6 t -86.23 106.5 15.66 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.896 -179.164 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . 0.413 ' HG ' ' CD2' ' A' ' 152' ' ' HIS . 4.2 tt -106.34 81.34 1.6 Allowed 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 178.497 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.527 HG12 ' HA ' ' A' ' 113' ' ' ALA . 1.2 mt -81.46 140.19 16.9 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 121.167 0.508 . . . . 0.0 111.674 -178.777 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.423 ' HG3' ' CG2' ' A' ' 112' ' ' ILE . 0.0 OUTLIER -99.01 145.9 26.6 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.551 -0.749 . . . . 0.0 110.27 179.873 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 3.8 mtt-85 -139.09 102.26 7.53 Favored Pre-proline 0 C--N 1.331 -0.232 0 CA-C-N 116.463 -0.335 . . . . 0.0 110.982 -179.782 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . 0.419 ' HB2' ' CE1' ' A' ' 93' ' ' TYR . 52.5 Cg_exo -55.09 -57.04 1.88 Allowed 'Trans proline' 0 C--N 1.347 0.478 0 C-N-CA 122.465 2.11 . . . . 0.0 112.35 -179.858 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.7 t0 -139.83 -168.67 2.55 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.869 0.366 . . . . 0.0 111.174 -179.86 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -83.32 -30.82 27.21 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.04 -179.924 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -68.13 -11.02 58.4 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.62 -179.694 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . 0.419 ' CE1' ' HB2' ' A' ' 89' ' ' PRO . 25.2 m-85 -82.88 178.17 8.3 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.507 -0.315 . . . . 0.0 110.784 179.839 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 8.3 mp0 -136.57 164.8 27.35 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.068 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -72.51 -60.21 2.34 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.781 179.847 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 121.4 14.0 5.06 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.657 -0.783 . . . . 0.0 113.174 179.797 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . 0.419 ' CD2' HG22 ' A' ' 104' ' ' ILE . 30.5 p90 -160.45 175.12 13.12 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.958 0.408 . . . . 0.0 111.197 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -118.42 141.19 48.79 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.009 -0.542 . . . . 0.0 110.771 179.86 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.433 ' CG1' ' CG2' ' A' ' 141' ' ' VAL . 6.3 p -109.98 136.0 47.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 121.1 0.476 . . . . 0.0 111.427 -179.858 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -126.92 89.78 3.04 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.048 179.457 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 2.5 m-20 62.27 12.2 5.01 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.814 -179.083 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 129.7 -37.65 2.13 Favored Glycine 0 N--CA 1.445 -0.716 0 C-N-CA 121.095 -0.574 . . . . 0.0 112.007 -179.871 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.456 HG12 ' CB ' ' A' ' 158' ' ' ALA . 41.8 mt -79.2 135.67 25.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-O 121.093 0.473 . . . . 0.0 111.801 -179.469 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.419 HG22 ' CD2' ' A' ' 97' ' ' PHE . 3.8 mp -91.54 141.27 14.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.825 179.799 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 36.9 m -116.82 -81.1 0.61 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.285 -179.556 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 4.6 m -77.13 139.16 39.88 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.991 -179.78 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 9.5 tt -156.38 120.75 4.5 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.636 179.867 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 19.2 mtm -90.75 129.0 36.87 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.985 -179.889 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 2.3 mpt_? -66.13 76.71 0.09 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.644 179.82 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 178.23 -34.8 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.927 -0.654 . . . . 0.0 112.126 -179.843 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.408 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -55.31 171.54 1.46 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.286 179.697 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . 0.423 ' CG2' ' HG3' ' A' ' 87' ' ' ARG . 0.5 OUTLIER -78.66 -17.59 13.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-O 120.82 0.343 . . . . 0.0 111.505 -179.778 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' ALA . . . . . 0.527 ' HA ' HG12 ' A' ' 86' ' ' ILE . . . -58.4 -30.78 67.1 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.87 0.367 . . . . 0.0 110.633 179.804 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' GLU . . . . . 0.408 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 10.9 pt-20 -60.02 -45.72 91.88 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.691 179.579 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 1.6 mmm180 -62.93 -49.08 76.18 Favored 'General case' 0 N--CA 1.452 -0.359 0 CA-C-N 115.843 -0.617 . . . . 0.0 111.132 -179.473 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.405 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -49.52 -74.33 0.28 Allowed Glycine 0 CA--C 1.519 0.318 0 C-N-CA 120.224 -0.989 . . . . 0.0 112.532 179.936 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . 0.42 ' O ' ' C ' ' A' ' 118' ' ' VAL . . . -179.81 -30.67 0.06 OUTLIER Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 121.124 -0.56 . . . . 0.0 112.181 179.864 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.463 ' N ' ' CG2' ' A' ' 84' ' ' VAL . 73.6 t -26.43 123.7 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.384 0 C-N-CA 122.956 0.503 . . . . 0.0 112.283 -179.771 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 14.1 mtt-85 -123.29 118.42 27.52 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.54 179.779 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 21.5 t -52.2 93.23 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.239 -179.919 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 122.78 37.9 0.6 Allowed Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.933 -0.651 . . . . 0.0 112.332 -179.861 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . 0.416 ' O ' ' HA ' ' A' ' 103' ' ' ILE . 10.3 m170 -138.77 169.25 18.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.753 0.311 . . . . 0.0 110.805 179.933 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.462 ' HB2' ' CB ' ' A' ' 158' ' ' ALA . 1.4 ttm180 -108.42 143.89 36.75 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.201 -179.877 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . 0.498 HG21 ' CG2' ' A' ' 132' ' ' VAL . 26.8 mt -101.29 155.36 4.6 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 178.465 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 125' ' ' ILE . . . . . 0.454 ' CG1' ' H ' ' A' ' 126' ' ' GLU . 0.7 OUTLIER -147.45 -84.31 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 N-CA-C 113.208 0.818 . . . . 0.0 113.208 -178.561 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . 0.454 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 6.1 mt-10 -79.87 85.34 5.53 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 112.626 0.602 . . . . 0.0 112.626 -178.093 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.465 ' HA ' ' CB ' ' A' ' 153' ' ' MET . 1.7 mt -91.18 103.35 14.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 121.025 0.441 . . . . 0.0 111.17 179.094 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 33.4 m-80 55.65 25.4 8.08 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.106 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 107.65 -13.91 38.69 Favored Glycine 0 CA--C 1.518 0.273 0 C-N-CA 120.624 -0.798 . . . . 0.0 112.775 179.895 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 22.3 tt0 -95.95 113.94 25.61 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.849 0.357 . . . . 0.0 110.875 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -77.54 91.4 3.95 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.141 -179.902 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . 0.498 ' CG2' HG21 ' A' ' 124' ' ' ILE . 32.4 m -75.41 -2.57 4.11 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.257 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.818 179.891 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 8.2 p -46.24 -38.3 3.22 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.142 0 CA-C-O 120.858 0.361 . . . . 0.0 111.445 -179.758 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -117.6 28.57 8.36 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.787 179.401 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 135' ' ' THR . . . . . 0.427 ' CG2' ' HD2' ' A' ' 136' ' ' PRO . 86.0 m -111.48 141.88 25.41 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 115.777 -0.647 . . . . 0.0 111.105 -179.772 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 136' ' ' PRO . . . . . 0.427 ' HD2' ' CG2' ' A' ' 135' ' ' THR . 9.5 Cg_endo -51.87 164.23 1.13 Allowed 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.8 2.333 . . . . 0.0 112.215 179.742 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 12.4 p80 -70.47 -47.64 59.6 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.376 -179.785 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -55.6 -32.74 63.33 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.249 -179.707 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 139' ' ' LYS . . . . . 0.458 ' O ' ' CD1' ' A' ' 143' ' ' ILE . 0.4 OUTLIER -65.08 -50.27 66.78 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.833 -179.917 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 8.8 mt -58.68 -43.46 87.68 Favored 'Isoleucine or valine' 0 C--O 1.235 0.311 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.577 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . 0.433 ' CG2' ' CG1' ' A' ' 99' ' ' VAL . 61.8 t -61.42 -32.93 54.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.292 179.189 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 0.5 OUTLIER -62.66 -53.47 54.05 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.968 179.924 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . 0.458 ' CD1' ' O ' ' A' ' 139' ' ' LYS . 4.3 mp -53.04 -57.23 4.96 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.393 0 CA-C-O 121.162 0.506 . . . . 0.0 110.371 179.558 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.556 HD21 HG12 ' A' ' 151' ' ' ILE . 1.8 mt -62.16 -30.04 70.77 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.417 -0.81 . . . . 0.0 110.42 179.557 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 9.2 t -68.16 -26.7 65.89 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.179 -0.464 . . . . 0.0 109.872 178.567 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 4.1 m-80 -131.19 35.01 3.95 Favored 'General case' 0 CA--C 1.528 0.107 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.199 179.918 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 147' ' ' ALA . . . . . 0.408 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . -114.29 48.75 1.07 Allowed 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.855 0.36 . . . . 0.0 111.304 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 29.8 m -54.09 150.35 1.76 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.285 -179.953 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 108.68 -107.72 2.51 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.445 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 40.9 mt-10 -138.05 104.32 5.2 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.711 0.291 . . . . 0.0 110.889 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . 0.556 HG12 HD21 ' A' ' 144' ' ' LEU . 1.2 mt -78.64 111.7 15.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.065 -179.91 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . 0.431 ' CE1' HG22 ' A' ' 83' ' ' THR . 0.6 OUTLIER -103.82 115.66 30.88 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.999 -0.546 . . . . 0.0 109.828 179.129 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 153' ' ' MET . . . . . 0.465 ' CB ' ' HA ' ' A' ' 127' ' ' ILE . 1.9 ptt? -145.91 167.08 24.15 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.089 0.471 . . . . 0.0 111.876 -179.077 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -115.06 153.28 30.99 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.625 -0.716 . . . . 0.0 109.899 179.234 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 155' ' ' THR . . . . . 0.42 HG23 ' HA ' ' A' ' 124' ' ' ILE . 51.8 p -142.69 140.29 31.48 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.235 0.54 . . . . 0.0 111.829 -179.302 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 156' ' ' MET . . . . . 0.41 ' N ' ' O ' ' A' ' 123' ' ' ARG . 0.2 OUTLIER -126.46 152.45 74.23 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 115.329 -0.85 . . . . 0.0 109.947 179.309 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 12.6 Cg_endo -56.16 115.8 2.72 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.497 2.131 . . . . 0.0 112.496 -179.784 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 158' ' ' ALA . . . . . 0.462 ' CB ' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.248 0.992 0 CA-C-O 118.234 -0.889 . . . . 0.0 110.943 179.733 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_endo . . . . . 0 N--CA 1.489 1.235 0 CA-C-O 120.703 0.21 . . . . 0.0 111.838 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 12.6 Cg_exo -69.76 85.77 0.6 Allowed 'Trans proline' 0 C--N 1.345 0.346 0 C-N-CA 122.734 2.289 . . . . 0.0 112.301 -179.853 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 37.0 t -102.09 122.79 54.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.995 179.859 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.3 m -111.12 138.4 47.6 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.85 179.934 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 9.5 m -98.63 111.14 23.6 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.166 179.266 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.501 ' HB ' ' HG2' ' A' ' 153' ' ' MET . 62.0 t -84.95 106.2 14.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.731 -179.432 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . 0.418 HD13 ' CD2' ' A' ' 152' ' ' HIS . 10.2 tt -104.36 83.8 2.11 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 178.431 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.465 HG12 ' HA ' ' A' ' 113' ' ' ALA . 7.3 mt -81.84 130.89 35.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.92 -178.342 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -92.18 124.41 36.24 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.388 -0.823 . . . . 0.0 110.447 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -126.48 120.26 23.29 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 116.451 -0.341 . . . . 0.0 110.874 -179.864 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 62.5 Cg_endo -73.41 -28.65 11.99 Favored 'Trans proline' 0 C--N 1.346 0.425 0 C-N-CA 122.465 2.11 . . . . 0.0 112.16 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -173.07 -169.38 0.54 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.959 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 1.9 mp -80.36 -5.56 56.59 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.556 -179.909 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 2.2 ptm85 -102.76 27.28 7.12 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.861 0.362 . . . . 0.0 111.153 -179.807 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 4.3 m-85 -138.37 81.53 1.86 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.914 179.858 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -60.97 161.85 7.78 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.98 -179.847 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . 0.4 ' CD1' ' HB3' ' A' ' 144' ' ' LEU . 0.5 OUTLIER -79.99 -65.31 1.02 Allowed 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.674 179.897 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 114.34 58.33 0.38 Allowed Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.916 179.512 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . 0.415 ' CE2' HG22 ' A' ' 99' ' ' VAL . 14.2 p90 -165.33 128.49 2.22 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.916 0.389 . . . . 0.0 111.106 179.698 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 6.4 t -71.98 144.09 48.99 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.832 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.45 ' CG1' ' HB ' ' A' ' 140' ' ' ILE . 48.9 t -111.9 136.9 46.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 121.032 0.444 . . . . 0.0 111.648 -179.705 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 4.1 mm-40 -135.72 88.06 2.37 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.722 -0.672 . . . . 0.0 109.507 178.563 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 85.6 m-20 53.57 21.65 2.63 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.985 -178.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.422 ' N ' HD11 ' A' ' 140' ' ' ILE . . . 121.88 -32.83 4.46 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.922 -0.656 . . . . 0.0 112.374 179.902 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.448 HG12 ' CB ' ' A' ' 158' ' ' ALA . 31.2 mt -77.49 128.65 38.01 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 121.003 0.43 . . . . 0.0 111.781 -179.649 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.41 ' CD1' ' CD1' ' A' ' 124' ' ' ILE . 3.6 mp -84.42 144.81 9.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.146 179.296 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 55.9 m -126.51 -80.64 0.61 Allowed 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 112.009 0.374 . . . . 0.0 112.009 -179.205 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 40.3 m -79.17 66.18 4.55 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 112.027 0.38 . . . . 0.0 112.027 -178.797 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.413 ' HB3' ' CG2' ' A' ' 120' ' ' VAL . 14.0 tp -89.12 100.58 13.33 Favored 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 178.859 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 2.0 ptm -81.33 140.51 34.74 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.317 -179.472 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.51 166.74 9.9 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.596 179.697 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 92.79 -41.97 2.69 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.533 -0.842 . . . . 0.0 112.23 -179.732 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.401 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -58.21 168.76 5.25 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.227 179.751 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -78.35 -16.23 13.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.733 0.301 . . . . 0.0 111.768 -179.797 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' ALA . . . . . 0.465 ' HA ' HG12 ' A' ' 86' ' ' ILE . . . -57.52 -30.34 65.07 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 121.015 0.436 . . . . 0.0 110.78 179.853 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' GLU . . . . . 0.401 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 15.3 pt-20 -60.15 -46.69 88.79 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.904 179.56 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 16.2 mtm180 -64.7 -46.38 82.62 Favored 'General case' 0 N--CA 1.453 -0.314 0 CA-C-N 116.009 -0.541 . . . . 0.0 111.127 -179.316 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -50.55 -73.41 0.37 Allowed Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.431 -0.89 . . . . 0.0 112.686 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 171.78 -21.27 0.07 OUTLIER Glycine 0 CA--C 1.519 0.284 0 C-N-CA 121.048 -0.596 . . . . 0.0 112.663 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.436 ' N ' ' CG2' ' A' ' 84' ' ' VAL . 1.2 t -37.95 135.9 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.261 0 CA-C-O 120.98 0.419 . . . . 0.0 111.638 -179.783 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 5.3 mtm180 -136.64 132.18 34.66 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.553 179.64 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . 0.413 ' CG2' ' HB3' ' A' ' 107' ' ' LEU . 15.4 t -57.11 89.45 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.852 0.358 . . . . 0.0 110.999 -179.866 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 131.98 -3.32 5.25 Favored Glycine 0 CA--C 1.52 0.375 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.861 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 1.6 m-70 -90.16 127.51 36.12 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-O 120.888 0.375 . . . . 0.0 110.73 179.899 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.446 ' HB2' ' CB ' ' A' ' 158' ' ' ALA . 20.8 ttm180 -82.62 92.35 7.12 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.926 -179.373 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . 0.492 HG22 ' CG2' ' A' ' 132' ' ' VAL . 10.0 mt -50.39 157.56 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.05 178.544 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 125' ' ' ILE . . . . . 0.423 ' CG2' ' HB ' ' A' ' 133' ' ' VAL . 0.6 OUTLIER -150.77 -85.66 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 N-CA-C 112.38 0.511 . . . . 0.0 112.38 -179.349 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . 0.416 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 1.7 mt-10 -75.29 85.12 2.46 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 112.067 0.395 . . . . 0.0 112.067 -178.959 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.517 ' HA ' ' CB ' ' A' ' 153' ' ' MET . 1.3 mt -92.61 102.6 13.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 120.951 0.405 . . . . 0.0 111.312 179.47 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 1.3 m-20 61.83 15.52 7.15 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.596 179.745 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 119.88 -16.95 10.15 Favored Glycine 0 C--N 1.333 0.368 0 C-N-CA 120.401 -0.904 . . . . 0.0 113.338 179.634 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 8.2 pt20 -101.94 123.08 45.24 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 117.091 0.445 . . . . 0.0 111.104 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 48.1 t -81.05 101.68 9.73 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.347 -179.68 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . 0.492 ' CG2' HG22 ' A' ' 124' ' ' ILE . 27.2 m -81.68 2.7 2.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.68 179.691 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . 0.423 ' HB ' ' CG2' ' A' ' 125' ' ' ILE . 8.0 p -44.7 -45.18 2.64 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.133 0 CA-C-O 120.853 0.358 . . . . 0.0 111.697 -179.674 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -112.46 30.22 7.27 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.869 179.73 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 86.2 m -109.28 142.47 25.68 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.942 -179.788 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 136' ' ' PRO . . . . . . . . . . . . . 71.2 Cg_exo -50.73 164.01 0.64 Allowed 'Trans proline' 0 C--N 1.348 0.535 0 C-N-CA 122.583 2.189 . . . . 0.0 112.431 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 28.1 p-80 -72.02 -51.22 22.84 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.161 -179.814 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -55.25 -30.96 61.1 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.986 -179.899 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 139' ' ' LYS . . . . . 0.468 ' O ' ' CD1' ' A' ' 143' ' ' ILE . 0.2 OUTLIER -64.62 -48.65 74.07 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.94 179.998 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . 0.45 ' HB ' ' CG1' ' A' ' 99' ' ' VAL . 5.4 mt -58.76 -45.01 91.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-O 121.048 0.452 . . . . 0.0 110.438 179.973 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 48.4 t -61.21 -32.43 52.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.417 179.24 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 1.6 m-70 -62.19 -53.09 60.32 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.723 179.79 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . 0.468 ' CD1' ' O ' ' A' ' 139' ' ' LYS . 4.2 mp -53.28 -56.27 8.97 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.44 0 CA-C-O 121.207 0.527 . . . . 0.0 110.222 179.157 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.629 HD21 HG12 ' A' ' 151' ' ' ILE . 2.9 mt -62.95 -30.36 71.5 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.466 179.741 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 2.8 m -67.22 -29.9 69.69 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.17 -0.468 . . . . 0.0 109.743 178.738 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 4.4 m-80 -131.13 38.28 3.67 Favored 'General case' 0 C--N 1.333 -0.135 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.625 179.596 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 147' ' ' ALA . . . . . 0.466 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . -90.15 -51.91 5.21 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.246 0.546 . . . . 0.0 111.258 -179.545 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER 57.01 164.61 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-N 115.292 -0.867 . . . . 0.0 111.078 -179.932 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 73.18 -133.41 18.26 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.524 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 -114.39 99.71 7.78 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.788 0.328 . . . . 0.0 110.92 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . 0.629 HG12 HD21 ' A' ' 144' ' ' LEU . 0.6 OUTLIER -68.1 111.9 2.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.987 179.982 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . 0.418 ' CD2' HD13 ' A' ' 85' ' ' LEU . 0.7 OUTLIER -108.31 115.75 30.69 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.251 179.455 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 153' ' ' MET . . . . . 0.517 ' CB ' ' HA ' ' A' ' 127' ' ' ILE . 0.0 OUTLIER -143.62 176.05 9.5 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.208 0.528 . . . . 0.0 111.846 -179.356 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 9.7 mttp -122.76 151.99 41.07 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.416 -0.811 . . . . 0.0 109.487 178.919 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 6.6 p -141.57 141.39 33.5 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.031 0.443 . . . . 0.0 111.598 -179.345 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 156' ' ' MET . . . . . . . . . . . . . 9.6 mtp -125.8 133.52 24.98 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.588 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 82.5 Cg_exo -44.68 120.19 2.66 Favored 'Trans proline' 0 C--N 1.345 0.344 0 C-N-CA 122.558 2.172 . . . . 0.0 112.752 -179.888 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 158' ' ' ALA . . . . . 0.448 ' CB ' HG12 ' A' ' 103' ' ' ILE . . . . . . . . 0 C--O 1.249 1.061 0 CA-C-O 118.181 -0.914 . . . . 0.0 111.061 179.87 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo . . . . . 0 N--CA 1.489 1.212 0 CA-C-O 120.88 0.283 . . . . 0.0 111.632 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 68.2 Cg_endo -74.14 94.49 0.89 Allowed 'Trans proline' 0 C--N 1.343 0.284 0 C-N-CA 122.531 2.154 . . . . 0.0 112.466 -179.918 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 39.0 t -117.84 142.04 34.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.9 179.835 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.0 m -123.18 140.93 52.51 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.01 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 20.0 m -97.34 111.37 23.65 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.059 179.134 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.454 HG12 HG13 ' A' ' 86' ' ' ILE . 78.9 t -88.98 105.73 16.15 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.42 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.792 -179.239 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . 0.465 ' O ' ' HA2' ' A' ' 116' ' ' GLY . 0.5 OUTLIER -103.21 83.87 2.26 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 178.395 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.454 HG13 HG12 ' A' ' 84' ' ' VAL . 19.8 mt -80.85 132.51 31.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 121.405 0.621 . . . . 0.0 111.862 -178.306 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.4 ' O ' ' CG2' ' A' ' 112' ' ' ILE . 2.9 mmt180 -79.38 149.01 31.8 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 114.957 -1.02 . . . . 0.0 111.137 -179.477 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . 0.519 ' HB3' ' HA ' ' A' ' 148' ' ' VAL . 2.7 mtt-85 -164.57 97.81 0.89 Allowed Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.846 179.689 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 70.3 Cg_endo -89.26 25.77 0.59 Allowed 'Trans proline' 0 N--CA 1.46 -0.483 0 C-N-CA 122.893 2.396 . . . . 0.0 113.414 -179.296 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 5.6 p-10 -179.03 177.74 0.79 Allowed 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.039 0.447 . . . . 0.0 111.741 179.922 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 6.0 mt -98.42 6.68 47.05 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.692 -0.686 . . . . 0.0 111.486 -179.89 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 8.6 ptt180 -129.18 42.06 3.37 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.853 0.359 . . . . 0.0 111.035 -179.78 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -120.52 126.04 49.37 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.748 179.828 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -86.02 136.6 33.18 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.963 -179.844 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . 0.427 ' CD1' ' HB3' ' A' ' 144' ' ' LEU . 2.2 mp -77.24 -28.28 53.59 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.804 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 75.08 73.17 0.98 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.835 -0.697 . . . . 0.0 112.782 179.622 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -176.14 156.75 1.72 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.806 0.336 . . . . 0.0 111.168 179.766 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.464 ' O ' ' HA ' ' A' ' 104' ' ' ILE . 3.3 t -106.15 133.81 50.27 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.422 179.559 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.417 ' CG1' ' CG2' ' A' ' 141' ' ' VAL . 9.7 p -118.49 134.84 60.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 121.026 0.441 . . . . 0.0 111.459 -179.581 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -131.75 89.24 2.67 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.23 179.405 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 12.1 m120 57.78 18.28 4.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.134 -179.468 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 128.18 -39.83 1.83 Allowed Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.531 179.858 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.421 HG12 ' CB ' ' A' ' 158' ' ' ALA . 26.6 mt -77.3 138.66 20.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 121.006 0.432 . . . . 0.0 111.531 -179.57 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.464 ' HA ' ' O ' ' A' ' 98' ' ' SER . 4.5 mp -99.07 137.83 25.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.911 179.917 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 43.4 t -105.0 -77.98 0.58 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.983 -179.781 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 77.0 p -90.63 119.24 30.71 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.707 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 25.7 tp -112.91 119.3 37.47 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.841 -179.938 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 9.3 mtp -68.13 98.26 0.77 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.975 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -60.86 117.59 5.61 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.826 -179.95 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 97.44 32.5 6.3 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.407 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.491 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -118.61 -160.74 11.56 Favored Glycine 0 N--CA 1.453 -0.216 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.968 -179.789 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . 0.4 ' CG2' ' O ' ' A' ' 87' ' ' ARG . 7.9 mt -80.62 -39.9 18.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-O 121.094 0.473 . . . . 0.0 111.506 -179.924 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' ALA . . . . . 0.406 ' CB ' HG12 ' A' ' 118' ' ' VAL . . . -57.67 -39.29 76.72 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.12 -179.481 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' GLU . . . . . 0.491 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 15.3 pt-20 -62.83 -37.83 88.33 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.503 179.499 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.487 ' N ' ' HG3' ' A' ' 114' ' ' GLU . 54.8 mtt85 -59.2 -46.71 87.71 Favored 'General case' 0 N--CA 1.452 -0.361 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.644 -179.866 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.465 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -56.33 -71.14 0.78 Allowed Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.343 -0.932 . . . . 0.0 112.501 179.719 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 175.04 -22.74 0.06 OUTLIER Glycine 0 CA--C 1.52 0.39 0 C-N-CA 120.788 -0.72 . . . . 0.0 113.064 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.45 ' N ' ' CG2' ' A' ' 84' ' ' VAL . 6.0 p -34.27 146.36 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 N-CA-C 112.128 0.418 . . . . 0.0 112.128 -179.604 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -140.95 153.84 45.81 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.917 -179.925 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 22.0 t -74.7 88.44 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.972 179.9 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 124.01 41.0 0.42 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.921 -0.657 . . . . 0.0 112.295 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 1.2 m170 -135.08 122.68 22.09 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.858 0.361 . . . . 0.0 110.764 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.486 ' HB2' ' CB ' ' A' ' 158' ' ' ALA . 34.9 ttp180 -79.74 93.6 5.6 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.538 -179.731 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . 0.5 HG22 ' CG2' ' A' ' 132' ' ' VAL . 9.2 mt -49.98 158.21 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 178.715 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 125' ' ' ILE . . . . . 0.432 ' N ' ' CG2' ' A' ' 124' ' ' ILE . 0.6 OUTLIER -148.99 -82.7 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 N-CA-C 112.446 0.535 . . . . 0.0 112.446 -179.49 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . 0.427 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 7.1 mt-10 -74.64 80.72 2.01 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 112.361 0.504 . . . . 0.0 112.361 -178.758 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.458 ' CG2' ' CG ' ' A' ' 153' ' ' MET . 2.7 mt -84.55 92.04 3.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 121.05 0.452 . . . . 0.0 111.01 179.259 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . 0.414 ' N ' ' O ' ' A' ' 152' ' ' HIS . 56.9 m-80 58.65 25.26 13.06 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.995 -179.81 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 113.36 -16.96 21.81 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.716 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 6.0 tt0 -94.4 111.15 22.89 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.809 0.338 . . . . 0.0 110.814 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -75.98 93.29 3.24 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.084 -179.822 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . 0.5 ' CG2' HG22 ' A' ' 124' ' ' ILE . 30.6 m -76.39 -1.58 3.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.881 179.835 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 8.7 p -42.94 -44.23 1.22 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.121 0 CA-C-O 120.825 0.345 . . . . 0.0 111.611 -179.653 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -117.24 29.75 7.71 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.772 179.714 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 52.3 m -108.71 142.17 24.87 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.057 -0.519 . . . . 0.0 111.161 -179.844 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 136' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -52.37 164.11 1.45 Allowed 'Trans proline' 0 C--N 1.346 0.442 0 C-N-CA 122.56 2.173 . . . . 0.0 112.284 179.677 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 31.9 p-80 -70.95 -49.81 41.44 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.368 -179.855 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 5.8 tp10 -54.36 -34.79 61.88 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.332 -0.394 . . . . 0.0 111.393 -179.695 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 139' ' ' LYS . . . . . 0.456 ' O ' ' CD1' ' A' ' 143' ' ' ILE . 3.3 tttp -62.76 -47.34 83.94 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.881 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . 0.493 HD13 HG23 ' A' ' 140' ' ' ILE . 15.1 mt -58.59 -45.45 90.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.603 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . 0.417 ' CG2' ' CG1' ' A' ' 99' ' ' VAL . 87.9 t -60.27 -32.5 50.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.326 178.987 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 1.8 t-80 -62.06 -53.56 53.77 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.012 179.774 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . 0.456 ' CD1' ' O ' ' A' ' 139' ' ' LYS . 4.1 mp -52.94 -56.8 6.11 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.463 0 CA-C-O 121.227 0.537 . . . . 0.0 110.265 179.44 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.62 HD21 HG12 ' A' ' 151' ' ' ILE . 1.9 mt -62.44 -30.33 71.16 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.313 -0.858 . . . . 0.0 110.397 179.674 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 27.5 t -67.67 -27.8 67.15 Favored 'General case' 0 N--CA 1.453 -0.29 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.085 178.884 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 7.8 m-80 -133.81 37.34 3.26 Favored 'General case' 0 CA--C 1.529 0.163 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.164 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 147' ' ' ALA . . . . . 0.444 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . -101.46 -37.66 8.34 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.118 0.485 . . . . 0.0 111.301 -179.861 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . 0.519 ' HA ' ' HB3' ' A' ' 88' ' ' ARG . 32.0 m 44.56 -172.67 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.37 -0.832 . . . . 0.0 112.036 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 58.38 -135.14 52.13 Favored Glycine 0 C--N 1.332 0.309 0 C-N-CA 121.035 -0.602 . . . . 0.0 112.704 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 62.2 mm-40 -110.09 91.28 3.59 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.851 0.357 . . . . 0.0 110.449 179.836 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . 0.62 HG12 HD21 ' A' ' 144' ' ' LEU . 0.7 OUTLIER -61.03 111.62 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.49 -179.448 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . 0.414 ' O ' ' N ' ' A' ' 128' ' ' ASN . 4.2 t60 -90.03 115.78 27.57 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 109.168 -0.679 . . . . 0.0 109.168 178.573 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 153' ' ' MET . . . . . 0.458 ' CG ' ' CG2' ' A' ' 127' ' ' ILE . 26.9 mtp -133.62 162.14 32.73 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.422 0.629 . . . . 0.0 112.452 -178.431 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 17.7 mttt -134.04 140.39 46.64 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 114.881 -1.054 . . . . 0.0 108.905 178.673 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 155' ' ' THR . . . . . 0.417 ' CG2' ' CG1' ' A' ' 124' ' ' ILE . 1.6 p -140.32 149.44 42.76 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.241 0.543 . . . . 0.0 112.046 -178.871 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 156' ' ' MET . . . . . . . . . . . . . 4.8 ptp -132.23 156.38 80.17 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 115.207 -0.906 . . . . 0.0 110.139 179.146 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_endo -57.4 120.41 8.31 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.366 2.044 . . . . 0.0 112.639 -179.726 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 158' ' ' ALA . . . . . 0.486 ' CB ' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.249 1.029 0 CA-C-O 118.289 -0.862 . . . . 0.0 111.114 179.876 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo . . . . . 0 N--CA 1.488 1.18 0 CA-C-O 120.734 0.223 . . . . 0.0 111.673 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -74.42 60.05 4.86 Favored 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.536 2.157 . . . . 0.0 112.44 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 20.2 t -96.24 137.36 24.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.01 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 1.9 m -115.2 139.03 50.28 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.951 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 8.4 m -95.79 111.31 23.31 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.014 179.091 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.486 HG12 HG13 ' A' ' 86' ' ' ILE . 67.3 t -90.63 105.76 16.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.757 -179.166 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . 0.441 ' O ' ' HA2' ' A' ' 116' ' ' GLY . 6.2 tt -103.0 84.36 2.35 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 178.633 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.486 HG13 HG12 ' A' ' 84' ' ' VAL . 3.6 mt -80.94 128.64 38.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 121.27 0.557 . . . . 0.0 111.864 -178.526 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.41 ' HB2' HG21 ' A' ' 112' ' ' ILE . 0.2 OUTLIER -74.81 153.01 38.94 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.459 179.962 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -148.33 100.1 3.61 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.109 179.845 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . 0.408 ' HG2' ' CD2' ' A' ' 93' ' ' TYR . 57.8 Cg_endo -71.21 -39.85 3.64 Favored 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.423 2.082 . . . . 0.0 112.497 -179.855 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -145.69 -169.24 3.18 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.167 -179.887 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -88.78 -53.27 4.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.057 -179.967 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.2 mpp_? -57.93 -20.06 34.65 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.522 -179.528 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . 0.408 ' CD2' ' HG2' ' A' ' 89' ' ' PRO . 12.7 m-85 -77.21 133.39 38.91 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.799 179.896 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 4.5 mp0 -89.58 177.48 6.53 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.986 -179.925 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . 0.415 ' HB2' ' CE1' ' A' ' 97' ' ' PHE . 2.3 mp -93.61 -67.62 0.85 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.858 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 134.8 52.53 0.07 OUTLIER Glycine 0 CA--C 1.519 0.332 0 C-N-CA 120.465 -0.874 . . . . 0.0 113.026 179.584 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . 0.459 ' CD2' ' HB2' ' A' ' 113' ' ' ALA . 0.0 OUTLIER 179.96 177.41 0.65 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.839 0.352 . . . . 0.0 111.402 179.663 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 71.0 m -125.73 137.09 53.8 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.762 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 7.1 p -109.74 135.26 49.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.453 -179.687 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 4.6 tt0 -131.58 89.4 2.7 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.068 179.359 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 61.05 15.85 6.55 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.016 -179.215 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 125.37 -37.01 2.64 Favored Glycine 0 N--CA 1.447 -0.569 0 C-N-CA 120.987 -0.625 . . . . 0.0 112.065 -179.924 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.428 HG12 ' CB ' ' A' ' 158' ' ' ALA . 44.8 mt -77.43 140.93 16.28 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-O 121.016 0.436 . . . . 0.0 111.574 -179.815 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.403 ' CD1' ' CD1' ' A' ' 124' ' ' ILE . 3.7 mp -98.53 141.21 16.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.985 -179.824 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 22.0 m -119.82 -48.45 2.36 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.936 -0.574 . . . . 0.0 111.003 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -96.81 151.66 19.44 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.871 -179.972 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -167.25 116.46 0.83 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.871 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 5.0 tmm? -85.49 116.31 23.72 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.939 -179.939 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -60.78 125.6 24.29 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.921 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 88.11 26.99 27.1 Favored Glycine 0 N--CA 1.453 -0.217 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.552 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.472 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -108.36 -161.61 20.55 Favored Glycine 0 CA--C 1.518 0.249 0 C-N-CA 120.782 -0.723 . . . . 0.0 113.031 -179.704 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . 0.41 HG21 ' HB2' ' A' ' 87' ' ' ARG . 7.6 mt -80.46 -42.68 21.32 Favored 'Isoleucine or valine' 0 C--O 1.237 0.434 0 CA-C-O 121.181 0.515 . . . . 0.0 111.41 -179.829 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' ALA . . . . . 0.475 ' HA ' HG12 ' A' ' 86' ' ' ILE . . . -57.76 -34.72 69.85 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.283 -179.251 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' GLU . . . . . 0.511 ' HG3' ' N ' ' A' ' 115' ' ' ARG . 7.3 pt-20 -67.9 -35.72 78.97 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.725 179.568 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.511 ' N ' ' HG3' ' A' ' 114' ' ' GLU . 36.1 mmt180 -61.71 -47.35 85.7 Favored 'General case' 0 N--CA 1.452 -0.368 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.885 -179.626 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.441 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -55.09 -72.58 0.53 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.225 -0.988 . . . . 0.0 112.615 179.894 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 175.49 -22.15 0.06 OUTLIER Glycine 0 CA--C 1.52 0.393 0 C-N-CA 120.936 -0.65 . . . . 0.0 112.857 -179.881 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.425 ' HB ' HG13 ' A' ' 84' ' ' VAL . 9.1 p -30.76 147.24 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 N-CA-C 112.637 0.606 . . . . 0.0 112.637 -179.723 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -142.79 130.47 21.42 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.653 179.748 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 26.0 t -62.0 95.75 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.209 -179.809 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 123.38 40.41 0.47 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.688 179.859 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -125.32 -165.98 1.48 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.656 0.265 . . . . 0.0 110.851 -179.982 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.435 ' HB2' ' CB ' ' A' ' 158' ' ' ALA . 0.1 OUTLIER -145.76 90.75 2.02 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.376 -0.375 . . . . 0.0 110.813 179.952 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . 0.488 HG22 ' CG2' ' A' ' 132' ' ' VAL . 8.0 mt -53.36 157.04 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.582 179.496 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 125' ' ' ILE . . . . . 0.424 ' CG1' ' H ' ' A' ' 126' ' ' GLU . 0.6 OUTLIER -150.31 -84.48 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 N-CA-C 112.209 0.448 . . . . 0.0 112.209 -179.474 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . 0.424 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 21.9 mt-10 -79.75 85.84 5.39 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 112.176 0.436 . . . . 0.0 112.176 -178.964 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.471 ' HA ' ' CB ' ' A' ' 153' ' ' MET . 1.9 mt -89.83 108.3 19.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 116.396 -0.365 . . . . 0.0 111.377 179.475 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . 0.401 ' OD1' ' CD2' ' A' ' 152' ' ' HIS . 55.2 m-80 54.42 24.88 5.54 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.128 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 105.26 -10.22 46.76 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.665 -0.779 . . . . 0.0 112.794 -179.85 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 21.4 tt0 -98.85 112.19 24.36 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.85 0.357 . . . . 0.0 110.756 179.855 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 1.5 m -74.49 91.09 2.24 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.286 -179.595 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . 0.488 ' CG2' HG22 ' A' ' 124' ' ' ILE . 29.6 m -71.54 -5.6 6.18 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.312 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.547 179.43 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 10.3 p -48.63 121.63 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.254 0 CA-C-O 120.893 0.378 . . . . 0.0 111.133 -179.916 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . 68.15 22.38 8.3 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.034 -179.395 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 135' ' ' THR . . . . . 0.441 ' HB ' ' O ' ' A' ' 132' ' ' VAL . 50.8 m -106.16 141.53 22.94 Favored Pre-proline 0 C--N 1.326 -0.438 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.698 179.559 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 136' ' ' PRO . . . . . 0.408 ' HD2' ' CG2' ' A' ' 135' ' ' THR . 80.2 Cg_exo -45.38 146.92 2.84 Favored 'Trans proline' 0 C--N 1.345 0.359 0 C-N-CA 122.609 2.206 . . . . 0.0 112.565 -179.922 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 137' ' ' HIS . . . . . 0.413 ' CE1' ' HG2' ' A' ' 138' ' ' GLU . 7.0 p80 -65.21 -41.74 94.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.019 -179.929 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . 0.413 ' HG2' ' CE1' ' A' ' 137' ' ' HIS . 4.7 mm-40 -56.25 -37.21 69.44 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.947 -179.899 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 139' ' ' LYS . . . . . 0.46 ' O ' ' CD1' ' A' ' 143' ' ' ILE . 27.9 tttt -63.66 -48.96 75.09 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.903 179.942 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . 0.436 HD12 HG22 ' A' ' 140' ' ' ILE . 16.1 mt -58.62 -42.15 84.07 Favored 'Isoleucine or valine' 0 C--O 1.236 0.364 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.628 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 89.2 t -62.49 -33.03 57.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.194 178.972 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -61.85 -51.74 66.99 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.64 179.736 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . 0.46 ' CD1' ' O ' ' A' ' 139' ' ' LYS . 4.4 mp -53.24 -57.18 5.3 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.433 0 CA-C-O 121.079 0.466 . . . . 0.0 110.316 179.167 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.542 HD22 HG12 ' A' ' 151' ' ' ILE . 2.9 mt -61.71 -30.24 70.63 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.25 179.597 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 2.1 m -69.27 -25.96 64.52 Favored 'General case' 0 N--CA 1.453 -0.317 0 CA-C-N 116.097 -0.501 . . . . 0.0 109.965 178.529 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 4.9 m-80 -130.15 33.91 4.29 Favored 'General case' 0 CA--C 1.529 0.149 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.213 179.861 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 147' ' ' ALA . . . . . 0.418 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . -117.89 54.88 0.89 Allowed 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.192 179.908 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 8.1 m -50.78 177.61 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.447 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 81.75 -111.62 3.35 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.458 -179.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 58.9 mt-10 -138.4 105.64 5.49 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.877 0.37 . . . . 0.0 110.715 179.841 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . 0.542 HG12 HD22 ' A' ' 144' ' ' LEU . 1.1 mt -73.01 111.36 7.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.069 -179.802 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . 0.401 ' CD2' ' OD1' ' A' ' 128' ' ' ASN . 8.3 p80 -106.34 115.58 30.46 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 178.918 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 153' ' ' MET . . . . . 0.471 ' CB ' ' HA ' ' A' ' 127' ' ' ILE . 1.5 ptt? -140.35 176.13 9.03 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.324 0.583 . . . . 0.0 112.085 -178.663 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 17.6 mttm -126.94 147.69 50.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.194 -0.912 . . . . 0.0 109.812 179.153 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 4.7 p -142.73 145.27 33.16 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.977 0.418 . . . . 0.0 111.163 -179.515 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 156' ' ' MET . . . . . 0.424 ' O ' ' N ' ' A' ' 123' ' ' ARG . 6.6 ptp -133.12 156.65 79.75 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.631 179.647 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_exo -49.46 126.18 15.42 Favored 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.508 2.139 . . . . 0.0 112.623 -179.887 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 158' ' ' ALA . . . . . 0.435 ' CB ' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.249 1.034 0 CA-C-O 118.26 -0.876 . . . . 0.0 111.016 179.823 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_endo . . . . . 0 N--CA 1.488 1.204 0 CA-C-O 120.691 0.204 . . . . 0.0 111.807 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -70.21 99.65 0.81 Allowed 'Trans proline' 0 C--N 1.344 0.309 0 C-N-CA 122.659 2.239 . . . . 0.0 112.29 -179.936 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 21.5 t -103.68 130.73 53.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.011 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.2 m -101.8 134.91 44.23 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.786 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 20.2 m -95.71 111.78 23.65 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.186 179.235 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.485 ' HB ' ' HB2' ' A' ' 153' ' ' MET . 62.2 t -85.63 105.37 14.29 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.41 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.401 -179.408 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . 0.413 ' O ' ' HA2' ' A' ' 116' ' ' GLY . 1.0 OUTLIER -103.17 83.68 2.23 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.058 -0.519 . . . . 0.0 109.652 178.893 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.462 HG13 HG11 ' A' ' 84' ' ' VAL . 12.6 mt -81.77 123.72 38.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-O 121.368 0.604 . . . . 0.0 111.717 -178.756 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.403 ' CB ' HG21 ' A' ' 112' ' ' ILE . 0.0 OUTLIER -71.98 132.5 44.39 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.776 -179.901 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -130.14 90.43 42.11 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.705 179.969 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . 0.426 ' HG2' ' CD2' ' A' ' 93' ' ' TYR . 48.7 Cg_endo -68.87 -25.28 33.07 Favored 'Trans proline' 0 C--N 1.345 0.376 0 C-N-CA 122.552 2.168 . . . . 0.0 112.569 -179.912 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -155.02 -169.57 3.23 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.978 0.418 . . . . 0.0 111.238 -179.856 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -97.44 -46.65 5.98 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.121 -179.82 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -57.01 -20.5 24.42 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.906 -0.588 . . . . 0.0 111.538 -179.631 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . 0.426 ' CD2' ' HG2' ' A' ' 89' ' ' PRO . 8.2 m-85 -60.3 -177.44 0.07 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.688 179.765 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -151.28 161.46 42.67 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.173 -179.941 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . 0.405 HD12 ' CD1' ' A' ' 144' ' ' LEU . 1.4 mt -96.89 -50.34 4.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.698 179.898 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 88.78 72.0 1.27 Allowed Glycine 0 N--CA 1.452 -0.249 0 C-N-CA 120.797 -0.716 . . . . 0.0 113.096 179.456 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 15.9 p90 -175.66 158.33 2.17 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.827 0.346 . . . . 0.0 111.174 179.57 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -105.17 146.64 28.96 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.681 179.924 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.405 ' CG1' ' CG2' ' A' ' 141' ' ' VAL . 7.3 p -130.63 134.02 62.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.307 -179.688 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -127.04 89.41 2.97 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.351 179.493 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 6.5 m120 57.11 18.74 4.27 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.052 -179.432 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 129.79 -41.44 1.54 Allowed Glycine 0 N--CA 1.448 -0.506 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.515 179.871 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.516 HG12 ' CB ' ' A' ' 158' ' ' ALA . 22.7 mt -77.57 129.5 37.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 121.077 0.465 . . . . 0.0 111.576 -179.344 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.404 ' CD1' ' CD1' ' A' ' 124' ' ' ILE . 3.6 mp -85.75 140.84 15.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.771 179.684 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 64.6 m -106.44 -69.89 0.81 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.826 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -100.86 141.25 34.01 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.788 179.859 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 5.7 tp -143.6 113.72 7.29 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.695 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 21.9 mmm -76.28 116.7 17.23 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.86 -179.839 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.05 78.88 0.05 OUTLIER 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.675 179.809 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 173.91 -34.24 0.11 Allowed Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.937 -0.649 . . . . 0.0 112.207 -179.811 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.421 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -57.85 174.63 2.31 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.258 179.853 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . 0.403 HG21 ' CB ' ' A' ' 87' ' ' ARG . 0.9 OUTLIER -78.53 -16.98 13.65 Favored 'Isoleucine or valine' 0 C--O 1.236 0.395 0 CA-C-O 120.91 0.386 . . . . 0.0 111.611 -179.886 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' ALA . . . . . 0.429 ' HA ' HG12 ' A' ' 86' ' ' ILE . . . -57.81 -30.68 65.91 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.997 0.427 . . . . 0.0 110.875 179.908 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 114' ' ' GLU . . . . . 0.421 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 17.0 pt-20 -63.96 -46.85 82.84 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.856 179.828 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.4 ' N ' ' CG ' ' A' ' 114' ' ' GLU . 8.8 mtt180 -58.91 -47.33 85.39 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.087 -179.557 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.413 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -50.1 -72.67 0.45 Allowed Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.368 -0.92 . . . . 0.0 112.689 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 172.34 -21.69 0.07 OUTLIER Glycine 0 CA--C 1.519 0.293 0 C-N-CA 120.972 -0.632 . . . . 0.0 112.674 -179.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.444 ' N ' ' CG2' ' A' ' 84' ' ' VAL . 3.8 p -30.34 144.58 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.29 0 N-CA-C 112.327 0.492 . . . . 0.0 112.327 -179.78 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.413 ' HB3' ' CD2' ' A' ' 122' ' ' HIS . 0.0 OUTLIER -136.64 126.65 26.02 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.643 -179.992 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 19.5 t -56.05 90.79 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.184 179.899 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 121.25 11.21 6.29 Favored Glycine 0 CA--C 1.52 0.379 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.8 -179.904 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . 0.413 ' CD2' ' HB3' ' A' ' 119' ' ' ARG . 6.9 m170 -98.24 132.21 43.94 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.891 0.377 . . . . 0.0 110.739 179.889 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.489 ' HB2' ' CB ' ' A' ' 158' ' ' ALA . 0.0 OUTLIER -79.41 90.78 5.04 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.586 -179.622 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . 0.453 HG23 ' CG2' ' A' ' 132' ' ' VAL . 7.7 mt -54.13 143.15 6.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 N-CA-C 109.709 -0.478 . . . . 0.0 109.709 178.577 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 125' ' ' ILE . . . . . 0.425 ' N ' HG22 ' A' ' 124' ' ' ILE . 0.5 OUTLIER -137.97 -82.84 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 N-CA-C 112.365 0.506 . . . . 0.0 112.365 -179.35 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . 0.417 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 11.6 mt-10 -73.92 81.35 1.66 Allowed 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 112.538 0.57 . . . . 0.0 112.538 -178.776 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.43 HD13 ' CG2' ' A' ' 132' ' ' VAL . 3.0 mt -82.61 92.44 2.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.95 179.045 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . 0.406 ' N ' ' O ' ' A' ' 152' ' ' HIS . 1.6 t-20 58.9 21.11 8.78 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.014 -179.915 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 119.08 -18.5 10.37 Favored Glycine 0 C--N 1.332 0.349 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.787 -179.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -94.72 112.02 23.77 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.837 0.351 . . . . 0.0 110.922 -179.842 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 3.6 p -76.22 96.4 3.91 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.0 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . 0.453 ' CG2' HG23 ' A' ' 124' ' ' ILE . 27.4 m -81.04 2.64 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.323 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.86 179.983 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . 0.418 ' HB ' ' CG2' ' A' ' 125' ' ' ILE . 9.0 p -44.43 -42.57 2.14 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.178 0 CA-C-O 120.922 0.392 . . . . 0.0 111.661 -179.761 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -116.55 29.73 7.77 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.843 179.587 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 85.4 m -111.92 140.17 23.11 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.089 -179.834 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 136' ' ' PRO . . . . . 0.412 ' HG2' ' HB2' ' A' ' 139' ' ' LYS . 10.6 Cg_endo -54.44 164.23 3.08 Favored 'Trans proline' 0 C--N 1.347 0.455 0 C-N-CA 122.646 2.23 . . . . 0.0 112.333 179.895 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 15.2 p80 -67.44 -46.65 72.47 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.603 -179.593 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -53.68 -35.21 60.83 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.387 -0.369 . . . . 0.0 111.468 -179.445 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 139' ' ' LYS . . . . . 0.456 ' O ' ' CD1' ' A' ' 143' ' ' ILE . 0.1 OUTLIER -65.36 -48.94 71.2 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.85 0.357 . . . . 0.0 111.079 -179.8 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 10.1 mt -58.58 -46.19 90.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.529 -179.925 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . 0.405 ' CG2' ' CG1' ' A' ' 99' ' ' VAL . 86.8 t -60.41 -32.29 50.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.058 178.797 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 1.9 t60 -60.65 -52.94 63.01 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.664 179.585 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . 0.456 ' CD1' ' O ' ' A' ' 139' ' ' LYS . 4.2 mp -53.25 -57.03 5.59 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.456 0 CA-C-O 121.151 0.5 . . . . 0.0 110.178 179.364 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.615 HD22 HG12 ' A' ' 151' ' ' ILE . 4.5 mt -60.96 -30.23 70.12 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.279 179.699 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 1.3 m -68.56 -27.0 65.69 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.13 -0.486 . . . . 0.0 109.887 178.572 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 9.0 m120 -127.82 32.59 4.93 Favored 'General case' 0 CA--C 1.528 0.109 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.124 179.813 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 147' ' ' ALA . . . . . 0.403 ' HB2' HG13 ' A' ' 151' ' ' ILE . . . -119.26 63.45 0.79 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.375 -0.375 . . . . 0.0 111.223 179.915 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . 0.443 ' CG2' ' H ' ' A' ' 149' ' ' GLY . 1.6 p -60.11 -157.28 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.983 -179.869 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . 0.443 ' H ' ' CG2' ' A' ' 148' ' ' VAL . . . 58.0 -109.94 2.15 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.867 -0.683 . . . . 0.0 112.438 -179.961 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 3.9 mm-40 -131.18 100.13 5.1 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.739 0.304 . . . . 0.0 110.526 179.791 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . 0.615 HG12 HD22 ' A' ' 144' ' ' LEU . 0.3 OUTLIER -63.04 111.73 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.982 0.42 . . . . 0.0 111.213 -179.751 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . 0.406 ' O ' ' N ' ' A' ' 128' ' ' ASN . 1.2 t-80 -95.56 121.32 37.13 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 178.943 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 153' ' ' MET . . . . . 0.485 ' HB2' ' HB ' ' A' ' 84' ' ' VAL . 29.3 mtp -137.74 166.43 23.98 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.386 0.612 . . . . 0.0 112.368 -178.525 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -143.34 132.19 22.74 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 114.852 -1.067 . . . . 0.0 108.811 178.762 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 155' ' ' THR . . . . . 0.423 ' CG2' ' CG1' ' A' ' 124' ' ' ILE . 1.3 p -138.57 161.25 37.56 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.333 0.587 . . . . 0.0 112.176 -178.53 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 156' ' ' MET . . . . . 0.42 ' O ' ' N ' ' A' ' 123' ' ' ARG . 5.1 ptp -135.58 160.03 69.28 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 115.133 -0.94 . . . . 0.0 109.953 179.174 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 21.6 Cg_endo -61.67 118.36 5.23 Favored 'Trans proline' 0 C--N 1.343 0.274 0 C-N-CA 122.366 2.044 . . . . 0.0 112.544 -179.675 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 158' ' ' ALA . . . . . 0.516 ' CB ' HG12 ' A' ' 103' ' ' ILE . . . . . . . . 0 C--O 1.25 1.092 0 CA-C-O 118.211 -0.9 . . . . 0.0 111.037 179.749 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_endo . . . . . 0 N--CA 1.488 1.183 0 CA-C-O 120.701 0.209 . . . . 0.0 111.717 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -71.2 99.52 0.91 Allowed 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.498 2.132 . . . . 0.0 112.364 179.916 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 10.3 p -80.83 130.35 36.03 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.864 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.8 m -121.35 142.94 49.49 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.013 -179.842 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 5.4 m -101.37 111.15 23.3 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.135 179.2 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.548 HG12 ' H ' ' A' ' 118' ' ' VAL . 41.4 t -82.85 105.95 13.18 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.562 0 CA-C-N 115.949 -0.569 . . . . 0.0 112.184 -179.215 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 7.1 tt -99.96 79.81 2.24 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 178.069 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.433 ' CD1' HG11 ' A' ' 84' ' ' VAL . 3.3 mt -82.66 104.95 11.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.767 -178.413 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.424 ' N ' HG21 ' A' ' 112' ' ' ILE . 0.0 OUTLIER -74.93 108.31 7.57 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.428 179.21 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 10.4 mtp180 -92.32 111.45 50.52 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.184 -179.646 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_exo -62.26 -63.9 0.09 OUTLIER 'Trans proline' 0 C--N 1.346 0.445 0 C-N-CA 122.572 2.181 . . . . 0.0 112.407 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 3.1 t0 -121.44 -173.36 2.61 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.919 0.39 . . . . 0.0 111.165 -179.71 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -94.82 -21.2 18.86 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.281 -179.905 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -96.7 23.28 7.14 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.81 0.338 . . . . 0.0 111.14 -179.877 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 2.0 m-85 -102.23 178.41 4.6 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.824 179.827 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -135.71 143.61 45.46 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.017 -179.918 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . 0.417 HD21 ' CE1' ' A' ' 97' ' ' PHE . 8.3 mp -72.57 -31.06 64.94 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.798 179.872 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 82.96 55.16 3.01 Favored Glycine 0 C--N 1.33 0.242 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.968 179.626 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . 0.417 ' CE1' HD21 ' A' ' 95' ' ' LEU . 0.1 OUTLIER -173.17 156.82 3.29 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.836 0.351 . . . . 0.0 111.144 179.82 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.2 m -99.28 155.92 17.25 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.677 179.804 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.43 ' CG1' ' CG2' ' A' ' 141' ' ' VAL . 8.5 p -133.0 132.15 58.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.927 0.394 . . . . 0.0 111.336 -179.86 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -128.97 89.27 2.85 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.27 179.509 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 3.3 m-80 58.25 17.25 4.52 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.126 -179.637 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 129.81 -40.09 1.73 Allowed Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.261 179.905 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.528 HG12 ' CB ' ' A' ' 158' ' ' ALA . 30.1 mt -77.24 130.19 36.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 121.098 0.475 . . . . 0.0 111.522 -179.677 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 3.8 mp -83.96 139.67 17.28 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.793 179.894 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -84.62 -75.62 0.34 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.328 -179.479 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -132.37 121.75 23.96 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.917 0.389 . . . . 0.0 111.114 -179.74 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 7.8 tp -105.57 116.2 31.53 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.463 179.761 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 36.2 mtm -69.27 132.94 47.26 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.056 -179.807 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -67.18 76.14 0.14 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.549 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 174.63 -34.22 0.1 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.285 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.45 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -56.54 176.26 1.05 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.438 179.774 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . 0.424 HG21 ' N ' ' A' ' 87' ' ' ARG . 1.8 mt -78.61 -22.04 13.09 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-O 120.782 0.325 . . . . 0.0 111.615 -179.846 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' ALA . . . . . . . . . . . . . . . -57.82 -30.31 65.63 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.008 0.432 . . . . 0.0 110.702 179.828 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 114' ' ' GLU . . . . . 0.45 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 19.6 pt-20 -60.63 -47.19 87.32 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.89 -0.595 . . . . 0.0 111.197 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 3.8 mtm180 -66.59 -41.33 88.67 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.241 -179.294 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -56.19 -72.63 0.54 Allowed Glycine 0 N--CA 1.448 -0.539 0 C-N-CA 120.398 -0.906 . . . . 0.0 112.669 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 161.09 -10.67 0.13 Allowed Glycine 0 CA--C 1.522 0.47 0 C-N-CA 121.219 -0.515 . . . . 0.0 112.851 -179.879 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.548 ' H ' HG12 ' A' ' 84' ' ' VAL . 2.2 t -29.75 -71.46 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 C-N-CA 123.11 0.564 . . . . 0.0 112.306 -179.677 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.429 ' N ' ' CG1' ' A' ' 118' ' ' VAL . 0.0 OUTLIER 64.32 136.12 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.467 -179.486 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 20.2 t -69.73 116.98 11.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.447 -0.342 . . . . 0.0 111.427 -179.69 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 112.55 33.25 2.12 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.799 179.644 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 1.5 m-70 -135.71 132.96 37.55 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.831 0.348 . . . . 0.0 110.991 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.461 ' HB2' ' CB ' ' A' ' 158' ' ' ALA . 72.3 ttt180 -88.76 95.29 10.22 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.65 -179.686 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . 0.488 HG21 ' CG2' ' A' ' 132' ' ' VAL . 11.7 mt -49.68 146.63 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 178.657 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 125' ' ' ILE . . . . . 0.42 ' CG1' ' H ' ' A' ' 126' ' ' GLU . 0.6 OUTLIER -137.11 -84.8 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 N-CA-C 112.772 0.656 . . . . 0.0 112.772 -178.924 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . 0.42 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 19.5 mt-10 -80.8 90.86 5.87 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 112.454 0.538 . . . . 0.0 112.454 -178.383 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.48 ' HA ' ' CB ' ' A' ' 153' ' ' MET . 1.8 mt -92.15 100.79 11.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.288 179.284 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . 0.404 ' N ' ' O ' ' A' ' 152' ' ' HIS . 52.7 m-80 57.82 17.87 4.52 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.622 179.815 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 121.69 -20.69 8.18 Favored Glycine 0 C--N 1.333 0.39 0 C-N-CA 120.348 -0.929 . . . . 0.0 113.381 179.406 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -98.22 120.96 39.53 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 117.256 0.528 . . . . 0.0 111.038 -179.727 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 67.4 p -79.25 94.62 5.47 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.362 -179.838 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . 0.488 ' CG2' HG21 ' A' ' 124' ' ' ILE . 31.0 m -74.62 -4.87 6.17 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.304 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.594 179.679 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . 0.412 ' HB ' ' CG2' ' A' ' 125' ' ' ILE . 6.6 p -46.5 -37.69 3.32 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.141 0 CA-C-O 120.895 0.379 . . . . 0.0 111.526 -179.683 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -116.99 29.66 7.79 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.719 179.602 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 135' ' ' THR . . . . . 0.421 ' CG2' ' HD2' ' A' ' 136' ' ' PRO . 87.9 m -117.24 141.94 29.37 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-N 115.881 -0.6 . . . . 0.0 111.033 -179.759 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 136' ' ' PRO . . . . . 0.421 ' HD2' ' CG2' ' A' ' 135' ' ' THR . 7.6 Cg_endo -49.65 164.04 0.41 Allowed 'Trans proline' 0 C--N 1.347 0.477 0 C-N-CA 122.77 2.313 . . . . 0.0 112.23 179.685 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 11.3 p80 -73.38 -45.95 51.84 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.539 -179.655 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -53.78 -36.94 62.95 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.373 -179.55 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 139' ' ' LYS . . . . . 0.44 ' O ' ' CD1' ' A' ' 143' ' ' ILE . 0.1 OUTLIER -63.26 -47.34 82.78 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.895 -179.857 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 8.6 mt -58.74 -41.79 83.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.965 0.412 . . . . 0.0 110.646 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . 0.43 ' CG2' ' CG1' ' A' ' 99' ' ' VAL . 90.1 t -63.51 -32.68 57.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.28 179.139 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 56.7 t60 -62.33 -54.57 38.54 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.828 179.943 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . 0.44 ' CD1' ' O ' ' A' ' 139' ' ' LYS . 4.3 mp -53.23 -56.83 6.36 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.395 0 CA-C-O 121.112 0.482 . . . . 0.0 110.138 179.373 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.566 ' CD2' HG12 ' A' ' 151' ' ' ILE . 5.1 mt -60.63 -30.28 69.77 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.47 -0.786 . . . . 0.0 110.313 179.409 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 2.3 m -67.65 -27.08 66.56 Favored 'General case' 0 N--CA 1.453 -0.323 0 CA-C-N 116.164 -0.471 . . . . 0.0 109.981 178.471 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 4.6 m-80 -130.28 34.73 4.16 Favored 'General case' 0 CA--C 1.527 0.087 0 CA-C-N 116.013 -0.54 . . . . 0.0 111.215 179.796 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 147' ' ' ALA . . . . . 0.411 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . -118.65 55.26 0.92 Allowed 'General case' 0 C--O 1.232 0.149 0 CA-C-O 120.864 0.364 . . . . 0.0 111.451 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 2.8 m -55.84 174.89 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.181 179.881 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 88.64 -101.69 2.77 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.813 -0.708 . . . . 0.0 112.606 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 29.8 mt-10 -148.95 94.49 2.26 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.786 0.327 . . . . 0.0 110.989 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . 0.566 HG12 ' CD2' ' A' ' 144' ' ' LEU . 1.2 mt -61.75 112.2 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.995 179.939 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . 0.404 ' O ' ' N ' ' A' ' 128' ' ' ASN . 0.3 OUTLIER -102.68 115.53 30.77 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.076 179.144 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 153' ' ' MET . . . . . 0.48 ' CB ' ' HA ' ' A' ' 127' ' ' ILE . 1.8 ptm -147.59 166.68 26.62 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.129 0.49 . . . . 0.0 111.875 -179.111 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 35.4 mttp -112.58 155.99 23.43 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.889 179.146 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 155' ' ' THR . . . . . 0.406 HG23 ' CG1' ' A' ' 124' ' ' ILE . 13.8 p -141.2 144.13 34.58 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.226 0.536 . . . . 0.0 111.915 -179.451 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 156' ' ' MET . . . . . 0.418 ' CB ' ' CD ' ' A' ' 157' ' ' PRO . 1.5 mtm -110.86 179.94 0.74 Allowed Pre-proline 0 C--N 1.33 -0.241 0 CA-C-N 115.257 -0.883 . . . . 0.0 110.072 179.593 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . 0.418 ' CD ' ' CB ' ' A' ' 156' ' ' MET . 90.2 Cg_endo -92.68 106.98 0.2 Allowed 'Trans proline' 0 N--CA 1.456 -0.725 0 C-N-CA 122.757 2.305 . . . . 0.0 112.511 -179.919 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 158' ' ' ALA . . . . . 0.528 ' CB ' HG12 ' A' ' 103' ' ' ILE . . . . . . . . 0 C--O 1.249 1.039 0 CA-C-O 118.186 -0.912 . . . . 0.0 111.036 179.801 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo . . . . . 0 N--CA 1.487 1.139 0 CA-C-O 120.725 0.219 . . . . 0.0 111.756 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -72.61 97.6 0.9 Allowed 'Trans proline' 0 C--N 1.344 0.313 0 C-N-CA 122.59 2.193 . . . . 0.0 112.376 -179.925 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 44.7 t -93.54 143.91 10.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.922 179.836 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.7 m -131.31 140.04 49.68 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.02 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 6.8 m -100.29 111.3 23.57 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.149 179.284 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.493 ' HB ' ' HG2' ' A' ' 153' ' ' MET . 49.5 t -83.68 106.57 14.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.929 -179.339 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 7.0 tt -105.88 81.57 1.67 Allowed 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 178.317 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.458 HG13 HG12 ' A' ' 84' ' ' VAL . 12.7 mt -81.52 152.26 4.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.549 -178.498 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.404 ' CG ' ' CG2' ' A' ' 112' ' ' ILE . 0.0 OUTLIER -111.68 141.39 45.35 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.797 -179.426 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 11.5 mtp85 -140.27 84.32 14.65 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.85 179.812 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 63.7 Cg_exo -51.66 -35.44 57.34 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.656 2.238 . . . . 0.0 112.516 -179.817 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -136.06 -169.64 2.47 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.942 0.401 . . . . 0.0 111.134 -179.777 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 3.9 mt -93.63 -43.17 8.8 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.783 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 2.3 mpp_? -63.27 -14.79 53.39 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.84 -0.618 . . . . 0.0 111.703 -179.595 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 7.5 m-85 -56.69 174.72 0.14 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.866 0.365 . . . . 0.0 110.915 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 9.0 mp0 -138.6 166.13 25.14 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.027 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 1.1 mt -97.66 -49.07 4.99 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.877 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 91.62 50.92 2.61 Favored Glycine 0 C--N 1.331 0.298 0 C-N-CA 120.728 -0.748 . . . . 0.0 113.108 179.5 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -168.95 162.97 11.39 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.795 0.331 . . . . 0.0 111.039 179.64 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -110.55 133.95 52.83 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.726 179.907 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.413 ' CG1' ' CG2' ' A' ' 141' ' ' VAL . 11.4 p -110.46 132.13 59.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.378 -179.813 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 3.6 mt-30 -129.08 89.51 2.88 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.222 179.485 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 2.4 m120 59.67 18.04 6.8 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.037 -0.528 . . . . 0.0 111.0 -179.406 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 124.9 -37.29 2.61 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.441 179.887 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.563 HG12 ' CB ' ' A' ' 158' ' ' ALA . 28.3 mt -77.28 140.29 17.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.97 0.414 . . . . 0.0 111.598 -179.603 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 4.5 mp -100.23 137.13 28.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.818 179.732 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -114.93 -64.31 1.33 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.876 -179.898 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 5.1 m -86.16 145.15 27.13 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.862 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 3.9 tt -162.26 116.54 1.83 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.705 179.81 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 3.6 tmm? -94.44 128.86 41.27 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.991 -179.774 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -65.44 79.5 0.06 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.64 179.744 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 176.89 -35.22 0.09 OUTLIER Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 120.927 -0.654 . . . . 0.0 111.956 -179.843 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.412 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -59.18 167.86 7.16 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.017 179.613 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . 0.404 ' CG2' ' CG ' ' A' ' 87' ' ' ARG . 1.0 OUTLIER -78.36 -16.54 13.79 Favored 'Isoleucine or valine' 0 C--O 1.235 0.313 0 CA-C-O 120.872 0.367 . . . . 0.0 111.6 -179.837 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' ALA . . . . . . . . . . . . . . . -57.97 -30.44 66.02 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.969 0.414 . . . . 0.0 110.556 179.797 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 114' ' ' GLU . . . . . 0.412 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 16.4 pt-20 -60.42 -47.02 87.91 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.859 179.665 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -63.16 -47.32 83.16 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.049 -179.52 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -49.64 -73.8 0.33 Allowed Glycine 0 CA--C 1.52 0.379 0 C-N-CA 120.414 -0.898 . . . . 0.0 112.6 -179.862 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 169.8 -19.79 0.07 OUTLIER Glycine 0 CA--C 1.519 0.296 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.719 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.441 ' N ' ' CG2' ' A' ' 84' ' ' VAL . 1.2 t -40.46 108.21 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.529 0.149 0 CA-C-O 120.999 0.428 . . . . 0.0 111.494 -179.791 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 6.1 mtp180 -102.75 128.34 49.52 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.612 179.751 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 22.2 t -54.06 92.61 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 121.017 0.437 . . . . 0.0 111.1 -179.815 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 128.58 -0.08 6.28 Favored Glycine 0 CA--C 1.519 0.297 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.999 -179.944 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . 0.407 ' HB3' ' HB ' ' A' ' 155' ' ' THR . 1.4 m170 -93.82 133.1 37.57 Favored 'General case' 0 C--O 1.232 0.156 0 CA-C-O 120.876 0.37 . . . . 0.0 110.865 179.953 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.436 ' HB2' ' CB ' ' A' ' 158' ' ' ALA . 0.2 OUTLIER -83.27 91.62 7.32 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.009 -0.541 . . . . 0.0 111.791 -179.509 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . 0.431 HG22 ' CG2' ' A' ' 132' ' ' VAL . 14.9 mt -51.03 142.93 3.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 N-CA-C 109.638 -0.504 . . . . 0.0 109.638 178.572 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 125' ' ' ILE . . . . . 0.432 ' CG1' ' H ' ' A' ' 126' ' ' GLU . 0.6 OUTLIER -136.65 -83.98 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 N-CA-C 112.995 0.739 . . . . 0.0 112.995 -178.581 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . 0.432 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 2.2 mt-10 -78.5 85.82 4.56 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 112.733 0.642 . . . . 0.0 112.733 -178.28 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.557 ' HA ' ' CB ' ' A' ' 153' ' ' MET . 1.4 mt -90.61 104.32 15.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-O 121.071 0.462 . . . . 0.0 110.897 178.872 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 59.1 m-20 53.19 24.35 3.62 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.202 -179.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 111.47 -16.42 26.7 Favored Glycine 0 CA--C 1.519 0.33 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.944 179.879 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 10.4 tt0 -94.09 113.12 25.02 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.865 0.365 . . . . 0.0 111.04 -179.855 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -77.52 93.96 4.24 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.087 -179.974 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . 0.431 ' CG2' HG22 ' A' ' 124' ' ' ILE . 28.2 m -75.88 -3.31 4.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.183 -0.462 . . . . 0.0 112.038 -179.977 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 7.2 p -45.16 -38.26 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 CA-C-O 120.856 0.36 . . . . 0.0 111.616 -179.596 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -121.14 28.16 8.0 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.765 179.508 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 135' ' ' THR . . . . . 0.412 ' HB ' ' HA ' ' A' ' 132' ' ' VAL . 43.3 m -109.48 140.52 22.18 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.999 -179.88 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 136' ' ' PRO . . . . . 0.407 ' HD2' ' CG2' ' A' ' 135' ' ' THR . 11.1 Cg_endo -54.26 151.02 30.54 Favored 'Trans proline' 0 C--N 1.346 0.403 0 C-N-CA 122.654 2.236 . . . . 0.0 112.1 179.694 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 3.8 p-80 -60.41 -33.69 72.86 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.51 -179.727 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -62.53 -39.3 93.14 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.815 0.34 . . . . 0.0 111.227 -179.661 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 139' ' ' LYS . . . . . 0.443 ' O ' ' CD1' ' A' ' 143' ' ' ILE . 1.7 tptp -62.84 -46.17 89.18 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.025 -179.72 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 7.5 mt -58.97 -46.13 91.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.697 -179.819 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . 0.413 ' CG2' ' CG1' ' A' ' 99' ' ' VAL . 89.1 t -60.87 -32.46 52.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.22 179.235 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -61.56 -54.95 36.26 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.966 179.888 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . 0.443 ' CD1' ' O ' ' A' ' 139' ' ' LYS . 3.9 mp -53.18 -57.42 4.8 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.476 0 CA-C-O 121.185 0.517 . . . . 0.0 110.229 179.463 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.736 HD21 HG12 ' A' ' 151' ' ' ILE . 2.6 mt -60.36 -30.06 69.31 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.219 -0.9 . . . . 0.0 110.445 179.571 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 2.2 m -67.23 -27.99 67.69 Favored 'General case' 0 N--CA 1.454 -0.251 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.024 178.825 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 10.8 m120 -134.35 37.73 3.14 Favored 'General case' 0 CA--C 1.527 0.095 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.192 179.83 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 147' ' ' ALA . . . . . 0.475 ' HB2' HG13 ' A' ' 151' ' ' ILE . . . -111.62 40.17 2.18 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.484 -0.326 . . . . 0.0 111.43 -179.848 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 4.3 m -48.27 143.52 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.818 0.342 . . . . 0.0 111.412 179.884 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 118.65 -109.55 1.77 Allowed Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.443 -179.829 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 70.4 mt-10 -137.86 90.17 2.47 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.758 0.313 . . . . 0.0 110.77 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . 0.736 HG12 HD21 ' A' ' 144' ' ' LEU . 1.2 mp -65.54 111.82 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-O 121.012 0.434 . . . . 0.0 110.804 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 4.0 t60 -109.64 115.8 30.56 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.358 179.559 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 153' ' ' MET . . . . . 0.557 ' CB ' ' HA ' ' A' ' 127' ' ' ILE . 0.0 OUTLIER -144.37 166.23 25.69 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.194 0.521 . . . . 0.0 112.033 -179.258 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -109.74 151.81 26.45 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.526 -0.761 . . . . 0.0 109.346 178.665 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 155' ' ' THR . . . . . 0.407 ' HB ' ' HB3' ' A' ' 122' ' ' HIS . 16.1 p -139.84 138.61 35.89 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.054 0.454 . . . . 0.0 111.697 -179.453 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 156' ' ' MET . . . . . 0.416 ' HB3' ' HD2' ' A' ' 157' ' ' PRO . 0.0 OUTLIER -101.72 178.68 1.16 Allowed Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 115.474 -0.784 . . . . 0.0 110.31 179.732 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . 0.416 ' HD2' ' HB3' ' A' ' 156' ' ' MET . 94.7 Cg_endo -91.99 96.19 0.19 Allowed 'Trans proline' 0 N--CA 1.456 -0.722 0 C-N-CA 122.765 2.31 . . . . 0.0 112.505 -179.773 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 158' ' ' ALA . . . . . 0.563 ' CB ' HG12 ' A' ' 103' ' ' ILE . . . . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.201 -0.904 . . . . 0.0 111.051 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_endo . . . . . 0 N--CA 1.488 1.192 0 CA-C-O 120.634 0.181 . . . . 0.0 111.798 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_exo -51.73 90.03 0.03 OUTLIER 'Trans proline' 0 C--N 1.345 0.366 0 C-N-CA 122.608 2.205 . . . . 0.0 112.382 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 40.6 t -88.54 140.36 15.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.932 179.971 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 1.8 m -124.62 142.65 51.21 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.931 179.842 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 4.1 m -101.73 111.44 23.69 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.22 179.267 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.447 ' HB ' ' HB2' ' A' ' 153' ' ' MET . 60.9 t -87.71 106.08 15.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.439 -179.461 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . 0.408 ' HG ' ' CD2' ' A' ' 152' ' ' HIS . 2.5 tt -104.33 85.55 2.38 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.094 -0.503 . . . . 0.0 109.827 178.778 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.47 HG12 ' HA ' ' A' ' 113' ' ' ALA . 3.5 mt -81.35 138.59 19.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 121.008 0.433 . . . . 0.0 111.306 -179.064 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.442 ' CB ' HG23 ' A' ' 112' ' ' ILE . 0.1 OUTLIER -98.77 108.83 21.61 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.507 -179.723 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 8.5 mmt180 -103.39 103.37 35.04 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.016 -179.84 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . 0.429 ' HG2' ' CG ' ' A' ' 93' ' ' TYR . 56.3 Cg_endo -70.49 -28.33 21.88 Favored 'Trans proline' 0 C--N 1.347 0.472 0 C-N-CA 122.385 2.056 . . . . 0.0 112.332 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . 0.42 ' HB2' ' CD1' ' A' ' 93' ' ' TYR . 2.9 m-20 -164.4 -175.49 3.93 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.876 0.37 . . . . 0.0 111.131 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 1.5 mp -80.32 -31.56 38.06 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.984 -179.884 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -73.84 -6.26 46.03 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.693 -179.708 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . 0.429 ' CG ' ' HG2' ' A' ' 89' ' ' PRO . 28.5 m-85 -104.7 110.37 22.66 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.803 0.335 . . . . 0.0 110.866 179.932 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 2.0 mp0 -80.29 179.34 7.72 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.981 -179.927 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -91.42 -66.67 0.91 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.749 179.902 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 118.83 63.51 0.29 Allowed Glycine 0 C--N 1.33 0.224 0 C-N-CA 120.566 -0.825 . . . . 0.0 112.959 179.57 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 19.5 p90 -176.82 161.64 2.04 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.807 0.337 . . . . 0.0 110.967 179.664 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 14.5 m -102.64 145.49 29.58 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.768 179.792 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.411 ' CG1' ' CG2' ' A' ' 141' ' ' VAL . 10.1 p -126.08 130.56 72.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.332 -179.809 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 4.3 mt-30 -129.83 89.5 2.83 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.253 179.625 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 85.7 m-20 60.22 18.22 7.68 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.858 -179.343 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 123.23 -36.95 2.91 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 120.934 -0.651 . . . . 0.0 112.409 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 26.6 mt -77.24 130.77 35.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 121.018 0.437 . . . . 0.0 111.506 -179.619 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 3.7 mp -82.32 139.52 17.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.87 179.787 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -100.52 -78.79 0.51 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.104 -179.793 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 18.4 m -108.43 135.57 49.51 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.91 -179.826 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -110.75 108.73 18.69 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.823 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 41.1 mtm -73.01 100.39 2.97 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.965 -179.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 25.0 mmt85 -56.97 122.09 11.48 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.78 179.888 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 129.44 -31.29 3.45 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.85 -0.691 . . . . 0.0 112.024 -179.683 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.437 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -66.68 175.81 21.46 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.716 -0.755 . . . . 0.0 112.273 179.688 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . 0.442 HG23 ' CB ' ' A' ' 87' ' ' ARG . 0.8 OUTLIER -78.63 -18.18 13.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-O 120.88 0.372 . . . . 0.0 111.62 -179.842 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 113' ' ' ALA . . . . . 0.47 ' HA ' HG12 ' A' ' 86' ' ' ILE . . . -58.31 -30.25 66.51 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.95 0.405 . . . . 0.0 110.611 179.817 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 114' ' ' GLU . . . . . 0.437 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 15.2 pt-20 -59.87 -45.65 91.79 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.731 179.503 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -64.69 -46.96 80.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.2 -179.433 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.403 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -51.05 -74.03 0.32 Allowed Glycine 0 CA--C 1.518 0.262 0 C-N-CA 120.355 -0.926 . . . . 0.0 112.59 -179.908 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 175.5 -20.91 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.938 -0.649 . . . . 0.0 112.808 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.43 ' HA ' HG23 ' A' ' 84' ' ' VAL . 0.3 OUTLIER -34.7 128.07 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.23 0 CA-C-O 120.912 0.387 . . . . 0.0 112.026 -179.801 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -136.66 144.85 44.21 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.847 -179.822 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 22.7 t -70.43 102.47 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.208 -179.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 119.7 49.11 0.32 Allowed Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.61 -0.805 . . . . 0.0 112.681 179.869 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 5.4 m170 -154.29 132.65 11.95 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.834 0.35 . . . . 0.0 110.857 179.849 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.485 ' HB2' ' CB ' ' A' ' 158' ' ' ALA . 2.8 ttt180 -87.85 95.71 10.2 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.664 -179.532 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . 0.493 HG22 ' CG2' ' A' ' 132' ' ' VAL . 9.1 mt -49.71 159.14 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 178.771 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 125' ' ' ILE . . . . . 0.449 ' N ' ' CG2' ' A' ' 124' ' ' ILE . 0.6 OUTLIER -148.79 -82.23 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 N-CA-C 112.567 0.58 . . . . 0.0 112.567 -179.579 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . 0.444 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 13.7 mt-10 -76.88 80.84 3.45 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 112.44 0.533 . . . . 0.0 112.44 -178.69 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.427 ' CG2' ' HG2' ' A' ' 153' ' ' MET . 2.8 mt -82.99 90.8 2.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 121.05 0.452 . . . . 0.0 111.153 179.117 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . 0.452 ' N ' ' O ' ' A' ' 152' ' ' HIS . 1.2 m-20 56.99 29.84 17.11 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.9 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 109.34 -15.11 32.93 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.774 -0.726 . . . . 0.0 112.686 -179.892 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 20.7 tt0 -95.04 106.03 17.99 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.895 0.379 . . . . 0.0 110.846 -179.921 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 11.7 p -73.5 90.3 1.72 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.851 179.971 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . 0.493 ' CG2' HG22 ' A' ' 124' ' ' ILE . 27.2 m -75.2 -2.86 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.29 0 CA-C-N 116.31 -0.405 . . . . 0.0 112.013 -179.828 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 10.4 p -44.77 -42.1 2.29 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.148 0 CA-C-O 120.862 0.363 . . . . 0.0 111.558 -179.731 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -116.2 29.54 7.9 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.891 179.578 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 38.1 m -114.73 140.06 24.9 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.175 -179.839 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 136' ' ' PRO . . . . . . . . . . . . . 11.5 Cg_endo -55.32 164.06 4.23 Favored 'Trans proline' 0 C--N 1.348 0.512 0 C-N-CA 122.652 2.235 . . . . 0.0 112.121 179.766 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 18.8 p-80 -66.43 -45.79 78.67 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.749 -179.557 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -53.71 -39.78 65.49 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.562 -179.341 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 139' ' ' LYS . . . . . 0.453 ' O ' ' CD1' ' A' ' 143' ' ' ILE . 8.7 tttt -62.7 -46.71 86.89 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.467 -0.333 . . . . 0.0 111.131 -179.7 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . 0.41 HG21 HD13 ' A' ' 140' ' ' ILE . 9.0 mt -58.32 -45.92 89.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.735 -179.836 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . 0.411 ' CG2' ' CG1' ' A' ' 99' ' ' VAL . 82.6 t -60.87 -32.64 52.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.334 179.244 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -62.02 -55.19 31.76 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.012 179.908 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . 0.453 ' CD1' ' O ' ' A' ' 139' ' ' LYS . 4.2 mp -52.83 -56.9 5.54 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.489 0 CA-C-O 121.321 0.581 . . . . 0.0 110.248 179.459 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.568 HD21 HG12 ' A' ' 151' ' ' ILE . 3.0 mt -61.2 -30.11 70.22 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.305 -0.861 . . . . 0.0 110.398 179.579 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 3.0 m -68.78 -26.74 65.36 Favored 'General case' 0 N--CA 1.454 -0.226 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.022 178.691 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 3.6 m-80 -129.92 33.92 4.34 Favored 'General case' 0 CA--C 1.527 0.093 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.182 179.894 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 147' ' ' ALA . . . . . 0.409 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . -112.28 45.73 1.25 Allowed 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.887 0.375 . . . . 0.0 111.242 179.992 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 3.1 m -50.48 152.33 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.592 -179.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 108.74 -104.42 1.97 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.539 -179.944 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 53.2 mt-10 -141.63 98.39 3.34 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.81 0.338 . . . . 0.0 110.558 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . 0.568 HG12 HD21 ' A' ' 144' ' ' LEU . 1.2 mt -73.41 111.79 8.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.353 -179.65 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . 0.452 ' O ' ' N ' ' A' ' 128' ' ' ASN . 0.0 OUTLIER -98.17 115.47 28.39 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 178.436 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 153' ' ' MET . . . . . 0.447 ' HB2' ' HB ' ' A' ' 84' ' ' VAL . 24.4 mtp -128.63 168.17 16.14 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.614 0.721 . . . . 0.0 112.677 -178.311 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 17.1 mttm -134.6 140.15 45.87 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 114.723 -1.126 . . . . 0.0 108.759 178.502 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 155' ' ' THR . . . . . 0.428 ' HA ' ' HA ' ' A' ' 124' ' ' ILE . 3.1 p -136.66 140.31 42.66 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.137 0.494 . . . . 0.0 111.909 -178.79 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 156' ' ' MET . . . . . . . . . . . . . 3.8 ptp -132.37 145.75 58.62 Favored Pre-proline 0 C--N 1.328 -0.362 0 CA-C-N 115.318 -0.855 . . . . 0.0 110.44 179.291 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_exo -44.43 122.7 4.02 Favored 'Trans proline' 0 C--N 1.345 0.35 0 C-N-CA 122.597 2.198 . . . . 0.0 112.879 -179.704 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 158' ' ' ALA . . . . . 0.485 ' CB ' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.25 1.081 0 CA-C-O 118.259 -0.877 . . . . 0.0 111.051 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.417 HG13 ' O ' ' A' ' 81' ' ' VAL . 14.4 p . . . . . 0 N--CA 1.456 -0.154 0 CA-C-O 120.769 0.318 . . . . 0.0 111.179 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.3 m -103.66 141.49 35.97 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.8 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 5.1 m -105.63 111.3 23.93 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.149 179.191 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.738 HG11 HG23 ' A' ' 118' ' ' VAL . 48.5 t -82.66 106.14 13.2 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.65 -179.418 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.404 ' HA ' ' O ' ' A' ' 151' ' ' ILE . 0.8 OUTLIER -105.55 84.04 2.03 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 178.456 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.7 HG13 HG12 ' A' ' 84' ' ' VAL . 4.0 mt -81.53 151.28 4.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.582 -178.671 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.462 ' CB ' HG21 ' A' ' 112' ' ' ILE . 0.0 OUTLIER -110.07 114.85 28.7 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.712 -0.677 . . . . 0.0 110.451 -179.789 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.439 ' HD2' HD11 ' A' ' 95' ' ' LEU . 0.0 OUTLIER -120.56 100.91 46.63 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.058 -179.728 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 89' ' ' PRO . . . . . 0.437 ' HG2' ' CD2' ' A' ' 93' ' ' TYR . 71.5 Cg_endo -74.54 -26.73 11.61 Favored 'Trans proline' 0 C--N 1.346 0.414 0 C-N-CA 122.585 2.19 . . . . 0.0 112.448 179.874 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -141.39 -166.01 2.1 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.087 -179.866 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 0.507 ' CD2' HG13 ' A' ' 148' ' ' VAL . 2.6 mt -102.59 -19.74 14.72 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.43 -179.823 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -95.08 21.81 7.35 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.48 -0.327 . . . . 0.0 111.291 -179.775 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 93' ' ' TYR . . . . . 0.437 ' CD2' ' HG2' ' A' ' 89' ' ' PRO . 7.4 m-85 -112.31 98.67 7.45 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.768 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 1.2 pm0 -57.97 146.76 31.35 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.136 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 0.866 ' CD2' HD13 ' A' ' 144' ' ' LEU . 6.7 mp -71.78 -52.5 17.31 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.758 -179.919 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 124.85 36.82 0.57 Allowed Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.579 -0.82 . . . . 0.0 113.023 179.576 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 97' ' ' PHE . . . . . 0.71 ' CZ ' HG21 ' A' ' 118' ' ' VAL . 31.8 p90 -177.36 169.24 2.24 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.839 0.352 . . . . 0.0 111.197 179.787 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -120.66 148.2 44.24 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.745 179.735 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.829 HG21 HG21 ' A' ' 140' ' ' ILE . 8.6 p -115.3 142.82 26.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.427 -179.878 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 100' ' ' GLN . . . . . 0.407 ' O ' ' N ' ' A' ' 102' ' ' GLY . 22.8 tt0 -132.14 88.42 2.55 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.905 -0.588 . . . . 0.0 110.233 179.049 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 101' ' ' ASN . . . . . 0.699 ' O ' HD11 ' A' ' 140' ' ' ILE . 2.2 t-20 65.36 -68.51 0.11 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.151 -179.838 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 102' ' ' GLY . . . . . 0.444 ' O ' ' HA ' ' A' ' 123' ' ' ARG . . . -142.9 -2.24 1.05 Allowed Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.387 -0.911 . . . . 0.0 113.4 -179.758 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.609 HD12 ' CB ' ' A' ' 158' ' ' ALA . 42.2 mm -122.86 151.36 26.99 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.128 0 CA-C-N 117.13 0.465 . . . . 0.0 111.529 -179.716 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.646 ' N ' HD12 ' A' ' 104' ' ' ILE . 2.8 mp -86.46 158.33 3.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.499 179.605 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 105' ' ' CYS . . . . . 0.482 ' N ' HG22 ' A' ' 104' ' ' ILE . 1.6 m -109.59 -71.68 0.75 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.475 -179.595 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 8.3 m -125.23 173.56 8.7 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.93 0.395 . . . . 0.0 111.17 -179.543 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.813 HD11 HG12 ' A' ' 118' ' ' VAL . 0.3 OUTLIER -148.48 140.63 24.05 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.779 179.901 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 2.0 mtm -106.22 114.21 28.2 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.868 -179.883 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -63.58 82.74 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.708 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 167.02 -31.36 0.19 Allowed Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.938 -0.648 . . . . 0.0 112.002 -179.858 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -64.34 172.48 17.46 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.132 179.651 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.462 HG21 ' CB ' ' A' ' 87' ' ' ARG . 0.5 OUTLIER -78.65 -16.66 13.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 120.744 0.306 . . . . 0.0 111.474 -179.952 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 113' ' ' ALA . . . . . 0.485 ' HA ' HG12 ' A' ' 86' ' ' ILE . . . -58.0 -30.35 66.0 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.002 0.429 . . . . 0.0 110.671 179.744 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 19.7 pt-20 -60.03 -46.63 88.86 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.876 179.67 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 23.3 mtt180 -65.0 -46.19 82.45 Favored 'General case' 0 N--CA 1.453 -0.301 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.21 -179.572 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -51.1 -73.57 0.37 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.557 -0.83 . . . . 0.0 112.641 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 117' ' ' GLY . . . . . 0.572 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 170.54 -20.11 0.07 OUTLIER Glycine 0 CA--C 1.518 0.271 0 C-N-CA 121.032 -0.604 . . . . 0.0 112.662 -179.773 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.813 HG12 HD11 ' A' ' 107' ' ' LEU . 0.9 OUTLIER -37.59 114.92 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.323 0 CA-C-O 120.937 0.399 . . . . 0.0 111.652 -179.819 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -117.46 100.95 8.0 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.577 179.799 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 120' ' ' VAL . . . . . 0.621 ' O ' HG13 ' A' ' 120' ' ' VAL . 10.1 p -48.11 101.76 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 121.057 0.456 . . . . 0.0 111.106 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 133.38 -10.19 5.01 Favored Glycine 0 N--CA 1.451 -0.36 0 CA-C-N 115.831 -0.622 . . . . 0.0 112.231 -179.318 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 122' ' ' HIS . . . . . 0.421 ' O ' HG23 ' A' ' 103' ' ' ILE . 35.7 m170 -86.1 -161.62 0.66 Allowed 'General case' 0 C--N 1.331 -0.231 0 N-CA-C 110.322 -0.251 . . . . 0.0 110.322 179.802 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 123' ' ' ARG . . . . . 0.749 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 10.1 ttm-85 -139.35 90.4 2.41 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.679 0.276 . . . . 0.0 110.802 -179.866 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 124' ' ' ILE . . . . . 0.581 ' CG1' HG22 ' A' ' 155' ' ' THR . 15.4 mt -55.99 157.13 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.251 179.225 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 125' ' ' ILE . . . . . 0.853 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.7 OUTLIER -151.54 -84.51 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.451 -0.383 0 N-CA-C 112.374 0.509 . . . . 0.0 112.374 -179.538 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 126' ' ' GLU . . . . . 0.42 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 13.5 mt-10 -79.99 88.24 5.36 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 112.498 0.555 . . . . 0.0 112.498 -178.793 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.878 HG23 ' HB3' ' A' ' 153' ' ' MET . 1.3 mt -92.44 103.05 14.22 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.185 0 CA-C-O 121.101 0.477 . . . . 0.0 111.344 179.281 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 128' ' ' ASN . . . . . 0.496 ' ND2' HG22 ' A' ' 127' ' ' ILE . 20.2 m-80 59.84 18.64 7.57 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.857 -0.61 . . . . 0.0 111.369 179.847 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 116.6 -17.18 13.88 Favored Glycine 0 C--N 1.333 0.372 0 C-N-CA 120.517 -0.849 . . . . 0.0 113.179 179.627 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 130' ' ' GLN . . . . . 0.556 HE22 HD13 ' A' ' 143' ' ' ILE . 1.2 pt20 -97.88 119.56 36.71 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 117.029 0.414 . . . . 0.0 110.963 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 2.5 m -79.06 93.15 5.09 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.119 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 132' ' ' VAL . . . . . 0.698 HG21 HD11 ' A' ' 127' ' ' ILE . 27.2 m -72.56 -5.38 6.22 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.298 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.978 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.853 ' HB ' HG22 ' A' ' 125' ' ' ILE . 8.3 p -45.36 -38.46 2.22 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.135 0 CA-C-O 120.818 0.342 . . . . 0.0 111.487 -179.807 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -120.08 28.22 8.2 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.748 179.465 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 135' ' ' THR . . . . . 0.416 ' CG2' ' HD2' ' A' ' 136' ' ' PRO . 36.0 m -110.73 143.15 27.63 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.181 -179.929 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 136' ' ' PRO . . . . . 0.416 ' HD2' ' CG2' ' A' ' 135' ' ' THR . 50.1 Cg_exo -53.41 164.21 2.14 Favored 'Trans proline' 0 C--N 1.347 0.456 0 C-N-CA 122.526 2.151 . . . . 0.0 112.119 179.704 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 137' ' ' HIS . . . . . 0.522 ' HA ' HD12 ' A' ' 140' ' ' ILE . 45.0 p-80 -74.05 -46.95 40.04 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.224 -179.798 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -54.16 -35.14 61.95 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.173 -179.786 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 139' ' ' LYS . . . . . 0.764 ' O ' HD12 ' A' ' 143' ' ' ILE . 0.0 OUTLIER -65.96 -48.87 69.86 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.943 -179.931 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 140' ' ' ILE . . . . . 0.829 HG21 HG21 ' A' ' 99' ' ' VAL . 8.7 mt -59.47 -46.41 92.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 121.033 0.444 . . . . 0.0 110.319 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 141' ' ' VAL . . . . . 0.411 HG23 ' CG1' ' A' ' 99' ' ' VAL . 55.6 t -59.54 -32.53 49.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 115.711 -0.677 . . . . 0.0 109.93 179.074 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -61.47 -54.22 46.27 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.009 -0.542 . . . . 0.0 110.835 179.808 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 143' ' ' ILE . . . . . 0.764 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.3 mp -53.39 -57.86 4.23 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.424 0 CA-C-O 121.015 0.436 . . . . 0.0 110.135 179.487 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.866 HD13 ' CD2' ' A' ' 95' ' ' LEU . 15.1 mt -60.39 -30.14 69.4 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.408 179.402 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 23.4 t -69.38 -28.55 66.28 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.219 -0.446 . . . . 0.0 109.934 178.811 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 4.9 m-80 -128.17 34.48 4.57 Favored 'General case' 0 C--N 1.333 -0.112 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.908 179.666 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 147' ' ' ALA . . . . . 0.844 ' CB ' HD11 ' A' ' 151' ' ' ILE . . . -103.62 79.21 1.65 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.207 -179.929 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.507 HG13 ' CD2' ' A' ' 91' ' ' LEU . 5.7 m -77.32 146.18 8.92 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.338 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.149 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 105.43 -104.68 2.35 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.525 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 53.4 mt-10 -145.58 114.73 7.03 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.79 0.328 . . . . 0.0 110.847 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 151' ' ' ILE . . . . . 0.844 HD11 ' CB ' ' A' ' 147' ' ' ALA . 1.8 mp -81.93 128.13 39.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 121.047 0.451 . . . . 0.0 110.628 179.854 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 152' ' ' HIS . . . . . 0.414 ' CD2' ' HA ' ' A' ' 128' ' ' ASN . 21.6 p-80 -125.47 115.77 20.77 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.361 179.819 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 153' ' ' MET . . . . . 0.878 ' HB3' HG23 ' A' ' 127' ' ' ILE . 0.0 OUTLIER -141.21 174.99 10.01 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.164 0.507 . . . . 0.0 111.619 -179.379 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -121.41 147.83 45.2 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.589 -0.732 . . . . 0.0 109.912 179.22 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 155' ' ' THR . . . . . 0.581 HG22 ' CG1' ' A' ' 124' ' ' ILE . 12.1 p -140.7 140.49 34.92 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.04 0.448 . . . . 0.0 111.175 -179.665 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 156' ' ' MET . . . . . 0.459 ' O ' ' N ' ' A' ' 123' ' ' ARG . 0.0 OUTLIER -108.7 178.86 0.95 Allowed Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 115.791 -0.64 . . . . 0.0 110.56 179.854 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 157' ' ' PRO . . . . . 0.413 ' CD ' ' CB ' ' A' ' 156' ' ' MET . 94.6 Cg_endo -89.85 111.01 0.46 Allowed 'Trans proline' 0 N--CA 1.458 -0.559 0 C-N-CA 122.532 2.154 . . . . 0.0 112.504 -179.776 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 158' ' ' ALA . . . . . 0.749 ' HB2' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.283 -0.865 . . . . 0.0 110.962 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 10.2 p . . . . . 0 C--O 1.231 0.112 0 CA-C-O 120.823 0.344 . . . . 0.0 111.015 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.9 m -126.52 140.99 52.03 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.984 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 6.6 m -99.86 111.18 23.51 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.147 179.272 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.918 HG11 HG23 ' A' ' 118' ' ' VAL . 47.2 t -82.66 108.57 15.64 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 CA-C-N 116.015 -0.539 . . . . 0.0 112.268 -179.112 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 6.7 tt -103.12 85.01 2.43 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.876 -0.602 . . . . 0.0 109.436 178.345 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.821 HG21 ' CD2' ' A' ' 95' ' ' LEU . 5.6 mt -82.81 118.81 31.17 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.251 0 CA-C-O 121.293 0.568 . . . . 0.0 111.893 -178.715 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.446 ' HB2' HG21 ' A' ' 112' ' ' ILE . 0.2 OUTLIER -73.13 153.06 40.92 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.089 -0.959 . . . . 0.0 109.99 179.21 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.438 ' HD2' HD11 ' A' ' 95' ' ' LEU . 0.0 OUTLIER -152.92 124.32 3.68 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 120.618 0.247 . . . . 0.0 111.11 -179.979 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 92.0 Cg_endo -83.47 -42.45 0.08 OUTLIER 'Trans proline' 0 C--N 1.347 0.465 0 C-N-CA 122.613 2.209 . . . . 0.0 112.584 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 57.4 p30 -156.78 -167.54 2.4 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.203 -179.781 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 7.3 mt -96.19 30.87 2.33 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.43 -179.519 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -138.9 32.06 2.21 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.886 0.374 . . . . 0.0 110.982 179.914 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 2.1 m-85 -136.84 104.06 5.37 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.832 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 3.0 mp0 -65.51 145.07 56.56 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.03 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 0.821 ' CD2' HG21 ' A' ' 86' ' ' ILE . 8.3 mp -78.49 -24.62 45.77 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.94 179.93 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 72.27 68.81 1.51 Allowed Glycine 0 C--N 1.331 0.257 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.868 179.709 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 97' ' ' PHE . . . . . 0.763 ' CZ ' HD12 ' A' ' 144' ' ' LEU . 1.8 p90 -161.37 -171.83 3.15 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.918 0.39 . . . . 0.0 111.212 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.419 ' O ' ' HA ' ' A' ' 104' ' ' ILE . 1.2 t -149.67 126.24 10.95 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.408 179.71 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.654 HG21 HG21 ' A' ' 140' ' ' ILE . 11.8 p -111.97 140.16 32.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 121.163 0.506 . . . . 0.0 111.764 -179.284 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 3.6 mp0 -133.03 89.75 2.66 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.598 -0.728 . . . . 0.0 109.847 179.156 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 60.35 15.64 5.59 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.756 -178.921 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 127.31 -39.3 1.97 Allowed Glycine 0 N--CA 1.449 -0.474 0 C-N-CA 121.012 -0.613 . . . . 0.0 112.228 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.81 HG23 ' O ' ' A' ' 122' ' ' HIS . 31.5 mt -77.27 138.67 20.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 121.007 0.432 . . . . 0.0 111.575 -179.587 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.832 HD11 ' CD1' ' A' ' 124' ' ' ILE . 4.1 mp -96.36 138.25 22.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.991 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -108.0 -65.62 1.1 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.653 179.878 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 9.5 p -94.22 155.06 17.23 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.614 179.724 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.478 ' HB3' HG22 ' A' ' 120' ' ' VAL . 0.6 OUTLIER -163.92 121.71 1.81 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.942 -179.855 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 20.2 ttp -82.36 120.94 26.06 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.881 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -67.97 71.92 0.16 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.143 0.497 . . . . 0.0 110.602 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 175.36 -33.85 0.1 OUTLIER Glycine 0 N--CA 1.45 -0.39 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.966 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 111' ' ' GLY . . . . . 0.429 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -55.26 176.33 0.6 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.781 -0.724 . . . . 0.0 112.275 179.788 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.446 HG21 ' HB2' ' A' ' 87' ' ' ARG . 1.1 mp -78.7 -18.57 13.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 N-CA-C 111.848 0.314 . . . . 0.0 111.848 -179.734 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 113' ' ' ALA . . . . . . . . . . . . . . . -58.01 -30.54 66.19 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.895 0.378 . . . . 0.0 110.757 179.855 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 114' ' ' GLU . . . . . 0.429 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 13.2 pt-20 -61.64 -47.42 85.48 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.871 179.8 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 43.4 mtm180 -62.27 -41.98 98.93 Favored 'General case' 0 N--CA 1.453 -0.31 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.832 -179.631 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -53.79 -73.83 0.37 Allowed Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.296 -0.954 . . . . 0.0 112.394 179.854 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 117' ' ' GLY . . . . . 0.55 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 164.57 -18.13 0.11 Allowed Glycine 0 CA--C 1.523 0.538 0 C-N-CA 121.249 -0.5 . . . . 0.0 112.74 -179.889 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.918 HG23 HG11 ' A' ' 84' ' ' VAL . 2.0 t -29.58 -64.26 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 C-N-CA 123.212 0.605 . . . . 0.0 112.569 -179.54 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.576 ' N ' HG12 ' A' ' 118' ' ' VAL . 30.0 mmt180 61.71 178.7 0.12 Allowed 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.303 -0.408 . . . . 0.0 109.941 -178.872 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 120' ' ' VAL . . . . . 0.478 HG22 ' HB3' ' A' ' 107' ' ' LEU . 11.8 t -111.18 101.12 12.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-O 120.917 0.389 . . . . 0.0 111.341 -179.86 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 126.17 42.34 0.3 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.894 -0.669 . . . . 0.0 112.417 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 122' ' ' HIS . . . . . 0.81 ' O ' HG23 ' A' ' 103' ' ' ILE . 15.3 m170 -129.87 -171.52 2.54 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.767 0.317 . . . . 0.0 110.963 -179.822 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 123' ' ' ARG . . . . . 0.799 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 5.7 ttm-85 -142.08 89.39 2.17 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.874 -179.756 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 124' ' ' ILE . . . . . 0.832 ' CD1' HD11 ' A' ' 104' ' ' ILE . 14.6 mt -51.67 142.5 4.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.547 -0.297 . . . . 0.0 110.285 179.375 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 125' ' ' ILE . . . . . 0.859 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.6 OUTLIER -137.18 -84.46 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 N-CA-C 112.668 0.618 . . . . 0.0 112.668 -179.05 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 126' ' ' GLU . . . . . 0.421 ' CD ' HD12 ' A' ' 125' ' ' ILE . 1.0 OUTLIER -80.52 83.73 6.26 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 112.421 0.526 . . . . 0.0 112.421 -178.538 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.862 HG23 ' HB3' ' A' ' 153' ' ' MET . 1.9 mt -86.26 104.37 13.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 120.97 0.414 . . . . 0.0 111.175 179.086 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 11.3 m-20 56.15 23.05 6.56 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.777 -0.647 . . . . 0.0 111.402 179.804 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 112.68 -14.21 24.71 Favored Glycine 0 C--N 1.332 0.318 0 C-N-CA 120.554 -0.831 . . . . 0.0 112.961 179.746 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 130' ' ' GLN . . . . . 0.4 ' O ' ' CG ' ' A' ' 130' ' ' GLN . 5.0 pt20 -96.16 122.07 38.61 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.742 0.306 . . . . 0.0 110.484 -179.888 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 21.3 p -83.75 90.02 7.26 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.892 0.377 . . . . 0.0 110.826 179.921 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 132' ' ' VAL . . . . . 0.624 HG21 HD11 ' A' ' 127' ' ' ILE . 35.0 m -72.69 -3.81 4.45 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.351 0 CA-C-N 116.013 -0.54 . . . . 0.0 112.04 -179.845 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.859 ' HB ' HG22 ' A' ' 125' ' ' ILE . 7.9 p -47.27 -35.13 3.41 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.158 0 CA-C-O 120.894 0.378 . . . . 0.0 111.228 -179.889 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -121.01 27.84 8.24 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.684 179.4 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 135' ' ' THR . . . . . 0.419 HG23 ' HD2' ' A' ' 136' ' ' PRO . 25.8 m -114.08 140.64 25.16 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 115.664 -0.698 . . . . 0.0 111.02 -179.8 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 136' ' ' PRO . . . . . 0.419 ' HD2' HG23 ' A' ' 135' ' ' THR . 8.3 Cg_endo -50.11 163.97 0.52 Allowed 'Trans proline' 0 C--N 1.347 0.458 0 C-N-CA 122.676 2.251 . . . . 0.0 112.181 179.64 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 137' ' ' HIS . . . . . 0.404 ' CD2' ' N ' ' A' ' 138' ' ' GLU . 22.9 p-80 -74.45 -41.85 60.11 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.284 -0.417 . . . . 0.0 111.439 -179.642 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 138' ' ' GLU . . . . . 0.404 ' N ' ' CD2' ' A' ' 137' ' ' HIS . 53.8 mt-10 -54.15 -38.04 65.06 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.753 0.311 . . . . 0.0 111.42 -179.516 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 139' ' ' LYS . . . . . 0.76 ' O ' HD12 ' A' ' 143' ' ' ILE . 6.9 tttp -64.67 -48.86 73.2 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.11 -179.728 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 140' ' ' ILE . . . . . 0.654 HG21 HG21 ' A' ' 99' ' ' VAL . 13.8 mt -59.26 -43.27 89.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.624 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 141' ' ' VAL . . . . . 0.574 HG22 HG12 ' A' ' 99' ' ' VAL . 86.6 t -62.29 -33.13 57.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.389 179.291 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -61.93 -56.46 18.98 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.07 -0.514 . . . . 0.0 111.104 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 143' ' ' ILE . . . . . 0.76 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.3 mp -52.9 -57.17 4.92 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.49 0 CA-C-O 121.095 0.474 . . . . 0.0 110.192 179.559 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.763 HD12 ' CZ ' ' A' ' 97' ' ' PHE . 6.3 mt -59.83 -29.91 68.58 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.575 179.409 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 14.0 t -73.18 -28.25 62.1 Favored 'General case' 0 N--CA 1.456 -0.141 0 CA-C-N 116.361 -0.382 . . . . 0.0 110.219 178.945 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 8.4 m120 -125.11 31.58 5.58 Favored 'General case' 0 C--O 1.232 0.152 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.189 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 147' ' ' ALA . . . . . 0.784 ' CB ' HD11 ' A' ' 151' ' ' ILE . . . -107.02 97.06 6.88 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.243 179.942 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 6.3 m -79.96 179.86 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.357 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.983 -179.744 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 67.94 -116.04 7.38 Favored Glycine 0 N--CA 1.453 -0.223 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.599 179.924 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.403 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 11.5 mt-10 -134.97 110.7 9.27 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.606 0.241 . . . . 0.0 110.984 -179.815 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 151' ' ' ILE . . . . . 0.784 HD11 ' CB ' ' A' ' 147' ' ' ALA . 1.7 mp -68.16 124.02 22.77 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-O 120.915 0.388 . . . . 0.0 110.778 179.776 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -113.51 115.56 28.18 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.801 -0.636 . . . . 0.0 109.964 179.192 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 153' ' ' MET . . . . . 0.862 ' HB3' HG23 ' A' ' 127' ' ' ILE . 1.4 ptt? -147.2 164.77 32.1 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.217 0.532 . . . . 0.0 111.732 -178.97 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 2.2 mttm -110.9 152.33 26.86 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.524 -0.762 . . . . 0.0 109.851 179.182 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 37.4 p -136.88 142.59 42.78 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.163 0.506 . . . . 0.0 111.604 -179.547 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 156' ' ' MET . . . . . 0.504 ' O ' ' N ' ' A' ' 123' ' ' ARG . 0.0 OUTLIER -111.82 179.0 0.86 Allowed Pre-proline 0 C--N 1.327 -0.392 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.39 179.755 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 157' ' ' PRO . . . . . 0.412 ' CD ' ' CB ' ' A' ' 156' ' ' MET . 80.2 Cg_endo -92.96 103.41 0.17 Allowed 'Trans proline' 0 N--CA 1.456 -0.688 0 C-N-CA 122.786 2.324 . . . . 0.0 112.543 -179.752 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 158' ' ' ALA . . . . . 0.799 ' HB2' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.25 1.085 0 CA-C-O 118.169 -0.92 . . . . 0.0 111.09 179.788 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.561 HG13 ' O ' ' A' ' 155' ' ' THR . 47.0 t . . . . . 0 C--O 1.231 0.101 0 CA-C-O 120.854 0.359 . . . . 0.0 111.04 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.7 m -118.61 134.25 55.25 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.848 179.849 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 6.9 m -95.25 111.52 23.36 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.178 179.324 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.759 HG12 HG13 ' A' ' 86' ' ' ILE . 58.3 t -82.56 105.73 12.7 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.547 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.742 -179.33 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.46 HD13 ' CE1' ' A' ' 152' ' ' HIS . 4.6 tp -107.73 80.1 1.35 Allowed 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 178.348 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.759 HG13 HG12 ' A' ' 84' ' ' VAL . 1.2 mt -81.67 130.95 34.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 121.173 0.511 . . . . 0.0 111.729 -178.272 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.431 ' H ' HG22 ' A' ' 112' ' ' ILE . 0.0 OUTLIER -84.19 142.87 30.0 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.443 -0.799 . . . . 0.0 110.256 179.929 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 3.7 ttt180 -144.88 114.16 5.01 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.964 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -75.32 -45.24 0.27 Allowed 'Trans proline' 0 C--N 1.347 0.466 0 C-N-CA 122.463 2.109 . . . . 0.0 112.616 -179.895 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -135.1 -173.97 3.47 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.196 -179.753 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 0.456 ' HG ' HG13 ' A' ' 148' ' ' VAL . 0.8 OUTLIER -86.96 -34.04 19.44 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.976 -179.928 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 3.2 ptm180 -73.07 -7.97 53.65 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.608 -179.842 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 10.9 m-85 -85.08 128.57 34.7 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.797 0.332 . . . . 0.0 110.876 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 21.2 mp0 -89.51 160.49 16.7 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.899 -179.895 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 0.797 ' CD1' HD13 ' A' ' 144' ' ' LEU . 59.3 mt -81.42 -69.21 0.63 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.903 179.917 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 135.9 40.96 0.13 Allowed Glycine 0 CA--C 1.518 0.277 0 C-N-CA 120.484 -0.865 . . . . 0.0 113.192 179.631 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 97' ' ' PHE . . . . . 0.455 ' CE1' HG21 ' A' ' 118' ' ' VAL . 33.1 p90 -175.12 174.67 2.4 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.879 0.371 . . . . 0.0 111.09 179.62 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -124.74 143.86 50.55 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.961 -179.814 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.673 HG21 HG21 ' A' ' 140' ' ' ILE . 10.6 p -111.54 139.48 35.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.026 179.907 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 100' ' ' GLN . . . . . 0.413 ' O ' ' N ' ' A' ' 102' ' ' GLY . 0.5 OUTLIER -130.53 89.01 2.71 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.806 179.758 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 101' ' ' ASN . . . . . 0.65 ' O ' HD11 ' A' ' 140' ' ' ILE . 7.3 m-80 64.34 -68.19 0.1 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.903 -0.59 . . . . 0.0 111.51 179.569 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 102' ' ' GLY . . . . . 0.432 ' O ' HD13 ' A' ' 103' ' ' ILE . . . -143.83 1.1 1.27 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.238 -0.982 . . . . 0.0 113.414 -179.731 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.732 HD12 ' CB ' ' A' ' 158' ' ' ALA . 44.2 mm -126.46 155.08 36.64 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 117.232 0.516 . . . . 0.0 111.209 -179.886 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.658 ' N ' HD12 ' A' ' 104' ' ' ILE . 3.2 mp -97.26 145.11 9.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.735 179.817 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 1.6 m -106.46 -79.48 0.57 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.171 -179.704 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 1.5 m -90.91 168.83 11.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.375 -0.375 . . . . 0.0 111.141 -179.7 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.586 HD23 HG23 ' A' ' 120' ' ' VAL . 62.1 tp -174.16 101.86 0.1 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.698 179.897 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 8.0 mtp -73.93 122.05 21.94 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.081 -179.819 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.03 78.2 0.09 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.692 179.775 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 174.25 -33.62 0.11 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.986 -0.626 . . . . 0.0 112.04 -179.837 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 111' ' ' GLY . . . . . 0.413 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -57.46 174.62 2.0 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.142 179.741 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.431 HG22 ' H ' ' A' ' 87' ' ' ARG . 0.9 OUTLIER -78.5 -17.46 13.59 Favored 'Isoleucine or valine' 0 C--O 1.236 0.36 0 CA-C-O 120.829 0.347 . . . . 0.0 111.522 -179.845 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 113' ' ' ALA . . . . . 0.534 ' HB1' HG21 ' A' ' 118' ' ' VAL . . . -58.11 -30.62 66.43 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.911 0.386 . . . . 0.0 110.703 179.863 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 114' ' ' GLU . . . . . 0.413 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 17.4 pt-20 -60.48 -47.21 87.15 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.969 -0.559 . . . . 0.0 110.766 179.634 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 2.4 mmt85 -62.32 -44.78 95.71 Favored 'General case' 0 N--CA 1.452 -0.337 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.892 -179.556 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -53.25 -74.01 0.35 Allowed Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.245 -0.979 . . . . 0.0 112.519 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 117' ' ' GLY . . . . . 0.56 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 172.45 -24.94 0.08 OUTLIER Glycine 0 CA--C 1.518 0.249 0 C-N-CA 121.065 -0.588 . . . . 0.0 112.701 -179.951 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.718 ' N ' HG22 ' A' ' 84' ' ' VAL . 18.0 t -15.11 -83.31 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.627 0 C-N-CA 123.235 0.614 . . . . 0.0 112.489 -179.835 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.651 ' N ' HG12 ' A' ' 118' ' ' VAL . 0.0 OUTLIER 62.56 143.19 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.725 -179.649 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 120' ' ' VAL . . . . . 0.586 HG23 HD23 ' A' ' 107' ' ' LEU . 11.4 t -81.97 132.06 32.37 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 116.439 -0.346 . . . . 0.0 111.198 -179.704 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 101.63 24.63 8.6 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.886 -0.673 . . . . 0.0 112.57 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 10.4 m170 -112.72 -174.42 2.45 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.656 0.265 . . . . 0.0 110.706 179.869 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 123' ' ' ARG . . . . . 0.714 ' CD ' HD11 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -140.58 90.14 2.33 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.819 -179.783 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 124' ' ' ILE . . . . . 0.62 ' O ' HG23 ' A' ' 125' ' ' ILE . 5.9 mt -50.82 154.95 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.811 179.484 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 125' ' ' ILE . . . . . 0.844 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.8 OUTLIER -157.79 -86.66 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 N-CA-C 112.481 0.549 . . . . 0.0 112.481 -179.88 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 126' ' ' GLU . . . . . 0.428 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 15.6 mt-10 -81.82 92.79 6.74 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 112.321 0.489 . . . . 0.0 112.321 -178.637 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.922 HD11 HG21 ' A' ' 132' ' ' VAL . 1.5 mt -91.3 99.16 9.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.126 179.297 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 52.8 m-20 63.96 15.92 9.52 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.451 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 121.19 -18.94 8.82 Favored Glycine 0 C--N 1.332 0.31 0 C-N-CA 120.452 -0.88 . . . . 0.0 113.117 179.629 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 130' ' ' GLN . . . . . 0.464 ' NE2' ' O ' ' A' ' 127' ' ' ILE . 0.5 OUTLIER -98.63 117.1 32.32 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.93 0.395 . . . . 0.0 110.948 -179.916 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 1.4 m -77.18 93.41 3.93 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.182 -179.787 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 132' ' ' VAL . . . . . 0.922 HG21 HD11 ' A' ' 127' ' ' ILE . 35.6 m -77.08 0.31 2.64 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.324 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.801 179.67 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.844 ' HB ' HG22 ' A' ' 125' ' ' ILE . 8.5 p -46.82 -40.23 4.72 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.14 0 CA-C-O 120.805 0.336 . . . . 0.0 111.261 -179.826 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -113.13 29.54 7.9 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.687 179.452 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 135' ' ' THR . . . . . 0.549 HG23 ' HD2' ' A' ' 136' ' ' PRO . 91.0 m -116.97 143.03 30.8 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.852 -179.805 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 136' ' ' PRO . . . . . 0.549 ' HD2' HG23 ' A' ' 135' ' ' THR . 6.1 Cg_endo -47.92 164.09 0.18 Allowed 'Trans proline' 0 C--N 1.347 0.451 0 C-N-CA 122.805 2.337 . . . . 0.0 112.281 179.795 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 45.1 p-80 -76.11 -44.55 38.02 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.301 -179.606 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -54.08 -33.53 57.79 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.362 -179.607 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 139' ' ' LYS . . . . . 0.823 ' O ' HD12 ' A' ' 143' ' ' ILE . 0.0 OUTLIER -66.41 -50.12 64.49 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.873 0.368 . . . . 0.0 111.033 -179.923 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 140' ' ' ILE . . . . . 0.786 HG23 ' CD1' ' A' ' 127' ' ' ILE . 8.5 mt -59.1 -46.18 92.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.421 179.827 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 141' ' ' VAL . . . . . 0.567 HG22 HG12 ' A' ' 99' ' ' VAL . 69.0 t -59.86 -32.38 49.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.906 -0.588 . . . . 0.0 109.885 178.73 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -60.57 -52.97 62.89 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.492 179.604 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 143' ' ' ILE . . . . . 0.823 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.5 mp -53.29 -57.78 4.28 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.394 0 CA-C-O 121.035 0.445 . . . . 0.0 110.108 179.202 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.797 HD13 ' CD1' ' A' ' 95' ' ' LEU . 9.7 mt -60.05 -30.19 69.04 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.627 -0.715 . . . . 0.0 110.231 179.389 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 38.9 t -70.81 -27.79 64.15 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.075 -0.511 . . . . 0.0 109.878 178.745 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 2.8 m-80 -124.85 31.47 5.65 Favored 'General case' 0 C--O 1.232 0.151 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.83 179.799 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 147' ' ' ALA . . . . . 0.784 ' CB ' HD11 ' A' ' 151' ' ' ILE . . . -113.14 101.06 9.08 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.952 179.789 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.456 HG13 ' HG ' ' A' ' 91' ' ' LEU . 3.4 m -101.59 158.62 4.24 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.433 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.321 -179.79 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 95.0 -95.89 1.94 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.564 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 14.4 mt-10 -146.81 104.93 3.76 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.716 0.294 . . . . 0.0 110.715 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 151' ' ' ILE . . . . . 0.784 HD11 ' CB ' ' A' ' 147' ' ' ALA . 1.5 mp -72.41 117.52 16.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 121.149 0.5 . . . . 0.0 111.204 -179.756 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 152' ' ' HIS . . . . . 0.46 ' CE1' HD13 ' A' ' 85' ' ' LEU . 0.2 OUTLIER -101.37 121.84 42.64 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.585 -0.734 . . . . 0.0 109.295 178.724 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 153' ' ' MET . . . . . 0.8 ' HB2' HG23 ' A' ' 127' ' ' ILE . 8.6 tmm? -153.41 155.16 35.84 Favored 'General case' 0 C--N 1.327 -0.385 0 C-N-CA 120.754 -0.378 . . . . 0.0 111.678 -178.436 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 154' ' ' LYS . . . . . 0.41 ' CG ' ' CG1' ' A' ' 81' ' ' VAL . 0.0 OUTLIER -109.23 152.27 25.41 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.605 179.893 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 155' ' ' THR . . . . . 0.561 ' O ' HG13 ' A' ' 81' ' ' VAL . 30.3 p -142.13 150.05 40.61 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 121.159 0.504 . . . . 0.0 111.644 -179.919 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 156' ' ' MET . . . . . 0.503 ' O ' ' N ' ' A' ' 123' ' ' ARG . 10.7 mmm -115.82 178.93 0.87 Allowed Pre-proline 0 C--N 1.328 -0.369 0 CA-C-N 115.556 -0.747 . . . . 0.0 110.302 179.413 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 157' ' ' PRO . . . . . 0.443 ' CD ' ' HB3' ' A' ' 156' ' ' MET . 88.5 Cg_endo -91.33 114.82 0.4 Allowed 'Trans proline' 0 N--CA 1.457 -0.632 0 C-N-CA 122.61 2.207 . . . . 0.0 112.546 -179.685 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 158' ' ' ALA . . . . . 0.732 ' CB ' HD12 ' A' ' 103' ' ' ILE . . . . . . . . 0 C--O 1.249 1.035 0 CA-C-O 118.285 -0.864 . . . . 0.0 111.071 179.727 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.588 HG13 ' CE ' ' A' ' 156' ' ' MET . 56.5 t . . . . . 0 C--O 1.231 0.129 0 CA-C-O 120.759 0.314 . . . . 0.0 110.884 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 82' ' ' THR . . . . . 0.429 HG21 ' O ' ' A' ' 117' ' ' GLY . 1.8 m -120.5 143.01 48.78 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.868 179.75 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 35.9 m -107.09 111.33 23.73 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.267 179.289 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.668 HG12 ' CD1' ' A' ' 86' ' ' ILE . 53.6 t -86.21 106.33 15.49 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.423 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.107 -179.759 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.413 ' O ' ' HA2' ' A' ' 116' ' ' GLY . 1.4 tt -110.09 81.93 1.51 Allowed 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.157 -0.474 . . . . 0.0 109.729 179.107 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.668 ' CD1' HG12 ' A' ' 84' ' ' VAL . 1.8 mp -81.83 134.17 27.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 121.106 0.479 . . . . 0.0 111.732 -178.965 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.51 ' O ' HG21 ' A' ' 112' ' ' ILE . 0.0 OUTLIER -91.36 108.69 20.06 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.99 179.813 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.537 ' HE ' HD13 ' A' ' 112' ' ' ILE . 1.0 OUTLIER -113.14 87.11 10.24 Favored Pre-proline 0 C--N 1.328 -0.365 0 CA-C-O 120.878 0.371 . . . . 0.0 111.676 -179.209 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 89' ' ' PRO . . . . . 0.405 ' HD2' ' NH2' ' A' ' 88' ' ' ARG . 96.4 Cg_endo -78.96 1.91 8.73 Favored 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.598 2.199 . . . . 0.0 112.952 179.776 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 90' ' ' ASP . . . . . 0.783 ' O ' HG12 ' A' ' 148' ' ' VAL . 1.0 OUTLIER -154.5 -162.29 1.37 Allowed 'General case' 0 C--N 1.332 -0.17 0 CA-C-O 120.743 0.306 . . . . 0.0 111.36 -179.884 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 0.609 HD12 HG11 ' A' ' 148' ' ' VAL . 0.1 OUTLIER -128.18 -40.58 1.64 Allowed 'General case' 0 C--N 1.332 -0.153 0 CA-C-O 120.925 0.393 . . . . 0.0 111.389 -179.622 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -53.44 -23.3 9.6 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.536 -179.524 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 93' ' ' TYR . . . . . 0.463 ' HB2' ' NH2' ' A' ' 88' ' ' ARG . 77.4 m-85 -95.65 148.89 22.06 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.828 179.824 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -97.03 175.6 6.26 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.155 -179.842 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 0.613 ' HG ' HD13 ' A' ' 144' ' ' LEU . 2.7 mm? -72.49 -51.68 19.06 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.661 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 121.74 31.74 1.09 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.9 179.784 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 47.8 p90 -175.55 145.14 0.71 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.832 0.349 . . . . 0.0 111.058 179.818 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.432 ' O ' ' HA ' ' A' ' 104' ' ' ILE . 14.8 m -91.76 148.44 22.24 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.747 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.78 HG21 HG21 ' A' ' 140' ' ' ILE . 5.1 p -118.82 137.02 54.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.366 -179.686 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -129.89 89.85 2.88 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.866 -0.607 . . . . 0.0 109.959 179.424 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 63.9 t30 60.6 17.38 7.39 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.627 -179.038 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 102' ' ' GLY . . . . . 0.411 ' HA2' ' HB ' ' A' ' 124' ' ' ILE . . . 124.58 -39.31 2.15 Favored Glycine 0 N--CA 1.448 -0.566 0 C-N-CA 120.957 -0.639 . . . . 0.0 112.031 -179.808 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.483 HG12 ' HB2' ' A' ' 158' ' ' ALA . 23.2 mt -78.35 131.41 34.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-O 120.989 0.423 . . . . 0.0 111.432 -179.693 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.766 HD11 ' CD1' ' A' ' 124' ' ' ILE . 3.6 mp -85.54 139.34 17.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.841 179.743 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 12.0 t -94.97 -67.35 0.86 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.047 -179.648 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 3.3 m -112.64 146.92 37.8 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.79 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.889 HD11 HG13 ' A' ' 118' ' ' VAL . 0.5 OUTLIER -133.24 100.89 4.99 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.662 179.979 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 2.7 tmm? -60.01 141.34 55.82 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.907 -179.888 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -93.4 44.14 1.13 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.09 0.471 . . . . 0.0 110.703 179.798 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -162.78 23.98 0.2 Allowed Glycine 0 N--CA 1.45 -0.375 0 CA-C-N 115.691 -0.686 . . . . 0.0 112.282 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 111' ' ' GLY . . . . . 0.489 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -112.77 175.46 16.8 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.851 -0.69 . . . . 0.0 111.952 179.798 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.537 HD13 ' HE ' ' A' ' 88' ' ' ARG . 0.5 OUTLIER -79.27 -23.55 12.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-O 120.933 0.397 . . . . 0.0 111.578 -179.772 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 113' ' ' ALA . . . . . 0.529 ' O ' HG12 ' A' ' 118' ' ' VAL . . . -57.92 -30.41 65.91 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.968 0.413 . . . . 0.0 110.604 -179.93 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 114' ' ' GLU . . . . . 0.489 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 8.6 pt-20 -59.92 -45.2 93.33 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.722 179.467 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 88.5 mtt180 -64.78 -46.26 82.83 Favored 'General case' 0 N--CA 1.452 -0.358 0 CA-C-N 115.96 -0.564 . . . . 0.0 111.087 -179.441 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.413 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -49.75 -74.65 0.25 Allowed Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.413 -0.899 . . . . 0.0 112.591 179.918 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 117' ' ' GLY . . . . . 0.429 ' O ' HG21 ' A' ' 82' ' ' THR . . . 175.21 -16.49 0.04 OUTLIER Glycine 0 CA--C 1.52 0.386 0 C-N-CA 120.77 -0.729 . . . . 0.0 113.112 179.945 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.889 HG13 HD11 ' A' ' 107' ' ' LEU . 5.0 p -34.13 148.8 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 N-CA-C 112.156 0.428 . . . . 0.0 112.156 -179.659 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 1.1 ttp85 -151.83 113.01 4.28 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.823 179.907 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 120' ' ' VAL . . . . . 0.55 ' O ' HG13 ' A' ' 120' ' ' VAL . 14.9 p -52.48 114.89 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.316 -179.976 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 113.5 19.12 6.74 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.433 -179.809 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 3.2 m170 -120.86 139.79 52.69 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.803 0.335 . . . . 0.0 110.773 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 123' ' ' ARG . . . . . 0.673 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 10.7 ttt180 -83.65 90.65 7.31 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.384 -179.673 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 124' ' ' ILE . . . . . 0.784 HG23 ' SD ' ' A' ' 153' ' ' MET . 71.4 mt -48.75 134.33 6.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 178.784 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 125' ' ' ILE . . . . . 0.867 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.8 OUTLIER -128.29 -84.46 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 N-CA-C 113.175 0.806 . . . . 0.0 113.175 -178.398 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 126' ' ' GLU . . . . . 0.435 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 4.3 mt-10 -80.88 92.16 6.08 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 112.922 0.712 . . . . 0.0 112.922 -178.236 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.702 HG23 ' HB2' ' A' ' 153' ' ' MET . 1.3 mt -94.34 94.87 4.74 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.668 178.722 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 128' ' ' ASN . . . . . 0.454 ' N ' ' O ' ' A' ' 152' ' ' HIS . 55.5 m-80 62.3 26.35 15.77 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.882 -179.813 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 108.91 -19.37 30.44 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.733 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 7.6 tt0 -90.77 110.39 21.59 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.785 0.326 . . . . 0.0 110.878 179.903 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 1.4 m -76.2 93.32 3.36 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.077 -179.822 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 132' ' ' VAL . . . . . 0.635 HG21 HD11 ' A' ' 127' ' ' ILE . 25.9 m -73.48 -5.15 6.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.877 179.859 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.867 ' HB ' HG22 ' A' ' 125' ' ' ILE . 11.4 p -47.26 -36.65 4.1 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-O 120.857 0.361 . . . . 0.0 111.41 -179.713 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -117.28 28.65 8.35 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.628 179.501 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 135' ' ' THR . . . . . 0.476 HG23 ' HD2' ' A' ' 136' ' ' PRO . 67.4 m -116.37 140.81 27.0 Favored Pre-proline 0 C--N 1.328 -0.363 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.343 -179.734 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 136' ' ' PRO . . . . . 0.476 ' HD2' HG23 ' A' ' 135' ' ' THR . 8.9 Cg_endo -50.99 164.36 0.63 Allowed 'Trans proline' 0 C--N 1.347 0.493 0 C-N-CA 122.759 2.306 . . . . 0.0 112.347 179.765 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 137' ' ' HIS . . . . . 0.405 ' CE1' ' HG3' ' A' ' 138' ' ' GLU . 20.9 p80 -70.91 -50.09 38.63 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.739 -179.42 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 138' ' ' GLU . . . . . 0.405 ' HG3' ' CE1' ' A' ' 137' ' ' HIS . 3.7 mt-10 -53.91 -33.79 57.66 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.607 -179.355 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 139' ' ' LYS . . . . . 0.745 ' O ' HD12 ' A' ' 143' ' ' ILE . 8.6 tptt -64.02 -48.05 77.86 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.369 -0.378 . . . . 0.0 111.098 -179.828 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 140' ' ' ILE . . . . . 0.78 HG21 HG21 ' A' ' 99' ' ' VAL . 13.9 mt -58.38 -46.15 89.38 Favored 'Isoleucine or valine' 0 C--O 1.235 0.318 0 CA-C-O 121.013 0.435 . . . . 0.0 110.669 -179.898 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 141' ' ' VAL . . . . . 0.535 HG22 HG12 ' A' ' 99' ' ' VAL . 58.9 t -60.05 -32.82 51.16 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.353 179.166 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 57.2 t-80 -62.77 -54.15 43.4 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.304 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 143' ' ' ILE . . . . . 0.745 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.2 mp -52.96 -57.21 4.9 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.451 0 CA-C-O 121.018 0.437 . . . . 0.0 110.375 179.647 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.613 HD13 ' HG ' ' A' ' 95' ' ' LEU . 1.4 mt -62.41 -30.04 70.93 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.55 -0.75 . . . . 0.0 110.381 179.581 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 3.4 m -66.63 -26.57 67.14 Favored 'General case' 0 N--CA 1.452 -0.347 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 178.448 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 8.0 m120 -132.86 35.86 3.53 Favored 'General case' 0 CA--C 1.529 0.145 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.377 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 147' ' ' ALA . . . . . 0.638 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -118.06 52.59 1.0 Allowed 'General case' 0 C--N 1.332 -0.178 0 CA-C-O 120.776 0.322 . . . . 0.0 111.464 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.783 HG12 ' O ' ' A' ' 90' ' ' ASP . 15.6 m -53.5 -178.48 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 120.877 0.37 . . . . 0.0 111.035 179.91 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 83.96 -108.47 3.08 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.424 -179.834 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 20.2 mt-10 -138.27 101.6 4.43 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.878 0.37 . . . . 0.0 110.454 179.787 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 151' ' ' ILE . . . . . 0.638 HD11 ' HB3' ' A' ' 147' ' ' ALA . 1.1 mt -76.15 111.72 13.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 121.051 0.453 . . . . 0.0 111.487 -179.516 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 152' ' ' HIS . . . . . 0.454 ' O ' ' N ' ' A' ' 128' ' ' ASN . 0.2 OUTLIER -99.72 124.23 44.76 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 178.356 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 153' ' ' MET . . . . . 0.784 ' SD ' HG23 ' A' ' 124' ' ' ILE . 11.5 tmm? -150.68 155.08 38.63 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.139 0.495 . . . . 0.0 112.25 -177.937 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -113.45 148.17 36.43 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.59 -0.732 . . . . 0.0 109.669 178.977 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 155' ' ' THR . . . . . 0.587 HG22 ' SD ' ' A' ' 153' ' ' MET . 16.3 p -130.7 141.02 50.39 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.28 0.562 . . . . 0.0 111.836 -179.266 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 156' ' ' MET . . . . . 0.59 ' HE3' HD11 ' A' ' 125' ' ' ILE . 0.0 OUTLIER -123.28 119.45 27.49 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 115.109 -0.951 . . . . 0.0 110.053 179.475 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 88.9 Cg_exo -42.24 110.63 0.16 Allowed 'Trans proline' 0 C--N 1.346 0.402 0 C-N-CA 122.56 2.173 . . . . 0.0 112.935 -179.756 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 158' ' ' ALA . . . . . 0.673 ' HB2' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.249 1.05 0 CA-C-O 118.23 -0.89 . . . . 0.0 111.043 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 12.5 p . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.795 0.331 . . . . 0.0 111.035 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 3.0 m -115.49 132.05 56.74 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.993 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 26.6 m -92.26 111.65 23.29 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.032 179.235 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.783 HG12 HG13 ' A' ' 86' ' ' ILE . 94.5 t -83.89 105.41 13.34 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.566 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.68 -179.093 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.443 HD23 ' C ' ' A' ' 85' ' ' LEU . 5.2 tt -105.2 80.07 1.56 Allowed 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 109.176 -0.676 . . . . 0.0 109.176 178.466 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.813 HG21 HD22 ' A' ' 95' ' ' LEU . 4.5 mt -82.04 125.33 39.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 121.236 0.541 . . . . 0.0 111.874 -178.354 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.465 ' HB2' HG21 ' A' ' 112' ' ' ILE . 0.1 OUTLIER -76.94 147.86 36.7 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.289 -0.869 . . . . 0.0 110.061 179.467 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 6.0 mtp85 -141.84 96.13 6.81 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 120.686 0.279 . . . . 0.0 111.089 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_exo -56.38 -60.28 0.51 Allowed 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 122.562 2.175 . . . . 0.0 112.447 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -127.5 -169.17 2.0 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 121.03 0.443 . . . . 0.0 111.033 -179.692 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -89.11 -43.16 11.26 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.988 -0.551 . . . . 0.0 111.04 -179.942 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 16.5 mtt-85 -64.81 -13.66 56.44 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.639 -179.689 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 24.1 m-85 -88.68 117.57 27.75 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.456 -0.338 . . . . 0.0 110.976 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -85.21 169.42 13.84 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.999 -179.918 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 0.813 HD22 HG21 ' A' ' 86' ' ' ILE . 76.9 mt -76.21 -69.4 0.51 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.779 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 128.23 54.13 0.12 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.457 -0.877 . . . . 0.0 113.1 179.531 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 97' ' ' PHE . . . . . 0.617 ' CE2' ' HB2' ' A' ' 113' ' ' ALA . 42.5 p90 -177.83 174.25 1.47 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.817 0.342 . . . . 0.0 111.053 179.635 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -116.52 150.3 38.17 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.866 179.869 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.625 HG21 HG21 ' A' ' 140' ' ' ILE . 9.3 p -125.6 136.36 61.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.314 -179.894 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 100' ' ' GLN . . . . . 0.409 ' HG3' ' HB ' ' A' ' 103' ' ' ILE . 1.6 pt20 -130.37 91.64 3.13 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.215 179.464 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER 60.74 13.83 4.64 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.175 -179.343 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 129.67 -38.4 2.0 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.872 -0.68 . . . . 0.0 112.366 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.848 HG23 ' O ' ' A' ' 122' ' ' HIS . 36.2 mt -77.13 136.86 23.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-O 121.105 0.479 . . . . 0.0 111.684 -179.559 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.726 HG12 HG13 ' A' ' 118' ' ' VAL . 4.0 mp -90.98 138.37 19.73 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.54 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 7.7 m -94.29 -84.28 0.32 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.509 -179.298 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 46.3 t -109.88 113.53 26.33 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.926 0.393 . . . . 0.0 111.203 -179.6 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.713 HD13 ' O ' ' A' ' 107' ' ' LEU . 1.4 tm? -105.74 110.06 22.23 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.45 179.645 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 9.0 ttp -58.08 116.84 3.79 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.024 -179.762 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 7.1 mtt85 -63.89 80.79 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.001 0.429 . . . . 0.0 110.671 179.789 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 166.74 -30.88 0.2 Allowed Glycine 0 N--CA 1.45 -0.399 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.894 -179.754 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 111' ' ' GLY . . . . . 0.441 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -59.1 176.18 2.7 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.131 179.625 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.465 HG21 ' HB2' ' A' ' 87' ' ' ARG . 1.2 mt -79.06 -19.53 12.88 Favored 'Isoleucine or valine' 0 C--O 1.236 0.343 0 CA-C-O 120.892 0.377 . . . . 0.0 111.729 -179.69 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 113' ' ' ALA . . . . . 0.617 ' HB2' ' CE2' ' A' ' 97' ' ' PHE . . . -57.77 -30.61 65.78 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.981 0.42 . . . . 0.0 110.74 179.909 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 114' ' ' GLU . . . . . 0.441 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 10.5 pt-20 -60.92 -46.46 90.59 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.746 179.703 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -62.23 -45.76 91.89 Favored 'General case' 0 N--CA 1.453 -0.304 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.946 -179.444 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.401 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -51.19 -74.35 0.3 Allowed Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.297 -0.954 . . . . 0.0 112.532 179.872 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 117' ' ' GLY . . . . . 0.562 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 174.29 -26.22 0.08 OUTLIER Glycine 0 CA--C 1.518 0.276 0 C-N-CA 121.116 -0.564 . . . . 0.0 112.61 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.736 ' N ' HG22 ' A' ' 84' ' ' VAL . 13.5 t -15.72 -81.98 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.471 0.594 0 C-N-CA 123.259 0.624 . . . . 0.0 112.632 -179.824 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.653 ' N ' HG12 ' A' ' 118' ' ' VAL . 0.8 OUTLIER 63.84 129.05 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.748 0.309 . . . . 0.0 110.454 -179.43 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 22.2 t -63.29 130.88 28.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.314 -179.799 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 97.41 34.22 5.65 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.685 179.756 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 122' ' ' HIS . . . . . 0.848 ' O ' HG23 ' A' ' 103' ' ' ILE . 5.1 m170 -122.65 -174.54 2.94 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.933 0.396 . . . . 0.0 110.878 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 123' ' ' ARG . . . . . 0.81 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 8.7 ttm-85 -144.23 89.43 2.02 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.87 -179.803 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 124' ' ' ILE . . . . . 0.653 HG13 HD11 ' A' ' 104' ' ' ILE . 78.3 mt -50.4 150.16 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 N-CA-C 110.208 -0.293 . . . . 0.0 110.208 179.246 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 125' ' ' ILE . . . . . 0.863 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.6 OUTLIER -146.07 -84.5 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 N-CA-C 112.87 0.693 . . . . 0.0 112.87 -178.892 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 126' ' ' GLU . . . . . 0.404 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 40.0 mt-10 -83.2 89.12 6.92 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 112.532 0.568 . . . . 0.0 112.532 -178.499 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.818 HG23 ' HB3' ' A' ' 153' ' ' MET . 1.8 mt -89.03 102.0 12.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.005 179.221 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 22.6 m-20 53.75 24.85 4.64 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.121 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 111.83 -16.51 25.76 Favored Glycine 0 CA--C 1.519 0.317 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.725 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -93.16 108.94 20.45 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.782 0.325 . . . . 0.0 110.889 -179.88 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 83.1 p -74.83 89.47 2.33 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.096 -179.874 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 132' ' ' VAL . . . . . 0.784 HG21 HD11 ' A' ' 127' ' ' ILE . 27.7 m -74.99 -4.08 5.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.832 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.863 ' HB ' HG22 ' A' ' 125' ' ' ILE . 12.1 p -46.37 -40.95 4.35 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-O 120.928 0.394 . . . . 0.0 111.343 -179.854 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 134' ' ' ALA . . . . . 0.411 ' N ' HG13 ' A' ' 133' ' ' VAL . . . -113.91 29.48 7.97 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.673 179.395 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 135' ' ' THR . . . . . 0.464 HG23 ' HD2' ' A' ' 136' ' ' PRO . 84.0 m -114.04 143.26 29.32 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.047 -179.746 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 136' ' ' PRO . . . . . 0.464 ' HD2' HG23 ' A' ' 135' ' ' THR . 74.8 Cg_exo -49.72 156.97 2.73 Favored 'Trans proline' 0 C--N 1.347 0.494 0 C-N-CA 122.45 2.1 . . . . 0.0 112.245 179.851 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 37.5 p-80 -68.08 -46.47 70.93 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.266 -179.762 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 18.1 mt-10 -55.56 -35.75 66.07 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.299 -179.791 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 139' ' ' LYS . . . . . 0.758 ' O ' HD12 ' A' ' 143' ' ' ILE . 5.4 tptt -62.78 -47.5 83.2 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.885 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 140' ' ' ILE . . . . . 0.625 HG21 HG21 ' A' ' 99' ' ' VAL . 16.4 mt -58.8 -43.04 87.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.584 179.951 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 141' ' ' VAL . . . . . 0.469 HG22 HG12 ' A' ' 99' ' ' VAL . 92.8 t -62.16 -32.72 55.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.177 179.051 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 2.0 t-80 -62.19 -54.48 40.36 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.907 179.901 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 143' ' ' ILE . . . . . 0.758 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.4 mp -53.09 -56.94 5.67 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.408 0 CA-C-O 121.207 0.527 . . . . 0.0 110.214 179.391 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.74 HD13 ' CD1' ' A' ' 95' ' ' LEU . 4.5 mt -60.94 -30.12 70.04 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.327 -0.852 . . . . 0.0 110.288 179.619 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 28.5 t -69.37 -26.45 64.67 Favored 'General case' 0 N--CA 1.452 -0.356 0 CA-C-N 116.183 -0.462 . . . . 0.0 109.929 178.672 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -128.9 33.42 4.62 Favored 'General case' 0 C--O 1.232 0.138 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.104 179.85 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 147' ' ' ALA . . . . . 0.652 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -115.81 46.17 1.58 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.859 0.361 . . . . 0.0 111.462 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 11.2 m -50.69 157.36 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.389 -179.864 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 102.68 -106.39 2.91 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.504 -179.966 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.417 ' HB3' HD21 ' A' ' 85' ' ' LEU . 30.1 mt-10 -139.14 94.44 2.8 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.805 0.336 . . . . 0.0 110.768 179.93 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 151' ' ' ILE . . . . . 0.652 HD11 ' HB3' ' A' ' 147' ' ' ALA . 1.0 OUTLIER -64.71 111.96 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.037 -179.867 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 152' ' ' HIS . . . . . 0.41 ' CD2' ' HG ' ' A' ' 85' ' ' LEU . 0.2 OUTLIER -99.43 115.94 30.42 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.046 -0.524 . . . . 0.0 109.962 179.135 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 153' ' ' MET . . . . . 0.818 ' HB3' HG23 ' A' ' 127' ' ' ILE . 0.1 OUTLIER -147.82 177.42 9.33 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.406 0.622 . . . . 0.0 111.58 -179.216 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 12.9 mttt -126.7 160.27 31.26 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 114.938 -1.028 . . . . 0.0 109.866 179.562 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 155' ' ' THR . . . . . 0.54 HG22 ' HA ' ' A' ' 124' ' ' ILE . 24.4 p -144.18 144.58 31.62 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.299 0.571 . . . . 0.0 111.814 -179.565 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 156' ' ' MET . . . . . 0.53 ' O ' ' N ' ' A' ' 123' ' ' ARG . 0.0 OUTLIER -115.87 177.51 1.19 Allowed Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 115.142 -0.936 . . . . 0.0 109.997 179.508 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 157' ' ' PRO . . . . . 0.401 ' HD2' ' HB3' ' A' ' 156' ' ' MET . 89.8 Cg_endo -92.4 102.07 0.19 Allowed 'Trans proline' 0 N--CA 1.455 -0.757 0 C-N-CA 122.585 2.19 . . . . 0.0 112.627 -179.684 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 158' ' ' ALA . . . . . 0.81 ' HB2' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.248 1.025 0 CA-C-O 118.168 -0.92 . . . . 0.0 111.054 179.739 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.644 HG13 ' CE ' ' A' ' 156' ' ' MET . 37.1 t . . . . . 0 C--O 1.231 0.089 0 CA-C-O 120.765 0.316 . . . . 0.0 111.061 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.5 m -98.69 139.24 34.69 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.869 179.912 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 10.3 m -109.29 111.46 23.06 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.106 -0.497 . . . . 0.0 109.93 179.015 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.723 HG11 HG23 ' A' ' 118' ' ' VAL . 66.2 t -81.72 106.38 12.68 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.638 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.506 -179.475 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 16.8 tp -104.91 87.06 2.57 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.592 178.859 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.678 HG21 HD22 ' A' ' 95' ' ' LEU . 3.7 mt -81.56 146.82 6.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.229 -179.088 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.485 ' CB ' HG21 ' A' ' 112' ' ' ILE . 0.0 OUTLIER -115.7 108.97 17.06 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.486 -179.602 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 53.5 ttt180 -104.02 108.28 59.49 Favored Pre-proline 0 C--N 1.33 -0.257 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.847 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -68.45 -27.56 33.4 Favored 'Trans proline' 0 C--N 1.347 0.487 0 C-N-CA 122.36 2.04 . . . . 0.0 112.402 -179.942 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 90' ' ' ASP . . . . . 0.417 ' HB2' ' CD1' ' A' ' 93' ' ' TYR . 1.1 m-20 -165.22 168.98 16.52 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.993 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -66.86 -36.87 83.3 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.067 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.21 -14.15 59.96 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.086 -0.507 . . . . 0.0 111.492 -179.769 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 93' ' ' TYR . . . . . 0.417 ' CD1' ' HB2' ' A' ' 90' ' ' ASP . 46.6 m-85 -99.39 113.11 25.26 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.42 -0.355 . . . . 0.0 110.889 179.881 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -73.98 165.93 24.27 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.007 -179.926 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 0.8 HD11 ' HB3' ' A' ' 144' ' ' LEU . 26.0 mt -77.44 -67.43 0.72 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.835 179.965 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.573 ' O ' HD23 ' A' ' 107' ' ' LEU . . . 132.51 40.6 0.2 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.566 -0.826 . . . . 0.0 112.956 179.624 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 35.3 p90 -177.05 159.55 1.67 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.796 0.331 . . . . 0.0 110.968 179.68 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -112.94 144.67 42.12 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.963 -179.92 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.83 HG21 HG21 ' A' ' 140' ' ' ILE . 12.7 p -111.47 138.0 41.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.591 -179.861 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 100' ' ' GLN . . . . . 0.422 ' O ' ' N ' ' A' ' 102' ' ' GLY . 5.2 mm-40 -130.04 88.58 2.68 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.007 179.013 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 101' ' ' ASN . . . . . 0.673 ' O ' HD11 ' A' ' 140' ' ' ILE . 3.7 t30 64.69 -70.66 0.08 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.951 -179.662 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 102' ' ' GLY . . . . . 0.508 ' O ' HD13 ' A' ' 103' ' ' ILE . . . -141.86 -1.19 1.4 Allowed Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 120.445 -0.883 . . . . 0.0 113.024 179.928 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.823 HD12 ' HB2' ' A' ' 158' ' ' ALA . 25.5 mm -119.55 159.2 20.68 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.166 0 CA-C-O 120.969 0.414 . . . . 0.0 111.304 -179.712 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.559 ' N ' HD12 ' A' ' 104' ' ' ILE . 3.3 mp -102.19 141.46 18.36 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.912 -179.762 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -83.51 -69.43 0.64 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.936 -179.845 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -142.9 168.98 18.42 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.941 -179.882 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.801 HD11 ' O ' ' A' ' 118' ' ' VAL . 0.6 OUTLIER -123.1 167.46 13.63 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.912 179.926 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 4.5 ttt -122.62 97.76 5.6 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.648 179.705 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -55.21 91.0 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.86 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 152.94 -29.38 0.82 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.947 -0.644 . . . . 0.0 112.029 -179.69 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -70.88 176.82 35.88 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.278 179.753 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.485 HG21 ' CB ' ' A' ' 87' ' ' ARG . 0.6 OUTLIER -78.74 -16.6 13.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 120.711 0.291 . . . . 0.0 111.664 -179.769 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 113' ' ' ALA . . . . . 0.495 ' HA ' HG12 ' A' ' 86' ' ' ILE . . . -57.75 -30.53 65.66 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.013 0.435 . . . . 0.0 110.726 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -60.34 -46.91 88.24 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.662 179.632 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -62.49 -47.8 82.39 Favored 'General case' 0 N--CA 1.452 -0.352 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.125 -179.684 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -49.91 -74.14 0.3 Allowed Glycine 0 CA--C 1.519 0.325 0 C-N-CA 120.454 -0.879 . . . . 0.0 112.452 179.866 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 117' ' ' GLY . . . . . 0.587 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 173.99 -25.16 0.07 OUTLIER Glycine 0 CA--C 1.519 0.299 0 C-N-CA 121.141 -0.552 . . . . 0.0 112.366 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.801 ' O ' HD11 ' A' ' 107' ' ' LEU . 1.1 t -40.24 113.76 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.256 0 CA-C-O 120.981 0.419 . . . . 0.0 111.802 -179.709 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 2.3 ttt180 -132.3 110.26 10.47 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.117 179.462 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 120' ' ' VAL . . . . . 0.726 ' H ' HD12 ' A' ' 107' ' ' LEU . 85.1 t -43.6 118.12 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.688 -179.451 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 118.5 28.13 2.21 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.845 -0.693 . . . . 0.0 112.932 179.73 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 122' ' ' HIS . . . . . 0.505 ' CE1' HD13 ' A' ' 104' ' ' ILE . 20.2 p-80 -137.3 -170.29 2.7 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.619 0.247 . . . . 0.0 111.07 179.752 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 123' ' ' ARG . . . . . 0.541 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 55.6 ttp85 -133.92 114.39 13.23 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-N 116.574 -0.285 . . . . 0.0 111.711 -179.555 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 124' ' ' ILE . . . . . 0.653 ' HA ' HG22 ' A' ' 155' ' ' THR . 34.7 mt -73.16 158.58 6.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 178.59 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 125' ' ' ILE . . . . . 0.573 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.8 OUTLIER -147.14 -83.02 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 N-CA-C 112.867 0.691 . . . . 0.0 112.867 -179.624 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 126' ' ' GLU . . . . . 0.47 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 5.4 mt-10 -87.41 87.7 7.48 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 112.44 0.533 . . . . 0.0 112.44 -178.477 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.855 HG23 ' HB3' ' A' ' 153' ' ' MET . 2.4 mt -87.06 103.83 13.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.29 179.197 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 7.5 m-20 53.01 25.32 3.96 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.905 -0.588 . . . . 0.0 111.193 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 110.08 -13.57 31.45 Favored Glycine 0 CA--C 1.519 0.3 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.846 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 11.6 tt0 -95.72 110.88 22.95 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.787 0.327 . . . . 0.0 110.772 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 131' ' ' SER . . . . . 0.415 ' HA ' ' O ' ' A' ' 125' ' ' ILE . 1.1 m -74.84 87.24 2.25 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.042 -179.901 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 132' ' ' VAL . . . . . 0.696 HG21 HD11 ' A' ' 127' ' ' ILE . 31.9 m -73.9 -5.3 6.53 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.369 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.956 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.573 ' HB ' HG22 ' A' ' 125' ' ' ILE . 9.8 p -46.31 -31.56 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-O 120.888 0.375 . . . . 0.0 111.566 -179.695 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -127.95 27.41 5.7 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.617 179.409 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 135' ' ' THR . . . . . 0.434 ' CG2' ' HD2' ' A' ' 136' ' ' PRO . 32.5 m -110.65 143.79 28.93 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 115.833 -0.621 . . . . 0.0 111.214 -179.736 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 136' ' ' PRO . . . . . 0.434 ' HD2' ' CG2' ' A' ' 135' ' ' THR . 50.5 Cg_exo -53.78 164.27 2.45 Favored 'Trans proline' 0 C--N 1.347 0.495 0 C-N-CA 122.545 2.163 . . . . 0.0 112.048 179.512 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 137' ' ' HIS . . . . . 0.615 ' HA ' HD12 ' A' ' 140' ' ' ILE . 33.8 p-80 -72.6 -46.83 52.27 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.517 -179.607 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 138' ' ' GLU . . . . . 0.405 ' N ' ' CG ' ' A' ' 137' ' ' HIS . 1.7 mm-40 -54.01 -39.13 65.85 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.472 -179.513 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 139' ' ' LYS . . . . . 0.785 ' O ' HD12 ' A' ' 143' ' ' ILE . 7.0 tttp -63.53 -45.97 88.18 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.225 -179.701 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 140' ' ' ILE . . . . . 0.83 HG21 HG21 ' A' ' 99' ' ' VAL . 9.7 mt -59.36 -46.08 92.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.983 0.421 . . . . 0.0 110.431 179.956 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 141' ' ' VAL . . . . . 0.483 HG23 ' CG1' ' A' ' 99' ' ' VAL . 55.4 t -60.08 -32.37 50.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.039 179.034 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 14.2 t-80 -61.08 -53.68 54.06 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.679 179.579 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 143' ' ' ILE . . . . . 0.785 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.3 mp -53.16 -56.9 5.98 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.379 0 CA-C-O 121.276 0.56 . . . . 0.0 110.263 179.209 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.8 ' HB3' HD11 ' A' ' 95' ' ' LEU . 3.9 mt -61.24 -30.32 70.38 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.254 -0.884 . . . . 0.0 110.275 179.453 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 30.9 t -69.31 -26.38 64.69 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.123 -0.489 . . . . 0.0 109.925 178.676 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 8.5 m120 -127.43 32.2 5.06 Favored 'General case' 0 C--O 1.231 0.099 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.985 179.697 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 147' ' ' ALA . . . . . 0.795 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -114.03 41.62 2.21 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.352 -0.386 . . . . 0.0 111.296 -179.966 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 18.5 m -51.72 138.76 8.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.447 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 120.88 -103.46 0.9 Allowed Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.442 -179.914 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 4.7 mt-10 -139.28 100.65 4.06 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.79 0.328 . . . . 0.0 110.877 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 151' ' ' ILE . . . . . 0.795 HD11 ' HB3' ' A' ' 147' ' ' ALA . 1.3 mt -78.86 111.78 16.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.942 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -106.97 115.55 30.37 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.141 179.325 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 153' ' ' MET . . . . . 0.855 ' HB3' HG23 ' A' ' 127' ' ' ILE . 1.7 ptm -136.64 161.98 34.43 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.071 0.463 . . . . 0.0 111.729 -179.318 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 154' ' ' LYS . . . . . 0.551 ' HB3' HD11 ' A' ' 125' ' ' ILE . 3.5 mttt -104.53 150.3 24.73 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.712 -0.676 . . . . 0.0 109.778 179.121 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 155' ' ' THR . . . . . 0.653 HG22 ' HA ' ' A' ' 124' ' ' ILE . 21.8 p -146.14 150.44 35.89 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.295 0.569 . . . . 0.0 112.076 -179.086 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 156' ' ' MET . . . . . 0.644 ' CE ' HG13 ' A' ' 81' ' ' VAL . 0.0 OUTLIER -144.76 145.33 27.58 Favored Pre-proline 0 C--N 1.327 -0.406 0 CA-C-N 115.226 -0.897 . . . . 0.0 110.346 179.102 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_exo -50.92 109.38 0.3 Allowed 'Trans proline' 0 C--N 1.343 0.263 0 C-N-CA 122.512 2.141 . . . . 0.0 112.628 -179.759 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 158' ' ' ALA . . . . . 0.823 ' HB2' HD12 ' A' ' 103' ' ' ILE . . . . . . . . 0 C--O 1.25 1.084 0 CA-C-O 118.266 -0.873 . . . . 0.0 111.343 179.863 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 18.3 t . . . . . 0 C--O 1.232 0.179 0 CA-C-O 120.802 0.334 . . . . 0.0 111.104 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.1 m -114.42 132.14 56.35 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.926 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 83' ' ' THR . . . . . 0.545 HG23 ' HE2' ' A' ' 154' ' ' LYS . 56.5 m -95.58 111.19 23.16 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.947 179.119 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.794 HG22 ' N ' ' A' ' 118' ' ' VAL . 86.3 t -88.39 105.38 15.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.58 -179.206 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.457 ' O ' ' HA2' ' A' ' 116' ' ' GLY . 2.7 tp -100.01 84.27 2.84 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 178.588 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.748 HG13 HG12 ' A' ' 84' ' ' VAL . 22.0 mt -81.27 127.31 39.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-O 121.4 0.619 . . . . 0.0 111.928 -178.501 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.803 ' O ' HG21 ' A' ' 112' ' ' ILE . 0.0 OUTLIER -74.49 153.34 39.16 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.136 -0.938 . . . . 0.0 110.407 179.856 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.471 ' HD2' HD21 ' A' ' 95' ' ' LEU . 5.5 ttt-85 -152.15 91.71 3.62 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 120.682 0.277 . . . . 0.0 111.161 -179.931 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -58.53 -63.48 0.14 Allowed 'Trans proline' 0 C--N 1.345 0.346 0 C-N-CA 122.583 2.189 . . . . 0.0 112.23 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 4.9 t0 -117.14 -173.68 2.45 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.169 -179.859 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 0.847 HD12 HG11 ' A' ' 148' ' ' VAL . 0.1 OUTLIER -91.79 -21.95 20.41 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.311 -179.864 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -95.76 22.7 6.97 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.469 -0.332 . . . . 0.0 111.219 -179.779 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 17.7 m-85 -121.04 117.97 28.59 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.801 0.334 . . . . 0.0 110.835 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 3.4 mp0 -64.57 177.93 0.83 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.874 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 0.83 ' CD1' HD13 ' A' ' 144' ' ' LEU . 42.5 mt -96.98 -61.35 1.42 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.932 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 132.05 53.91 0.09 OUTLIER Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.718 179.912 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 97' ' ' PHE . . . . . 0.514 ' HZ ' HD12 ' A' ' 144' ' ' LEU . 0.2 OUTLIER -176.68 -171.96 0.41 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.904 0.383 . . . . 0.0 110.991 179.9 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 8.3 t -137.44 130.35 30.36 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.793 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 1.058 HG21 HG21 ' A' ' 140' ' ' ILE . 10.4 p -109.97 114.35 46.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.06 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 100' ' ' GLN . . . . . 0.421 ' O ' ' N ' ' A' ' 102' ' ' GLY . 1.2 tt0 -110.31 89.0 2.9 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.817 0.341 . . . . 0.0 110.908 -180.0 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 101' ' ' ASN . . . . . 0.717 ' O ' HD11 ' A' ' 140' ' ' ILE . 1.6 t30 65.18 -64.64 0.17 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.51 179.702 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 102' ' ' GLY . . . . . 0.421 ' N ' ' O ' ' A' ' 100' ' ' GLN . . . -146.88 -4.49 0.42 Allowed Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.336 -0.935 . . . . 0.0 113.661 -179.623 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.727 HD12 ' CB ' ' A' ' 158' ' ' ALA . 31.5 mm -125.09 142.64 41.35 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 117.389 0.594 . . . . 0.0 111.307 -179.543 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.678 HD11 HG13 ' A' ' 124' ' ' ILE . 3.9 mp -84.44 142.58 13.16 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.788 179.712 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -105.42 -77.73 0.58 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.991 -179.829 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 62.6 p -90.64 146.98 23.6 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.944 0.402 . . . . 0.0 110.9 -179.973 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.728 ' HB2' HG22 ' A' ' 120' ' ' VAL . 0.2 OUTLIER -136.72 123.92 21.77 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.883 179.993 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 4.1 mtt -77.06 120.37 22.05 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.882 -179.949 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -81.33 105.59 12.63 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.765 179.893 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 101.66 26.63 7.52 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.394 -179.917 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 111' ' ' GLY . . . . . 0.5 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -111.76 -158.25 14.53 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.701 -0.762 . . . . 0.0 113.209 -179.761 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.803 HG21 ' O ' ' A' ' 87' ' ' ARG . 16.3 mt -80.16 -41.92 21.35 Favored 'Isoleucine or valine' 0 C--O 1.238 0.463 0 CA-C-O 121.076 0.465 . . . . 0.0 111.766 -179.588 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 113' ' ' ALA . . . . . 0.804 ' O ' HG12 ' A' ' 118' ' ' VAL . . . -57.7 -36.21 71.67 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.193 -179.394 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 114' ' ' GLU . . . . . 0.53 ' HG3' ' N ' ' A' ' 115' ' ' ARG . 8.3 pt-20 -66.9 -36.26 81.87 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.484 179.561 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.53 ' N ' ' HG3' ' A' ' 114' ' ' GLU . 0.0 OUTLIER -59.39 -46.55 88.35 Favored 'General case' 0 N--CA 1.452 -0.359 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.559 -179.905 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.457 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -56.05 -71.31 0.75 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.205 -0.998 . . . . 0.0 112.539 179.635 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 117' ' ' GLY . . . . . 0.481 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 174.32 -22.76 0.06 OUTLIER Glycine 0 CA--C 1.519 0.282 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.824 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.804 HG12 ' O ' ' A' ' 113' ' ' ALA . 7.3 p -31.75 145.72 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 N-CA-C 112.265 0.469 . . . . 0.0 112.265 -179.621 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.441 ' HB3' ' CD2' ' A' ' 122' ' ' HIS . 0.1 OUTLIER -147.83 134.43 19.85 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.734 179.899 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 120' ' ' VAL . . . . . 0.728 HG22 ' HB2' ' A' ' 107' ' ' LEU . 22.0 t -59.48 111.26 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.036 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 109.72 18.49 8.91 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.602 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 122' ' ' HIS . . . . . 0.566 ' O ' HG23 ' A' ' 103' ' ' ILE . 1.7 m-70 -102.22 -173.02 2.24 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.682 0.277 . . . . 0.0 110.693 179.909 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 123' ' ' ARG . . . . . 0.626 ' HD2' HD11 ' A' ' 103' ' ' ILE . 40.4 ttt180 -142.76 90.71 2.24 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.363 -0.38 . . . . 0.0 111.335 -179.647 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 124' ' ' ILE . . . . . 0.678 HG13 HD11 ' A' ' 104' ' ' ILE . 25.2 mt -51.48 157.07 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.307 179.112 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 125' ' ' ILE . . . . . 0.771 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.6 OUTLIER -149.38 -82.99 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 N-CA-C 112.576 0.584 . . . . 0.0 112.576 -179.389 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 126' ' ' GLU . . . . . 0.411 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 72.7 mt-10 -89.29 89.4 7.89 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 112.353 0.501 . . . . 0.0 112.353 -178.62 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.831 HG23 ' HB3' ' A' ' 153' ' ' MET . 2.1 mt -88.89 106.87 17.24 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.181 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.573 179.43 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 128' ' ' ASN . . . . . 0.429 ' HA ' ' CE1' ' A' ' 152' ' ' HIS . 3.1 t-20 53.45 31.69 12.64 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.899 -0.591 . . . . 0.0 111.066 179.726 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 98.23 -7.26 62.06 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.754 -179.74 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 2.9 tt0 -99.92 106.23 18.02 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.836 0.351 . . . . 0.0 110.756 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 1.6 m -71.12 84.26 0.72 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.157 -179.773 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 132' ' ' VAL . . . . . 0.706 HG11 HD12 ' A' ' 127' ' ' ILE . 34.1 m -67.73 -10.03 11.67 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.759 179.867 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.771 ' HB ' HG22 ' A' ' 125' ' ' ILE . 9.3 p -51.06 117.85 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.925 0.393 . . . . 0.0 110.961 179.969 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 134' ' ' ALA . . . . . 0.521 ' HB3' ' O ' ' A' ' 133' ' ' VAL . . . 75.1 21.2 1.98 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.754 -178.997 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 135' ' ' THR . . . . . 0.47 ' CG2' ' HD2' ' A' ' 136' ' ' PRO . 29.3 m -103.5 142.52 24.74 Favored Pre-proline 0 C--N 1.327 -0.402 0 CA-C-N 115.648 -0.706 . . . . 0.0 110.802 179.828 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 136' ' ' PRO . . . . . 0.47 ' HD2' ' CG2' ' A' ' 135' ' ' THR . 94.9 Cg_exo -42.77 164.2 0.04 OUTLIER 'Trans proline' 0 C--N 1.348 0.533 0 C-N-CA 122.849 2.366 . . . . 0.0 112.9 -179.869 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 137' ' ' HIS . . . . . 0.447 ' CE1' ' O ' ' A' ' 99' ' ' VAL . 3.1 t-160 -74.17 -59.35 2.76 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.558 -179.525 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -53.67 -27.17 26.07 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.901 -179.135 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 139' ' ' LYS . . . . . 0.762 ' O ' HD12 ' A' ' 143' ' ' ILE . 0.9 OUTLIER -67.52 -51.44 50.85 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.651 0.262 . . . . 0.0 111.172 -179.535 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 140' ' ' ILE . . . . . 1.058 HG21 HG21 ' A' ' 99' ' ' VAL . 17.4 mt -59.54 -46.35 93.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 121.026 0.441 . . . . 0.0 110.751 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 141' ' ' VAL . . . . . 0.437 HG22 HG12 ' A' ' 99' ' ' VAL . 93.5 t -60.11 -32.44 50.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.227 179.237 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -61.75 -54.88 36.48 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.971 179.723 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 143' ' ' ILE . . . . . 0.762 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.1 mp -52.88 -56.9 5.62 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.391 0 CA-C-O 121.232 0.539 . . . . 0.0 110.267 179.569 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.83 HD13 ' CD1' ' A' ' 95' ' ' LEU . 1.6 mt -61.75 -29.97 70.48 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.394 179.582 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 25.8 t -69.25 -26.56 64.84 Favored 'General case' 0 C--N 1.33 -0.242 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 178.523 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -126.91 31.61 5.26 Favored 'General case' 0 CA--C 1.53 0.181 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.093 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 147' ' ' ALA . . . . . 0.772 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -116.98 58.19 0.78 Allowed 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.356 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.847 HG11 HD12 ' A' ' 91' ' ' LEU . 3.9 m -53.28 173.7 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.346 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 149' ' ' GLY . . . . . 0.409 ' N ' ' HB3' ' A' ' 88' ' ' ARG . . . 87.9 -113.38 4.01 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.468 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 -139.76 102.84 4.53 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.835 0.35 . . . . 0.0 110.778 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 151' ' ' ILE . . . . . 0.772 HD11 ' HB3' ' A' ' 147' ' ' ALA . 1.3 mt -73.99 111.67 9.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.098 -179.905 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 152' ' ' HIS . . . . . 0.429 ' CE1' ' HA ' ' A' ' 128' ' ' ASN . 8.7 p80 -104.58 115.58 30.59 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.136 -0.484 . . . . 0.0 109.733 178.84 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 153' ' ' MET . . . . . 0.831 ' HB3' HG23 ' A' ' 127' ' ' ILE . 0.8 OUTLIER -136.72 174.66 10.37 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.193 0.52 . . . . 0.0 111.874 -178.737 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 154' ' ' LYS . . . . . 0.685 ' HB3' HD11 ' A' ' 125' ' ' ILE . 0.0 OUTLIER -118.56 151.62 37.55 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.77 179.268 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 155' ' ' THR . . . . . 0.419 HG22 ' HA ' ' A' ' 124' ' ' ILE . 44.4 p -139.65 143.22 37.07 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.027 0.441 . . . . 0.0 111.479 -179.551 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 156' ' ' MET . . . . . 0.45 ' O ' ' N ' ' A' ' 123' ' ' ARG . 0.0 OUTLIER -110.77 176.63 1.45 Allowed Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 115.538 -0.755 . . . . 0.0 110.545 179.764 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 96.3 Cg_endo -90.12 118.75 0.74 Allowed 'Trans proline' 0 N--CA 1.457 -0.619 0 C-N-CA 122.735 2.29 . . . . 0.0 112.546 -179.856 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 158' ' ' ALA . . . . . 0.727 ' CB ' HD12 ' A' ' 103' ' ' ILE . . . . . . . . 0 C--O 1.249 1.071 0 CA-C-O 118.242 -0.885 . . . . 0.0 111.019 179.781 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.4 HG23 ' O ' ' A' ' 155' ' ' THR . 9.4 p . . . . . 0 N--CA 1.456 -0.129 0 CA-C-O 120.721 0.296 . . . . 0.0 111.048 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.6 m -111.1 121.28 44.92 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.871 179.764 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 83' ' ' THR . . . . . 0.433 ' HA ' ' O ' ' A' ' 153' ' ' MET . 8.9 m -92.65 110.82 22.26 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.039 179.046 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.858 HG11 HG23 ' A' ' 118' ' ' VAL . 76.2 t -83.31 106.0 13.54 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.597 0 CA-C-N 116.298 -0.41 . . . . 0.0 112.059 -179.17 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.418 HD12 ' NE2' ' A' ' 152' ' ' HIS . 3.9 tt -102.97 81.11 1.94 Allowed 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 177.974 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.842 HG13 HG12 ' A' ' 84' ' ' VAL . 4.4 mt -81.49 123.88 38.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 121.281 0.562 . . . . 0.0 111.769 -178.328 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.565 ' HB2' HG21 ' A' ' 112' ' ' ILE . 0.1 OUTLIER -70.43 142.62 51.98 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.307 -0.86 . . . . 0.0 110.496 179.761 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.511 ' HG3' HD12 ' A' ' 151' ' ' ILE . 10.2 mtp180 -141.93 98.73 6.22 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.891 179.993 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 89' ' ' PRO . . . . . 0.447 ' HG2' ' CG ' ' A' ' 93' ' ' TYR . 64.1 Cg_endo -73.61 -41.62 1.09 Allowed 'Trans proline' 0 C--N 1.346 0.403 0 C-N-CA 122.552 2.168 . . . . 0.0 112.561 -179.877 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -137.05 -168.09 2.22 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.149 -179.824 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 0.607 ' HG ' HG11 ' A' ' 148' ' ' VAL . 3.9 mt -95.08 -22.74 17.69 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.204 -179.861 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 4.5 ptt-85 -96.23 22.84 7.2 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.144 -179.834 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 93' ' ' TYR . . . . . 0.447 ' CG ' ' HG2' ' A' ' 89' ' ' PRO . 12.9 m-85 -106.05 96.63 6.61 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.922 0.391 . . . . 0.0 110.894 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 1.3 pp0? -50.58 159.21 0.54 Allowed 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.276 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 0.83 HD23 HD13 ' A' ' 86' ' ' ILE . 2.1 mp -88.05 -66.8 0.88 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.861 179.872 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 130.49 37.77 0.32 Allowed Glycine 0 CA--C 1.519 0.29 0 C-N-CA 120.562 -0.828 . . . . 0.0 112.885 179.661 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 97' ' ' PHE . . . . . 0.439 ' CD1' ' HB2' ' A' ' 113' ' ' ALA . 50.2 p90 -176.93 178.06 1.21 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.707 0.289 . . . . 0.0 110.936 179.775 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.6 t -128.36 146.1 50.88 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.97 0.414 . . . . 0.0 111.06 -179.787 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 1.086 HG21 HG21 ' A' ' 140' ' ' ILE . 5.5 p -113.09 124.33 69.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.832 179.9 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 100' ' ' GLN . . . . . 0.423 HE21 ' HB2' ' A' ' 100' ' ' GLN . 0.0 OUTLIER -115.55 88.77 2.95 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.803 179.766 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 101' ' ' ASN . . . . . 0.65 ' O ' HD11 ' A' ' 140' ' ' ILE . 1.2 m-80 64.94 -67.16 0.12 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.87 -0.605 . . . . 0.0 111.424 179.685 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 102' ' ' GLY . . . . . 0.423 ' O ' ' HA ' ' A' ' 123' ' ' ARG . . . -144.52 -3.7 0.7 Allowed Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.29 -0.957 . . . . 0.0 113.41 -179.629 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.653 HD12 ' HB2' ' A' ' 158' ' ' ALA . 39.2 mm -122.99 148.57 26.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 117.315 0.557 . . . . 0.0 111.406 -179.574 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.638 HD11 ' CD1' ' A' ' 124' ' ' ILE . 2.8 mp -85.08 141.91 13.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.507 179.594 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 94.1 m -97.81 -80.11 0.45 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.125 -179.677 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 1.4 m -109.13 145.63 35.41 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.981 -179.872 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.874 HD12 HG12 ' A' ' 118' ' ' VAL . 1.2 tt -143.2 113.2 7.14 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.808 179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -74.83 142.55 44.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.719 179.852 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.87 47.52 1.42 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.974 0.416 . . . . 0.0 110.808 -179.904 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -161.35 25.83 0.26 Allowed Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.39 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 111' ' ' GLY . . . . . 0.454 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -121.05 -174.63 14.98 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.331 179.867 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.565 HG21 ' HB2' ' A' ' 87' ' ' ARG . 1.2 mp -78.92 -22.56 12.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 120.785 0.326 . . . . 0.0 111.463 -179.876 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 113' ' ' ALA . . . . . 0.439 ' HB2' ' CD1' ' A' ' 97' ' ' PHE . . . -58.2 -30.57 66.56 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.894 0.378 . . . . 0.0 110.723 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 114' ' ' GLU . . . . . 0.454 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 12.4 pt-20 -61.26 -46.42 90.42 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.796 179.734 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 3.5 mtp85 -63.38 -44.13 95.62 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.908 -179.617 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -53.73 -73.97 0.35 Allowed Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.386 -0.911 . . . . 0.0 112.504 179.885 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 117' ' ' GLY . . . . . 0.564 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 174.98 -27.01 0.08 OUTLIER Glycine 0 CA--C 1.519 0.331 0 C-N-CA 120.922 -0.656 . . . . 0.0 112.65 -179.824 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.874 HG12 HD12 ' A' ' 107' ' ' LEU . 94.3 t -31.87 116.56 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 CA-C-O 121.026 0.441 . . . . 0.0 111.709 -179.82 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 11.7 mtt-85 -128.62 112.64 14.49 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.294 179.583 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 120' ' ' VAL . . . . . 0.567 HG22 ' HB2' ' A' ' 107' ' ' LEU . 32.2 t -46.99 108.42 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.239 -179.768 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 120.36 16.28 4.76 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 121.009 -0.615 . . . . 0.0 112.54 -179.721 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 122' ' ' HIS . . . . . 0.464 ' O ' HG23 ' A' ' 103' ' ' ILE . 3.9 m170 -110.35 -172.39 2.03 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.597 0.237 . . . . 0.0 110.562 179.923 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 123' ' ' ARG . . . . . 0.74 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 4.1 ttt180 -139.88 92.87 2.59 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.682 0.277 . . . . 0.0 111.418 -179.657 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 124' ' ' ILE . . . . . 0.638 ' CD1' HD11 ' A' ' 104' ' ' ILE . 7.2 mt -52.76 147.65 1.91 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.077 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 125' ' ' ILE . . . . . 0.905 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.6 OUTLIER -141.42 -84.79 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 N-CA-C 112.393 0.516 . . . . 0.0 112.393 -179.335 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 8.5 mm-40 -86.39 90.06 8.08 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 112.316 0.488 . . . . 0.0 112.316 -178.719 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.889 HG23 ' HB3' ' A' ' 153' ' ' MET . 2.3 mt -85.45 105.72 14.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 121.24 0.543 . . . . 0.0 111.473 179.307 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 128' ' ' ASN . . . . . 0.44 ' N ' ' O ' ' A' ' 152' ' ' HIS . 0.6 OUTLIER 56.61 20.81 5.23 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.694 -0.684 . . . . 0.0 111.512 179.667 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 115.14 -12.8 19.54 Favored Glycine 0 C--N 1.331 0.301 0 C-N-CA 120.519 -0.848 . . . . 0.0 113.434 179.665 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 1.1 pt20 -103.17 117.54 34.78 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-O 120.958 0.408 . . . . 0.0 110.834 179.957 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 95.9 p -74.85 85.8 2.22 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.31 -179.643 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 132' ' ' VAL . . . . . 0.596 HG11 HD12 ' A' ' 127' ' ' ILE . 33.8 m -66.61 -10.89 12.39 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.315 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.535 179.537 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.905 ' HB ' HG22 ' A' ' 125' ' ' ILE . 8.9 p -49.69 117.73 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 120.915 0.388 . . . . 0.0 110.964 -179.952 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 134' ' ' ALA . . . . . 0.529 ' HB3' ' O ' ' A' ' 133' ' ' VAL . . . 76.15 20.77 1.58 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.789 -179.141 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 135' ' ' THR . . . . . 0.471 HG23 ' HD2' ' A' ' 136' ' ' PRO . 36.9 m -104.21 143.21 26.2 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.691 179.637 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 136' ' ' PRO . . . . . 0.471 ' HD2' HG23 ' A' ' 135' ' ' THR . 1.9 Cg_endo -41.51 141.19 1.47 Allowed 'Trans proline' 0 C--N 1.347 0.499 0 C-N-CA 123.113 2.542 . . . . 0.0 112.631 179.898 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 38.0 p-80 -63.95 -48.49 76.3 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.024 -0.534 . . . . 0.0 111.464 -179.62 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -54.73 -36.58 64.92 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.301 -179.625 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 139' ' ' LYS . . . . . 0.808 ' O ' HD12 ' A' ' 143' ' ' ILE . 19.2 tttm -63.34 -48.81 76.41 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.83 -179.933 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 140' ' ' ILE . . . . . 1.086 HG21 HG21 ' A' ' 99' ' ' VAL . 21.6 mt -58.47 -46.12 89.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.722 -179.861 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 141' ' ' VAL . . . . . 0.485 HG22 HG12 ' A' ' 99' ' ' VAL . 99.3 t -59.34 -32.5 48.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.014 178.869 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 1.7 t60 -61.78 -52.01 65.96 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.71 179.628 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 143' ' ' ILE . . . . . 0.808 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.3 mp -53.19 -57.23 5.14 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.414 0 CA-C-O 121.024 0.44 . . . . 0.0 110.222 179.416 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.749 HD13 ' CD2' ' A' ' 95' ' ' LEU . 3.4 mt -60.53 -30.15 69.57 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.562 -0.745 . . . . 0.0 110.23 179.574 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 1.1 m -69.33 -26.91 64.94 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-N 116.062 -0.517 . . . . 0.0 109.895 178.557 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 3.6 m-80 -129.82 34.61 4.27 Favored 'General case' 0 CA--C 1.528 0.114 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.216 179.837 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 147' ' ' ALA . . . . . 0.586 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -116.82 56.39 0.8 Allowed 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.835 0.35 . . . . 0.0 111.325 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.607 HG11 ' HG ' ' A' ' 91' ' ' LEU . 27.7 m -54.21 -177.96 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.403 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 81.67 -100.96 2.11 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.552 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 13.0 mt-10 -152.9 98.2 2.29 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.813 0.34 . . . . 0.0 110.707 -179.898 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 151' ' ' ILE . . . . . 0.586 HD11 ' HB3' ' A' ' 147' ' ' ALA . 1.2 mt -63.09 111.56 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.185 -179.718 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 152' ' ' HIS . . . . . 0.44 ' O ' ' N ' ' A' ' 128' ' ' ASN . 1.5 t-160 -107.1 115.64 30.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.983 -0.553 . . . . 0.0 109.805 179.121 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 153' ' ' MET . . . . . 0.889 ' HB3' HG23 ' A' ' 127' ' ' ILE . 1.0 OUTLIER -141.96 176.17 9.15 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.041 0.448 . . . . 0.0 111.82 -178.893 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 53.1 mttt -124.23 148.9 46.99 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.064 179.401 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 155' ' ' THR . . . . . 0.4 ' O ' HG23 ' A' ' 81' ' ' VAL . 20.0 p -137.1 132.17 33.7 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.942 0.401 . . . . 0.0 111.466 -179.57 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 156' ' ' MET . . . . . 0.476 ' O ' ' N ' ' A' ' 123' ' ' ARG . 0.0 OUTLIER -104.78 154.43 38.58 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.266 179.51 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 17.1 Cg_exo -66.77 118.78 5.82 Favored 'Trans proline' 0 C--N 1.342 0.228 0 C-N-CA 122.359 2.04 . . . . 0.0 112.136 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 158' ' ' ALA . . . . . 0.74 ' HB2' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.249 1.058 0 CA-C-O 118.262 -0.875 . . . . 0.0 111.107 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.589 HG13 ' O ' ' A' ' 155' ' ' THR . 41.7 t . . . . . 0 N--CA 1.457 -0.084 0 CA-C-O 120.781 0.324 . . . . 0.0 111.094 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.5 m -117.09 143.4 45.83 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.913 179.854 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 17.7 m -105.67 111.56 24.3 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.247 179.279 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.74 HG11 HG23 ' A' ' 118' ' ' VAL . 43.4 t -82.34 105.94 12.73 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.552 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.78 -179.359 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.49 HD23 ' C ' ' A' ' 85' ' ' LEU . 6.3 tt -108.14 82.3 1.61 Allowed 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 109.122 -0.696 . . . . 0.0 109.122 178.574 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.992 HG21 HD22 ' A' ' 95' ' ' LEU . 5.1 mt -81.36 145.21 9.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.009 -0.541 . . . . 0.0 111.807 -178.165 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.418 ' HG2' ' CG2' ' A' ' 112' ' ' ILE . 0.1 OUTLIER -97.71 114.71 26.75 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.518 -179.831 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.472 ' HD2' HD12 ' A' ' 151' ' ' ILE . 2.3 ttt-85 -112.26 103.09 55.15 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.136 -179.714 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 89' ' ' PRO . . . . . 0.429 ' HB2' ' CD2' ' A' ' 93' ' ' TYR . 34.8 Cg_exo -57.63 -53.6 4.37 Favored 'Trans proline' 0 C--N 1.347 0.475 0 C-N-CA 122.498 2.132 . . . . 0.0 112.369 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -140.41 -167.07 2.25 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.986 -179.921 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 0.423 ' HG ' HG11 ' A' ' 148' ' ' VAL . 8.2 mt -84.01 -20.1 33.37 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.313 -179.868 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -96.41 23.33 6.86 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.095 -179.808 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 93' ' ' TYR . . . . . 0.429 ' CD2' ' HB2' ' A' ' 89' ' ' PRO . 15.9 m-85 -115.04 122.04 44.96 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.951 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -79.58 162.11 25.53 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.818 -179.979 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 0.992 HD22 HG21 ' A' ' 86' ' ' ILE . 53.9 mt -89.5 -69.94 0.69 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.837 179.964 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.407 ' O ' HD12 ' A' ' 107' ' ' LEU . . . 138.54 43.66 0.08 OUTLIER Glycine 0 CA--C 1.518 0.234 0 C-N-CA 120.42 -0.895 . . . . 0.0 113.011 179.724 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 35.4 p90 -176.74 161.97 2.12 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.849 0.357 . . . . 0.0 111.07 179.65 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -115.63 139.16 50.37 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.761 179.876 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.785 HG21 HG21 ' A' ' 140' ' ' ILE . 12.3 p -109.88 131.7 60.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.487 -179.818 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 100' ' ' GLN . . . . . 0.412 ' O ' ' N ' ' A' ' 102' ' ' GLY . 10.0 mt-30 -122.58 88.57 2.95 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.13 179.224 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 101' ' ' ASN . . . . . 0.649 ' O ' HD11 ' A' ' 140' ' ' ILE . 2.0 m120 63.89 -73.94 0.05 OUTLIER 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.971 -179.725 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 102' ' ' GLY . . . . . 0.526 ' O ' HD13 ' A' ' 103' ' ' ILE . . . -137.82 0.67 2.74 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.299 -0.953 . . . . 0.0 113.05 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.813 HD12 ' HB2' ' A' ' 158' ' ' ALA . 38.1 mm -124.17 151.88 29.51 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.127 0 CA-C-O 121.014 0.435 . . . . 0.0 111.435 -179.617 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.765 HD11 HG13 ' A' ' 124' ' ' ILE . 3.2 mp -93.32 152.15 3.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.739 179.858 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 96.3 m -105.59 -67.54 0.92 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.107 -179.8 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 78.8 p -123.98 154.24 40.1 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.387 -0.369 . . . . 0.0 111.167 -179.853 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.407 HD12 ' O ' ' A' ' 96' ' ' GLY . 27.1 tp -139.55 103.42 4.69 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.619 179.861 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 6.8 ttm -60.89 110.91 1.46 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.006 -179.861 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 2.2 tmt_? -68.7 72.21 0.23 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.768 179.747 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 174.34 -34.12 0.11 Allowed Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.973 -0.632 . . . . 0.0 112.149 -179.853 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 111' ' ' GLY . . . . . 0.402 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -60.0 -176.73 1.31 Allowed Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.21 179.697 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.482 ' H ' HD12 ' A' ' 112' ' ' ILE . 0.8 OUTLIER -78.7 -17.09 13.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-O 120.822 0.344 . . . . 0.0 111.625 -179.89 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 113' ' ' ALA . . . . . 0.446 ' HA ' HG12 ' A' ' 86' ' ' ILE . . . -58.08 -30.46 66.25 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.937 0.398 . . . . 0.0 110.827 179.961 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 114' ' ' GLU . . . . . 0.402 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 14.5 pt-20 -61.56 -46.84 88.21 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.74 179.687 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 27.9 mtm-85 -62.1 -44.59 96.33 Favored 'General case' 0 N--CA 1.451 -0.406 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.082 -179.64 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.415 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -52.92 -73.75 0.37 Allowed Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.36 -0.924 . . . . 0.0 112.536 179.975 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 117' ' ' GLY . . . . . 0.567 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 167.33 -19.31 0.09 OUTLIER Glycine 0 CA--C 1.52 0.377 0 C-N-CA 121.0 -0.619 . . . . 0.0 112.75 -179.702 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.74 HG23 HG11 ' A' ' 84' ' ' VAL . 0.9 OUTLIER -38.5 129.47 0.36 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.244 0 CA-C-O 121.007 0.432 . . . . 0.0 111.607 -179.862 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -127.63 101.94 6.62 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.603 179.752 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 120' ' ' VAL . . . . . 0.513 ' O ' HG13 ' A' ' 120' ' ' VAL . 12.5 p -49.86 117.81 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.013 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 115.91 -14.56 16.77 Favored Glycine 0 CA--C 1.518 0.228 0 C-N-CA 120.854 -0.689 . . . . 0.0 112.333 -179.488 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -84.65 -165.6 1.23 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.64 0.257 . . . . 0.0 110.54 179.872 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 123' ' ' ARG . . . . . 0.595 ' HA ' HD13 ' A' ' 103' ' ' ILE . 51.6 ttt85 -130.39 102.2 6.07 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.881 0.372 . . . . 0.0 111.445 -179.718 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 124' ' ' ILE . . . . . 0.842 ' HA ' HG22 ' A' ' 155' ' ' THR . 9.1 mt -60.63 157.95 2.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.092 178.86 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 125' ' ' ILE . . . . . 0.839 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.7 OUTLIER -154.79 -85.04 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 N-CA-C 113.086 0.773 . . . . 0.0 113.086 -179.708 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 126' ' ' GLU . . . . . 0.401 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 3.3 mt-10 -84.28 91.21 7.7 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 112.932 0.716 . . . . 0.0 112.932 -178.117 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.875 HD11 HG21 ' A' ' 132' ' ' VAL . 1.7 mt -90.88 98.79 8.76 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.146 0 CA-C-N 116.374 -0.376 . . . . 0.0 110.878 178.628 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 128' ' ' ASN . . . . . 0.422 ' N ' ' O ' ' A' ' 152' ' ' HIS . 45.8 m-20 60.84 26.13 16.0 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.703 -179.848 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 106.98 -16.14 39.55 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.556 -179.841 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -92.35 108.17 19.76 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.909 0.385 . . . . 0.0 110.715 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 27.4 m -74.59 90.9 2.28 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.125 -179.772 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 132' ' ' VAL . . . . . 0.875 HG21 HD11 ' A' ' 127' ' ' ILE . 35.0 m -81.62 4.39 2.02 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.341 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.967 179.904 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.839 ' HB ' HG22 ' A' ' 125' ' ' ILE . 9.8 p -47.81 -32.42 3.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 120.914 0.388 . . . . 0.0 111.253 -179.857 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -124.68 27.69 6.78 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.601 179.313 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 135' ' ' THR . . . . . 0.523 HG23 ' HD2' ' A' ' 136' ' ' PRO . 90.6 m -109.5 143.69 28.31 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.982 -179.841 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 136' ' ' PRO . . . . . 0.523 ' HD2' HG23 ' A' ' 135' ' ' THR . 80.3 Cg_exo -48.27 164.16 0.21 Allowed 'Trans proline' 0 C--N 1.349 0.565 0 C-N-CA 122.496 2.13 . . . . 0.0 112.483 179.909 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 137' ' ' HIS . . . . . 0.557 ' HA ' HD12 ' A' ' 140' ' ' ILE . 57.1 p-80 -76.23 -48.45 20.29 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.492 -179.606 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -55.53 -34.66 64.87 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.939 0.4 . . . . 0.0 111.197 -179.636 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 139' ' ' LYS . . . . . 0.791 ' O ' HD12 ' A' ' 143' ' ' ILE . 0.8 OUTLIER -64.43 -47.47 78.98 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.021 -179.831 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 140' ' ' ILE . . . . . 0.785 HG21 HG21 ' A' ' 99' ' ' VAL . 8.7 mt -59.18 -46.5 92.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 121.155 0.503 . . . . 0.0 110.553 -179.868 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 141' ' ' VAL . . . . . 0.486 HG23 ' CG1' ' A' ' 99' ' ' VAL . 54.1 t -59.68 -32.45 49.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.057 179.013 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 1.4 t-80 -61.58 -53.44 56.31 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.909 179.738 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 143' ' ' ILE . . . . . 0.791 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.2 mp -53.06 -56.95 5.62 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.468 0 CA-C-O 121.203 0.525 . . . . 0.0 110.455 179.494 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.651 HD22 HG12 ' A' ' 151' ' ' ILE . 1.6 mt -63.3 -29.82 71.07 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.414 -0.812 . . . . 0.0 110.455 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 4.0 m -69.66 -28.47 65.9 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 178.773 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 9.0 m120 -129.67 35.42 4.19 Favored 'General case' 0 CA--C 1.528 0.128 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.227 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 147' ' ' ALA . . . . . 0.949 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -101.05 -33.27 10.22 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.945 0.402 . . . . 0.0 111.28 -179.917 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.438 HG22 ' O ' ' A' ' 147' ' ' ALA . 35.5 m 44.44 -173.63 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.527 -0.76 . . . . 0.0 111.849 -179.877 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 50.78 -148.67 7.42 Favored Glycine 0 C--N 1.332 0.341 0 C-N-CA 120.854 -0.689 . . . . 0.0 112.772 -179.963 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.443 ' HB3' HD21 ' A' ' 85' ' ' LEU . 7.9 mt-10 -89.41 105.33 17.73 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.72 0.295 . . . . 0.0 110.845 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 151' ' ' ILE . . . . . 0.949 HD11 ' HB3' ' A' ' 147' ' ' ALA . 0.6 OUTLIER -78.25 111.58 15.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.387 -0.37 . . . . 0.0 111.12 -179.917 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 152' ' ' HIS . . . . . 0.422 ' O ' ' N ' ' A' ' 128' ' ' ASN . 0.0 OUTLIER -93.29 124.79 37.51 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 178.889 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 153' ' ' MET . . . . . 0.745 ' HG3' HG23 ' A' ' 127' ' ' ILE . 5.2 tmm? -147.92 151.89 36.62 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.873 0.368 . . . . 0.0 111.79 -178.721 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 154' ' ' LYS . . . . . 0.401 ' HG2' HG11 ' A' ' 81' ' ' VAL . 0.0 OUTLIER -111.86 148.14 34.27 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.476 179.644 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 155' ' ' THR . . . . . 0.842 HG22 ' HA ' ' A' ' 124' ' ' ILE . 37.6 p -145.23 151.32 38.21 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.086 0.47 . . . . 0.0 111.702 -179.755 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 156' ' ' MET . . . . . 0.435 ' O ' ' N ' ' A' ' 123' ' ' ARG . 5.0 ptp -139.43 156.3 71.65 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.295 179.061 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 12.7 Cg_endo -56.43 120.44 8.31 Favored 'Trans proline' 0 C--N 1.342 0.229 0 C-N-CA 122.5 2.133 . . . . 0.0 112.609 -179.714 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 158' ' ' ALA . . . . . 0.813 ' HB2' HD12 ' A' ' 103' ' ' ILE . . . . . . . . 0 C--O 1.249 1.051 0 CA-C-O 118.308 -0.853 . . . . 0.0 110.995 179.845 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.703 HG23 ' O ' ' A' ' 155' ' ' THR . 11.6 p . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.72 0.295 . . . . 0.0 110.969 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 1.4 m -82.2 146.03 29.75 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.87 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 8.8 m -108.3 111.16 22.96 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.188 179.13 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.652 HG12 ' CD1' ' A' ' 86' ' ' ILE . 49.9 t -90.29 106.13 16.97 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.448 0 CA-C-N 116.024 -0.534 . . . . 0.0 111.078 -179.708 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.409 ' O ' ' HA2' ' A' ' 116' ' ' GLY . 0.9 OUTLIER -107.01 81.55 1.56 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.02 179.134 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.652 ' CD1' HG12 ' A' ' 84' ' ' VAL . 1.7 mp -81.59 149.09 4.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 121.067 0.46 . . . . 0.0 111.047 -179.235 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.452 ' CB ' HG21 ' A' ' 112' ' ' ILE . 0.3 OUTLIER -109.43 108.8 19.45 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.761 -179.354 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -102.82 104.75 41.12 Favored Pre-proline 0 C--N 1.33 -0.257 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.812 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 89' ' ' PRO . . . . . 0.445 ' HG2' ' CG ' ' A' ' 93' ' ' TYR . 37.9 Cg_endo -66.46 -49.21 1.88 Allowed 'Trans proline' 0 C--N 1.347 0.479 0 C-N-CA 122.341 2.027 . . . . 0.0 112.546 -179.814 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -136.2 178.95 6.66 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.157 -179.86 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 25.5 mt -77.64 -19.89 54.74 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.194 -179.897 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 2.9 ptt180 -96.85 23.26 7.29 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.48 -0.327 . . . . 0.0 111.158 -179.895 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 93' ' ' TYR . . . . . 0.445 ' CG ' ' HG2' ' A' ' 89' ' ' PRO . 16.8 m-85 -120.15 92.3 3.74 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.942 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -59.49 165.92 2.63 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.049 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 0.542 ' HG ' HG21 ' A' ' 86' ' ' ILE . 2.4 mp -82.63 -37.46 24.91 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.709 179.836 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 96.11 50.85 1.84 Allowed Glycine 0 C--N 1.33 0.229 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.84 179.653 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 1.3 p90 -160.58 -172.92 3.72 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.905 0.383 . . . . 0.0 111.077 179.873 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.428 ' O ' ' HA ' ' A' ' 104' ' ' ILE . 6.4 t -135.71 128.64 31.34 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.458 179.757 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.431 ' CG1' HG23 ' A' ' 141' ' ' VAL . 9.9 p -109.79 131.59 60.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.918 0.389 . . . . 0.0 111.675 -179.525 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 13.0 mt-30 -123.33 88.32 2.9 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.908 -0.587 . . . . 0.0 109.527 178.842 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 4.6 m120 56.59 18.97 3.9 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.932 -178.961 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 128.68 -41.43 1.57 Allowed Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.854 -0.688 . . . . 0.0 112.572 179.835 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.53 HG12 ' CB ' ' A' ' 158' ' ' ALA . 21.0 mt -77.42 133.38 30.8 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-O 121.061 0.457 . . . . 0.0 111.678 -179.361 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.885 HD11 ' CD1' ' A' ' 124' ' ' ILE . 4.5 mp -93.14 137.57 22.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.609 179.487 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 53.5 t -108.89 -75.39 0.63 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.094 -179.576 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 2.7 m -90.6 124.3 34.93 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.052 -179.826 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.612 HD11 ' CG1' ' A' ' 118' ' ' VAL . 1.1 tt -130.91 110.06 11.0 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.646 179.857 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -64.63 150.12 47.62 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.786 -179.905 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -91.96 45.53 1.22 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.164 0.507 . . . . 0.0 110.619 179.79 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -153.2 -33.81 0.03 OUTLIER Glycine 0 N--CA 1.45 -0.419 0 CA-C-N 115.617 -0.72 . . . . 0.0 112.283 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 111' ' ' GLY . . . . . 0.438 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -49.39 166.53 0.31 Allowed Glycine 0 C--N 1.333 0.411 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.431 179.812 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.455 ' H ' HD12 ' A' ' 112' ' ' ILE . 0.8 OUTLIER -78.86 -19.44 13.04 Favored 'Isoleucine or valine' 0 C--O 1.237 0.404 0 CA-C-O 120.822 0.344 . . . . 0.0 111.835 -179.652 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 113' ' ' ALA . . . . . 0.613 ' O ' HG12 ' A' ' 118' ' ' VAL . . . -58.12 -30.38 66.26 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.939 0.399 . . . . 0.0 110.529 179.796 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 114' ' ' GLU . . . . . 0.438 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 20.2 pt-20 -59.34 -44.98 92.58 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.682 179.525 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 7.9 mtm180 -64.55 -47.48 78.6 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.151 -179.48 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.409 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -49.04 -74.5 0.26 Allowed Glycine 0 CA--C 1.519 0.297 0 C-N-CA 120.296 -0.954 . . . . 0.0 112.744 -179.933 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 175.45 -14.97 0.04 OUTLIER Glycine 0 CA--C 1.52 0.398 0 C-N-CA 120.863 -0.684 . . . . 0.0 113.116 -179.876 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.628 ' N ' HG22 ' A' ' 84' ' ' VAL . 7.6 p -35.49 153.19 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.275 0 N-CA-C 112.132 0.419 . . . . 0.0 112.132 -179.727 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 9.5 mmt180 -139.73 138.86 36.29 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.881 179.924 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 19.4 t -71.22 81.5 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.154 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 132.1 41.02 0.2 Allowed Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.664 179.902 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 12.9 m170 -131.64 132.0 43.66 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.843 0.354 . . . . 0.0 110.766 179.856 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 123' ' ' ARG . . . . . 0.978 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 0.2 OUTLIER -81.3 92.39 6.37 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.391 -179.768 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 124' ' ' ILE . . . . . 0.885 ' CD1' HD11 ' A' ' 104' ' ' ILE . 9.0 mt -46.16 156.7 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.164 178.753 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 125' ' ' ILE . . . . . 0.786 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.6 OUTLIER -153.89 -86.06 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 N-CA-C 112.48 0.548 . . . . 0.0 112.48 -179.497 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 13.5 mt-10 -77.01 92.64 3.73 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 112.131 0.419 . . . . 0.0 112.131 -178.707 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.754 HG23 ' CG ' ' A' ' 153' ' ' MET . 1.2 mt -91.52 98.77 8.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 121.008 0.432 . . . . 0.0 110.991 179.194 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 128' ' ' ASN . . . . . 0.423 ' N ' ' O ' ' A' ' 152' ' ' HIS . 19.3 p30 48.18 26.51 1.06 Allowed 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.651 -0.704 . . . . 0.0 112.133 179.752 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 125.2 -26.22 5.59 Favored Glycine 0 C--N 1.332 0.357 0 C-N-CA 120.239 -0.981 . . . . 0.0 113.878 178.905 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -100.03 114.02 27.02 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 117.27 0.535 . . . . 0.0 111.428 -179.497 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 12.0 t -78.33 101.99 7.48 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.047 179.847 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 132' ' ' VAL . . . . . 0.634 HG21 HD11 ' A' ' 127' ' ' ILE . 21.5 m -83.08 6.94 1.57 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.282 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.825 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.786 ' HB ' HG22 ' A' ' 125' ' ' ILE . 11.1 p -51.91 119.7 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.18 0 CA-C-O 120.958 0.409 . . . . 0.0 110.82 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 134' ' ' ALA . . . . . 0.408 ' HB3' ' O ' ' A' ' 133' ' ' VAL . . . 68.45 22.84 7.67 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.751 -179.101 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 135' ' ' THR . . . . . 0.443 HG21 ' HD2' ' A' ' 139' ' ' LYS . 28.8 m -99.47 142.05 23.92 Favored Pre-proline 0 C--N 1.328 -0.364 0 CA-C-N 115.669 -0.696 . . . . 0.0 110.702 179.864 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 136' ' ' PRO . . . . . 0.425 ' HD2' ' CG2' ' A' ' 135' ' ' THR . 87.1 Cg_exo -44.97 142.65 5.15 Favored 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 122.628 2.219 . . . . 0.0 112.549 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 32.0 p-80 -62.86 -48.05 80.71 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.468 -179.599 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 1.4 tt0 -55.23 -33.44 63.11 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.244 -179.726 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 139' ' ' LYS . . . . . 0.752 ' O ' HD12 ' A' ' 143' ' ' ILE . 1.6 tmtp? -66.14 -49.44 67.44 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.933 -179.928 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 8.0 mt -58.82 -45.14 91.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 121.102 0.477 . . . . 0.0 110.405 179.888 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 141' ' ' VAL . . . . . 0.431 HG23 ' CG1' ' A' ' 99' ' ' VAL . 93.3 t -60.78 -32.67 52.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.06 178.794 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 9.7 t-80 -59.9 -52.57 64.87 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.538 179.586 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 143' ' ' ILE . . . . . 0.752 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.1 mp -53.15 -56.85 6.15 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.433 0 CA-C-O 121.197 0.522 . . . . 0.0 110.282 179.253 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.594 HD22 HG12 ' A' ' 151' ' ' ILE . 1.2 mt -61.9 -29.97 70.56 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.315 -0.857 . . . . 0.0 110.45 179.625 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 1.5 m -68.84 -26.73 65.3 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.124 -0.489 . . . . 0.0 109.939 178.549 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 3.8 m-80 -127.41 32.07 5.09 Favored 'General case' 0 C--O 1.232 0.152 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.173 179.796 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 147' ' ' ALA . . . . . 0.718 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -117.62 59.52 0.78 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.819 0.343 . . . . 0.0 111.16 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 28.1 m -54.74 175.7 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.37 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 79.3 -118.62 4.82 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.779 -0.725 . . . . 0.0 112.393 179.912 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -123.8 117.15 24.23 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.714 0.293 . . . . 0.0 110.582 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 151' ' ' ILE . . . . . 0.718 HD11 ' HB3' ' A' ' 147' ' ' ALA . 0.9 OUTLIER -89.32 111.87 23.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.365 -179.679 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 152' ' ' HIS . . . . . 0.423 ' O ' ' N ' ' A' ' 128' ' ' ASN . 6.4 m-70 -94.83 120.02 34.36 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 178.357 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 153' ' ' MET . . . . . 0.754 ' CG ' HG23 ' A' ' 127' ' ' ILE . 27.4 ttp -139.86 162.93 33.97 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 112.44 0.533 . . . . 0.0 112.44 -178.106 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 6.1 mttp -129.96 141.3 50.79 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.226 -0.897 . . . . 0.0 109.831 179.276 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 155' ' ' THR . . . . . 0.703 ' O ' HG23 ' A' ' 81' ' ' VAL . 4.7 p -139.61 147.4 41.05 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.948 0.404 . . . . 0.0 111.726 -179.174 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 156' ' ' MET . . . . . 0.448 ' CB ' ' CD ' ' A' ' 157' ' ' PRO . 1.0 OUTLIER -113.75 -179.78 0.67 Allowed Pre-proline 0 C--N 1.328 -0.368 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.24 179.59 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 157' ' ' PRO . . . . . 0.448 ' CD ' ' CB ' ' A' ' 156' ' ' MET . 89.3 Cg_endo -85.11 112.09 1.41 Allowed 'Trans proline' 0 N--CA 1.462 -0.375 0 C-N-CA 122.493 2.128 . . . . 0.0 112.558 -179.883 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 158' ' ' ALA . . . . . 0.978 ' HB2' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.249 1.074 0 CA-C-O 118.141 -0.933 . . . . 0.0 111.092 179.864 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 29.6 t . . . . . 0 C--O 1.232 0.137 0 CA-C-O 120.719 0.295 . . . . 0.0 111.062 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 1.6 m -104.64 145.79 29.84 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.994 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 91.7 m -107.05 111.09 23.39 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.049 -0.523 . . . . 0.0 109.917 178.92 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.742 HG13 ' H ' ' A' ' 118' ' ' VAL . 33.5 t -93.15 105.94 17.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.696 -179.415 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.475 HD21 ' OE1' ' A' ' 150' ' ' GLU . 4.2 tt -102.77 83.28 2.23 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.21 -0.45 . . . . 0.0 109.823 179.047 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.8 HD13 HD12 ' A' ' 95' ' ' LEU . 2.0 mt -81.7 132.46 31.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-O 121.096 0.474 . . . . 0.0 111.389 -178.932 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.441 ' O ' HG21 ' A' ' 112' ' ' ILE . 0.0 OUTLIER -89.45 114.01 25.44 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.692 -0.685 . . . . 0.0 110.531 -179.917 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.534 ' HG3' HD12 ' A' ' 151' ' ' ILE . 5.9 mmm180 -104.91 104.4 46.28 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.451 -0.341 . . . . 0.0 111.133 -179.733 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 89' ' ' PRO . . . . . 0.425 ' HG2' ' CE2' ' A' ' 93' ' ' TYR . 29.7 Cg_exo -61.96 -39.81 48.07 Favored 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.581 2.187 . . . . 0.0 112.427 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -153.61 -171.26 3.84 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.939 0.399 . . . . 0.0 111.303 -179.87 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 0.541 ' HG ' HG11 ' A' ' 148' ' ' VAL . 6.0 mt -86.14 -19.23 30.43 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.491 -179.757 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -93.97 21.58 6.55 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.707 0.289 . . . . 0.0 111.344 -179.585 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 93' ' ' TYR . . . . . 0.425 ' CE2' ' HG2' ' A' ' 89' ' ' PRO . 15.8 m-85 -104.25 175.56 5.45 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.654 179.547 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -128.35 149.71 50.41 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.897 0.38 . . . . 0.0 111.131 -179.876 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 0.8 HD12 HD13 ' A' ' 86' ' ' ILE . 4.6 mm? -67.59 -56.55 9.01 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.662 179.799 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 118.1 29.63 1.94 Allowed Glycine 0 C--N 1.333 0.401 0 C-N-CA 120.637 -0.792 . . . . 0.0 112.995 179.424 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 97' ' ' PHE . . . . . 0.432 ' CE2' ' HB3' ' A' ' 95' ' ' LEU . 47.8 p90 -166.81 165.23 16.36 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.852 0.358 . . . . 0.0 111.374 179.843 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -101.16 138.18 38.54 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.626 179.843 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.58 HG21 HG21 ' A' ' 140' ' ' ILE . 9.7 p -115.36 132.75 63.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.923 0.392 . . . . 0.0 111.591 -179.716 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 24.6 mt-30 -131.11 89.25 2.71 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.1 179.387 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 44.7 m-80 60.61 16.25 6.4 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.004 -179.436 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 102' ' ' GLY . . . . . 0.419 ' O ' ' HB ' ' A' ' 124' ' ' ILE . . . 124.87 -36.25 2.9 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.969 -0.634 . . . . 0.0 112.293 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.701 HG23 ' O ' ' A' ' 122' ' ' HIS . 36.7 mt -77.77 134.97 27.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-O 121.067 0.461 . . . . 0.0 111.738 -179.639 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.769 HD11 ' CD1' ' A' ' 124' ' ' ILE . 4.4 mp -90.29 135.48 26.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.519 179.666 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -106.15 -72.18 0.72 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.208 -179.591 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 1.5 m -101.87 142.26 33.45 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.145 -179.691 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.627 HD11 HG11 ' A' ' 118' ' ' VAL . 1.2 tt -144.68 124.54 13.44 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.646 179.695 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 19.8 mtp -82.09 149.76 27.86 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.03 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 4.6 mtm-85 -93.25 44.47 1.14 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.213 0.53 . . . . 0.0 110.367 179.649 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -161.03 22.43 0.23 Allowed Glycine 0 N--CA 1.449 -0.447 0 CA-C-N 115.617 -0.72 . . . . 0.0 112.284 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 111' ' ' GLY . . . . . 0.514 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -110.35 174.2 17.17 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 120.934 -0.651 . . . . 0.0 111.901 179.743 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.441 HG21 ' O ' ' A' ' 87' ' ' ARG . 0.6 OUTLIER -79.22 -21.94 12.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-O 120.854 0.359 . . . . 0.0 111.585 -179.713 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 113' ' ' ALA . . . . . 0.735 ' O ' HG12 ' A' ' 118' ' ' VAL . . . -58.35 -30.76 66.99 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.934 0.397 . . . . 0.0 110.549 179.775 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 114' ' ' GLU . . . . . 0.514 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 9.0 pt-20 -59.76 -44.59 93.79 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.753 179.672 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 85.1 mtt180 -65.36 -46.74 78.99 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.32 -179.468 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.404 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -48.94 -74.43 0.27 Allowed Glycine 0 CA--C 1.519 0.316 0 C-N-CA 120.302 -0.951 . . . . 0.0 112.709 -179.903 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 117' ' ' GLY . . . . . 0.433 ' O ' ' C ' ' A' ' 118' ' ' VAL . . . 175.59 -20.46 0.05 OUTLIER Glycine 0 CA--C 1.519 0.283 0 C-N-CA 121.013 -0.613 . . . . 0.0 112.72 -179.902 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.742 ' H ' HG13 ' A' ' 84' ' ' VAL . 11.0 p -24.91 136.87 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.399 0 N-CA-C 112.575 0.583 . . . . 0.0 112.575 -179.847 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 3.3 ttt180 -134.33 110.69 9.64 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.855 179.902 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 120' ' ' VAL . . . . . 0.489 HG22 ' HB2' ' A' ' 107' ' ' LEU . 21.0 t -57.11 100.21 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.083 -179.88 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 124.02 40.67 0.44 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.39 -179.83 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 122' ' ' HIS . . . . . 0.701 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.1 OUTLIER -134.91 -167.22 1.95 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.664 0.269 . . . . 0.0 110.657 -179.917 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 123' ' ' ARG . . . . . 0.718 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 13.8 ttt180 -137.26 90.44 2.52 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.883 179.976 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 124' ' ' ILE . . . . . 0.769 ' CD1' HD11 ' A' ' 104' ' ' ILE . 9.4 mt -50.06 156.08 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 N-CA-C 110.158 -0.312 . . . . 0.0 110.158 179.199 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 125' ' ' ILE . . . . . 0.848 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.6 OUTLIER -148.59 -84.71 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 N-CA-C 112.171 0.434 . . . . 0.0 112.171 -179.577 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 126' ' ' GLU . . . . . 0.404 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 12.2 mt-10 -80.34 86.16 5.74 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 112.164 0.431 . . . . 0.0 112.164 -178.999 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.845 HD11 HG21 ' A' ' 132' ' ' VAL . 1.4 mt -89.53 102.43 13.1 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 CA-C-O 120.899 0.381 . . . . 0.0 110.839 179.117 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 128' ' ' ASN . . . . . 0.461 ' HA ' ' CD2' ' A' ' 152' ' ' HIS . 0.9 OUTLIER 59.97 24.83 13.98 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.077 -0.511 . . . . 0.0 111.109 179.902 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 107.29 -13.43 40.07 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.919 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -97.62 113.07 24.72 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.789 0.328 . . . . 0.0 111.025 -179.878 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 1.2 p -77.44 94.68 4.3 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.019 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 132' ' ' VAL . . . . . 0.845 HG21 HD11 ' A' ' 127' ' ' ILE . 27.1 m -80.14 1.38 2.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.883 -179.879 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.848 ' HB ' HG22 ' A' ' 125' ' ' ILE . 9.2 p -46.79 -38.11 3.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-O 120.907 0.384 . . . . 0.0 111.619 -179.65 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -115.97 28.89 8.32 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.747 179.554 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 135' ' ' THR . . . . . 0.506 HG23 ' HD2' ' A' ' 136' ' ' PRO . 97.9 m -116.32 144.61 33.36 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 115.912 -0.585 . . . . 0.0 111.172 -179.834 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 136' ' ' PRO . . . . . 0.506 ' HD2' HG23 ' A' ' 135' ' ' THR . 48.9 Cg_exo -55.75 164.29 4.66 Favored 'Trans proline' 0 C--N 1.348 0.516 0 C-N-CA 122.528 2.152 . . . . 0.0 112.245 179.842 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 41.7 p-80 -67.18 -48.9 66.56 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.299 -179.837 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 6.0 tp10 -54.47 -36.66 64.36 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.388 -179.692 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 139' ' ' LYS . . . . . 0.796 ' O ' HD12 ' A' ' 143' ' ' ILE . 4.1 mmmt -61.63 -46.54 89.35 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.723 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 140' ' ' ILE . . . . . 0.825 HG23 ' CD1' ' A' ' 127' ' ' ILE . 16.8 mt -58.86 -46.03 91.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.581 -179.909 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 141' ' ' VAL . . . . . 0.411 ' CG2' ' CG1' ' A' ' 99' ' ' VAL . 93.7 t -59.8 -32.42 49.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.089 179.086 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -61.77 -54.0 48.33 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.834 179.764 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 143' ' ' ILE . . . . . 0.796 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.3 mp -52.88 -56.44 7.56 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.454 0 CA-C-O 121.194 0.521 . . . . 0.0 110.312 179.413 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.732 HD22 HG12 ' A' ' 151' ' ' ILE . 2.2 mt -63.0 -29.92 71.2 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.294 -0.866 . . . . 0.0 110.361 179.83 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 15.5 t -69.83 -30.14 67.58 Favored 'General case' 0 N--CA 1.453 -0.289 0 CA-C-N 116.302 -0.408 . . . . 0.0 109.933 178.676 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 3.0 m-80 -125.65 34.66 4.86 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.864 179.722 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 147' ' ' ALA . . . . . 1.06 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -100.3 -39.33 8.07 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.036 0.446 . . . . 0.0 111.585 -179.68 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.541 HG11 ' HG ' ' A' ' 91' ' ' LEU . 24.8 m 44.86 -171.38 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.488 -0.778 . . . . 0.0 111.662 -179.88 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 55.76 -135.35 48.88 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.569 -179.813 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.475 ' OE1' HD21 ' A' ' 85' ' ' LEU . 27.9 mt-10 -107.69 101.24 10.56 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.839 0.352 . . . . 0.0 110.761 179.884 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 151' ' ' ILE . . . . . 1.06 HD11 ' HB3' ' A' ' 147' ' ' ALA . 0.5 OUTLIER -76.07 111.76 12.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.189 -179.768 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 152' ' ' HIS . . . . . 0.461 ' CD2' ' HA ' ' A' ' 128' ' ' ASN . 0.8 OUTLIER -98.94 115.13 28.2 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 178.241 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 153' ' ' MET . . . . . 0.68 ' CG ' HG23 ' A' ' 127' ' ' ILE . 13.1 ttp -123.17 163.3 20.86 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.318 0.58 . . . . 0.0 112.139 -178.064 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -128.97 139.39 52.12 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.118 -0.946 . . . . 0.0 109.454 179.077 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 155' ' ' THR . . . . . 0.665 HG22 ' CG1' ' A' ' 124' ' ' ILE . 10.4 p -136.0 143.48 44.81 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.125 0.488 . . . . 0.0 111.738 -179.253 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 156' ' ' MET . . . . . 0.465 ' O ' ' CB ' ' A' ' 123' ' ' ARG . 8.9 mtp -132.64 149.66 73.65 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 115.28 -0.873 . . . . 0.0 110.298 179.646 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 77.2 Cg_exo -47.96 116.8 2.11 Favored 'Trans proline' 0 C--N 1.343 0.286 0 C-N-CA 122.37 2.047 . . . . 0.0 112.713 -179.834 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 158' ' ' ALA . . . . . 0.718 ' HB2' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.248 1.019 0 CA-C-O 118.317 -0.849 . . . . 0.0 110.958 179.837 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.573 HG13 ' O ' ' A' ' 155' ' ' THR . 35.0 t . . . . . 0 C--O 1.232 0.133 0 CA-C-O 120.71 0.29 . . . . 0.0 110.936 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.8 m -117.3 134.56 54.67 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.867 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 3.5 m -94.58 111.27 23.03 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.128 179.314 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.838 HG11 HG23 ' A' ' 118' ' ' VAL . 63.7 t -82.77 106.2 13.35 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.938 -179.249 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.408 ' O ' ' HA2' ' A' ' 116' ' ' GLY . 0.9 OUTLIER -106.83 80.81 1.48 Allowed 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 178.491 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.777 HG13 HG12 ' A' ' 84' ' ' VAL . 3.3 mt -81.53 136.02 23.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-O 121.252 0.549 . . . . 0.0 111.945 -178.195 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.426 ' H ' HG22 ' A' ' 112' ' ' ILE . 0.0 OUTLIER -90.45 148.44 22.77 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.368 -0.833 . . . . 0.0 110.194 179.685 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -155.05 102.91 2.27 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.595 -0.275 . . . . 0.0 110.96 -179.819 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 67.3 Cg_endo -74.06 -24.59 14.78 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.514 2.143 . . . . 0.0 112.494 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -149.59 -166.94 2.69 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.914 0.388 . . . . 0.0 111.236 -179.786 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 0.56 ' HG ' HG11 ' A' ' 148' ' ' VAL . 4.2 mt -96.54 -44.4 7.18 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.349 -179.598 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -58.06 -18.77 26.77 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.96 -0.564 . . . . 0.0 111.634 -179.436 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 38.4 m-85 -88.2 87.71 7.4 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.805 179.833 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -66.42 -177.83 0.6 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.079 -179.948 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 0.771 ' CD2' HD13 ' A' ' 86' ' ' ILE . 6.5 mp -94.74 -56.18 2.86 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.771 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 98.06 71.07 1.01 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.848 179.745 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 97' ' ' PHE . . . . . 0.665 ' CZ ' HD12 ' A' ' 144' ' ' LEU . 14.0 p90 -166.27 162.4 17.34 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.918 0.389 . . . . 0.0 111.01 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.42 ' O ' ' HA ' ' A' ' 104' ' ' ILE . 1.5 m -106.18 120.49 41.96 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.607 179.724 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.427 ' CG1' ' CG2' ' A' ' 141' ' ' VAL . 8.4 p -109.78 139.05 34.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.448 -179.697 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -135.87 89.15 2.46 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.309 179.491 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 56.8 m-80 58.26 18.91 5.78 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.174 -179.529 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 126.73 -38.16 2.25 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.575 179.884 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.49 HG12 ' CB ' ' A' ' 158' ' ' ALA . 31.8 mt -76.88 141.9 15.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 121.034 0.445 . . . . 0.0 111.452 -179.611 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.904 HD11 ' CD1' ' A' ' 124' ' ' ILE . 5.2 mp -109.54 130.01 63.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.863 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 1.8 m -123.52 28.97 6.78 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.969 -179.872 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 106' ' ' SER . . . . . 0.433 ' H ' HG22 ' A' ' 104' ' ' ILE . 0.3 OUTLIER -178.19 141.24 0.24 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.772 179.988 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -159.09 107.63 1.86 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.844 -179.826 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 2.8 ttp -68.13 113.14 5.53 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.74 179.918 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 26.1 mtt180 -58.81 86.49 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.798 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 163.79 -33.97 0.29 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.913 -0.66 . . . . 0.0 112.012 -179.818 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 111' ' ' GLY . . . . . 0.405 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -61.13 171.43 7.8 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.193 179.693 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.426 HG22 ' H ' ' A' ' 87' ' ' ARG . 0.8 OUTLIER -78.64 -16.93 13.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 120.777 0.323 . . . . 0.0 111.477 -179.789 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 113' ' ' ALA . . . . . 0.47 ' HA ' HG12 ' A' ' 86' ' ' ILE . . . -58.12 -30.5 66.35 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.056 0.455 . . . . 0.0 110.707 179.882 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 114' ' ' GLU . . . . . 0.405 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 21.7 pt-20 -62.0 -46.51 88.9 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.768 -0.651 . . . . 0.0 111.105 179.823 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.4 ' N ' ' CG ' ' A' ' 114' ' ' GLU . 25.2 mtt-85 -62.75 -46.16 89.33 Favored 'General case' 0 N--CA 1.452 -0.347 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.142 -179.378 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.408 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -50.29 -74.05 0.31 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.338 -0.934 . . . . 0.0 112.578 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 117' ' ' GLY . . . . . 0.572 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 175.97 -27.4 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.736 -179.782 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.838 HG23 HG11 ' A' ' 84' ' ' VAL . 12.0 t -31.25 102.04 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 CA-C-O 120.993 0.425 . . . . 0.0 111.8 -179.722 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -104.13 123.89 48.09 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.643 179.765 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 21.4 t -53.76 99.99 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.188 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 120.7 14.67 5.15 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.934 -0.651 . . . . 0.0 112.79 -179.879 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 14.0 m170 -115.61 132.89 56.49 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.744 0.307 . . . . 0.0 110.626 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 123' ' ' ARG . . . . . 0.858 ' HB3' ' HB2' ' A' ' 158' ' ' ALA . 13.1 ptt180 -84.55 91.85 7.97 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.677 -179.734 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 124' ' ' ILE . . . . . 0.904 ' CD1' HD11 ' A' ' 104' ' ' ILE . 19.1 mt -48.09 157.85 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.333 -0.133 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 178.72 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 125' ' ' ILE . . . . . 0.845 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.6 OUTLIER -150.73 -83.37 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 N-CA-C 113.064 0.765 . . . . 0.0 113.064 -179.008 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -75.62 81.85 2.62 Favored 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 112.695 0.628 . . . . 0.0 112.695 -178.247 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.743 HG23 ' HB3' ' A' ' 153' ' ' MET . 1.7 mt -91.02 95.25 5.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.931 0.395 . . . . 0.0 111.062 179.015 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 128' ' ' ASN . . . . . 0.442 ' N ' ' O ' ' A' ' 152' ' ' HIS . 33.0 m-20 57.76 39.93 26.72 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.934 179.966 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 91.51 -4.18 79.56 Favored Glycine 0 CA--C 1.519 0.329 0 C-N-CA 120.632 -0.794 . . . . 0.0 112.813 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 2.2 tt0 -104.08 107.51 18.44 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.824 0.345 . . . . 0.0 110.836 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 26.0 p -75.6 92.01 2.9 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.093 -179.824 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 132' ' ' VAL . . . . . 0.734 HG21 HD11 ' A' ' 127' ' ' ILE . 31.4 m -74.74 -3.67 4.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.724 179.838 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.845 ' HB ' HG22 ' A' ' 125' ' ' ILE . 9.0 p -43.79 -44.6 1.87 Allowed 'Isoleucine or valine' 0 C--O 1.231 0.111 0 CA-C-O 120.806 0.336 . . . . 0.0 111.804 -179.775 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 134' ' ' ALA . . . . . 0.474 ' N ' HG13 ' A' ' 133' ' ' VAL . . . -113.37 30.24 7.36 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.958 179.906 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 135' ' ' THR . . . . . 0.499 HG21 ' HD2' ' A' ' 139' ' ' LYS . 91.6 m -115.15 140.47 25.71 Favored Pre-proline 0 C--N 1.33 -0.244 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.015 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 136' ' ' PRO . . . . . 0.481 ' HD2' HG23 ' A' ' 135' ' ' THR . 7.6 Cg_endo -50.33 164.18 0.53 Allowed 'Trans proline' 0 C--N 1.347 0.494 0 C-N-CA 122.64 2.226 . . . . 0.0 112.244 179.841 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 137' ' ' HIS . . . . . 0.439 ' CD2' ' N ' ' A' ' 138' ' ' GLU . 32.9 p-80 -72.77 -46.69 52.03 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.606 -179.5 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 138' ' ' GLU . . . . . 0.439 ' N ' ' CD2' ' A' ' 137' ' ' HIS . 16.7 mt-10 -53.69 -36.69 62.46 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.396 -179.59 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 139' ' ' LYS . . . . . 0.821 ' O ' HD12 ' A' ' 143' ' ' ILE . 6.7 tmtm? -62.93 -47.02 85.04 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.927 -179.816 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 8.6 mt -58.41 -44.71 89.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.523 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 141' ' ' VAL . . . . . 0.427 ' CG2' ' CG1' ' A' ' 99' ' ' VAL . 93.1 t -60.78 -32.46 52.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.107 178.856 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -61.46 -52.32 65.01 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.641 179.558 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 143' ' ' ILE . . . . . 0.821 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.4 mp -53.23 -56.67 7.1 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.395 0 CA-C-O 121.098 0.475 . . . . 0.0 110.205 179.422 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.718 HD13 ' CD2' ' A' ' 95' ' ' LEU . 4.9 mt -62.31 -30.31 71.06 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.518 -0.764 . . . . 0.0 110.326 179.506 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 34.5 t -70.09 -28.31 65.31 Favored 'General case' 0 N--CA 1.453 -0.283 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.117 178.901 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 41.9 m-20 -131.71 37.4 3.65 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.082 179.808 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 147' ' ' ALA . . . . . 0.635 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -99.79 -44.71 5.99 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.094 0.473 . . . . 0.0 111.512 -179.68 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.56 HG11 ' HG ' ' A' ' 91' ' ' LEU . 32.4 m 45.96 -174.68 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 115.321 -0.854 . . . . 0.0 111.788 -179.684 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 59.64 -108.07 1.54 Allowed Glycine 0 N--CA 1.453 -0.214 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.361 -179.819 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 46.1 mt-10 -136.81 114.1 10.8 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.778 0.323 . . . . 0.0 110.856 179.892 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 151' ' ' ILE . . . . . 0.635 HD11 ' HB3' ' A' ' 147' ' ' ALA . 1.5 mt -82.84 112.0 19.96 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.139 -179.912 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 152' ' ' HIS . . . . . 0.442 ' O ' ' N ' ' A' ' 128' ' ' ASN . 0.1 OUTLIER -99.09 115.88 30.01 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.978 -0.556 . . . . 0.0 109.82 179.04 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 153' ' ' MET . . . . . 0.743 ' HB3' HG23 ' A' ' 127' ' ' ILE . 0.0 OUTLIER -144.64 177.83 8.41 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.548 0.69 . . . . 0.0 111.751 -179.048 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 14.4 mttp -139.43 152.66 47.23 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 114.633 -1.167 . . . . 0.0 109.977 179.546 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 155' ' ' THR . . . . . 0.693 HG22 HG12 ' A' ' 124' ' ' ILE . 2.0 p -142.99 150.4 39.59 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.195 0.522 . . . . 0.0 111.888 -179.488 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 156' ' ' MET . . . . . 0.423 ' CB ' ' CD ' ' A' ' 157' ' ' PRO . 2.3 mtp -118.69 178.93 0.94 Allowed Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 115.235 -0.893 . . . . 0.0 109.898 179.343 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 157' ' ' PRO . . . . . 0.423 ' CD ' ' CB ' ' A' ' 156' ' ' MET . 89.9 Cg_endo -86.45 106.16 0.75 Allowed 'Trans proline' 0 N--CA 1.459 -0.555 0 C-N-CA 122.44 2.094 . . . . 0.0 112.493 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 158' ' ' ALA . . . . . 0.858 ' HB2' ' HB3' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.249 1.057 0 CA-C-O 118.253 -0.879 . . . . 0.0 111.052 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.516 HG23 ' O ' ' A' ' 155' ' ' THR . 11.2 p . . . . . 0 CA--C 1.527 0.094 0 CA-C-O 120.706 0.288 . . . . 0.0 110.77 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.5 m -104.26 146.09 29.29 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.925 0.393 . . . . 0.0 111.203 -179.709 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 11.6 m -110.17 111.09 22.21 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.002 178.972 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.769 HG22 ' N ' ' A' ' 118' ' ' VAL . 72.6 t -86.23 106.5 15.66 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.896 -179.164 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.423 ' O ' ' HA2' ' A' ' 116' ' ' GLY . 4.2 tt -106.34 81.34 1.6 Allowed 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 178.497 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.866 HG21 ' CD1' ' A' ' 95' ' ' LEU . 1.2 mt -81.46 140.19 16.9 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 121.167 0.508 . . . . 0.0 111.674 -178.777 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.439 ' HG3' ' CG2' ' A' ' 112' ' ' ILE . 0.0 OUTLIER -99.01 145.9 26.6 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.551 -0.749 . . . . 0.0 110.27 179.873 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 3.8 mtt-85 -139.09 102.26 7.53 Favored Pre-proline 0 C--N 1.331 -0.232 0 CA-C-N 116.463 -0.335 . . . . 0.0 110.982 -179.782 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 89' ' ' PRO . . . . . 0.434 ' HB2' ' CE1' ' A' ' 93' ' ' TYR . 52.5 Cg_exo -55.09 -57.04 1.88 Allowed 'Trans proline' 0 C--N 1.347 0.478 0 C-N-CA 122.465 2.11 . . . . 0.0 112.35 -179.858 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.7 t0 -139.83 -168.67 2.55 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.869 0.366 . . . . 0.0 111.174 -179.86 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 0.424 ' CD1' HG11 ' A' ' 148' ' ' VAL . 0.2 OUTLIER -83.32 -30.82 27.21 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.04 -179.924 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -68.13 -11.02 58.4 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.62 -179.694 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 93' ' ' TYR . . . . . 0.434 ' CE1' ' HB2' ' A' ' 89' ' ' PRO . 25.2 m-85 -82.88 178.17 8.3 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.507 -0.315 . . . . 0.0 110.784 179.839 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 8.3 mp0 -136.57 164.8 27.35 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.068 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 0.866 ' CD1' HG21 ' A' ' 86' ' ' ILE . 0.7 OUTLIER -72.51 -60.21 2.34 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.781 179.847 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 121.4 14.0 5.06 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.657 -0.783 . . . . 0.0 113.174 179.797 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 97' ' ' PHE . . . . . 0.62 ' HD2' HG23 ' A' ' 104' ' ' ILE . 30.5 p90 -160.45 175.12 13.12 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.958 0.408 . . . . 0.0 111.197 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -118.42 141.19 48.79 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.009 -0.542 . . . . 0.0 110.771 179.86 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.719 HG21 HG21 ' A' ' 140' ' ' ILE . 6.3 p -109.98 136.0 47.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 121.1 0.476 . . . . 0.0 111.427 -179.858 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -126.92 89.78 3.04 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.048 179.457 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 2.5 m-20 62.27 12.2 5.01 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.814 -179.083 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 129.7 -37.65 2.13 Favored Glycine 0 N--CA 1.445 -0.716 0 C-N-CA 121.095 -0.574 . . . . 0.0 112.007 -179.871 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.55 HG12 ' HB2' ' A' ' 158' ' ' ALA . 41.8 mt -79.2 135.67 25.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-O 121.093 0.473 . . . . 0.0 111.801 -179.469 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.843 HD11 ' CD1' ' A' ' 124' ' ' ILE . 3.8 mp -91.54 141.27 14.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.825 179.799 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 105' ' ' CYS . . . . . 0.413 ' O ' HG13 ' A' ' 120' ' ' VAL . 36.9 m -116.82 -81.1 0.61 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.285 -179.556 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 4.6 m -77.13 139.16 39.88 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.991 -179.78 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.475 ' HB3' HG22 ' A' ' 120' ' ' VAL . 9.5 tt -156.38 120.75 4.5 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.636 179.867 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 19.2 mtm -90.75 129.0 36.87 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.985 -179.889 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 2.3 mpt_? -66.13 76.71 0.09 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.644 179.82 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 178.23 -34.8 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.927 -0.654 . . . . 0.0 112.126 -179.843 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -55.31 171.54 1.46 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.286 179.697 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.439 ' CG2' ' HG3' ' A' ' 87' ' ' ARG . 0.5 OUTLIER -78.66 -17.59 13.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-O 120.82 0.343 . . . . 0.0 111.505 -179.778 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 113' ' ' ALA . . . . . 0.563 ' HA ' HG12 ' A' ' 86' ' ' ILE . . . -58.4 -30.78 67.1 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.87 0.367 . . . . 0.0 110.633 179.804 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -60.02 -45.72 91.88 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.691 179.579 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 1.6 mmm180 -62.93 -49.08 76.18 Favored 'General case' 0 N--CA 1.452 -0.359 0 CA-C-N 115.843 -0.617 . . . . 0.0 111.132 -179.473 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.423 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -49.52 -74.33 0.28 Allowed Glycine 0 CA--C 1.519 0.318 0 C-N-CA 120.224 -0.989 . . . . 0.0 112.532 179.936 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 117' ' ' GLY . . . . . 0.555 ' C ' HG22 ' A' ' 84' ' ' VAL . . . -179.81 -30.67 0.06 OUTLIER Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 121.124 -0.56 . . . . 0.0 112.181 179.864 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.769 ' N ' HG22 ' A' ' 84' ' ' VAL . 73.6 t -26.43 123.7 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.384 0 C-N-CA 122.956 0.503 . . . . 0.0 112.283 -179.771 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 14.1 mtt-85 -123.29 118.42 27.52 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.54 179.779 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 120' ' ' VAL . . . . . 0.475 HG22 ' HB3' ' A' ' 107' ' ' LEU . 21.5 t -52.2 93.23 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.239 -179.919 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 122.78 37.9 0.6 Allowed Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.933 -0.651 . . . . 0.0 112.332 -179.861 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 122' ' ' HIS . . . . . 0.436 ' O ' HG23 ' A' ' 103' ' ' ILE . 10.3 m170 -138.77 169.25 18.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.753 0.311 . . . . 0.0 110.805 179.933 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 123' ' ' ARG . . . . . 0.742 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 1.4 ttm180 -108.42 143.89 36.75 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.201 -179.877 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 124' ' ' ILE . . . . . 0.843 ' CD1' HD11 ' A' ' 104' ' ' ILE . 26.8 mt -101.29 155.36 4.6 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 178.465 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 125' ' ' ILE . . . . . 0.868 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.7 OUTLIER -147.45 -84.31 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 N-CA-C 113.208 0.818 . . . . 0.0 113.208 -178.561 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 126' ' ' GLU . . . . . 0.42 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 6.1 mt-10 -79.87 85.34 5.53 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 112.626 0.602 . . . . 0.0 112.626 -178.093 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.8 HD11 HG21 ' A' ' 132' ' ' VAL . 1.7 mt -91.18 103.35 14.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 121.025 0.441 . . . . 0.0 111.17 179.094 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 128' ' ' ASN . . . . . 0.547 ' ND2' HG22 ' A' ' 127' ' ' ILE . 33.4 m-80 55.65 25.4 8.08 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.106 -179.969 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 107.65 -13.91 38.69 Favored Glycine 0 CA--C 1.518 0.273 0 C-N-CA 120.624 -0.798 . . . . 0.0 112.775 179.895 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 22.3 tt0 -95.95 113.94 25.61 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.849 0.357 . . . . 0.0 110.875 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -77.54 91.4 3.95 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.141 -179.902 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 132' ' ' VAL . . . . . 0.8 HG21 HD11 ' A' ' 127' ' ' ILE . 32.4 m -75.41 -2.57 4.11 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.257 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.818 179.891 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.868 ' HB ' HG22 ' A' ' 125' ' ' ILE . 8.2 p -46.24 -38.3 3.22 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.142 0 CA-C-O 120.858 0.361 . . . . 0.0 111.445 -179.758 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -117.6 28.57 8.36 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.787 179.401 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 135' ' ' THR . . . . . 0.505 HG23 ' HD2' ' A' ' 136' ' ' PRO . 86.0 m -111.48 141.88 25.41 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 115.777 -0.647 . . . . 0.0 111.105 -179.772 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 136' ' ' PRO . . . . . 0.505 ' HD2' HG23 ' A' ' 135' ' ' THR . 9.5 Cg_endo -51.87 164.23 1.13 Allowed 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.8 2.333 . . . . 0.0 112.215 179.742 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 137' ' ' HIS . . . . . 0.403 ' O ' HG23 ' A' ' 141' ' ' VAL . 12.4 p80 -70.47 -47.64 59.6 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.376 -179.785 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -55.6 -32.74 63.33 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.249 -179.707 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 139' ' ' LYS . . . . . 0.761 ' O ' HD12 ' A' ' 143' ' ' ILE . 0.4 OUTLIER -65.08 -50.27 66.78 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.833 -179.917 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 140' ' ' ILE . . . . . 0.719 HG21 HG21 ' A' ' 99' ' ' VAL . 8.8 mt -58.68 -43.46 87.68 Favored 'Isoleucine or valine' 0 C--O 1.235 0.311 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.577 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 141' ' ' VAL . . . . . 0.569 HG22 HG12 ' A' ' 99' ' ' VAL . 61.8 t -61.42 -32.93 54.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.292 179.189 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 0.5 OUTLIER -62.66 -53.47 54.05 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.968 179.924 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 143' ' ' ILE . . . . . 0.761 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.3 mp -53.04 -57.23 4.96 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.393 0 CA-C-O 121.162 0.506 . . . . 0.0 110.371 179.558 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.565 HD22 HG12 ' A' ' 151' ' ' ILE . 1.8 mt -62.16 -30.04 70.77 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.417 -0.81 . . . . 0.0 110.42 179.557 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 9.2 t -68.16 -26.7 65.89 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.179 -0.464 . . . . 0.0 109.872 178.567 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 8.5 m120 -131.19 35.01 3.95 Favored 'General case' 0 CA--C 1.528 0.107 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.199 179.918 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 147' ' ' ALA . . . . . 0.67 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -114.29 48.75 1.07 Allowed 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.855 0.36 . . . . 0.0 111.304 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.424 HG11 ' CD1' ' A' ' 91' ' ' LEU . 29.8 m -54.09 150.35 1.76 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.285 -179.953 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 108.68 -107.72 2.51 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.445 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 40.9 mt-10 -138.05 104.32 5.2 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.711 0.291 . . . . 0.0 110.889 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 151' ' ' ILE . . . . . 0.67 HD11 ' HB3' ' A' ' 147' ' ' ALA . 1.2 mt -78.64 111.7 15.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.065 -179.91 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 152' ' ' HIS . . . . . 0.42 ' CD2' ' HG ' ' A' ' 85' ' ' LEU . 0.6 OUTLIER -103.82 115.66 30.88 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.999 -0.546 . . . . 0.0 109.828 179.129 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 153' ' ' MET . . . . . 0.772 ' HB3' HG23 ' A' ' 127' ' ' ILE . 1.9 ptt? -145.91 167.08 24.15 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.089 0.471 . . . . 0.0 111.876 -179.077 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -115.06 153.28 30.99 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.625 -0.716 . . . . 0.0 109.899 179.234 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 155' ' ' THR . . . . . 0.707 HG22 ' HA ' ' A' ' 124' ' ' ILE . 51.8 p -142.69 140.29 31.48 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.235 0.54 . . . . 0.0 111.829 -179.302 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 156' ' ' MET . . . . . 0.41 ' N ' ' O ' ' A' ' 123' ' ' ARG . 0.2 OUTLIER -126.46 152.45 74.23 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 115.329 -0.85 . . . . 0.0 109.947 179.309 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 12.6 Cg_endo -56.16 115.8 2.72 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.497 2.131 . . . . 0.0 112.496 -179.784 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 158' ' ' ALA . . . . . 0.742 ' HB2' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.248 0.992 0 CA-C-O 118.234 -0.889 . . . . 0.0 110.943 179.733 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 37.0 t . . . . . 0 C--O 1.232 0.135 0 CA-C-O 120.772 0.32 . . . . 0.0 110.995 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.3 m -111.12 138.4 47.6 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.85 179.934 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 9.5 m -98.63 111.14 23.6 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.166 179.266 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.771 HG11 HG23 ' A' ' 118' ' ' VAL . 62.0 t -84.95 106.2 14.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.731 -179.432 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.608 ' O ' HD23 ' A' ' 85' ' ' LEU . 10.2 tt -104.36 83.8 2.11 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 178.431 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 1.064 HG21 HD23 ' A' ' 95' ' ' LEU . 7.3 mt -81.84 130.89 35.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.92 -178.342 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.415 ' HG3' ' CG2' ' A' ' 112' ' ' ILE . 0.0 OUTLIER -92.18 124.41 36.24 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.388 -0.823 . . . . 0.0 110.447 -179.958 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -126.48 120.26 23.29 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 116.451 -0.341 . . . . 0.0 110.874 -179.864 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 62.5 Cg_endo -73.41 -28.65 11.99 Favored 'Trans proline' 0 C--N 1.346 0.425 0 C-N-CA 122.465 2.11 . . . . 0.0 112.16 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -173.07 -169.38 0.54 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.959 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 1.9 mp -80.36 -5.56 56.59 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.556 -179.909 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 2.2 ptm85 -102.76 27.28 7.12 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.861 0.362 . . . . 0.0 111.153 -179.807 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 4.3 m-85 -138.37 81.53 1.86 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.914 179.858 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -60.97 161.85 7.78 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.98 -179.847 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 1.064 HD23 HG21 ' A' ' 86' ' ' ILE . 0.5 OUTLIER -79.99 -65.31 1.02 Allowed 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.674 179.897 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 114.34 58.33 0.38 Allowed Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.916 179.512 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 97' ' ' PHE . . . . . 0.564 ' HD2' HG23 ' A' ' 104' ' ' ILE . 14.2 p90 -165.33 128.49 2.22 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.916 0.389 . . . . 0.0 111.106 179.698 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 6.4 t -71.98 144.09 48.99 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.832 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.941 HG11 ' HB ' ' A' ' 140' ' ' ILE . 48.9 t -111.9 136.9 46.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 121.032 0.444 . . . . 0.0 111.648 -179.705 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 4.1 mm-40 -135.72 88.06 2.37 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.722 -0.672 . . . . 0.0 109.507 178.563 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 85.6 m-20 53.57 21.65 2.63 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.985 -178.968 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 102' ' ' GLY . . . . . 0.404 ' N ' ' CD1' ' A' ' 140' ' ' ILE . . . 121.88 -32.83 4.46 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.922 -0.656 . . . . 0.0 112.374 179.902 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.623 HG12 ' HB2' ' A' ' 158' ' ' ALA . 31.2 mt -77.49 128.65 38.01 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 121.003 0.43 . . . . 0.0 111.781 -179.649 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.848 HD11 ' CD1' ' A' ' 124' ' ' ILE . 3.6 mp -84.42 144.81 9.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.146 179.296 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 105' ' ' CYS . . . . . 0.551 ' O ' HG13 ' A' ' 120' ' ' VAL . 55.9 m -126.51 -80.64 0.61 Allowed 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 112.009 0.374 . . . . 0.0 112.009 -179.205 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 40.3 m -79.17 66.18 4.55 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 112.027 0.38 . . . . 0.0 112.027 -178.797 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.803 ' HB3' HG22 ' A' ' 120' ' ' VAL . 14.0 tp -89.12 100.58 13.33 Favored 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 178.859 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 2.0 ptm -81.33 140.51 34.74 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.317 -179.472 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.51 166.74 9.9 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.596 179.697 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 92.79 -41.97 2.69 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.533 -0.842 . . . . 0.0 112.23 -179.732 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -58.21 168.76 5.25 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.227 179.751 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.415 ' CG2' ' HG3' ' A' ' 87' ' ' ARG . 0.9 OUTLIER -78.35 -16.23 13.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.733 0.301 . . . . 0.0 111.768 -179.797 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 113' ' ' ALA . . . . . 0.482 ' HA ' HG12 ' A' ' 86' ' ' ILE . . . -57.52 -30.34 65.07 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 121.015 0.436 . . . . 0.0 110.78 179.853 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 15.3 pt-20 -60.15 -46.69 88.79 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.904 179.56 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 16.2 mtm180 -64.7 -46.38 82.62 Favored 'General case' 0 N--CA 1.453 -0.314 0 CA-C-N 116.009 -0.541 . . . . 0.0 111.127 -179.316 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -50.55 -73.41 0.37 Allowed Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.431 -0.89 . . . . 0.0 112.686 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 117' ' ' GLY . . . . . 0.576 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 171.78 -21.27 0.07 OUTLIER Glycine 0 CA--C 1.519 0.284 0 C-N-CA 121.048 -0.596 . . . . 0.0 112.663 -179.971 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.771 HG23 HG11 ' A' ' 84' ' ' VAL . 1.2 t -37.95 135.9 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.261 0 CA-C-O 120.98 0.419 . . . . 0.0 111.638 -179.783 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 5.3 mtm180 -136.64 132.18 34.66 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.553 179.64 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 120' ' ' VAL . . . . . 0.803 HG22 ' HB3' ' A' ' 107' ' ' LEU . 15.4 t -57.11 89.45 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.852 0.358 . . . . 0.0 110.999 -179.866 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 131.98 -3.32 5.25 Favored Glycine 0 CA--C 1.52 0.375 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.861 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 1.6 m-70 -90.16 127.51 36.12 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-O 120.888 0.375 . . . . 0.0 110.73 179.899 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 123' ' ' ARG . . . . . 0.914 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 20.8 ttm180 -82.62 92.35 7.12 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.926 -179.373 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 124' ' ' ILE . . . . . 0.848 ' CD1' HD11 ' A' ' 104' ' ' ILE . 10.0 mt -50.39 157.56 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.05 178.544 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 125' ' ' ILE . . . . . 0.793 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.6 OUTLIER -150.77 -85.66 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 N-CA-C 112.38 0.511 . . . . 0.0 112.38 -179.349 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -75.29 85.12 2.46 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 112.067 0.395 . . . . 0.0 112.067 -178.959 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.801 HG23 ' HB3' ' A' ' 153' ' ' MET . 1.3 mt -92.61 102.6 13.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 120.951 0.405 . . . . 0.0 111.312 179.47 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 1.3 m-20 61.83 15.52 7.15 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.596 179.745 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 119.88 -16.95 10.15 Favored Glycine 0 C--N 1.333 0.368 0 C-N-CA 120.401 -0.904 . . . . 0.0 113.338 179.634 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 8.2 pt20 -101.94 123.08 45.24 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 117.091 0.445 . . . . 0.0 111.104 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 48.1 t -81.05 101.68 9.73 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.347 -179.68 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 132' ' ' VAL . . . . . 0.784 HG21 HD11 ' A' ' 127' ' ' ILE . 27.2 m -81.68 2.7 2.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.68 179.691 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.793 ' HB ' HG22 ' A' ' 125' ' ' ILE . 8.0 p -44.7 -45.18 2.64 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.133 0 CA-C-O 120.853 0.358 . . . . 0.0 111.697 -179.674 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 134' ' ' ALA . . . . . 0.484 ' N ' HG13 ' A' ' 133' ' ' VAL . . . -112.46 30.22 7.27 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.869 179.73 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 135' ' ' THR . . . . . 0.514 HG22 ' HB3' ' A' ' 139' ' ' LYS . 86.2 m -109.28 142.47 25.68 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.942 -179.788 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 136' ' ' PRO . . . . . 0.472 ' HD2' HG23 ' A' ' 135' ' ' THR . 71.2 Cg_exo -50.73 164.01 0.64 Allowed 'Trans proline' 0 C--N 1.348 0.535 0 C-N-CA 122.583 2.189 . . . . 0.0 112.431 179.864 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 28.1 p-80 -72.02 -51.22 22.84 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.161 -179.814 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -55.25 -30.96 61.1 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.986 -179.899 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 139' ' ' LYS . . . . . 0.726 ' O ' HD12 ' A' ' 143' ' ' ILE . 0.2 OUTLIER -64.62 -48.65 74.07 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.94 179.998 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 140' ' ' ILE . . . . . 0.941 ' HB ' HG11 ' A' ' 99' ' ' VAL . 5.4 mt -58.76 -45.01 91.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-O 121.048 0.452 . . . . 0.0 110.438 179.973 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 48.4 t -61.21 -32.43 52.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.417 179.24 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 1.6 m-70 -62.19 -53.09 60.32 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.723 179.79 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 143' ' ' ILE . . . . . 0.726 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.2 mp -53.28 -56.27 8.97 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.44 0 CA-C-O 121.207 0.527 . . . . 0.0 110.222 179.157 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.785 ' HB3' HD11 ' A' ' 95' ' ' LEU . 2.9 mt -62.95 -30.36 71.5 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.466 179.741 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 2.8 m -67.22 -29.9 69.69 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.17 -0.468 . . . . 0.0 109.743 178.738 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 8.4 m120 -131.13 38.28 3.67 Favored 'General case' 0 C--N 1.333 -0.135 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.625 179.596 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 147' ' ' ALA . . . . . 1.079 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -90.15 -51.91 5.21 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.246 0.546 . . . . 0.0 111.258 -179.545 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.505 HG23 ' C ' ' A' ' 147' ' ' ALA . 0.2 OUTLIER 57.01 164.61 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-N 115.292 -0.867 . . . . 0.0 111.078 -179.932 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 73.18 -133.41 18.26 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.524 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 -114.39 99.71 7.78 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.788 0.328 . . . . 0.0 110.92 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 151' ' ' ILE . . . . . 1.079 HD11 ' HB3' ' A' ' 147' ' ' ALA . 0.6 OUTLIER -68.1 111.9 2.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.987 179.982 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 152' ' ' HIS . . . . . 0.476 ' CE1' HD12 ' A' ' 85' ' ' LEU . 3.5 t60 -108.31 115.75 30.69 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.251 179.455 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 153' ' ' MET . . . . . 0.801 ' HB3' HG23 ' A' ' 127' ' ' ILE . 0.0 OUTLIER -143.62 176.05 9.5 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.208 0.528 . . . . 0.0 111.846 -179.356 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 9.7 mttp -122.76 151.99 41.07 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.416 -0.811 . . . . 0.0 109.487 178.919 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 155' ' ' THR . . . . . 0.466 HG22 ' CG1' ' A' ' 124' ' ' ILE . 6.6 p -141.57 141.39 33.5 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.031 0.443 . . . . 0.0 111.598 -179.345 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 156' ' ' MET . . . . . . . . . . . . . 9.6 mtp -125.8 133.52 24.98 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.588 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 82.5 Cg_exo -44.68 120.19 2.66 Favored 'Trans proline' 0 C--N 1.345 0.344 0 C-N-CA 122.558 2.172 . . . . 0.0 112.752 -179.888 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 158' ' ' ALA . . . . . 0.914 ' HB2' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.249 1.061 0 CA-C-O 118.181 -0.914 . . . . 0.0 111.061 179.87 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 39.0 t . . . . . 0 C--O 1.232 0.142 0 CA-C-O 120.794 0.331 . . . . 0.0 110.9 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.0 m -123.18 140.93 52.51 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.01 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 20.0 m -97.34 111.37 23.65 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.059 179.134 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.814 HG22 ' N ' ' A' ' 118' ' ' VAL . 78.9 t -88.98 105.73 16.15 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.42 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.792 -179.239 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.487 ' O ' ' HA2' ' A' ' 116' ' ' GLY . 0.5 OUTLIER -103.21 83.87 2.26 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 178.395 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 1.067 HG21 HD23 ' A' ' 95' ' ' LEU . 19.8 mt -80.85 132.51 31.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 121.405 0.621 . . . . 0.0 111.862 -178.306 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.865 ' O ' HG21 ' A' ' 112' ' ' ILE . 2.9 mmt180 -79.38 149.01 31.8 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 114.957 -1.02 . . . . 0.0 111.137 -179.477 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.534 ' HB3' ' HA ' ' A' ' 148' ' ' VAL . 2.7 mtt-85 -164.57 97.81 0.89 Allowed Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.846 179.689 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 70.3 Cg_endo -89.26 25.77 0.59 Allowed 'Trans proline' 0 N--CA 1.46 -0.483 0 C-N-CA 122.893 2.396 . . . . 0.0 113.414 -179.296 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 90' ' ' ASP . . . . . 0.729 ' O ' HG12 ' A' ' 148' ' ' VAL . 5.6 p-10 -179.03 177.74 0.79 Allowed 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.039 0.447 . . . . 0.0 111.741 179.922 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 0.822 ' HG ' HG11 ' A' ' 148' ' ' VAL . 6.0 mt -98.42 6.68 47.05 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.692 -0.686 . . . . 0.0 111.486 -179.89 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 8.6 ptt180 -129.18 42.06 3.37 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.853 0.359 . . . . 0.0 111.035 -179.78 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -120.52 126.04 49.37 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.748 179.828 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -86.02 136.6 33.18 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.963 -179.844 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 1.067 HD23 HG21 ' A' ' 86' ' ' ILE . 2.2 mp -77.24 -28.28 53.59 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.804 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 75.08 73.17 0.98 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.835 -0.697 . . . . 0.0 112.782 179.622 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 97' ' ' PHE . . . . . 0.71 ' CZ ' HD12 ' A' ' 144' ' ' LEU . 0.3 OUTLIER -176.14 156.75 1.72 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.806 0.336 . . . . 0.0 111.168 179.766 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.466 ' O ' ' HA ' ' A' ' 104' ' ' ILE . 3.3 t -106.15 133.81 50.27 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.422 179.559 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.529 HG21 HG21 ' A' ' 140' ' ' ILE . 9.7 p -118.49 134.84 60.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 121.026 0.441 . . . . 0.0 111.459 -179.581 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -131.75 89.24 2.67 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.23 179.405 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 12.1 m120 57.78 18.28 4.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.134 -179.468 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 128.18 -39.83 1.83 Allowed Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.531 179.858 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.529 HG12 ' HB2' ' A' ' 158' ' ' ALA . 26.6 mt -77.3 138.66 20.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 121.006 0.432 . . . . 0.0 111.531 -179.57 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.888 HD11 ' CD1' ' A' ' 124' ' ' ILE . 4.5 mp -99.07 137.83 25.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.911 179.917 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 43.4 t -105.0 -77.98 0.58 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.983 -179.781 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 77.0 p -90.63 119.24 30.71 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.707 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 25.7 tp -112.91 119.3 37.47 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.841 -179.938 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 9.3 mtp -68.13 98.26 0.77 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.975 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -60.86 117.59 5.61 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.826 -179.95 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 97.44 32.5 6.3 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.407 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 111' ' ' GLY . . . . . 0.513 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -118.61 -160.74 11.56 Favored Glycine 0 N--CA 1.453 -0.216 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.968 -179.789 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.865 HG21 ' O ' ' A' ' 87' ' ' ARG . 7.9 mt -80.62 -39.9 18.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-O 121.094 0.473 . . . . 0.0 111.506 -179.924 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 113' ' ' ALA . . . . . 0.595 ' HB1' HG11 ' A' ' 118' ' ' VAL . . . -57.67 -39.29 76.72 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.12 -179.481 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 114' ' ' GLU . . . . . 0.513 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 15.3 pt-20 -62.83 -37.83 88.33 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.503 179.499 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.497 ' N ' ' HG3' ' A' ' 114' ' ' GLU . 54.8 mtt85 -59.2 -46.71 87.71 Favored 'General case' 0 N--CA 1.452 -0.361 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.644 -179.866 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.487 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -56.33 -71.14 0.78 Allowed Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.343 -0.932 . . . . 0.0 112.501 179.719 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 117' ' ' GLY . . . . . 0.47 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 175.04 -22.74 0.06 OUTLIER Glycine 0 CA--C 1.52 0.39 0 C-N-CA 120.788 -0.72 . . . . 0.0 113.064 -179.902 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.814 ' N ' HG22 ' A' ' 84' ' ' VAL . 6.0 p -34.27 146.36 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 N-CA-C 112.128 0.418 . . . . 0.0 112.128 -179.604 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -140.95 153.84 45.81 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.917 -179.925 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 22.0 t -74.7 88.44 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.972 179.9 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 124.01 41.0 0.42 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.921 -0.657 . . . . 0.0 112.295 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 1.2 m170 -135.08 122.68 22.09 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.858 0.361 . . . . 0.0 110.764 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 123' ' ' ARG . . . . . 0.958 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 34.9 ttp180 -79.74 93.6 5.6 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.538 -179.731 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 124' ' ' ILE . . . . . 0.888 ' CD1' HD11 ' A' ' 104' ' ' ILE . 9.2 mt -49.98 158.21 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 178.715 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 125' ' ' ILE . . . . . 0.789 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.6 OUTLIER -148.99 -82.7 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 N-CA-C 112.446 0.535 . . . . 0.0 112.446 -179.49 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 -74.64 80.72 2.01 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 112.361 0.504 . . . . 0.0 112.361 -178.758 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.991 HG23 ' CG ' ' A' ' 153' ' ' MET . 2.7 mt -84.55 92.04 3.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 121.05 0.452 . . . . 0.0 111.01 179.259 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 128' ' ' ASN . . . . . 0.414 ' N ' ' O ' ' A' ' 152' ' ' HIS . 56.9 m-80 58.65 25.26 13.06 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.995 -179.81 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 113.36 -16.96 21.81 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.716 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 8.3 tt0 -94.4 111.15 22.89 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.809 0.338 . . . . 0.0 110.814 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -75.98 93.29 3.24 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.084 -179.822 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 132' ' ' VAL . . . . . 0.73 HG11 HD12 ' A' ' 127' ' ' ILE . 30.6 m -76.39 -1.58 3.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.881 179.835 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.789 ' HB ' HG22 ' A' ' 125' ' ' ILE . 8.7 p -42.94 -44.23 1.22 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.121 0 CA-C-O 120.825 0.345 . . . . 0.0 111.611 -179.653 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 134' ' ' ALA . . . . . 0.474 ' N ' HG13 ' A' ' 133' ' ' VAL . . . -117.24 29.75 7.71 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.772 179.714 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 135' ' ' THR . . . . . 0.485 HG22 ' HB3' ' A' ' 139' ' ' LYS . 52.3 m -108.71 142.17 24.87 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.057 -0.519 . . . . 0.0 111.161 -179.844 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 136' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -52.37 164.11 1.45 Allowed 'Trans proline' 0 C--N 1.346 0.442 0 C-N-CA 122.56 2.173 . . . . 0.0 112.284 179.677 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 31.9 p-80 -70.95 -49.81 41.44 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.368 -179.855 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 5.8 tp10 -54.36 -34.79 61.88 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.332 -0.394 . . . . 0.0 111.393 -179.695 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 139' ' ' LYS . . . . . 0.724 ' O ' HD12 ' A' ' 143' ' ' ILE . 3.3 tttp -62.76 -47.34 83.94 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.881 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 140' ' ' ILE . . . . . 0.529 HG21 HG21 ' A' ' 99' ' ' VAL . 15.1 mt -58.59 -45.45 90.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.603 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 141' ' ' VAL . . . . . 0.417 ' CG2' ' CG1' ' A' ' 99' ' ' VAL . 87.9 t -60.27 -32.5 50.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.326 178.987 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 1.8 t-80 -62.06 -53.56 53.77 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.012 179.774 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 143' ' ' ILE . . . . . 0.724 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.1 mp -52.94 -56.8 6.11 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.463 0 CA-C-O 121.227 0.537 . . . . 0.0 110.265 179.44 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.728 HD13 HD22 ' A' ' 95' ' ' LEU . 1.9 mt -62.44 -30.33 71.16 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.313 -0.858 . . . . 0.0 110.397 179.674 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 27.5 t -67.67 -27.8 67.15 Favored 'General case' 0 N--CA 1.453 -0.29 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.085 178.884 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 10.7 m120 -133.81 37.34 3.26 Favored 'General case' 0 CA--C 1.529 0.163 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.164 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 147' ' ' ALA . . . . . 0.944 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -101.46 -37.66 8.34 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.118 0.485 . . . . 0.0 111.301 -179.861 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.822 HG11 ' HG ' ' A' ' 91' ' ' LEU . 32.0 m 44.56 -172.67 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.37 -0.832 . . . . 0.0 112.036 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 58.38 -135.14 52.13 Favored Glycine 0 C--N 1.332 0.309 0 C-N-CA 121.035 -0.602 . . . . 0.0 112.704 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.429 ' OE1' HD21 ' A' ' 85' ' ' LEU . 62.2 mm-40 -110.09 91.28 3.59 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.851 0.357 . . . . 0.0 110.449 179.836 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 151' ' ' ILE . . . . . 0.944 HD11 ' HB3' ' A' ' 147' ' ' ALA . 0.7 OUTLIER -61.03 111.62 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.49 -179.448 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 152' ' ' HIS . . . . . 0.414 ' O ' ' N ' ' A' ' 128' ' ' ASN . 4.2 t60 -90.03 115.78 27.57 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 109.168 -0.679 . . . . 0.0 109.168 178.573 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 153' ' ' MET . . . . . 0.991 ' CG ' HG23 ' A' ' 127' ' ' ILE . 26.9 mtp -133.62 162.14 32.73 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.422 0.629 . . . . 0.0 112.452 -178.431 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 17.7 mttt -134.04 140.39 46.64 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 114.881 -1.054 . . . . 0.0 108.905 178.673 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 155' ' ' THR . . . . . 0.61 HG22 ' CG1' ' A' ' 124' ' ' ILE . 1.6 p -140.32 149.44 42.76 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.241 0.543 . . . . 0.0 112.046 -178.871 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 156' ' ' MET . . . . . . . . . . . . . 4.8 ptp -132.23 156.38 80.17 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 115.207 -0.906 . . . . 0.0 110.139 179.146 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_endo -57.4 120.41 8.31 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.366 2.044 . . . . 0.0 112.639 -179.726 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 158' ' ' ALA . . . . . 0.958 ' HB2' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.249 1.029 0 CA-C-O 118.289 -0.862 . . . . 0.0 111.114 179.876 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 20.2 t . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.741 0.305 . . . . 0.0 111.01 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 1.9 m -115.2 139.03 50.28 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.951 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 8.4 m -95.79 111.31 23.31 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.014 179.091 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.766 HG22 ' N ' ' A' ' 118' ' ' VAL . 67.3 t -90.63 105.76 16.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.757 -179.166 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.462 ' O ' ' HA2' ' A' ' 116' ' ' GLY . 6.2 tt -103.0 84.36 2.35 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 178.633 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.977 HG21 HD23 ' A' ' 95' ' ' LEU . 3.6 mt -80.94 128.64 38.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 121.27 0.557 . . . . 0.0 111.864 -178.526 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.829 ' O ' HG21 ' A' ' 112' ' ' ILE . 0.2 OUTLIER -74.81 153.01 38.94 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.459 179.962 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.401 ' HB3' ' N ' ' A' ' 149' ' ' GLY . 0.2 OUTLIER -148.33 100.1 3.61 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.109 179.845 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 89' ' ' PRO . . . . . 0.424 ' HG2' ' CD2' ' A' ' 93' ' ' TYR . 57.8 Cg_endo -71.21 -39.85 3.64 Favored 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.423 2.082 . . . . 0.0 112.497 -179.855 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -145.69 -169.24 3.18 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.167 -179.887 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 0.584 HD12 HG11 ' A' ' 148' ' ' VAL . 0.4 OUTLIER -88.78 -53.27 4.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.057 -179.967 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.2 mpp_? -57.93 -20.06 34.65 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.522 -179.528 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 93' ' ' TYR . . . . . 0.424 ' CD2' ' HG2' ' A' ' 89' ' ' PRO . 12.7 m-85 -77.21 133.39 38.91 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.799 179.896 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 4.5 mp0 -89.58 177.48 6.53 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.986 -179.925 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 0.977 HD23 HG21 ' A' ' 86' ' ' ILE . 2.3 mp -93.61 -67.62 0.85 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.858 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 134.8 52.53 0.07 OUTLIER Glycine 0 CA--C 1.519 0.332 0 C-N-CA 120.465 -0.874 . . . . 0.0 113.026 179.584 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 97' ' ' PHE . . . . . 0.598 ' HD2' HG21 ' A' ' 118' ' ' VAL . 0.0 OUTLIER 179.96 177.41 0.65 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.839 0.352 . . . . 0.0 111.402 179.663 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 71.0 m -125.73 137.09 53.8 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.762 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.758 HG21 HG21 ' A' ' 140' ' ' ILE . 7.1 p -109.74 135.26 49.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.453 -179.687 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 4.6 tt0 -131.58 89.4 2.7 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.068 179.359 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 61.05 15.85 6.55 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.016 -179.215 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 125.37 -37.01 2.64 Favored Glycine 0 N--CA 1.447 -0.569 0 C-N-CA 120.987 -0.625 . . . . 0.0 112.065 -179.924 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.828 HG23 ' O ' ' A' ' 122' ' ' HIS . 44.8 mt -77.43 140.93 16.28 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-O 121.016 0.436 . . . . 0.0 111.574 -179.815 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.838 HD11 ' CD1' ' A' ' 124' ' ' ILE . 3.7 mp -98.53 141.21 16.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.985 -179.824 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 22.0 m -119.82 -48.45 2.36 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.936 -0.574 . . . . 0.0 111.003 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -96.81 151.66 19.44 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.871 -179.972 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.725 HD11 HG13 ' A' ' 118' ' ' VAL . 0.4 OUTLIER -167.25 116.46 0.83 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.871 179.988 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 5.0 tmm? -85.49 116.31 23.72 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.939 -179.939 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -60.78 125.6 24.29 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.921 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 88.11 26.99 27.1 Favored Glycine 0 N--CA 1.453 -0.217 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.552 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 111' ' ' GLY . . . . . 0.496 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -108.36 -161.61 20.55 Favored Glycine 0 CA--C 1.518 0.249 0 C-N-CA 120.782 -0.723 . . . . 0.0 113.031 -179.704 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.829 HG21 ' O ' ' A' ' 87' ' ' ARG . 7.6 mt -80.46 -42.68 21.32 Favored 'Isoleucine or valine' 0 C--O 1.237 0.434 0 CA-C-O 121.181 0.515 . . . . 0.0 111.41 -179.829 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 113' ' ' ALA . . . . . 0.787 ' O ' HG12 ' A' ' 118' ' ' VAL . . . -57.76 -34.72 69.85 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.283 -179.251 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 114' ' ' GLU . . . . . 0.518 ' HG3' ' N ' ' A' ' 115' ' ' ARG . 7.3 pt-20 -67.9 -35.72 78.97 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.725 179.568 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.518 ' N ' ' HG3' ' A' ' 114' ' ' GLU . 36.1 mmt180 -61.71 -47.35 85.7 Favored 'General case' 0 N--CA 1.452 -0.368 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.885 -179.626 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.462 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -55.09 -72.58 0.53 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.225 -0.988 . . . . 0.0 112.615 179.894 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 117' ' ' GLY . . . . . 0.406 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 175.49 -22.15 0.06 OUTLIER Glycine 0 CA--C 1.52 0.393 0 C-N-CA 120.936 -0.65 . . . . 0.0 112.857 -179.881 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.787 HG12 ' O ' ' A' ' 113' ' ' ALA . 9.1 p -30.76 147.24 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 N-CA-C 112.637 0.606 . . . . 0.0 112.637 -179.723 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -142.79 130.47 21.42 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.653 179.748 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 120' ' ' VAL . . . . . 0.439 HG22 ' HB2' ' A' ' 107' ' ' LEU . 26.0 t -62.0 95.75 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.209 -179.809 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 123.38 40.41 0.47 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.688 179.859 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 122' ' ' HIS . . . . . 0.828 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -125.32 -165.98 1.48 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.656 0.265 . . . . 0.0 110.851 -179.982 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 123' ' ' ARG . . . . . 0.642 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 0.1 OUTLIER -145.76 90.75 2.02 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.376 -0.375 . . . . 0.0 110.813 179.952 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 124' ' ' ILE . . . . . 0.838 ' CD1' HD11 ' A' ' 104' ' ' ILE . 8.0 mt -53.36 157.04 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.582 179.496 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 125' ' ' ILE . . . . . 0.8 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.6 OUTLIER -150.31 -84.48 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 N-CA-C 112.209 0.448 . . . . 0.0 112.209 -179.474 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 21.9 mt-10 -79.75 85.84 5.39 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 112.176 0.436 . . . . 0.0 112.176 -178.964 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.797 HG23 ' HB3' ' A' ' 153' ' ' MET . 1.9 mt -89.83 108.3 19.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 116.396 -0.365 . . . . 0.0 111.377 179.475 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 128' ' ' ASN . . . . . 0.51 HD22 HG22 ' A' ' 127' ' ' ILE . 55.2 m-80 54.42 24.88 5.54 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.128 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 105.26 -10.22 46.76 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.665 -0.779 . . . . 0.0 112.794 -179.85 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 130' ' ' GLN . . . . . 0.492 HE22 HD11 ' A' ' 143' ' ' ILE . 21.4 tt0 -98.85 112.19 24.36 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.85 0.357 . . . . 0.0 110.756 179.855 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 1.5 m -74.49 91.09 2.24 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.286 -179.595 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 132' ' ' VAL . . . . . 0.691 HG11 HD12 ' A' ' 127' ' ' ILE . 29.6 m -71.54 -5.6 6.18 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.312 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.547 179.43 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.8 ' HB ' HG22 ' A' ' 125' ' ' ILE . 10.3 p -48.63 121.63 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.254 0 CA-C-O 120.893 0.378 . . . . 0.0 111.133 -179.916 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 134' ' ' ALA . . . . . 0.414 ' HB3' ' O ' ' A' ' 133' ' ' VAL . . . 68.15 22.38 8.3 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.034 -179.395 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 135' ' ' THR . . . . . 0.449 ' HB ' ' O ' ' A' ' 132' ' ' VAL . 50.8 m -106.16 141.53 22.94 Favored Pre-proline 0 C--N 1.326 -0.438 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.698 179.559 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 136' ' ' PRO . . . . . 0.418 ' HD2' HG23 ' A' ' 135' ' ' THR . 80.2 Cg_exo -45.38 146.92 2.84 Favored 'Trans proline' 0 C--N 1.345 0.359 0 C-N-CA 122.609 2.206 . . . . 0.0 112.565 -179.922 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 137' ' ' HIS . . . . . 0.416 ' CE1' ' HG2' ' A' ' 138' ' ' GLU . 7.0 p80 -65.21 -41.74 94.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.019 -179.929 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 138' ' ' GLU . . . . . 0.416 ' HG2' ' CE1' ' A' ' 137' ' ' HIS . 4.7 mm-40 -56.25 -37.21 69.44 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.947 -179.899 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 139' ' ' LYS . . . . . 0.795 ' O ' HD12 ' A' ' 143' ' ' ILE . 27.9 tttt -63.66 -48.96 75.09 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.903 179.942 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 140' ' ' ILE . . . . . 0.758 HG21 HG21 ' A' ' 99' ' ' VAL . 16.1 mt -58.62 -42.15 84.07 Favored 'Isoleucine or valine' 0 C--O 1.236 0.364 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.628 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 141' ' ' VAL . . . . . 0.45 HG22 HG12 ' A' ' 99' ' ' VAL . 89.2 t -62.49 -33.03 57.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.194 178.972 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -61.85 -51.74 66.99 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.64 179.736 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 143' ' ' ILE . . . . . 0.795 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.4 mp -53.24 -57.18 5.3 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.433 0 CA-C-O 121.079 0.466 . . . . 0.0 110.316 179.167 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.595 HD13 HD22 ' A' ' 95' ' ' LEU . 2.9 mt -61.71 -30.24 70.63 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.25 179.597 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 2.1 m -69.27 -25.96 64.52 Favored 'General case' 0 N--CA 1.453 -0.317 0 CA-C-N 116.097 -0.501 . . . . 0.0 109.965 178.529 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 4.9 m-80 -130.15 33.91 4.29 Favored 'General case' 0 CA--C 1.529 0.149 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.213 179.861 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 147' ' ' ALA . . . . . 0.573 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -117.89 54.88 0.89 Allowed 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.192 179.908 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.584 HG11 HD12 ' A' ' 91' ' ' LEU . 8.1 m -50.78 177.61 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.447 -179.972 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 149' ' ' GLY . . . . . 0.401 ' N ' ' HB3' ' A' ' 88' ' ' ARG . . . 81.75 -111.62 3.35 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.458 -179.948 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 58.9 mt-10 -138.4 105.64 5.49 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.877 0.37 . . . . 0.0 110.715 179.841 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 151' ' ' ILE . . . . . 0.574 HG12 HD22 ' A' ' 144' ' ' LEU . 1.1 mt -73.01 111.36 7.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.069 -179.802 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 152' ' ' HIS . . . . . 0.403 ' CE1' ' HA ' ' A' ' 128' ' ' ASN . 8.3 p80 -106.34 115.58 30.46 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 178.918 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 153' ' ' MET . . . . . 0.797 ' HB3' HG23 ' A' ' 127' ' ' ILE . 1.5 ptt? -140.35 176.13 9.03 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.324 0.583 . . . . 0.0 112.085 -178.663 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 17.6 mttm -126.94 147.69 50.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.194 -0.912 . . . . 0.0 109.812 179.153 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 155' ' ' THR . . . . . 0.554 HG22 ' CG1' ' A' ' 124' ' ' ILE . 4.7 p -142.73 145.27 33.16 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.977 0.418 . . . . 0.0 111.163 -179.515 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 156' ' ' MET . . . . . 0.424 ' O ' ' N ' ' A' ' 123' ' ' ARG . 6.6 ptp -133.12 156.65 79.75 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.631 179.647 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_exo -49.46 126.18 15.42 Favored 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.508 2.139 . . . . 0.0 112.623 -179.887 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 158' ' ' ALA . . . . . 0.646 ' HB2' HG12 ' A' ' 103' ' ' ILE . . . . . . . . 0 C--O 1.249 1.034 0 CA-C-O 118.26 -0.876 . . . . 0.0 111.016 179.823 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 21.5 t . . . . . 0 C--O 1.23 0.051 0 CA-C-O 120.811 0.338 . . . . 0.0 111.011 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.2 m -101.8 134.91 44.23 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.786 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 20.2 m -95.71 111.78 23.65 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.186 179.235 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.762 HG22 ' N ' ' A' ' 118' ' ' VAL . 62.2 t -85.63 105.37 14.29 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.41 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.401 -179.408 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.48 HD21 ' HB3' ' A' ' 150' ' ' GLU . 1.0 OUTLIER -103.17 83.68 2.23 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.058 -0.519 . . . . 0.0 109.652 178.893 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.845 HG21 ' CD2' ' A' ' 95' ' ' LEU . 12.6 mt -81.77 123.72 38.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-O 121.368 0.604 . . . . 0.0 111.717 -178.756 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.474 ' HB2' HG21 ' A' ' 112' ' ' ILE . 0.0 OUTLIER -71.98 132.5 44.39 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.776 -179.901 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.442 ' HG3' HD12 ' A' ' 151' ' ' ILE . 0.0 OUTLIER -130.14 90.43 42.11 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.705 179.969 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 89' ' ' PRO . . . . . 0.456 ' HG2' ' CD2' ' A' ' 93' ' ' TYR . 48.7 Cg_endo -68.87 -25.28 33.07 Favored 'Trans proline' 0 C--N 1.345 0.376 0 C-N-CA 122.552 2.168 . . . . 0.0 112.569 -179.912 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 90' ' ' ASP . . . . . 0.572 ' O ' HG23 ' A' ' 148' ' ' VAL . 0.6 OUTLIER -155.02 -169.57 3.23 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.978 0.418 . . . . 0.0 111.238 -179.856 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -97.44 -46.65 5.98 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.121 -179.82 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -57.01 -20.5 24.42 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.906 -0.588 . . . . 0.0 111.538 -179.631 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 93' ' ' TYR . . . . . 0.456 ' CD2' ' HG2' ' A' ' 89' ' ' PRO . 8.2 m-85 -60.3 -177.44 0.07 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.688 179.765 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -151.28 161.46 42.67 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.173 -179.941 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 0.845 ' CD2' HG21 ' A' ' 86' ' ' ILE . 1.4 mt -96.89 -50.34 4.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.698 179.898 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 88.78 72.0 1.27 Allowed Glycine 0 N--CA 1.452 -0.249 0 C-N-CA 120.797 -0.716 . . . . 0.0 113.096 179.456 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 97' ' ' PHE . . . . . 0.593 ' HE1' HD13 ' A' ' 95' ' ' LEU . 15.9 p90 -175.66 158.33 2.17 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.827 0.346 . . . . 0.0 111.174 179.57 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -105.17 146.64 28.96 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.681 179.924 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.436 ' CG2' HD12 ' A' ' 140' ' ' ILE . 7.3 p -130.63 134.02 62.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.307 -179.688 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -127.04 89.41 2.97 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.351 179.493 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 6.5 m120 57.11 18.74 4.27 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.052 -179.432 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 129.79 -41.44 1.54 Allowed Glycine 0 N--CA 1.448 -0.506 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.515 179.871 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.52 HG12 ' CB ' ' A' ' 158' ' ' ALA . 22.7 mt -77.57 129.5 37.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 121.077 0.465 . . . . 0.0 111.576 -179.344 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.872 HD11 ' CD1' ' A' ' 124' ' ' ILE . 3.6 mp -85.75 140.84 15.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.771 179.684 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 64.6 m -106.44 -69.89 0.81 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.826 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -100.86 141.25 34.01 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.788 179.859 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.405 ' CB ' HG22 ' A' ' 120' ' ' VAL . 5.7 tp -143.6 113.72 7.29 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.695 179.93 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 21.9 mmm -76.28 116.7 17.23 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.86 -179.839 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.05 78.88 0.05 OUTLIER 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.675 179.809 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 173.91 -34.24 0.11 Allowed Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.937 -0.649 . . . . 0.0 112.207 -179.811 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 111' ' ' GLY . . . . . 0.412 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -57.85 174.63 2.31 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.258 179.853 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.474 HG21 ' HB2' ' A' ' 87' ' ' ARG . 0.9 OUTLIER -78.53 -16.98 13.65 Favored 'Isoleucine or valine' 0 C--O 1.236 0.395 0 CA-C-O 120.91 0.386 . . . . 0.0 111.611 -179.886 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 113' ' ' ALA . . . . . 0.623 ' O ' HG12 ' A' ' 118' ' ' VAL . . . -57.81 -30.68 65.91 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.997 0.427 . . . . 0.0 110.875 179.908 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 114' ' ' GLU . . . . . 0.412 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 17.0 pt-20 -63.96 -46.85 82.84 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.856 179.828 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.4 ' N ' ' CG ' ' A' ' 114' ' ' GLU . 8.8 mtt180 -58.91 -47.33 85.39 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.087 -179.557 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.429 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -50.1 -72.67 0.45 Allowed Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.368 -0.92 . . . . 0.0 112.689 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 117' ' ' GLY . . . . . 0.521 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 172.34 -21.69 0.07 OUTLIER Glycine 0 CA--C 1.519 0.293 0 C-N-CA 120.972 -0.632 . . . . 0.0 112.674 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.762 ' N ' HG22 ' A' ' 84' ' ' VAL . 3.8 p -30.34 144.58 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.29 0 N-CA-C 112.327 0.492 . . . . 0.0 112.327 -179.78 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.425 ' HB3' ' CD2' ' A' ' 122' ' ' HIS . 0.0 OUTLIER -136.64 126.65 26.02 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.643 -179.992 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 120' ' ' VAL . . . . . 0.405 HG22 ' CB ' ' A' ' 107' ' ' LEU . 19.5 t -56.05 90.79 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.184 179.899 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 121.25 11.21 6.29 Favored Glycine 0 CA--C 1.52 0.379 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.8 -179.904 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 122' ' ' HIS . . . . . 0.425 ' CD2' ' HB3' ' A' ' 119' ' ' ARG . 6.9 m170 -98.24 132.21 43.94 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.891 0.377 . . . . 0.0 110.739 179.889 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 123' ' ' ARG . . . . . 0.871 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 0.0 OUTLIER -79.41 90.78 5.04 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.586 -179.622 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 124' ' ' ILE . . . . . 0.872 ' CD1' HD11 ' A' ' 104' ' ' ILE . 7.7 mt -54.13 143.15 6.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 N-CA-C 109.709 -0.478 . . . . 0.0 109.709 178.577 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 125' ' ' ILE . . . . . 0.796 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.5 OUTLIER -137.97 -82.84 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 N-CA-C 112.365 0.506 . . . . 0.0 112.365 -179.35 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 11.6 mt-10 -73.92 81.35 1.66 Allowed 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 112.538 0.57 . . . . 0.0 112.538 -178.776 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.97 HG23 ' CG ' ' A' ' 153' ' ' MET . 3.0 mt -82.61 92.44 2.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.95 179.045 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 128' ' ' ASN . . . . . 0.406 ' N ' ' O ' ' A' ' 152' ' ' HIS . 1.6 t-20 58.9 21.11 8.78 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.014 -179.915 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 119.08 -18.5 10.37 Favored Glycine 0 C--N 1.332 0.349 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.787 -179.944 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -94.72 112.02 23.77 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.837 0.351 . . . . 0.0 110.922 -179.842 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 3.6 p -76.22 96.4 3.91 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.0 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 132' ' ' VAL . . . . . 0.699 HG11 HD12 ' A' ' 127' ' ' ILE . 27.4 m -81.04 2.64 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.323 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.86 179.983 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.796 ' HB ' HG22 ' A' ' 125' ' ' ILE . 9.0 p -44.43 -42.57 2.14 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.178 0 CA-C-O 120.922 0.392 . . . . 0.0 111.661 -179.761 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 134' ' ' ALA . . . . . 0.429 ' N ' HG13 ' A' ' 133' ' ' VAL . . . -116.55 29.73 7.77 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.843 179.587 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 135' ' ' THR . . . . . 0.478 HG23 ' HD2' ' A' ' 136' ' ' PRO . 85.4 m -111.92 140.17 23.11 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.089 -179.834 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 136' ' ' PRO . . . . . 0.478 ' HD2' HG23 ' A' ' 135' ' ' THR . 10.6 Cg_endo -54.44 164.23 3.08 Favored 'Trans proline' 0 C--N 1.347 0.455 0 C-N-CA 122.646 2.23 . . . . 0.0 112.333 179.895 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 15.2 p80 -67.44 -46.65 72.47 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.603 -179.593 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -53.68 -35.21 60.83 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.387 -0.369 . . . . 0.0 111.468 -179.445 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 139' ' ' LYS . . . . . 0.783 ' O ' HD12 ' A' ' 143' ' ' ILE . 0.1 OUTLIER -65.36 -48.94 71.2 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.85 0.357 . . . . 0.0 111.079 -179.8 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 140' ' ' ILE . . . . . 0.836 HG23 ' CD1' ' A' ' 127' ' ' ILE . 10.1 mt -58.58 -46.19 90.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.529 -179.925 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 141' ' ' VAL . . . . . 0.405 ' CG2' ' CG1' ' A' ' 99' ' ' VAL . 86.8 t -60.41 -32.29 50.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.058 178.797 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 9.1 t-80 -60.65 -52.94 63.01 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.664 179.585 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 143' ' ' ILE . . . . . 0.783 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.2 mp -53.25 -57.03 5.59 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.456 0 CA-C-O 121.151 0.5 . . . . 0.0 110.178 179.364 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.686 HD22 HG12 ' A' ' 151' ' ' ILE . 4.5 mt -60.96 -30.23 70.12 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.279 179.699 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 1.3 m -68.56 -27.0 65.69 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.13 -0.486 . . . . 0.0 109.887 178.572 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 9.0 m120 -127.82 32.59 4.93 Favored 'General case' 0 CA--C 1.528 0.109 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.124 179.813 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 147' ' ' ALA . . . . . 0.512 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -119.26 63.45 0.79 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.375 -0.375 . . . . 0.0 111.223 179.915 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.694 HG22 ' H ' ' A' ' 149' ' ' GLY . 1.6 p -60.11 -157.28 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.983 -179.869 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 149' ' ' GLY . . . . . 0.694 ' H ' HG22 ' A' ' 148' ' ' VAL . . . 58.0 -109.94 2.15 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.867 -0.683 . . . . 0.0 112.438 -179.961 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.48 ' HB3' HD21 ' A' ' 85' ' ' LEU . 3.9 mm-40 -131.18 100.13 5.1 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.739 0.304 . . . . 0.0 110.526 179.791 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 151' ' ' ILE . . . . . 0.686 HG12 HD22 ' A' ' 144' ' ' LEU . 0.3 OUTLIER -63.04 111.73 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.982 0.42 . . . . 0.0 111.213 -179.751 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 152' ' ' HIS . . . . . 0.406 ' O ' ' N ' ' A' ' 128' ' ' ASN . 1.2 t-80 -95.56 121.32 37.13 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 178.943 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 153' ' ' MET . . . . . 0.97 ' CG ' HG23 ' A' ' 127' ' ' ILE . 29.3 mtp -137.74 166.43 23.98 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.386 0.612 . . . . 0.0 112.368 -178.525 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 154' ' ' LYS . . . . . 0.405 ' O ' HG13 ' A' ' 125' ' ' ILE . 0.9 OUTLIER -143.34 132.19 22.74 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 114.852 -1.067 . . . . 0.0 108.811 178.762 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 155' ' ' THR . . . . . 0.441 HG22 HG12 ' A' ' 124' ' ' ILE . 1.3 p -138.57 161.25 37.56 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.333 0.587 . . . . 0.0 112.176 -178.53 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 156' ' ' MET . . . . . 0.42 ' O ' ' N ' ' A' ' 123' ' ' ARG . 5.1 ptp -135.58 160.03 69.28 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 115.133 -0.94 . . . . 0.0 109.953 179.174 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 21.6 Cg_endo -61.67 118.36 5.23 Favored 'Trans proline' 0 C--N 1.343 0.274 0 C-N-CA 122.366 2.044 . . . . 0.0 112.544 -179.675 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 158' ' ' ALA . . . . . 0.871 ' HB2' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.25 1.092 0 CA-C-O 118.211 -0.9 . . . . 0.0 111.037 179.749 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 10.3 p . . . . . 0 C--O 1.231 0.1 0 CA-C-O 120.718 0.294 . . . . 0.0 110.864 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.8 m -121.35 142.94 49.49 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.013 -179.842 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 5.4 m -101.37 111.15 23.3 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.135 179.2 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 1.018 HG11 HG23 ' A' ' 118' ' ' VAL . 41.4 t -82.85 105.95 13.18 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.562 0 CA-C-N 115.949 -0.569 . . . . 0.0 112.184 -179.215 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.456 ' O ' HD23 ' A' ' 85' ' ' LEU . 7.1 tt -99.96 79.81 2.24 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 178.069 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.892 HG13 HG12 ' A' ' 84' ' ' VAL . 3.3 mt -82.66 104.95 11.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.767 -178.413 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.785 ' O ' HG21 ' A' ' 112' ' ' ILE . 0.0 OUTLIER -74.93 108.31 7.57 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.428 179.21 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.494 ' HG3' HD12 ' A' ' 151' ' ' ILE . 10.4 mtp180 -92.32 111.45 50.52 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.184 -179.646 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_exo -62.26 -63.9 0.09 OUTLIER 'Trans proline' 0 C--N 1.346 0.445 0 C-N-CA 122.572 2.181 . . . . 0.0 112.407 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 3.1 t0 -121.44 -173.36 2.61 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.919 0.39 . . . . 0.0 111.165 -179.71 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 0.552 ' HG ' HG13 ' A' ' 148' ' ' VAL . 0.0 OUTLIER -94.82 -21.2 18.86 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.281 -179.905 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -96.7 23.28 7.14 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.81 0.338 . . . . 0.0 111.14 -179.877 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 2.0 m-85 -102.23 178.41 4.6 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.824 179.827 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -135.71 143.61 45.46 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.017 -179.918 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 0.778 ' CD2' HD13 ' A' ' 86' ' ' ILE . 8.3 mp -72.57 -31.06 64.94 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.798 179.872 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 82.96 55.16 3.01 Favored Glycine 0 C--N 1.33 0.242 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.968 179.626 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -173.17 156.82 3.29 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.836 0.351 . . . . 0.0 111.144 179.82 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.2 m -99.28 155.92 17.25 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.677 179.804 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.43 ' CG1' ' CG2' ' A' ' 141' ' ' VAL . 8.5 p -133.0 132.15 58.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.927 0.394 . . . . 0.0 111.336 -179.86 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -128.97 89.27 2.85 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.27 179.509 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 3.3 m-80 58.25 17.25 4.52 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.126 -179.637 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 129.81 -40.09 1.73 Allowed Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.261 179.905 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.524 HG12 ' CB ' ' A' ' 158' ' ' ALA . 30.1 mt -77.24 130.19 36.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 121.098 0.475 . . . . 0.0 111.522 -179.677 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.807 HD11 ' CD1' ' A' ' 124' ' ' ILE . 3.8 mp -83.96 139.67 17.28 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.793 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -84.62 -75.62 0.34 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.328 -179.479 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -132.37 121.75 23.96 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.917 0.389 . . . . 0.0 111.114 -179.74 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.408 HD12 ' N ' ' A' ' 108' ' ' MET . 7.8 tp -105.57 116.2 31.53 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.463 179.761 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 108' ' ' MET . . . . . 0.408 ' N ' HD12 ' A' ' 107' ' ' LEU . 36.2 mtm -69.27 132.94 47.26 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.056 -179.807 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -67.18 76.14 0.14 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.549 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 174.63 -34.22 0.1 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.285 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 111' ' ' GLY . . . . . 0.439 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -56.54 176.26 1.05 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.438 179.774 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.785 HG21 ' O ' ' A' ' 87' ' ' ARG . 1.8 mt -78.61 -22.04 13.09 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-O 120.782 0.325 . . . . 0.0 111.615 -179.846 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 113' ' ' ALA . . . . . . . . . . . . . . . -57.82 -30.31 65.63 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.008 0.432 . . . . 0.0 110.702 179.828 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 114' ' ' GLU . . . . . 0.439 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 19.6 pt-20 -60.63 -47.19 87.32 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.89 -0.595 . . . . 0.0 111.197 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 3.8 mtm180 -66.59 -41.33 88.67 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.241 -179.294 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -56.19 -72.63 0.54 Allowed Glycine 0 N--CA 1.448 -0.539 0 C-N-CA 120.398 -0.906 . . . . 0.0 112.669 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 117' ' ' GLY . . . . . 0.428 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 161.09 -10.67 0.13 Allowed Glycine 0 CA--C 1.522 0.47 0 C-N-CA 121.219 -0.515 . . . . 0.0 112.851 -179.879 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 1.018 HG23 HG11 ' A' ' 84' ' ' VAL . 2.2 t -29.75 -71.46 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 C-N-CA 123.11 0.564 . . . . 0.0 112.306 -179.677 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.654 ' N ' HG12 ' A' ' 118' ' ' VAL . 0.0 OUTLIER 64.32 136.12 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.467 -179.486 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 120' ' ' VAL . . . . . 0.403 ' CG2' ' HB3' ' A' ' 107' ' ' LEU . 20.2 t -69.73 116.98 11.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.447 -0.342 . . . . 0.0 111.427 -179.69 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 112.55 33.25 2.12 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.799 179.644 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 1.5 m-70 -135.71 132.96 37.55 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.831 0.348 . . . . 0.0 110.991 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 123' ' ' ARG . . . . . 0.977 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 72.3 ttt180 -88.76 95.29 10.22 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.65 -179.686 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 124' ' ' ILE . . . . . 0.807 ' CD1' HD11 ' A' ' 104' ' ' ILE . 11.7 mt -49.68 146.63 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 178.657 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 125' ' ' ILE . . . . . 0.924 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.6 OUTLIER -137.11 -84.8 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 N-CA-C 112.772 0.656 . . . . 0.0 112.772 -178.924 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 19.5 mt-10 -80.8 90.86 5.87 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 112.454 0.538 . . . . 0.0 112.454 -178.383 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.823 HG23 ' HB3' ' A' ' 153' ' ' MET . 1.8 mt -92.15 100.79 11.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.288 179.284 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 128' ' ' ASN . . . . . 0.404 ' N ' ' O ' ' A' ' 152' ' ' HIS . 20.3 m120 57.82 17.87 4.52 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.622 179.815 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 121.69 -20.69 8.18 Favored Glycine 0 C--N 1.333 0.39 0 C-N-CA 120.348 -0.929 . . . . 0.0 113.381 179.406 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -98.22 120.96 39.53 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 117.256 0.528 . . . . 0.0 111.038 -179.727 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 67.4 p -79.25 94.62 5.47 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.362 -179.838 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 132' ' ' VAL . . . . . 0.782 HG21 HD11 ' A' ' 127' ' ' ILE . 31.0 m -74.62 -4.87 6.17 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.304 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.594 179.679 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.924 ' HB ' HG22 ' A' ' 125' ' ' ILE . 6.6 p -46.5 -37.69 3.32 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.141 0 CA-C-O 120.895 0.379 . . . . 0.0 111.526 -179.683 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -116.99 29.66 7.79 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.719 179.602 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 135' ' ' THR . . . . . 0.526 HG23 ' HD2' ' A' ' 136' ' ' PRO . 87.9 m -117.24 141.94 29.37 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-N 115.881 -0.6 . . . . 0.0 111.033 -179.759 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 136' ' ' PRO . . . . . 0.526 ' HD2' HG23 ' A' ' 135' ' ' THR . 7.6 Cg_endo -49.65 164.04 0.41 Allowed 'Trans proline' 0 C--N 1.347 0.477 0 C-N-CA 122.77 2.313 . . . . 0.0 112.23 179.685 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 51.4 p-80 -73.38 -45.95 51.84 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.539 -179.655 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -53.78 -36.94 62.95 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.373 -179.55 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 139' ' ' LYS . . . . . 0.728 ' O ' HD12 ' A' ' 143' ' ' ILE . 0.1 OUTLIER -63.26 -47.34 82.78 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.895 -179.857 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 8.6 mt -58.74 -41.79 83.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.965 0.412 . . . . 0.0 110.646 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 141' ' ' VAL . . . . . 0.43 ' CG2' ' CG1' ' A' ' 99' ' ' VAL . 90.1 t -63.51 -32.68 57.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.28 179.139 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 56.7 t60 -62.33 -54.57 38.54 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.828 179.943 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 143' ' ' ILE . . . . . 0.728 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.3 mp -53.23 -56.83 6.36 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.395 0 CA-C-O 121.112 0.482 . . . . 0.0 110.138 179.373 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.721 HD13 ' CD2' ' A' ' 95' ' ' LEU . 5.1 mt -60.63 -30.28 69.77 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.47 -0.786 . . . . 0.0 110.313 179.409 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 2.3 m -67.65 -27.08 66.56 Favored 'General case' 0 N--CA 1.453 -0.323 0 CA-C-N 116.164 -0.471 . . . . 0.0 109.981 178.471 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 4.6 m-80 -130.28 34.73 4.16 Favored 'General case' 0 CA--C 1.527 0.087 0 CA-C-N 116.013 -0.54 . . . . 0.0 111.215 179.796 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 147' ' ' ALA . . . . . 0.569 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -118.65 55.26 0.92 Allowed 'General case' 0 C--O 1.232 0.149 0 CA-C-O 120.864 0.364 . . . . 0.0 111.451 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.552 HG13 ' HG ' ' A' ' 91' ' ' LEU . 2.8 m -55.84 174.89 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.181 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 88.64 -101.69 2.77 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.813 -0.708 . . . . 0.0 112.606 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 29.8 mt-10 -148.95 94.49 2.26 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.786 0.327 . . . . 0.0 110.989 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 151' ' ' ILE . . . . . 0.569 HD11 ' HB3' ' A' ' 147' ' ' ALA . 1.2 mt -61.75 112.2 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.995 179.939 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 152' ' ' HIS . . . . . 0.404 ' O ' ' N ' ' A' ' 128' ' ' ASN . 0.3 OUTLIER -102.68 115.53 30.77 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.076 179.144 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 153' ' ' MET . . . . . 0.823 ' HB3' HG23 ' A' ' 127' ' ' ILE . 1.8 ptm -147.59 166.68 26.62 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.129 0.49 . . . . 0.0 111.875 -179.111 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 35.4 mttp -112.58 155.99 23.43 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.889 179.146 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 155' ' ' THR . . . . . 0.436 HG23 HG23 ' A' ' 84' ' ' VAL . 13.8 p -141.2 144.13 34.58 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.226 0.536 . . . . 0.0 111.915 -179.451 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 156' ' ' MET . . . . . 0.597 ' CE ' HD13 ' A' ' 125' ' ' ILE . 1.5 mtm -110.86 179.94 0.74 Allowed Pre-proline 0 C--N 1.33 -0.241 0 CA-C-N 115.257 -0.883 . . . . 0.0 110.072 179.593 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 157' ' ' PRO . . . . . 0.418 ' CD ' ' CB ' ' A' ' 156' ' ' MET . 90.2 Cg_endo -92.68 106.98 0.2 Allowed 'Trans proline' 0 N--CA 1.456 -0.725 0 C-N-CA 122.757 2.305 . . . . 0.0 112.511 -179.919 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 158' ' ' ALA . . . . . 0.977 ' HB2' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.249 1.039 0 CA-C-O 118.186 -0.912 . . . . 0.0 111.036 179.801 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.498 HG22 ' HE3' ' A' ' 156' ' ' MET . 44.7 t . . . . . 0 C--O 1.232 0.144 0 CA-C-O 120.819 0.342 . . . . 0.0 110.922 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.7 m -131.31 140.04 49.68 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.02 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 6.8 m -100.29 111.3 23.57 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.149 179.284 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.829 HG12 HG13 ' A' ' 86' ' ' ILE . 49.5 t -83.68 106.57 14.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.929 -179.339 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.474 HD23 ' C ' ' A' ' 85' ' ' LEU . 7.0 tt -105.88 81.57 1.67 Allowed 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 178.317 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.829 HG13 HG12 ' A' ' 84' ' ' VAL . 12.7 mt -81.52 152.26 4.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.549 -178.498 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.404 ' CG ' ' CG2' ' A' ' 112' ' ' ILE . 0.0 OUTLIER -111.68 141.39 45.35 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.797 -179.426 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 11.5 mtp85 -140.27 84.32 14.65 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.85 179.812 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 63.7 Cg_exo -51.66 -35.44 57.34 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.656 2.238 . . . . 0.0 112.516 -179.817 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 90' ' ' ASP . . . . . 0.621 ' O ' HG12 ' A' ' 148' ' ' VAL . 0.3 OUTLIER -136.06 -169.64 2.47 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.942 0.401 . . . . 0.0 111.134 -179.777 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 0.787 ' HG ' HG11 ' A' ' 148' ' ' VAL . 3.9 mt -93.63 -43.17 8.8 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.783 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 2.3 mpp_? -63.27 -14.79 53.39 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.84 -0.618 . . . . 0.0 111.703 -179.595 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 7.5 m-85 -56.69 174.72 0.14 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.866 0.365 . . . . 0.0 110.915 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.491 ' O ' HD12 ' A' ' 112' ' ' ILE . 9.0 mp0 -138.6 166.13 25.14 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.027 -179.943 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 0.67 HD11 ' HB3' ' A' ' 144' ' ' LEU . 1.1 mt -97.66 -49.07 4.99 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.877 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 91.62 50.92 2.61 Favored Glycine 0 C--N 1.331 0.298 0 C-N-CA 120.728 -0.748 . . . . 0.0 113.108 179.5 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 97' ' ' PHE . . . . . 0.519 ' HE1' HD13 ' A' ' 95' ' ' LEU . 0.5 OUTLIER -168.95 162.97 11.39 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.795 0.331 . . . . 0.0 111.039 179.64 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -110.55 133.95 52.83 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.726 179.907 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.629 HG21 HG21 ' A' ' 140' ' ' ILE . 11.4 p -110.46 132.13 59.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.378 -179.813 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 3.6 mt-30 -129.08 89.51 2.88 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.222 179.485 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 2.4 m120 59.67 18.04 6.8 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.037 -0.528 . . . . 0.0 111.0 -179.406 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 124.9 -37.29 2.61 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.441 179.887 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.56 HG12 ' CB ' ' A' ' 158' ' ' ALA . 28.3 mt -77.28 140.29 17.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.97 0.414 . . . . 0.0 111.598 -179.603 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.875 HD11 ' CD1' ' A' ' 124' ' ' ILE . 4.5 mp -100.23 137.13 28.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.818 179.732 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -114.93 -64.31 1.33 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.876 -179.898 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 5.1 m -86.16 145.15 27.13 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.862 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 3.9 tt -162.26 116.54 1.83 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.705 179.81 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 3.6 tmm? -94.44 128.86 41.27 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.991 -179.774 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -65.44 79.5 0.06 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.64 179.744 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 176.89 -35.22 0.09 OUTLIER Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 120.927 -0.654 . . . . 0.0 111.956 -179.843 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 111' ' ' GLY . . . . . 0.402 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -59.18 167.86 7.16 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.017 179.613 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.491 HD12 ' O ' ' A' ' 94' ' ' GLN . 1.0 OUTLIER -78.36 -16.54 13.79 Favored 'Isoleucine or valine' 0 C--O 1.235 0.313 0 CA-C-O 120.872 0.367 . . . . 0.0 111.6 -179.837 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 113' ' ' ALA . . . . . 0.4 ' HA ' HG12 ' A' ' 86' ' ' ILE . . . -57.97 -30.44 66.02 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.969 0.414 . . . . 0.0 110.556 179.797 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 114' ' ' GLU . . . . . 0.402 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 16.4 pt-20 -60.42 -47.02 87.91 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.859 179.665 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -63.16 -47.32 83.16 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.049 -179.52 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.401 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -49.64 -73.8 0.33 Allowed Glycine 0 CA--C 1.52 0.379 0 C-N-CA 120.414 -0.898 . . . . 0.0 112.6 -179.862 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 117' ' ' GLY . . . . . 0.555 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 169.8 -19.79 0.07 OUTLIER Glycine 0 CA--C 1.519 0.296 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.719 -179.937 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.764 ' N ' HG22 ' A' ' 84' ' ' VAL . 1.2 t -40.46 108.21 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.529 0.149 0 CA-C-O 120.999 0.428 . . . . 0.0 111.494 -179.791 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 6.1 mtp180 -102.75 128.34 49.52 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.612 179.751 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 22.2 t -54.06 92.61 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 121.017 0.437 . . . . 0.0 111.1 -179.815 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 128.58 -0.08 6.28 Favored Glycine 0 CA--C 1.519 0.297 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.999 -179.944 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 1.4 m170 -93.82 133.1 37.57 Favored 'General case' 0 C--O 1.232 0.156 0 CA-C-O 120.876 0.37 . . . . 0.0 110.865 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 123' ' ' ARG . . . . . 0.941 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 0.2 OUTLIER -83.27 91.62 7.32 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.009 -0.541 . . . . 0.0 111.791 -179.509 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 124' ' ' ILE . . . . . 0.875 ' CD1' HD11 ' A' ' 104' ' ' ILE . 14.9 mt -51.03 142.93 3.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 N-CA-C 109.638 -0.504 . . . . 0.0 109.638 178.572 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 125' ' ' ILE . . . . . 0.815 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.6 OUTLIER -136.65 -83.98 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 N-CA-C 112.995 0.739 . . . . 0.0 112.995 -178.581 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -78.5 85.82 4.56 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 112.733 0.642 . . . . 0.0 112.733 -178.28 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.858 HG23 ' HB3' ' A' ' 153' ' ' MET . 1.4 mt -90.61 104.32 15.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-O 121.071 0.462 . . . . 0.0 110.897 178.872 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 59.1 m-20 53.19 24.35 3.62 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.202 -179.93 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 111.47 -16.42 26.7 Favored Glycine 0 CA--C 1.519 0.33 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.944 179.879 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 10.4 tt0 -94.09 113.12 25.02 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.865 0.365 . . . . 0.0 111.04 -179.855 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -77.52 93.96 4.24 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.087 -179.974 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 132' ' ' VAL . . . . . 0.617 HG11 ' CD1' ' A' ' 127' ' ' ILE . 28.2 m -75.88 -3.31 4.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.183 -0.462 . . . . 0.0 112.038 -179.977 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.815 ' HB ' HG22 ' A' ' 125' ' ' ILE . 7.2 p -45.16 -38.26 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 CA-C-O 120.856 0.36 . . . . 0.0 111.616 -179.596 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -121.14 28.16 8.0 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.765 179.508 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 135' ' ' THR . . . . . 0.565 HG22 ' HB3' ' A' ' 139' ' ' LYS . 43.3 m -109.48 140.52 22.18 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.999 -179.88 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 136' ' ' PRO . . . . . 0.46 ' HD2' HG23 ' A' ' 135' ' ' THR . 11.1 Cg_endo -54.26 151.02 30.54 Favored 'Trans proline' 0 C--N 1.346 0.403 0 C-N-CA 122.654 2.236 . . . . 0.0 112.1 179.694 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 3.8 p-80 -60.41 -33.69 72.86 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.51 -179.727 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -62.53 -39.3 93.14 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.815 0.34 . . . . 0.0 111.227 -179.661 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 139' ' ' LYS . . . . . 0.677 ' O ' HD12 ' A' ' 143' ' ' ILE . 1.7 tptp -62.84 -46.17 89.18 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.025 -179.72 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 140' ' ' ILE . . . . . 0.629 HG21 HG21 ' A' ' 99' ' ' VAL . 7.5 mt -58.97 -46.13 91.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.697 -179.819 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 141' ' ' VAL . . . . . 0.413 ' CG2' ' CG1' ' A' ' 99' ' ' VAL . 89.1 t -60.87 -32.46 52.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.22 179.235 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -61.56 -54.95 36.26 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.966 179.888 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 143' ' ' ILE . . . . . 0.677 HD12 ' O ' ' A' ' 139' ' ' LYS . 3.9 mp -53.18 -57.42 4.8 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.476 0 CA-C-O 121.185 0.517 . . . . 0.0 110.229 179.463 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.743 HD22 HG12 ' A' ' 151' ' ' ILE . 2.6 mt -60.36 -30.06 69.31 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.219 -0.9 . . . . 0.0 110.445 179.571 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 2.2 m -67.23 -27.99 67.69 Favored 'General case' 0 N--CA 1.454 -0.251 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.024 178.825 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 44.1 m-20 -134.35 37.73 3.14 Favored 'General case' 0 CA--C 1.527 0.095 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.192 179.83 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 147' ' ' ALA . . . . . 0.616 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -111.62 40.17 2.18 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.484 -0.326 . . . . 0.0 111.43 -179.848 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.787 HG11 ' HG ' ' A' ' 91' ' ' LEU . 4.3 m -48.27 143.52 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.818 0.342 . . . . 0.0 111.412 179.884 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 118.65 -109.55 1.77 Allowed Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.443 -179.829 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.405 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 70.4 mt-10 -137.86 90.17 2.47 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.758 0.313 . . . . 0.0 110.77 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 151' ' ' ILE . . . . . 0.743 HG12 HD22 ' A' ' 144' ' ' LEU . 1.2 mp -65.54 111.82 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-O 121.012 0.434 . . . . 0.0 110.804 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 4.0 t60 -109.64 115.8 30.56 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.358 179.559 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 153' ' ' MET . . . . . 0.858 ' HB3' HG23 ' A' ' 127' ' ' ILE . 0.0 OUTLIER -144.37 166.23 25.69 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.194 0.521 . . . . 0.0 112.033 -179.258 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 154' ' ' LYS . . . . . 0.406 ' HG2' ' CG1' ' A' ' 81' ' ' VAL . 0.0 OUTLIER -109.74 151.81 26.45 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.526 -0.761 . . . . 0.0 109.346 178.665 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 155' ' ' THR . . . . . 0.453 HG22 HG12 ' A' ' 124' ' ' ILE . 16.1 p -139.84 138.61 35.89 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.054 0.454 . . . . 0.0 111.697 -179.453 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 156' ' ' MET . . . . . 0.498 ' HE3' HG22 ' A' ' 81' ' ' VAL . 0.0 OUTLIER -101.72 178.68 1.16 Allowed Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 115.474 -0.784 . . . . 0.0 110.31 179.732 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 157' ' ' PRO . . . . . 0.42 ' HD2' ' HB3' ' A' ' 156' ' ' MET . 94.7 Cg_endo -91.99 96.19 0.19 Allowed 'Trans proline' 0 N--CA 1.456 -0.722 0 C-N-CA 122.765 2.31 . . . . 0.0 112.505 -179.773 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 158' ' ' ALA . . . . . 0.941 ' HB2' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.201 -0.904 . . . . 0.0 111.051 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 40.6 t . . . . . 0 C--O 1.23 0.049 0 CA-C-O 120.846 0.355 . . . . 0.0 110.932 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 1.8 m -124.62 142.65 51.21 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.931 179.842 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 4.1 m -101.73 111.44 23.69 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.22 179.267 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.76 HG22 ' N ' ' A' ' 118' ' ' VAL . 60.9 t -87.71 106.08 15.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.439 -179.461 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.424 ' O ' ' HA2' ' A' ' 116' ' ' GLY . 2.5 tt -104.33 85.55 2.38 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.094 -0.503 . . . . 0.0 109.827 178.778 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 1.054 HG21 HD23 ' A' ' 95' ' ' LEU . 3.5 mt -81.35 138.59 19.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 121.008 0.433 . . . . 0.0 111.306 -179.064 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.489 ' HG2' HG22 ' A' ' 112' ' ' ILE . 0.1 OUTLIER -98.77 108.83 21.61 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.507 -179.723 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 8.5 mmt180 -103.39 103.37 35.04 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.016 -179.84 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 89' ' ' PRO . . . . . 0.454 ' HG2' ' CG ' ' A' ' 93' ' ' TYR . 56.3 Cg_endo -70.49 -28.33 21.88 Favored 'Trans proline' 0 C--N 1.347 0.472 0 C-N-CA 122.385 2.056 . . . . 0.0 112.332 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 90' ' ' ASP . . . . . 0.442 ' HB2' ' CD1' ' A' ' 93' ' ' TYR . 2.9 m-20 -164.4 -175.49 3.93 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.876 0.37 . . . . 0.0 111.131 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 1.5 mp -80.32 -31.56 38.06 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.984 -179.884 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -73.84 -6.26 46.03 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.693 -179.708 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 93' ' ' TYR . . . . . 0.454 ' CG ' ' HG2' ' A' ' 89' ' ' PRO . 28.5 m-85 -104.7 110.37 22.66 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.803 0.335 . . . . 0.0 110.866 179.932 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -80.29 179.34 7.72 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.981 -179.927 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 1.054 HD23 HG21 ' A' ' 86' ' ' ILE . 0.6 OUTLIER -91.42 -66.67 0.91 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.749 179.902 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 118.83 63.51 0.29 Allowed Glycine 0 C--N 1.33 0.224 0 C-N-CA 120.566 -0.825 . . . . 0.0 112.959 179.57 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 19.5 p90 -176.82 161.64 2.04 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.807 0.337 . . . . 0.0 110.967 179.664 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 14.5 m -102.64 145.49 29.58 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.768 179.792 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.683 HG21 HG21 ' A' ' 140' ' ' ILE . 10.1 p -126.08 130.56 72.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.332 -179.809 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 4.3 mt-30 -129.83 89.5 2.83 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.253 179.625 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 85.7 m-20 60.22 18.22 7.68 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.858 -179.343 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 123.23 -36.95 2.91 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 120.934 -0.651 . . . . 0.0 112.409 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.695 HG12 ' HB2' ' A' ' 158' ' ' ALA . 26.6 mt -77.24 130.77 35.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 121.018 0.437 . . . . 0.0 111.506 -179.619 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.732 HD11 ' CD1' ' A' ' 124' ' ' ILE . 3.7 mp -82.32 139.52 17.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.87 179.787 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -100.52 -78.79 0.51 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.104 -179.793 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 18.4 m -108.43 135.57 49.51 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.91 -179.826 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.618 HD11 HG13 ' A' ' 118' ' ' VAL . 0.9 OUTLIER -110.75 108.73 18.69 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.823 179.89 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 41.1 mtm -73.01 100.39 2.97 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.965 -179.929 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 25.0 mmt85 -56.97 122.09 11.48 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.78 179.888 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 129.44 -31.29 3.45 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.85 -0.691 . . . . 0.0 112.024 -179.683 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 111' ' ' GLY . . . . . 0.424 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -66.68 175.81 21.46 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.716 -0.755 . . . . 0.0 112.273 179.688 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.489 HG22 ' HG2' ' A' ' 87' ' ' ARG . 0.8 OUTLIER -78.63 -18.18 13.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-O 120.88 0.372 . . . . 0.0 111.62 -179.842 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 113' ' ' ALA . . . . . 0.533 ' HB1' HG11 ' A' ' 118' ' ' VAL . . . -58.31 -30.25 66.51 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.95 0.405 . . . . 0.0 110.611 179.817 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 114' ' ' GLU . . . . . 0.424 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 15.2 pt-20 -59.87 -45.65 91.79 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.731 179.503 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -64.69 -46.96 80.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.2 -179.433 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.424 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -51.05 -74.03 0.32 Allowed Glycine 0 CA--C 1.518 0.262 0 C-N-CA 120.355 -0.926 . . . . 0.0 112.59 -179.908 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 117' ' ' GLY . . . . . 0.443 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 175.5 -20.91 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.938 -0.649 . . . . 0.0 112.808 -179.958 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.76 ' N ' HG22 ' A' ' 84' ' ' VAL . 0.3 OUTLIER -34.7 128.07 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.23 0 CA-C-O 120.912 0.387 . . . . 0.0 112.026 -179.801 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -136.66 144.85 44.21 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.847 -179.822 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 120' ' ' VAL . . . . . 0.519 HG22 ' HB2' ' A' ' 107' ' ' LEU . 22.7 t -70.43 102.47 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.208 -179.981 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 119.7 49.11 0.32 Allowed Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.61 -0.805 . . . . 0.0 112.681 179.869 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 5.4 m170 -154.29 132.65 11.95 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.834 0.35 . . . . 0.0 110.857 179.849 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 123' ' ' ARG . . . . . 0.919 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 2.8 ttt180 -87.85 95.71 10.2 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.664 -179.532 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 124' ' ' ILE . . . . . 0.732 ' CD1' HD11 ' A' ' 104' ' ' ILE . 9.1 mt -49.71 159.14 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 178.771 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 125' ' ' ILE . . . . . 0.813 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.6 OUTLIER -148.79 -82.23 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 N-CA-C 112.567 0.58 . . . . 0.0 112.567 -179.579 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 126' ' ' GLU . . . . . 0.41 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 13.7 mt-10 -76.88 80.84 3.45 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 112.44 0.533 . . . . 0.0 112.44 -178.69 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.954 HG23 ' CG ' ' A' ' 153' ' ' MET . 2.8 mt -82.99 90.8 2.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 121.05 0.452 . . . . 0.0 111.153 179.117 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 128' ' ' ASN . . . . . 0.452 ' N ' ' O ' ' A' ' 152' ' ' HIS . 1.2 m-20 56.99 29.84 17.11 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.9 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 109.34 -15.11 32.93 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.774 -0.726 . . . . 0.0 112.686 -179.892 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 20.7 tt0 -95.04 106.03 17.99 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.895 0.379 . . . . 0.0 110.846 -179.921 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 11.7 p -73.5 90.3 1.72 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.851 179.971 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 132' ' ' VAL . . . . . 0.747 HG11 HD12 ' A' ' 127' ' ' ILE . 27.2 m -75.2 -2.86 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.29 0 CA-C-N 116.31 -0.405 . . . . 0.0 112.013 -179.828 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.813 ' HB ' HG22 ' A' ' 125' ' ' ILE . 10.4 p -44.77 -42.1 2.29 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.148 0 CA-C-O 120.862 0.363 . . . . 0.0 111.558 -179.731 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 134' ' ' ALA . . . . . 0.439 ' N ' HG13 ' A' ' 133' ' ' VAL . . . -116.2 29.54 7.9 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.891 179.578 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 135' ' ' THR . . . . . 0.479 HG22 ' HB3' ' A' ' 139' ' ' LYS . 38.1 m -114.73 140.06 24.9 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.175 -179.839 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 136' ' ' PRO . . . . . 0.447 ' HD2' HG23 ' A' ' 135' ' ' THR . 11.5 Cg_endo -55.32 164.06 4.23 Favored 'Trans proline' 0 C--N 1.348 0.512 0 C-N-CA 122.652 2.235 . . . . 0.0 112.121 179.766 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 18.8 p-80 -66.43 -45.79 78.67 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.749 -179.557 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -53.71 -39.78 65.49 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.562 -179.341 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 139' ' ' LYS . . . . . 0.725 ' O ' HD12 ' A' ' 143' ' ' ILE . 8.7 tttt -62.7 -46.71 86.89 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.467 -0.333 . . . . 0.0 111.131 -179.7 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 140' ' ' ILE . . . . . 0.683 HG21 HG21 ' A' ' 99' ' ' VAL . 9.0 mt -58.32 -45.92 89.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.735 -179.836 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 141' ' ' VAL . . . . . 0.411 ' CG2' ' CG1' ' A' ' 99' ' ' VAL . 82.6 t -60.87 -32.64 52.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.334 179.244 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -62.02 -55.19 31.76 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.012 179.908 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 143' ' ' ILE . . . . . 0.725 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.2 mp -52.83 -56.9 5.54 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.489 0 CA-C-O 121.321 0.581 . . . . 0.0 110.248 179.459 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.794 ' HB3' HD11 ' A' ' 95' ' ' LEU . 3.0 mt -61.2 -30.11 70.22 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.305 -0.861 . . . . 0.0 110.398 179.579 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 3.0 m -68.78 -26.74 65.36 Favored 'General case' 0 N--CA 1.454 -0.226 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.022 178.691 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 8.0 m120 -129.92 33.92 4.34 Favored 'General case' 0 CA--C 1.527 0.093 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.182 179.894 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 147' ' ' ALA . . . . . 0.806 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -112.28 45.73 1.25 Allowed 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.887 0.375 . . . . 0.0 111.242 179.992 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 3.1 m -50.48 152.33 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.592 -179.929 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 108.74 -104.42 1.97 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.539 -179.944 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 53.2 mt-10 -141.63 98.39 3.34 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.81 0.338 . . . . 0.0 110.558 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 151' ' ' ILE . . . . . 0.806 HD11 ' HB3' ' A' ' 147' ' ' ALA . 1.2 mt -73.41 111.79 8.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.353 -179.65 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 152' ' ' HIS . . . . . 0.452 ' O ' ' N ' ' A' ' 128' ' ' ASN . 0.0 OUTLIER -98.17 115.47 28.39 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 178.436 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 153' ' ' MET . . . . . 0.954 ' CG ' HG23 ' A' ' 127' ' ' ILE . 24.4 mtp -128.63 168.17 16.14 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.614 0.721 . . . . 0.0 112.677 -178.311 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 154' ' ' LYS . . . . . 0.416 ' O ' HG13 ' A' ' 125' ' ' ILE . 17.1 mttm -134.6 140.15 45.87 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 114.723 -1.126 . . . . 0.0 108.759 178.502 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 155' ' ' THR . . . . . 0.698 HG22 ' CG1' ' A' ' 124' ' ' ILE . 3.1 p -136.66 140.31 42.66 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.137 0.494 . . . . 0.0 111.909 -178.79 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 156' ' ' MET . . . . . . . . . . . . . 3.8 ptp -132.37 145.75 58.62 Favored Pre-proline 0 C--N 1.328 -0.362 0 CA-C-N 115.318 -0.855 . . . . 0.0 110.44 179.291 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_exo -44.43 122.7 4.02 Favored 'Trans proline' 0 C--N 1.345 0.35 0 C-N-CA 122.597 2.198 . . . . 0.0 112.879 -179.704 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 158' ' ' ALA . . . . . 0.919 ' HB2' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.25 1.081 0 CA-C-O 118.259 -0.877 . . . . 0.0 111.051 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_endo . . . . . 0 N--CA 1.49 1.286 0 CA-C-O 120.798 0.249 . . . . 0.0 111.763 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo -78.4 55.67 5.52 Favored 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.684 2.256 . . . . 0.0 112.527 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.417 HG13 ' O ' ' A' ' 81' ' ' VAL . 14.4 p -90.88 126.31 43.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.179 179.934 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.3 m -103.66 141.49 35.97 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.8 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 5.1 m -105.63 111.3 23.93 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.149 179.191 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.738 HG11 HG23 ' A' ' 118' ' ' VAL . 48.5 t -82.66 106.14 13.2 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.65 -179.418 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.404 ' HA ' ' O ' ' A' ' 151' ' ' ILE . 0.8 OUTLIER -105.55 84.04 2.03 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 178.456 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.7 HG13 HG12 ' A' ' 84' ' ' VAL . 4.0 mt -81.53 151.28 4.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.582 -178.671 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.462 ' CB ' HG21 ' A' ' 112' ' ' ILE . 0.0 OUTLIER -110.07 114.85 28.7 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.712 -0.677 . . . . 0.0 110.451 -179.789 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.439 ' HD2' HD11 ' A' ' 95' ' ' LEU . 0.0 OUTLIER -120.56 100.91 46.63 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.058 -179.728 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 89' ' ' PRO . . . . . 0.437 ' HG2' ' CD2' ' A' ' 93' ' ' TYR . 71.5 Cg_endo -74.54 -26.73 11.61 Favored 'Trans proline' 0 C--N 1.346 0.414 0 C-N-CA 122.585 2.19 . . . . 0.0 112.448 179.874 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -141.39 -166.01 2.1 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.087 -179.866 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.507 ' CD2' HG13 ' A' ' 148' ' ' VAL . 2.6 mt -102.59 -19.74 14.72 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.43 -179.823 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -95.08 21.81 7.35 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.48 -0.327 . . . . 0.0 111.291 -179.775 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 93' ' ' TYR . . . . . 0.437 ' CD2' ' HG2' ' A' ' 89' ' ' PRO . 7.4 m-85 -112.31 98.67 7.45 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.768 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 1.2 pm0 -57.97 146.76 31.35 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.136 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 0.866 ' CD2' HD13 ' A' ' 144' ' ' LEU . 6.7 mp -71.78 -52.5 17.31 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.758 -179.919 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 124.85 36.82 0.57 Allowed Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.579 -0.82 . . . . 0.0 113.023 179.576 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 97' ' ' PHE . . . . . 0.71 ' CZ ' HG21 ' A' ' 118' ' ' VAL . 31.8 p90 -177.36 169.24 2.24 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.839 0.352 . . . . 0.0 111.197 179.787 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -120.66 148.2 44.24 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.745 179.735 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.829 HG21 HG21 ' A' ' 140' ' ' ILE . 8.6 p -115.3 142.82 26.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.427 -179.878 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 100' ' ' GLN . . . . . 0.407 ' O ' ' N ' ' A' ' 102' ' ' GLY . 22.8 tt0 -132.14 88.42 2.55 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.905 -0.588 . . . . 0.0 110.233 179.049 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 101' ' ' ASN . . . . . 0.699 ' O ' HD11 ' A' ' 140' ' ' ILE . 2.2 t-20 65.36 -68.51 0.11 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.151 -179.838 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.444 ' O ' ' HA ' ' A' ' 123' ' ' ARG . . . -142.9 -2.24 1.05 Allowed Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.387 -0.911 . . . . 0.0 113.4 -179.758 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.609 HD12 ' CB ' ' A' ' 158' ' ' ALA . 42.2 mm -122.86 151.36 26.99 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.128 0 CA-C-N 117.13 0.465 . . . . 0.0 111.529 -179.716 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.646 ' N ' HD12 ' A' ' 104' ' ' ILE . 2.8 mp -86.46 158.33 3.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.499 179.605 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 105' ' ' CYS . . . . . 0.482 ' N ' HG22 ' A' ' 104' ' ' ILE . 1.6 m -109.59 -71.68 0.75 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.475 -179.595 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 8.3 m -125.23 173.56 8.7 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.93 0.395 . . . . 0.0 111.17 -179.543 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.813 HD11 HG12 ' A' ' 118' ' ' VAL . 0.3 OUTLIER -148.48 140.63 24.05 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.779 179.901 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 2.0 mtm -106.22 114.21 28.2 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.868 -179.883 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -63.58 82.74 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.708 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 167.02 -31.36 0.19 Allowed Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.938 -0.648 . . . . 0.0 112.002 -179.858 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -64.34 172.48 17.46 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.132 179.651 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.462 HG21 ' CB ' ' A' ' 87' ' ' ARG . 0.5 OUTLIER -78.65 -16.66 13.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 120.744 0.306 . . . . 0.0 111.474 -179.952 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 113' ' ' ALA . . . . . 0.485 ' HA ' HG12 ' A' ' 86' ' ' ILE . . . -58.0 -30.35 66.0 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.002 0.429 . . . . 0.0 110.671 179.744 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 19.7 pt-20 -60.03 -46.63 88.86 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.876 179.67 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 23.3 mtt180 -65.0 -46.19 82.45 Favored 'General case' 0 N--CA 1.453 -0.301 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.21 -179.572 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -51.1 -73.57 0.37 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.557 -0.83 . . . . 0.0 112.641 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 117' ' ' GLY . . . . . 0.572 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 170.54 -20.11 0.07 OUTLIER Glycine 0 CA--C 1.518 0.271 0 C-N-CA 121.032 -0.604 . . . . 0.0 112.662 -179.773 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.813 HG12 HD11 ' A' ' 107' ' ' LEU . 0.9 OUTLIER -37.59 114.92 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.323 0 CA-C-O 120.937 0.399 . . . . 0.0 111.652 -179.819 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -117.46 100.95 8.0 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.577 179.799 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 120' ' ' VAL . . . . . 0.621 ' O ' HG13 ' A' ' 120' ' ' VAL . 10.1 p -48.11 101.76 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 121.057 0.456 . . . . 0.0 111.106 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 133.38 -10.19 5.01 Favored Glycine 0 N--CA 1.451 -0.36 0 CA-C-N 115.831 -0.622 . . . . 0.0 112.231 -179.318 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 122' ' ' HIS . . . . . 0.421 ' O ' HG23 ' A' ' 103' ' ' ILE . 35.7 m170 -86.1 -161.62 0.66 Allowed 'General case' 0 C--N 1.331 -0.231 0 N-CA-C 110.322 -0.251 . . . . 0.0 110.322 179.802 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.749 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 10.1 ttm-85 -139.35 90.4 2.41 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.679 0.276 . . . . 0.0 110.802 -179.866 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 124' ' ' ILE . . . . . 0.581 ' CG1' HG22 ' A' ' 155' ' ' THR . 15.4 mt -55.99 157.13 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.251 179.225 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 125' ' ' ILE . . . . . 0.853 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.7 OUTLIER -151.54 -84.51 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.451 -0.383 0 N-CA-C 112.374 0.509 . . . . 0.0 112.374 -179.538 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 126' ' ' GLU . . . . . 0.42 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 13.5 mt-10 -79.99 88.24 5.36 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 112.498 0.555 . . . . 0.0 112.498 -178.793 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.878 HG23 ' HB3' ' A' ' 153' ' ' MET . 1.3 mt -92.44 103.05 14.22 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.185 0 CA-C-O 121.101 0.477 . . . . 0.0 111.344 179.281 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 128' ' ' ASN . . . . . 0.496 ' ND2' HG22 ' A' ' 127' ' ' ILE . 20.2 m-80 59.84 18.64 7.57 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.857 -0.61 . . . . 0.0 111.369 179.847 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 116.6 -17.18 13.88 Favored Glycine 0 C--N 1.333 0.372 0 C-N-CA 120.517 -0.849 . . . . 0.0 113.179 179.627 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 130' ' ' GLN . . . . . 0.556 HE22 HD13 ' A' ' 143' ' ' ILE . 1.2 pt20 -97.88 119.56 36.71 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 117.029 0.414 . . . . 0.0 110.963 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 2.5 m -79.06 93.15 5.09 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.119 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 132' ' ' VAL . . . . . 0.698 HG21 HD11 ' A' ' 127' ' ' ILE . 27.2 m -72.56 -5.38 6.22 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.298 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.978 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.853 ' HB ' HG22 ' A' ' 125' ' ' ILE . 8.3 p -45.36 -38.46 2.22 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.135 0 CA-C-O 120.818 0.342 . . . . 0.0 111.487 -179.807 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -120.08 28.22 8.2 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.748 179.465 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 135' ' ' THR . . . . . 0.416 ' CG2' ' HD2' ' A' ' 136' ' ' PRO . 36.0 m -110.73 143.15 27.63 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.181 -179.929 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 136' ' ' PRO . . . . . 0.416 ' HD2' ' CG2' ' A' ' 135' ' ' THR . 50.1 Cg_exo -53.41 164.21 2.14 Favored 'Trans proline' 0 C--N 1.347 0.456 0 C-N-CA 122.526 2.151 . . . . 0.0 112.119 179.704 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 137' ' ' HIS . . . . . 0.522 ' HA ' HD12 ' A' ' 140' ' ' ILE . 45.0 p-80 -74.05 -46.95 40.04 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.224 -179.798 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -54.16 -35.14 61.95 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.173 -179.786 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 139' ' ' LYS . . . . . 0.764 ' O ' HD12 ' A' ' 143' ' ' ILE . 0.0 OUTLIER -65.96 -48.87 69.86 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.943 -179.931 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 140' ' ' ILE . . . . . 0.829 HG21 HG21 ' A' ' 99' ' ' VAL . 8.7 mt -59.47 -46.41 92.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 121.033 0.444 . . . . 0.0 110.319 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 141' ' ' VAL . . . . . 0.411 HG23 ' CG1' ' A' ' 99' ' ' VAL . 55.6 t -59.54 -32.53 49.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 115.711 -0.677 . . . . 0.0 109.93 179.074 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -61.47 -54.22 46.27 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.009 -0.542 . . . . 0.0 110.835 179.808 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 143' ' ' ILE . . . . . 0.764 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.3 mp -53.39 -57.86 4.23 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.424 0 CA-C-O 121.015 0.436 . . . . 0.0 110.135 179.487 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.866 HD13 ' CD2' ' A' ' 95' ' ' LEU . 15.1 mt -60.39 -30.14 69.4 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.408 179.402 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 23.4 t -69.38 -28.55 66.28 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.219 -0.446 . . . . 0.0 109.934 178.811 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 4.9 m-80 -128.17 34.48 4.57 Favored 'General case' 0 C--N 1.333 -0.112 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.908 179.666 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 147' ' ' ALA . . . . . 0.844 ' CB ' HD11 ' A' ' 151' ' ' ILE . . . -103.62 79.21 1.65 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.207 -179.929 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.507 HG13 ' CD2' ' A' ' 91' ' ' LEU . 5.7 m -77.32 146.18 8.92 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.338 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.149 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 105.43 -104.68 2.35 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.525 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 53.4 mt-10 -145.58 114.73 7.03 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.79 0.328 . . . . 0.0 110.847 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 151' ' ' ILE . . . . . 0.844 HD11 ' CB ' ' A' ' 147' ' ' ALA . 1.8 mp -81.93 128.13 39.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 121.047 0.451 . . . . 0.0 110.628 179.854 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 152' ' ' HIS . . . . . 0.414 ' CD2' ' HA ' ' A' ' 128' ' ' ASN . 21.6 p-80 -125.47 115.77 20.77 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.361 179.819 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 153' ' ' MET . . . . . 0.878 ' HB3' HG23 ' A' ' 127' ' ' ILE . 0.0 OUTLIER -141.21 174.99 10.01 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.164 0.507 . . . . 0.0 111.619 -179.379 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -121.41 147.83 45.2 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.589 -0.732 . . . . 0.0 109.912 179.22 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 155' ' ' THR . . . . . 0.581 HG22 ' CG1' ' A' ' 124' ' ' ILE . 12.1 p -140.7 140.49 34.92 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.04 0.448 . . . . 0.0 111.175 -179.665 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 156' ' ' MET . . . . . 0.459 ' O ' ' N ' ' A' ' 123' ' ' ARG . 0.0 OUTLIER -108.7 178.86 0.95 Allowed Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 115.791 -0.64 . . . . 0.0 110.56 179.854 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 157' ' ' PRO . . . . . 0.413 ' CD ' ' CB ' ' A' ' 156' ' ' MET . 94.6 Cg_endo -89.85 111.01 0.46 Allowed 'Trans proline' 0 N--CA 1.458 -0.559 0 C-N-CA 122.532 2.154 . . . . 0.0 112.504 -179.776 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 158' ' ' ALA . . . . . 0.749 ' HB2' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.283 -0.865 . . . . 0.0 110.962 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_endo . . . . . 0 N--CA 1.489 1.24 0 CA-C-O 120.67 0.196 . . . . 0.0 111.736 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -72.3 99.52 1.03 Allowed 'Trans proline' 0 C--N 1.345 0.351 0 C-N-CA 122.524 2.15 . . . . 0.0 112.396 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 10.2 p -81.4 140.58 16.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.015 179.933 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.9 m -126.52 140.99 52.03 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.984 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 6.6 m -99.86 111.18 23.51 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.147 179.272 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.918 HG11 HG23 ' A' ' 118' ' ' VAL . 47.2 t -82.66 108.57 15.64 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 CA-C-N 116.015 -0.539 . . . . 0.0 112.268 -179.112 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 6.7 tt -103.12 85.01 2.43 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.876 -0.602 . . . . 0.0 109.436 178.345 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.821 HG21 ' CD2' ' A' ' 95' ' ' LEU . 5.6 mt -82.81 118.81 31.17 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.251 0 CA-C-O 121.293 0.568 . . . . 0.0 111.893 -178.715 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.446 ' HB2' HG21 ' A' ' 112' ' ' ILE . 0.2 OUTLIER -73.13 153.06 40.92 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.089 -0.959 . . . . 0.0 109.99 179.21 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.438 ' HD2' HD11 ' A' ' 95' ' ' LEU . 0.0 OUTLIER -152.92 124.32 3.68 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 120.618 0.247 . . . . 0.0 111.11 -179.979 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 92.0 Cg_endo -83.47 -42.45 0.08 OUTLIER 'Trans proline' 0 C--N 1.347 0.465 0 C-N-CA 122.613 2.209 . . . . 0.0 112.584 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 57.4 p30 -156.78 -167.54 2.4 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.203 -179.781 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 7.3 mt -96.19 30.87 2.33 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.43 -179.519 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -138.9 32.06 2.21 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.886 0.374 . . . . 0.0 110.982 179.914 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 2.1 m-85 -136.84 104.06 5.37 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.832 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 3.0 mp0 -65.51 145.07 56.56 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.03 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 0.821 ' CD2' HG21 ' A' ' 86' ' ' ILE . 8.3 mp -78.49 -24.62 45.77 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.94 179.93 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 72.27 68.81 1.51 Allowed Glycine 0 C--N 1.331 0.257 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.868 179.709 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 97' ' ' PHE . . . . . 0.763 ' CZ ' HD12 ' A' ' 144' ' ' LEU . 1.8 p90 -161.37 -171.83 3.15 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.918 0.39 . . . . 0.0 111.212 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.419 ' O ' ' HA ' ' A' ' 104' ' ' ILE . 1.2 t -149.67 126.24 10.95 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.408 179.71 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.654 HG21 HG21 ' A' ' 140' ' ' ILE . 11.8 p -111.97 140.16 32.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 121.163 0.506 . . . . 0.0 111.764 -179.284 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 3.6 mp0 -133.03 89.75 2.66 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.598 -0.728 . . . . 0.0 109.847 179.156 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 60.35 15.64 5.59 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.756 -178.921 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 127.31 -39.3 1.97 Allowed Glycine 0 N--CA 1.449 -0.474 0 C-N-CA 121.012 -0.613 . . . . 0.0 112.228 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.81 HG23 ' O ' ' A' ' 122' ' ' HIS . 31.5 mt -77.27 138.67 20.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 121.007 0.432 . . . . 0.0 111.575 -179.587 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.832 HD11 ' CD1' ' A' ' 124' ' ' ILE . 4.1 mp -96.36 138.25 22.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.991 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -108.0 -65.62 1.1 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.653 179.878 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 9.5 p -94.22 155.06 17.23 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.614 179.724 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.478 ' HB3' HG22 ' A' ' 120' ' ' VAL . 0.6 OUTLIER -163.92 121.71 1.81 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.942 -179.855 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 20.2 ttp -82.36 120.94 26.06 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.881 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -67.97 71.92 0.16 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.143 0.497 . . . . 0.0 110.602 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 175.36 -33.85 0.1 OUTLIER Glycine 0 N--CA 1.45 -0.39 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.966 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 111' ' ' GLY . . . . . 0.429 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -55.26 176.33 0.6 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.781 -0.724 . . . . 0.0 112.275 179.788 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.446 HG21 ' HB2' ' A' ' 87' ' ' ARG . 1.1 mp -78.7 -18.57 13.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 N-CA-C 111.848 0.314 . . . . 0.0 111.848 -179.734 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 113' ' ' ALA . . . . . . . . . . . . . . . -58.01 -30.54 66.19 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.895 0.378 . . . . 0.0 110.757 179.855 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 114' ' ' GLU . . . . . 0.429 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 13.2 pt-20 -61.64 -47.42 85.48 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.871 179.8 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 43.4 mtm180 -62.27 -41.98 98.93 Favored 'General case' 0 N--CA 1.453 -0.31 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.832 -179.631 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -53.79 -73.83 0.37 Allowed Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.296 -0.954 . . . . 0.0 112.394 179.854 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 117' ' ' GLY . . . . . 0.55 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 164.57 -18.13 0.11 Allowed Glycine 0 CA--C 1.523 0.538 0 C-N-CA 121.249 -0.5 . . . . 0.0 112.74 -179.889 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.918 HG23 HG11 ' A' ' 84' ' ' VAL . 2.0 t -29.58 -64.26 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 C-N-CA 123.212 0.605 . . . . 0.0 112.569 -179.54 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.576 ' N ' HG12 ' A' ' 118' ' ' VAL . 30.0 mmt180 61.71 178.7 0.12 Allowed 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.303 -0.408 . . . . 0.0 109.941 -178.872 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 120' ' ' VAL . . . . . 0.478 HG22 ' HB3' ' A' ' 107' ' ' LEU . 11.8 t -111.18 101.12 12.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-O 120.917 0.389 . . . . 0.0 111.341 -179.86 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 126.17 42.34 0.3 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.894 -0.669 . . . . 0.0 112.417 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 122' ' ' HIS . . . . . 0.81 ' O ' HG23 ' A' ' 103' ' ' ILE . 15.3 m170 -129.87 -171.52 2.54 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.767 0.317 . . . . 0.0 110.963 -179.822 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.799 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 5.7 ttm-85 -142.08 89.39 2.17 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.874 -179.756 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 124' ' ' ILE . . . . . 0.832 ' CD1' HD11 ' A' ' 104' ' ' ILE . 14.6 mt -51.67 142.5 4.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.547 -0.297 . . . . 0.0 110.285 179.375 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 125' ' ' ILE . . . . . 0.859 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.6 OUTLIER -137.18 -84.46 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 N-CA-C 112.668 0.618 . . . . 0.0 112.668 -179.05 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 126' ' ' GLU . . . . . 0.421 ' CD ' HD12 ' A' ' 125' ' ' ILE . 1.0 OUTLIER -80.52 83.73 6.26 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 112.421 0.526 . . . . 0.0 112.421 -178.538 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.862 HG23 ' HB3' ' A' ' 153' ' ' MET . 1.9 mt -86.26 104.37 13.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 120.97 0.414 . . . . 0.0 111.175 179.086 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 11.3 m-20 56.15 23.05 6.56 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.777 -0.647 . . . . 0.0 111.402 179.804 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 112.68 -14.21 24.71 Favored Glycine 0 C--N 1.332 0.318 0 C-N-CA 120.554 -0.831 . . . . 0.0 112.961 179.746 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 130' ' ' GLN . . . . . 0.4 ' O ' ' CG ' ' A' ' 130' ' ' GLN . 5.0 pt20 -96.16 122.07 38.61 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.742 0.306 . . . . 0.0 110.484 -179.888 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 21.3 p -83.75 90.02 7.26 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.892 0.377 . . . . 0.0 110.826 179.921 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 132' ' ' VAL . . . . . 0.624 HG21 HD11 ' A' ' 127' ' ' ILE . 35.0 m -72.69 -3.81 4.45 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.351 0 CA-C-N 116.013 -0.54 . . . . 0.0 112.04 -179.845 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.859 ' HB ' HG22 ' A' ' 125' ' ' ILE . 7.9 p -47.27 -35.13 3.41 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.158 0 CA-C-O 120.894 0.378 . . . . 0.0 111.228 -179.889 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -121.01 27.84 8.24 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.684 179.4 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 135' ' ' THR . . . . . 0.419 HG23 ' HD2' ' A' ' 136' ' ' PRO . 25.8 m -114.08 140.64 25.16 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 115.664 -0.698 . . . . 0.0 111.02 -179.8 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 136' ' ' PRO . . . . . 0.419 ' HD2' HG23 ' A' ' 135' ' ' THR . 8.3 Cg_endo -50.11 163.97 0.52 Allowed 'Trans proline' 0 C--N 1.347 0.458 0 C-N-CA 122.676 2.251 . . . . 0.0 112.181 179.64 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 137' ' ' HIS . . . . . 0.404 ' CD2' ' N ' ' A' ' 138' ' ' GLU . 22.9 p-80 -74.45 -41.85 60.11 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.284 -0.417 . . . . 0.0 111.439 -179.642 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 138' ' ' GLU . . . . . 0.404 ' N ' ' CD2' ' A' ' 137' ' ' HIS . 53.8 mt-10 -54.15 -38.04 65.06 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.753 0.311 . . . . 0.0 111.42 -179.516 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 139' ' ' LYS . . . . . 0.76 ' O ' HD12 ' A' ' 143' ' ' ILE . 6.9 tttp -64.67 -48.86 73.2 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.11 -179.728 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 140' ' ' ILE . . . . . 0.654 HG21 HG21 ' A' ' 99' ' ' VAL . 13.8 mt -59.26 -43.27 89.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.624 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 141' ' ' VAL . . . . . 0.574 HG22 HG12 ' A' ' 99' ' ' VAL . 86.6 t -62.29 -33.13 57.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.389 179.291 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -61.93 -56.46 18.98 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.07 -0.514 . . . . 0.0 111.104 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 143' ' ' ILE . . . . . 0.76 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.3 mp -52.9 -57.17 4.92 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.49 0 CA-C-O 121.095 0.474 . . . . 0.0 110.192 179.559 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.763 HD12 ' CZ ' ' A' ' 97' ' ' PHE . 6.3 mt -59.83 -29.91 68.58 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.575 179.409 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 14.0 t -73.18 -28.25 62.1 Favored 'General case' 0 N--CA 1.456 -0.141 0 CA-C-N 116.361 -0.382 . . . . 0.0 110.219 178.945 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 8.4 m120 -125.11 31.58 5.58 Favored 'General case' 0 C--O 1.232 0.152 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.189 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 147' ' ' ALA . . . . . 0.784 ' CB ' HD11 ' A' ' 151' ' ' ILE . . . -107.02 97.06 6.88 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.243 179.942 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 6.3 m -79.96 179.86 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.357 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.983 -179.744 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 67.94 -116.04 7.38 Favored Glycine 0 N--CA 1.453 -0.223 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.599 179.924 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.403 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 11.5 mt-10 -134.97 110.7 9.27 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.606 0.241 . . . . 0.0 110.984 -179.815 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 151' ' ' ILE . . . . . 0.784 HD11 ' CB ' ' A' ' 147' ' ' ALA . 1.7 mp -68.16 124.02 22.77 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-O 120.915 0.388 . . . . 0.0 110.778 179.776 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -113.51 115.56 28.18 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.801 -0.636 . . . . 0.0 109.964 179.192 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 153' ' ' MET . . . . . 0.862 ' HB3' HG23 ' A' ' 127' ' ' ILE . 1.4 ptt? -147.2 164.77 32.1 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.217 0.532 . . . . 0.0 111.732 -178.97 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 2.2 mttm -110.9 152.33 26.86 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.524 -0.762 . . . . 0.0 109.851 179.182 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 37.4 p -136.88 142.59 42.78 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.163 0.506 . . . . 0.0 111.604 -179.547 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 156' ' ' MET . . . . . 0.504 ' O ' ' N ' ' A' ' 123' ' ' ARG . 0.0 OUTLIER -111.82 179.0 0.86 Allowed Pre-proline 0 C--N 1.327 -0.392 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.39 179.755 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 157' ' ' PRO . . . . . 0.412 ' CD ' ' CB ' ' A' ' 156' ' ' MET . 80.2 Cg_endo -92.96 103.41 0.17 Allowed 'Trans proline' 0 N--CA 1.456 -0.688 0 C-N-CA 122.786 2.324 . . . . 0.0 112.543 -179.752 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 158' ' ' ALA . . . . . 0.799 ' HB2' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.25 1.085 0 CA-C-O 118.169 -0.92 . . . . 0.0 111.09 179.788 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' PRO . . . . . 0.474 ' CB ' ' CD ' ' A' ' 80' ' ' PRO . 2.0 Cg_endo . . . . . 0 N--CA 1.484 0.944 0 CA-C-O 120.522 0.134 . . . . 0.0 112.155 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' PRO . . . . . 0.474 ' CD ' ' CB ' ' A' ' 79' ' ' PRO . 42.4 Cg_endo -67.93 165.58 27.57 Favored 'Trans proline' 0 C--N 1.343 0.284 0 C-N-CA 122.51 2.14 . . . . 0.0 112.355 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.561 HG13 ' O ' ' A' ' 155' ' ' THR . 47.0 t -81.16 140.93 15.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.04 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.7 m -118.61 134.25 55.25 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.848 179.849 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 6.9 m -95.25 111.52 23.36 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.178 179.324 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.759 HG12 HG13 ' A' ' 86' ' ' ILE . 58.3 t -82.56 105.73 12.7 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.547 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.742 -179.33 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.46 HD13 ' CE1' ' A' ' 152' ' ' HIS . 4.6 tp -107.73 80.1 1.35 Allowed 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 178.348 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.759 HG13 HG12 ' A' ' 84' ' ' VAL . 1.2 mt -81.67 130.95 34.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 121.173 0.511 . . . . 0.0 111.729 -178.272 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.431 ' H ' HG22 ' A' ' 112' ' ' ILE . 0.0 OUTLIER -84.19 142.87 30.0 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.443 -0.799 . . . . 0.0 110.256 179.929 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 3.7 ttt180 -144.88 114.16 5.01 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.964 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -75.32 -45.24 0.27 Allowed 'Trans proline' 0 C--N 1.347 0.466 0 C-N-CA 122.463 2.109 . . . . 0.0 112.616 -179.895 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -135.1 -173.97 3.47 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.196 -179.753 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.456 ' HG ' HG13 ' A' ' 148' ' ' VAL . 0.8 OUTLIER -86.96 -34.04 19.44 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.976 -179.928 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 3.2 ptm180 -73.07 -7.97 53.65 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.608 -179.842 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 10.9 m-85 -85.08 128.57 34.7 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.797 0.332 . . . . 0.0 110.876 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 21.2 mp0 -89.51 160.49 16.7 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.899 -179.895 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 0.797 ' CD1' HD13 ' A' ' 144' ' ' LEU . 59.3 mt -81.42 -69.21 0.63 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.903 179.917 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 135.9 40.96 0.13 Allowed Glycine 0 CA--C 1.518 0.277 0 C-N-CA 120.484 -0.865 . . . . 0.0 113.192 179.631 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 97' ' ' PHE . . . . . 0.455 ' CE1' HG21 ' A' ' 118' ' ' VAL . 33.1 p90 -175.12 174.67 2.4 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.879 0.371 . . . . 0.0 111.09 179.62 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -124.74 143.86 50.55 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.961 -179.814 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.673 HG21 HG21 ' A' ' 140' ' ' ILE . 10.6 p -111.54 139.48 35.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.026 179.907 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 100' ' ' GLN . . . . . 0.413 ' O ' ' N ' ' A' ' 102' ' ' GLY . 0.5 OUTLIER -130.53 89.01 2.71 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.806 179.758 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 101' ' ' ASN . . . . . 0.65 ' O ' HD11 ' A' ' 140' ' ' ILE . 7.3 m-80 64.34 -68.19 0.1 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.903 -0.59 . . . . 0.0 111.51 179.569 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.432 ' O ' HD13 ' A' ' 103' ' ' ILE . . . -143.83 1.1 1.27 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.238 -0.982 . . . . 0.0 113.414 -179.731 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.732 HD12 ' CB ' ' A' ' 158' ' ' ALA . 44.2 mm -126.46 155.08 36.64 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 117.232 0.516 . . . . 0.0 111.209 -179.886 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.658 ' N ' HD12 ' A' ' 104' ' ' ILE . 3.2 mp -97.26 145.11 9.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.735 179.817 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 1.6 m -106.46 -79.48 0.57 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.171 -179.704 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 1.5 m -90.91 168.83 11.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.375 -0.375 . . . . 0.0 111.141 -179.7 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.586 HD23 HG23 ' A' ' 120' ' ' VAL . 62.1 tp -174.16 101.86 0.1 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.698 179.897 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 8.0 mtp -73.93 122.05 21.94 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.081 -179.819 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.03 78.2 0.09 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.692 179.775 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 174.25 -33.62 0.11 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.986 -0.626 . . . . 0.0 112.04 -179.837 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 111' ' ' GLY . . . . . 0.413 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -57.46 174.62 2.0 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.142 179.741 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.431 HG22 ' H ' ' A' ' 87' ' ' ARG . 0.9 OUTLIER -78.5 -17.46 13.59 Favored 'Isoleucine or valine' 0 C--O 1.236 0.36 0 CA-C-O 120.829 0.347 . . . . 0.0 111.522 -179.845 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 113' ' ' ALA . . . . . 0.534 ' HB1' HG21 ' A' ' 118' ' ' VAL . . . -58.11 -30.62 66.43 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.911 0.386 . . . . 0.0 110.703 179.863 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 114' ' ' GLU . . . . . 0.413 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 17.4 pt-20 -60.48 -47.21 87.15 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.969 -0.559 . . . . 0.0 110.766 179.634 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 2.4 mmt85 -62.32 -44.78 95.71 Favored 'General case' 0 N--CA 1.452 -0.337 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.892 -179.556 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -53.25 -74.01 0.35 Allowed Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.245 -0.979 . . . . 0.0 112.519 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 117' ' ' GLY . . . . . 0.56 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 172.45 -24.94 0.08 OUTLIER Glycine 0 CA--C 1.518 0.249 0 C-N-CA 121.065 -0.588 . . . . 0.0 112.701 -179.951 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.718 ' N ' HG22 ' A' ' 84' ' ' VAL . 18.0 t -15.11 -83.31 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.627 0 C-N-CA 123.235 0.614 . . . . 0.0 112.489 -179.835 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.651 ' N ' HG12 ' A' ' 118' ' ' VAL . 0.0 OUTLIER 62.56 143.19 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.725 -179.649 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 120' ' ' VAL . . . . . 0.586 HG23 HD23 ' A' ' 107' ' ' LEU . 11.4 t -81.97 132.06 32.37 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 116.439 -0.346 . . . . 0.0 111.198 -179.704 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 101.63 24.63 8.6 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.886 -0.673 . . . . 0.0 112.57 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 10.4 m170 -112.72 -174.42 2.45 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.656 0.265 . . . . 0.0 110.706 179.869 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.714 ' CD ' HD11 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -140.58 90.14 2.33 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.819 -179.783 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 124' ' ' ILE . . . . . 0.62 ' O ' HG23 ' A' ' 125' ' ' ILE . 5.9 mt -50.82 154.95 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.811 179.484 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 125' ' ' ILE . . . . . 0.844 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.8 OUTLIER -157.79 -86.66 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 N-CA-C 112.481 0.549 . . . . 0.0 112.481 -179.88 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 126' ' ' GLU . . . . . 0.428 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 15.6 mt-10 -81.82 92.79 6.74 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 112.321 0.489 . . . . 0.0 112.321 -178.637 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.922 HD11 HG21 ' A' ' 132' ' ' VAL . 1.5 mt -91.3 99.16 9.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.126 179.297 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 52.8 m-20 63.96 15.92 9.52 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.451 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 121.19 -18.94 8.82 Favored Glycine 0 C--N 1.332 0.31 0 C-N-CA 120.452 -0.88 . . . . 0.0 113.117 179.629 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 130' ' ' GLN . . . . . 0.464 ' NE2' ' O ' ' A' ' 127' ' ' ILE . 0.5 OUTLIER -98.63 117.1 32.32 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.93 0.395 . . . . 0.0 110.948 -179.916 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 1.4 m -77.18 93.41 3.93 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.182 -179.787 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 132' ' ' VAL . . . . . 0.922 HG21 HD11 ' A' ' 127' ' ' ILE . 35.6 m -77.08 0.31 2.64 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.324 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.801 179.67 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.844 ' HB ' HG22 ' A' ' 125' ' ' ILE . 8.5 p -46.82 -40.23 4.72 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.14 0 CA-C-O 120.805 0.336 . . . . 0.0 111.261 -179.826 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -113.13 29.54 7.9 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.687 179.452 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 135' ' ' THR . . . . . 0.549 HG23 ' HD2' ' A' ' 136' ' ' PRO . 91.0 m -116.97 143.03 30.8 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.852 -179.805 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 136' ' ' PRO . . . . . 0.549 ' HD2' HG23 ' A' ' 135' ' ' THR . 6.1 Cg_endo -47.92 164.09 0.18 Allowed 'Trans proline' 0 C--N 1.347 0.451 0 C-N-CA 122.805 2.337 . . . . 0.0 112.281 179.795 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 45.1 p-80 -76.11 -44.55 38.02 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.301 -179.606 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -54.08 -33.53 57.79 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.362 -179.607 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 139' ' ' LYS . . . . . 0.823 ' O ' HD12 ' A' ' 143' ' ' ILE . 0.0 OUTLIER -66.41 -50.12 64.49 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.873 0.368 . . . . 0.0 111.033 -179.923 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 140' ' ' ILE . . . . . 0.786 HG23 ' CD1' ' A' ' 127' ' ' ILE . 8.5 mt -59.1 -46.18 92.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.421 179.827 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 141' ' ' VAL . . . . . 0.567 HG22 HG12 ' A' ' 99' ' ' VAL . 69.0 t -59.86 -32.38 49.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.906 -0.588 . . . . 0.0 109.885 178.73 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -60.57 -52.97 62.89 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.492 179.604 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 143' ' ' ILE . . . . . 0.823 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.5 mp -53.29 -57.78 4.28 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.394 0 CA-C-O 121.035 0.445 . . . . 0.0 110.108 179.202 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.797 HD13 ' CD1' ' A' ' 95' ' ' LEU . 9.7 mt -60.05 -30.19 69.04 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.627 -0.715 . . . . 0.0 110.231 179.389 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 38.9 t -70.81 -27.79 64.15 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.075 -0.511 . . . . 0.0 109.878 178.745 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 2.8 m-80 -124.85 31.47 5.65 Favored 'General case' 0 C--O 1.232 0.151 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.83 179.799 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 147' ' ' ALA . . . . . 0.784 ' CB ' HD11 ' A' ' 151' ' ' ILE . . . -113.14 101.06 9.08 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.952 179.789 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.456 HG13 ' HG ' ' A' ' 91' ' ' LEU . 3.4 m -101.59 158.62 4.24 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.433 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.321 -179.79 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 95.0 -95.89 1.94 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.564 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 14.4 mt-10 -146.81 104.93 3.76 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.716 0.294 . . . . 0.0 110.715 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 151' ' ' ILE . . . . . 0.784 HD11 ' CB ' ' A' ' 147' ' ' ALA . 1.5 mp -72.41 117.52 16.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 121.149 0.5 . . . . 0.0 111.204 -179.756 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 152' ' ' HIS . . . . . 0.46 ' CE1' HD13 ' A' ' 85' ' ' LEU . 0.2 OUTLIER -101.37 121.84 42.64 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.585 -0.734 . . . . 0.0 109.295 178.724 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 153' ' ' MET . . . . . 0.8 ' HB2' HG23 ' A' ' 127' ' ' ILE . 8.6 tmm? -153.41 155.16 35.84 Favored 'General case' 0 C--N 1.327 -0.385 0 C-N-CA 120.754 -0.378 . . . . 0.0 111.678 -178.436 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 154' ' ' LYS . . . . . 0.41 ' CG ' ' CG1' ' A' ' 81' ' ' VAL . 0.0 OUTLIER -109.23 152.27 25.41 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.605 179.893 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 155' ' ' THR . . . . . 0.561 ' O ' HG13 ' A' ' 81' ' ' VAL . 30.3 p -142.13 150.05 40.61 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 121.159 0.504 . . . . 0.0 111.644 -179.919 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 156' ' ' MET . . . . . 0.503 ' O ' ' N ' ' A' ' 123' ' ' ARG . 10.7 mmm -115.82 178.93 0.87 Allowed Pre-proline 0 C--N 1.328 -0.369 0 CA-C-N 115.556 -0.747 . . . . 0.0 110.302 179.413 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 157' ' ' PRO . . . . . 0.443 ' CD ' ' HB3' ' A' ' 156' ' ' MET . 88.5 Cg_endo -91.33 114.82 0.4 Allowed 'Trans proline' 0 N--CA 1.457 -0.632 0 C-N-CA 122.61 2.207 . . . . 0.0 112.546 -179.685 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 158' ' ' ALA . . . . . 0.732 ' CB ' HD12 ' A' ' 103' ' ' ILE . . . . . . . . 0 C--O 1.249 1.035 0 CA-C-O 118.285 -0.864 . . . . 0.0 111.071 179.727 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo . . . . . 0 N--CA 1.488 1.175 0 CA-C-O 120.671 0.196 . . . . 0.0 111.706 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -75.48 129.57 12.04 Favored 'Trans proline' 0 C--N 1.345 0.354 0 C-N-CA 122.616 2.211 . . . . 0.0 112.592 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.588 HG13 ' CE ' ' A' ' 156' ' ' MET . 56.5 t -87.95 142.39 13.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.884 179.843 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 82' ' ' THR . . . . . 0.429 HG21 ' O ' ' A' ' 117' ' ' GLY . 1.8 m -120.5 143.01 48.78 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.868 179.75 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 35.9 m -107.09 111.33 23.73 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.267 179.289 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.668 HG12 ' CD1' ' A' ' 86' ' ' ILE . 53.6 t -86.21 106.33 15.49 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.423 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.107 -179.759 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.413 ' O ' ' HA2' ' A' ' 116' ' ' GLY . 1.4 tt -110.09 81.93 1.51 Allowed 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.157 -0.474 . . . . 0.0 109.729 179.107 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.668 ' CD1' HG12 ' A' ' 84' ' ' VAL . 1.8 mp -81.83 134.17 27.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 121.106 0.479 . . . . 0.0 111.732 -178.965 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.51 ' O ' HG21 ' A' ' 112' ' ' ILE . 0.0 OUTLIER -91.36 108.69 20.06 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.99 179.813 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.537 ' HE ' HD13 ' A' ' 112' ' ' ILE . 1.0 OUTLIER -113.14 87.11 10.24 Favored Pre-proline 0 C--N 1.328 -0.365 0 CA-C-O 120.878 0.371 . . . . 0.0 111.676 -179.209 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 89' ' ' PRO . . . . . 0.405 ' HD2' ' NH2' ' A' ' 88' ' ' ARG . 96.4 Cg_endo -78.96 1.91 8.73 Favored 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.598 2.199 . . . . 0.0 112.952 179.776 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 90' ' ' ASP . . . . . 0.783 ' O ' HG12 ' A' ' 148' ' ' VAL . 1.0 OUTLIER -154.5 -162.29 1.37 Allowed 'General case' 0 C--N 1.332 -0.17 0 CA-C-O 120.743 0.306 . . . . 0.0 111.36 -179.884 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.609 HD12 HG11 ' A' ' 148' ' ' VAL . 0.1 OUTLIER -128.18 -40.58 1.64 Allowed 'General case' 0 C--N 1.332 -0.153 0 CA-C-O 120.925 0.393 . . . . 0.0 111.389 -179.622 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -53.44 -23.3 9.6 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.536 -179.524 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 93' ' ' TYR . . . . . 0.463 ' HB2' ' NH2' ' A' ' 88' ' ' ARG . 77.4 m-85 -95.65 148.89 22.06 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.828 179.824 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -97.03 175.6 6.26 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.155 -179.842 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 0.613 ' HG ' HD13 ' A' ' 144' ' ' LEU . 2.7 mm? -72.49 -51.68 19.06 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.661 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 121.74 31.74 1.09 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.9 179.784 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 47.8 p90 -175.55 145.14 0.71 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.832 0.349 . . . . 0.0 111.058 179.818 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.432 ' O ' ' HA ' ' A' ' 104' ' ' ILE . 14.8 m -91.76 148.44 22.24 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.747 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.78 HG21 HG21 ' A' ' 140' ' ' ILE . 5.1 p -118.82 137.02 54.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.366 -179.686 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -129.89 89.85 2.88 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.866 -0.607 . . . . 0.0 109.959 179.424 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 63.9 t30 60.6 17.38 7.39 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.627 -179.038 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.411 ' HA2' ' HB ' ' A' ' 124' ' ' ILE . . . 124.58 -39.31 2.15 Favored Glycine 0 N--CA 1.448 -0.566 0 C-N-CA 120.957 -0.639 . . . . 0.0 112.031 -179.808 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.483 HG12 ' HB2' ' A' ' 158' ' ' ALA . 23.2 mt -78.35 131.41 34.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-O 120.989 0.423 . . . . 0.0 111.432 -179.693 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.766 HD11 ' CD1' ' A' ' 124' ' ' ILE . 3.6 mp -85.54 139.34 17.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.841 179.743 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 12.0 t -94.97 -67.35 0.86 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.047 -179.648 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 3.3 m -112.64 146.92 37.8 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.79 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.889 HD11 HG13 ' A' ' 118' ' ' VAL . 0.5 OUTLIER -133.24 100.89 4.99 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.662 179.979 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 2.7 tmm? -60.01 141.34 55.82 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.907 -179.888 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -93.4 44.14 1.13 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.09 0.471 . . . . 0.0 110.703 179.798 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -162.78 23.98 0.2 Allowed Glycine 0 N--CA 1.45 -0.375 0 CA-C-N 115.691 -0.686 . . . . 0.0 112.282 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 111' ' ' GLY . . . . . 0.489 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -112.77 175.46 16.8 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.851 -0.69 . . . . 0.0 111.952 179.798 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.537 HD13 ' HE ' ' A' ' 88' ' ' ARG . 0.5 OUTLIER -79.27 -23.55 12.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-O 120.933 0.397 . . . . 0.0 111.578 -179.772 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 113' ' ' ALA . . . . . 0.529 ' O ' HG12 ' A' ' 118' ' ' VAL . . . -57.92 -30.41 65.91 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.968 0.413 . . . . 0.0 110.604 -179.93 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 114' ' ' GLU . . . . . 0.489 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 8.6 pt-20 -59.92 -45.2 93.33 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.722 179.467 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 88.5 mtt180 -64.78 -46.26 82.83 Favored 'General case' 0 N--CA 1.452 -0.358 0 CA-C-N 115.96 -0.564 . . . . 0.0 111.087 -179.441 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.413 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -49.75 -74.65 0.25 Allowed Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.413 -0.899 . . . . 0.0 112.591 179.918 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 117' ' ' GLY . . . . . 0.429 ' O ' HG21 ' A' ' 82' ' ' THR . . . 175.21 -16.49 0.04 OUTLIER Glycine 0 CA--C 1.52 0.386 0 C-N-CA 120.77 -0.729 . . . . 0.0 113.112 179.945 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.889 HG13 HD11 ' A' ' 107' ' ' LEU . 5.0 p -34.13 148.8 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 N-CA-C 112.156 0.428 . . . . 0.0 112.156 -179.659 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 1.1 ttp85 -151.83 113.01 4.28 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.823 179.907 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 120' ' ' VAL . . . . . 0.55 ' O ' HG13 ' A' ' 120' ' ' VAL . 14.9 p -52.48 114.89 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.316 -179.976 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 113.5 19.12 6.74 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.433 -179.809 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 3.2 m170 -120.86 139.79 52.69 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.803 0.335 . . . . 0.0 110.773 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.673 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 10.7 ttt180 -83.65 90.65 7.31 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.384 -179.673 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 124' ' ' ILE . . . . . 0.784 HG23 ' SD ' ' A' ' 153' ' ' MET . 71.4 mt -48.75 134.33 6.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 178.784 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 125' ' ' ILE . . . . . 0.867 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.8 OUTLIER -128.29 -84.46 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 N-CA-C 113.175 0.806 . . . . 0.0 113.175 -178.398 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 126' ' ' GLU . . . . . 0.435 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 4.3 mt-10 -80.88 92.16 6.08 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 112.922 0.712 . . . . 0.0 112.922 -178.236 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.702 HG23 ' HB2' ' A' ' 153' ' ' MET . 1.3 mt -94.34 94.87 4.74 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.668 178.722 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 128' ' ' ASN . . . . . 0.454 ' N ' ' O ' ' A' ' 152' ' ' HIS . 55.5 m-80 62.3 26.35 15.77 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.882 -179.813 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 108.91 -19.37 30.44 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.733 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 7.6 tt0 -90.77 110.39 21.59 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.785 0.326 . . . . 0.0 110.878 179.903 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 1.4 m -76.2 93.32 3.36 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.077 -179.822 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 132' ' ' VAL . . . . . 0.635 HG21 HD11 ' A' ' 127' ' ' ILE . 25.9 m -73.48 -5.15 6.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.877 179.859 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.867 ' HB ' HG22 ' A' ' 125' ' ' ILE . 11.4 p -47.26 -36.65 4.1 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-O 120.857 0.361 . . . . 0.0 111.41 -179.713 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -117.28 28.65 8.35 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.628 179.501 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 135' ' ' THR . . . . . 0.476 HG23 ' HD2' ' A' ' 136' ' ' PRO . 67.4 m -116.37 140.81 27.0 Favored Pre-proline 0 C--N 1.328 -0.363 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.343 -179.734 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 136' ' ' PRO . . . . . 0.476 ' HD2' HG23 ' A' ' 135' ' ' THR . 8.9 Cg_endo -50.99 164.36 0.63 Allowed 'Trans proline' 0 C--N 1.347 0.493 0 C-N-CA 122.759 2.306 . . . . 0.0 112.347 179.765 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 137' ' ' HIS . . . . . 0.405 ' CE1' ' HG3' ' A' ' 138' ' ' GLU . 20.9 p80 -70.91 -50.09 38.63 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.739 -179.42 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 138' ' ' GLU . . . . . 0.405 ' HG3' ' CE1' ' A' ' 137' ' ' HIS . 3.7 mt-10 -53.91 -33.79 57.66 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.607 -179.355 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 139' ' ' LYS . . . . . 0.745 ' O ' HD12 ' A' ' 143' ' ' ILE . 8.6 tptt -64.02 -48.05 77.86 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.369 -0.378 . . . . 0.0 111.098 -179.828 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 140' ' ' ILE . . . . . 0.78 HG21 HG21 ' A' ' 99' ' ' VAL . 13.9 mt -58.38 -46.15 89.38 Favored 'Isoleucine or valine' 0 C--O 1.235 0.318 0 CA-C-O 121.013 0.435 . . . . 0.0 110.669 -179.898 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 141' ' ' VAL . . . . . 0.535 HG22 HG12 ' A' ' 99' ' ' VAL . 58.9 t -60.05 -32.82 51.16 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.353 179.166 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 57.2 t-80 -62.77 -54.15 43.4 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.304 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 143' ' ' ILE . . . . . 0.745 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.2 mp -52.96 -57.21 4.9 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.451 0 CA-C-O 121.018 0.437 . . . . 0.0 110.375 179.647 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.613 HD13 ' HG ' ' A' ' 95' ' ' LEU . 1.4 mt -62.41 -30.04 70.93 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.55 -0.75 . . . . 0.0 110.381 179.581 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 3.4 m -66.63 -26.57 67.14 Favored 'General case' 0 N--CA 1.452 -0.347 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 178.448 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 8.0 m120 -132.86 35.86 3.53 Favored 'General case' 0 CA--C 1.529 0.145 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.377 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 147' ' ' ALA . . . . . 0.638 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -118.06 52.59 1.0 Allowed 'General case' 0 C--N 1.332 -0.178 0 CA-C-O 120.776 0.322 . . . . 0.0 111.464 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.783 HG12 ' O ' ' A' ' 90' ' ' ASP . 15.6 m -53.5 -178.48 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 120.877 0.37 . . . . 0.0 111.035 179.91 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 83.96 -108.47 3.08 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.424 -179.834 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 20.2 mt-10 -138.27 101.6 4.43 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.878 0.37 . . . . 0.0 110.454 179.787 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 151' ' ' ILE . . . . . 0.638 HD11 ' HB3' ' A' ' 147' ' ' ALA . 1.1 mt -76.15 111.72 13.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 121.051 0.453 . . . . 0.0 111.487 -179.516 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 152' ' ' HIS . . . . . 0.454 ' O ' ' N ' ' A' ' 128' ' ' ASN . 0.2 OUTLIER -99.72 124.23 44.76 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 178.356 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 153' ' ' MET . . . . . 0.784 ' SD ' HG23 ' A' ' 124' ' ' ILE . 11.5 tmm? -150.68 155.08 38.63 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.139 0.495 . . . . 0.0 112.25 -177.937 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -113.45 148.17 36.43 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.59 -0.732 . . . . 0.0 109.669 178.977 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 155' ' ' THR . . . . . 0.587 HG22 ' SD ' ' A' ' 153' ' ' MET . 16.3 p -130.7 141.02 50.39 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.28 0.562 . . . . 0.0 111.836 -179.266 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 156' ' ' MET . . . . . 0.59 ' HE3' HD11 ' A' ' 125' ' ' ILE . 0.0 OUTLIER -123.28 119.45 27.49 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 115.109 -0.951 . . . . 0.0 110.053 179.475 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 88.9 Cg_exo -42.24 110.63 0.16 Allowed 'Trans proline' 0 C--N 1.346 0.402 0 C-N-CA 122.56 2.173 . . . . 0.0 112.935 -179.756 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 158' ' ' ALA . . . . . 0.673 ' HB2' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.249 1.05 0 CA-C-O 118.23 -0.89 . . . . 0.0 111.043 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_endo . . . . . 0 N--CA 1.488 1.196 0 CA-C-O 120.604 0.168 . . . . 0.0 111.753 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 55.1 Cg_exo -52.05 88.87 0.03 OUTLIER 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 122.519 2.146 . . . . 0.0 112.377 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 12.5 p -86.16 141.43 14.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.035 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 3.0 m -115.49 132.05 56.74 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.993 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 26.6 m -92.26 111.65 23.29 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.032 179.235 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.783 HG12 HG13 ' A' ' 86' ' ' ILE . 94.5 t -83.89 105.41 13.34 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.566 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.68 -179.093 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.443 HD23 ' C ' ' A' ' 85' ' ' LEU . 5.2 tt -105.2 80.07 1.56 Allowed 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 109.176 -0.676 . . . . 0.0 109.176 178.466 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.813 HG21 HD22 ' A' ' 95' ' ' LEU . 4.5 mt -82.04 125.33 39.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 121.236 0.541 . . . . 0.0 111.874 -178.354 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.465 ' HB2' HG21 ' A' ' 112' ' ' ILE . 0.1 OUTLIER -76.94 147.86 36.7 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.289 -0.869 . . . . 0.0 110.061 179.467 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 6.0 mtp85 -141.84 96.13 6.81 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 120.686 0.279 . . . . 0.0 111.089 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_exo -56.38 -60.28 0.51 Allowed 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 122.562 2.175 . . . . 0.0 112.447 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -127.5 -169.17 2.0 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 121.03 0.443 . . . . 0.0 111.033 -179.692 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -89.11 -43.16 11.26 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.988 -0.551 . . . . 0.0 111.04 -179.942 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 16.5 mtt-85 -64.81 -13.66 56.44 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.639 -179.689 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 24.1 m-85 -88.68 117.57 27.75 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.456 -0.338 . . . . 0.0 110.976 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -85.21 169.42 13.84 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.999 -179.918 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 0.813 HD22 HG21 ' A' ' 86' ' ' ILE . 76.9 mt -76.21 -69.4 0.51 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.779 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 128.23 54.13 0.12 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.457 -0.877 . . . . 0.0 113.1 179.531 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' PHE . . . . . 0.617 ' CE2' ' HB2' ' A' ' 113' ' ' ALA . 42.5 p90 -177.83 174.25 1.47 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.817 0.342 . . . . 0.0 111.053 179.635 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -116.52 150.3 38.17 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.866 179.869 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.625 HG21 HG21 ' A' ' 140' ' ' ILE . 9.3 p -125.6 136.36 61.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.314 -179.894 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 100' ' ' GLN . . . . . 0.409 ' HG3' ' HB ' ' A' ' 103' ' ' ILE . 1.6 pt20 -130.37 91.64 3.13 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.215 179.464 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER 60.74 13.83 4.64 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.175 -179.343 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 129.67 -38.4 2.0 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.872 -0.68 . . . . 0.0 112.366 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.848 HG23 ' O ' ' A' ' 122' ' ' HIS . 36.2 mt -77.13 136.86 23.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-O 121.105 0.479 . . . . 0.0 111.684 -179.559 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.726 HG12 HG13 ' A' ' 118' ' ' VAL . 4.0 mp -90.98 138.37 19.73 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.54 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 7.7 m -94.29 -84.28 0.32 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.509 -179.298 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 46.3 t -109.88 113.53 26.33 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.926 0.393 . . . . 0.0 111.203 -179.6 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.713 HD13 ' O ' ' A' ' 107' ' ' LEU . 1.4 tm? -105.74 110.06 22.23 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.45 179.645 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 9.0 ttp -58.08 116.84 3.79 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.024 -179.762 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 7.1 mtt85 -63.89 80.79 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.001 0.429 . . . . 0.0 110.671 179.789 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 166.74 -30.88 0.2 Allowed Glycine 0 N--CA 1.45 -0.399 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.894 -179.754 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 111' ' ' GLY . . . . . 0.441 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -59.1 176.18 2.7 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.131 179.625 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.465 HG21 ' HB2' ' A' ' 87' ' ' ARG . 1.2 mt -79.06 -19.53 12.88 Favored 'Isoleucine or valine' 0 C--O 1.236 0.343 0 CA-C-O 120.892 0.377 . . . . 0.0 111.729 -179.69 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 113' ' ' ALA . . . . . 0.617 ' HB2' ' CE2' ' A' ' 97' ' ' PHE . . . -57.77 -30.61 65.78 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.981 0.42 . . . . 0.0 110.74 179.909 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 114' ' ' GLU . . . . . 0.441 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 10.5 pt-20 -60.92 -46.46 90.59 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.746 179.703 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -62.23 -45.76 91.89 Favored 'General case' 0 N--CA 1.453 -0.304 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.946 -179.444 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.401 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -51.19 -74.35 0.3 Allowed Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.297 -0.954 . . . . 0.0 112.532 179.872 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 117' ' ' GLY . . . . . 0.562 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 174.29 -26.22 0.08 OUTLIER Glycine 0 CA--C 1.518 0.276 0 C-N-CA 121.116 -0.564 . . . . 0.0 112.61 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.736 ' N ' HG22 ' A' ' 84' ' ' VAL . 13.5 t -15.72 -81.98 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.471 0.594 0 C-N-CA 123.259 0.624 . . . . 0.0 112.632 -179.824 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.653 ' N ' HG12 ' A' ' 118' ' ' VAL . 0.8 OUTLIER 63.84 129.05 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.748 0.309 . . . . 0.0 110.454 -179.43 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 22.2 t -63.29 130.88 28.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.314 -179.799 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 97.41 34.22 5.65 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.685 179.756 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 122' ' ' HIS . . . . . 0.848 ' O ' HG23 ' A' ' 103' ' ' ILE . 5.1 m170 -122.65 -174.54 2.94 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.933 0.396 . . . . 0.0 110.878 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.81 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 8.7 ttm-85 -144.23 89.43 2.02 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.87 -179.803 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 124' ' ' ILE . . . . . 0.653 HG13 HD11 ' A' ' 104' ' ' ILE . 78.3 mt -50.4 150.16 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 N-CA-C 110.208 -0.293 . . . . 0.0 110.208 179.246 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 125' ' ' ILE . . . . . 0.863 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.6 OUTLIER -146.07 -84.5 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 N-CA-C 112.87 0.693 . . . . 0.0 112.87 -178.892 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 126' ' ' GLU . . . . . 0.404 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 40.0 mt-10 -83.2 89.12 6.92 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 112.532 0.568 . . . . 0.0 112.532 -178.499 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.818 HG23 ' HB3' ' A' ' 153' ' ' MET . 1.8 mt -89.03 102.0 12.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.005 179.221 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 22.6 m-20 53.75 24.85 4.64 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.121 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 111.83 -16.51 25.76 Favored Glycine 0 CA--C 1.519 0.317 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.725 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -93.16 108.94 20.45 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.782 0.325 . . . . 0.0 110.889 -179.88 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 83.1 p -74.83 89.47 2.33 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.096 -179.874 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 132' ' ' VAL . . . . . 0.784 HG21 HD11 ' A' ' 127' ' ' ILE . 27.7 m -74.99 -4.08 5.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.832 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.863 ' HB ' HG22 ' A' ' 125' ' ' ILE . 12.1 p -46.37 -40.95 4.35 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-O 120.928 0.394 . . . . 0.0 111.343 -179.854 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 134' ' ' ALA . . . . . 0.411 ' N ' HG13 ' A' ' 133' ' ' VAL . . . -113.91 29.48 7.97 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.673 179.395 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 135' ' ' THR . . . . . 0.464 HG23 ' HD2' ' A' ' 136' ' ' PRO . 84.0 m -114.04 143.26 29.32 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.047 -179.746 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 136' ' ' PRO . . . . . 0.464 ' HD2' HG23 ' A' ' 135' ' ' THR . 74.8 Cg_exo -49.72 156.97 2.73 Favored 'Trans proline' 0 C--N 1.347 0.494 0 C-N-CA 122.45 2.1 . . . . 0.0 112.245 179.851 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 37.5 p-80 -68.08 -46.47 70.93 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.266 -179.762 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 18.1 mt-10 -55.56 -35.75 66.07 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.299 -179.791 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 139' ' ' LYS . . . . . 0.758 ' O ' HD12 ' A' ' 143' ' ' ILE . 5.4 tptt -62.78 -47.5 83.2 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.885 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 140' ' ' ILE . . . . . 0.625 HG21 HG21 ' A' ' 99' ' ' VAL . 16.4 mt -58.8 -43.04 87.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.584 179.951 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 141' ' ' VAL . . . . . 0.469 HG22 HG12 ' A' ' 99' ' ' VAL . 92.8 t -62.16 -32.72 55.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.177 179.051 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 2.0 t-80 -62.19 -54.48 40.36 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.907 179.901 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 143' ' ' ILE . . . . . 0.758 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.4 mp -53.09 -56.94 5.67 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.408 0 CA-C-O 121.207 0.527 . . . . 0.0 110.214 179.391 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.74 HD13 ' CD1' ' A' ' 95' ' ' LEU . 4.5 mt -60.94 -30.12 70.04 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.327 -0.852 . . . . 0.0 110.288 179.619 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 28.5 t -69.37 -26.45 64.67 Favored 'General case' 0 N--CA 1.452 -0.356 0 CA-C-N 116.183 -0.462 . . . . 0.0 109.929 178.672 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -128.9 33.42 4.62 Favored 'General case' 0 C--O 1.232 0.138 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.104 179.85 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 147' ' ' ALA . . . . . 0.652 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -115.81 46.17 1.58 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.859 0.361 . . . . 0.0 111.462 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 11.2 m -50.69 157.36 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.389 -179.864 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 102.68 -106.39 2.91 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.504 -179.966 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.417 ' HB3' HD21 ' A' ' 85' ' ' LEU . 30.1 mt-10 -139.14 94.44 2.8 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.805 0.336 . . . . 0.0 110.768 179.93 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 151' ' ' ILE . . . . . 0.652 HD11 ' HB3' ' A' ' 147' ' ' ALA . 1.0 OUTLIER -64.71 111.96 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.037 -179.867 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 152' ' ' HIS . . . . . 0.41 ' CD2' ' HG ' ' A' ' 85' ' ' LEU . 0.2 OUTLIER -99.43 115.94 30.42 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.046 -0.524 . . . . 0.0 109.962 179.135 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 153' ' ' MET . . . . . 0.818 ' HB3' HG23 ' A' ' 127' ' ' ILE . 0.1 OUTLIER -147.82 177.42 9.33 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.406 0.622 . . . . 0.0 111.58 -179.216 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 12.9 mttt -126.7 160.27 31.26 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 114.938 -1.028 . . . . 0.0 109.866 179.562 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 155' ' ' THR . . . . . 0.54 HG22 ' HA ' ' A' ' 124' ' ' ILE . 24.4 p -144.18 144.58 31.62 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.299 0.571 . . . . 0.0 111.814 -179.565 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 156' ' ' MET . . . . . 0.53 ' O ' ' N ' ' A' ' 123' ' ' ARG . 0.0 OUTLIER -115.87 177.51 1.19 Allowed Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 115.142 -0.936 . . . . 0.0 109.997 179.508 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 157' ' ' PRO . . . . . 0.401 ' HD2' ' HB3' ' A' ' 156' ' ' MET . 89.8 Cg_endo -92.4 102.07 0.19 Allowed 'Trans proline' 0 N--CA 1.455 -0.757 0 C-N-CA 122.585 2.19 . . . . 0.0 112.627 -179.684 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 158' ' ' ALA . . . . . 0.81 ' HB2' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.248 1.025 0 CA-C-O 118.168 -0.92 . . . . 0.0 111.054 179.739 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_endo . . . . . 0 N--CA 1.489 1.25 0 CA-C-O 120.652 0.188 . . . . 0.0 111.772 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -72.08 65.46 3.4 Favored 'Trans proline' 0 C--N 1.343 0.248 0 C-N-CA 122.575 2.183 . . . . 0.0 112.37 -179.878 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.644 HG13 ' CE ' ' A' ' 156' ' ' MET . 37.1 t -108.02 121.6 61.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.061 179.796 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.5 m -98.69 139.24 34.69 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.869 179.912 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 10.3 m -109.29 111.46 23.06 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.106 -0.497 . . . . 0.0 109.93 179.015 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.723 HG11 HG23 ' A' ' 118' ' ' VAL . 66.2 t -81.72 106.38 12.68 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.638 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.506 -179.475 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 16.8 tp -104.91 87.06 2.57 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.592 178.859 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.678 HG21 HD22 ' A' ' 95' ' ' LEU . 3.7 mt -81.56 146.82 6.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.229 -179.088 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.485 ' CB ' HG21 ' A' ' 112' ' ' ILE . 0.0 OUTLIER -115.7 108.97 17.06 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.486 -179.602 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 53.5 ttt180 -104.02 108.28 59.49 Favored Pre-proline 0 C--N 1.33 -0.257 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.847 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -68.45 -27.56 33.4 Favored 'Trans proline' 0 C--N 1.347 0.487 0 C-N-CA 122.36 2.04 . . . . 0.0 112.402 -179.942 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' ASP . . . . . 0.417 ' HB2' ' CD1' ' A' ' 93' ' ' TYR . 1.1 m-20 -165.22 168.98 16.52 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.993 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -66.86 -36.87 83.3 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.067 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.21 -14.15 59.96 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.086 -0.507 . . . . 0.0 111.492 -179.769 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 93' ' ' TYR . . . . . 0.417 ' CD1' ' HB2' ' A' ' 90' ' ' ASP . 46.6 m-85 -99.39 113.11 25.26 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.42 -0.355 . . . . 0.0 110.889 179.881 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -73.98 165.93 24.27 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.007 -179.926 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 0.8 HD11 ' HB3' ' A' ' 144' ' ' LEU . 26.0 mt -77.44 -67.43 0.72 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.835 179.965 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.573 ' O ' HD23 ' A' ' 107' ' ' LEU . . . 132.51 40.6 0.2 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.566 -0.826 . . . . 0.0 112.956 179.624 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 35.3 p90 -177.05 159.55 1.67 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.796 0.331 . . . . 0.0 110.968 179.68 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -112.94 144.67 42.12 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.963 -179.92 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.83 HG21 HG21 ' A' ' 140' ' ' ILE . 12.7 p -111.47 138.0 41.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.591 -179.861 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 100' ' ' GLN . . . . . 0.422 ' O ' ' N ' ' A' ' 102' ' ' GLY . 5.2 mm-40 -130.04 88.58 2.68 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.007 179.013 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 101' ' ' ASN . . . . . 0.673 ' O ' HD11 ' A' ' 140' ' ' ILE . 3.7 t30 64.69 -70.66 0.08 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.951 -179.662 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.508 ' O ' HD13 ' A' ' 103' ' ' ILE . . . -141.86 -1.19 1.4 Allowed Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 120.445 -0.883 . . . . 0.0 113.024 179.928 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.823 HD12 ' HB2' ' A' ' 158' ' ' ALA . 25.5 mm -119.55 159.2 20.68 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.166 0 CA-C-O 120.969 0.414 . . . . 0.0 111.304 -179.712 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.559 ' N ' HD12 ' A' ' 104' ' ' ILE . 3.3 mp -102.19 141.46 18.36 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.912 -179.762 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -83.51 -69.43 0.64 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.936 -179.845 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -142.9 168.98 18.42 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.941 -179.882 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.801 HD11 ' O ' ' A' ' 118' ' ' VAL . 0.6 OUTLIER -123.1 167.46 13.63 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.912 179.926 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 4.5 ttt -122.62 97.76 5.6 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.648 179.705 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -55.21 91.0 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.86 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 152.94 -29.38 0.82 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.947 -0.644 . . . . 0.0 112.029 -179.69 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -70.88 176.82 35.88 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.278 179.753 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.485 HG21 ' CB ' ' A' ' 87' ' ' ARG . 0.6 OUTLIER -78.74 -16.6 13.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 120.711 0.291 . . . . 0.0 111.664 -179.769 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 113' ' ' ALA . . . . . 0.495 ' HA ' HG12 ' A' ' 86' ' ' ILE . . . -57.75 -30.53 65.66 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.013 0.435 . . . . 0.0 110.726 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -60.34 -46.91 88.24 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.662 179.632 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -62.49 -47.8 82.39 Favored 'General case' 0 N--CA 1.452 -0.352 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.125 -179.684 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -49.91 -74.14 0.3 Allowed Glycine 0 CA--C 1.519 0.325 0 C-N-CA 120.454 -0.879 . . . . 0.0 112.452 179.866 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 117' ' ' GLY . . . . . 0.587 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 173.99 -25.16 0.07 OUTLIER Glycine 0 CA--C 1.519 0.299 0 C-N-CA 121.141 -0.552 . . . . 0.0 112.366 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.801 ' O ' HD11 ' A' ' 107' ' ' LEU . 1.1 t -40.24 113.76 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.256 0 CA-C-O 120.981 0.419 . . . . 0.0 111.802 -179.709 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 2.3 ttt180 -132.3 110.26 10.47 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.117 179.462 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 120' ' ' VAL . . . . . 0.726 ' H ' HD12 ' A' ' 107' ' ' LEU . 85.1 t -43.6 118.12 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.688 -179.451 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 118.5 28.13 2.21 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.845 -0.693 . . . . 0.0 112.932 179.73 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 122' ' ' HIS . . . . . 0.505 ' CE1' HD13 ' A' ' 104' ' ' ILE . 20.2 p-80 -137.3 -170.29 2.7 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.619 0.247 . . . . 0.0 111.07 179.752 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.541 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 55.6 ttp85 -133.92 114.39 13.23 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-N 116.574 -0.285 . . . . 0.0 111.711 -179.555 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 124' ' ' ILE . . . . . 0.653 ' HA ' HG22 ' A' ' 155' ' ' THR . 34.7 mt -73.16 158.58 6.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 178.59 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 125' ' ' ILE . . . . . 0.573 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.8 OUTLIER -147.14 -83.02 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 N-CA-C 112.867 0.691 . . . . 0.0 112.867 -179.624 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 126' ' ' GLU . . . . . 0.47 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 5.4 mt-10 -87.41 87.7 7.48 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 112.44 0.533 . . . . 0.0 112.44 -178.477 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.855 HG23 ' HB3' ' A' ' 153' ' ' MET . 2.4 mt -87.06 103.83 13.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.29 179.197 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 7.5 m-20 53.01 25.32 3.96 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.905 -0.588 . . . . 0.0 111.193 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 110.08 -13.57 31.45 Favored Glycine 0 CA--C 1.519 0.3 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.846 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 11.6 tt0 -95.72 110.88 22.95 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.787 0.327 . . . . 0.0 110.772 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 131' ' ' SER . . . . . 0.415 ' HA ' ' O ' ' A' ' 125' ' ' ILE . 1.1 m -74.84 87.24 2.25 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.042 -179.901 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 132' ' ' VAL . . . . . 0.696 HG21 HD11 ' A' ' 127' ' ' ILE . 31.9 m -73.9 -5.3 6.53 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.369 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.956 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.573 ' HB ' HG22 ' A' ' 125' ' ' ILE . 9.8 p -46.31 -31.56 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-O 120.888 0.375 . . . . 0.0 111.566 -179.695 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -127.95 27.41 5.7 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.617 179.409 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 135' ' ' THR . . . . . 0.434 ' CG2' ' HD2' ' A' ' 136' ' ' PRO . 32.5 m -110.65 143.79 28.93 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 115.833 -0.621 . . . . 0.0 111.214 -179.736 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 136' ' ' PRO . . . . . 0.434 ' HD2' ' CG2' ' A' ' 135' ' ' THR . 50.5 Cg_exo -53.78 164.27 2.45 Favored 'Trans proline' 0 C--N 1.347 0.495 0 C-N-CA 122.545 2.163 . . . . 0.0 112.048 179.512 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 137' ' ' HIS . . . . . 0.615 ' HA ' HD12 ' A' ' 140' ' ' ILE . 33.8 p-80 -72.6 -46.83 52.27 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.517 -179.607 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 138' ' ' GLU . . . . . 0.405 ' N ' ' CG ' ' A' ' 137' ' ' HIS . 1.7 mm-40 -54.01 -39.13 65.85 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.472 -179.513 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 139' ' ' LYS . . . . . 0.785 ' O ' HD12 ' A' ' 143' ' ' ILE . 7.0 tttp -63.53 -45.97 88.18 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.225 -179.701 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 140' ' ' ILE . . . . . 0.83 HG21 HG21 ' A' ' 99' ' ' VAL . 9.7 mt -59.36 -46.08 92.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.983 0.421 . . . . 0.0 110.431 179.956 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 141' ' ' VAL . . . . . 0.483 HG23 ' CG1' ' A' ' 99' ' ' VAL . 55.4 t -60.08 -32.37 50.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.039 179.034 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 14.2 t-80 -61.08 -53.68 54.06 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.679 179.579 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 143' ' ' ILE . . . . . 0.785 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.3 mp -53.16 -56.9 5.98 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.379 0 CA-C-O 121.276 0.56 . . . . 0.0 110.263 179.209 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.8 ' HB3' HD11 ' A' ' 95' ' ' LEU . 3.9 mt -61.24 -30.32 70.38 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.254 -0.884 . . . . 0.0 110.275 179.453 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 30.9 t -69.31 -26.38 64.69 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.123 -0.489 . . . . 0.0 109.925 178.676 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 8.5 m120 -127.43 32.2 5.06 Favored 'General case' 0 C--O 1.231 0.099 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.985 179.697 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 147' ' ' ALA . . . . . 0.795 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -114.03 41.62 2.21 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.352 -0.386 . . . . 0.0 111.296 -179.966 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 18.5 m -51.72 138.76 8.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.447 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 120.88 -103.46 0.9 Allowed Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.442 -179.914 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 4.7 mt-10 -139.28 100.65 4.06 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.79 0.328 . . . . 0.0 110.877 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 151' ' ' ILE . . . . . 0.795 HD11 ' HB3' ' A' ' 147' ' ' ALA . 1.3 mt -78.86 111.78 16.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.942 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -106.97 115.55 30.37 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.141 179.325 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 153' ' ' MET . . . . . 0.855 ' HB3' HG23 ' A' ' 127' ' ' ILE . 1.7 ptm -136.64 161.98 34.43 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.071 0.463 . . . . 0.0 111.729 -179.318 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 154' ' ' LYS . . . . . 0.551 ' HB3' HD11 ' A' ' 125' ' ' ILE . 3.5 mttt -104.53 150.3 24.73 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.712 -0.676 . . . . 0.0 109.778 179.121 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 155' ' ' THR . . . . . 0.653 HG22 ' HA ' ' A' ' 124' ' ' ILE . 21.8 p -146.14 150.44 35.89 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.295 0.569 . . . . 0.0 112.076 -179.086 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 156' ' ' MET . . . . . 0.644 ' CE ' HG13 ' A' ' 81' ' ' VAL . 0.0 OUTLIER -144.76 145.33 27.58 Favored Pre-proline 0 C--N 1.327 -0.406 0 CA-C-N 115.226 -0.897 . . . . 0.0 110.346 179.102 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_exo -50.92 109.38 0.3 Allowed 'Trans proline' 0 C--N 1.343 0.263 0 C-N-CA 122.512 2.141 . . . . 0.0 112.628 -179.759 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 158' ' ' ALA . . . . . 0.823 ' HB2' HD12 ' A' ' 103' ' ' ILE . . . . . . . . 0 C--O 1.25 1.084 0 CA-C-O 118.266 -0.873 . . . . 0.0 111.343 179.863 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_exo . . . . . 0 N--CA 1.489 1.252 0 CA-C-O 120.716 0.215 . . . . 0.0 111.733 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -70.22 115.36 4.12 Favored 'Trans proline' 0 C--N 1.343 0.265 0 C-N-CA 122.515 2.143 . . . . 0.0 112.372 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 18.3 t -93.17 139.42 18.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.104 179.945 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.1 m -114.42 132.14 56.35 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.926 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.545 HG23 ' HE2' ' A' ' 154' ' ' LYS . 56.5 m -95.58 111.19 23.16 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.947 179.119 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.794 HG22 ' N ' ' A' ' 118' ' ' VAL . 86.3 t -88.39 105.38 15.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.58 -179.206 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.457 ' O ' ' HA2' ' A' ' 116' ' ' GLY . 2.7 tp -100.01 84.27 2.84 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 178.588 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.748 HG13 HG12 ' A' ' 84' ' ' VAL . 22.0 mt -81.27 127.31 39.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-O 121.4 0.619 . . . . 0.0 111.928 -178.501 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.803 ' O ' HG21 ' A' ' 112' ' ' ILE . 0.0 OUTLIER -74.49 153.34 39.16 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.136 -0.938 . . . . 0.0 110.407 179.856 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.471 ' HD2' HD21 ' A' ' 95' ' ' LEU . 5.5 ttt-85 -152.15 91.71 3.62 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 120.682 0.277 . . . . 0.0 111.161 -179.931 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -58.53 -63.48 0.14 Allowed 'Trans proline' 0 C--N 1.345 0.346 0 C-N-CA 122.583 2.189 . . . . 0.0 112.23 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 4.9 t0 -117.14 -173.68 2.45 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.169 -179.859 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.847 HD12 HG11 ' A' ' 148' ' ' VAL . 0.1 OUTLIER -91.79 -21.95 20.41 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.311 -179.864 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -95.76 22.7 6.97 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.469 -0.332 . . . . 0.0 111.219 -179.779 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 17.7 m-85 -121.04 117.97 28.59 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.801 0.334 . . . . 0.0 110.835 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 3.4 mp0 -64.57 177.93 0.83 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.874 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 0.83 ' CD1' HD13 ' A' ' 144' ' ' LEU . 42.5 mt -96.98 -61.35 1.42 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.932 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 132.05 53.91 0.09 OUTLIER Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.718 179.912 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 97' ' ' PHE . . . . . 0.514 ' HZ ' HD12 ' A' ' 144' ' ' LEU . 0.2 OUTLIER -176.68 -171.96 0.41 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.904 0.383 . . . . 0.0 110.991 179.9 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 8.3 t -137.44 130.35 30.36 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.793 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 1.058 HG21 HG21 ' A' ' 140' ' ' ILE . 10.4 p -109.97 114.35 46.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.06 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 100' ' ' GLN . . . . . 0.421 ' O ' ' N ' ' A' ' 102' ' ' GLY . 1.2 tt0 -110.31 89.0 2.9 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.817 0.341 . . . . 0.0 110.908 -180.0 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 101' ' ' ASN . . . . . 0.717 ' O ' HD11 ' A' ' 140' ' ' ILE . 1.6 t30 65.18 -64.64 0.17 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.51 179.702 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.421 ' N ' ' O ' ' A' ' 100' ' ' GLN . . . -146.88 -4.49 0.42 Allowed Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.336 -0.935 . . . . 0.0 113.661 -179.623 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.727 HD12 ' CB ' ' A' ' 158' ' ' ALA . 31.5 mm -125.09 142.64 41.35 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 117.389 0.594 . . . . 0.0 111.307 -179.543 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.678 HD11 HG13 ' A' ' 124' ' ' ILE . 3.9 mp -84.44 142.58 13.16 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.788 179.712 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -105.42 -77.73 0.58 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.991 -179.829 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 62.6 p -90.64 146.98 23.6 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.944 0.402 . . . . 0.0 110.9 -179.973 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.728 ' HB2' HG22 ' A' ' 120' ' ' VAL . 0.2 OUTLIER -136.72 123.92 21.77 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.883 179.993 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 4.1 mtt -77.06 120.37 22.05 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.882 -179.949 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -81.33 105.59 12.63 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.765 179.893 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 101.66 26.63 7.52 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.394 -179.917 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 111' ' ' GLY . . . . . 0.5 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -111.76 -158.25 14.53 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.701 -0.762 . . . . 0.0 113.209 -179.761 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.803 HG21 ' O ' ' A' ' 87' ' ' ARG . 16.3 mt -80.16 -41.92 21.35 Favored 'Isoleucine or valine' 0 C--O 1.238 0.463 0 CA-C-O 121.076 0.465 . . . . 0.0 111.766 -179.588 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 113' ' ' ALA . . . . . 0.804 ' O ' HG12 ' A' ' 118' ' ' VAL . . . -57.7 -36.21 71.67 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.193 -179.394 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 114' ' ' GLU . . . . . 0.53 ' HG3' ' N ' ' A' ' 115' ' ' ARG . 8.3 pt-20 -66.9 -36.26 81.87 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.484 179.561 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.53 ' N ' ' HG3' ' A' ' 114' ' ' GLU . 0.0 OUTLIER -59.39 -46.55 88.35 Favored 'General case' 0 N--CA 1.452 -0.359 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.559 -179.905 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.457 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -56.05 -71.31 0.75 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.205 -0.998 . . . . 0.0 112.539 179.635 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 117' ' ' GLY . . . . . 0.481 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 174.32 -22.76 0.06 OUTLIER Glycine 0 CA--C 1.519 0.282 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.824 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.804 HG12 ' O ' ' A' ' 113' ' ' ALA . 7.3 p -31.75 145.72 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 N-CA-C 112.265 0.469 . . . . 0.0 112.265 -179.621 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.441 ' HB3' ' CD2' ' A' ' 122' ' ' HIS . 0.1 OUTLIER -147.83 134.43 19.85 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.734 179.899 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 120' ' ' VAL . . . . . 0.728 HG22 ' HB2' ' A' ' 107' ' ' LEU . 22.0 t -59.48 111.26 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.036 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 109.72 18.49 8.91 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.602 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 122' ' ' HIS . . . . . 0.566 ' O ' HG23 ' A' ' 103' ' ' ILE . 1.7 m-70 -102.22 -173.02 2.24 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.682 0.277 . . . . 0.0 110.693 179.909 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.626 ' HD2' HD11 ' A' ' 103' ' ' ILE . 40.4 ttt180 -142.76 90.71 2.24 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.363 -0.38 . . . . 0.0 111.335 -179.647 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 124' ' ' ILE . . . . . 0.678 HG13 HD11 ' A' ' 104' ' ' ILE . 25.2 mt -51.48 157.07 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.307 179.112 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 125' ' ' ILE . . . . . 0.771 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.6 OUTLIER -149.38 -82.99 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 N-CA-C 112.576 0.584 . . . . 0.0 112.576 -179.389 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 126' ' ' GLU . . . . . 0.411 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 72.7 mt-10 -89.29 89.4 7.89 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 112.353 0.501 . . . . 0.0 112.353 -178.62 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.831 HG23 ' HB3' ' A' ' 153' ' ' MET . 2.1 mt -88.89 106.87 17.24 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.181 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.573 179.43 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 128' ' ' ASN . . . . . 0.429 ' HA ' ' CE1' ' A' ' 152' ' ' HIS . 3.1 t-20 53.45 31.69 12.64 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.899 -0.591 . . . . 0.0 111.066 179.726 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 98.23 -7.26 62.06 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.754 -179.74 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 2.9 tt0 -99.92 106.23 18.02 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.836 0.351 . . . . 0.0 110.756 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 1.6 m -71.12 84.26 0.72 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.157 -179.773 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 132' ' ' VAL . . . . . 0.706 HG11 HD12 ' A' ' 127' ' ' ILE . 34.1 m -67.73 -10.03 11.67 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.759 179.867 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.771 ' HB ' HG22 ' A' ' 125' ' ' ILE . 9.3 p -51.06 117.85 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.925 0.393 . . . . 0.0 110.961 179.969 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 134' ' ' ALA . . . . . 0.521 ' HB3' ' O ' ' A' ' 133' ' ' VAL . . . 75.1 21.2 1.98 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.754 -178.997 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 135' ' ' THR . . . . . 0.47 ' CG2' ' HD2' ' A' ' 136' ' ' PRO . 29.3 m -103.5 142.52 24.74 Favored Pre-proline 0 C--N 1.327 -0.402 0 CA-C-N 115.648 -0.706 . . . . 0.0 110.802 179.828 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 136' ' ' PRO . . . . . 0.47 ' HD2' ' CG2' ' A' ' 135' ' ' THR . 94.9 Cg_exo -42.77 164.2 0.04 OUTLIER 'Trans proline' 0 C--N 1.348 0.533 0 C-N-CA 122.849 2.366 . . . . 0.0 112.9 -179.869 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 137' ' ' HIS . . . . . 0.447 ' CE1' ' O ' ' A' ' 99' ' ' VAL . 3.1 t-160 -74.17 -59.35 2.76 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.558 -179.525 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -53.67 -27.17 26.07 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.901 -179.135 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 139' ' ' LYS . . . . . 0.762 ' O ' HD12 ' A' ' 143' ' ' ILE . 0.9 OUTLIER -67.52 -51.44 50.85 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.651 0.262 . . . . 0.0 111.172 -179.535 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 140' ' ' ILE . . . . . 1.058 HG21 HG21 ' A' ' 99' ' ' VAL . 17.4 mt -59.54 -46.35 93.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 121.026 0.441 . . . . 0.0 110.751 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 141' ' ' VAL . . . . . 0.437 HG22 HG12 ' A' ' 99' ' ' VAL . 93.5 t -60.11 -32.44 50.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.227 179.237 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -61.75 -54.88 36.48 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.971 179.723 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 143' ' ' ILE . . . . . 0.762 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.1 mp -52.88 -56.9 5.62 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.391 0 CA-C-O 121.232 0.539 . . . . 0.0 110.267 179.569 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.83 HD13 ' CD1' ' A' ' 95' ' ' LEU . 1.6 mt -61.75 -29.97 70.48 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.394 179.582 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 25.8 t -69.25 -26.56 64.84 Favored 'General case' 0 C--N 1.33 -0.242 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 178.523 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -126.91 31.61 5.26 Favored 'General case' 0 CA--C 1.53 0.181 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.093 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 147' ' ' ALA . . . . . 0.772 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -116.98 58.19 0.78 Allowed 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.356 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.847 HG11 HD12 ' A' ' 91' ' ' LEU . 3.9 m -53.28 173.7 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.346 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 149' ' ' GLY . . . . . 0.409 ' N ' ' HB3' ' A' ' 88' ' ' ARG . . . 87.9 -113.38 4.01 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.468 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 -139.76 102.84 4.53 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.835 0.35 . . . . 0.0 110.778 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 151' ' ' ILE . . . . . 0.772 HD11 ' HB3' ' A' ' 147' ' ' ALA . 1.3 mt -73.99 111.67 9.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.098 -179.905 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 152' ' ' HIS . . . . . 0.429 ' CE1' ' HA ' ' A' ' 128' ' ' ASN . 8.7 p80 -104.58 115.58 30.59 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.136 -0.484 . . . . 0.0 109.733 178.84 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 153' ' ' MET . . . . . 0.831 ' HB3' HG23 ' A' ' 127' ' ' ILE . 0.8 OUTLIER -136.72 174.66 10.37 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.193 0.52 . . . . 0.0 111.874 -178.737 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 154' ' ' LYS . . . . . 0.685 ' HB3' HD11 ' A' ' 125' ' ' ILE . 0.0 OUTLIER -118.56 151.62 37.55 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.77 179.268 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 155' ' ' THR . . . . . 0.419 HG22 ' HA ' ' A' ' 124' ' ' ILE . 44.4 p -139.65 143.22 37.07 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.027 0.441 . . . . 0.0 111.479 -179.551 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 156' ' ' MET . . . . . 0.45 ' O ' ' N ' ' A' ' 123' ' ' ARG . 0.0 OUTLIER -110.77 176.63 1.45 Allowed Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 115.538 -0.755 . . . . 0.0 110.545 179.764 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 96.3 Cg_endo -90.12 118.75 0.74 Allowed 'Trans proline' 0 N--CA 1.457 -0.619 0 C-N-CA 122.735 2.29 . . . . 0.0 112.546 -179.856 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 158' ' ' ALA . . . . . 0.727 ' CB ' HD12 ' A' ' 103' ' ' ILE . . . . . . . . 0 C--O 1.249 1.071 0 CA-C-O 118.242 -0.885 . . . . 0.0 111.019 179.781 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_exo . . . . . 0 N--CA 1.488 1.178 0 N-CA-C 111.656 -0.171 . . . . 0.0 111.656 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_exo -66.64 62.57 0.56 Allowed 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.79 2.327 . . . . 0.0 112.351 -179.79 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.4 HG23 ' O ' ' A' ' 155' ' ' THR . 9.4 p -87.33 146.57 6.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.048 179.92 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.6 m -111.1 121.28 44.92 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.871 179.764 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.433 ' HA ' ' O ' ' A' ' 153' ' ' MET . 8.9 m -92.65 110.82 22.26 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.039 179.046 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.858 HG11 HG23 ' A' ' 118' ' ' VAL . 76.2 t -83.31 106.0 13.54 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.597 0 CA-C-N 116.298 -0.41 . . . . 0.0 112.059 -179.17 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.418 HD12 ' NE2' ' A' ' 152' ' ' HIS . 3.9 tt -102.97 81.11 1.94 Allowed 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 177.974 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.842 HG13 HG12 ' A' ' 84' ' ' VAL . 4.4 mt -81.49 123.88 38.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 121.281 0.562 . . . . 0.0 111.769 -178.328 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.565 ' HB2' HG21 ' A' ' 112' ' ' ILE . 0.1 OUTLIER -70.43 142.62 51.98 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.307 -0.86 . . . . 0.0 110.496 179.761 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.511 ' HG3' HD12 ' A' ' 151' ' ' ILE . 10.2 mtp180 -141.93 98.73 6.22 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.891 179.993 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 89' ' ' PRO . . . . . 0.447 ' HG2' ' CG ' ' A' ' 93' ' ' TYR . 64.1 Cg_endo -73.61 -41.62 1.09 Allowed 'Trans proline' 0 C--N 1.346 0.403 0 C-N-CA 122.552 2.168 . . . . 0.0 112.561 -179.877 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -137.05 -168.09 2.22 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.149 -179.824 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.607 ' HG ' HG11 ' A' ' 148' ' ' VAL . 3.9 mt -95.08 -22.74 17.69 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.204 -179.861 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 4.5 ptt-85 -96.23 22.84 7.2 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.144 -179.834 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 93' ' ' TYR . . . . . 0.447 ' CG ' ' HG2' ' A' ' 89' ' ' PRO . 12.9 m-85 -106.05 96.63 6.61 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.922 0.391 . . . . 0.0 110.894 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 1.3 pp0? -50.58 159.21 0.54 Allowed 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.276 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 0.83 HD23 HD13 ' A' ' 86' ' ' ILE . 2.1 mp -88.05 -66.8 0.88 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.861 179.872 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 130.49 37.77 0.32 Allowed Glycine 0 CA--C 1.519 0.29 0 C-N-CA 120.562 -0.828 . . . . 0.0 112.885 179.661 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 97' ' ' PHE . . . . . 0.439 ' CD1' ' HB2' ' A' ' 113' ' ' ALA . 50.2 p90 -176.93 178.06 1.21 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.707 0.289 . . . . 0.0 110.936 179.775 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.6 t -128.36 146.1 50.88 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.97 0.414 . . . . 0.0 111.06 -179.787 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 1.086 HG21 HG21 ' A' ' 140' ' ' ILE . 5.5 p -113.09 124.33 69.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.832 179.9 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 100' ' ' GLN . . . . . 0.423 HE21 ' HB2' ' A' ' 100' ' ' GLN . 0.0 OUTLIER -115.55 88.77 2.95 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.803 179.766 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 101' ' ' ASN . . . . . 0.65 ' O ' HD11 ' A' ' 140' ' ' ILE . 1.2 m-80 64.94 -67.16 0.12 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.87 -0.605 . . . . 0.0 111.424 179.685 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.423 ' O ' ' HA ' ' A' ' 123' ' ' ARG . . . -144.52 -3.7 0.7 Allowed Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.29 -0.957 . . . . 0.0 113.41 -179.629 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.653 HD12 ' HB2' ' A' ' 158' ' ' ALA . 39.2 mm -122.99 148.57 26.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 117.315 0.557 . . . . 0.0 111.406 -179.574 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.638 HD11 ' CD1' ' A' ' 124' ' ' ILE . 2.8 mp -85.08 141.91 13.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.507 179.594 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 94.1 m -97.81 -80.11 0.45 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.125 -179.677 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 1.4 m -109.13 145.63 35.41 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.981 -179.872 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.874 HD12 HG12 ' A' ' 118' ' ' VAL . 1.2 tt -143.2 113.2 7.14 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.808 179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -74.83 142.55 44.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.719 179.852 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.87 47.52 1.42 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.974 0.416 . . . . 0.0 110.808 -179.904 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -161.35 25.83 0.26 Allowed Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.39 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 111' ' ' GLY . . . . . 0.454 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -121.05 -174.63 14.98 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.331 179.867 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.565 HG21 ' HB2' ' A' ' 87' ' ' ARG . 1.2 mp -78.92 -22.56 12.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 120.785 0.326 . . . . 0.0 111.463 -179.876 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 113' ' ' ALA . . . . . 0.439 ' HB2' ' CD1' ' A' ' 97' ' ' PHE . . . -58.2 -30.57 66.56 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.894 0.378 . . . . 0.0 110.723 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 114' ' ' GLU . . . . . 0.454 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 12.4 pt-20 -61.26 -46.42 90.42 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.796 179.734 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 3.5 mtp85 -63.38 -44.13 95.62 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.908 -179.617 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -53.73 -73.97 0.35 Allowed Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.386 -0.911 . . . . 0.0 112.504 179.885 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 117' ' ' GLY . . . . . 0.564 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 174.98 -27.01 0.08 OUTLIER Glycine 0 CA--C 1.519 0.331 0 C-N-CA 120.922 -0.656 . . . . 0.0 112.65 -179.824 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.874 HG12 HD12 ' A' ' 107' ' ' LEU . 94.3 t -31.87 116.56 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 CA-C-O 121.026 0.441 . . . . 0.0 111.709 -179.82 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 11.7 mtt-85 -128.62 112.64 14.49 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.294 179.583 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 120' ' ' VAL . . . . . 0.567 HG22 ' HB2' ' A' ' 107' ' ' LEU . 32.2 t -46.99 108.42 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.239 -179.768 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 120.36 16.28 4.76 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 121.009 -0.615 . . . . 0.0 112.54 -179.721 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 122' ' ' HIS . . . . . 0.464 ' O ' HG23 ' A' ' 103' ' ' ILE . 3.9 m170 -110.35 -172.39 2.03 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.597 0.237 . . . . 0.0 110.562 179.923 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.74 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 4.1 ttt180 -139.88 92.87 2.59 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.682 0.277 . . . . 0.0 111.418 -179.657 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 124' ' ' ILE . . . . . 0.638 ' CD1' HD11 ' A' ' 104' ' ' ILE . 7.2 mt -52.76 147.65 1.91 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.077 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 125' ' ' ILE . . . . . 0.905 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.6 OUTLIER -141.42 -84.79 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 N-CA-C 112.393 0.516 . . . . 0.0 112.393 -179.335 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 8.5 mm-40 -86.39 90.06 8.08 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 112.316 0.488 . . . . 0.0 112.316 -178.719 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.889 HG23 ' HB3' ' A' ' 153' ' ' MET . 2.3 mt -85.45 105.72 14.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 121.24 0.543 . . . . 0.0 111.473 179.307 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 128' ' ' ASN . . . . . 0.44 ' N ' ' O ' ' A' ' 152' ' ' HIS . 0.6 OUTLIER 56.61 20.81 5.23 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.694 -0.684 . . . . 0.0 111.512 179.667 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 115.14 -12.8 19.54 Favored Glycine 0 C--N 1.331 0.301 0 C-N-CA 120.519 -0.848 . . . . 0.0 113.434 179.665 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 1.1 pt20 -103.17 117.54 34.78 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-O 120.958 0.408 . . . . 0.0 110.834 179.957 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 95.9 p -74.85 85.8 2.22 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.31 -179.643 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 132' ' ' VAL . . . . . 0.596 HG11 HD12 ' A' ' 127' ' ' ILE . 33.8 m -66.61 -10.89 12.39 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.315 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.535 179.537 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.905 ' HB ' HG22 ' A' ' 125' ' ' ILE . 8.9 p -49.69 117.73 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 120.915 0.388 . . . . 0.0 110.964 -179.952 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 134' ' ' ALA . . . . . 0.529 ' HB3' ' O ' ' A' ' 133' ' ' VAL . . . 76.15 20.77 1.58 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.789 -179.141 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 135' ' ' THR . . . . . 0.471 HG23 ' HD2' ' A' ' 136' ' ' PRO . 36.9 m -104.21 143.21 26.2 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.691 179.637 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 136' ' ' PRO . . . . . 0.471 ' HD2' HG23 ' A' ' 135' ' ' THR . 1.9 Cg_endo -41.51 141.19 1.47 Allowed 'Trans proline' 0 C--N 1.347 0.499 0 C-N-CA 123.113 2.542 . . . . 0.0 112.631 179.898 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 38.0 p-80 -63.95 -48.49 76.3 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.024 -0.534 . . . . 0.0 111.464 -179.62 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -54.73 -36.58 64.92 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.301 -179.625 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 139' ' ' LYS . . . . . 0.808 ' O ' HD12 ' A' ' 143' ' ' ILE . 19.2 tttm -63.34 -48.81 76.41 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.83 -179.933 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 140' ' ' ILE . . . . . 1.086 HG21 HG21 ' A' ' 99' ' ' VAL . 21.6 mt -58.47 -46.12 89.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.722 -179.861 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 141' ' ' VAL . . . . . 0.485 HG22 HG12 ' A' ' 99' ' ' VAL . 99.3 t -59.34 -32.5 48.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.014 178.869 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 1.7 t60 -61.78 -52.01 65.96 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.71 179.628 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 143' ' ' ILE . . . . . 0.808 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.3 mp -53.19 -57.23 5.14 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.414 0 CA-C-O 121.024 0.44 . . . . 0.0 110.222 179.416 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.749 HD13 ' CD2' ' A' ' 95' ' ' LEU . 3.4 mt -60.53 -30.15 69.57 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.562 -0.745 . . . . 0.0 110.23 179.574 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 1.1 m -69.33 -26.91 64.94 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-N 116.062 -0.517 . . . . 0.0 109.895 178.557 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 3.6 m-80 -129.82 34.61 4.27 Favored 'General case' 0 CA--C 1.528 0.114 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.216 179.837 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 147' ' ' ALA . . . . . 0.586 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -116.82 56.39 0.8 Allowed 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.835 0.35 . . . . 0.0 111.325 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.607 HG11 ' HG ' ' A' ' 91' ' ' LEU . 27.7 m -54.21 -177.96 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.403 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 81.67 -100.96 2.11 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.552 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 13.0 mt-10 -152.9 98.2 2.29 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.813 0.34 . . . . 0.0 110.707 -179.898 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 151' ' ' ILE . . . . . 0.586 HD11 ' HB3' ' A' ' 147' ' ' ALA . 1.2 mt -63.09 111.56 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.185 -179.718 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 152' ' ' HIS . . . . . 0.44 ' O ' ' N ' ' A' ' 128' ' ' ASN . 1.5 t-160 -107.1 115.64 30.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.983 -0.553 . . . . 0.0 109.805 179.121 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 153' ' ' MET . . . . . 0.889 ' HB3' HG23 ' A' ' 127' ' ' ILE . 1.0 OUTLIER -141.96 176.17 9.15 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.041 0.448 . . . . 0.0 111.82 -178.893 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 53.1 mttt -124.23 148.9 46.99 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.064 179.401 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 155' ' ' THR . . . . . 0.4 ' O ' HG23 ' A' ' 81' ' ' VAL . 20.0 p -137.1 132.17 33.7 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.942 0.401 . . . . 0.0 111.466 -179.57 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 156' ' ' MET . . . . . 0.476 ' O ' ' N ' ' A' ' 123' ' ' ARG . 0.0 OUTLIER -104.78 154.43 38.58 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.266 179.51 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 17.1 Cg_exo -66.77 118.78 5.82 Favored 'Trans proline' 0 C--N 1.342 0.228 0 C-N-CA 122.359 2.04 . . . . 0.0 112.136 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 158' ' ' ALA . . . . . 0.74 ' HB2' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.249 1.058 0 CA-C-O 118.262 -0.875 . . . . 0.0 111.107 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_exo . . . . . 0 N--CA 1.488 1.18 0 CA-C-O 120.772 0.238 . . . . 0.0 111.804 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 62.5 Cg_endo -73.81 -172.98 1.22 Allowed 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.507 2.138 . . . . 0.0 112.292 -179.835 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.589 HG13 ' O ' ' A' ' 155' ' ' THR . 41.7 t -87.65 141.19 14.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.094 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.5 m -117.09 143.4 45.83 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.913 179.854 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 17.7 m -105.67 111.56 24.3 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.247 179.279 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.74 HG11 HG23 ' A' ' 118' ' ' VAL . 43.4 t -82.34 105.94 12.73 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.552 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.78 -179.359 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.49 HD23 ' C ' ' A' ' 85' ' ' LEU . 6.3 tt -108.14 82.3 1.61 Allowed 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 109.122 -0.696 . . . . 0.0 109.122 178.574 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.992 HG21 HD22 ' A' ' 95' ' ' LEU . 5.1 mt -81.36 145.21 9.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.009 -0.541 . . . . 0.0 111.807 -178.165 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.418 ' HG2' ' CG2' ' A' ' 112' ' ' ILE . 0.1 OUTLIER -97.71 114.71 26.75 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.518 -179.831 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.472 ' HD2' HD12 ' A' ' 151' ' ' ILE . 2.3 ttt-85 -112.26 103.09 55.15 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.136 -179.714 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 89' ' ' PRO . . . . . 0.429 ' HB2' ' CD2' ' A' ' 93' ' ' TYR . 34.8 Cg_exo -57.63 -53.6 4.37 Favored 'Trans proline' 0 C--N 1.347 0.475 0 C-N-CA 122.498 2.132 . . . . 0.0 112.369 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -140.41 -167.07 2.25 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.986 -179.921 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.423 ' HG ' HG11 ' A' ' 148' ' ' VAL . 8.2 mt -84.01 -20.1 33.37 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.313 -179.868 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -96.41 23.33 6.86 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.095 -179.808 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 93' ' ' TYR . . . . . 0.429 ' CD2' ' HB2' ' A' ' 89' ' ' PRO . 15.9 m-85 -115.04 122.04 44.96 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.951 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -79.58 162.11 25.53 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.818 -179.979 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 0.992 HD22 HG21 ' A' ' 86' ' ' ILE . 53.9 mt -89.5 -69.94 0.69 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.837 179.964 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.407 ' O ' HD12 ' A' ' 107' ' ' LEU . . . 138.54 43.66 0.08 OUTLIER Glycine 0 CA--C 1.518 0.234 0 C-N-CA 120.42 -0.895 . . . . 0.0 113.011 179.724 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 35.4 p90 -176.74 161.97 2.12 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.849 0.357 . . . . 0.0 111.07 179.65 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -115.63 139.16 50.37 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.761 179.876 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.785 HG21 HG21 ' A' ' 140' ' ' ILE . 12.3 p -109.88 131.7 60.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.487 -179.818 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 100' ' ' GLN . . . . . 0.412 ' O ' ' N ' ' A' ' 102' ' ' GLY . 10.0 mt-30 -122.58 88.57 2.95 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.13 179.224 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 101' ' ' ASN . . . . . 0.649 ' O ' HD11 ' A' ' 140' ' ' ILE . 2.0 m120 63.89 -73.94 0.05 OUTLIER 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.971 -179.725 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.526 ' O ' HD13 ' A' ' 103' ' ' ILE . . . -137.82 0.67 2.74 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.299 -0.953 . . . . 0.0 113.05 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.813 HD12 ' HB2' ' A' ' 158' ' ' ALA . 38.1 mm -124.17 151.88 29.51 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.127 0 CA-C-O 121.014 0.435 . . . . 0.0 111.435 -179.617 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.765 HD11 HG13 ' A' ' 124' ' ' ILE . 3.2 mp -93.32 152.15 3.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.739 179.858 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 96.3 m -105.59 -67.54 0.92 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.107 -179.8 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 78.8 p -123.98 154.24 40.1 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.387 -0.369 . . . . 0.0 111.167 -179.853 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.407 HD12 ' O ' ' A' ' 96' ' ' GLY . 27.1 tp -139.55 103.42 4.69 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.619 179.861 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 6.8 ttm -60.89 110.91 1.46 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.006 -179.861 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 2.2 tmt_? -68.7 72.21 0.23 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.768 179.747 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 174.34 -34.12 0.11 Allowed Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.973 -0.632 . . . . 0.0 112.149 -179.853 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 111' ' ' GLY . . . . . 0.402 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -60.0 -176.73 1.31 Allowed Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.21 179.697 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.482 ' H ' HD12 ' A' ' 112' ' ' ILE . 0.8 OUTLIER -78.7 -17.09 13.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-O 120.822 0.344 . . . . 0.0 111.625 -179.89 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 113' ' ' ALA . . . . . 0.446 ' HA ' HG12 ' A' ' 86' ' ' ILE . . . -58.08 -30.46 66.25 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.937 0.398 . . . . 0.0 110.827 179.961 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 114' ' ' GLU . . . . . 0.402 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 14.5 pt-20 -61.56 -46.84 88.21 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.74 179.687 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 27.9 mtm-85 -62.1 -44.59 96.33 Favored 'General case' 0 N--CA 1.451 -0.406 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.082 -179.64 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.415 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -52.92 -73.75 0.37 Allowed Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.36 -0.924 . . . . 0.0 112.536 179.975 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 117' ' ' GLY . . . . . 0.567 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 167.33 -19.31 0.09 OUTLIER Glycine 0 CA--C 1.52 0.377 0 C-N-CA 121.0 -0.619 . . . . 0.0 112.75 -179.702 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.74 HG23 HG11 ' A' ' 84' ' ' VAL . 0.9 OUTLIER -38.5 129.47 0.36 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.244 0 CA-C-O 121.007 0.432 . . . . 0.0 111.607 -179.862 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -127.63 101.94 6.62 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.603 179.752 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 120' ' ' VAL . . . . . 0.513 ' O ' HG13 ' A' ' 120' ' ' VAL . 12.5 p -49.86 117.81 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.013 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 115.91 -14.56 16.77 Favored Glycine 0 CA--C 1.518 0.228 0 C-N-CA 120.854 -0.689 . . . . 0.0 112.333 -179.488 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -84.65 -165.6 1.23 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.64 0.257 . . . . 0.0 110.54 179.872 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.595 ' HA ' HD13 ' A' ' 103' ' ' ILE . 51.6 ttt85 -130.39 102.2 6.07 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.881 0.372 . . . . 0.0 111.445 -179.718 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 124' ' ' ILE . . . . . 0.842 ' HA ' HG22 ' A' ' 155' ' ' THR . 9.1 mt -60.63 157.95 2.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.092 178.86 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 125' ' ' ILE . . . . . 0.839 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.7 OUTLIER -154.79 -85.04 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 N-CA-C 113.086 0.773 . . . . 0.0 113.086 -179.708 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 126' ' ' GLU . . . . . 0.401 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 3.3 mt-10 -84.28 91.21 7.7 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 112.932 0.716 . . . . 0.0 112.932 -178.117 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.875 HD11 HG21 ' A' ' 132' ' ' VAL . 1.7 mt -90.88 98.79 8.76 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.146 0 CA-C-N 116.374 -0.376 . . . . 0.0 110.878 178.628 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 128' ' ' ASN . . . . . 0.422 ' N ' ' O ' ' A' ' 152' ' ' HIS . 45.8 m-20 60.84 26.13 16.0 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.703 -179.848 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 106.98 -16.14 39.55 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.556 -179.841 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -92.35 108.17 19.76 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.909 0.385 . . . . 0.0 110.715 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 27.4 m -74.59 90.9 2.28 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.125 -179.772 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 132' ' ' VAL . . . . . 0.875 HG21 HD11 ' A' ' 127' ' ' ILE . 35.0 m -81.62 4.39 2.02 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.341 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.967 179.904 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.839 ' HB ' HG22 ' A' ' 125' ' ' ILE . 9.8 p -47.81 -32.42 3.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 120.914 0.388 . . . . 0.0 111.253 -179.857 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -124.68 27.69 6.78 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.601 179.313 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 135' ' ' THR . . . . . 0.523 HG23 ' HD2' ' A' ' 136' ' ' PRO . 90.6 m -109.5 143.69 28.31 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.982 -179.841 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 136' ' ' PRO . . . . . 0.523 ' HD2' HG23 ' A' ' 135' ' ' THR . 80.3 Cg_exo -48.27 164.16 0.21 Allowed 'Trans proline' 0 C--N 1.349 0.565 0 C-N-CA 122.496 2.13 . . . . 0.0 112.483 179.909 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 137' ' ' HIS . . . . . 0.557 ' HA ' HD12 ' A' ' 140' ' ' ILE . 57.1 p-80 -76.23 -48.45 20.29 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.492 -179.606 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -55.53 -34.66 64.87 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.939 0.4 . . . . 0.0 111.197 -179.636 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 139' ' ' LYS . . . . . 0.791 ' O ' HD12 ' A' ' 143' ' ' ILE . 0.8 OUTLIER -64.43 -47.47 78.98 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.021 -179.831 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 140' ' ' ILE . . . . . 0.785 HG21 HG21 ' A' ' 99' ' ' VAL . 8.7 mt -59.18 -46.5 92.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 121.155 0.503 . . . . 0.0 110.553 -179.868 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 141' ' ' VAL . . . . . 0.486 HG23 ' CG1' ' A' ' 99' ' ' VAL . 54.1 t -59.68 -32.45 49.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.057 179.013 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 1.4 t-80 -61.58 -53.44 56.31 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.909 179.738 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 143' ' ' ILE . . . . . 0.791 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.2 mp -53.06 -56.95 5.62 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.468 0 CA-C-O 121.203 0.525 . . . . 0.0 110.455 179.494 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.651 HD22 HG12 ' A' ' 151' ' ' ILE . 1.6 mt -63.3 -29.82 71.07 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.414 -0.812 . . . . 0.0 110.455 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 4.0 m -69.66 -28.47 65.9 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 178.773 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 9.0 m120 -129.67 35.42 4.19 Favored 'General case' 0 CA--C 1.528 0.128 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.227 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 147' ' ' ALA . . . . . 0.949 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -101.05 -33.27 10.22 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.945 0.402 . . . . 0.0 111.28 -179.917 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.438 HG22 ' O ' ' A' ' 147' ' ' ALA . 35.5 m 44.44 -173.63 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.527 -0.76 . . . . 0.0 111.849 -179.877 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 50.78 -148.67 7.42 Favored Glycine 0 C--N 1.332 0.341 0 C-N-CA 120.854 -0.689 . . . . 0.0 112.772 -179.963 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.443 ' HB3' HD21 ' A' ' 85' ' ' LEU . 7.9 mt-10 -89.41 105.33 17.73 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.72 0.295 . . . . 0.0 110.845 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 151' ' ' ILE . . . . . 0.949 HD11 ' HB3' ' A' ' 147' ' ' ALA . 0.6 OUTLIER -78.25 111.58 15.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.387 -0.37 . . . . 0.0 111.12 -179.917 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 152' ' ' HIS . . . . . 0.422 ' O ' ' N ' ' A' ' 128' ' ' ASN . 0.0 OUTLIER -93.29 124.79 37.51 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 178.889 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 153' ' ' MET . . . . . 0.745 ' HG3' HG23 ' A' ' 127' ' ' ILE . 5.2 tmm? -147.92 151.89 36.62 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.873 0.368 . . . . 0.0 111.79 -178.721 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 154' ' ' LYS . . . . . 0.401 ' HG2' HG11 ' A' ' 81' ' ' VAL . 0.0 OUTLIER -111.86 148.14 34.27 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.476 179.644 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 155' ' ' THR . . . . . 0.842 HG22 ' HA ' ' A' ' 124' ' ' ILE . 37.6 p -145.23 151.32 38.21 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.086 0.47 . . . . 0.0 111.702 -179.755 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 156' ' ' MET . . . . . 0.435 ' O ' ' N ' ' A' ' 123' ' ' ARG . 5.0 ptp -139.43 156.3 71.65 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.295 179.061 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 12.7 Cg_endo -56.43 120.44 8.31 Favored 'Trans proline' 0 C--N 1.342 0.229 0 C-N-CA 122.5 2.133 . . . . 0.0 112.609 -179.714 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 158' ' ' ALA . . . . . 0.813 ' HB2' HD12 ' A' ' 103' ' ' ILE . . . . . . . . 0 C--O 1.249 1.051 0 CA-C-O 118.308 -0.853 . . . . 0.0 110.995 179.845 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_endo . . . . . 0 N--CA 1.489 1.252 0 CA-C-O 120.831 0.263 . . . . 0.0 111.7 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -70.13 126.67 13.32 Favored 'Trans proline' 0 C--N 1.345 0.348 0 C-N-CA 122.566 2.178 . . . . 0.0 112.351 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.703 HG23 ' O ' ' A' ' 155' ' ' THR . 11.6 p -83.89 140.48 16.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.969 179.857 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 1.4 m -82.2 146.03 29.75 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.87 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 8.8 m -108.3 111.16 22.96 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.188 179.13 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.652 HG12 ' CD1' ' A' ' 86' ' ' ILE . 49.9 t -90.29 106.13 16.97 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.448 0 CA-C-N 116.024 -0.534 . . . . 0.0 111.078 -179.708 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.409 ' O ' ' HA2' ' A' ' 116' ' ' GLY . 0.9 OUTLIER -107.01 81.55 1.56 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.02 179.134 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.652 ' CD1' HG12 ' A' ' 84' ' ' VAL . 1.7 mp -81.59 149.09 4.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 121.067 0.46 . . . . 0.0 111.047 -179.235 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.452 ' CB ' HG21 ' A' ' 112' ' ' ILE . 0.3 OUTLIER -109.43 108.8 19.45 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.761 -179.354 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -102.82 104.75 41.12 Favored Pre-proline 0 C--N 1.33 -0.257 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.812 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 89' ' ' PRO . . . . . 0.445 ' HG2' ' CG ' ' A' ' 93' ' ' TYR . 37.9 Cg_endo -66.46 -49.21 1.88 Allowed 'Trans proline' 0 C--N 1.347 0.479 0 C-N-CA 122.341 2.027 . . . . 0.0 112.546 -179.814 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -136.2 178.95 6.66 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.157 -179.86 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 25.5 mt -77.64 -19.89 54.74 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.194 -179.897 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 2.9 ptt180 -96.85 23.26 7.29 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.48 -0.327 . . . . 0.0 111.158 -179.895 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' TYR . . . . . 0.445 ' CG ' ' HG2' ' A' ' 89' ' ' PRO . 16.8 m-85 -120.15 92.3 3.74 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.942 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -59.49 165.92 2.63 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.049 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 0.542 ' HG ' HG21 ' A' ' 86' ' ' ILE . 2.4 mp -82.63 -37.46 24.91 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.709 179.836 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 96.11 50.85 1.84 Allowed Glycine 0 C--N 1.33 0.229 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.84 179.653 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 1.3 p90 -160.58 -172.92 3.72 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.905 0.383 . . . . 0.0 111.077 179.873 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.428 ' O ' ' HA ' ' A' ' 104' ' ' ILE . 6.4 t -135.71 128.64 31.34 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.458 179.757 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.431 ' CG1' HG23 ' A' ' 141' ' ' VAL . 9.9 p -109.79 131.59 60.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.918 0.389 . . . . 0.0 111.675 -179.525 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 13.0 mt-30 -123.33 88.32 2.9 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.908 -0.587 . . . . 0.0 109.527 178.842 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 4.6 m120 56.59 18.97 3.9 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.932 -178.961 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 128.68 -41.43 1.57 Allowed Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.854 -0.688 . . . . 0.0 112.572 179.835 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.53 HG12 ' CB ' ' A' ' 158' ' ' ALA . 21.0 mt -77.42 133.38 30.8 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-O 121.061 0.457 . . . . 0.0 111.678 -179.361 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.885 HD11 ' CD1' ' A' ' 124' ' ' ILE . 4.5 mp -93.14 137.57 22.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.609 179.487 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 53.5 t -108.89 -75.39 0.63 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.094 -179.576 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 2.7 m -90.6 124.3 34.93 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.052 -179.826 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.612 HD11 ' CG1' ' A' ' 118' ' ' VAL . 1.1 tt -130.91 110.06 11.0 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.646 179.857 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -64.63 150.12 47.62 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.786 -179.905 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -91.96 45.53 1.22 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.164 0.507 . . . . 0.0 110.619 179.79 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -153.2 -33.81 0.03 OUTLIER Glycine 0 N--CA 1.45 -0.419 0 CA-C-N 115.617 -0.72 . . . . 0.0 112.283 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 111' ' ' GLY . . . . . 0.438 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -49.39 166.53 0.31 Allowed Glycine 0 C--N 1.333 0.411 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.431 179.812 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.455 ' H ' HD12 ' A' ' 112' ' ' ILE . 0.8 OUTLIER -78.86 -19.44 13.04 Favored 'Isoleucine or valine' 0 C--O 1.237 0.404 0 CA-C-O 120.822 0.344 . . . . 0.0 111.835 -179.652 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 113' ' ' ALA . . . . . 0.613 ' O ' HG12 ' A' ' 118' ' ' VAL . . . -58.12 -30.38 66.26 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.939 0.399 . . . . 0.0 110.529 179.796 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 114' ' ' GLU . . . . . 0.438 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 20.2 pt-20 -59.34 -44.98 92.58 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.682 179.525 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 7.9 mtm180 -64.55 -47.48 78.6 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.151 -179.48 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.409 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -49.04 -74.5 0.26 Allowed Glycine 0 CA--C 1.519 0.297 0 C-N-CA 120.296 -0.954 . . . . 0.0 112.744 -179.933 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 175.45 -14.97 0.04 OUTLIER Glycine 0 CA--C 1.52 0.398 0 C-N-CA 120.863 -0.684 . . . . 0.0 113.116 -179.876 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.628 ' N ' HG22 ' A' ' 84' ' ' VAL . 7.6 p -35.49 153.19 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.275 0 N-CA-C 112.132 0.419 . . . . 0.0 112.132 -179.727 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 9.5 mmt180 -139.73 138.86 36.29 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.881 179.924 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 19.4 t -71.22 81.5 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.154 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 132.1 41.02 0.2 Allowed Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.664 179.902 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 12.9 m170 -131.64 132.0 43.66 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.843 0.354 . . . . 0.0 110.766 179.856 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.978 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 0.2 OUTLIER -81.3 92.39 6.37 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.391 -179.768 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 124' ' ' ILE . . . . . 0.885 ' CD1' HD11 ' A' ' 104' ' ' ILE . 9.0 mt -46.16 156.7 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.164 178.753 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 125' ' ' ILE . . . . . 0.786 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.6 OUTLIER -153.89 -86.06 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 N-CA-C 112.48 0.548 . . . . 0.0 112.48 -179.497 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 13.5 mt-10 -77.01 92.64 3.73 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 112.131 0.419 . . . . 0.0 112.131 -178.707 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.754 HG23 ' CG ' ' A' ' 153' ' ' MET . 1.2 mt -91.52 98.77 8.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 121.008 0.432 . . . . 0.0 110.991 179.194 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 128' ' ' ASN . . . . . 0.423 ' N ' ' O ' ' A' ' 152' ' ' HIS . 19.3 p30 48.18 26.51 1.06 Allowed 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.651 -0.704 . . . . 0.0 112.133 179.752 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 125.2 -26.22 5.59 Favored Glycine 0 C--N 1.332 0.357 0 C-N-CA 120.239 -0.981 . . . . 0.0 113.878 178.905 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -100.03 114.02 27.02 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 117.27 0.535 . . . . 0.0 111.428 -179.497 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 12.0 t -78.33 101.99 7.48 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.047 179.847 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 132' ' ' VAL . . . . . 0.634 HG21 HD11 ' A' ' 127' ' ' ILE . 21.5 m -83.08 6.94 1.57 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.282 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.825 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.786 ' HB ' HG22 ' A' ' 125' ' ' ILE . 11.1 p -51.91 119.7 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.18 0 CA-C-O 120.958 0.409 . . . . 0.0 110.82 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 134' ' ' ALA . . . . . 0.408 ' HB3' ' O ' ' A' ' 133' ' ' VAL . . . 68.45 22.84 7.67 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.751 -179.101 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 135' ' ' THR . . . . . 0.443 HG21 ' HD2' ' A' ' 139' ' ' LYS . 28.8 m -99.47 142.05 23.92 Favored Pre-proline 0 C--N 1.328 -0.364 0 CA-C-N 115.669 -0.696 . . . . 0.0 110.702 179.864 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 136' ' ' PRO . . . . . 0.425 ' HD2' ' CG2' ' A' ' 135' ' ' THR . 87.1 Cg_exo -44.97 142.65 5.15 Favored 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 122.628 2.219 . . . . 0.0 112.549 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 32.0 p-80 -62.86 -48.05 80.71 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.468 -179.599 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 1.4 tt0 -55.23 -33.44 63.11 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.244 -179.726 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 139' ' ' LYS . . . . . 0.752 ' O ' HD12 ' A' ' 143' ' ' ILE . 1.6 tmtp? -66.14 -49.44 67.44 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.933 -179.928 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 8.0 mt -58.82 -45.14 91.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 121.102 0.477 . . . . 0.0 110.405 179.888 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 141' ' ' VAL . . . . . 0.431 HG23 ' CG1' ' A' ' 99' ' ' VAL . 93.3 t -60.78 -32.67 52.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.06 178.794 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 9.7 t-80 -59.9 -52.57 64.87 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.538 179.586 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 143' ' ' ILE . . . . . 0.752 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.1 mp -53.15 -56.85 6.15 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.433 0 CA-C-O 121.197 0.522 . . . . 0.0 110.282 179.253 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.594 HD22 HG12 ' A' ' 151' ' ' ILE . 1.2 mt -61.9 -29.97 70.56 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.315 -0.857 . . . . 0.0 110.45 179.625 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 1.5 m -68.84 -26.73 65.3 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.124 -0.489 . . . . 0.0 109.939 178.549 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 3.8 m-80 -127.41 32.07 5.09 Favored 'General case' 0 C--O 1.232 0.152 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.173 179.796 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 147' ' ' ALA . . . . . 0.718 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -117.62 59.52 0.78 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.819 0.343 . . . . 0.0 111.16 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 28.1 m -54.74 175.7 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.37 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 79.3 -118.62 4.82 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.779 -0.725 . . . . 0.0 112.393 179.912 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -123.8 117.15 24.23 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.714 0.293 . . . . 0.0 110.582 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 151' ' ' ILE . . . . . 0.718 HD11 ' HB3' ' A' ' 147' ' ' ALA . 0.9 OUTLIER -89.32 111.87 23.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.365 -179.679 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 152' ' ' HIS . . . . . 0.423 ' O ' ' N ' ' A' ' 128' ' ' ASN . 6.4 m-70 -94.83 120.02 34.36 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 178.357 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 153' ' ' MET . . . . . 0.754 ' CG ' HG23 ' A' ' 127' ' ' ILE . 27.4 ttp -139.86 162.93 33.97 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 112.44 0.533 . . . . 0.0 112.44 -178.106 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 6.1 mttp -129.96 141.3 50.79 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.226 -0.897 . . . . 0.0 109.831 179.276 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 155' ' ' THR . . . . . 0.703 ' O ' HG23 ' A' ' 81' ' ' VAL . 4.7 p -139.61 147.4 41.05 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.948 0.404 . . . . 0.0 111.726 -179.174 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 156' ' ' MET . . . . . 0.448 ' CB ' ' CD ' ' A' ' 157' ' ' PRO . 1.0 OUTLIER -113.75 -179.78 0.67 Allowed Pre-proline 0 C--N 1.328 -0.368 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.24 179.59 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 157' ' ' PRO . . . . . 0.448 ' CD ' ' CB ' ' A' ' 156' ' ' MET . 89.3 Cg_endo -85.11 112.09 1.41 Allowed 'Trans proline' 0 N--CA 1.462 -0.375 0 C-N-CA 122.493 2.128 . . . . 0.0 112.558 -179.883 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 158' ' ' ALA . . . . . 0.978 ' HB2' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.249 1.074 0 CA-C-O 118.141 -0.933 . . . . 0.0 111.092 179.864 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_exo . . . . . 0 N--CA 1.488 1.194 0 CA-C-O 120.689 0.204 . . . . 0.0 111.671 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -74.55 94.76 0.93 Allowed 'Trans proline' 0 C--N 1.344 0.315 0 C-N-CA 122.64 2.227 . . . . 0.0 112.343 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 29.6 t -107.79 126.85 64.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.062 179.938 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 1.6 m -104.64 145.79 29.84 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.994 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 91.7 m -107.05 111.09 23.39 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.049 -0.523 . . . . 0.0 109.917 178.92 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.742 HG13 ' H ' ' A' ' 118' ' ' VAL . 33.5 t -93.15 105.94 17.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.696 -179.415 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.475 HD21 ' OE1' ' A' ' 150' ' ' GLU . 4.2 tt -102.77 83.28 2.23 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.21 -0.45 . . . . 0.0 109.823 179.047 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.8 HD13 HD12 ' A' ' 95' ' ' LEU . 2.0 mt -81.7 132.46 31.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-O 121.096 0.474 . . . . 0.0 111.389 -178.932 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.441 ' O ' HG21 ' A' ' 112' ' ' ILE . 0.0 OUTLIER -89.45 114.01 25.44 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.692 -0.685 . . . . 0.0 110.531 -179.917 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.534 ' HG3' HD12 ' A' ' 151' ' ' ILE . 5.9 mmm180 -104.91 104.4 46.28 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.451 -0.341 . . . . 0.0 111.133 -179.733 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 89' ' ' PRO . . . . . 0.425 ' HG2' ' CE2' ' A' ' 93' ' ' TYR . 29.7 Cg_exo -61.96 -39.81 48.07 Favored 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.581 2.187 . . . . 0.0 112.427 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -153.61 -171.26 3.84 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.939 0.399 . . . . 0.0 111.303 -179.87 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.541 ' HG ' HG11 ' A' ' 148' ' ' VAL . 6.0 mt -86.14 -19.23 30.43 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.491 -179.757 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -93.97 21.58 6.55 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.707 0.289 . . . . 0.0 111.344 -179.585 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 93' ' ' TYR . . . . . 0.425 ' CE2' ' HG2' ' A' ' 89' ' ' PRO . 15.8 m-85 -104.25 175.56 5.45 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.654 179.547 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -128.35 149.71 50.41 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.897 0.38 . . . . 0.0 111.131 -179.876 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 0.8 HD12 HD13 ' A' ' 86' ' ' ILE . 4.6 mm? -67.59 -56.55 9.01 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.662 179.799 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 118.1 29.63 1.94 Allowed Glycine 0 C--N 1.333 0.401 0 C-N-CA 120.637 -0.792 . . . . 0.0 112.995 179.424 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 97' ' ' PHE . . . . . 0.432 ' CE2' ' HB3' ' A' ' 95' ' ' LEU . 47.8 p90 -166.81 165.23 16.36 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.852 0.358 . . . . 0.0 111.374 179.843 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -101.16 138.18 38.54 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.626 179.843 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.58 HG21 HG21 ' A' ' 140' ' ' ILE . 9.7 p -115.36 132.75 63.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.923 0.392 . . . . 0.0 111.591 -179.716 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 24.6 mt-30 -131.11 89.25 2.71 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.1 179.387 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 44.7 m-80 60.61 16.25 6.4 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.004 -179.436 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.419 ' O ' ' HB ' ' A' ' 124' ' ' ILE . . . 124.87 -36.25 2.9 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.969 -0.634 . . . . 0.0 112.293 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.701 HG23 ' O ' ' A' ' 122' ' ' HIS . 36.7 mt -77.77 134.97 27.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-O 121.067 0.461 . . . . 0.0 111.738 -179.639 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.769 HD11 ' CD1' ' A' ' 124' ' ' ILE . 4.4 mp -90.29 135.48 26.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.519 179.666 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -106.15 -72.18 0.72 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.208 -179.591 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 1.5 m -101.87 142.26 33.45 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.145 -179.691 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.627 HD11 HG11 ' A' ' 118' ' ' VAL . 1.2 tt -144.68 124.54 13.44 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.646 179.695 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 19.8 mtp -82.09 149.76 27.86 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.03 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 4.6 mtm-85 -93.25 44.47 1.14 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.213 0.53 . . . . 0.0 110.367 179.649 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -161.03 22.43 0.23 Allowed Glycine 0 N--CA 1.449 -0.447 0 CA-C-N 115.617 -0.72 . . . . 0.0 112.284 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 111' ' ' GLY . . . . . 0.514 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -110.35 174.2 17.17 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 120.934 -0.651 . . . . 0.0 111.901 179.743 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.441 HG21 ' O ' ' A' ' 87' ' ' ARG . 0.6 OUTLIER -79.22 -21.94 12.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-O 120.854 0.359 . . . . 0.0 111.585 -179.713 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 113' ' ' ALA . . . . . 0.735 ' O ' HG12 ' A' ' 118' ' ' VAL . . . -58.35 -30.76 66.99 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.934 0.397 . . . . 0.0 110.549 179.775 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 114' ' ' GLU . . . . . 0.514 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 9.0 pt-20 -59.76 -44.59 93.79 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.753 179.672 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 85.1 mtt180 -65.36 -46.74 78.99 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.32 -179.468 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.404 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -48.94 -74.43 0.27 Allowed Glycine 0 CA--C 1.519 0.316 0 C-N-CA 120.302 -0.951 . . . . 0.0 112.709 -179.903 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 117' ' ' GLY . . . . . 0.433 ' O ' ' C ' ' A' ' 118' ' ' VAL . . . 175.59 -20.46 0.05 OUTLIER Glycine 0 CA--C 1.519 0.283 0 C-N-CA 121.013 -0.613 . . . . 0.0 112.72 -179.902 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.742 ' H ' HG13 ' A' ' 84' ' ' VAL . 11.0 p -24.91 136.87 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.399 0 N-CA-C 112.575 0.583 . . . . 0.0 112.575 -179.847 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 3.3 ttt180 -134.33 110.69 9.64 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.855 179.902 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 120' ' ' VAL . . . . . 0.489 HG22 ' HB2' ' A' ' 107' ' ' LEU . 21.0 t -57.11 100.21 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.083 -179.88 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 124.02 40.67 0.44 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.39 -179.83 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 122' ' ' HIS . . . . . 0.701 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.1 OUTLIER -134.91 -167.22 1.95 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.664 0.269 . . . . 0.0 110.657 -179.917 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.718 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 13.8 ttt180 -137.26 90.44 2.52 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.883 179.976 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 124' ' ' ILE . . . . . 0.769 ' CD1' HD11 ' A' ' 104' ' ' ILE . 9.4 mt -50.06 156.08 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 N-CA-C 110.158 -0.312 . . . . 0.0 110.158 179.199 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 125' ' ' ILE . . . . . 0.848 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.6 OUTLIER -148.59 -84.71 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 N-CA-C 112.171 0.434 . . . . 0.0 112.171 -179.577 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 126' ' ' GLU . . . . . 0.404 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 12.2 mt-10 -80.34 86.16 5.74 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 112.164 0.431 . . . . 0.0 112.164 -178.999 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.845 HD11 HG21 ' A' ' 132' ' ' VAL . 1.4 mt -89.53 102.43 13.1 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 CA-C-O 120.899 0.381 . . . . 0.0 110.839 179.117 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 128' ' ' ASN . . . . . 0.461 ' HA ' ' CD2' ' A' ' 152' ' ' HIS . 0.9 OUTLIER 59.97 24.83 13.98 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.077 -0.511 . . . . 0.0 111.109 179.902 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 107.29 -13.43 40.07 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.919 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -97.62 113.07 24.72 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.789 0.328 . . . . 0.0 111.025 -179.878 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 1.2 p -77.44 94.68 4.3 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.019 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 132' ' ' VAL . . . . . 0.845 HG21 HD11 ' A' ' 127' ' ' ILE . 27.1 m -80.14 1.38 2.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.883 -179.879 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.848 ' HB ' HG22 ' A' ' 125' ' ' ILE . 9.2 p -46.79 -38.11 3.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-O 120.907 0.384 . . . . 0.0 111.619 -179.65 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -115.97 28.89 8.32 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.747 179.554 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 135' ' ' THR . . . . . 0.506 HG23 ' HD2' ' A' ' 136' ' ' PRO . 97.9 m -116.32 144.61 33.36 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 115.912 -0.585 . . . . 0.0 111.172 -179.834 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 136' ' ' PRO . . . . . 0.506 ' HD2' HG23 ' A' ' 135' ' ' THR . 48.9 Cg_exo -55.75 164.29 4.66 Favored 'Trans proline' 0 C--N 1.348 0.516 0 C-N-CA 122.528 2.152 . . . . 0.0 112.245 179.842 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 41.7 p-80 -67.18 -48.9 66.56 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.299 -179.837 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 6.0 tp10 -54.47 -36.66 64.36 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.388 -179.692 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 139' ' ' LYS . . . . . 0.796 ' O ' HD12 ' A' ' 143' ' ' ILE . 4.1 mmmt -61.63 -46.54 89.35 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.723 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 140' ' ' ILE . . . . . 0.825 HG23 ' CD1' ' A' ' 127' ' ' ILE . 16.8 mt -58.86 -46.03 91.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.581 -179.909 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 141' ' ' VAL . . . . . 0.411 ' CG2' ' CG1' ' A' ' 99' ' ' VAL . 93.7 t -59.8 -32.42 49.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.089 179.086 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -61.77 -54.0 48.33 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.834 179.764 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 143' ' ' ILE . . . . . 0.796 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.3 mp -52.88 -56.44 7.56 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.454 0 CA-C-O 121.194 0.521 . . . . 0.0 110.312 179.413 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.732 HD22 HG12 ' A' ' 151' ' ' ILE . 2.2 mt -63.0 -29.92 71.2 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.294 -0.866 . . . . 0.0 110.361 179.83 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 15.5 t -69.83 -30.14 67.58 Favored 'General case' 0 N--CA 1.453 -0.289 0 CA-C-N 116.302 -0.408 . . . . 0.0 109.933 178.676 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 3.0 m-80 -125.65 34.66 4.86 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.864 179.722 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 147' ' ' ALA . . . . . 1.06 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -100.3 -39.33 8.07 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.036 0.446 . . . . 0.0 111.585 -179.68 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.541 HG11 ' HG ' ' A' ' 91' ' ' LEU . 24.8 m 44.86 -171.38 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.488 -0.778 . . . . 0.0 111.662 -179.88 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 55.76 -135.35 48.88 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.569 -179.813 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.475 ' OE1' HD21 ' A' ' 85' ' ' LEU . 27.9 mt-10 -107.69 101.24 10.56 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.839 0.352 . . . . 0.0 110.761 179.884 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 151' ' ' ILE . . . . . 1.06 HD11 ' HB3' ' A' ' 147' ' ' ALA . 0.5 OUTLIER -76.07 111.76 12.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.189 -179.768 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 152' ' ' HIS . . . . . 0.461 ' CD2' ' HA ' ' A' ' 128' ' ' ASN . 0.8 OUTLIER -98.94 115.13 28.2 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 178.241 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 153' ' ' MET . . . . . 0.68 ' CG ' HG23 ' A' ' 127' ' ' ILE . 13.1 ttp -123.17 163.3 20.86 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.318 0.58 . . . . 0.0 112.139 -178.064 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -128.97 139.39 52.12 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.118 -0.946 . . . . 0.0 109.454 179.077 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 155' ' ' THR . . . . . 0.665 HG22 ' CG1' ' A' ' 124' ' ' ILE . 10.4 p -136.0 143.48 44.81 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.125 0.488 . . . . 0.0 111.738 -179.253 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 156' ' ' MET . . . . . 0.465 ' O ' ' CB ' ' A' ' 123' ' ' ARG . 8.9 mtp -132.64 149.66 73.65 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 115.28 -0.873 . . . . 0.0 110.298 179.646 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 77.2 Cg_exo -47.96 116.8 2.11 Favored 'Trans proline' 0 C--N 1.343 0.286 0 C-N-CA 122.37 2.047 . . . . 0.0 112.713 -179.834 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 158' ' ' ALA . . . . . 0.718 ' HB2' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.248 1.019 0 CA-C-O 118.317 -0.849 . . . . 0.0 110.958 179.837 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_endo . . . . . 0 N--CA 1.488 1.154 0 CA-C-O 120.805 0.252 . . . . 0.0 111.792 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.54 169.41 18.69 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.444 2.096 . . . . 0.0 112.351 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.573 HG13 ' O ' ' A' ' 155' ' ' THR . 35.0 t -80.88 142.02 14.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.936 -179.995 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.8 m -117.3 134.56 54.67 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.867 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 3.5 m -94.58 111.27 23.03 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.128 179.314 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.838 HG11 HG23 ' A' ' 118' ' ' VAL . 63.7 t -82.77 106.2 13.35 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.938 -179.249 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.408 ' O ' ' HA2' ' A' ' 116' ' ' GLY . 0.9 OUTLIER -106.83 80.81 1.48 Allowed 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 178.491 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.777 HG13 HG12 ' A' ' 84' ' ' VAL . 3.3 mt -81.53 136.02 23.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-O 121.252 0.549 . . . . 0.0 111.945 -178.195 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.426 ' H ' HG22 ' A' ' 112' ' ' ILE . 0.0 OUTLIER -90.45 148.44 22.77 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.368 -0.833 . . . . 0.0 110.194 179.685 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -155.05 102.91 2.27 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.595 -0.275 . . . . 0.0 110.96 -179.819 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 67.3 Cg_endo -74.06 -24.59 14.78 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.514 2.143 . . . . 0.0 112.494 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -149.59 -166.94 2.69 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.914 0.388 . . . . 0.0 111.236 -179.786 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.56 ' HG ' HG11 ' A' ' 148' ' ' VAL . 4.2 mt -96.54 -44.4 7.18 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.349 -179.598 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -58.06 -18.77 26.77 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.96 -0.564 . . . . 0.0 111.634 -179.436 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 38.4 m-85 -88.2 87.71 7.4 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.805 179.833 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -66.42 -177.83 0.6 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.079 -179.948 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 0.771 ' CD2' HD13 ' A' ' 86' ' ' ILE . 6.5 mp -94.74 -56.18 2.86 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.771 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 98.06 71.07 1.01 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.848 179.745 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 97' ' ' PHE . . . . . 0.665 ' CZ ' HD12 ' A' ' 144' ' ' LEU . 14.0 p90 -166.27 162.4 17.34 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.918 0.389 . . . . 0.0 111.01 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.42 ' O ' ' HA ' ' A' ' 104' ' ' ILE . 1.5 m -106.18 120.49 41.96 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.607 179.724 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.427 ' CG1' ' CG2' ' A' ' 141' ' ' VAL . 8.4 p -109.78 139.05 34.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.448 -179.697 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -135.87 89.15 2.46 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.309 179.491 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 56.8 m-80 58.26 18.91 5.78 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.174 -179.529 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 126.73 -38.16 2.25 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.575 179.884 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.49 HG12 ' CB ' ' A' ' 158' ' ' ALA . 31.8 mt -76.88 141.9 15.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 121.034 0.445 . . . . 0.0 111.452 -179.611 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.904 HD11 ' CD1' ' A' ' 124' ' ' ILE . 5.2 mp -109.54 130.01 63.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.863 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 1.8 m -123.52 28.97 6.78 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.969 -179.872 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 106' ' ' SER . . . . . 0.433 ' H ' HG22 ' A' ' 104' ' ' ILE . 0.3 OUTLIER -178.19 141.24 0.24 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.772 179.988 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -159.09 107.63 1.86 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.844 -179.826 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 2.8 ttp -68.13 113.14 5.53 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.74 179.918 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 26.1 mtt180 -58.81 86.49 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.798 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 163.79 -33.97 0.29 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.913 -0.66 . . . . 0.0 112.012 -179.818 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 111' ' ' GLY . . . . . 0.405 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -61.13 171.43 7.8 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.193 179.693 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.426 HG22 ' H ' ' A' ' 87' ' ' ARG . 0.8 OUTLIER -78.64 -16.93 13.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 120.777 0.323 . . . . 0.0 111.477 -179.789 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 113' ' ' ALA . . . . . 0.47 ' HA ' HG12 ' A' ' 86' ' ' ILE . . . -58.12 -30.5 66.35 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.056 0.455 . . . . 0.0 110.707 179.882 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 114' ' ' GLU . . . . . 0.405 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 21.7 pt-20 -62.0 -46.51 88.9 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.768 -0.651 . . . . 0.0 111.105 179.823 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.4 ' N ' ' CG ' ' A' ' 114' ' ' GLU . 25.2 mtt-85 -62.75 -46.16 89.33 Favored 'General case' 0 N--CA 1.452 -0.347 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.142 -179.378 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.408 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -50.29 -74.05 0.31 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.338 -0.934 . . . . 0.0 112.578 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 117' ' ' GLY . . . . . 0.572 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 175.97 -27.4 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.736 -179.782 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.838 HG23 HG11 ' A' ' 84' ' ' VAL . 12.0 t -31.25 102.04 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 CA-C-O 120.993 0.425 . . . . 0.0 111.8 -179.722 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -104.13 123.89 48.09 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.643 179.765 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 21.4 t -53.76 99.99 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.188 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 120.7 14.67 5.15 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.934 -0.651 . . . . 0.0 112.79 -179.879 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 14.0 m170 -115.61 132.89 56.49 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.744 0.307 . . . . 0.0 110.626 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.858 ' HB3' ' HB2' ' A' ' 158' ' ' ALA . 13.1 ptt180 -84.55 91.85 7.97 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.677 -179.734 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 124' ' ' ILE . . . . . 0.904 ' CD1' HD11 ' A' ' 104' ' ' ILE . 19.1 mt -48.09 157.85 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.333 -0.133 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 178.72 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 125' ' ' ILE . . . . . 0.845 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.6 OUTLIER -150.73 -83.37 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 N-CA-C 113.064 0.765 . . . . 0.0 113.064 -179.008 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -75.62 81.85 2.62 Favored 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 112.695 0.628 . . . . 0.0 112.695 -178.247 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.743 HG23 ' HB3' ' A' ' 153' ' ' MET . 1.7 mt -91.02 95.25 5.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.931 0.395 . . . . 0.0 111.062 179.015 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 128' ' ' ASN . . . . . 0.442 ' N ' ' O ' ' A' ' 152' ' ' HIS . 33.0 m-20 57.76 39.93 26.72 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.934 179.966 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 91.51 -4.18 79.56 Favored Glycine 0 CA--C 1.519 0.329 0 C-N-CA 120.632 -0.794 . . . . 0.0 112.813 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 2.2 tt0 -104.08 107.51 18.44 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.824 0.345 . . . . 0.0 110.836 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 26.0 p -75.6 92.01 2.9 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.093 -179.824 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 132' ' ' VAL . . . . . 0.734 HG21 HD11 ' A' ' 127' ' ' ILE . 31.4 m -74.74 -3.67 4.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.724 179.838 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.845 ' HB ' HG22 ' A' ' 125' ' ' ILE . 9.0 p -43.79 -44.6 1.87 Allowed 'Isoleucine or valine' 0 C--O 1.231 0.111 0 CA-C-O 120.806 0.336 . . . . 0.0 111.804 -179.775 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 134' ' ' ALA . . . . . 0.474 ' N ' HG13 ' A' ' 133' ' ' VAL . . . -113.37 30.24 7.36 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.958 179.906 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 135' ' ' THR . . . . . 0.499 HG21 ' HD2' ' A' ' 139' ' ' LYS . 91.6 m -115.15 140.47 25.71 Favored Pre-proline 0 C--N 1.33 -0.244 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.015 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 136' ' ' PRO . . . . . 0.481 ' HD2' HG23 ' A' ' 135' ' ' THR . 7.6 Cg_endo -50.33 164.18 0.53 Allowed 'Trans proline' 0 C--N 1.347 0.494 0 C-N-CA 122.64 2.226 . . . . 0.0 112.244 179.841 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 137' ' ' HIS . . . . . 0.439 ' CD2' ' N ' ' A' ' 138' ' ' GLU . 32.9 p-80 -72.77 -46.69 52.03 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.606 -179.5 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 138' ' ' GLU . . . . . 0.439 ' N ' ' CD2' ' A' ' 137' ' ' HIS . 16.7 mt-10 -53.69 -36.69 62.46 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.396 -179.59 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 139' ' ' LYS . . . . . 0.821 ' O ' HD12 ' A' ' 143' ' ' ILE . 6.7 tmtm? -62.93 -47.02 85.04 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.927 -179.816 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 8.6 mt -58.41 -44.71 89.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.523 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 141' ' ' VAL . . . . . 0.427 ' CG2' ' CG1' ' A' ' 99' ' ' VAL . 93.1 t -60.78 -32.46 52.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.107 178.856 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -61.46 -52.32 65.01 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.641 179.558 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 143' ' ' ILE . . . . . 0.821 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.4 mp -53.23 -56.67 7.1 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.395 0 CA-C-O 121.098 0.475 . . . . 0.0 110.205 179.422 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.718 HD13 ' CD2' ' A' ' 95' ' ' LEU . 4.9 mt -62.31 -30.31 71.06 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.518 -0.764 . . . . 0.0 110.326 179.506 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 34.5 t -70.09 -28.31 65.31 Favored 'General case' 0 N--CA 1.453 -0.283 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.117 178.901 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 41.9 m-20 -131.71 37.4 3.65 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.082 179.808 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 147' ' ' ALA . . . . . 0.635 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -99.79 -44.71 5.99 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.094 0.473 . . . . 0.0 111.512 -179.68 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.56 HG11 ' HG ' ' A' ' 91' ' ' LEU . 32.4 m 45.96 -174.68 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 115.321 -0.854 . . . . 0.0 111.788 -179.684 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 59.64 -108.07 1.54 Allowed Glycine 0 N--CA 1.453 -0.214 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.361 -179.819 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 46.1 mt-10 -136.81 114.1 10.8 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.778 0.323 . . . . 0.0 110.856 179.892 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 151' ' ' ILE . . . . . 0.635 HD11 ' HB3' ' A' ' 147' ' ' ALA . 1.5 mt -82.84 112.0 19.96 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.139 -179.912 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 152' ' ' HIS . . . . . 0.442 ' O ' ' N ' ' A' ' 128' ' ' ASN . 0.1 OUTLIER -99.09 115.88 30.01 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.978 -0.556 . . . . 0.0 109.82 179.04 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 153' ' ' MET . . . . . 0.743 ' HB3' HG23 ' A' ' 127' ' ' ILE . 0.0 OUTLIER -144.64 177.83 8.41 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.548 0.69 . . . . 0.0 111.751 -179.048 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 14.4 mttp -139.43 152.66 47.23 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 114.633 -1.167 . . . . 0.0 109.977 179.546 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 155' ' ' THR . . . . . 0.693 HG22 HG12 ' A' ' 124' ' ' ILE . 2.0 p -142.99 150.4 39.59 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.195 0.522 . . . . 0.0 111.888 -179.488 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 156' ' ' MET . . . . . 0.423 ' CB ' ' CD ' ' A' ' 157' ' ' PRO . 2.3 mtp -118.69 178.93 0.94 Allowed Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 115.235 -0.893 . . . . 0.0 109.898 179.343 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 157' ' ' PRO . . . . . 0.423 ' CD ' ' CB ' ' A' ' 156' ' ' MET . 89.9 Cg_endo -86.45 106.16 0.75 Allowed 'Trans proline' 0 N--CA 1.459 -0.555 0 C-N-CA 122.44 2.094 . . . . 0.0 112.493 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 158' ' ' ALA . . . . . 0.858 ' HB2' ' HB3' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.249 1.057 0 CA-C-O 118.253 -0.879 . . . . 0.0 111.052 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 6.6 Cg_endo . . . . . 0 N--CA 1.49 1.319 0 CA-C-O 120.722 0.218 . . . . 0.0 111.744 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_exo -61.18 113.38 1.73 Allowed 'Trans proline' 0 C--N 1.346 0.412 0 C-N-CA 122.582 2.188 . . . . 0.0 112.295 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.516 HG23 ' O ' ' A' ' 155' ' ' THR . 11.2 p -81.4 145.49 8.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.77 179.816 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.5 m -104.26 146.09 29.29 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.925 0.393 . . . . 0.0 111.203 -179.709 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 11.6 m -110.17 111.09 22.21 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.002 178.972 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.769 HG22 ' N ' ' A' ' 118' ' ' VAL . 72.6 t -86.23 106.5 15.66 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.896 -179.164 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.423 ' O ' ' HA2' ' A' ' 116' ' ' GLY . 4.2 tt -106.34 81.34 1.6 Allowed 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 178.497 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.866 HG21 ' CD1' ' A' ' 95' ' ' LEU . 1.2 mt -81.46 140.19 16.9 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 121.167 0.508 . . . . 0.0 111.674 -178.777 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.439 ' HG3' ' CG2' ' A' ' 112' ' ' ILE . 0.0 OUTLIER -99.01 145.9 26.6 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.551 -0.749 . . . . 0.0 110.27 179.873 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 3.8 mtt-85 -139.09 102.26 7.53 Favored Pre-proline 0 C--N 1.331 -0.232 0 CA-C-N 116.463 -0.335 . . . . 0.0 110.982 -179.782 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 89' ' ' PRO . . . . . 0.434 ' HB2' ' CE1' ' A' ' 93' ' ' TYR . 52.5 Cg_exo -55.09 -57.04 1.88 Allowed 'Trans proline' 0 C--N 1.347 0.478 0 C-N-CA 122.465 2.11 . . . . 0.0 112.35 -179.858 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.7 t0 -139.83 -168.67 2.55 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.869 0.366 . . . . 0.0 111.174 -179.86 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.424 ' CD1' HG11 ' A' ' 148' ' ' VAL . 0.2 OUTLIER -83.32 -30.82 27.21 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.04 -179.924 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -68.13 -11.02 58.4 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.62 -179.694 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 93' ' ' TYR . . . . . 0.434 ' CE1' ' HB2' ' A' ' 89' ' ' PRO . 25.2 m-85 -82.88 178.17 8.3 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.507 -0.315 . . . . 0.0 110.784 179.839 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 8.3 mp0 -136.57 164.8 27.35 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.068 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 0.866 ' CD1' HG21 ' A' ' 86' ' ' ILE . 0.7 OUTLIER -72.51 -60.21 2.34 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.781 179.847 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 121.4 14.0 5.06 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.657 -0.783 . . . . 0.0 113.174 179.797 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 97' ' ' PHE . . . . . 0.62 ' HD2' HG23 ' A' ' 104' ' ' ILE . 30.5 p90 -160.45 175.12 13.12 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.958 0.408 . . . . 0.0 111.197 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -118.42 141.19 48.79 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.009 -0.542 . . . . 0.0 110.771 179.86 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.719 HG21 HG21 ' A' ' 140' ' ' ILE . 6.3 p -109.98 136.0 47.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 121.1 0.476 . . . . 0.0 111.427 -179.858 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -126.92 89.78 3.04 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.048 179.457 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 2.5 m-20 62.27 12.2 5.01 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.814 -179.083 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 129.7 -37.65 2.13 Favored Glycine 0 N--CA 1.445 -0.716 0 C-N-CA 121.095 -0.574 . . . . 0.0 112.007 -179.871 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.55 HG12 ' HB2' ' A' ' 158' ' ' ALA . 41.8 mt -79.2 135.67 25.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-O 121.093 0.473 . . . . 0.0 111.801 -179.469 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.843 HD11 ' CD1' ' A' ' 124' ' ' ILE . 3.8 mp -91.54 141.27 14.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.825 179.799 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 105' ' ' CYS . . . . . 0.413 ' O ' HG13 ' A' ' 120' ' ' VAL . 36.9 m -116.82 -81.1 0.61 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.285 -179.556 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 4.6 m -77.13 139.16 39.88 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.991 -179.78 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.475 ' HB3' HG22 ' A' ' 120' ' ' VAL . 9.5 tt -156.38 120.75 4.5 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.636 179.867 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 19.2 mtm -90.75 129.0 36.87 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.985 -179.889 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 2.3 mpt_? -66.13 76.71 0.09 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.644 179.82 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 178.23 -34.8 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.927 -0.654 . . . . 0.0 112.126 -179.843 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -55.31 171.54 1.46 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.286 179.697 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.439 ' CG2' ' HG3' ' A' ' 87' ' ' ARG . 0.5 OUTLIER -78.66 -17.59 13.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-O 120.82 0.343 . . . . 0.0 111.505 -179.778 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 113' ' ' ALA . . . . . 0.563 ' HA ' HG12 ' A' ' 86' ' ' ILE . . . -58.4 -30.78 67.1 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.87 0.367 . . . . 0.0 110.633 179.804 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -60.02 -45.72 91.88 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.691 179.579 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 1.6 mmm180 -62.93 -49.08 76.18 Favored 'General case' 0 N--CA 1.452 -0.359 0 CA-C-N 115.843 -0.617 . . . . 0.0 111.132 -179.473 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.423 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -49.52 -74.33 0.28 Allowed Glycine 0 CA--C 1.519 0.318 0 C-N-CA 120.224 -0.989 . . . . 0.0 112.532 179.936 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 117' ' ' GLY . . . . . 0.555 ' C ' HG22 ' A' ' 84' ' ' VAL . . . -179.81 -30.67 0.06 OUTLIER Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 121.124 -0.56 . . . . 0.0 112.181 179.864 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.769 ' N ' HG22 ' A' ' 84' ' ' VAL . 73.6 t -26.43 123.7 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.384 0 C-N-CA 122.956 0.503 . . . . 0.0 112.283 -179.771 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 14.1 mtt-85 -123.29 118.42 27.52 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.54 179.779 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 120' ' ' VAL . . . . . 0.475 HG22 ' HB3' ' A' ' 107' ' ' LEU . 21.5 t -52.2 93.23 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.239 -179.919 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 122.78 37.9 0.6 Allowed Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.933 -0.651 . . . . 0.0 112.332 -179.861 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 122' ' ' HIS . . . . . 0.436 ' O ' HG23 ' A' ' 103' ' ' ILE . 10.3 m170 -138.77 169.25 18.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.753 0.311 . . . . 0.0 110.805 179.933 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.742 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 1.4 ttm180 -108.42 143.89 36.75 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.201 -179.877 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 124' ' ' ILE . . . . . 0.843 ' CD1' HD11 ' A' ' 104' ' ' ILE . 26.8 mt -101.29 155.36 4.6 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 178.465 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 125' ' ' ILE . . . . . 0.868 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.7 OUTLIER -147.45 -84.31 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 N-CA-C 113.208 0.818 . . . . 0.0 113.208 -178.561 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 126' ' ' GLU . . . . . 0.42 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 6.1 mt-10 -79.87 85.34 5.53 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 112.626 0.602 . . . . 0.0 112.626 -178.093 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.8 HD11 HG21 ' A' ' 132' ' ' VAL . 1.7 mt -91.18 103.35 14.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 121.025 0.441 . . . . 0.0 111.17 179.094 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 128' ' ' ASN . . . . . 0.547 ' ND2' HG22 ' A' ' 127' ' ' ILE . 33.4 m-80 55.65 25.4 8.08 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.106 -179.969 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 107.65 -13.91 38.69 Favored Glycine 0 CA--C 1.518 0.273 0 C-N-CA 120.624 -0.798 . . . . 0.0 112.775 179.895 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 22.3 tt0 -95.95 113.94 25.61 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.849 0.357 . . . . 0.0 110.875 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -77.54 91.4 3.95 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.141 -179.902 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 132' ' ' VAL . . . . . 0.8 HG21 HD11 ' A' ' 127' ' ' ILE . 32.4 m -75.41 -2.57 4.11 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.257 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.818 179.891 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.868 ' HB ' HG22 ' A' ' 125' ' ' ILE . 8.2 p -46.24 -38.3 3.22 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.142 0 CA-C-O 120.858 0.361 . . . . 0.0 111.445 -179.758 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -117.6 28.57 8.36 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.787 179.401 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 135' ' ' THR . . . . . 0.505 HG23 ' HD2' ' A' ' 136' ' ' PRO . 86.0 m -111.48 141.88 25.41 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 115.777 -0.647 . . . . 0.0 111.105 -179.772 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 136' ' ' PRO . . . . . 0.505 ' HD2' HG23 ' A' ' 135' ' ' THR . 9.5 Cg_endo -51.87 164.23 1.13 Allowed 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.8 2.333 . . . . 0.0 112.215 179.742 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 137' ' ' HIS . . . . . 0.403 ' O ' HG23 ' A' ' 141' ' ' VAL . 12.4 p80 -70.47 -47.64 59.6 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.376 -179.785 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -55.6 -32.74 63.33 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.249 -179.707 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 139' ' ' LYS . . . . . 0.761 ' O ' HD12 ' A' ' 143' ' ' ILE . 0.4 OUTLIER -65.08 -50.27 66.78 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.833 -179.917 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 140' ' ' ILE . . . . . 0.719 HG21 HG21 ' A' ' 99' ' ' VAL . 8.8 mt -58.68 -43.46 87.68 Favored 'Isoleucine or valine' 0 C--O 1.235 0.311 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.577 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 141' ' ' VAL . . . . . 0.569 HG22 HG12 ' A' ' 99' ' ' VAL . 61.8 t -61.42 -32.93 54.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.292 179.189 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 0.5 OUTLIER -62.66 -53.47 54.05 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.968 179.924 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 143' ' ' ILE . . . . . 0.761 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.3 mp -53.04 -57.23 4.96 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.393 0 CA-C-O 121.162 0.506 . . . . 0.0 110.371 179.558 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.565 HD22 HG12 ' A' ' 151' ' ' ILE . 1.8 mt -62.16 -30.04 70.77 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.417 -0.81 . . . . 0.0 110.42 179.557 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 9.2 t -68.16 -26.7 65.89 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.179 -0.464 . . . . 0.0 109.872 178.567 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 8.5 m120 -131.19 35.01 3.95 Favored 'General case' 0 CA--C 1.528 0.107 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.199 179.918 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 147' ' ' ALA . . . . . 0.67 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -114.29 48.75 1.07 Allowed 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.855 0.36 . . . . 0.0 111.304 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.424 HG11 ' CD1' ' A' ' 91' ' ' LEU . 29.8 m -54.09 150.35 1.76 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.285 -179.953 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 108.68 -107.72 2.51 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.445 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 40.9 mt-10 -138.05 104.32 5.2 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.711 0.291 . . . . 0.0 110.889 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 151' ' ' ILE . . . . . 0.67 HD11 ' HB3' ' A' ' 147' ' ' ALA . 1.2 mt -78.64 111.7 15.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.065 -179.91 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 152' ' ' HIS . . . . . 0.42 ' CD2' ' HG ' ' A' ' 85' ' ' LEU . 0.6 OUTLIER -103.82 115.66 30.88 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.999 -0.546 . . . . 0.0 109.828 179.129 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 153' ' ' MET . . . . . 0.772 ' HB3' HG23 ' A' ' 127' ' ' ILE . 1.9 ptt? -145.91 167.08 24.15 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.089 0.471 . . . . 0.0 111.876 -179.077 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -115.06 153.28 30.99 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.625 -0.716 . . . . 0.0 109.899 179.234 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 155' ' ' THR . . . . . 0.707 HG22 ' HA ' ' A' ' 124' ' ' ILE . 51.8 p -142.69 140.29 31.48 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.235 0.54 . . . . 0.0 111.829 -179.302 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 156' ' ' MET . . . . . 0.41 ' N ' ' O ' ' A' ' 123' ' ' ARG . 0.2 OUTLIER -126.46 152.45 74.23 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 115.329 -0.85 . . . . 0.0 109.947 179.309 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 12.6 Cg_endo -56.16 115.8 2.72 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.497 2.131 . . . . 0.0 112.496 -179.784 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 158' ' ' ALA . . . . . 0.742 ' HB2' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.248 0.992 0 CA-C-O 118.234 -0.889 . . . . 0.0 110.943 179.733 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_endo . . . . . 0 N--CA 1.489 1.235 0 CA-C-O 120.703 0.21 . . . . 0.0 111.838 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 12.6 Cg_exo -69.76 85.77 0.6 Allowed 'Trans proline' 0 C--N 1.345 0.346 0 C-N-CA 122.734 2.289 . . . . 0.0 112.301 -179.853 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 37.0 t -102.09 122.79 54.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.995 179.859 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.3 m -111.12 138.4 47.6 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.85 179.934 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 9.5 m -98.63 111.14 23.6 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.166 179.266 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.771 HG11 HG23 ' A' ' 118' ' ' VAL . 62.0 t -84.95 106.2 14.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.731 -179.432 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.608 ' O ' HD23 ' A' ' 85' ' ' LEU . 10.2 tt -104.36 83.8 2.11 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 178.431 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 1.064 HG21 HD23 ' A' ' 95' ' ' LEU . 7.3 mt -81.84 130.89 35.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.92 -178.342 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.415 ' HG3' ' CG2' ' A' ' 112' ' ' ILE . 0.0 OUTLIER -92.18 124.41 36.24 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.388 -0.823 . . . . 0.0 110.447 -179.958 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -126.48 120.26 23.29 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 116.451 -0.341 . . . . 0.0 110.874 -179.864 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 62.5 Cg_endo -73.41 -28.65 11.99 Favored 'Trans proline' 0 C--N 1.346 0.425 0 C-N-CA 122.465 2.11 . . . . 0.0 112.16 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -173.07 -169.38 0.54 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.959 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 1.9 mp -80.36 -5.56 56.59 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.556 -179.909 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 2.2 ptm85 -102.76 27.28 7.12 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.861 0.362 . . . . 0.0 111.153 -179.807 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 4.3 m-85 -138.37 81.53 1.86 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.914 179.858 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -60.97 161.85 7.78 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.98 -179.847 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 1.064 HD23 HG21 ' A' ' 86' ' ' ILE . 0.5 OUTLIER -79.99 -65.31 1.02 Allowed 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.674 179.897 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 114.34 58.33 0.38 Allowed Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.916 179.512 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 97' ' ' PHE . . . . . 0.564 ' HD2' HG23 ' A' ' 104' ' ' ILE . 14.2 p90 -165.33 128.49 2.22 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.916 0.389 . . . . 0.0 111.106 179.698 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 6.4 t -71.98 144.09 48.99 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.832 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.941 HG11 ' HB ' ' A' ' 140' ' ' ILE . 48.9 t -111.9 136.9 46.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 121.032 0.444 . . . . 0.0 111.648 -179.705 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 4.1 mm-40 -135.72 88.06 2.37 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.722 -0.672 . . . . 0.0 109.507 178.563 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 85.6 m-20 53.57 21.65 2.63 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.985 -178.968 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.404 ' N ' ' CD1' ' A' ' 140' ' ' ILE . . . 121.88 -32.83 4.46 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.922 -0.656 . . . . 0.0 112.374 179.902 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.623 HG12 ' HB2' ' A' ' 158' ' ' ALA . 31.2 mt -77.49 128.65 38.01 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 121.003 0.43 . . . . 0.0 111.781 -179.649 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.848 HD11 ' CD1' ' A' ' 124' ' ' ILE . 3.6 mp -84.42 144.81 9.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.146 179.296 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 105' ' ' CYS . . . . . 0.551 ' O ' HG13 ' A' ' 120' ' ' VAL . 55.9 m -126.51 -80.64 0.61 Allowed 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 112.009 0.374 . . . . 0.0 112.009 -179.205 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 40.3 m -79.17 66.18 4.55 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 112.027 0.38 . . . . 0.0 112.027 -178.797 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.803 ' HB3' HG22 ' A' ' 120' ' ' VAL . 14.0 tp -89.12 100.58 13.33 Favored 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 178.859 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 2.0 ptm -81.33 140.51 34.74 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.317 -179.472 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.51 166.74 9.9 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.596 179.697 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 92.79 -41.97 2.69 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.533 -0.842 . . . . 0.0 112.23 -179.732 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -58.21 168.76 5.25 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.227 179.751 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.415 ' CG2' ' HG3' ' A' ' 87' ' ' ARG . 0.9 OUTLIER -78.35 -16.23 13.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.733 0.301 . . . . 0.0 111.768 -179.797 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 113' ' ' ALA . . . . . 0.482 ' HA ' HG12 ' A' ' 86' ' ' ILE . . . -57.52 -30.34 65.07 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 121.015 0.436 . . . . 0.0 110.78 179.853 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 15.3 pt-20 -60.15 -46.69 88.79 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.904 179.56 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 16.2 mtm180 -64.7 -46.38 82.62 Favored 'General case' 0 N--CA 1.453 -0.314 0 CA-C-N 116.009 -0.541 . . . . 0.0 111.127 -179.316 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -50.55 -73.41 0.37 Allowed Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.431 -0.89 . . . . 0.0 112.686 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 117' ' ' GLY . . . . . 0.576 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 171.78 -21.27 0.07 OUTLIER Glycine 0 CA--C 1.519 0.284 0 C-N-CA 121.048 -0.596 . . . . 0.0 112.663 -179.971 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.771 HG23 HG11 ' A' ' 84' ' ' VAL . 1.2 t -37.95 135.9 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.261 0 CA-C-O 120.98 0.419 . . . . 0.0 111.638 -179.783 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 5.3 mtm180 -136.64 132.18 34.66 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.553 179.64 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 120' ' ' VAL . . . . . 0.803 HG22 ' HB3' ' A' ' 107' ' ' LEU . 15.4 t -57.11 89.45 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.852 0.358 . . . . 0.0 110.999 -179.866 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 131.98 -3.32 5.25 Favored Glycine 0 CA--C 1.52 0.375 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.861 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 1.6 m-70 -90.16 127.51 36.12 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-O 120.888 0.375 . . . . 0.0 110.73 179.899 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.914 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 20.8 ttm180 -82.62 92.35 7.12 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.926 -179.373 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 124' ' ' ILE . . . . . 0.848 ' CD1' HD11 ' A' ' 104' ' ' ILE . 10.0 mt -50.39 157.56 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.05 178.544 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 125' ' ' ILE . . . . . 0.793 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.6 OUTLIER -150.77 -85.66 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 N-CA-C 112.38 0.511 . . . . 0.0 112.38 -179.349 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -75.29 85.12 2.46 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 112.067 0.395 . . . . 0.0 112.067 -178.959 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.801 HG23 ' HB3' ' A' ' 153' ' ' MET . 1.3 mt -92.61 102.6 13.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 120.951 0.405 . . . . 0.0 111.312 179.47 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 1.3 m-20 61.83 15.52 7.15 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.596 179.745 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 119.88 -16.95 10.15 Favored Glycine 0 C--N 1.333 0.368 0 C-N-CA 120.401 -0.904 . . . . 0.0 113.338 179.634 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 8.2 pt20 -101.94 123.08 45.24 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 117.091 0.445 . . . . 0.0 111.104 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 48.1 t -81.05 101.68 9.73 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.347 -179.68 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 132' ' ' VAL . . . . . 0.784 HG21 HD11 ' A' ' 127' ' ' ILE . 27.2 m -81.68 2.7 2.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.68 179.691 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.793 ' HB ' HG22 ' A' ' 125' ' ' ILE . 8.0 p -44.7 -45.18 2.64 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.133 0 CA-C-O 120.853 0.358 . . . . 0.0 111.697 -179.674 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 134' ' ' ALA . . . . . 0.484 ' N ' HG13 ' A' ' 133' ' ' VAL . . . -112.46 30.22 7.27 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.869 179.73 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 135' ' ' THR . . . . . 0.514 HG22 ' HB3' ' A' ' 139' ' ' LYS . 86.2 m -109.28 142.47 25.68 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.942 -179.788 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 136' ' ' PRO . . . . . 0.472 ' HD2' HG23 ' A' ' 135' ' ' THR . 71.2 Cg_exo -50.73 164.01 0.64 Allowed 'Trans proline' 0 C--N 1.348 0.535 0 C-N-CA 122.583 2.189 . . . . 0.0 112.431 179.864 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 28.1 p-80 -72.02 -51.22 22.84 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.161 -179.814 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -55.25 -30.96 61.1 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.986 -179.899 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 139' ' ' LYS . . . . . 0.726 ' O ' HD12 ' A' ' 143' ' ' ILE . 0.2 OUTLIER -64.62 -48.65 74.07 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.94 179.998 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 140' ' ' ILE . . . . . 0.941 ' HB ' HG11 ' A' ' 99' ' ' VAL . 5.4 mt -58.76 -45.01 91.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-O 121.048 0.452 . . . . 0.0 110.438 179.973 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 48.4 t -61.21 -32.43 52.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.417 179.24 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 1.6 m-70 -62.19 -53.09 60.32 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.723 179.79 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 143' ' ' ILE . . . . . 0.726 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.2 mp -53.28 -56.27 8.97 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.44 0 CA-C-O 121.207 0.527 . . . . 0.0 110.222 179.157 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.785 ' HB3' HD11 ' A' ' 95' ' ' LEU . 2.9 mt -62.95 -30.36 71.5 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.466 179.741 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 2.8 m -67.22 -29.9 69.69 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.17 -0.468 . . . . 0.0 109.743 178.738 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 8.4 m120 -131.13 38.28 3.67 Favored 'General case' 0 C--N 1.333 -0.135 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.625 179.596 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 147' ' ' ALA . . . . . 1.079 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -90.15 -51.91 5.21 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.246 0.546 . . . . 0.0 111.258 -179.545 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.505 HG23 ' C ' ' A' ' 147' ' ' ALA . 0.2 OUTLIER 57.01 164.61 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-N 115.292 -0.867 . . . . 0.0 111.078 -179.932 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 73.18 -133.41 18.26 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.524 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 -114.39 99.71 7.78 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.788 0.328 . . . . 0.0 110.92 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 151' ' ' ILE . . . . . 1.079 HD11 ' HB3' ' A' ' 147' ' ' ALA . 0.6 OUTLIER -68.1 111.9 2.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.987 179.982 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 152' ' ' HIS . . . . . 0.476 ' CE1' HD12 ' A' ' 85' ' ' LEU . 3.5 t60 -108.31 115.75 30.69 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.251 179.455 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 153' ' ' MET . . . . . 0.801 ' HB3' HG23 ' A' ' 127' ' ' ILE . 0.0 OUTLIER -143.62 176.05 9.5 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.208 0.528 . . . . 0.0 111.846 -179.356 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 9.7 mttp -122.76 151.99 41.07 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.416 -0.811 . . . . 0.0 109.487 178.919 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 155' ' ' THR . . . . . 0.466 HG22 ' CG1' ' A' ' 124' ' ' ILE . 6.6 p -141.57 141.39 33.5 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.031 0.443 . . . . 0.0 111.598 -179.345 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 156' ' ' MET . . . . . . . . . . . . . 9.6 mtp -125.8 133.52 24.98 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.588 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 82.5 Cg_exo -44.68 120.19 2.66 Favored 'Trans proline' 0 C--N 1.345 0.344 0 C-N-CA 122.558 2.172 . . . . 0.0 112.752 -179.888 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 158' ' ' ALA . . . . . 0.914 ' HB2' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.249 1.061 0 CA-C-O 118.181 -0.914 . . . . 0.0 111.061 179.87 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo . . . . . 0 N--CA 1.489 1.212 0 CA-C-O 120.88 0.283 . . . . 0.0 111.632 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 68.2 Cg_endo -74.14 94.49 0.89 Allowed 'Trans proline' 0 C--N 1.343 0.284 0 C-N-CA 122.531 2.154 . . . . 0.0 112.466 -179.918 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 39.0 t -117.84 142.04 34.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.9 179.835 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.0 m -123.18 140.93 52.51 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.01 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 20.0 m -97.34 111.37 23.65 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.059 179.134 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.814 HG22 ' N ' ' A' ' 118' ' ' VAL . 78.9 t -88.98 105.73 16.15 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.42 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.792 -179.239 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.487 ' O ' ' HA2' ' A' ' 116' ' ' GLY . 0.5 OUTLIER -103.21 83.87 2.26 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 178.395 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 1.067 HG21 HD23 ' A' ' 95' ' ' LEU . 19.8 mt -80.85 132.51 31.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 121.405 0.621 . . . . 0.0 111.862 -178.306 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.865 ' O ' HG21 ' A' ' 112' ' ' ILE . 2.9 mmt180 -79.38 149.01 31.8 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 114.957 -1.02 . . . . 0.0 111.137 -179.477 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.534 ' HB3' ' HA ' ' A' ' 148' ' ' VAL . 2.7 mtt-85 -164.57 97.81 0.89 Allowed Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.846 179.689 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 70.3 Cg_endo -89.26 25.77 0.59 Allowed 'Trans proline' 0 N--CA 1.46 -0.483 0 C-N-CA 122.893 2.396 . . . . 0.0 113.414 -179.296 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 90' ' ' ASP . . . . . 0.729 ' O ' HG12 ' A' ' 148' ' ' VAL . 5.6 p-10 -179.03 177.74 0.79 Allowed 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.039 0.447 . . . . 0.0 111.741 179.922 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.822 ' HG ' HG11 ' A' ' 148' ' ' VAL . 6.0 mt -98.42 6.68 47.05 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.692 -0.686 . . . . 0.0 111.486 -179.89 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 8.6 ptt180 -129.18 42.06 3.37 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.853 0.359 . . . . 0.0 111.035 -179.78 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -120.52 126.04 49.37 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.748 179.828 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -86.02 136.6 33.18 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.963 -179.844 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 1.067 HD23 HG21 ' A' ' 86' ' ' ILE . 2.2 mp -77.24 -28.28 53.59 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.804 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 75.08 73.17 0.98 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.835 -0.697 . . . . 0.0 112.782 179.622 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 97' ' ' PHE . . . . . 0.71 ' CZ ' HD12 ' A' ' 144' ' ' LEU . 0.3 OUTLIER -176.14 156.75 1.72 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.806 0.336 . . . . 0.0 111.168 179.766 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.466 ' O ' ' HA ' ' A' ' 104' ' ' ILE . 3.3 t -106.15 133.81 50.27 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.422 179.559 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.529 HG21 HG21 ' A' ' 140' ' ' ILE . 9.7 p -118.49 134.84 60.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 121.026 0.441 . . . . 0.0 111.459 -179.581 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -131.75 89.24 2.67 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.23 179.405 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 12.1 m120 57.78 18.28 4.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.134 -179.468 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 128.18 -39.83 1.83 Allowed Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.531 179.858 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.529 HG12 ' HB2' ' A' ' 158' ' ' ALA . 26.6 mt -77.3 138.66 20.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 121.006 0.432 . . . . 0.0 111.531 -179.57 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.888 HD11 ' CD1' ' A' ' 124' ' ' ILE . 4.5 mp -99.07 137.83 25.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.911 179.917 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 43.4 t -105.0 -77.98 0.58 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.983 -179.781 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 77.0 p -90.63 119.24 30.71 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.707 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 25.7 tp -112.91 119.3 37.47 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.841 -179.938 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 9.3 mtp -68.13 98.26 0.77 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.975 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -60.86 117.59 5.61 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.826 -179.95 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 97.44 32.5 6.3 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.407 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 111' ' ' GLY . . . . . 0.513 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -118.61 -160.74 11.56 Favored Glycine 0 N--CA 1.453 -0.216 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.968 -179.789 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.865 HG21 ' O ' ' A' ' 87' ' ' ARG . 7.9 mt -80.62 -39.9 18.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-O 121.094 0.473 . . . . 0.0 111.506 -179.924 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 113' ' ' ALA . . . . . 0.595 ' HB1' HG11 ' A' ' 118' ' ' VAL . . . -57.67 -39.29 76.72 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.12 -179.481 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 114' ' ' GLU . . . . . 0.513 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 15.3 pt-20 -62.83 -37.83 88.33 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.503 179.499 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.497 ' N ' ' HG3' ' A' ' 114' ' ' GLU . 54.8 mtt85 -59.2 -46.71 87.71 Favored 'General case' 0 N--CA 1.452 -0.361 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.644 -179.866 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.487 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -56.33 -71.14 0.78 Allowed Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.343 -0.932 . . . . 0.0 112.501 179.719 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 117' ' ' GLY . . . . . 0.47 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 175.04 -22.74 0.06 OUTLIER Glycine 0 CA--C 1.52 0.39 0 C-N-CA 120.788 -0.72 . . . . 0.0 113.064 -179.902 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.814 ' N ' HG22 ' A' ' 84' ' ' VAL . 6.0 p -34.27 146.36 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 N-CA-C 112.128 0.418 . . . . 0.0 112.128 -179.604 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -140.95 153.84 45.81 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.917 -179.925 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 22.0 t -74.7 88.44 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.972 179.9 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 124.01 41.0 0.42 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.921 -0.657 . . . . 0.0 112.295 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 1.2 m170 -135.08 122.68 22.09 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.858 0.361 . . . . 0.0 110.764 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.958 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 34.9 ttp180 -79.74 93.6 5.6 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.538 -179.731 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 124' ' ' ILE . . . . . 0.888 ' CD1' HD11 ' A' ' 104' ' ' ILE . 9.2 mt -49.98 158.21 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 178.715 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 125' ' ' ILE . . . . . 0.789 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.6 OUTLIER -148.99 -82.7 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 N-CA-C 112.446 0.535 . . . . 0.0 112.446 -179.49 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 -74.64 80.72 2.01 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 112.361 0.504 . . . . 0.0 112.361 -178.758 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.991 HG23 ' CG ' ' A' ' 153' ' ' MET . 2.7 mt -84.55 92.04 3.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 121.05 0.452 . . . . 0.0 111.01 179.259 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 128' ' ' ASN . . . . . 0.414 ' N ' ' O ' ' A' ' 152' ' ' HIS . 56.9 m-80 58.65 25.26 13.06 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.995 -179.81 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 113.36 -16.96 21.81 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.716 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 8.3 tt0 -94.4 111.15 22.89 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.809 0.338 . . . . 0.0 110.814 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -75.98 93.29 3.24 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.084 -179.822 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 132' ' ' VAL . . . . . 0.73 HG11 HD12 ' A' ' 127' ' ' ILE . 30.6 m -76.39 -1.58 3.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.881 179.835 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.789 ' HB ' HG22 ' A' ' 125' ' ' ILE . 8.7 p -42.94 -44.23 1.22 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.121 0 CA-C-O 120.825 0.345 . . . . 0.0 111.611 -179.653 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 134' ' ' ALA . . . . . 0.474 ' N ' HG13 ' A' ' 133' ' ' VAL . . . -117.24 29.75 7.71 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.772 179.714 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 135' ' ' THR . . . . . 0.485 HG22 ' HB3' ' A' ' 139' ' ' LYS . 52.3 m -108.71 142.17 24.87 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.057 -0.519 . . . . 0.0 111.161 -179.844 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 136' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -52.37 164.11 1.45 Allowed 'Trans proline' 0 C--N 1.346 0.442 0 C-N-CA 122.56 2.173 . . . . 0.0 112.284 179.677 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 31.9 p-80 -70.95 -49.81 41.44 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.368 -179.855 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 5.8 tp10 -54.36 -34.79 61.88 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.332 -0.394 . . . . 0.0 111.393 -179.695 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 139' ' ' LYS . . . . . 0.724 ' O ' HD12 ' A' ' 143' ' ' ILE . 3.3 tttp -62.76 -47.34 83.94 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.881 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 140' ' ' ILE . . . . . 0.529 HG21 HG21 ' A' ' 99' ' ' VAL . 15.1 mt -58.59 -45.45 90.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.603 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 141' ' ' VAL . . . . . 0.417 ' CG2' ' CG1' ' A' ' 99' ' ' VAL . 87.9 t -60.27 -32.5 50.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.326 178.987 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 1.8 t-80 -62.06 -53.56 53.77 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.012 179.774 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 143' ' ' ILE . . . . . 0.724 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.1 mp -52.94 -56.8 6.11 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.463 0 CA-C-O 121.227 0.537 . . . . 0.0 110.265 179.44 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.728 HD13 HD22 ' A' ' 95' ' ' LEU . 1.9 mt -62.44 -30.33 71.16 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.313 -0.858 . . . . 0.0 110.397 179.674 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 27.5 t -67.67 -27.8 67.15 Favored 'General case' 0 N--CA 1.453 -0.29 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.085 178.884 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 10.7 m120 -133.81 37.34 3.26 Favored 'General case' 0 CA--C 1.529 0.163 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.164 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 147' ' ' ALA . . . . . 0.944 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -101.46 -37.66 8.34 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.118 0.485 . . . . 0.0 111.301 -179.861 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.822 HG11 ' HG ' ' A' ' 91' ' ' LEU . 32.0 m 44.56 -172.67 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.37 -0.832 . . . . 0.0 112.036 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 58.38 -135.14 52.13 Favored Glycine 0 C--N 1.332 0.309 0 C-N-CA 121.035 -0.602 . . . . 0.0 112.704 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.429 ' OE1' HD21 ' A' ' 85' ' ' LEU . 62.2 mm-40 -110.09 91.28 3.59 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.851 0.357 . . . . 0.0 110.449 179.836 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 151' ' ' ILE . . . . . 0.944 HD11 ' HB3' ' A' ' 147' ' ' ALA . 0.7 OUTLIER -61.03 111.62 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.49 -179.448 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 152' ' ' HIS . . . . . 0.414 ' O ' ' N ' ' A' ' 128' ' ' ASN . 4.2 t60 -90.03 115.78 27.57 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 109.168 -0.679 . . . . 0.0 109.168 178.573 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 153' ' ' MET . . . . . 0.991 ' CG ' HG23 ' A' ' 127' ' ' ILE . 26.9 mtp -133.62 162.14 32.73 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.422 0.629 . . . . 0.0 112.452 -178.431 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 17.7 mttt -134.04 140.39 46.64 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 114.881 -1.054 . . . . 0.0 108.905 178.673 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 155' ' ' THR . . . . . 0.61 HG22 ' CG1' ' A' ' 124' ' ' ILE . 1.6 p -140.32 149.44 42.76 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.241 0.543 . . . . 0.0 112.046 -178.871 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 156' ' ' MET . . . . . . . . . . . . . 4.8 ptp -132.23 156.38 80.17 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 115.207 -0.906 . . . . 0.0 110.139 179.146 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_endo -57.4 120.41 8.31 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.366 2.044 . . . . 0.0 112.639 -179.726 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 158' ' ' ALA . . . . . 0.958 ' HB2' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.249 1.029 0 CA-C-O 118.289 -0.862 . . . . 0.0 111.114 179.876 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' PRO . . . . . 0.526 ' HB2' HG23 ' A' ' 81' ' ' VAL . 2.8 Cg_exo . . . . . 0 N--CA 1.488 1.18 0 CA-C-O 120.734 0.223 . . . . 0.0 111.673 . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -74.42 60.05 4.86 Favored 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.536 2.157 . . . . 0.0 112.44 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.526 HG23 ' HB2' ' A' ' 79' ' ' PRO . 20.2 t -96.24 137.36 24.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.01 179.93 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 1.9 m -115.2 139.03 50.28 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.951 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 8.4 m -95.79 111.31 23.31 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.014 179.091 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.766 HG22 ' N ' ' A' ' 118' ' ' VAL . 67.3 t -90.63 105.76 16.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.757 -179.166 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.462 ' O ' ' HA2' ' A' ' 116' ' ' GLY . 6.2 tt -103.0 84.36 2.35 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 178.633 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.977 HG21 HD23 ' A' ' 95' ' ' LEU . 3.6 mt -80.94 128.64 38.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 121.27 0.557 . . . . 0.0 111.864 -178.526 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.829 ' O ' HG21 ' A' ' 112' ' ' ILE . 0.2 OUTLIER -74.81 153.01 38.94 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.459 179.962 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.401 ' HB3' ' N ' ' A' ' 149' ' ' GLY . 0.2 OUTLIER -148.33 100.1 3.61 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.109 179.845 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 89' ' ' PRO . . . . . 0.424 ' HG2' ' CD2' ' A' ' 93' ' ' TYR . 57.8 Cg_endo -71.21 -39.85 3.64 Favored 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.423 2.082 . . . . 0.0 112.497 -179.855 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -145.69 -169.24 3.18 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.167 -179.887 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.584 HD12 HG11 ' A' ' 148' ' ' VAL . 0.4 OUTLIER -88.78 -53.27 4.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.057 -179.967 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.2 mpp_? -57.93 -20.06 34.65 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.522 -179.528 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 93' ' ' TYR . . . . . 0.424 ' CD2' ' HG2' ' A' ' 89' ' ' PRO . 12.7 m-85 -77.21 133.39 38.91 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.799 179.896 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 4.5 mp0 -89.58 177.48 6.53 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.986 -179.925 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 0.977 HD23 HG21 ' A' ' 86' ' ' ILE . 2.3 mp -93.61 -67.62 0.85 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.858 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 134.8 52.53 0.07 OUTLIER Glycine 0 CA--C 1.519 0.332 0 C-N-CA 120.465 -0.874 . . . . 0.0 113.026 179.584 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 97' ' ' PHE . . . . . 0.598 ' HD2' HG21 ' A' ' 118' ' ' VAL . 0.0 OUTLIER 179.96 177.41 0.65 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.839 0.352 . . . . 0.0 111.402 179.663 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 71.0 m -125.73 137.09 53.8 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.762 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.758 HG21 HG21 ' A' ' 140' ' ' ILE . 7.1 p -109.74 135.26 49.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.453 -179.687 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 4.6 tt0 -131.58 89.4 2.7 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.068 179.359 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 61.05 15.85 6.55 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.016 -179.215 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 125.37 -37.01 2.64 Favored Glycine 0 N--CA 1.447 -0.569 0 C-N-CA 120.987 -0.625 . . . . 0.0 112.065 -179.924 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.828 HG23 ' O ' ' A' ' 122' ' ' HIS . 44.8 mt -77.43 140.93 16.28 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-O 121.016 0.436 . . . . 0.0 111.574 -179.815 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.838 HD11 ' CD1' ' A' ' 124' ' ' ILE . 3.7 mp -98.53 141.21 16.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.985 -179.824 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 22.0 m -119.82 -48.45 2.36 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.936 -0.574 . . . . 0.0 111.003 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -96.81 151.66 19.44 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.871 -179.972 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.725 HD11 HG13 ' A' ' 118' ' ' VAL . 0.4 OUTLIER -167.25 116.46 0.83 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.871 179.988 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 5.0 tmm? -85.49 116.31 23.72 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.939 -179.939 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -60.78 125.6 24.29 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.921 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 88.11 26.99 27.1 Favored Glycine 0 N--CA 1.453 -0.217 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.552 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 111' ' ' GLY . . . . . 0.496 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -108.36 -161.61 20.55 Favored Glycine 0 CA--C 1.518 0.249 0 C-N-CA 120.782 -0.723 . . . . 0.0 113.031 -179.704 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.829 HG21 ' O ' ' A' ' 87' ' ' ARG . 7.6 mt -80.46 -42.68 21.32 Favored 'Isoleucine or valine' 0 C--O 1.237 0.434 0 CA-C-O 121.181 0.515 . . . . 0.0 111.41 -179.829 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 113' ' ' ALA . . . . . 0.787 ' O ' HG12 ' A' ' 118' ' ' VAL . . . -57.76 -34.72 69.85 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.283 -179.251 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 114' ' ' GLU . . . . . 0.518 ' HG3' ' N ' ' A' ' 115' ' ' ARG . 7.3 pt-20 -67.9 -35.72 78.97 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.725 179.568 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.518 ' N ' ' HG3' ' A' ' 114' ' ' GLU . 36.1 mmt180 -61.71 -47.35 85.7 Favored 'General case' 0 N--CA 1.452 -0.368 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.885 -179.626 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.462 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -55.09 -72.58 0.53 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.225 -0.988 . . . . 0.0 112.615 179.894 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 117' ' ' GLY . . . . . 0.406 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 175.49 -22.15 0.06 OUTLIER Glycine 0 CA--C 1.52 0.393 0 C-N-CA 120.936 -0.65 . . . . 0.0 112.857 -179.881 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.787 HG12 ' O ' ' A' ' 113' ' ' ALA . 9.1 p -30.76 147.24 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 N-CA-C 112.637 0.606 . . . . 0.0 112.637 -179.723 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -142.79 130.47 21.42 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.653 179.748 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 120' ' ' VAL . . . . . 0.439 HG22 ' HB2' ' A' ' 107' ' ' LEU . 26.0 t -62.0 95.75 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.209 -179.809 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 123.38 40.41 0.47 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.688 179.859 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 122' ' ' HIS . . . . . 0.828 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -125.32 -165.98 1.48 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.656 0.265 . . . . 0.0 110.851 -179.982 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.642 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 0.1 OUTLIER -145.76 90.75 2.02 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.376 -0.375 . . . . 0.0 110.813 179.952 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 124' ' ' ILE . . . . . 0.838 ' CD1' HD11 ' A' ' 104' ' ' ILE . 8.0 mt -53.36 157.04 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.582 179.496 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 125' ' ' ILE . . . . . 0.8 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.6 OUTLIER -150.31 -84.48 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 N-CA-C 112.209 0.448 . . . . 0.0 112.209 -179.474 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 21.9 mt-10 -79.75 85.84 5.39 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 112.176 0.436 . . . . 0.0 112.176 -178.964 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.797 HG23 ' HB3' ' A' ' 153' ' ' MET . 1.9 mt -89.83 108.3 19.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 116.396 -0.365 . . . . 0.0 111.377 179.475 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 128' ' ' ASN . . . . . 0.51 HD22 HG22 ' A' ' 127' ' ' ILE . 55.2 m-80 54.42 24.88 5.54 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.128 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 105.26 -10.22 46.76 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.665 -0.779 . . . . 0.0 112.794 -179.85 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 130' ' ' GLN . . . . . 0.492 HE22 HD11 ' A' ' 143' ' ' ILE . 21.4 tt0 -98.85 112.19 24.36 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.85 0.357 . . . . 0.0 110.756 179.855 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 1.5 m -74.49 91.09 2.24 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.286 -179.595 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 132' ' ' VAL . . . . . 0.691 HG11 HD12 ' A' ' 127' ' ' ILE . 29.6 m -71.54 -5.6 6.18 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.312 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.547 179.43 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.8 ' HB ' HG22 ' A' ' 125' ' ' ILE . 10.3 p -48.63 121.63 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.254 0 CA-C-O 120.893 0.378 . . . . 0.0 111.133 -179.916 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 134' ' ' ALA . . . . . 0.414 ' HB3' ' O ' ' A' ' 133' ' ' VAL . . . 68.15 22.38 8.3 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.034 -179.395 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 135' ' ' THR . . . . . 0.449 ' HB ' ' O ' ' A' ' 132' ' ' VAL . 50.8 m -106.16 141.53 22.94 Favored Pre-proline 0 C--N 1.326 -0.438 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.698 179.559 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 136' ' ' PRO . . . . . 0.418 ' HD2' HG23 ' A' ' 135' ' ' THR . 80.2 Cg_exo -45.38 146.92 2.84 Favored 'Trans proline' 0 C--N 1.345 0.359 0 C-N-CA 122.609 2.206 . . . . 0.0 112.565 -179.922 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 137' ' ' HIS . . . . . 0.416 ' CE1' ' HG2' ' A' ' 138' ' ' GLU . 7.0 p80 -65.21 -41.74 94.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.019 -179.929 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 138' ' ' GLU . . . . . 0.416 ' HG2' ' CE1' ' A' ' 137' ' ' HIS . 4.7 mm-40 -56.25 -37.21 69.44 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.947 -179.899 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 139' ' ' LYS . . . . . 0.795 ' O ' HD12 ' A' ' 143' ' ' ILE . 27.9 tttt -63.66 -48.96 75.09 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.903 179.942 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 140' ' ' ILE . . . . . 0.758 HG21 HG21 ' A' ' 99' ' ' VAL . 16.1 mt -58.62 -42.15 84.07 Favored 'Isoleucine or valine' 0 C--O 1.236 0.364 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.628 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 141' ' ' VAL . . . . . 0.45 HG22 HG12 ' A' ' 99' ' ' VAL . 89.2 t -62.49 -33.03 57.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.194 178.972 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -61.85 -51.74 66.99 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.64 179.736 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 143' ' ' ILE . . . . . 0.795 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.4 mp -53.24 -57.18 5.3 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.433 0 CA-C-O 121.079 0.466 . . . . 0.0 110.316 179.167 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.595 HD13 HD22 ' A' ' 95' ' ' LEU . 2.9 mt -61.71 -30.24 70.63 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.25 179.597 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 2.1 m -69.27 -25.96 64.52 Favored 'General case' 0 N--CA 1.453 -0.317 0 CA-C-N 116.097 -0.501 . . . . 0.0 109.965 178.529 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 4.9 m-80 -130.15 33.91 4.29 Favored 'General case' 0 CA--C 1.529 0.149 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.213 179.861 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 147' ' ' ALA . . . . . 0.573 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -117.89 54.88 0.89 Allowed 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.192 179.908 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.584 HG11 HD12 ' A' ' 91' ' ' LEU . 8.1 m -50.78 177.61 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.447 -179.972 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 149' ' ' GLY . . . . . 0.401 ' N ' ' HB3' ' A' ' 88' ' ' ARG . . . 81.75 -111.62 3.35 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.458 -179.948 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 58.9 mt-10 -138.4 105.64 5.49 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.877 0.37 . . . . 0.0 110.715 179.841 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 151' ' ' ILE . . . . . 0.574 HG12 HD22 ' A' ' 144' ' ' LEU . 1.1 mt -73.01 111.36 7.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.069 -179.802 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 152' ' ' HIS . . . . . 0.403 ' CE1' ' HA ' ' A' ' 128' ' ' ASN . 8.3 p80 -106.34 115.58 30.46 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 178.918 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 153' ' ' MET . . . . . 0.797 ' HB3' HG23 ' A' ' 127' ' ' ILE . 1.5 ptt? -140.35 176.13 9.03 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.324 0.583 . . . . 0.0 112.085 -178.663 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 17.6 mttm -126.94 147.69 50.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.194 -0.912 . . . . 0.0 109.812 179.153 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 155' ' ' THR . . . . . 0.554 HG22 ' CG1' ' A' ' 124' ' ' ILE . 4.7 p -142.73 145.27 33.16 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.977 0.418 . . . . 0.0 111.163 -179.515 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 156' ' ' MET . . . . . 0.424 ' O ' ' N ' ' A' ' 123' ' ' ARG . 6.6 ptp -133.12 156.65 79.75 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.631 179.647 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_exo -49.46 126.18 15.42 Favored 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.508 2.139 . . . . 0.0 112.623 -179.887 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 158' ' ' ALA . . . . . 0.646 ' HB2' HG12 ' A' ' 103' ' ' ILE . . . . . . . . 0 C--O 1.249 1.034 0 CA-C-O 118.26 -0.876 . . . . 0.0 111.016 179.823 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_endo . . . . . 0 N--CA 1.488 1.204 0 CA-C-O 120.691 0.204 . . . . 0.0 111.807 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -70.21 99.65 0.81 Allowed 'Trans proline' 0 C--N 1.344 0.309 0 C-N-CA 122.659 2.239 . . . . 0.0 112.29 -179.936 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 21.5 t -103.68 130.73 53.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.011 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.2 m -101.8 134.91 44.23 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.786 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 20.2 m -95.71 111.78 23.65 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.186 179.235 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.762 HG22 ' N ' ' A' ' 118' ' ' VAL . 62.2 t -85.63 105.37 14.29 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.41 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.401 -179.408 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.48 HD21 ' HB3' ' A' ' 150' ' ' GLU . 1.0 OUTLIER -103.17 83.68 2.23 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.058 -0.519 . . . . 0.0 109.652 178.893 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.845 HG21 ' CD2' ' A' ' 95' ' ' LEU . 12.6 mt -81.77 123.72 38.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-O 121.368 0.604 . . . . 0.0 111.717 -178.756 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.474 ' HB2' HG21 ' A' ' 112' ' ' ILE . 0.0 OUTLIER -71.98 132.5 44.39 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.776 -179.901 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.442 ' HG3' HD12 ' A' ' 151' ' ' ILE . 0.0 OUTLIER -130.14 90.43 42.11 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.705 179.969 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 89' ' ' PRO . . . . . 0.456 ' HG2' ' CD2' ' A' ' 93' ' ' TYR . 48.7 Cg_endo -68.87 -25.28 33.07 Favored 'Trans proline' 0 C--N 1.345 0.376 0 C-N-CA 122.552 2.168 . . . . 0.0 112.569 -179.912 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 90' ' ' ASP . . . . . 0.572 ' O ' HG23 ' A' ' 148' ' ' VAL . 0.6 OUTLIER -155.02 -169.57 3.23 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.978 0.418 . . . . 0.0 111.238 -179.856 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -97.44 -46.65 5.98 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.121 -179.82 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -57.01 -20.5 24.42 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.906 -0.588 . . . . 0.0 111.538 -179.631 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 93' ' ' TYR . . . . . 0.456 ' CD2' ' HG2' ' A' ' 89' ' ' PRO . 8.2 m-85 -60.3 -177.44 0.07 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.688 179.765 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -151.28 161.46 42.67 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.173 -179.941 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 0.845 ' CD2' HG21 ' A' ' 86' ' ' ILE . 1.4 mt -96.89 -50.34 4.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.698 179.898 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 88.78 72.0 1.27 Allowed Glycine 0 N--CA 1.452 -0.249 0 C-N-CA 120.797 -0.716 . . . . 0.0 113.096 179.456 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 97' ' ' PHE . . . . . 0.593 ' HE1' HD13 ' A' ' 95' ' ' LEU . 15.9 p90 -175.66 158.33 2.17 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.827 0.346 . . . . 0.0 111.174 179.57 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -105.17 146.64 28.96 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.681 179.924 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.436 ' CG2' HD12 ' A' ' 140' ' ' ILE . 7.3 p -130.63 134.02 62.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.307 -179.688 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -127.04 89.41 2.97 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.351 179.493 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 6.5 m120 57.11 18.74 4.27 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.052 -179.432 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 129.79 -41.44 1.54 Allowed Glycine 0 N--CA 1.448 -0.506 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.515 179.871 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.52 HG12 ' CB ' ' A' ' 158' ' ' ALA . 22.7 mt -77.57 129.5 37.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 121.077 0.465 . . . . 0.0 111.576 -179.344 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.872 HD11 ' CD1' ' A' ' 124' ' ' ILE . 3.6 mp -85.75 140.84 15.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.771 179.684 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 64.6 m -106.44 -69.89 0.81 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.826 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -100.86 141.25 34.01 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.788 179.859 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.405 ' CB ' HG22 ' A' ' 120' ' ' VAL . 5.7 tp -143.6 113.72 7.29 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.695 179.93 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 21.9 mmm -76.28 116.7 17.23 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.86 -179.839 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.05 78.88 0.05 OUTLIER 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.675 179.809 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 173.91 -34.24 0.11 Allowed Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.937 -0.649 . . . . 0.0 112.207 -179.811 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 111' ' ' GLY . . . . . 0.412 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -57.85 174.63 2.31 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.258 179.853 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.474 HG21 ' HB2' ' A' ' 87' ' ' ARG . 0.9 OUTLIER -78.53 -16.98 13.65 Favored 'Isoleucine or valine' 0 C--O 1.236 0.395 0 CA-C-O 120.91 0.386 . . . . 0.0 111.611 -179.886 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 113' ' ' ALA . . . . . 0.623 ' O ' HG12 ' A' ' 118' ' ' VAL . . . -57.81 -30.68 65.91 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.997 0.427 . . . . 0.0 110.875 179.908 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 114' ' ' GLU . . . . . 0.412 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 17.0 pt-20 -63.96 -46.85 82.84 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.856 179.828 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.4 ' N ' ' CG ' ' A' ' 114' ' ' GLU . 8.8 mtt180 -58.91 -47.33 85.39 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.087 -179.557 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.429 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -50.1 -72.67 0.45 Allowed Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.368 -0.92 . . . . 0.0 112.689 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 117' ' ' GLY . . . . . 0.521 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 172.34 -21.69 0.07 OUTLIER Glycine 0 CA--C 1.519 0.293 0 C-N-CA 120.972 -0.632 . . . . 0.0 112.674 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.762 ' N ' HG22 ' A' ' 84' ' ' VAL . 3.8 p -30.34 144.58 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.29 0 N-CA-C 112.327 0.492 . . . . 0.0 112.327 -179.78 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.425 ' HB3' ' CD2' ' A' ' 122' ' ' HIS . 0.0 OUTLIER -136.64 126.65 26.02 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.643 -179.992 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 120' ' ' VAL . . . . . 0.405 HG22 ' CB ' ' A' ' 107' ' ' LEU . 19.5 t -56.05 90.79 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.184 179.899 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 121.25 11.21 6.29 Favored Glycine 0 CA--C 1.52 0.379 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.8 -179.904 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 122' ' ' HIS . . . . . 0.425 ' CD2' ' HB3' ' A' ' 119' ' ' ARG . 6.9 m170 -98.24 132.21 43.94 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.891 0.377 . . . . 0.0 110.739 179.889 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.871 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 0.0 OUTLIER -79.41 90.78 5.04 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.586 -179.622 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 124' ' ' ILE . . . . . 0.872 ' CD1' HD11 ' A' ' 104' ' ' ILE . 7.7 mt -54.13 143.15 6.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 N-CA-C 109.709 -0.478 . . . . 0.0 109.709 178.577 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 125' ' ' ILE . . . . . 0.796 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.5 OUTLIER -137.97 -82.84 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 N-CA-C 112.365 0.506 . . . . 0.0 112.365 -179.35 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 11.6 mt-10 -73.92 81.35 1.66 Allowed 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 112.538 0.57 . . . . 0.0 112.538 -178.776 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.97 HG23 ' CG ' ' A' ' 153' ' ' MET . 3.0 mt -82.61 92.44 2.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.95 179.045 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 128' ' ' ASN . . . . . 0.406 ' N ' ' O ' ' A' ' 152' ' ' HIS . 1.6 t-20 58.9 21.11 8.78 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.014 -179.915 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 119.08 -18.5 10.37 Favored Glycine 0 C--N 1.332 0.349 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.787 -179.944 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -94.72 112.02 23.77 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.837 0.351 . . . . 0.0 110.922 -179.842 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 3.6 p -76.22 96.4 3.91 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.0 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 132' ' ' VAL . . . . . 0.699 HG11 HD12 ' A' ' 127' ' ' ILE . 27.4 m -81.04 2.64 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.323 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.86 179.983 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.796 ' HB ' HG22 ' A' ' 125' ' ' ILE . 9.0 p -44.43 -42.57 2.14 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.178 0 CA-C-O 120.922 0.392 . . . . 0.0 111.661 -179.761 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 134' ' ' ALA . . . . . 0.429 ' N ' HG13 ' A' ' 133' ' ' VAL . . . -116.55 29.73 7.77 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.843 179.587 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 135' ' ' THR . . . . . 0.478 HG23 ' HD2' ' A' ' 136' ' ' PRO . 85.4 m -111.92 140.17 23.11 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.089 -179.834 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 136' ' ' PRO . . . . . 0.478 ' HD2' HG23 ' A' ' 135' ' ' THR . 10.6 Cg_endo -54.44 164.23 3.08 Favored 'Trans proline' 0 C--N 1.347 0.455 0 C-N-CA 122.646 2.23 . . . . 0.0 112.333 179.895 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 15.2 p80 -67.44 -46.65 72.47 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.603 -179.593 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -53.68 -35.21 60.83 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.387 -0.369 . . . . 0.0 111.468 -179.445 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 139' ' ' LYS . . . . . 0.783 ' O ' HD12 ' A' ' 143' ' ' ILE . 0.1 OUTLIER -65.36 -48.94 71.2 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.85 0.357 . . . . 0.0 111.079 -179.8 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 140' ' ' ILE . . . . . 0.836 HG23 ' CD1' ' A' ' 127' ' ' ILE . 10.1 mt -58.58 -46.19 90.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.529 -179.925 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 141' ' ' VAL . . . . . 0.405 ' CG2' ' CG1' ' A' ' 99' ' ' VAL . 86.8 t -60.41 -32.29 50.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.058 178.797 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 9.1 t-80 -60.65 -52.94 63.01 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.664 179.585 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 143' ' ' ILE . . . . . 0.783 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.2 mp -53.25 -57.03 5.59 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.456 0 CA-C-O 121.151 0.5 . . . . 0.0 110.178 179.364 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.686 HD22 HG12 ' A' ' 151' ' ' ILE . 4.5 mt -60.96 -30.23 70.12 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.279 179.699 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 1.3 m -68.56 -27.0 65.69 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.13 -0.486 . . . . 0.0 109.887 178.572 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 9.0 m120 -127.82 32.59 4.93 Favored 'General case' 0 CA--C 1.528 0.109 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.124 179.813 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 147' ' ' ALA . . . . . 0.512 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -119.26 63.45 0.79 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.375 -0.375 . . . . 0.0 111.223 179.915 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.694 HG22 ' H ' ' A' ' 149' ' ' GLY . 1.6 p -60.11 -157.28 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.983 -179.869 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 149' ' ' GLY . . . . . 0.694 ' H ' HG22 ' A' ' 148' ' ' VAL . . . 58.0 -109.94 2.15 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.867 -0.683 . . . . 0.0 112.438 -179.961 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.48 ' HB3' HD21 ' A' ' 85' ' ' LEU . 3.9 mm-40 -131.18 100.13 5.1 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.739 0.304 . . . . 0.0 110.526 179.791 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 151' ' ' ILE . . . . . 0.686 HG12 HD22 ' A' ' 144' ' ' LEU . 0.3 OUTLIER -63.04 111.73 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.982 0.42 . . . . 0.0 111.213 -179.751 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 152' ' ' HIS . . . . . 0.406 ' O ' ' N ' ' A' ' 128' ' ' ASN . 1.2 t-80 -95.56 121.32 37.13 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 178.943 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 153' ' ' MET . . . . . 0.97 ' CG ' HG23 ' A' ' 127' ' ' ILE . 29.3 mtp -137.74 166.43 23.98 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.386 0.612 . . . . 0.0 112.368 -178.525 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 154' ' ' LYS . . . . . 0.405 ' O ' HG13 ' A' ' 125' ' ' ILE . 0.9 OUTLIER -143.34 132.19 22.74 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 114.852 -1.067 . . . . 0.0 108.811 178.762 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 155' ' ' THR . . . . . 0.441 HG22 HG12 ' A' ' 124' ' ' ILE . 1.3 p -138.57 161.25 37.56 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.333 0.587 . . . . 0.0 112.176 -178.53 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 156' ' ' MET . . . . . 0.42 ' O ' ' N ' ' A' ' 123' ' ' ARG . 5.1 ptp -135.58 160.03 69.28 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 115.133 -0.94 . . . . 0.0 109.953 179.174 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 21.6 Cg_endo -61.67 118.36 5.23 Favored 'Trans proline' 0 C--N 1.343 0.274 0 C-N-CA 122.366 2.044 . . . . 0.0 112.544 -179.675 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 158' ' ' ALA . . . . . 0.871 ' HB2' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.25 1.092 0 CA-C-O 118.211 -0.9 . . . . 0.0 111.037 179.749 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_endo . . . . . 0 N--CA 1.488 1.183 0 CA-C-O 120.701 0.209 . . . . 0.0 111.717 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -71.2 99.52 0.91 Allowed 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.498 2.132 . . . . 0.0 112.364 179.916 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 10.3 p -80.83 130.35 36.03 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.864 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.8 m -121.35 142.94 49.49 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.013 -179.842 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 5.4 m -101.37 111.15 23.3 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.135 179.2 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 1.018 HG11 HG23 ' A' ' 118' ' ' VAL . 41.4 t -82.85 105.95 13.18 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.562 0 CA-C-N 115.949 -0.569 . . . . 0.0 112.184 -179.215 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.456 ' O ' HD23 ' A' ' 85' ' ' LEU . 7.1 tt -99.96 79.81 2.24 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 178.069 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.892 HG13 HG12 ' A' ' 84' ' ' VAL . 3.3 mt -82.66 104.95 11.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.767 -178.413 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.785 ' O ' HG21 ' A' ' 112' ' ' ILE . 0.0 OUTLIER -74.93 108.31 7.57 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.428 179.21 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.494 ' HG3' HD12 ' A' ' 151' ' ' ILE . 10.4 mtp180 -92.32 111.45 50.52 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.184 -179.646 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_exo -62.26 -63.9 0.09 OUTLIER 'Trans proline' 0 C--N 1.346 0.445 0 C-N-CA 122.572 2.181 . . . . 0.0 112.407 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 3.1 t0 -121.44 -173.36 2.61 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.919 0.39 . . . . 0.0 111.165 -179.71 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.552 ' HG ' HG13 ' A' ' 148' ' ' VAL . 0.0 OUTLIER -94.82 -21.2 18.86 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.281 -179.905 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -96.7 23.28 7.14 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.81 0.338 . . . . 0.0 111.14 -179.877 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 2.0 m-85 -102.23 178.41 4.6 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.824 179.827 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -135.71 143.61 45.46 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.017 -179.918 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 0.778 ' CD2' HD13 ' A' ' 86' ' ' ILE . 8.3 mp -72.57 -31.06 64.94 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.798 179.872 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 82.96 55.16 3.01 Favored Glycine 0 C--N 1.33 0.242 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.968 179.626 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -173.17 156.82 3.29 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.836 0.351 . . . . 0.0 111.144 179.82 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.2 m -99.28 155.92 17.25 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.677 179.804 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.43 ' CG1' ' CG2' ' A' ' 141' ' ' VAL . 8.5 p -133.0 132.15 58.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.927 0.394 . . . . 0.0 111.336 -179.86 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -128.97 89.27 2.85 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.27 179.509 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 3.3 m-80 58.25 17.25 4.52 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.126 -179.637 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 129.81 -40.09 1.73 Allowed Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.261 179.905 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.524 HG12 ' CB ' ' A' ' 158' ' ' ALA . 30.1 mt -77.24 130.19 36.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 121.098 0.475 . . . . 0.0 111.522 -179.677 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.807 HD11 ' CD1' ' A' ' 124' ' ' ILE . 3.8 mp -83.96 139.67 17.28 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.793 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -84.62 -75.62 0.34 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.328 -179.479 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -132.37 121.75 23.96 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.917 0.389 . . . . 0.0 111.114 -179.74 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.408 HD12 ' N ' ' A' ' 108' ' ' MET . 7.8 tp -105.57 116.2 31.53 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.463 179.761 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 108' ' ' MET . . . . . 0.408 ' N ' HD12 ' A' ' 107' ' ' LEU . 36.2 mtm -69.27 132.94 47.26 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.056 -179.807 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -67.18 76.14 0.14 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.549 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 174.63 -34.22 0.1 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.285 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 111' ' ' GLY . . . . . 0.439 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -56.54 176.26 1.05 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.438 179.774 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.785 HG21 ' O ' ' A' ' 87' ' ' ARG . 1.8 mt -78.61 -22.04 13.09 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-O 120.782 0.325 . . . . 0.0 111.615 -179.846 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 113' ' ' ALA . . . . . . . . . . . . . . . -57.82 -30.31 65.63 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.008 0.432 . . . . 0.0 110.702 179.828 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 114' ' ' GLU . . . . . 0.439 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 19.6 pt-20 -60.63 -47.19 87.32 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.89 -0.595 . . . . 0.0 111.197 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 3.8 mtm180 -66.59 -41.33 88.67 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.241 -179.294 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -56.19 -72.63 0.54 Allowed Glycine 0 N--CA 1.448 -0.539 0 C-N-CA 120.398 -0.906 . . . . 0.0 112.669 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 117' ' ' GLY . . . . . 0.428 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 161.09 -10.67 0.13 Allowed Glycine 0 CA--C 1.522 0.47 0 C-N-CA 121.219 -0.515 . . . . 0.0 112.851 -179.879 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 1.018 HG23 HG11 ' A' ' 84' ' ' VAL . 2.2 t -29.75 -71.46 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 C-N-CA 123.11 0.564 . . . . 0.0 112.306 -179.677 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.654 ' N ' HG12 ' A' ' 118' ' ' VAL . 0.0 OUTLIER 64.32 136.12 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.467 -179.486 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 120' ' ' VAL . . . . . 0.403 ' CG2' ' HB3' ' A' ' 107' ' ' LEU . 20.2 t -69.73 116.98 11.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.447 -0.342 . . . . 0.0 111.427 -179.69 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 112.55 33.25 2.12 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.799 179.644 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 1.5 m-70 -135.71 132.96 37.55 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.831 0.348 . . . . 0.0 110.991 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.977 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 72.3 ttt180 -88.76 95.29 10.22 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.65 -179.686 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 124' ' ' ILE . . . . . 0.807 ' CD1' HD11 ' A' ' 104' ' ' ILE . 11.7 mt -49.68 146.63 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 178.657 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 125' ' ' ILE . . . . . 0.924 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.6 OUTLIER -137.11 -84.8 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 N-CA-C 112.772 0.656 . . . . 0.0 112.772 -178.924 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 19.5 mt-10 -80.8 90.86 5.87 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 112.454 0.538 . . . . 0.0 112.454 -178.383 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.823 HG23 ' HB3' ' A' ' 153' ' ' MET . 1.8 mt -92.15 100.79 11.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.288 179.284 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 128' ' ' ASN . . . . . 0.404 ' N ' ' O ' ' A' ' 152' ' ' HIS . 20.3 m120 57.82 17.87 4.52 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.622 179.815 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 121.69 -20.69 8.18 Favored Glycine 0 C--N 1.333 0.39 0 C-N-CA 120.348 -0.929 . . . . 0.0 113.381 179.406 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -98.22 120.96 39.53 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 117.256 0.528 . . . . 0.0 111.038 -179.727 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 67.4 p -79.25 94.62 5.47 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.362 -179.838 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 132' ' ' VAL . . . . . 0.782 HG21 HD11 ' A' ' 127' ' ' ILE . 31.0 m -74.62 -4.87 6.17 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.304 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.594 179.679 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.924 ' HB ' HG22 ' A' ' 125' ' ' ILE . 6.6 p -46.5 -37.69 3.32 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.141 0 CA-C-O 120.895 0.379 . . . . 0.0 111.526 -179.683 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -116.99 29.66 7.79 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.719 179.602 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 135' ' ' THR . . . . . 0.526 HG23 ' HD2' ' A' ' 136' ' ' PRO . 87.9 m -117.24 141.94 29.37 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-N 115.881 -0.6 . . . . 0.0 111.033 -179.759 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 136' ' ' PRO . . . . . 0.526 ' HD2' HG23 ' A' ' 135' ' ' THR . 7.6 Cg_endo -49.65 164.04 0.41 Allowed 'Trans proline' 0 C--N 1.347 0.477 0 C-N-CA 122.77 2.313 . . . . 0.0 112.23 179.685 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 51.4 p-80 -73.38 -45.95 51.84 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.539 -179.655 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -53.78 -36.94 62.95 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.373 -179.55 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 139' ' ' LYS . . . . . 0.728 ' O ' HD12 ' A' ' 143' ' ' ILE . 0.1 OUTLIER -63.26 -47.34 82.78 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.895 -179.857 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 8.6 mt -58.74 -41.79 83.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.965 0.412 . . . . 0.0 110.646 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 141' ' ' VAL . . . . . 0.43 ' CG2' ' CG1' ' A' ' 99' ' ' VAL . 90.1 t -63.51 -32.68 57.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.28 179.139 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 56.7 t60 -62.33 -54.57 38.54 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.828 179.943 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 143' ' ' ILE . . . . . 0.728 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.3 mp -53.23 -56.83 6.36 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.395 0 CA-C-O 121.112 0.482 . . . . 0.0 110.138 179.373 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.721 HD13 ' CD2' ' A' ' 95' ' ' LEU . 5.1 mt -60.63 -30.28 69.77 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.47 -0.786 . . . . 0.0 110.313 179.409 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 2.3 m -67.65 -27.08 66.56 Favored 'General case' 0 N--CA 1.453 -0.323 0 CA-C-N 116.164 -0.471 . . . . 0.0 109.981 178.471 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 4.6 m-80 -130.28 34.73 4.16 Favored 'General case' 0 CA--C 1.527 0.087 0 CA-C-N 116.013 -0.54 . . . . 0.0 111.215 179.796 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 147' ' ' ALA . . . . . 0.569 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -118.65 55.26 0.92 Allowed 'General case' 0 C--O 1.232 0.149 0 CA-C-O 120.864 0.364 . . . . 0.0 111.451 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.552 HG13 ' HG ' ' A' ' 91' ' ' LEU . 2.8 m -55.84 174.89 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.181 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 88.64 -101.69 2.77 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.813 -0.708 . . . . 0.0 112.606 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 29.8 mt-10 -148.95 94.49 2.26 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.786 0.327 . . . . 0.0 110.989 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 151' ' ' ILE . . . . . 0.569 HD11 ' HB3' ' A' ' 147' ' ' ALA . 1.2 mt -61.75 112.2 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.995 179.939 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 152' ' ' HIS . . . . . 0.404 ' O ' ' N ' ' A' ' 128' ' ' ASN . 0.3 OUTLIER -102.68 115.53 30.77 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.076 179.144 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 153' ' ' MET . . . . . 0.823 ' HB3' HG23 ' A' ' 127' ' ' ILE . 1.8 ptm -147.59 166.68 26.62 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.129 0.49 . . . . 0.0 111.875 -179.111 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 35.4 mttp -112.58 155.99 23.43 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.889 179.146 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 155' ' ' THR . . . . . 0.436 HG23 HG23 ' A' ' 84' ' ' VAL . 13.8 p -141.2 144.13 34.58 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.226 0.536 . . . . 0.0 111.915 -179.451 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 156' ' ' MET . . . . . 0.597 ' CE ' HD13 ' A' ' 125' ' ' ILE . 1.5 mtm -110.86 179.94 0.74 Allowed Pre-proline 0 C--N 1.33 -0.241 0 CA-C-N 115.257 -0.883 . . . . 0.0 110.072 179.593 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 157' ' ' PRO . . . . . 0.418 ' CD ' ' CB ' ' A' ' 156' ' ' MET . 90.2 Cg_endo -92.68 106.98 0.2 Allowed 'Trans proline' 0 N--CA 1.456 -0.725 0 C-N-CA 122.757 2.305 . . . . 0.0 112.511 -179.919 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 158' ' ' ALA . . . . . 0.977 ' HB2' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.249 1.039 0 CA-C-O 118.186 -0.912 . . . . 0.0 111.036 179.801 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo . . . . . 0 N--CA 1.487 1.139 0 CA-C-O 120.725 0.219 . . . . 0.0 111.756 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -72.61 97.6 0.9 Allowed 'Trans proline' 0 C--N 1.344 0.313 0 C-N-CA 122.59 2.193 . . . . 0.0 112.376 -179.925 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.498 HG22 ' HE3' ' A' ' 156' ' ' MET . 44.7 t -93.54 143.91 10.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.922 179.836 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.7 m -131.31 140.04 49.68 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.02 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 6.8 m -100.29 111.3 23.57 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.149 179.284 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.829 HG12 HG13 ' A' ' 86' ' ' ILE . 49.5 t -83.68 106.57 14.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.929 -179.339 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.474 HD23 ' C ' ' A' ' 85' ' ' LEU . 7.0 tt -105.88 81.57 1.67 Allowed 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 178.317 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.829 HG13 HG12 ' A' ' 84' ' ' VAL . 12.7 mt -81.52 152.26 4.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.549 -178.498 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.404 ' CG ' ' CG2' ' A' ' 112' ' ' ILE . 0.0 OUTLIER -111.68 141.39 45.35 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.797 -179.426 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 11.5 mtp85 -140.27 84.32 14.65 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.85 179.812 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 63.7 Cg_exo -51.66 -35.44 57.34 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.656 2.238 . . . . 0.0 112.516 -179.817 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 90' ' ' ASP . . . . . 0.621 ' O ' HG12 ' A' ' 148' ' ' VAL . 0.3 OUTLIER -136.06 -169.64 2.47 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.942 0.401 . . . . 0.0 111.134 -179.777 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.787 ' HG ' HG11 ' A' ' 148' ' ' VAL . 3.9 mt -93.63 -43.17 8.8 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.783 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 2.3 mpp_? -63.27 -14.79 53.39 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.84 -0.618 . . . . 0.0 111.703 -179.595 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 7.5 m-85 -56.69 174.72 0.14 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.866 0.365 . . . . 0.0 110.915 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.491 ' O ' HD12 ' A' ' 112' ' ' ILE . 9.0 mp0 -138.6 166.13 25.14 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.027 -179.943 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 0.67 HD11 ' HB3' ' A' ' 144' ' ' LEU . 1.1 mt -97.66 -49.07 4.99 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.877 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 91.62 50.92 2.61 Favored Glycine 0 C--N 1.331 0.298 0 C-N-CA 120.728 -0.748 . . . . 0.0 113.108 179.5 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 97' ' ' PHE . . . . . 0.519 ' HE1' HD13 ' A' ' 95' ' ' LEU . 0.5 OUTLIER -168.95 162.97 11.39 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.795 0.331 . . . . 0.0 111.039 179.64 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -110.55 133.95 52.83 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.726 179.907 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.629 HG21 HG21 ' A' ' 140' ' ' ILE . 11.4 p -110.46 132.13 59.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.378 -179.813 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 3.6 mt-30 -129.08 89.51 2.88 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.222 179.485 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 2.4 m120 59.67 18.04 6.8 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.037 -0.528 . . . . 0.0 111.0 -179.406 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 124.9 -37.29 2.61 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.441 179.887 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.56 HG12 ' CB ' ' A' ' 158' ' ' ALA . 28.3 mt -77.28 140.29 17.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.97 0.414 . . . . 0.0 111.598 -179.603 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.875 HD11 ' CD1' ' A' ' 124' ' ' ILE . 4.5 mp -100.23 137.13 28.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.818 179.732 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -114.93 -64.31 1.33 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.876 -179.898 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 5.1 m -86.16 145.15 27.13 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.862 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 3.9 tt -162.26 116.54 1.83 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.705 179.81 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 3.6 tmm? -94.44 128.86 41.27 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.991 -179.774 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -65.44 79.5 0.06 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.64 179.744 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 176.89 -35.22 0.09 OUTLIER Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 120.927 -0.654 . . . . 0.0 111.956 -179.843 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 111' ' ' GLY . . . . . 0.402 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -59.18 167.86 7.16 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.017 179.613 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.491 HD12 ' O ' ' A' ' 94' ' ' GLN . 1.0 OUTLIER -78.36 -16.54 13.79 Favored 'Isoleucine or valine' 0 C--O 1.235 0.313 0 CA-C-O 120.872 0.367 . . . . 0.0 111.6 -179.837 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 113' ' ' ALA . . . . . 0.4 ' HA ' HG12 ' A' ' 86' ' ' ILE . . . -57.97 -30.44 66.02 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.969 0.414 . . . . 0.0 110.556 179.797 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 114' ' ' GLU . . . . . 0.402 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 16.4 pt-20 -60.42 -47.02 87.91 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.859 179.665 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -63.16 -47.32 83.16 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.049 -179.52 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.401 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -49.64 -73.8 0.33 Allowed Glycine 0 CA--C 1.52 0.379 0 C-N-CA 120.414 -0.898 . . . . 0.0 112.6 -179.862 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 117' ' ' GLY . . . . . 0.555 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 169.8 -19.79 0.07 OUTLIER Glycine 0 CA--C 1.519 0.296 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.719 -179.937 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.764 ' N ' HG22 ' A' ' 84' ' ' VAL . 1.2 t -40.46 108.21 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.529 0.149 0 CA-C-O 120.999 0.428 . . . . 0.0 111.494 -179.791 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 6.1 mtp180 -102.75 128.34 49.52 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.612 179.751 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 22.2 t -54.06 92.61 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 121.017 0.437 . . . . 0.0 111.1 -179.815 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 128.58 -0.08 6.28 Favored Glycine 0 CA--C 1.519 0.297 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.999 -179.944 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 1.4 m170 -93.82 133.1 37.57 Favored 'General case' 0 C--O 1.232 0.156 0 CA-C-O 120.876 0.37 . . . . 0.0 110.865 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.941 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 0.2 OUTLIER -83.27 91.62 7.32 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.009 -0.541 . . . . 0.0 111.791 -179.509 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 124' ' ' ILE . . . . . 0.875 ' CD1' HD11 ' A' ' 104' ' ' ILE . 14.9 mt -51.03 142.93 3.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 N-CA-C 109.638 -0.504 . . . . 0.0 109.638 178.572 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 125' ' ' ILE . . . . . 0.815 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.6 OUTLIER -136.65 -83.98 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 N-CA-C 112.995 0.739 . . . . 0.0 112.995 -178.581 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -78.5 85.82 4.56 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 112.733 0.642 . . . . 0.0 112.733 -178.28 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.858 HG23 ' HB3' ' A' ' 153' ' ' MET . 1.4 mt -90.61 104.32 15.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-O 121.071 0.462 . . . . 0.0 110.897 178.872 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 59.1 m-20 53.19 24.35 3.62 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.202 -179.93 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 111.47 -16.42 26.7 Favored Glycine 0 CA--C 1.519 0.33 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.944 179.879 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 10.4 tt0 -94.09 113.12 25.02 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.865 0.365 . . . . 0.0 111.04 -179.855 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -77.52 93.96 4.24 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.087 -179.974 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 132' ' ' VAL . . . . . 0.617 HG11 ' CD1' ' A' ' 127' ' ' ILE . 28.2 m -75.88 -3.31 4.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.183 -0.462 . . . . 0.0 112.038 -179.977 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.815 ' HB ' HG22 ' A' ' 125' ' ' ILE . 7.2 p -45.16 -38.26 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 CA-C-O 120.856 0.36 . . . . 0.0 111.616 -179.596 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -121.14 28.16 8.0 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.765 179.508 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 135' ' ' THR . . . . . 0.565 HG22 ' HB3' ' A' ' 139' ' ' LYS . 43.3 m -109.48 140.52 22.18 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.999 -179.88 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 136' ' ' PRO . . . . . 0.46 ' HD2' HG23 ' A' ' 135' ' ' THR . 11.1 Cg_endo -54.26 151.02 30.54 Favored 'Trans proline' 0 C--N 1.346 0.403 0 C-N-CA 122.654 2.236 . . . . 0.0 112.1 179.694 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 3.8 p-80 -60.41 -33.69 72.86 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.51 -179.727 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -62.53 -39.3 93.14 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.815 0.34 . . . . 0.0 111.227 -179.661 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 139' ' ' LYS . . . . . 0.677 ' O ' HD12 ' A' ' 143' ' ' ILE . 1.7 tptp -62.84 -46.17 89.18 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.025 -179.72 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 140' ' ' ILE . . . . . 0.629 HG21 HG21 ' A' ' 99' ' ' VAL . 7.5 mt -58.97 -46.13 91.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.697 -179.819 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 141' ' ' VAL . . . . . 0.413 ' CG2' ' CG1' ' A' ' 99' ' ' VAL . 89.1 t -60.87 -32.46 52.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.22 179.235 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -61.56 -54.95 36.26 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.966 179.888 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 143' ' ' ILE . . . . . 0.677 HD12 ' O ' ' A' ' 139' ' ' LYS . 3.9 mp -53.18 -57.42 4.8 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.476 0 CA-C-O 121.185 0.517 . . . . 0.0 110.229 179.463 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.743 HD22 HG12 ' A' ' 151' ' ' ILE . 2.6 mt -60.36 -30.06 69.31 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.219 -0.9 . . . . 0.0 110.445 179.571 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 2.2 m -67.23 -27.99 67.69 Favored 'General case' 0 N--CA 1.454 -0.251 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.024 178.825 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 44.1 m-20 -134.35 37.73 3.14 Favored 'General case' 0 CA--C 1.527 0.095 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.192 179.83 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 147' ' ' ALA . . . . . 0.616 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -111.62 40.17 2.18 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.484 -0.326 . . . . 0.0 111.43 -179.848 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.787 HG11 ' HG ' ' A' ' 91' ' ' LEU . 4.3 m -48.27 143.52 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.818 0.342 . . . . 0.0 111.412 179.884 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 118.65 -109.55 1.77 Allowed Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.443 -179.829 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.405 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 70.4 mt-10 -137.86 90.17 2.47 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.758 0.313 . . . . 0.0 110.77 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 151' ' ' ILE . . . . . 0.743 HG12 HD22 ' A' ' 144' ' ' LEU . 1.2 mp -65.54 111.82 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-O 121.012 0.434 . . . . 0.0 110.804 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 4.0 t60 -109.64 115.8 30.56 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.358 179.559 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 153' ' ' MET . . . . . 0.858 ' HB3' HG23 ' A' ' 127' ' ' ILE . 0.0 OUTLIER -144.37 166.23 25.69 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.194 0.521 . . . . 0.0 112.033 -179.258 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 154' ' ' LYS . . . . . 0.406 ' HG2' ' CG1' ' A' ' 81' ' ' VAL . 0.0 OUTLIER -109.74 151.81 26.45 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.526 -0.761 . . . . 0.0 109.346 178.665 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 155' ' ' THR . . . . . 0.453 HG22 HG12 ' A' ' 124' ' ' ILE . 16.1 p -139.84 138.61 35.89 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.054 0.454 . . . . 0.0 111.697 -179.453 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 156' ' ' MET . . . . . 0.498 ' HE3' HG22 ' A' ' 81' ' ' VAL . 0.0 OUTLIER -101.72 178.68 1.16 Allowed Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 115.474 -0.784 . . . . 0.0 110.31 179.732 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 157' ' ' PRO . . . . . 0.42 ' HD2' ' HB3' ' A' ' 156' ' ' MET . 94.7 Cg_endo -91.99 96.19 0.19 Allowed 'Trans proline' 0 N--CA 1.456 -0.722 0 C-N-CA 122.765 2.31 . . . . 0.0 112.505 -179.773 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 158' ' ' ALA . . . . . 0.941 ' HB2' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.201 -0.904 . . . . 0.0 111.051 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 79' ' ' PRO . . . . . 0.673 ' O ' HG23 ' A' ' 81' ' ' VAL . 4.8 Cg_endo . . . . . 0 N--CA 1.488 1.192 0 CA-C-O 120.634 0.181 . . . . 0.0 111.798 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_exo -51.73 90.03 0.03 OUTLIER 'Trans proline' 0 C--N 1.345 0.366 0 C-N-CA 122.608 2.205 . . . . 0.0 112.382 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.673 HG23 ' O ' ' A' ' 79' ' ' PRO . 40.6 t -88.54 140.36 15.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.932 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 1.8 m -124.62 142.65 51.21 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.931 179.842 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 4.1 m -101.73 111.44 23.69 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.22 179.267 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.76 HG22 ' N ' ' A' ' 118' ' ' VAL . 60.9 t -87.71 106.08 15.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.439 -179.461 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.424 ' O ' ' HA2' ' A' ' 116' ' ' GLY . 2.5 tt -104.33 85.55 2.38 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.094 -0.503 . . . . 0.0 109.827 178.778 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 1.054 HG21 HD23 ' A' ' 95' ' ' LEU . 3.5 mt -81.35 138.59 19.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 121.008 0.433 . . . . 0.0 111.306 -179.064 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.489 ' HG2' HG22 ' A' ' 112' ' ' ILE . 0.1 OUTLIER -98.77 108.83 21.61 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.507 -179.723 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 8.5 mmt180 -103.39 103.37 35.04 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.016 -179.84 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 89' ' ' PRO . . . . . 0.454 ' HG2' ' CG ' ' A' ' 93' ' ' TYR . 56.3 Cg_endo -70.49 -28.33 21.88 Favored 'Trans proline' 0 C--N 1.347 0.472 0 C-N-CA 122.385 2.056 . . . . 0.0 112.332 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 90' ' ' ASP . . . . . 0.442 ' HB2' ' CD1' ' A' ' 93' ' ' TYR . 2.9 m-20 -164.4 -175.49 3.93 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.876 0.37 . . . . 0.0 111.131 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 1.5 mp -80.32 -31.56 38.06 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.984 -179.884 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -73.84 -6.26 46.03 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.693 -179.708 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 93' ' ' TYR . . . . . 0.454 ' CG ' ' HG2' ' A' ' 89' ' ' PRO . 28.5 m-85 -104.7 110.37 22.66 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.803 0.335 . . . . 0.0 110.866 179.932 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -80.29 179.34 7.72 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.981 -179.927 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 1.054 HD23 HG21 ' A' ' 86' ' ' ILE . 0.6 OUTLIER -91.42 -66.67 0.91 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.749 179.902 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 118.83 63.51 0.29 Allowed Glycine 0 C--N 1.33 0.224 0 C-N-CA 120.566 -0.825 . . . . 0.0 112.959 179.57 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 19.5 p90 -176.82 161.64 2.04 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.807 0.337 . . . . 0.0 110.967 179.664 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 14.5 m -102.64 145.49 29.58 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.768 179.792 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.683 HG21 HG21 ' A' ' 140' ' ' ILE . 10.1 p -126.08 130.56 72.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.332 -179.809 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 4.3 mt-30 -129.83 89.5 2.83 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.253 179.625 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 85.7 m-20 60.22 18.22 7.68 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.858 -179.343 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 123.23 -36.95 2.91 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 120.934 -0.651 . . . . 0.0 112.409 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.695 HG12 ' HB2' ' A' ' 158' ' ' ALA . 26.6 mt -77.24 130.77 35.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 121.018 0.437 . . . . 0.0 111.506 -179.619 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.732 HD11 ' CD1' ' A' ' 124' ' ' ILE . 3.7 mp -82.32 139.52 17.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.87 179.787 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -100.52 -78.79 0.51 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.104 -179.793 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 18.4 m -108.43 135.57 49.51 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.91 -179.826 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.618 HD11 HG13 ' A' ' 118' ' ' VAL . 0.9 OUTLIER -110.75 108.73 18.69 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.823 179.89 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 41.1 mtm -73.01 100.39 2.97 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.965 -179.929 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 25.0 mmt85 -56.97 122.09 11.48 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.78 179.888 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 129.44 -31.29 3.45 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.85 -0.691 . . . . 0.0 112.024 -179.683 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 111' ' ' GLY . . . . . 0.424 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -66.68 175.81 21.46 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.716 -0.755 . . . . 0.0 112.273 179.688 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.489 HG22 ' HG2' ' A' ' 87' ' ' ARG . 0.8 OUTLIER -78.63 -18.18 13.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-O 120.88 0.372 . . . . 0.0 111.62 -179.842 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 113' ' ' ALA . . . . . 0.533 ' HB1' HG11 ' A' ' 118' ' ' VAL . . . -58.31 -30.25 66.51 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.95 0.405 . . . . 0.0 110.611 179.817 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 114' ' ' GLU . . . . . 0.424 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 15.2 pt-20 -59.87 -45.65 91.79 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.731 179.503 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -64.69 -46.96 80.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.2 -179.433 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.424 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -51.05 -74.03 0.32 Allowed Glycine 0 CA--C 1.518 0.262 0 C-N-CA 120.355 -0.926 . . . . 0.0 112.59 -179.908 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 117' ' ' GLY . . . . . 0.443 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 175.5 -20.91 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.938 -0.649 . . . . 0.0 112.808 -179.958 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.76 ' N ' HG22 ' A' ' 84' ' ' VAL . 0.3 OUTLIER -34.7 128.07 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.23 0 CA-C-O 120.912 0.387 . . . . 0.0 112.026 -179.801 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -136.66 144.85 44.21 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.847 -179.822 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 120' ' ' VAL . . . . . 0.519 HG22 ' HB2' ' A' ' 107' ' ' LEU . 22.7 t -70.43 102.47 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.208 -179.981 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 119.7 49.11 0.32 Allowed Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.61 -0.805 . . . . 0.0 112.681 179.869 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 5.4 m170 -154.29 132.65 11.95 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.834 0.35 . . . . 0.0 110.857 179.849 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.919 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 2.8 ttt180 -87.85 95.71 10.2 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.664 -179.532 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 124' ' ' ILE . . . . . 0.732 ' CD1' HD11 ' A' ' 104' ' ' ILE . 9.1 mt -49.71 159.14 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 178.771 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 125' ' ' ILE . . . . . 0.813 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.6 OUTLIER -148.79 -82.23 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 N-CA-C 112.567 0.58 . . . . 0.0 112.567 -179.579 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 126' ' ' GLU . . . . . 0.41 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 13.7 mt-10 -76.88 80.84 3.45 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 112.44 0.533 . . . . 0.0 112.44 -178.69 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.954 HG23 ' CG ' ' A' ' 153' ' ' MET . 2.8 mt -82.99 90.8 2.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 121.05 0.452 . . . . 0.0 111.153 179.117 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 128' ' ' ASN . . . . . 0.452 ' N ' ' O ' ' A' ' 152' ' ' HIS . 1.2 m-20 56.99 29.84 17.11 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.9 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 109.34 -15.11 32.93 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.774 -0.726 . . . . 0.0 112.686 -179.892 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 20.7 tt0 -95.04 106.03 17.99 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.895 0.379 . . . . 0.0 110.846 -179.921 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 11.7 p -73.5 90.3 1.72 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.851 179.971 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 132' ' ' VAL . . . . . 0.747 HG11 HD12 ' A' ' 127' ' ' ILE . 27.2 m -75.2 -2.86 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.29 0 CA-C-N 116.31 -0.405 . . . . 0.0 112.013 -179.828 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.813 ' HB ' HG22 ' A' ' 125' ' ' ILE . 10.4 p -44.77 -42.1 2.29 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.148 0 CA-C-O 120.862 0.363 . . . . 0.0 111.558 -179.731 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 134' ' ' ALA . . . . . 0.439 ' N ' HG13 ' A' ' 133' ' ' VAL . . . -116.2 29.54 7.9 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.891 179.578 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 135' ' ' THR . . . . . 0.479 HG22 ' HB3' ' A' ' 139' ' ' LYS . 38.1 m -114.73 140.06 24.9 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.175 -179.839 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 136' ' ' PRO . . . . . 0.447 ' HD2' HG23 ' A' ' 135' ' ' THR . 11.5 Cg_endo -55.32 164.06 4.23 Favored 'Trans proline' 0 C--N 1.348 0.512 0 C-N-CA 122.652 2.235 . . . . 0.0 112.121 179.766 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 18.8 p-80 -66.43 -45.79 78.67 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.749 -179.557 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -53.71 -39.78 65.49 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.562 -179.341 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 139' ' ' LYS . . . . . 0.725 ' O ' HD12 ' A' ' 143' ' ' ILE . 8.7 tttt -62.7 -46.71 86.89 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.467 -0.333 . . . . 0.0 111.131 -179.7 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 140' ' ' ILE . . . . . 0.683 HG21 HG21 ' A' ' 99' ' ' VAL . 9.0 mt -58.32 -45.92 89.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.735 -179.836 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 141' ' ' VAL . . . . . 0.411 ' CG2' ' CG1' ' A' ' 99' ' ' VAL . 82.6 t -60.87 -32.64 52.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.334 179.244 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -62.02 -55.19 31.76 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.012 179.908 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 143' ' ' ILE . . . . . 0.725 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.2 mp -52.83 -56.9 5.54 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.489 0 CA-C-O 121.321 0.581 . . . . 0.0 110.248 179.459 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.794 ' HB3' HD11 ' A' ' 95' ' ' LEU . 3.0 mt -61.2 -30.11 70.22 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.305 -0.861 . . . . 0.0 110.398 179.579 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 3.0 m -68.78 -26.74 65.36 Favored 'General case' 0 N--CA 1.454 -0.226 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.022 178.691 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 8.0 m120 -129.92 33.92 4.34 Favored 'General case' 0 CA--C 1.527 0.093 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.182 179.894 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 147' ' ' ALA . . . . . 0.806 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -112.28 45.73 1.25 Allowed 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.887 0.375 . . . . 0.0 111.242 179.992 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 3.1 m -50.48 152.33 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.592 -179.929 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 108.74 -104.42 1.97 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.539 -179.944 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 53.2 mt-10 -141.63 98.39 3.34 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.81 0.338 . . . . 0.0 110.558 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 151' ' ' ILE . . . . . 0.806 HD11 ' HB3' ' A' ' 147' ' ' ALA . 1.2 mt -73.41 111.79 8.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.353 -179.65 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 152' ' ' HIS . . . . . 0.452 ' O ' ' N ' ' A' ' 128' ' ' ASN . 0.0 OUTLIER -98.17 115.47 28.39 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 178.436 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 153' ' ' MET . . . . . 0.954 ' CG ' HG23 ' A' ' 127' ' ' ILE . 24.4 mtp -128.63 168.17 16.14 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.614 0.721 . . . . 0.0 112.677 -178.311 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 154' ' ' LYS . . . . . 0.416 ' O ' HG13 ' A' ' 125' ' ' ILE . 17.1 mttm -134.6 140.15 45.87 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 114.723 -1.126 . . . . 0.0 108.759 178.502 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 155' ' ' THR . . . . . 0.698 HG22 ' CG1' ' A' ' 124' ' ' ILE . 3.1 p -136.66 140.31 42.66 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.137 0.494 . . . . 0.0 111.909 -178.79 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 156' ' ' MET . . . . . . . . . . . . . 3.8 ptp -132.37 145.75 58.62 Favored Pre-proline 0 C--N 1.328 -0.362 0 CA-C-N 115.318 -0.855 . . . . 0.0 110.44 179.291 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_exo -44.43 122.7 4.02 Favored 'Trans proline' 0 C--N 1.345 0.35 0 C-N-CA 122.597 2.198 . . . . 0.0 112.879 -179.704 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 158' ' ' ALA . . . . . 0.919 ' HB2' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.25 1.081 0 CA-C-O 118.259 -0.877 . . . . 0.0 111.051 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.417 HG13 ' O ' ' A' ' 81' ' ' VAL . 14.4 p . . . . . 0 N--CA 1.456 -0.154 0 CA-C-O 120.769 0.318 . . . . 0.0 111.179 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.3 m -103.66 141.49 35.97 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.8 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 5.1 m -105.63 111.3 23.93 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.149 179.191 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.738 HG11 HG23 ' A' ' 118' ' ' VAL . 48.5 t -82.66 106.14 13.2 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.65 -179.418 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.404 ' HA ' ' O ' ' A' ' 151' ' ' ILE . 0.8 OUTLIER -105.55 84.04 2.03 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 178.456 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.7 HG13 HG12 ' A' ' 84' ' ' VAL . 4.0 mt -81.53 151.28 4.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.582 -178.671 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.462 ' CB ' HG21 ' A' ' 112' ' ' ILE . 0.0 OUTLIER -110.07 114.85 28.7 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.712 -0.677 . . . . 0.0 110.451 -179.789 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.439 ' HD2' HD11 ' A' ' 95' ' ' LEU . 0.0 OUTLIER -120.56 100.91 46.63 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.058 -179.728 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' PRO . . . . . 0.437 ' HG2' ' CD2' ' A' ' 93' ' ' TYR . 71.5 Cg_endo -74.54 -26.73 11.61 Favored 'Trans proline' 0 C--N 1.346 0.414 0 C-N-CA 122.585 2.19 . . . . 0.0 112.448 179.874 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -141.39 -166.01 2.1 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.087 -179.866 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 0.507 ' CD2' HG13 ' A' ' 148' ' ' VAL . 2.6 mt -102.59 -19.74 14.72 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.43 -179.823 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -95.08 21.81 7.35 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.48 -0.327 . . . . 0.0 111.291 -179.775 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . 0.437 ' CD2' ' HG2' ' A' ' 89' ' ' PRO . 7.4 m-85 -112.31 98.67 7.45 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.768 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 1.2 pm0 -57.97 146.76 31.35 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.136 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 0.866 ' CD2' HD13 ' A' ' 144' ' ' LEU . 6.7 mp -71.78 -52.5 17.31 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.758 -179.919 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 124.85 36.82 0.57 Allowed Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.579 -0.82 . . . . 0.0 113.023 179.576 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . 0.71 ' CZ ' HG21 ' A' ' 118' ' ' VAL . 31.8 p90 -177.36 169.24 2.24 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.839 0.352 . . . . 0.0 111.197 179.787 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -120.66 148.2 44.24 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.745 179.735 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.829 HG21 HG21 ' A' ' 140' ' ' ILE . 8.6 p -115.3 142.82 26.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.427 -179.878 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' GLN . . . . . 0.407 ' O ' ' N ' ' A' ' 102' ' ' GLY . 22.8 tt0 -132.14 88.42 2.55 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.905 -0.588 . . . . 0.0 110.233 179.049 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' ASN . . . . . 0.699 ' O ' HD11 ' A' ' 140' ' ' ILE . 2.2 t-20 65.36 -68.51 0.11 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.151 -179.838 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . 0.444 ' O ' ' HA ' ' A' ' 123' ' ' ARG . . . -142.9 -2.24 1.05 Allowed Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.387 -0.911 . . . . 0.0 113.4 -179.758 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.609 HD12 ' CB ' ' A' ' 158' ' ' ALA . 42.2 mm -122.86 151.36 26.99 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.128 0 CA-C-N 117.13 0.465 . . . . 0.0 111.529 -179.716 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.646 ' N ' HD12 ' A' ' 104' ' ' ILE . 2.8 mp -86.46 158.33 3.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.499 179.605 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' CYS . . . . . 0.482 ' N ' HG22 ' A' ' 104' ' ' ILE . 1.6 m -109.59 -71.68 0.75 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.475 -179.595 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 8.3 m -125.23 173.56 8.7 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.93 0.395 . . . . 0.0 111.17 -179.543 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.813 HD11 HG12 ' A' ' 118' ' ' VAL . 0.3 OUTLIER -148.48 140.63 24.05 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.779 179.901 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 2.0 mtm -106.22 114.21 28.2 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.868 -179.883 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -63.58 82.74 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.708 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 167.02 -31.36 0.19 Allowed Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.938 -0.648 . . . . 0.0 112.002 -179.858 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -64.34 172.48 17.46 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.132 179.651 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.462 HG21 ' CB ' ' A' ' 87' ' ' ARG . 0.5 OUTLIER -78.65 -16.66 13.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 120.744 0.306 . . . . 0.0 111.474 -179.952 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 113' ' ' ALA . . . . . 0.485 ' HA ' HG12 ' A' ' 86' ' ' ILE . . . -58.0 -30.35 66.0 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.002 0.429 . . . . 0.0 110.671 179.744 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 19.7 pt-20 -60.03 -46.63 88.86 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.876 179.67 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 23.3 mtt180 -65.0 -46.19 82.45 Favored 'General case' 0 N--CA 1.453 -0.301 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.21 -179.572 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -51.1 -73.57 0.37 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.557 -0.83 . . . . 0.0 112.641 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . 0.572 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 170.54 -20.11 0.07 OUTLIER Glycine 0 CA--C 1.518 0.271 0 C-N-CA 121.032 -0.604 . . . . 0.0 112.662 -179.773 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.813 HG12 HD11 ' A' ' 107' ' ' LEU . 0.9 OUTLIER -37.59 114.92 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.323 0 CA-C-O 120.937 0.399 . . . . 0.0 111.652 -179.819 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -117.46 100.95 8.0 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.577 179.799 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 120' ' ' VAL . . . . . 0.621 ' O ' HG13 ' A' ' 120' ' ' VAL . 10.1 p -48.11 101.76 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 121.057 0.456 . . . . 0.0 111.106 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 133.38 -10.19 5.01 Favored Glycine 0 N--CA 1.451 -0.36 0 CA-C-N 115.831 -0.622 . . . . 0.0 112.231 -179.318 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . 0.421 ' O ' HG23 ' A' ' 103' ' ' ILE . 35.7 m170 -86.1 -161.62 0.66 Allowed 'General case' 0 C--N 1.331 -0.231 0 N-CA-C 110.322 -0.251 . . . . 0.0 110.322 179.802 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . 0.749 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 10.1 ttm-85 -139.35 90.4 2.41 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.679 0.276 . . . . 0.0 110.802 -179.866 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . 0.581 ' CG1' HG22 ' A' ' 155' ' ' THR . 15.4 mt -55.99 157.13 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.251 179.225 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 125' ' ' ILE . . . . . 0.853 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.7 OUTLIER -151.54 -84.51 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.451 -0.383 0 N-CA-C 112.374 0.509 . . . . 0.0 112.374 -179.538 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . 0.42 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 13.5 mt-10 -79.99 88.24 5.36 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 112.498 0.555 . . . . 0.0 112.498 -178.793 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.878 HG23 ' HB3' ' A' ' 153' ' ' MET . 1.3 mt -92.44 103.05 14.22 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.185 0 CA-C-O 121.101 0.477 . . . . 0.0 111.344 179.281 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . 0.496 ' ND2' HG22 ' A' ' 127' ' ' ILE . 20.2 m-80 59.84 18.64 7.57 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.857 -0.61 . . . . 0.0 111.369 179.847 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 116.6 -17.18 13.88 Favored Glycine 0 C--N 1.333 0.372 0 C-N-CA 120.517 -0.849 . . . . 0.0 113.179 179.627 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 130' ' ' GLN . . . . . 0.556 HE22 HD13 ' A' ' 143' ' ' ILE . 1.2 pt20 -97.88 119.56 36.71 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 117.029 0.414 . . . . 0.0 110.963 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 2.5 m -79.06 93.15 5.09 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.119 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . 0.698 HG21 HD11 ' A' ' 127' ' ' ILE . 27.2 m -72.56 -5.38 6.22 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.298 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.978 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.853 ' HB ' HG22 ' A' ' 125' ' ' ILE . 8.3 p -45.36 -38.46 2.22 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.135 0 CA-C-O 120.818 0.342 . . . . 0.0 111.487 -179.807 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -120.08 28.22 8.2 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.748 179.465 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . 0.416 ' CG2' ' HD2' ' A' ' 136' ' ' PRO . 36.0 m -110.73 143.15 27.63 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.181 -179.929 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 136' ' ' PRO . . . . . 0.416 ' HD2' ' CG2' ' A' ' 135' ' ' THR . 50.1 Cg_exo -53.41 164.21 2.14 Favored 'Trans proline' 0 C--N 1.347 0.456 0 C-N-CA 122.526 2.151 . . . . 0.0 112.119 179.704 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 137' ' ' HIS . . . . . 0.522 ' HA ' HD12 ' A' ' 140' ' ' ILE . 9.3 p80 -74.05 -46.95 40.04 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.224 -179.798 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -54.16 -35.14 61.95 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.173 -179.786 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 139' ' ' LYS . . . . . 0.764 ' O ' HD12 ' A' ' 143' ' ' ILE . 0.0 OUTLIER -65.96 -48.87 69.86 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.943 -179.931 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . 0.829 HG21 HG21 ' A' ' 99' ' ' VAL . 8.7 mt -59.47 -46.41 92.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 121.033 0.444 . . . . 0.0 110.319 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . 0.411 HG23 ' CG1' ' A' ' 99' ' ' VAL . 55.6 t -59.54 -32.53 49.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 115.711 -0.677 . . . . 0.0 109.93 179.074 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -61.47 -54.22 46.27 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.009 -0.542 . . . . 0.0 110.835 179.808 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . 0.764 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.3 mp -53.39 -57.86 4.23 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.424 0 CA-C-O 121.015 0.436 . . . . 0.0 110.135 179.487 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.866 HD13 ' CD2' ' A' ' 95' ' ' LEU . 15.1 mt -60.39 -30.14 69.4 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.408 179.402 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 23.4 t -69.38 -28.55 66.28 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.219 -0.446 . . . . 0.0 109.934 178.811 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 4.9 m-80 -128.17 34.48 4.57 Favored 'General case' 0 C--N 1.333 -0.112 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.908 179.666 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 147' ' ' ALA . . . . . 0.844 ' CB ' HD11 ' A' ' 151' ' ' ILE . . . -103.62 79.21 1.65 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.207 -179.929 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.507 HG13 ' CD2' ' A' ' 91' ' ' LEU . 5.7 m -77.32 146.18 8.92 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.338 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.149 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 105.43 -104.68 2.35 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.525 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 53.4 mt-10 -145.58 114.73 7.03 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.79 0.328 . . . . 0.0 110.847 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . 0.844 HD11 ' CB ' ' A' ' 147' ' ' ALA . 1.8 mp -81.93 128.13 39.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 121.047 0.451 . . . . 0.0 110.628 179.854 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . 0.414 ' CD2' ' HA ' ' A' ' 128' ' ' ASN . 21.6 p-80 -125.47 115.77 20.77 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.361 179.819 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 153' ' ' MET . . . . . 0.878 ' HB3' HG23 ' A' ' 127' ' ' ILE . 0.0 OUTLIER -141.21 174.99 10.01 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.164 0.507 . . . . 0.0 111.619 -179.379 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -121.41 147.83 45.2 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.589 -0.732 . . . . 0.0 109.912 179.22 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . 0.581 HG22 ' CG1' ' A' ' 124' ' ' ILE . 12.1 p -140.7 140.49 34.92 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.04 0.448 . . . . 0.0 111.175 -179.665 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 156' ' ' MET . . . . . 0.459 ' O ' ' N ' ' A' ' 123' ' ' ARG . 0.0 OUTLIER -108.7 178.86 0.95 Allowed Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 115.791 -0.64 . . . . 0.0 110.56 179.854 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 157' ' ' PRO . . . . . 0.413 ' CD ' ' CB ' ' A' ' 156' ' ' MET . 94.6 Cg_endo -89.85 111.01 0.46 Allowed 'Trans proline' 0 N--CA 1.458 -0.559 0 C-N-CA 122.532 2.154 . . . . 0.0 112.504 -179.776 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 158' ' ' ALA . . . . . 0.749 ' HB2' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.283 -0.865 . . . . 0.0 110.962 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 10.2 p . . . . . 0 C--O 1.231 0.112 0 CA-C-O 120.823 0.344 . . . . 0.0 111.015 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.9 m -126.52 140.99 52.03 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.984 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 6.6 m -99.86 111.18 23.51 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.147 179.272 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.918 HG11 HG23 ' A' ' 118' ' ' VAL . 47.2 t -82.66 108.57 15.64 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 CA-C-N 116.015 -0.539 . . . . 0.0 112.268 -179.112 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 6.7 tt -103.12 85.01 2.43 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.876 -0.602 . . . . 0.0 109.436 178.345 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.821 HG21 ' CD2' ' A' ' 95' ' ' LEU . 5.6 mt -82.81 118.81 31.17 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.251 0 CA-C-O 121.293 0.568 . . . . 0.0 111.893 -178.715 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.446 ' HB2' HG21 ' A' ' 112' ' ' ILE . 0.2 OUTLIER -73.13 153.06 40.92 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.089 -0.959 . . . . 0.0 109.99 179.21 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.438 ' HD2' HD11 ' A' ' 95' ' ' LEU . 0.0 OUTLIER -152.92 124.32 3.68 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 120.618 0.247 . . . . 0.0 111.11 -179.979 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 92.0 Cg_endo -83.47 -42.45 0.08 OUTLIER 'Trans proline' 0 C--N 1.347 0.465 0 C-N-CA 122.613 2.209 . . . . 0.0 112.584 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 57.4 p30 -156.78 -167.54 2.4 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.203 -179.781 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 7.3 mt -96.19 30.87 2.33 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.43 -179.519 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -138.9 32.06 2.21 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.886 0.374 . . . . 0.0 110.982 179.914 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 2.1 m-85 -136.84 104.06 5.37 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.832 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 3.0 mp0 -65.51 145.07 56.56 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.03 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 0.821 ' CD2' HG21 ' A' ' 86' ' ' ILE . 8.3 mp -78.49 -24.62 45.77 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.94 179.93 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 72.27 68.81 1.51 Allowed Glycine 0 C--N 1.331 0.257 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.868 179.709 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . 0.763 ' CZ ' HD12 ' A' ' 144' ' ' LEU . 1.8 p90 -161.37 -171.83 3.15 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.918 0.39 . . . . 0.0 111.212 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.419 ' O ' ' HA ' ' A' ' 104' ' ' ILE . 1.2 t -149.67 126.24 10.95 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.408 179.71 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.654 HG21 HG21 ' A' ' 140' ' ' ILE . 11.8 p -111.97 140.16 32.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 121.163 0.506 . . . . 0.0 111.764 -179.284 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 3.6 mp0 -133.03 89.75 2.66 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.598 -0.728 . . . . 0.0 109.847 179.156 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 9.8 t-20 60.35 15.64 5.59 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.756 -178.921 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 127.31 -39.3 1.97 Allowed Glycine 0 N--CA 1.449 -0.474 0 C-N-CA 121.012 -0.613 . . . . 0.0 112.228 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.81 HG23 ' O ' ' A' ' 122' ' ' HIS . 31.5 mt -77.27 138.67 20.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 121.007 0.432 . . . . 0.0 111.575 -179.587 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.832 HD11 ' CD1' ' A' ' 124' ' ' ILE . 4.1 mp -96.36 138.25 22.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.991 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -108.0 -65.62 1.1 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.653 179.878 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 9.5 p -94.22 155.06 17.23 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.614 179.724 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.478 ' HB3' HG22 ' A' ' 120' ' ' VAL . 0.6 OUTLIER -163.92 121.71 1.81 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.942 -179.855 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 20.2 ttp -82.36 120.94 26.06 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.881 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -67.97 71.92 0.16 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.143 0.497 . . . . 0.0 110.602 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 175.36 -33.85 0.1 OUTLIER Glycine 0 N--CA 1.45 -0.39 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.966 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . 0.429 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -55.26 176.33 0.6 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.781 -0.724 . . . . 0.0 112.275 179.788 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.446 HG21 ' HB2' ' A' ' 87' ' ' ARG . 1.1 mp -78.7 -18.57 13.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 N-CA-C 111.848 0.314 . . . . 0.0 111.848 -179.734 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 113' ' ' ALA . . . . . . . . . . . . . . . -58.01 -30.54 66.19 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.895 0.378 . . . . 0.0 110.757 179.855 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 114' ' ' GLU . . . . . 0.429 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 13.2 pt-20 -61.64 -47.42 85.48 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.871 179.8 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 43.4 mtm180 -62.27 -41.98 98.93 Favored 'General case' 0 N--CA 1.453 -0.31 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.832 -179.631 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -53.79 -73.83 0.37 Allowed Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.296 -0.954 . . . . 0.0 112.394 179.854 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . 0.55 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 164.57 -18.13 0.11 Allowed Glycine 0 CA--C 1.523 0.538 0 C-N-CA 121.249 -0.5 . . . . 0.0 112.74 -179.889 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.918 HG23 HG11 ' A' ' 84' ' ' VAL . 2.0 t -29.58 -64.26 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 C-N-CA 123.212 0.605 . . . . 0.0 112.569 -179.54 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.576 ' N ' HG12 ' A' ' 118' ' ' VAL . 30.0 mmt180 61.71 178.7 0.12 Allowed 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.303 -0.408 . . . . 0.0 109.941 -178.872 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 120' ' ' VAL . . . . . 0.478 HG22 ' HB3' ' A' ' 107' ' ' LEU . 11.8 t -111.18 101.12 12.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-O 120.917 0.389 . . . . 0.0 111.341 -179.86 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 126.17 42.34 0.3 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.894 -0.669 . . . . 0.0 112.417 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . 0.81 ' O ' HG23 ' A' ' 103' ' ' ILE . 15.3 m170 -129.87 -171.52 2.54 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.767 0.317 . . . . 0.0 110.963 -179.822 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . 0.799 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 5.7 ttm-85 -142.08 89.39 2.17 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.874 -179.756 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . 0.832 ' CD1' HD11 ' A' ' 104' ' ' ILE . 14.6 mt -51.67 142.5 4.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.547 -0.297 . . . . 0.0 110.285 179.375 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 125' ' ' ILE . . . . . 0.859 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.6 OUTLIER -137.18 -84.46 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 N-CA-C 112.668 0.618 . . . . 0.0 112.668 -179.05 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . 0.421 ' CD ' HD12 ' A' ' 125' ' ' ILE . 1.0 OUTLIER -80.52 83.73 6.26 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 112.421 0.526 . . . . 0.0 112.421 -178.538 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.862 HG23 ' HB3' ' A' ' 153' ' ' MET . 1.9 mt -86.26 104.37 13.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 120.97 0.414 . . . . 0.0 111.175 179.086 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 11.3 m-20 56.15 23.05 6.56 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.777 -0.647 . . . . 0.0 111.402 179.804 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 112.68 -14.21 24.71 Favored Glycine 0 C--N 1.332 0.318 0 C-N-CA 120.554 -0.831 . . . . 0.0 112.961 179.746 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 130' ' ' GLN . . . . . 0.4 ' O ' ' CG ' ' A' ' 130' ' ' GLN . 5.0 pt20 -96.16 122.07 38.61 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.742 0.306 . . . . 0.0 110.484 -179.888 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 21.3 p -83.75 90.02 7.26 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.892 0.377 . . . . 0.0 110.826 179.921 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . 0.624 HG21 HD11 ' A' ' 127' ' ' ILE . 35.0 m -72.69 -3.81 4.45 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.351 0 CA-C-N 116.013 -0.54 . . . . 0.0 112.04 -179.845 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.859 ' HB ' HG22 ' A' ' 125' ' ' ILE . 7.9 p -47.27 -35.13 3.41 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.158 0 CA-C-O 120.894 0.378 . . . . 0.0 111.228 -179.889 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -121.01 27.84 8.24 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.684 179.4 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . 0.419 HG23 ' HD2' ' A' ' 136' ' ' PRO . 25.8 m -114.08 140.64 25.16 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 115.664 -0.698 . . . . 0.0 111.02 -179.8 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 136' ' ' PRO . . . . . 0.419 ' HD2' HG23 ' A' ' 135' ' ' THR . 8.3 Cg_endo -50.11 163.97 0.52 Allowed 'Trans proline' 0 C--N 1.347 0.458 0 C-N-CA 122.676 2.251 . . . . 0.0 112.181 179.64 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 137' ' ' HIS . . . . . 0.404 ' CD2' ' N ' ' A' ' 138' ' ' GLU . 22.9 p-80 -74.45 -41.85 60.11 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.284 -0.417 . . . . 0.0 111.439 -179.642 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . 0.404 ' N ' ' CD2' ' A' ' 137' ' ' HIS . 53.8 mt-10 -54.15 -38.04 65.06 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.753 0.311 . . . . 0.0 111.42 -179.516 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 139' ' ' LYS . . . . . 0.76 ' O ' HD12 ' A' ' 143' ' ' ILE . 6.9 tttp -64.67 -48.86 73.2 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.11 -179.728 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . 0.654 HG21 HG21 ' A' ' 99' ' ' VAL . 13.8 mt -59.26 -43.27 89.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.624 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . 0.574 HG22 HG12 ' A' ' 99' ' ' VAL . 86.6 t -62.29 -33.13 57.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.389 179.291 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -61.93 -56.46 18.98 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.07 -0.514 . . . . 0.0 111.104 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . 0.76 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.3 mp -52.9 -57.17 4.92 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.49 0 CA-C-O 121.095 0.474 . . . . 0.0 110.192 179.559 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.763 HD12 ' CZ ' ' A' ' 97' ' ' PHE . 6.3 mt -59.83 -29.91 68.58 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.575 179.409 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 14.0 t -73.18 -28.25 62.1 Favored 'General case' 0 N--CA 1.456 -0.141 0 CA-C-N 116.361 -0.382 . . . . 0.0 110.219 178.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 3.1 m-80 -125.11 31.58 5.58 Favored 'General case' 0 C--O 1.232 0.152 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.189 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 147' ' ' ALA . . . . . 0.784 ' CB ' HD11 ' A' ' 151' ' ' ILE . . . -107.02 97.06 6.88 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.243 179.942 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 6.3 m -79.96 179.86 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.357 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.983 -179.744 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 67.94 -116.04 7.38 Favored Glycine 0 N--CA 1.453 -0.223 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.599 179.924 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.403 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 11.5 mt-10 -134.97 110.7 9.27 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.606 0.241 . . . . 0.0 110.984 -179.815 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . 0.784 HD11 ' CB ' ' A' ' 147' ' ' ALA . 1.7 mp -68.16 124.02 22.77 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-O 120.915 0.388 . . . . 0.0 110.778 179.776 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -113.51 115.56 28.18 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.801 -0.636 . . . . 0.0 109.964 179.192 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 153' ' ' MET . . . . . 0.862 ' HB3' HG23 ' A' ' 127' ' ' ILE . 1.4 ptt? -147.2 164.77 32.1 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.217 0.532 . . . . 0.0 111.732 -178.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 2.2 mttm -110.9 152.33 26.86 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.524 -0.762 . . . . 0.0 109.851 179.182 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 37.4 p -136.88 142.59 42.78 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.163 0.506 . . . . 0.0 111.604 -179.547 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 156' ' ' MET . . . . . 0.504 ' O ' ' N ' ' A' ' 123' ' ' ARG . 0.0 OUTLIER -111.82 179.0 0.86 Allowed Pre-proline 0 C--N 1.327 -0.392 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.39 179.755 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 157' ' ' PRO . . . . . 0.412 ' CD ' ' CB ' ' A' ' 156' ' ' MET . 80.2 Cg_endo -92.96 103.41 0.17 Allowed 'Trans proline' 0 N--CA 1.456 -0.688 0 C-N-CA 122.786 2.324 . . . . 0.0 112.543 -179.752 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 158' ' ' ALA . . . . . 0.799 ' HB2' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.25 1.085 0 CA-C-O 118.169 -0.92 . . . . 0.0 111.09 179.788 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.561 HG13 ' O ' ' A' ' 155' ' ' THR . 47.0 t . . . . . 0 C--O 1.231 0.101 0 CA-C-O 120.854 0.359 . . . . 0.0 111.04 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.7 m -118.61 134.25 55.25 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.848 179.849 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 6.9 m -95.25 111.52 23.36 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.178 179.324 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.759 HG12 HG13 ' A' ' 86' ' ' ILE . 58.3 t -82.56 105.73 12.7 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.547 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.742 -179.33 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.45 ' CD1' ' CD2' ' A' ' 152' ' ' HIS . 4.6 tp -107.73 80.1 1.35 Allowed 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 178.348 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.759 HG13 HG12 ' A' ' 84' ' ' VAL . 1.2 mt -81.67 130.95 34.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 121.173 0.511 . . . . 0.0 111.729 -178.272 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.431 ' H ' HG22 ' A' ' 112' ' ' ILE . 0.0 OUTLIER -84.19 142.87 30.0 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.443 -0.799 . . . . 0.0 110.256 179.929 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 3.7 ttt180 -144.88 114.16 5.01 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.964 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -75.32 -45.24 0.27 Allowed 'Trans proline' 0 C--N 1.347 0.466 0 C-N-CA 122.463 2.109 . . . . 0.0 112.616 -179.895 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -135.1 -173.97 3.47 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.196 -179.753 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 0.456 ' HG ' HG13 ' A' ' 148' ' ' VAL . 0.8 OUTLIER -86.96 -34.04 19.44 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.976 -179.928 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 3.2 ptm180 -73.07 -7.97 53.65 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.608 -179.842 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 10.9 m-85 -85.08 128.57 34.7 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.797 0.332 . . . . 0.0 110.876 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 4.0 mp0 -89.51 160.49 16.7 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.899 -179.895 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 0.797 ' CD1' HD13 ' A' ' 144' ' ' LEU . 59.3 mt -81.42 -69.21 0.63 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.903 179.917 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 135.9 40.96 0.13 Allowed Glycine 0 CA--C 1.518 0.277 0 C-N-CA 120.484 -0.865 . . . . 0.0 113.192 179.631 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . 0.455 ' CE1' HG21 ' A' ' 118' ' ' VAL . 33.1 p90 -175.12 174.67 2.4 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.879 0.371 . . . . 0.0 111.09 179.62 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -124.74 143.86 50.55 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.961 -179.814 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.673 HG21 HG21 ' A' ' 140' ' ' ILE . 10.6 p -111.54 139.48 35.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.026 179.907 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' GLN . . . . . 0.413 ' O ' ' N ' ' A' ' 102' ' ' GLY . 0.5 OUTLIER -130.53 89.01 2.71 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.806 179.758 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' ASN . . . . . 0.65 ' O ' HD11 ' A' ' 140' ' ' ILE . 7.3 m-80 64.34 -68.19 0.1 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.903 -0.59 . . . . 0.0 111.51 179.569 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . 0.432 ' O ' HD13 ' A' ' 103' ' ' ILE . . . -143.83 1.1 1.27 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.238 -0.982 . . . . 0.0 113.414 -179.731 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.732 HD12 ' CB ' ' A' ' 158' ' ' ALA . 44.2 mm -126.46 155.08 36.64 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 117.232 0.516 . . . . 0.0 111.209 -179.886 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.658 ' N ' HD12 ' A' ' 104' ' ' ILE . 3.2 mp -97.26 145.11 9.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.735 179.817 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 1.6 m -106.46 -79.48 0.57 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.171 -179.704 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 1.5 m -90.91 168.83 11.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.375 -0.375 . . . . 0.0 111.141 -179.7 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.586 HD23 HG23 ' A' ' 120' ' ' VAL . 62.1 tp -174.16 101.86 0.1 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.698 179.897 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 8.0 mtp -73.93 122.05 21.94 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.081 -179.819 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.03 78.2 0.09 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.692 179.775 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 174.25 -33.62 0.11 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.986 -0.626 . . . . 0.0 112.04 -179.837 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . 0.413 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -57.46 174.62 2.0 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.142 179.741 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.431 HG22 ' H ' ' A' ' 87' ' ' ARG . 0.9 OUTLIER -78.5 -17.46 13.59 Favored 'Isoleucine or valine' 0 C--O 1.236 0.36 0 CA-C-O 120.829 0.347 . . . . 0.0 111.522 -179.845 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 113' ' ' ALA . . . . . 0.534 ' HB1' HG21 ' A' ' 118' ' ' VAL . . . -58.11 -30.62 66.43 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.911 0.386 . . . . 0.0 110.703 179.863 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 114' ' ' GLU . . . . . 0.413 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 17.4 pt-20 -60.48 -47.21 87.15 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.969 -0.559 . . . . 0.0 110.766 179.634 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 2.4 mmt85 -62.32 -44.78 95.71 Favored 'General case' 0 N--CA 1.452 -0.337 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.892 -179.556 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -53.25 -74.01 0.35 Allowed Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.245 -0.979 . . . . 0.0 112.519 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . 0.56 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 172.45 -24.94 0.08 OUTLIER Glycine 0 CA--C 1.518 0.249 0 C-N-CA 121.065 -0.588 . . . . 0.0 112.701 -179.951 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.718 ' N ' HG22 ' A' ' 84' ' ' VAL . 18.0 t -15.11 -83.31 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.627 0 C-N-CA 123.235 0.614 . . . . 0.0 112.489 -179.835 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.651 ' N ' HG12 ' A' ' 118' ' ' VAL . 0.0 OUTLIER 62.56 143.19 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.725 -179.649 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 120' ' ' VAL . . . . . 0.586 HG23 HD23 ' A' ' 107' ' ' LEU . 11.4 t -81.97 132.06 32.37 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 116.439 -0.346 . . . . 0.0 111.198 -179.704 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 101.63 24.63 8.6 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.886 -0.673 . . . . 0.0 112.57 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 10.4 m170 -112.72 -174.42 2.45 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.656 0.265 . . . . 0.0 110.706 179.869 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . 0.714 ' CD ' HD11 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -140.58 90.14 2.33 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.819 -179.783 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . 0.62 ' O ' HG23 ' A' ' 125' ' ' ILE . 5.9 mt -50.82 154.95 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.811 179.484 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 125' ' ' ILE . . . . . 0.844 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.8 OUTLIER -157.79 -86.66 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 N-CA-C 112.481 0.549 . . . . 0.0 112.481 -179.88 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . 0.428 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 15.6 mt-10 -81.82 92.79 6.74 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 112.321 0.489 . . . . 0.0 112.321 -178.637 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.922 HD11 HG21 ' A' ' 132' ' ' VAL . 1.5 mt -91.3 99.16 9.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.126 179.297 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 52.8 m-20 63.96 15.92 9.52 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.451 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 121.19 -18.94 8.82 Favored Glycine 0 C--N 1.332 0.31 0 C-N-CA 120.452 -0.88 . . . . 0.0 113.117 179.629 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 1.8 pt20 -98.63 117.1 32.32 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.93 0.395 . . . . 0.0 110.948 -179.916 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 1.4 m -77.18 93.41 3.93 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.182 -179.787 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . 0.922 HG21 HD11 ' A' ' 127' ' ' ILE . 35.6 m -77.08 0.31 2.64 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.324 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.801 179.67 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.844 ' HB ' HG22 ' A' ' 125' ' ' ILE . 8.5 p -46.82 -40.23 4.72 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.14 0 CA-C-O 120.805 0.336 . . . . 0.0 111.261 -179.826 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -113.13 29.54 7.9 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.687 179.452 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . 0.549 HG23 ' HD2' ' A' ' 136' ' ' PRO . 91.0 m -116.97 143.03 30.8 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.852 -179.805 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 136' ' ' PRO . . . . . 0.549 ' HD2' HG23 ' A' ' 135' ' ' THR . 6.1 Cg_endo -47.92 164.09 0.18 Allowed 'Trans proline' 0 C--N 1.347 0.451 0 C-N-CA 122.805 2.337 . . . . 0.0 112.281 179.795 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 45.1 p-80 -76.11 -44.55 38.02 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.301 -179.606 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -54.08 -33.53 57.79 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.362 -179.607 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 139' ' ' LYS . . . . . 0.823 ' O ' HD12 ' A' ' 143' ' ' ILE . 0.0 OUTLIER -66.41 -50.12 64.49 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.873 0.368 . . . . 0.0 111.033 -179.923 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . 0.786 HG23 ' CD1' ' A' ' 127' ' ' ILE . 8.5 mt -59.1 -46.18 92.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.421 179.827 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . 0.567 HG22 HG12 ' A' ' 99' ' ' VAL . 69.0 t -59.86 -32.38 49.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.906 -0.588 . . . . 0.0 109.885 178.73 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 2.1 t-160 -60.57 -52.97 62.89 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.492 179.604 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . 0.823 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.5 mp -53.29 -57.78 4.28 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.394 0 CA-C-O 121.035 0.445 . . . . 0.0 110.108 179.202 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.797 HD13 ' CD1' ' A' ' 95' ' ' LEU . 9.7 mt -60.05 -30.19 69.04 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.627 -0.715 . . . . 0.0 110.231 179.389 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 38.9 t -70.81 -27.79 64.15 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.075 -0.511 . . . . 0.0 109.878 178.745 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 2.8 m-80 -124.85 31.47 5.65 Favored 'General case' 0 C--O 1.232 0.151 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.83 179.799 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 147' ' ' ALA . . . . . 0.784 ' CB ' HD11 ' A' ' 151' ' ' ILE . . . -113.14 101.06 9.08 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.952 179.789 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.456 HG13 ' HG ' ' A' ' 91' ' ' LEU . 3.4 m -101.59 158.62 4.24 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.433 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.321 -179.79 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 95.0 -95.89 1.94 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.564 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 14.4 mt-10 -146.81 104.93 3.76 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.716 0.294 . . . . 0.0 110.715 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . 0.784 HD11 ' CB ' ' A' ' 147' ' ' ALA . 1.5 mp -72.41 117.52 16.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 121.149 0.5 . . . . 0.0 111.204 -179.756 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . 0.45 ' CD2' ' CD1' ' A' ' 85' ' ' LEU . 0.2 OUTLIER -101.37 121.84 42.64 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.585 -0.734 . . . . 0.0 109.295 178.724 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 153' ' ' MET . . . . . 0.8 ' HB2' HG23 ' A' ' 127' ' ' ILE . 8.6 tmm? -153.41 155.16 35.84 Favored 'General case' 0 C--N 1.327 -0.385 0 C-N-CA 120.754 -0.378 . . . . 0.0 111.678 -178.436 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 154' ' ' LYS . . . . . 0.41 ' CG ' ' CG1' ' A' ' 81' ' ' VAL . 0.0 OUTLIER -109.23 152.27 25.41 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.605 179.893 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . 0.561 ' O ' HG13 ' A' ' 81' ' ' VAL . 30.3 p -142.13 150.05 40.61 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 121.159 0.504 . . . . 0.0 111.644 -179.919 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 156' ' ' MET . . . . . 0.503 ' O ' ' N ' ' A' ' 123' ' ' ARG . 10.7 mmm -115.82 178.93 0.87 Allowed Pre-proline 0 C--N 1.328 -0.369 0 CA-C-N 115.556 -0.747 . . . . 0.0 110.302 179.413 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 157' ' ' PRO . . . . . 0.443 ' CD ' ' HB3' ' A' ' 156' ' ' MET . 88.5 Cg_endo -91.33 114.82 0.4 Allowed 'Trans proline' 0 N--CA 1.457 -0.632 0 C-N-CA 122.61 2.207 . . . . 0.0 112.546 -179.685 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 158' ' ' ALA . . . . . 0.732 ' CB ' HD12 ' A' ' 103' ' ' ILE . . . . . . . . 0 C--O 1.249 1.035 0 CA-C-O 118.285 -0.864 . . . . 0.0 111.071 179.727 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.588 HG13 ' CE ' ' A' ' 156' ' ' MET . 56.5 t . . . . . 0 C--O 1.231 0.129 0 CA-C-O 120.759 0.314 . . . . 0.0 110.884 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . 0.429 HG21 ' O ' ' A' ' 117' ' ' GLY . 1.8 m -120.5 143.01 48.78 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.868 179.75 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 35.9 m -107.09 111.33 23.73 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.267 179.289 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.668 HG12 ' CD1' ' A' ' 86' ' ' ILE . 53.6 t -86.21 106.33 15.49 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.423 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.107 -179.759 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.413 ' O ' ' HA2' ' A' ' 116' ' ' GLY . 1.4 tt -110.09 81.93 1.51 Allowed 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.157 -0.474 . . . . 0.0 109.729 179.107 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.668 ' CD1' HG12 ' A' ' 84' ' ' VAL . 1.8 mp -81.83 134.17 27.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 121.106 0.479 . . . . 0.0 111.732 -178.965 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.51 ' O ' HG21 ' A' ' 112' ' ' ILE . 0.0 OUTLIER -91.36 108.69 20.06 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.99 179.813 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.537 ' HE ' HD13 ' A' ' 112' ' ' ILE . 1.0 OUTLIER -113.14 87.11 10.24 Favored Pre-proline 0 C--N 1.328 -0.365 0 CA-C-O 120.878 0.371 . . . . 0.0 111.676 -179.209 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' PRO . . . . . 0.405 ' HD2' ' NH2' ' A' ' 88' ' ' ARG . 96.4 Cg_endo -78.96 1.91 8.73 Favored 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.598 2.199 . . . . 0.0 112.952 179.776 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . 0.783 ' O ' HG12 ' A' ' 148' ' ' VAL . 1.0 OUTLIER -154.5 -162.29 1.37 Allowed 'General case' 0 C--N 1.332 -0.17 0 CA-C-O 120.743 0.306 . . . . 0.0 111.36 -179.884 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 0.609 HD12 HG11 ' A' ' 148' ' ' VAL . 0.1 OUTLIER -128.18 -40.58 1.64 Allowed 'General case' 0 C--N 1.332 -0.153 0 CA-C-O 120.925 0.393 . . . . 0.0 111.389 -179.622 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -53.44 -23.3 9.6 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.536 -179.524 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . 0.463 ' HB2' ' NH2' ' A' ' 88' ' ' ARG . 77.4 m-85 -95.65 148.89 22.06 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.828 179.824 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -97.03 175.6 6.26 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.155 -179.842 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 0.613 ' HG ' HD13 ' A' ' 144' ' ' LEU . 2.7 mm? -72.49 -51.68 19.06 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.661 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 121.74 31.74 1.09 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.9 179.784 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 47.8 p90 -175.55 145.14 0.71 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.832 0.349 . . . . 0.0 111.058 179.818 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.432 ' O ' ' HA ' ' A' ' 104' ' ' ILE . 14.8 m -91.76 148.44 22.24 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.747 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.78 HG21 HG21 ' A' ' 140' ' ' ILE . 5.1 p -118.82 137.02 54.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.366 -179.686 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -129.89 89.85 2.88 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.866 -0.607 . . . . 0.0 109.959 179.424 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 63.9 t30 60.6 17.38 7.39 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.627 -179.038 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . 0.411 ' HA2' ' HB ' ' A' ' 124' ' ' ILE . . . 124.58 -39.31 2.15 Favored Glycine 0 N--CA 1.448 -0.566 0 C-N-CA 120.957 -0.639 . . . . 0.0 112.031 -179.808 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.483 HG12 ' HB2' ' A' ' 158' ' ' ALA . 23.2 mt -78.35 131.41 34.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-O 120.989 0.423 . . . . 0.0 111.432 -179.693 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.766 HD11 ' CD1' ' A' ' 124' ' ' ILE . 3.6 mp -85.54 139.34 17.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.841 179.743 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 12.0 t -94.97 -67.35 0.86 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.047 -179.648 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 3.3 m -112.64 146.92 37.8 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.79 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.889 HD11 HG13 ' A' ' 118' ' ' VAL . 0.5 OUTLIER -133.24 100.89 4.99 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.662 179.979 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 2.7 tmm? -60.01 141.34 55.82 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.907 -179.888 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -93.4 44.14 1.13 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.09 0.471 . . . . 0.0 110.703 179.798 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -162.78 23.98 0.2 Allowed Glycine 0 N--CA 1.45 -0.375 0 CA-C-N 115.691 -0.686 . . . . 0.0 112.282 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . 0.489 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -112.77 175.46 16.8 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.851 -0.69 . . . . 0.0 111.952 179.798 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.537 HD13 ' HE ' ' A' ' 88' ' ' ARG . 0.5 OUTLIER -79.27 -23.55 12.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-O 120.933 0.397 . . . . 0.0 111.578 -179.772 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 113' ' ' ALA . . . . . 0.529 ' O ' HG12 ' A' ' 118' ' ' VAL . . . -57.92 -30.41 65.91 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.968 0.413 . . . . 0.0 110.604 -179.93 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 114' ' ' GLU . . . . . 0.489 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 8.6 pt-20 -59.92 -45.2 93.33 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.722 179.467 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 88.5 mtt180 -64.78 -46.26 82.83 Favored 'General case' 0 N--CA 1.452 -0.358 0 CA-C-N 115.96 -0.564 . . . . 0.0 111.087 -179.441 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.413 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -49.75 -74.65 0.25 Allowed Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.413 -0.899 . . . . 0.0 112.591 179.918 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . 0.429 ' O ' HG21 ' A' ' 82' ' ' THR . . . 175.21 -16.49 0.04 OUTLIER Glycine 0 CA--C 1.52 0.386 0 C-N-CA 120.77 -0.729 . . . . 0.0 113.112 179.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.889 HG13 HD11 ' A' ' 107' ' ' LEU . 5.0 p -34.13 148.8 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 N-CA-C 112.156 0.428 . . . . 0.0 112.156 -179.659 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 1.1 ttp85 -151.83 113.01 4.28 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.823 179.907 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 120' ' ' VAL . . . . . 0.55 ' O ' HG13 ' A' ' 120' ' ' VAL . 14.9 p -52.48 114.89 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.316 -179.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 113.5 19.12 6.74 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.433 -179.809 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 3.2 m170 -120.86 139.79 52.69 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.803 0.335 . . . . 0.0 110.773 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . 0.673 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 10.7 ttt180 -83.65 90.65 7.31 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.384 -179.673 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . 0.784 HG23 ' SD ' ' A' ' 153' ' ' MET . 71.4 mt -48.75 134.33 6.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 178.784 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 125' ' ' ILE . . . . . 0.867 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.8 OUTLIER -128.29 -84.46 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 N-CA-C 113.175 0.806 . . . . 0.0 113.175 -178.398 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . 0.435 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 4.3 mt-10 -80.88 92.16 6.08 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 112.922 0.712 . . . . 0.0 112.922 -178.236 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.702 HG23 ' HB2' ' A' ' 153' ' ' MET . 1.3 mt -94.34 94.87 4.74 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.668 178.722 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . 0.454 ' N ' ' O ' ' A' ' 152' ' ' HIS . 55.5 m-80 62.3 26.35 15.77 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.882 -179.813 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 108.91 -19.37 30.44 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.733 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 5.5 tt0 -90.77 110.39 21.59 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.785 0.326 . . . . 0.0 110.878 179.903 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 1.4 m -76.2 93.32 3.36 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.077 -179.822 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . 0.635 HG21 HD11 ' A' ' 127' ' ' ILE . 25.9 m -73.48 -5.15 6.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.877 179.859 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.867 ' HB ' HG22 ' A' ' 125' ' ' ILE . 11.4 p -47.26 -36.65 4.1 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-O 120.857 0.361 . . . . 0.0 111.41 -179.713 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -117.28 28.65 8.35 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.628 179.501 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . 0.476 HG23 ' HD2' ' A' ' 136' ' ' PRO . 67.4 m -116.37 140.81 27.0 Favored Pre-proline 0 C--N 1.328 -0.363 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.343 -179.734 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 136' ' ' PRO . . . . . 0.476 ' HD2' HG23 ' A' ' 135' ' ' THR . 8.9 Cg_endo -50.99 164.36 0.63 Allowed 'Trans proline' 0 C--N 1.347 0.493 0 C-N-CA 122.759 2.306 . . . . 0.0 112.347 179.765 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 137' ' ' HIS . . . . . 0.405 ' CE1' ' HG3' ' A' ' 138' ' ' GLU . 20.9 p80 -70.91 -50.09 38.63 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.739 -179.42 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . 0.405 ' HG3' ' CE1' ' A' ' 137' ' ' HIS . 3.7 mt-10 -53.91 -33.79 57.66 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.607 -179.355 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 139' ' ' LYS . . . . . 0.745 ' O ' HD12 ' A' ' 143' ' ' ILE . 8.6 tptt -64.02 -48.05 77.86 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.369 -0.378 . . . . 0.0 111.098 -179.828 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . 0.78 HG21 HG21 ' A' ' 99' ' ' VAL . 13.9 mt -58.38 -46.15 89.38 Favored 'Isoleucine or valine' 0 C--O 1.235 0.318 0 CA-C-O 121.013 0.435 . . . . 0.0 110.669 -179.898 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . 0.535 HG22 HG12 ' A' ' 99' ' ' VAL . 58.9 t -60.05 -32.82 51.16 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.353 179.166 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 57.2 t-80 -62.77 -54.15 43.4 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.304 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . 0.745 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.2 mp -52.96 -57.21 4.9 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.451 0 CA-C-O 121.018 0.437 . . . . 0.0 110.375 179.647 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.613 HD13 ' HG ' ' A' ' 95' ' ' LEU . 1.4 mt -62.41 -30.04 70.93 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.55 -0.75 . . . . 0.0 110.381 179.581 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 3.4 m -66.63 -26.57 67.14 Favored 'General case' 0 N--CA 1.452 -0.347 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 178.448 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 4.3 m-80 -132.86 35.86 3.53 Favored 'General case' 0 CA--C 1.529 0.145 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.377 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 147' ' ' ALA . . . . . 0.638 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -118.06 52.59 1.0 Allowed 'General case' 0 C--N 1.332 -0.178 0 CA-C-O 120.776 0.322 . . . . 0.0 111.464 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.783 HG12 ' O ' ' A' ' 90' ' ' ASP . 15.6 m -53.5 -178.48 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 120.877 0.37 . . . . 0.0 111.035 179.91 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 83.96 -108.47 3.08 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.424 -179.834 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 20.2 mt-10 -138.27 101.6 4.43 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.878 0.37 . . . . 0.0 110.454 179.787 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . 0.638 HD11 ' HB3' ' A' ' 147' ' ' ALA . 1.1 mt -76.15 111.72 13.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 121.051 0.453 . . . . 0.0 111.487 -179.516 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . 0.454 ' O ' ' N ' ' A' ' 128' ' ' ASN . 0.2 OUTLIER -99.72 124.23 44.76 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 178.356 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 153' ' ' MET . . . . . 0.784 ' SD ' HG23 ' A' ' 124' ' ' ILE . 11.5 tmm? -150.68 155.08 38.63 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.139 0.495 . . . . 0.0 112.25 -177.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -113.45 148.17 36.43 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.59 -0.732 . . . . 0.0 109.669 178.977 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . 0.587 HG22 ' SD ' ' A' ' 153' ' ' MET . 16.3 p -130.7 141.02 50.39 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.28 0.562 . . . . 0.0 111.836 -179.266 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 156' ' ' MET . . . . . 0.59 ' HE3' HD11 ' A' ' 125' ' ' ILE . 0.0 OUTLIER -123.28 119.45 27.49 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 115.109 -0.951 . . . . 0.0 110.053 179.475 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 88.9 Cg_exo -42.24 110.63 0.16 Allowed 'Trans proline' 0 C--N 1.346 0.402 0 C-N-CA 122.56 2.173 . . . . 0.0 112.935 -179.756 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 158' ' ' ALA . . . . . 0.673 ' HB2' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.249 1.05 0 CA-C-O 118.23 -0.89 . . . . 0.0 111.043 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 12.5 p . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.795 0.331 . . . . 0.0 111.035 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 3.0 m -115.49 132.05 56.74 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.993 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 26.6 m -92.26 111.65 23.29 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.032 179.235 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.783 HG12 HG13 ' A' ' 86' ' ' ILE . 94.5 t -83.89 105.41 13.34 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.566 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.68 -179.093 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.443 HD23 ' C ' ' A' ' 85' ' ' LEU . 5.2 tt -105.2 80.07 1.56 Allowed 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 109.176 -0.676 . . . . 0.0 109.176 178.466 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.813 HG21 HD22 ' A' ' 95' ' ' LEU . 4.5 mt -82.04 125.33 39.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 121.236 0.541 . . . . 0.0 111.874 -178.354 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.465 ' HB2' HG21 ' A' ' 112' ' ' ILE . 0.1 OUTLIER -76.94 147.86 36.7 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.289 -0.869 . . . . 0.0 110.061 179.467 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 6.0 mtp85 -141.84 96.13 6.81 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 120.686 0.279 . . . . 0.0 111.089 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_exo -56.38 -60.28 0.51 Allowed 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 122.562 2.175 . . . . 0.0 112.447 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -127.5 -169.17 2.0 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 121.03 0.443 . . . . 0.0 111.033 -179.692 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -89.11 -43.16 11.26 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.988 -0.551 . . . . 0.0 111.04 -179.942 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 16.5 mtt-85 -64.81 -13.66 56.44 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.639 -179.689 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 24.1 m-85 -88.68 117.57 27.75 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.456 -0.338 . . . . 0.0 110.976 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -85.21 169.42 13.84 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.999 -179.918 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 0.813 HD22 HG21 ' A' ' 86' ' ' ILE . 76.9 mt -76.21 -69.4 0.51 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.779 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 128.23 54.13 0.12 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.457 -0.877 . . . . 0.0 113.1 179.531 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . 0.617 ' CE2' ' HB2' ' A' ' 113' ' ' ALA . 42.5 p90 -177.83 174.25 1.47 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.817 0.342 . . . . 0.0 111.053 179.635 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -116.52 150.3 38.17 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.866 179.869 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.625 HG21 HG21 ' A' ' 140' ' ' ILE . 9.3 p -125.6 136.36 61.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.314 -179.894 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' GLN . . . . . 0.409 ' HG3' ' HB ' ' A' ' 103' ' ' ILE . 1.6 pt20 -130.37 91.64 3.13 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.215 179.464 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER 60.74 13.83 4.64 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.175 -179.343 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 129.67 -38.4 2.0 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.872 -0.68 . . . . 0.0 112.366 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.848 HG23 ' O ' ' A' ' 122' ' ' HIS . 36.2 mt -77.13 136.86 23.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-O 121.105 0.479 . . . . 0.0 111.684 -179.559 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.726 HG12 HG13 ' A' ' 118' ' ' VAL . 4.0 mp -90.98 138.37 19.73 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.54 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 7.7 m -94.29 -84.28 0.32 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.509 -179.298 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 46.3 t -109.88 113.53 26.33 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.926 0.393 . . . . 0.0 111.203 -179.6 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.713 HD13 ' O ' ' A' ' 107' ' ' LEU . 1.4 tm? -105.74 110.06 22.23 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.45 179.645 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 9.0 ttp -58.08 116.84 3.79 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.024 -179.762 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 7.1 mtt85 -63.89 80.79 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.001 0.429 . . . . 0.0 110.671 179.789 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 166.74 -30.88 0.2 Allowed Glycine 0 N--CA 1.45 -0.399 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.894 -179.754 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . 0.441 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -59.1 176.18 2.7 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.131 179.625 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.465 HG21 ' HB2' ' A' ' 87' ' ' ARG . 1.2 mt -79.06 -19.53 12.88 Favored 'Isoleucine or valine' 0 C--O 1.236 0.343 0 CA-C-O 120.892 0.377 . . . . 0.0 111.729 -179.69 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 113' ' ' ALA . . . . . 0.617 ' HB2' ' CE2' ' A' ' 97' ' ' PHE . . . -57.77 -30.61 65.78 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.981 0.42 . . . . 0.0 110.74 179.909 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 114' ' ' GLU . . . . . 0.441 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 10.5 pt-20 -60.92 -46.46 90.59 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.746 179.703 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -62.23 -45.76 91.89 Favored 'General case' 0 N--CA 1.453 -0.304 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.946 -179.444 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.401 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -51.19 -74.35 0.3 Allowed Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.297 -0.954 . . . . 0.0 112.532 179.872 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . 0.562 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 174.29 -26.22 0.08 OUTLIER Glycine 0 CA--C 1.518 0.276 0 C-N-CA 121.116 -0.564 . . . . 0.0 112.61 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.736 ' N ' HG22 ' A' ' 84' ' ' VAL . 13.5 t -15.72 -81.98 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.471 0.594 0 C-N-CA 123.259 0.624 . . . . 0.0 112.632 -179.824 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.653 ' N ' HG12 ' A' ' 118' ' ' VAL . 0.8 OUTLIER 63.84 129.05 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.748 0.309 . . . . 0.0 110.454 -179.43 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 22.2 t -63.29 130.88 28.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.314 -179.799 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 97.41 34.22 5.65 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.685 179.756 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . 0.848 ' O ' HG23 ' A' ' 103' ' ' ILE . 5.1 m170 -122.65 -174.54 2.94 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.933 0.396 . . . . 0.0 110.878 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . 0.81 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 8.7 ttm-85 -144.23 89.43 2.02 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.87 -179.803 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . 0.653 HG13 HD11 ' A' ' 104' ' ' ILE . 78.3 mt -50.4 150.16 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 N-CA-C 110.208 -0.293 . . . . 0.0 110.208 179.246 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 125' ' ' ILE . . . . . 0.863 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.6 OUTLIER -146.07 -84.5 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 N-CA-C 112.87 0.693 . . . . 0.0 112.87 -178.892 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . 0.404 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 40.0 mt-10 -83.2 89.12 6.92 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 112.532 0.568 . . . . 0.0 112.532 -178.499 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.818 HG23 ' HB3' ' A' ' 153' ' ' MET . 1.8 mt -89.03 102.0 12.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.005 179.221 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 22.6 m-20 53.75 24.85 4.64 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.121 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 111.83 -16.51 25.76 Favored Glycine 0 CA--C 1.519 0.317 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.725 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -93.16 108.94 20.45 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.782 0.325 . . . . 0.0 110.889 -179.88 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 83.1 p -74.83 89.47 2.33 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.096 -179.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . 0.784 HG21 HD11 ' A' ' 127' ' ' ILE . 27.7 m -74.99 -4.08 5.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.832 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.863 ' HB ' HG22 ' A' ' 125' ' ' ILE . 12.1 p -46.37 -40.95 4.35 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-O 120.928 0.394 . . . . 0.0 111.343 -179.854 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 134' ' ' ALA . . . . . 0.411 ' N ' HG13 ' A' ' 133' ' ' VAL . . . -113.91 29.48 7.97 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.673 179.395 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . 0.464 HG23 ' HD2' ' A' ' 136' ' ' PRO . 84.0 m -114.04 143.26 29.32 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.047 -179.746 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 136' ' ' PRO . . . . . 0.464 ' HD2' HG23 ' A' ' 135' ' ' THR . 74.8 Cg_exo -49.72 156.97 2.73 Favored 'Trans proline' 0 C--N 1.347 0.494 0 C-N-CA 122.45 2.1 . . . . 0.0 112.245 179.851 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 137' ' ' HIS . . . . . 0.426 ' CE1' ' HG3' ' A' ' 138' ' ' GLU . 7.6 p80 -68.08 -46.47 70.93 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.266 -179.762 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . 0.426 ' HG3' ' CE1' ' A' ' 137' ' ' HIS . 18.1 mt-10 -55.56 -35.75 66.07 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.299 -179.791 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 139' ' ' LYS . . . . . 0.758 ' O ' HD12 ' A' ' 143' ' ' ILE . 5.4 tptt -62.78 -47.5 83.2 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.885 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . 0.625 HG21 HG21 ' A' ' 99' ' ' VAL . 16.4 mt -58.8 -43.04 87.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.584 179.951 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . 0.469 HG22 HG12 ' A' ' 99' ' ' VAL . 92.8 t -62.16 -32.72 55.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.177 179.051 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 2.0 t-80 -62.19 -54.48 40.36 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.907 179.901 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . 0.758 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.4 mp -53.09 -56.94 5.67 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.408 0 CA-C-O 121.207 0.527 . . . . 0.0 110.214 179.391 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.74 HD13 ' CD1' ' A' ' 95' ' ' LEU . 4.5 mt -60.94 -30.12 70.04 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.327 -0.852 . . . . 0.0 110.288 179.619 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 28.5 t -69.37 -26.45 64.67 Favored 'General case' 0 N--CA 1.452 -0.356 0 CA-C-N 116.183 -0.462 . . . . 0.0 109.929 178.672 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -128.9 33.42 4.62 Favored 'General case' 0 C--O 1.232 0.138 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.104 179.85 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 147' ' ' ALA . . . . . 0.652 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -115.81 46.17 1.58 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.859 0.361 . . . . 0.0 111.462 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 11.2 m -50.69 157.36 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.389 -179.864 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 102.68 -106.39 2.91 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.504 -179.966 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.417 ' HB3' HD21 ' A' ' 85' ' ' LEU . 30.1 mt-10 -139.14 94.44 2.8 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.805 0.336 . . . . 0.0 110.768 179.93 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . 0.652 HD11 ' HB3' ' A' ' 147' ' ' ALA . 1.0 OUTLIER -64.71 111.96 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.037 -179.867 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . 0.41 ' CD2' ' HG ' ' A' ' 85' ' ' LEU . 0.2 OUTLIER -99.43 115.94 30.42 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.046 -0.524 . . . . 0.0 109.962 179.135 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 153' ' ' MET . . . . . 0.818 ' HB3' HG23 ' A' ' 127' ' ' ILE . 0.1 OUTLIER -147.82 177.42 9.33 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.406 0.622 . . . . 0.0 111.58 -179.216 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 12.9 mttt -126.7 160.27 31.26 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 114.938 -1.028 . . . . 0.0 109.866 179.562 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . 0.54 HG22 ' HA ' ' A' ' 124' ' ' ILE . 24.4 p -144.18 144.58 31.62 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.299 0.571 . . . . 0.0 111.814 -179.565 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 156' ' ' MET . . . . . 0.53 ' O ' ' N ' ' A' ' 123' ' ' ARG . 0.0 OUTLIER -115.87 177.51 1.19 Allowed Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 115.142 -0.936 . . . . 0.0 109.997 179.508 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 157' ' ' PRO . . . . . 0.401 ' HD2' ' HB3' ' A' ' 156' ' ' MET . 89.8 Cg_endo -92.4 102.07 0.19 Allowed 'Trans proline' 0 N--CA 1.455 -0.757 0 C-N-CA 122.585 2.19 . . . . 0.0 112.627 -179.684 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 158' ' ' ALA . . . . . 0.81 ' HB2' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.248 1.025 0 CA-C-O 118.168 -0.92 . . . . 0.0 111.054 179.739 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.644 HG13 ' CE ' ' A' ' 156' ' ' MET . 37.1 t . . . . . 0 C--O 1.231 0.089 0 CA-C-O 120.765 0.316 . . . . 0.0 111.061 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.5 m -98.69 139.24 34.69 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.869 179.912 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 10.3 m -109.29 111.46 23.06 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.106 -0.497 . . . . 0.0 109.93 179.015 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.723 HG11 HG23 ' A' ' 118' ' ' VAL . 66.2 t -81.72 106.38 12.68 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.638 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.506 -179.475 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.514 HD13 ' CD2' ' A' ' 152' ' ' HIS . 16.8 tp -104.91 87.06 2.57 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.592 178.859 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.678 HG21 HD22 ' A' ' 95' ' ' LEU . 3.7 mt -81.56 146.82 6.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.229 -179.088 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.485 ' CB ' HG21 ' A' ' 112' ' ' ILE . 0.0 OUTLIER -115.7 108.97 17.06 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.486 -179.602 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 53.5 ttt180 -104.02 108.28 59.49 Favored Pre-proline 0 C--N 1.33 -0.257 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.847 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -68.45 -27.56 33.4 Favored 'Trans proline' 0 C--N 1.347 0.487 0 C-N-CA 122.36 2.04 . . . . 0.0 112.402 -179.942 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . 0.417 ' HB2' ' CD1' ' A' ' 93' ' ' TYR . 1.1 m-20 -165.22 168.98 16.52 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.993 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -66.86 -36.87 83.3 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.067 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.21 -14.15 59.96 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.086 -0.507 . . . . 0.0 111.492 -179.769 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . 0.417 ' CD1' ' HB2' ' A' ' 90' ' ' ASP . 46.6 m-85 -99.39 113.11 25.26 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.42 -0.355 . . . . 0.0 110.889 179.881 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -73.98 165.93 24.27 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.007 -179.926 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 0.8 HD11 ' HB3' ' A' ' 144' ' ' LEU . 26.0 mt -77.44 -67.43 0.72 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.835 179.965 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.573 ' O ' HD23 ' A' ' 107' ' ' LEU . . . 132.51 40.6 0.2 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.566 -0.826 . . . . 0.0 112.956 179.624 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 35.3 p90 -177.05 159.55 1.67 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.796 0.331 . . . . 0.0 110.968 179.68 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -112.94 144.67 42.12 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.963 -179.92 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.83 HG21 HG21 ' A' ' 140' ' ' ILE . 12.7 p -111.47 138.0 41.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.591 -179.861 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' GLN . . . . . 0.422 ' O ' ' N ' ' A' ' 102' ' ' GLY . 5.2 mm-40 -130.04 88.58 2.68 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.007 179.013 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' ASN . . . . . 0.673 ' O ' HD11 ' A' ' 140' ' ' ILE . 3.7 t30 64.69 -70.66 0.08 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.951 -179.662 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . 0.508 ' O ' HD13 ' A' ' 103' ' ' ILE . . . -141.86 -1.19 1.4 Allowed Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 120.445 -0.883 . . . . 0.0 113.024 179.928 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.823 HD12 ' HB2' ' A' ' 158' ' ' ALA . 25.5 mm -119.55 159.2 20.68 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.166 0 CA-C-O 120.969 0.414 . . . . 0.0 111.304 -179.712 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.559 ' N ' HD12 ' A' ' 104' ' ' ILE . 3.3 mp -102.19 141.46 18.36 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.912 -179.762 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -83.51 -69.43 0.64 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.936 -179.845 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -142.9 168.98 18.42 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.941 -179.882 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.801 HD11 ' O ' ' A' ' 118' ' ' VAL . 0.6 OUTLIER -123.1 167.46 13.63 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.912 179.926 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 4.5 ttt -122.62 97.76 5.6 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.648 179.705 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -55.21 91.0 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.86 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 152.94 -29.38 0.82 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.947 -0.644 . . . . 0.0 112.029 -179.69 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -70.88 176.82 35.88 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.278 179.753 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.485 HG21 ' CB ' ' A' ' 87' ' ' ARG . 0.6 OUTLIER -78.74 -16.6 13.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 120.711 0.291 . . . . 0.0 111.664 -179.769 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 113' ' ' ALA . . . . . 0.495 ' HA ' HG12 ' A' ' 86' ' ' ILE . . . -57.75 -30.53 65.66 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.013 0.435 . . . . 0.0 110.726 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -60.34 -46.91 88.24 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.662 179.632 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -62.49 -47.8 82.39 Favored 'General case' 0 N--CA 1.452 -0.352 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.125 -179.684 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -49.91 -74.14 0.3 Allowed Glycine 0 CA--C 1.519 0.325 0 C-N-CA 120.454 -0.879 . . . . 0.0 112.452 179.866 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . 0.587 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 173.99 -25.16 0.07 OUTLIER Glycine 0 CA--C 1.519 0.299 0 C-N-CA 121.141 -0.552 . . . . 0.0 112.366 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.801 ' O ' HD11 ' A' ' 107' ' ' LEU . 1.1 t -40.24 113.76 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.256 0 CA-C-O 120.981 0.419 . . . . 0.0 111.802 -179.709 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 2.3 ttt180 -132.3 110.26 10.47 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.117 179.462 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 120' ' ' VAL . . . . . 0.726 ' H ' HD12 ' A' ' 107' ' ' LEU . 85.1 t -43.6 118.12 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.688 -179.451 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 118.5 28.13 2.21 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.845 -0.693 . . . . 0.0 112.932 179.73 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . 0.505 ' CE1' HD13 ' A' ' 104' ' ' ILE . 20.2 p-80 -137.3 -170.29 2.7 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.619 0.247 . . . . 0.0 111.07 179.752 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . 0.541 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 55.6 ttp85 -133.92 114.39 13.23 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-N 116.574 -0.285 . . . . 0.0 111.711 -179.555 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . 0.653 ' HA ' HG22 ' A' ' 155' ' ' THR . 34.7 mt -73.16 158.58 6.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 178.59 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 125' ' ' ILE . . . . . 0.573 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.8 OUTLIER -147.14 -83.02 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 N-CA-C 112.867 0.691 . . . . 0.0 112.867 -179.624 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . 0.47 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 5.4 mt-10 -87.41 87.7 7.48 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 112.44 0.533 . . . . 0.0 112.44 -178.477 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.855 HG23 ' HB3' ' A' ' 153' ' ' MET . 2.4 mt -87.06 103.83 13.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.29 179.197 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 7.5 m-20 53.01 25.32 3.96 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.905 -0.588 . . . . 0.0 111.193 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 110.08 -13.57 31.45 Favored Glycine 0 CA--C 1.519 0.3 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.846 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 11.6 tt0 -95.72 110.88 22.95 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.787 0.327 . . . . 0.0 110.772 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 131' ' ' SER . . . . . 0.415 ' HA ' ' O ' ' A' ' 125' ' ' ILE . 1.1 m -74.84 87.24 2.25 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.042 -179.901 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . 0.696 HG21 HD11 ' A' ' 127' ' ' ILE . 31.9 m -73.9 -5.3 6.53 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.369 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.956 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.573 ' HB ' HG22 ' A' ' 125' ' ' ILE . 9.8 p -46.31 -31.56 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-O 120.888 0.375 . . . . 0.0 111.566 -179.695 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -127.95 27.41 5.7 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.617 179.409 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . 0.434 ' CG2' ' HD2' ' A' ' 136' ' ' PRO . 32.5 m -110.65 143.79 28.93 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 115.833 -0.621 . . . . 0.0 111.214 -179.736 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 136' ' ' PRO . . . . . 0.434 ' HD2' ' CG2' ' A' ' 135' ' ' THR . 50.5 Cg_exo -53.78 164.27 2.45 Favored 'Trans proline' 0 C--N 1.347 0.495 0 C-N-CA 122.545 2.163 . . . . 0.0 112.048 179.512 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 137' ' ' HIS . . . . . 0.615 ' HA ' HD12 ' A' ' 140' ' ' ILE . 6.8 p80 -72.6 -46.83 52.27 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.517 -179.607 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . 0.405 ' N ' ' CG ' ' A' ' 137' ' ' HIS . 1.7 mm-40 -54.01 -39.13 65.85 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.472 -179.513 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 139' ' ' LYS . . . . . 0.785 ' O ' HD12 ' A' ' 143' ' ' ILE . 7.0 tttp -63.53 -45.97 88.18 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.225 -179.701 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . 0.83 HG21 HG21 ' A' ' 99' ' ' VAL . 9.7 mt -59.36 -46.08 92.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.983 0.421 . . . . 0.0 110.431 179.956 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . 0.483 HG23 ' CG1' ' A' ' 99' ' ' VAL . 55.4 t -60.08 -32.37 50.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.039 179.034 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 4.6 t60 -61.08 -53.68 54.06 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.679 179.579 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . 0.785 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.3 mp -53.16 -56.9 5.98 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.379 0 CA-C-O 121.276 0.56 . . . . 0.0 110.263 179.209 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.8 ' HB3' HD11 ' A' ' 95' ' ' LEU . 3.9 mt -61.24 -30.32 70.38 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.254 -0.884 . . . . 0.0 110.275 179.453 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 30.9 t -69.31 -26.38 64.69 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.123 -0.489 . . . . 0.0 109.925 178.676 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -127.43 32.2 5.06 Favored 'General case' 0 C--O 1.231 0.099 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.985 179.697 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 147' ' ' ALA . . . . . 0.795 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -114.03 41.62 2.21 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.352 -0.386 . . . . 0.0 111.296 -179.966 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 18.5 m -51.72 138.76 8.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.447 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 120.88 -103.46 0.9 Allowed Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.442 -179.914 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 4.7 mt-10 -139.28 100.65 4.06 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.79 0.328 . . . . 0.0 110.877 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . 0.795 HD11 ' HB3' ' A' ' 147' ' ' ALA . 1.3 mt -78.86 111.78 16.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.942 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . 0.514 ' CD2' HD13 ' A' ' 85' ' ' LEU . 0.5 OUTLIER -106.97 115.55 30.37 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.141 179.325 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 153' ' ' MET . . . . . 0.855 ' HB3' HG23 ' A' ' 127' ' ' ILE . 1.7 ptm -136.64 161.98 34.43 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.071 0.463 . . . . 0.0 111.729 -179.318 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 154' ' ' LYS . . . . . 0.551 ' HB3' HD11 ' A' ' 125' ' ' ILE . 3.5 mttt -104.53 150.3 24.73 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.712 -0.676 . . . . 0.0 109.778 179.121 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . 0.653 HG22 ' HA ' ' A' ' 124' ' ' ILE . 21.8 p -146.14 150.44 35.89 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.295 0.569 . . . . 0.0 112.076 -179.086 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 156' ' ' MET . . . . . 0.644 ' CE ' HG13 ' A' ' 81' ' ' VAL . 0.0 OUTLIER -144.76 145.33 27.58 Favored Pre-proline 0 C--N 1.327 -0.406 0 CA-C-N 115.226 -0.897 . . . . 0.0 110.346 179.102 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_exo -50.92 109.38 0.3 Allowed 'Trans proline' 0 C--N 1.343 0.263 0 C-N-CA 122.512 2.141 . . . . 0.0 112.628 -179.759 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 158' ' ' ALA . . . . . 0.823 ' HB2' HD12 ' A' ' 103' ' ' ILE . . . . . . . . 0 C--O 1.25 1.084 0 CA-C-O 118.266 -0.873 . . . . 0.0 111.343 179.863 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 18.3 t . . . . . 0 C--O 1.232 0.179 0 CA-C-O 120.802 0.334 . . . . 0.0 111.104 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.1 m -114.42 132.14 56.35 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.926 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . 0.545 HG23 ' HE2' ' A' ' 154' ' ' LYS . 56.5 m -95.58 111.19 23.16 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.947 179.119 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.794 HG22 ' N ' ' A' ' 118' ' ' VAL . 86.3 t -88.39 105.38 15.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.58 -179.206 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.457 ' O ' ' HA2' ' A' ' 116' ' ' GLY . 2.7 tp -100.01 84.27 2.84 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 178.588 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.748 HG13 HG12 ' A' ' 84' ' ' VAL . 22.0 mt -81.27 127.31 39.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-O 121.4 0.619 . . . . 0.0 111.928 -178.501 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.803 ' O ' HG21 ' A' ' 112' ' ' ILE . 0.0 OUTLIER -74.49 153.34 39.16 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.136 -0.938 . . . . 0.0 110.407 179.856 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.471 ' HD2' HD21 ' A' ' 95' ' ' LEU . 5.5 ttt-85 -152.15 91.71 3.62 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 120.682 0.277 . . . . 0.0 111.161 -179.931 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -58.53 -63.48 0.14 Allowed 'Trans proline' 0 C--N 1.345 0.346 0 C-N-CA 122.583 2.189 . . . . 0.0 112.23 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 4.9 t0 -117.14 -173.68 2.45 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.169 -179.859 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 0.847 HD12 HG11 ' A' ' 148' ' ' VAL . 0.1 OUTLIER -91.79 -21.95 20.41 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.311 -179.864 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -95.76 22.7 6.97 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.469 -0.332 . . . . 0.0 111.219 -179.779 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 17.7 m-85 -121.04 117.97 28.59 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.801 0.334 . . . . 0.0 110.835 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 3.4 mp0 -64.57 177.93 0.83 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.874 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 0.83 ' CD1' HD13 ' A' ' 144' ' ' LEU . 42.5 mt -96.98 -61.35 1.42 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.932 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 132.05 53.91 0.09 OUTLIER Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.718 179.912 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . 0.514 ' HZ ' HD12 ' A' ' 144' ' ' LEU . 0.2 OUTLIER -176.68 -171.96 0.41 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.904 0.383 . . . . 0.0 110.991 179.9 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 8.3 t -137.44 130.35 30.36 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.793 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 1.058 HG21 HG21 ' A' ' 140' ' ' ILE . 10.4 p -109.97 114.35 46.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.06 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' GLN . . . . . 0.421 ' O ' ' N ' ' A' ' 102' ' ' GLY . 1.2 tt0 -110.31 89.0 2.9 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.817 0.341 . . . . 0.0 110.908 -180.0 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' ASN . . . . . 0.717 ' O ' HD11 ' A' ' 140' ' ' ILE . 1.6 t30 65.18 -64.64 0.17 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.51 179.702 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . 0.421 ' N ' ' O ' ' A' ' 100' ' ' GLN . . . -146.88 -4.49 0.42 Allowed Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.336 -0.935 . . . . 0.0 113.661 -179.623 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.727 HD12 ' CB ' ' A' ' 158' ' ' ALA . 31.5 mm -125.09 142.64 41.35 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 117.389 0.594 . . . . 0.0 111.307 -179.543 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.678 HD11 HG13 ' A' ' 124' ' ' ILE . 3.9 mp -84.44 142.58 13.16 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.788 179.712 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -105.42 -77.73 0.58 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.991 -179.829 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 62.6 p -90.64 146.98 23.6 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.944 0.402 . . . . 0.0 110.9 -179.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.728 ' HB2' HG22 ' A' ' 120' ' ' VAL . 0.2 OUTLIER -136.72 123.92 21.77 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.883 179.993 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 4.1 mtt -77.06 120.37 22.05 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.882 -179.949 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -81.33 105.59 12.63 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.765 179.893 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 101.66 26.63 7.52 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.394 -179.917 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . 0.5 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -111.76 -158.25 14.53 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.701 -0.762 . . . . 0.0 113.209 -179.761 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.803 HG21 ' O ' ' A' ' 87' ' ' ARG . 16.3 mt -80.16 -41.92 21.35 Favored 'Isoleucine or valine' 0 C--O 1.238 0.463 0 CA-C-O 121.076 0.465 . . . . 0.0 111.766 -179.588 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 113' ' ' ALA . . . . . 0.804 ' O ' HG12 ' A' ' 118' ' ' VAL . . . -57.7 -36.21 71.67 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.193 -179.394 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 114' ' ' GLU . . . . . 0.53 ' HG3' ' N ' ' A' ' 115' ' ' ARG . 8.3 pt-20 -66.9 -36.26 81.87 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.484 179.561 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.53 ' N ' ' HG3' ' A' ' 114' ' ' GLU . 0.0 OUTLIER -59.39 -46.55 88.35 Favored 'General case' 0 N--CA 1.452 -0.359 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.559 -179.905 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.457 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -56.05 -71.31 0.75 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.205 -0.998 . . . . 0.0 112.539 179.635 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . 0.481 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 174.32 -22.76 0.06 OUTLIER Glycine 0 CA--C 1.519 0.282 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.824 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.804 HG12 ' O ' ' A' ' 113' ' ' ALA . 7.3 p -31.75 145.72 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 N-CA-C 112.265 0.469 . . . . 0.0 112.265 -179.621 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.441 ' HB3' ' CD2' ' A' ' 122' ' ' HIS . 0.1 OUTLIER -147.83 134.43 19.85 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.734 179.899 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 120' ' ' VAL . . . . . 0.728 HG22 ' HB2' ' A' ' 107' ' ' LEU . 22.0 t -59.48 111.26 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.036 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 109.72 18.49 8.91 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.602 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . 0.566 ' O ' HG23 ' A' ' 103' ' ' ILE . 1.7 m-70 -102.22 -173.02 2.24 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.682 0.277 . . . . 0.0 110.693 179.909 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . 0.626 ' HD2' HD11 ' A' ' 103' ' ' ILE . 40.4 ttt180 -142.76 90.71 2.24 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.363 -0.38 . . . . 0.0 111.335 -179.647 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . 0.678 HG13 HD11 ' A' ' 104' ' ' ILE . 25.2 mt -51.48 157.07 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.307 179.112 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 125' ' ' ILE . . . . . 0.771 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.6 OUTLIER -149.38 -82.99 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 N-CA-C 112.576 0.584 . . . . 0.0 112.576 -179.389 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . 0.411 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 72.7 mt-10 -89.29 89.4 7.89 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 112.353 0.501 . . . . 0.0 112.353 -178.62 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.831 HG23 ' HB3' ' A' ' 153' ' ' MET . 2.1 mt -88.89 106.87 17.24 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.181 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.573 179.43 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . 0.429 ' HA ' ' CE1' ' A' ' 152' ' ' HIS . 3.1 t-20 53.45 31.69 12.64 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.899 -0.591 . . . . 0.0 111.066 179.726 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 98.23 -7.26 62.06 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.754 -179.74 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 2.9 tt0 -99.92 106.23 18.02 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.836 0.351 . . . . 0.0 110.756 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 1.6 m -71.12 84.26 0.72 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.157 -179.773 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . 0.706 HG11 HD12 ' A' ' 127' ' ' ILE . 34.1 m -67.73 -10.03 11.67 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.759 179.867 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.771 ' HB ' HG22 ' A' ' 125' ' ' ILE . 9.3 p -51.06 117.85 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.925 0.393 . . . . 0.0 110.961 179.969 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 134' ' ' ALA . . . . . 0.521 ' HB3' ' O ' ' A' ' 133' ' ' VAL . . . 75.1 21.2 1.98 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.754 -178.997 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . 0.47 ' CG2' ' HD2' ' A' ' 136' ' ' PRO . 29.3 m -103.5 142.52 24.74 Favored Pre-proline 0 C--N 1.327 -0.402 0 CA-C-N 115.648 -0.706 . . . . 0.0 110.802 179.828 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 136' ' ' PRO . . . . . 0.47 ' HD2' ' CG2' ' A' ' 135' ' ' THR . 94.9 Cg_exo -42.77 164.2 0.04 OUTLIER 'Trans proline' 0 C--N 1.348 0.533 0 C-N-CA 122.849 2.366 . . . . 0.0 112.9 -179.869 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 137' ' ' HIS . . . . . 0.447 ' CE1' ' O ' ' A' ' 99' ' ' VAL . 3.1 t-160 -74.17 -59.35 2.76 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.558 -179.525 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -53.67 -27.17 26.07 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.901 -179.135 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 139' ' ' LYS . . . . . 0.762 ' O ' HD12 ' A' ' 143' ' ' ILE . 0.9 OUTLIER -67.52 -51.44 50.85 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.651 0.262 . . . . 0.0 111.172 -179.535 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . 1.058 HG21 HG21 ' A' ' 99' ' ' VAL . 17.4 mt -59.54 -46.35 93.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 121.026 0.441 . . . . 0.0 110.751 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . 0.437 HG22 HG12 ' A' ' 99' ' ' VAL . 93.5 t -60.11 -32.44 50.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.227 179.237 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -61.75 -54.88 36.48 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.971 179.723 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . 0.762 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.1 mp -52.88 -56.9 5.62 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.391 0 CA-C-O 121.232 0.539 . . . . 0.0 110.267 179.569 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.83 HD13 ' CD1' ' A' ' 95' ' ' LEU . 1.6 mt -61.75 -29.97 70.48 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.394 179.582 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 25.8 t -69.25 -26.56 64.84 Favored 'General case' 0 C--N 1.33 -0.242 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 178.523 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -126.91 31.61 5.26 Favored 'General case' 0 CA--C 1.53 0.181 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.093 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 147' ' ' ALA . . . . . 0.772 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -116.98 58.19 0.78 Allowed 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.356 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.847 HG11 HD12 ' A' ' 91' ' ' LEU . 3.9 m -53.28 173.7 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.346 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . 0.409 ' N ' ' HB3' ' A' ' 88' ' ' ARG . . . 87.9 -113.38 4.01 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.468 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 -139.76 102.84 4.53 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.835 0.35 . . . . 0.0 110.778 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . 0.772 HD11 ' HB3' ' A' ' 147' ' ' ALA . 1.3 mt -73.99 111.67 9.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.098 -179.905 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . 0.429 ' CE1' ' HA ' ' A' ' 128' ' ' ASN . 8.7 p80 -104.58 115.58 30.59 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.136 -0.484 . . . . 0.0 109.733 178.84 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 153' ' ' MET . . . . . 0.831 ' HB3' HG23 ' A' ' 127' ' ' ILE . 0.8 OUTLIER -136.72 174.66 10.37 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.193 0.52 . . . . 0.0 111.874 -178.737 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 154' ' ' LYS . . . . . 0.685 ' HB3' HD11 ' A' ' 125' ' ' ILE . 0.0 OUTLIER -118.56 151.62 37.55 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.77 179.268 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . 0.419 HG22 ' HA ' ' A' ' 124' ' ' ILE . 44.4 p -139.65 143.22 37.07 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.027 0.441 . . . . 0.0 111.479 -179.551 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 156' ' ' MET . . . . . 0.45 ' O ' ' N ' ' A' ' 123' ' ' ARG . 0.0 OUTLIER -110.77 176.63 1.45 Allowed Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 115.538 -0.755 . . . . 0.0 110.545 179.764 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 96.3 Cg_endo -90.12 118.75 0.74 Allowed 'Trans proline' 0 N--CA 1.457 -0.619 0 C-N-CA 122.735 2.29 . . . . 0.0 112.546 -179.856 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 158' ' ' ALA . . . . . 0.727 ' CB ' HD12 ' A' ' 103' ' ' ILE . . . . . . . . 0 C--O 1.249 1.071 0 CA-C-O 118.242 -0.885 . . . . 0.0 111.019 179.781 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.4 HG23 ' O ' ' A' ' 155' ' ' THR . 9.4 p . . . . . 0 N--CA 1.456 -0.129 0 CA-C-O 120.721 0.296 . . . . 0.0 111.048 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.6 m -111.1 121.28 44.92 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.871 179.764 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . 0.433 ' HA ' ' O ' ' A' ' 153' ' ' MET . 8.9 m -92.65 110.82 22.26 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.039 179.046 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.858 HG11 HG23 ' A' ' 118' ' ' VAL . 76.2 t -83.31 106.0 13.54 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.597 0 CA-C-N 116.298 -0.41 . . . . 0.0 112.059 -179.17 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.418 HD12 ' NE2' ' A' ' 152' ' ' HIS . 3.9 tt -102.97 81.11 1.94 Allowed 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 177.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.842 HG13 HG12 ' A' ' 84' ' ' VAL . 4.4 mt -81.49 123.88 38.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 121.281 0.562 . . . . 0.0 111.769 -178.328 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.565 ' HB2' HG21 ' A' ' 112' ' ' ILE . 0.1 OUTLIER -70.43 142.62 51.98 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.307 -0.86 . . . . 0.0 110.496 179.761 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.511 ' HG3' HD12 ' A' ' 151' ' ' ILE . 10.2 mtp180 -141.93 98.73 6.22 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.891 179.993 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' PRO . . . . . 0.447 ' HG2' ' CG ' ' A' ' 93' ' ' TYR . 64.1 Cg_endo -73.61 -41.62 1.09 Allowed 'Trans proline' 0 C--N 1.346 0.403 0 C-N-CA 122.552 2.168 . . . . 0.0 112.561 -179.877 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -137.05 -168.09 2.22 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.149 -179.824 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 0.607 ' HG ' HG11 ' A' ' 148' ' ' VAL . 3.9 mt -95.08 -22.74 17.69 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.204 -179.861 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 4.5 ptt-85 -96.23 22.84 7.2 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.144 -179.834 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . 0.447 ' CG ' ' HG2' ' A' ' 89' ' ' PRO . 12.9 m-85 -106.05 96.63 6.61 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.922 0.391 . . . . 0.0 110.894 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 1.3 pp0? -50.58 159.21 0.54 Allowed 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.276 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 0.83 HD23 HD13 ' A' ' 86' ' ' ILE . 2.1 mp -88.05 -66.8 0.88 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.861 179.872 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 130.49 37.77 0.32 Allowed Glycine 0 CA--C 1.519 0.29 0 C-N-CA 120.562 -0.828 . . . . 0.0 112.885 179.661 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . 0.439 ' CD1' ' HB2' ' A' ' 113' ' ' ALA . 50.2 p90 -176.93 178.06 1.21 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.707 0.289 . . . . 0.0 110.936 179.775 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.6 t -128.36 146.1 50.88 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.97 0.414 . . . . 0.0 111.06 -179.787 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 1.086 HG21 HG21 ' A' ' 140' ' ' ILE . 5.5 p -113.09 124.33 69.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.832 179.9 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' GLN . . . . . 0.417 ' O ' ' N ' ' A' ' 102' ' ' GLY . 1.9 tt0 -115.55 88.77 2.95 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.803 179.766 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' ASN . . . . . 0.65 ' O ' HD11 ' A' ' 140' ' ' ILE . 1.2 m-80 64.94 -67.16 0.12 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.87 -0.605 . . . . 0.0 111.424 179.685 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . 0.423 ' O ' ' HA ' ' A' ' 123' ' ' ARG . . . -144.52 -3.7 0.7 Allowed Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.29 -0.957 . . . . 0.0 113.41 -179.629 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.653 HD12 ' HB2' ' A' ' 158' ' ' ALA . 39.2 mm -122.99 148.57 26.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 117.315 0.557 . . . . 0.0 111.406 -179.574 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.638 HD11 ' CD1' ' A' ' 124' ' ' ILE . 2.8 mp -85.08 141.91 13.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.507 179.594 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 94.1 m -97.81 -80.11 0.45 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.125 -179.677 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 1.4 m -109.13 145.63 35.41 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.981 -179.872 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.874 HD12 HG12 ' A' ' 118' ' ' VAL . 1.2 tt -143.2 113.2 7.14 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.808 179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -74.83 142.55 44.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.719 179.852 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.87 47.52 1.42 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.974 0.416 . . . . 0.0 110.808 -179.904 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -161.35 25.83 0.26 Allowed Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.39 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . 0.454 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -121.05 -174.63 14.98 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.331 179.867 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.565 HG21 ' HB2' ' A' ' 87' ' ' ARG . 1.2 mp -78.92 -22.56 12.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 120.785 0.326 . . . . 0.0 111.463 -179.876 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 113' ' ' ALA . . . . . 0.439 ' HB2' ' CD1' ' A' ' 97' ' ' PHE . . . -58.2 -30.57 66.56 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.894 0.378 . . . . 0.0 110.723 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 114' ' ' GLU . . . . . 0.454 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 12.4 pt-20 -61.26 -46.42 90.42 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.796 179.734 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 3.5 mtp85 -63.38 -44.13 95.62 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.908 -179.617 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -53.73 -73.97 0.35 Allowed Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.386 -0.911 . . . . 0.0 112.504 179.885 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . 0.564 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 174.98 -27.01 0.08 OUTLIER Glycine 0 CA--C 1.519 0.331 0 C-N-CA 120.922 -0.656 . . . . 0.0 112.65 -179.824 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.874 HG12 HD12 ' A' ' 107' ' ' LEU . 94.3 t -31.87 116.56 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 CA-C-O 121.026 0.441 . . . . 0.0 111.709 -179.82 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 11.7 mtt-85 -128.62 112.64 14.49 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.294 179.583 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 120' ' ' VAL . . . . . 0.567 HG22 ' HB2' ' A' ' 107' ' ' LEU . 32.2 t -46.99 108.42 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.239 -179.768 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 120.36 16.28 4.76 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 121.009 -0.615 . . . . 0.0 112.54 -179.721 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . 0.464 ' O ' HG23 ' A' ' 103' ' ' ILE . 3.9 m170 -110.35 -172.39 2.03 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.597 0.237 . . . . 0.0 110.562 179.923 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . 0.74 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 4.1 ttt180 -139.88 92.87 2.59 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.682 0.277 . . . . 0.0 111.418 -179.657 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . 0.638 ' CD1' HD11 ' A' ' 104' ' ' ILE . 7.2 mt -52.76 147.65 1.91 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.077 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 125' ' ' ILE . . . . . 0.905 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.6 OUTLIER -141.42 -84.79 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 N-CA-C 112.393 0.516 . . . . 0.0 112.393 -179.335 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 8.5 mm-40 -86.39 90.06 8.08 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 112.316 0.488 . . . . 0.0 112.316 -178.719 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.889 HG23 ' HB3' ' A' ' 153' ' ' MET . 2.3 mt -85.45 105.72 14.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 121.24 0.543 . . . . 0.0 111.473 179.307 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . 0.44 ' N ' ' O ' ' A' ' 152' ' ' HIS . 0.6 OUTLIER 56.61 20.81 5.23 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.694 -0.684 . . . . 0.0 111.512 179.667 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 115.14 -12.8 19.54 Favored Glycine 0 C--N 1.331 0.301 0 C-N-CA 120.519 -0.848 . . . . 0.0 113.434 179.665 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 1.1 pt20 -103.17 117.54 34.78 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-O 120.958 0.408 . . . . 0.0 110.834 179.957 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 95.9 p -74.85 85.8 2.22 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.31 -179.643 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . 0.596 HG11 HD12 ' A' ' 127' ' ' ILE . 33.8 m -66.61 -10.89 12.39 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.315 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.535 179.537 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.905 ' HB ' HG22 ' A' ' 125' ' ' ILE . 8.9 p -49.69 117.73 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 120.915 0.388 . . . . 0.0 110.964 -179.952 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 134' ' ' ALA . . . . . 0.529 ' HB3' ' O ' ' A' ' 133' ' ' VAL . . . 76.15 20.77 1.58 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.789 -179.141 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . 0.471 HG23 ' HD2' ' A' ' 136' ' ' PRO . 36.9 m -104.21 143.21 26.2 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.691 179.637 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 136' ' ' PRO . . . . . 0.471 ' HD2' HG23 ' A' ' 135' ' ' THR . 1.9 Cg_endo -41.51 141.19 1.47 Allowed 'Trans proline' 0 C--N 1.347 0.499 0 C-N-CA 123.113 2.542 . . . . 0.0 112.631 179.898 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 38.0 p-80 -63.95 -48.49 76.3 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.024 -0.534 . . . . 0.0 111.464 -179.62 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -54.73 -36.58 64.92 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.301 -179.625 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 139' ' ' LYS . . . . . 0.808 ' O ' HD12 ' A' ' 143' ' ' ILE . 19.2 tttm -63.34 -48.81 76.41 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.83 -179.933 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . 1.086 HG21 HG21 ' A' ' 99' ' ' VAL . 21.6 mt -58.47 -46.12 89.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.722 -179.861 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . 0.485 HG22 HG12 ' A' ' 99' ' ' VAL . 99.3 t -59.34 -32.5 48.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.014 178.869 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 1.7 t60 -61.78 -52.01 65.96 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.71 179.628 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . 0.808 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.3 mp -53.19 -57.23 5.14 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.414 0 CA-C-O 121.024 0.44 . . . . 0.0 110.222 179.416 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.749 HD13 ' CD2' ' A' ' 95' ' ' LEU . 3.4 mt -60.53 -30.15 69.57 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.562 -0.745 . . . . 0.0 110.23 179.574 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 1.1 m -69.33 -26.91 64.94 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-N 116.062 -0.517 . . . . 0.0 109.895 178.557 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 3.6 m-80 -129.82 34.61 4.27 Favored 'General case' 0 CA--C 1.528 0.114 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.216 179.837 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 147' ' ' ALA . . . . . 0.586 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -116.82 56.39 0.8 Allowed 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.835 0.35 . . . . 0.0 111.325 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.607 HG11 ' HG ' ' A' ' 91' ' ' LEU . 27.7 m -54.21 -177.96 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.403 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 81.67 -100.96 2.11 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.552 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 13.0 mt-10 -152.9 98.2 2.29 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.813 0.34 . . . . 0.0 110.707 -179.898 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . 0.586 HD11 ' HB3' ' A' ' 147' ' ' ALA . 1.2 mt -63.09 111.56 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.185 -179.718 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . 0.44 ' O ' ' N ' ' A' ' 128' ' ' ASN . 1.5 t-160 -107.1 115.64 30.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.983 -0.553 . . . . 0.0 109.805 179.121 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 153' ' ' MET . . . . . 0.889 ' HB3' HG23 ' A' ' 127' ' ' ILE . 1.0 OUTLIER -141.96 176.17 9.15 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.041 0.448 . . . . 0.0 111.82 -178.893 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 53.1 mttt -124.23 148.9 46.99 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.064 179.401 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . 0.4 ' O ' HG23 ' A' ' 81' ' ' VAL . 20.0 p -137.1 132.17 33.7 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.942 0.401 . . . . 0.0 111.466 -179.57 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 156' ' ' MET . . . . . 0.476 ' O ' ' N ' ' A' ' 123' ' ' ARG . 0.0 OUTLIER -104.78 154.43 38.58 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.266 179.51 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 17.1 Cg_exo -66.77 118.78 5.82 Favored 'Trans proline' 0 C--N 1.342 0.228 0 C-N-CA 122.359 2.04 . . . . 0.0 112.136 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 158' ' ' ALA . . . . . 0.74 ' HB2' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.249 1.058 0 CA-C-O 118.262 -0.875 . . . . 0.0 111.107 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.589 HG13 ' O ' ' A' ' 155' ' ' THR . 41.7 t . . . . . 0 N--CA 1.457 -0.084 0 CA-C-O 120.781 0.324 . . . . 0.0 111.094 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.5 m -117.09 143.4 45.83 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.913 179.854 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 17.7 m -105.67 111.56 24.3 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.247 179.279 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.74 HG11 HG23 ' A' ' 118' ' ' VAL . 43.4 t -82.34 105.94 12.73 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.552 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.78 -179.359 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.49 HD23 ' C ' ' A' ' 85' ' ' LEU . 6.3 tt -108.14 82.3 1.61 Allowed 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 109.122 -0.696 . . . . 0.0 109.122 178.574 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.992 HG21 HD22 ' A' ' 95' ' ' LEU . 5.1 mt -81.36 145.21 9.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.009 -0.541 . . . . 0.0 111.807 -178.165 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.418 ' HG2' ' CG2' ' A' ' 112' ' ' ILE . 0.1 OUTLIER -97.71 114.71 26.75 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.518 -179.831 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.472 ' HD2' HD12 ' A' ' 151' ' ' ILE . 2.3 ttt-85 -112.26 103.09 55.15 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.136 -179.714 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' PRO . . . . . 0.429 ' HB2' ' CD2' ' A' ' 93' ' ' TYR . 34.8 Cg_exo -57.63 -53.6 4.37 Favored 'Trans proline' 0 C--N 1.347 0.475 0 C-N-CA 122.498 2.132 . . . . 0.0 112.369 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -140.41 -167.07 2.25 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.986 -179.921 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 0.423 ' HG ' HG11 ' A' ' 148' ' ' VAL . 8.2 mt -84.01 -20.1 33.37 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.313 -179.868 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -96.41 23.33 6.86 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.095 -179.808 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . 0.429 ' CD2' ' HB2' ' A' ' 89' ' ' PRO . 15.9 m-85 -115.04 122.04 44.96 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.951 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -79.58 162.11 25.53 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.818 -179.979 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 0.992 HD22 HG21 ' A' ' 86' ' ' ILE . 53.9 mt -89.5 -69.94 0.69 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.837 179.964 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.407 ' O ' HD12 ' A' ' 107' ' ' LEU . . . 138.54 43.66 0.08 OUTLIER Glycine 0 CA--C 1.518 0.234 0 C-N-CA 120.42 -0.895 . . . . 0.0 113.011 179.724 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 35.4 p90 -176.74 161.97 2.12 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.849 0.357 . . . . 0.0 111.07 179.65 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -115.63 139.16 50.37 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.761 179.876 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.785 HG21 HG21 ' A' ' 140' ' ' ILE . 12.3 p -109.88 131.7 60.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.487 -179.818 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' GLN . . . . . 0.412 ' O ' ' N ' ' A' ' 102' ' ' GLY . 10.0 mt-30 -122.58 88.57 2.95 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.13 179.224 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' ASN . . . . . 0.649 ' O ' HD11 ' A' ' 140' ' ' ILE . 2.0 m120 63.89 -73.94 0.05 OUTLIER 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.971 -179.725 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . 0.526 ' O ' HD13 ' A' ' 103' ' ' ILE . . . -137.82 0.67 2.74 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.299 -0.953 . . . . 0.0 113.05 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.813 HD12 ' HB2' ' A' ' 158' ' ' ALA . 38.1 mm -124.17 151.88 29.51 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.127 0 CA-C-O 121.014 0.435 . . . . 0.0 111.435 -179.617 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.765 HD11 HG13 ' A' ' 124' ' ' ILE . 3.2 mp -93.32 152.15 3.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.739 179.858 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 96.3 m -105.59 -67.54 0.92 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.107 -179.8 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 78.8 p -123.98 154.24 40.1 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.387 -0.369 . . . . 0.0 111.167 -179.853 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.407 HD12 ' O ' ' A' ' 96' ' ' GLY . 27.1 tp -139.55 103.42 4.69 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.619 179.861 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 6.8 ttm -60.89 110.91 1.46 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.006 -179.861 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 2.2 tmt_? -68.7 72.21 0.23 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.768 179.747 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 174.34 -34.12 0.11 Allowed Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.973 -0.632 . . . . 0.0 112.149 -179.853 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . 0.402 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -60.0 -176.73 1.31 Allowed Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.21 179.697 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.482 ' H ' HD12 ' A' ' 112' ' ' ILE . 0.8 OUTLIER -78.7 -17.09 13.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-O 120.822 0.344 . . . . 0.0 111.625 -179.89 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 113' ' ' ALA . . . . . 0.446 ' HA ' HG12 ' A' ' 86' ' ' ILE . . . -58.08 -30.46 66.25 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.937 0.398 . . . . 0.0 110.827 179.961 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 114' ' ' GLU . . . . . 0.402 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 14.5 pt-20 -61.56 -46.84 88.21 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.74 179.687 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 27.9 mtm-85 -62.1 -44.59 96.33 Favored 'General case' 0 N--CA 1.451 -0.406 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.082 -179.64 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.415 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -52.92 -73.75 0.37 Allowed Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.36 -0.924 . . . . 0.0 112.536 179.975 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . 0.567 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 167.33 -19.31 0.09 OUTLIER Glycine 0 CA--C 1.52 0.377 0 C-N-CA 121.0 -0.619 . . . . 0.0 112.75 -179.702 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.74 HG23 HG11 ' A' ' 84' ' ' VAL . 0.9 OUTLIER -38.5 129.47 0.36 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.244 0 CA-C-O 121.007 0.432 . . . . 0.0 111.607 -179.862 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -127.63 101.94 6.62 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.603 179.752 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 120' ' ' VAL . . . . . 0.513 ' O ' HG13 ' A' ' 120' ' ' VAL . 12.5 p -49.86 117.81 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.013 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 115.91 -14.56 16.77 Favored Glycine 0 CA--C 1.518 0.228 0 C-N-CA 120.854 -0.689 . . . . 0.0 112.333 -179.488 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -84.65 -165.6 1.23 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.64 0.257 . . . . 0.0 110.54 179.872 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . 0.595 ' HA ' HD13 ' A' ' 103' ' ' ILE . 51.6 ttt85 -130.39 102.2 6.07 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.881 0.372 . . . . 0.0 111.445 -179.718 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . 0.842 ' HA ' HG22 ' A' ' 155' ' ' THR . 9.1 mt -60.63 157.95 2.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.092 178.86 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 125' ' ' ILE . . . . . 0.839 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.7 OUTLIER -154.79 -85.04 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 N-CA-C 113.086 0.773 . . . . 0.0 113.086 -179.708 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . 0.401 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 3.3 mt-10 -84.28 91.21 7.7 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 112.932 0.716 . . . . 0.0 112.932 -178.117 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.875 HD11 HG21 ' A' ' 132' ' ' VAL . 1.7 mt -90.88 98.79 8.76 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.146 0 CA-C-N 116.374 -0.376 . . . . 0.0 110.878 178.628 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . 0.422 ' N ' ' O ' ' A' ' 152' ' ' HIS . 45.8 m-20 60.84 26.13 16.0 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.703 -179.848 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 106.98 -16.14 39.55 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.556 -179.841 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -92.35 108.17 19.76 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.909 0.385 . . . . 0.0 110.715 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 27.4 m -74.59 90.9 2.28 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.125 -179.772 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . 0.875 HG21 HD11 ' A' ' 127' ' ' ILE . 35.0 m -81.62 4.39 2.02 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.341 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.967 179.904 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.839 ' HB ' HG22 ' A' ' 125' ' ' ILE . 9.8 p -47.81 -32.42 3.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 120.914 0.388 . . . . 0.0 111.253 -179.857 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -124.68 27.69 6.78 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.601 179.313 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . 0.523 HG23 ' HD2' ' A' ' 136' ' ' PRO . 90.6 m -109.5 143.69 28.31 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.982 -179.841 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 136' ' ' PRO . . . . . 0.523 ' HD2' HG23 ' A' ' 135' ' ' THR . 80.3 Cg_exo -48.27 164.16 0.21 Allowed 'Trans proline' 0 C--N 1.349 0.565 0 C-N-CA 122.496 2.13 . . . . 0.0 112.483 179.909 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 137' ' ' HIS . . . . . 0.557 ' HA ' HD12 ' A' ' 140' ' ' ILE . 57.1 p-80 -76.23 -48.45 20.29 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.492 -179.606 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -55.53 -34.66 64.87 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.939 0.4 . . . . 0.0 111.197 -179.636 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 139' ' ' LYS . . . . . 0.791 ' O ' HD12 ' A' ' 143' ' ' ILE . 0.8 OUTLIER -64.43 -47.47 78.98 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.021 -179.831 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . 0.785 HG21 HG21 ' A' ' 99' ' ' VAL . 8.7 mt -59.18 -46.5 92.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 121.155 0.503 . . . . 0.0 110.553 -179.868 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . 0.486 HG23 ' CG1' ' A' ' 99' ' ' VAL . 54.1 t -59.68 -32.45 49.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.057 179.013 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 5.6 t-160 -61.58 -53.44 56.31 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.909 179.738 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . 0.791 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.2 mp -53.06 -56.95 5.62 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.468 0 CA-C-O 121.203 0.525 . . . . 0.0 110.455 179.494 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.651 HD22 HG12 ' A' ' 151' ' ' ILE . 1.6 mt -63.3 -29.82 71.07 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.414 -0.812 . . . . 0.0 110.455 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 4.0 m -69.66 -28.47 65.9 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 178.773 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 4.6 m-80 -129.67 35.42 4.19 Favored 'General case' 0 CA--C 1.528 0.128 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.227 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 147' ' ' ALA . . . . . 0.949 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -101.05 -33.27 10.22 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.945 0.402 . . . . 0.0 111.28 -179.917 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.438 HG22 ' O ' ' A' ' 147' ' ' ALA . 35.5 m 44.44 -173.63 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.527 -0.76 . . . . 0.0 111.849 -179.877 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 50.78 -148.67 7.42 Favored Glycine 0 C--N 1.332 0.341 0 C-N-CA 120.854 -0.689 . . . . 0.0 112.772 -179.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.443 ' HB3' HD21 ' A' ' 85' ' ' LEU . 7.9 mt-10 -89.41 105.33 17.73 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.72 0.295 . . . . 0.0 110.845 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . 0.949 HD11 ' HB3' ' A' ' 147' ' ' ALA . 0.6 OUTLIER -78.25 111.58 15.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.387 -0.37 . . . . 0.0 111.12 -179.917 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . 0.422 ' O ' ' N ' ' A' ' 128' ' ' ASN . 0.0 OUTLIER -93.29 124.79 37.51 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 178.889 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 153' ' ' MET . . . . . 0.745 ' HG3' HG23 ' A' ' 127' ' ' ILE . 5.2 tmm? -147.92 151.89 36.62 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.873 0.368 . . . . 0.0 111.79 -178.721 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 154' ' ' LYS . . . . . 0.401 ' HG2' HG11 ' A' ' 81' ' ' VAL . 0.0 OUTLIER -111.86 148.14 34.27 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.476 179.644 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . 0.842 HG22 ' HA ' ' A' ' 124' ' ' ILE . 37.6 p -145.23 151.32 38.21 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.086 0.47 . . . . 0.0 111.702 -179.755 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 156' ' ' MET . . . . . 0.435 ' O ' ' N ' ' A' ' 123' ' ' ARG . 5.0 ptp -139.43 156.3 71.65 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.295 179.061 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 12.7 Cg_endo -56.43 120.44 8.31 Favored 'Trans proline' 0 C--N 1.342 0.229 0 C-N-CA 122.5 2.133 . . . . 0.0 112.609 -179.714 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 158' ' ' ALA . . . . . 0.813 ' HB2' HD12 ' A' ' 103' ' ' ILE . . . . . . . . 0 C--O 1.249 1.051 0 CA-C-O 118.308 -0.853 . . . . 0.0 110.995 179.845 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.703 HG23 ' O ' ' A' ' 155' ' ' THR . 11.6 p . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.72 0.295 . . . . 0.0 110.969 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 1.4 m -82.2 146.03 29.75 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.87 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 8.8 m -108.3 111.16 22.96 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.188 179.13 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.652 HG12 ' CD1' ' A' ' 86' ' ' ILE . 49.9 t -90.29 106.13 16.97 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.448 0 CA-C-N 116.024 -0.534 . . . . 0.0 111.078 -179.708 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.409 ' O ' ' HA2' ' A' ' 116' ' ' GLY . 0.9 OUTLIER -107.01 81.55 1.56 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.02 179.134 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.652 ' CD1' HG12 ' A' ' 84' ' ' VAL . 1.7 mp -81.59 149.09 4.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 121.067 0.46 . . . . 0.0 111.047 -179.235 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.452 ' CB ' HG21 ' A' ' 112' ' ' ILE . 0.3 OUTLIER -109.43 108.8 19.45 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.761 -179.354 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -102.82 104.75 41.12 Favored Pre-proline 0 C--N 1.33 -0.257 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.812 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' PRO . . . . . 0.445 ' HG2' ' CG ' ' A' ' 93' ' ' TYR . 37.9 Cg_endo -66.46 -49.21 1.88 Allowed 'Trans proline' 0 C--N 1.347 0.479 0 C-N-CA 122.341 2.027 . . . . 0.0 112.546 -179.814 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -136.2 178.95 6.66 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.157 -179.86 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 25.5 mt -77.64 -19.89 54.74 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.194 -179.897 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 2.9 ptt180 -96.85 23.26 7.29 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.48 -0.327 . . . . 0.0 111.158 -179.895 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . 0.445 ' CG ' ' HG2' ' A' ' 89' ' ' PRO . 16.8 m-85 -120.15 92.3 3.74 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.942 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -59.49 165.92 2.63 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.049 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 0.542 ' HG ' HG21 ' A' ' 86' ' ' ILE . 2.4 mp -82.63 -37.46 24.91 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.709 179.836 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 96.11 50.85 1.84 Allowed Glycine 0 C--N 1.33 0.229 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.84 179.653 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 1.3 p90 -160.58 -172.92 3.72 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.905 0.383 . . . . 0.0 111.077 179.873 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.428 ' O ' ' HA ' ' A' ' 104' ' ' ILE . 6.4 t -135.71 128.64 31.34 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.458 179.757 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.431 ' CG1' HG23 ' A' ' 141' ' ' VAL . 9.9 p -109.79 131.59 60.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.918 0.389 . . . . 0.0 111.675 -179.525 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 13.0 mt-30 -123.33 88.32 2.9 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.908 -0.587 . . . . 0.0 109.527 178.842 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 4.6 m120 56.59 18.97 3.9 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.932 -178.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 128.68 -41.43 1.57 Allowed Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.854 -0.688 . . . . 0.0 112.572 179.835 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.53 HG12 ' CB ' ' A' ' 158' ' ' ALA . 21.0 mt -77.42 133.38 30.8 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-O 121.061 0.457 . . . . 0.0 111.678 -179.361 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.885 HD11 ' CD1' ' A' ' 124' ' ' ILE . 4.5 mp -93.14 137.57 22.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.609 179.487 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 53.5 t -108.89 -75.39 0.63 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.094 -179.576 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 2.7 m -90.6 124.3 34.93 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.052 -179.826 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.612 HD11 ' CG1' ' A' ' 118' ' ' VAL . 1.1 tt -130.91 110.06 11.0 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.646 179.857 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -64.63 150.12 47.62 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.786 -179.905 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -91.96 45.53 1.22 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.164 0.507 . . . . 0.0 110.619 179.79 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -153.2 -33.81 0.03 OUTLIER Glycine 0 N--CA 1.45 -0.419 0 CA-C-N 115.617 -0.72 . . . . 0.0 112.283 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . 0.438 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -49.39 166.53 0.31 Allowed Glycine 0 C--N 1.333 0.411 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.431 179.812 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.455 ' H ' HD12 ' A' ' 112' ' ' ILE . 0.8 OUTLIER -78.86 -19.44 13.04 Favored 'Isoleucine or valine' 0 C--O 1.237 0.404 0 CA-C-O 120.822 0.344 . . . . 0.0 111.835 -179.652 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 113' ' ' ALA . . . . . 0.613 ' O ' HG12 ' A' ' 118' ' ' VAL . . . -58.12 -30.38 66.26 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.939 0.399 . . . . 0.0 110.529 179.796 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 114' ' ' GLU . . . . . 0.438 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 20.2 pt-20 -59.34 -44.98 92.58 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.682 179.525 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 7.9 mtm180 -64.55 -47.48 78.6 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.151 -179.48 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.409 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -49.04 -74.5 0.26 Allowed Glycine 0 CA--C 1.519 0.297 0 C-N-CA 120.296 -0.954 . . . . 0.0 112.744 -179.933 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 175.45 -14.97 0.04 OUTLIER Glycine 0 CA--C 1.52 0.398 0 C-N-CA 120.863 -0.684 . . . . 0.0 113.116 -179.876 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.628 ' N ' HG22 ' A' ' 84' ' ' VAL . 7.6 p -35.49 153.19 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.275 0 N-CA-C 112.132 0.419 . . . . 0.0 112.132 -179.727 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 9.5 mmt180 -139.73 138.86 36.29 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.881 179.924 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 19.4 t -71.22 81.5 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.154 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 132.1 41.02 0.2 Allowed Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.664 179.902 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 12.9 m170 -131.64 132.0 43.66 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.843 0.354 . . . . 0.0 110.766 179.856 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . 0.978 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 0.2 OUTLIER -81.3 92.39 6.37 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.391 -179.768 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . 0.885 ' CD1' HD11 ' A' ' 104' ' ' ILE . 9.0 mt -46.16 156.7 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.164 178.753 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 125' ' ' ILE . . . . . 0.786 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.6 OUTLIER -153.89 -86.06 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 N-CA-C 112.48 0.548 . . . . 0.0 112.48 -179.497 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 13.5 mt-10 -77.01 92.64 3.73 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 112.131 0.419 . . . . 0.0 112.131 -178.707 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.754 HG23 ' CG ' ' A' ' 153' ' ' MET . 1.2 mt -91.52 98.77 8.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 121.008 0.432 . . . . 0.0 110.991 179.194 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . 0.423 ' N ' ' O ' ' A' ' 152' ' ' HIS . 19.3 p30 48.18 26.51 1.06 Allowed 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.651 -0.704 . . . . 0.0 112.133 179.752 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 125.2 -26.22 5.59 Favored Glycine 0 C--N 1.332 0.357 0 C-N-CA 120.239 -0.981 . . . . 0.0 113.878 178.905 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -100.03 114.02 27.02 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 117.27 0.535 . . . . 0.0 111.428 -179.497 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 12.0 t -78.33 101.99 7.48 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.047 179.847 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . 0.634 HG21 HD11 ' A' ' 127' ' ' ILE . 21.5 m -83.08 6.94 1.57 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.282 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.825 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.786 ' HB ' HG22 ' A' ' 125' ' ' ILE . 11.1 p -51.91 119.7 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.18 0 CA-C-O 120.958 0.409 . . . . 0.0 110.82 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 134' ' ' ALA . . . . . 0.408 ' HB3' ' O ' ' A' ' 133' ' ' VAL . . . 68.45 22.84 7.67 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.751 -179.101 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . 0.443 HG21 ' HD2' ' A' ' 139' ' ' LYS . 28.8 m -99.47 142.05 23.92 Favored Pre-proline 0 C--N 1.328 -0.364 0 CA-C-N 115.669 -0.696 . . . . 0.0 110.702 179.864 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 136' ' ' PRO . . . . . 0.425 ' HD2' ' CG2' ' A' ' 135' ' ' THR . 87.1 Cg_exo -44.97 142.65 5.15 Favored 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 122.628 2.219 . . . . 0.0 112.549 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 6.8 p80 -62.86 -48.05 80.71 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.468 -179.599 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 1.4 tt0 -55.23 -33.44 63.11 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.244 -179.726 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 139' ' ' LYS . . . . . 0.752 ' O ' HD12 ' A' ' 143' ' ' ILE . 1.6 tmtp? -66.14 -49.44 67.44 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.933 -179.928 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 8.0 mt -58.82 -45.14 91.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 121.102 0.477 . . . . 0.0 110.405 179.888 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . 0.431 HG23 ' CG1' ' A' ' 99' ' ' VAL . 93.3 t -60.78 -32.67 52.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.06 178.794 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 3.8 t-160 -59.9 -52.57 64.87 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.538 179.586 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . 0.752 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.1 mp -53.15 -56.85 6.15 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.433 0 CA-C-O 121.197 0.522 . . . . 0.0 110.282 179.253 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.594 HD22 HG12 ' A' ' 151' ' ' ILE . 1.2 mt -61.9 -29.97 70.56 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.315 -0.857 . . . . 0.0 110.45 179.625 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 1.5 m -68.84 -26.73 65.3 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.124 -0.489 . . . . 0.0 109.939 178.549 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 3.8 m-80 -127.41 32.07 5.09 Favored 'General case' 0 C--O 1.232 0.152 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.173 179.796 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 147' ' ' ALA . . . . . 0.718 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -117.62 59.52 0.78 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.819 0.343 . . . . 0.0 111.16 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 28.1 m -54.74 175.7 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.37 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 79.3 -118.62 4.82 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.779 -0.725 . . . . 0.0 112.393 179.912 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -123.8 117.15 24.23 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.714 0.293 . . . . 0.0 110.582 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . 0.718 HD11 ' HB3' ' A' ' 147' ' ' ALA . 0.9 OUTLIER -89.32 111.87 23.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.365 -179.679 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . 0.423 ' O ' ' N ' ' A' ' 128' ' ' ASN . 6.4 m-70 -94.83 120.02 34.36 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 178.357 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 153' ' ' MET . . . . . 0.754 ' CG ' HG23 ' A' ' 127' ' ' ILE . 27.4 ttp -139.86 162.93 33.97 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 112.44 0.533 . . . . 0.0 112.44 -178.106 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 6.1 mttp -129.96 141.3 50.79 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.226 -0.897 . . . . 0.0 109.831 179.276 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . 0.703 ' O ' HG23 ' A' ' 81' ' ' VAL . 4.7 p -139.61 147.4 41.05 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.948 0.404 . . . . 0.0 111.726 -179.174 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 156' ' ' MET . . . . . 0.448 ' CB ' ' CD ' ' A' ' 157' ' ' PRO . 1.0 OUTLIER -113.75 -179.78 0.67 Allowed Pre-proline 0 C--N 1.328 -0.368 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.24 179.59 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 157' ' ' PRO . . . . . 0.448 ' CD ' ' CB ' ' A' ' 156' ' ' MET . 89.3 Cg_endo -85.11 112.09 1.41 Allowed 'Trans proline' 0 N--CA 1.462 -0.375 0 C-N-CA 122.493 2.128 . . . . 0.0 112.558 -179.883 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 158' ' ' ALA . . . . . 0.978 ' HB2' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.249 1.074 0 CA-C-O 118.141 -0.933 . . . . 0.0 111.092 179.864 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 29.6 t . . . . . 0 C--O 1.232 0.137 0 CA-C-O 120.719 0.295 . . . . 0.0 111.062 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 1.6 m -104.64 145.79 29.84 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.994 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 91.7 m -107.05 111.09 23.39 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.049 -0.523 . . . . 0.0 109.917 178.92 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.742 HG13 ' H ' ' A' ' 118' ' ' VAL . 33.5 t -93.15 105.94 17.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.696 -179.415 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.475 HD21 ' OE1' ' A' ' 150' ' ' GLU . 4.2 tt -102.77 83.28 2.23 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.21 -0.45 . . . . 0.0 109.823 179.047 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.8 HD13 HD12 ' A' ' 95' ' ' LEU . 2.0 mt -81.7 132.46 31.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-O 121.096 0.474 . . . . 0.0 111.389 -178.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.441 ' O ' HG21 ' A' ' 112' ' ' ILE . 0.0 OUTLIER -89.45 114.01 25.44 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.692 -0.685 . . . . 0.0 110.531 -179.917 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.534 ' HG3' HD12 ' A' ' 151' ' ' ILE . 5.9 mmm180 -104.91 104.4 46.28 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.451 -0.341 . . . . 0.0 111.133 -179.733 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' PRO . . . . . 0.425 ' HG2' ' CE2' ' A' ' 93' ' ' TYR . 29.7 Cg_exo -61.96 -39.81 48.07 Favored 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.581 2.187 . . . . 0.0 112.427 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -153.61 -171.26 3.84 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.939 0.399 . . . . 0.0 111.303 -179.87 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 0.541 ' HG ' HG11 ' A' ' 148' ' ' VAL . 6.0 mt -86.14 -19.23 30.43 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.491 -179.757 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -93.97 21.58 6.55 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.707 0.289 . . . . 0.0 111.344 -179.585 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . 0.425 ' CE2' ' HG2' ' A' ' 89' ' ' PRO . 15.8 m-85 -104.25 175.56 5.45 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.654 179.547 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -128.35 149.71 50.41 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.897 0.38 . . . . 0.0 111.131 -179.876 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 0.8 HD12 HD13 ' A' ' 86' ' ' ILE . 4.6 mm? -67.59 -56.55 9.01 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.662 179.799 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 118.1 29.63 1.94 Allowed Glycine 0 C--N 1.333 0.401 0 C-N-CA 120.637 -0.792 . . . . 0.0 112.995 179.424 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . 0.432 ' CE2' ' HB3' ' A' ' 95' ' ' LEU . 47.8 p90 -166.81 165.23 16.36 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.852 0.358 . . . . 0.0 111.374 179.843 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -101.16 138.18 38.54 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.626 179.843 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.58 HG21 HG21 ' A' ' 140' ' ' ILE . 9.7 p -115.36 132.75 63.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.923 0.392 . . . . 0.0 111.591 -179.716 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 24.6 mt-30 -131.11 89.25 2.71 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.1 179.387 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 44.7 m-80 60.61 16.25 6.4 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.004 -179.436 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . 0.419 ' O ' ' HB ' ' A' ' 124' ' ' ILE . . . 124.87 -36.25 2.9 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.969 -0.634 . . . . 0.0 112.293 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.701 HG23 ' O ' ' A' ' 122' ' ' HIS . 36.7 mt -77.77 134.97 27.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-O 121.067 0.461 . . . . 0.0 111.738 -179.639 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.769 HD11 ' CD1' ' A' ' 124' ' ' ILE . 4.4 mp -90.29 135.48 26.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.519 179.666 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -106.15 -72.18 0.72 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.208 -179.591 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 1.5 m -101.87 142.26 33.45 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.145 -179.691 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.627 HD11 HG11 ' A' ' 118' ' ' VAL . 1.2 tt -144.68 124.54 13.44 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.646 179.695 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 19.8 mtp -82.09 149.76 27.86 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.03 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 4.6 mtm-85 -93.25 44.47 1.14 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.213 0.53 . . . . 0.0 110.367 179.649 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -161.03 22.43 0.23 Allowed Glycine 0 N--CA 1.449 -0.447 0 CA-C-N 115.617 -0.72 . . . . 0.0 112.284 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . 0.514 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -110.35 174.2 17.17 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 120.934 -0.651 . . . . 0.0 111.901 179.743 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.441 HG21 ' O ' ' A' ' 87' ' ' ARG . 0.6 OUTLIER -79.22 -21.94 12.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-O 120.854 0.359 . . . . 0.0 111.585 -179.713 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 113' ' ' ALA . . . . . 0.735 ' O ' HG12 ' A' ' 118' ' ' VAL . . . -58.35 -30.76 66.99 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.934 0.397 . . . . 0.0 110.549 179.775 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 114' ' ' GLU . . . . . 0.514 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 9.0 pt-20 -59.76 -44.59 93.79 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.753 179.672 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 85.1 mtt180 -65.36 -46.74 78.99 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.32 -179.468 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.404 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -48.94 -74.43 0.27 Allowed Glycine 0 CA--C 1.519 0.316 0 C-N-CA 120.302 -0.951 . . . . 0.0 112.709 -179.903 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . 0.433 ' O ' ' C ' ' A' ' 118' ' ' VAL . . . 175.59 -20.46 0.05 OUTLIER Glycine 0 CA--C 1.519 0.283 0 C-N-CA 121.013 -0.613 . . . . 0.0 112.72 -179.902 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.742 ' H ' HG13 ' A' ' 84' ' ' VAL . 11.0 p -24.91 136.87 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.399 0 N-CA-C 112.575 0.583 . . . . 0.0 112.575 -179.847 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 3.3 ttt180 -134.33 110.69 9.64 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.855 179.902 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 120' ' ' VAL . . . . . 0.489 HG22 ' HB2' ' A' ' 107' ' ' LEU . 21.0 t -57.11 100.21 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.083 -179.88 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 124.02 40.67 0.44 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.39 -179.83 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . 0.701 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.1 OUTLIER -134.91 -167.22 1.95 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.664 0.269 . . . . 0.0 110.657 -179.917 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . 0.718 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 13.8 ttt180 -137.26 90.44 2.52 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.883 179.976 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . 0.769 ' CD1' HD11 ' A' ' 104' ' ' ILE . 9.4 mt -50.06 156.08 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 N-CA-C 110.158 -0.312 . . . . 0.0 110.158 179.199 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 125' ' ' ILE . . . . . 0.848 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.6 OUTLIER -148.59 -84.71 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 N-CA-C 112.171 0.434 . . . . 0.0 112.171 -179.577 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . 0.404 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 12.2 mt-10 -80.34 86.16 5.74 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 112.164 0.431 . . . . 0.0 112.164 -178.999 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.845 HD11 HG21 ' A' ' 132' ' ' VAL . 1.4 mt -89.53 102.43 13.1 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 CA-C-O 120.899 0.381 . . . . 0.0 110.839 179.117 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . 0.461 ' HA ' ' CD2' ' A' ' 152' ' ' HIS . 0.9 OUTLIER 59.97 24.83 13.98 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.077 -0.511 . . . . 0.0 111.109 179.902 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 107.29 -13.43 40.07 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.919 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -97.62 113.07 24.72 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.789 0.328 . . . . 0.0 111.025 -179.878 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 1.2 p -77.44 94.68 4.3 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.019 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . 0.845 HG21 HD11 ' A' ' 127' ' ' ILE . 27.1 m -80.14 1.38 2.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.883 -179.879 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.848 ' HB ' HG22 ' A' ' 125' ' ' ILE . 9.2 p -46.79 -38.11 3.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-O 120.907 0.384 . . . . 0.0 111.619 -179.65 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -115.97 28.89 8.32 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.747 179.554 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . 0.506 HG23 ' HD2' ' A' ' 136' ' ' PRO . 97.9 m -116.32 144.61 33.36 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 115.912 -0.585 . . . . 0.0 111.172 -179.834 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 136' ' ' PRO . . . . . 0.506 ' HD2' HG23 ' A' ' 135' ' ' THR . 48.9 Cg_exo -55.75 164.29 4.66 Favored 'Trans proline' 0 C--N 1.348 0.516 0 C-N-CA 122.528 2.152 . . . . 0.0 112.245 179.842 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 41.7 p-80 -67.18 -48.9 66.56 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.299 -179.837 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 6.0 tp10 -54.47 -36.66 64.36 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.388 -179.692 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 139' ' ' LYS . . . . . 0.796 ' O ' HD12 ' A' ' 143' ' ' ILE . 4.1 mmmt -61.63 -46.54 89.35 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.723 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . 0.825 HG23 ' CD1' ' A' ' 127' ' ' ILE . 16.8 mt -58.86 -46.03 91.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.581 -179.909 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . 0.411 ' CG2' ' CG1' ' A' ' 99' ' ' VAL . 93.7 t -59.8 -32.42 49.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.089 179.086 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -61.77 -54.0 48.33 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.834 179.764 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . 0.796 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.3 mp -52.88 -56.44 7.56 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.454 0 CA-C-O 121.194 0.521 . . . . 0.0 110.312 179.413 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.732 HD22 HG12 ' A' ' 151' ' ' ILE . 2.2 mt -63.0 -29.92 71.2 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.294 -0.866 . . . . 0.0 110.361 179.83 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 15.5 t -69.83 -30.14 67.58 Favored 'General case' 0 N--CA 1.453 -0.289 0 CA-C-N 116.302 -0.408 . . . . 0.0 109.933 178.676 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 3.0 m-80 -125.65 34.66 4.86 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.864 179.722 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 147' ' ' ALA . . . . . 1.06 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -100.3 -39.33 8.07 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.036 0.446 . . . . 0.0 111.585 -179.68 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.541 HG11 ' HG ' ' A' ' 91' ' ' LEU . 24.8 m 44.86 -171.38 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.488 -0.778 . . . . 0.0 111.662 -179.88 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 55.76 -135.35 48.88 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.569 -179.813 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.475 ' OE1' HD21 ' A' ' 85' ' ' LEU . 27.9 mt-10 -107.69 101.24 10.56 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.839 0.352 . . . . 0.0 110.761 179.884 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . 1.06 HD11 ' HB3' ' A' ' 147' ' ' ALA . 0.5 OUTLIER -76.07 111.76 12.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.189 -179.768 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . 0.461 ' CD2' ' HA ' ' A' ' 128' ' ' ASN . 0.8 OUTLIER -98.94 115.13 28.2 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 178.241 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 153' ' ' MET . . . . . 0.68 ' CG ' HG23 ' A' ' 127' ' ' ILE . 13.1 ttp -123.17 163.3 20.86 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.318 0.58 . . . . 0.0 112.139 -178.064 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -128.97 139.39 52.12 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.118 -0.946 . . . . 0.0 109.454 179.077 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . 0.665 HG22 ' CG1' ' A' ' 124' ' ' ILE . 10.4 p -136.0 143.48 44.81 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.125 0.488 . . . . 0.0 111.738 -179.253 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 156' ' ' MET . . . . . 0.465 ' O ' ' CB ' ' A' ' 123' ' ' ARG . 8.9 mtp -132.64 149.66 73.65 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 115.28 -0.873 . . . . 0.0 110.298 179.646 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 77.2 Cg_exo -47.96 116.8 2.11 Favored 'Trans proline' 0 C--N 1.343 0.286 0 C-N-CA 122.37 2.047 . . . . 0.0 112.713 -179.834 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 158' ' ' ALA . . . . . 0.718 ' HB2' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.248 1.019 0 CA-C-O 118.317 -0.849 . . . . 0.0 110.958 179.837 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.573 HG13 ' O ' ' A' ' 155' ' ' THR . 35.0 t . . . . . 0 C--O 1.232 0.133 0 CA-C-O 120.71 0.29 . . . . 0.0 110.936 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.8 m -117.3 134.56 54.67 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.867 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 3.5 m -94.58 111.27 23.03 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.128 179.314 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.838 HG11 HG23 ' A' ' 118' ' ' VAL . 63.7 t -82.77 106.2 13.35 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.938 -179.249 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.408 ' O ' ' HA2' ' A' ' 116' ' ' GLY . 0.9 OUTLIER -106.83 80.81 1.48 Allowed 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 178.491 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.777 HG13 HG12 ' A' ' 84' ' ' VAL . 3.3 mt -81.53 136.02 23.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-O 121.252 0.549 . . . . 0.0 111.945 -178.195 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.426 ' H ' HG22 ' A' ' 112' ' ' ILE . 0.0 OUTLIER -90.45 148.44 22.77 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.368 -0.833 . . . . 0.0 110.194 179.685 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -155.05 102.91 2.27 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.595 -0.275 . . . . 0.0 110.96 -179.819 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 67.3 Cg_endo -74.06 -24.59 14.78 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.514 2.143 . . . . 0.0 112.494 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -149.59 -166.94 2.69 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.914 0.388 . . . . 0.0 111.236 -179.786 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 0.56 ' HG ' HG11 ' A' ' 148' ' ' VAL . 4.2 mt -96.54 -44.4 7.18 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.349 -179.598 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -58.06 -18.77 26.77 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.96 -0.564 . . . . 0.0 111.634 -179.436 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 38.4 m-85 -88.2 87.71 7.4 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.805 179.833 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -66.42 -177.83 0.6 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.079 -179.948 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 0.771 ' CD2' HD13 ' A' ' 86' ' ' ILE . 6.5 mp -94.74 -56.18 2.86 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.771 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 98.06 71.07 1.01 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.848 179.745 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . 0.665 ' CZ ' HD12 ' A' ' 144' ' ' LEU . 14.0 p90 -166.27 162.4 17.34 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.918 0.389 . . . . 0.0 111.01 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.42 ' O ' ' HA ' ' A' ' 104' ' ' ILE . 1.5 m -106.18 120.49 41.96 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.607 179.724 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.427 ' CG1' ' CG2' ' A' ' 141' ' ' VAL . 8.4 p -109.78 139.05 34.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.448 -179.697 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -135.87 89.15 2.46 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.309 179.491 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' ASN . . . . . 0.406 ' ND2' ' HA ' ' A' ' 136' ' ' PRO . 27.2 m120 58.26 18.91 5.78 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.174 -179.529 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 126.73 -38.16 2.25 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.575 179.884 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.49 HG12 ' CB ' ' A' ' 158' ' ' ALA . 31.8 mt -76.88 141.9 15.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 121.034 0.445 . . . . 0.0 111.452 -179.611 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.904 HD11 ' CD1' ' A' ' 124' ' ' ILE . 5.2 mp -109.54 130.01 63.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.863 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 1.8 m -123.52 28.97 6.78 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.969 -179.872 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 106' ' ' SER . . . . . 0.433 ' H ' HG22 ' A' ' 104' ' ' ILE . 0.3 OUTLIER -178.19 141.24 0.24 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.772 179.988 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -159.09 107.63 1.86 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.844 -179.826 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 2.8 ttp -68.13 113.14 5.53 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.74 179.918 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 26.1 mtt180 -58.81 86.49 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.798 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 163.79 -33.97 0.29 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.913 -0.66 . . . . 0.0 112.012 -179.818 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . 0.405 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -61.13 171.43 7.8 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.193 179.693 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.426 HG22 ' H ' ' A' ' 87' ' ' ARG . 0.8 OUTLIER -78.64 -16.93 13.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 120.777 0.323 . . . . 0.0 111.477 -179.789 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 113' ' ' ALA . . . . . 0.47 ' HA ' HG12 ' A' ' 86' ' ' ILE . . . -58.12 -30.5 66.35 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.056 0.455 . . . . 0.0 110.707 179.882 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 114' ' ' GLU . . . . . 0.405 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 21.7 pt-20 -62.0 -46.51 88.9 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.768 -0.651 . . . . 0.0 111.105 179.823 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.4 ' N ' ' CG ' ' A' ' 114' ' ' GLU . 25.2 mtt-85 -62.75 -46.16 89.33 Favored 'General case' 0 N--CA 1.452 -0.347 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.142 -179.378 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.408 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -50.29 -74.05 0.31 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.338 -0.934 . . . . 0.0 112.578 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . 0.572 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 175.97 -27.4 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.736 -179.782 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.838 HG23 HG11 ' A' ' 84' ' ' VAL . 12.0 t -31.25 102.04 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 CA-C-O 120.993 0.425 . . . . 0.0 111.8 -179.722 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -104.13 123.89 48.09 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.643 179.765 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 21.4 t -53.76 99.99 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.188 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 120.7 14.67 5.15 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.934 -0.651 . . . . 0.0 112.79 -179.879 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 14.0 m170 -115.61 132.89 56.49 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.744 0.307 . . . . 0.0 110.626 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . 0.858 ' HB3' ' HB2' ' A' ' 158' ' ' ALA . 13.1 ptt180 -84.55 91.85 7.97 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.677 -179.734 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . 0.904 ' CD1' HD11 ' A' ' 104' ' ' ILE . 19.1 mt -48.09 157.85 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.333 -0.133 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 178.72 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 125' ' ' ILE . . . . . 0.845 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.6 OUTLIER -150.73 -83.37 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 N-CA-C 113.064 0.765 . . . . 0.0 113.064 -179.008 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -75.62 81.85 2.62 Favored 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 112.695 0.628 . . . . 0.0 112.695 -178.247 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.743 HG23 ' HB3' ' A' ' 153' ' ' MET . 1.7 mt -91.02 95.25 5.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.931 0.395 . . . . 0.0 111.062 179.015 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . 0.442 ' N ' ' O ' ' A' ' 152' ' ' HIS . 33.0 m-20 57.76 39.93 26.72 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.934 179.966 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 91.51 -4.18 79.56 Favored Glycine 0 CA--C 1.519 0.329 0 C-N-CA 120.632 -0.794 . . . . 0.0 112.813 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 2.9 tt0 -104.08 107.51 18.44 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.824 0.345 . . . . 0.0 110.836 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 26.0 p -75.6 92.01 2.9 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.093 -179.824 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . 0.734 HG21 HD11 ' A' ' 127' ' ' ILE . 31.4 m -74.74 -3.67 4.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.724 179.838 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.845 ' HB ' HG22 ' A' ' 125' ' ' ILE . 9.0 p -43.79 -44.6 1.87 Allowed 'Isoleucine or valine' 0 C--O 1.231 0.111 0 CA-C-O 120.806 0.336 . . . . 0.0 111.804 -179.775 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 134' ' ' ALA . . . . . 0.474 ' N ' HG13 ' A' ' 133' ' ' VAL . . . -113.37 30.24 7.36 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.958 179.906 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . 0.499 HG21 ' HD2' ' A' ' 139' ' ' LYS . 91.6 m -115.15 140.47 25.71 Favored Pre-proline 0 C--N 1.33 -0.244 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.015 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 136' ' ' PRO . . . . . 0.481 ' HD2' HG23 ' A' ' 135' ' ' THR . 7.6 Cg_endo -50.33 164.18 0.53 Allowed 'Trans proline' 0 C--N 1.347 0.494 0 C-N-CA 122.64 2.226 . . . . 0.0 112.244 179.841 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 137' ' ' HIS . . . . . 0.439 ' CD2' ' N ' ' A' ' 138' ' ' GLU . 32.9 p-80 -72.77 -46.69 52.03 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.606 -179.5 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . 0.439 ' N ' ' CD2' ' A' ' 137' ' ' HIS . 16.7 mt-10 -53.69 -36.69 62.46 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.396 -179.59 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 139' ' ' LYS . . . . . 0.821 ' O ' HD12 ' A' ' 143' ' ' ILE . 6.7 tmtm? -62.93 -47.02 85.04 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.927 -179.816 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 8.6 mt -58.41 -44.71 89.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.523 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . 0.427 ' CG2' ' CG1' ' A' ' 99' ' ' VAL . 93.1 t -60.78 -32.46 52.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.107 178.856 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -61.46 -52.32 65.01 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.641 179.558 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . 0.821 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.4 mp -53.23 -56.67 7.1 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.395 0 CA-C-O 121.098 0.475 . . . . 0.0 110.205 179.422 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.718 HD13 ' CD2' ' A' ' 95' ' ' LEU . 4.9 mt -62.31 -30.31 71.06 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.518 -0.764 . . . . 0.0 110.326 179.506 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 34.5 t -70.09 -28.31 65.31 Favored 'General case' 0 N--CA 1.453 -0.283 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.117 178.901 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 10.3 m120 -131.71 37.4 3.65 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.082 179.808 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 147' ' ' ALA . . . . . 0.635 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -99.79 -44.71 5.99 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.094 0.473 . . . . 0.0 111.512 -179.68 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.56 HG11 ' HG ' ' A' ' 91' ' ' LEU . 32.4 m 45.96 -174.68 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 115.321 -0.854 . . . . 0.0 111.788 -179.684 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 59.64 -108.07 1.54 Allowed Glycine 0 N--CA 1.453 -0.214 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.361 -179.819 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 46.1 mt-10 -136.81 114.1 10.8 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.778 0.323 . . . . 0.0 110.856 179.892 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . 0.635 HD11 ' HB3' ' A' ' 147' ' ' ALA . 1.5 mt -82.84 112.0 19.96 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.139 -179.912 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . 0.442 ' O ' ' N ' ' A' ' 128' ' ' ASN . 0.1 OUTLIER -99.09 115.88 30.01 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.978 -0.556 . . . . 0.0 109.82 179.04 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 153' ' ' MET . . . . . 0.743 ' HB3' HG23 ' A' ' 127' ' ' ILE . 0.0 OUTLIER -144.64 177.83 8.41 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.548 0.69 . . . . 0.0 111.751 -179.048 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 14.4 mttp -139.43 152.66 47.23 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 114.633 -1.167 . . . . 0.0 109.977 179.546 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . 0.693 HG22 HG12 ' A' ' 124' ' ' ILE . 2.0 p -142.99 150.4 39.59 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.195 0.522 . . . . 0.0 111.888 -179.488 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 156' ' ' MET . . . . . 0.423 ' CB ' ' CD ' ' A' ' 157' ' ' PRO . 2.3 mtp -118.69 178.93 0.94 Allowed Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 115.235 -0.893 . . . . 0.0 109.898 179.343 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 157' ' ' PRO . . . . . 0.423 ' CD ' ' CB ' ' A' ' 156' ' ' MET . 89.9 Cg_endo -86.45 106.16 0.75 Allowed 'Trans proline' 0 N--CA 1.459 -0.555 0 C-N-CA 122.44 2.094 . . . . 0.0 112.493 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 158' ' ' ALA . . . . . 0.858 ' HB2' ' HB3' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.249 1.057 0 CA-C-O 118.253 -0.879 . . . . 0.0 111.052 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.516 HG23 ' O ' ' A' ' 155' ' ' THR . 11.2 p . . . . . 0 CA--C 1.527 0.094 0 CA-C-O 120.706 0.288 . . . . 0.0 110.77 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.5 m -104.26 146.09 29.29 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.925 0.393 . . . . 0.0 111.203 -179.709 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 11.6 m -110.17 111.09 22.21 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.002 178.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.769 HG22 ' N ' ' A' ' 118' ' ' VAL . 72.6 t -86.23 106.5 15.66 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.896 -179.164 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.423 ' O ' ' HA2' ' A' ' 116' ' ' GLY . 4.2 tt -106.34 81.34 1.6 Allowed 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 178.497 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.866 HG21 ' CD1' ' A' ' 95' ' ' LEU . 1.2 mt -81.46 140.19 16.9 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 121.167 0.508 . . . . 0.0 111.674 -178.777 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.439 ' HG3' ' CG2' ' A' ' 112' ' ' ILE . 0.0 OUTLIER -99.01 145.9 26.6 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.551 -0.749 . . . . 0.0 110.27 179.873 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 3.8 mtt-85 -139.09 102.26 7.53 Favored Pre-proline 0 C--N 1.331 -0.232 0 CA-C-N 116.463 -0.335 . . . . 0.0 110.982 -179.782 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' PRO . . . . . 0.434 ' HB2' ' CE1' ' A' ' 93' ' ' TYR . 52.5 Cg_exo -55.09 -57.04 1.88 Allowed 'Trans proline' 0 C--N 1.347 0.478 0 C-N-CA 122.465 2.11 . . . . 0.0 112.35 -179.858 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.7 t0 -139.83 -168.67 2.55 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.869 0.366 . . . . 0.0 111.174 -179.86 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 0.424 ' CD1' HG11 ' A' ' 148' ' ' VAL . 0.2 OUTLIER -83.32 -30.82 27.21 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.04 -179.924 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -68.13 -11.02 58.4 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.62 -179.694 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . 0.434 ' CE1' ' HB2' ' A' ' 89' ' ' PRO . 25.2 m-85 -82.88 178.17 8.3 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.507 -0.315 . . . . 0.0 110.784 179.839 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 8.3 mp0 -136.57 164.8 27.35 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.068 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 0.866 ' CD1' HG21 ' A' ' 86' ' ' ILE . 0.7 OUTLIER -72.51 -60.21 2.34 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.781 179.847 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 121.4 14.0 5.06 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.657 -0.783 . . . . 0.0 113.174 179.797 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . 0.62 ' HD2' HG23 ' A' ' 104' ' ' ILE . 30.5 p90 -160.45 175.12 13.12 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.958 0.408 . . . . 0.0 111.197 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -118.42 141.19 48.79 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.009 -0.542 . . . . 0.0 110.771 179.86 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.719 HG21 HG21 ' A' ' 140' ' ' ILE . 6.3 p -109.98 136.0 47.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 121.1 0.476 . . . . 0.0 111.427 -179.858 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -126.92 89.78 3.04 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.048 179.457 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 2.5 m-20 62.27 12.2 5.01 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.814 -179.083 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 129.7 -37.65 2.13 Favored Glycine 0 N--CA 1.445 -0.716 0 C-N-CA 121.095 -0.574 . . . . 0.0 112.007 -179.871 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.55 HG12 ' HB2' ' A' ' 158' ' ' ALA . 41.8 mt -79.2 135.67 25.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-O 121.093 0.473 . . . . 0.0 111.801 -179.469 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.843 HD11 ' CD1' ' A' ' 124' ' ' ILE . 3.8 mp -91.54 141.27 14.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.825 179.799 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' CYS . . . . . 0.413 ' O ' HG13 ' A' ' 120' ' ' VAL . 36.9 m -116.82 -81.1 0.61 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.285 -179.556 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 4.6 m -77.13 139.16 39.88 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.991 -179.78 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.475 ' HB3' HG22 ' A' ' 120' ' ' VAL . 9.5 tt -156.38 120.75 4.5 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.636 179.867 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 19.2 mtm -90.75 129.0 36.87 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.985 -179.889 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 2.3 mpt_? -66.13 76.71 0.09 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.644 179.82 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 178.23 -34.8 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.927 -0.654 . . . . 0.0 112.126 -179.843 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -55.31 171.54 1.46 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.286 179.697 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.439 ' CG2' ' HG3' ' A' ' 87' ' ' ARG . 0.5 OUTLIER -78.66 -17.59 13.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-O 120.82 0.343 . . . . 0.0 111.505 -179.778 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 113' ' ' ALA . . . . . 0.563 ' HA ' HG12 ' A' ' 86' ' ' ILE . . . -58.4 -30.78 67.1 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.87 0.367 . . . . 0.0 110.633 179.804 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -60.02 -45.72 91.88 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.691 179.579 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 1.6 mmm180 -62.93 -49.08 76.18 Favored 'General case' 0 N--CA 1.452 -0.359 0 CA-C-N 115.843 -0.617 . . . . 0.0 111.132 -179.473 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.423 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -49.52 -74.33 0.28 Allowed Glycine 0 CA--C 1.519 0.318 0 C-N-CA 120.224 -0.989 . . . . 0.0 112.532 179.936 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . 0.555 ' C ' HG22 ' A' ' 84' ' ' VAL . . . -179.81 -30.67 0.06 OUTLIER Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 121.124 -0.56 . . . . 0.0 112.181 179.864 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.769 ' N ' HG22 ' A' ' 84' ' ' VAL . 73.6 t -26.43 123.7 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.384 0 C-N-CA 122.956 0.503 . . . . 0.0 112.283 -179.771 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 14.1 mtt-85 -123.29 118.42 27.52 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.54 179.779 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 120' ' ' VAL . . . . . 0.475 HG22 ' HB3' ' A' ' 107' ' ' LEU . 21.5 t -52.2 93.23 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.239 -179.919 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 122.78 37.9 0.6 Allowed Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.933 -0.651 . . . . 0.0 112.332 -179.861 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . 0.436 ' O ' HG23 ' A' ' 103' ' ' ILE . 10.3 m170 -138.77 169.25 18.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.753 0.311 . . . . 0.0 110.805 179.933 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . 0.742 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 1.4 ttm180 -108.42 143.89 36.75 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.201 -179.877 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . 0.843 ' CD1' HD11 ' A' ' 104' ' ' ILE . 26.8 mt -101.29 155.36 4.6 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 178.465 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 125' ' ' ILE . . . . . 0.868 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.7 OUTLIER -147.45 -84.31 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 N-CA-C 113.208 0.818 . . . . 0.0 113.208 -178.561 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . 0.42 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 6.1 mt-10 -79.87 85.34 5.53 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 112.626 0.602 . . . . 0.0 112.626 -178.093 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.8 HD11 HG21 ' A' ' 132' ' ' VAL . 1.7 mt -91.18 103.35 14.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 121.025 0.441 . . . . 0.0 111.17 179.094 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . 0.547 ' ND2' HG22 ' A' ' 127' ' ' ILE . 33.4 m-80 55.65 25.4 8.08 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.106 -179.969 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 107.65 -13.91 38.69 Favored Glycine 0 CA--C 1.518 0.273 0 C-N-CA 120.624 -0.798 . . . . 0.0 112.775 179.895 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 22.3 tt0 -95.95 113.94 25.61 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.849 0.357 . . . . 0.0 110.875 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -77.54 91.4 3.95 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.141 -179.902 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . 0.8 HG21 HD11 ' A' ' 127' ' ' ILE . 32.4 m -75.41 -2.57 4.11 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.257 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.818 179.891 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.868 ' HB ' HG22 ' A' ' 125' ' ' ILE . 8.2 p -46.24 -38.3 3.22 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.142 0 CA-C-O 120.858 0.361 . . . . 0.0 111.445 -179.758 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -117.6 28.57 8.36 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.787 179.401 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . 0.505 HG23 ' HD2' ' A' ' 136' ' ' PRO . 86.0 m -111.48 141.88 25.41 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 115.777 -0.647 . . . . 0.0 111.105 -179.772 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 136' ' ' PRO . . . . . 0.505 ' HD2' HG23 ' A' ' 135' ' ' THR . 9.5 Cg_endo -51.87 164.23 1.13 Allowed 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.8 2.333 . . . . 0.0 112.215 179.742 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 137' ' ' HIS . . . . . 0.403 ' O ' HG23 ' A' ' 141' ' ' VAL . 12.4 p80 -70.47 -47.64 59.6 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.376 -179.785 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -55.6 -32.74 63.33 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.249 -179.707 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 139' ' ' LYS . . . . . 0.761 ' O ' HD12 ' A' ' 143' ' ' ILE . 0.4 OUTLIER -65.08 -50.27 66.78 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.833 -179.917 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . 0.719 HG21 HG21 ' A' ' 99' ' ' VAL . 8.8 mt -58.68 -43.46 87.68 Favored 'Isoleucine or valine' 0 C--O 1.235 0.311 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.577 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . 0.569 HG22 HG12 ' A' ' 99' ' ' VAL . 61.8 t -61.42 -32.93 54.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.292 179.189 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 0.5 OUTLIER -62.66 -53.47 54.05 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.968 179.924 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . 0.761 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.3 mp -53.04 -57.23 4.96 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.393 0 CA-C-O 121.162 0.506 . . . . 0.0 110.371 179.558 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.565 HD22 HG12 ' A' ' 151' ' ' ILE . 1.8 mt -62.16 -30.04 70.77 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.417 -0.81 . . . . 0.0 110.42 179.557 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 9.2 t -68.16 -26.7 65.89 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.179 -0.464 . . . . 0.0 109.872 178.567 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 4.1 m-80 -131.19 35.01 3.95 Favored 'General case' 0 CA--C 1.528 0.107 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.199 179.918 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 147' ' ' ALA . . . . . 0.67 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -114.29 48.75 1.07 Allowed 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.855 0.36 . . . . 0.0 111.304 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.424 HG11 ' CD1' ' A' ' 91' ' ' LEU . 29.8 m -54.09 150.35 1.76 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.285 -179.953 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 108.68 -107.72 2.51 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.445 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 40.9 mt-10 -138.05 104.32 5.2 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.711 0.291 . . . . 0.0 110.889 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . 0.67 HD11 ' HB3' ' A' ' 147' ' ' ALA . 1.2 mt -78.64 111.7 15.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.065 -179.91 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . 0.42 ' CD2' ' HG ' ' A' ' 85' ' ' LEU . 0.6 OUTLIER -103.82 115.66 30.88 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.999 -0.546 . . . . 0.0 109.828 179.129 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 153' ' ' MET . . . . . 0.772 ' HB3' HG23 ' A' ' 127' ' ' ILE . 1.9 ptt? -145.91 167.08 24.15 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.089 0.471 . . . . 0.0 111.876 -179.077 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -115.06 153.28 30.99 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.625 -0.716 . . . . 0.0 109.899 179.234 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . 0.707 HG22 ' HA ' ' A' ' 124' ' ' ILE . 51.8 p -142.69 140.29 31.48 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.235 0.54 . . . . 0.0 111.829 -179.302 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 156' ' ' MET . . . . . 0.41 ' N ' ' O ' ' A' ' 123' ' ' ARG . 0.2 OUTLIER -126.46 152.45 74.23 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 115.329 -0.85 . . . . 0.0 109.947 179.309 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 12.6 Cg_endo -56.16 115.8 2.72 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.497 2.131 . . . . 0.0 112.496 -179.784 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 158' ' ' ALA . . . . . 0.742 ' HB2' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.248 0.992 0 CA-C-O 118.234 -0.889 . . . . 0.0 110.943 179.733 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 37.0 t . . . . . 0 C--O 1.232 0.135 0 CA-C-O 120.772 0.32 . . . . 0.0 110.995 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.3 m -111.12 138.4 47.6 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.85 179.934 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 9.5 m -98.63 111.14 23.6 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.166 179.266 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.771 HG11 HG23 ' A' ' 118' ' ' VAL . 62.0 t -84.95 106.2 14.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.731 -179.432 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.608 ' O ' HD23 ' A' ' 85' ' ' LEU . 10.2 tt -104.36 83.8 2.11 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 178.431 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 1.064 HG21 HD23 ' A' ' 95' ' ' LEU . 7.3 mt -81.84 130.89 35.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.92 -178.342 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.415 ' HG3' ' CG2' ' A' ' 112' ' ' ILE . 0.0 OUTLIER -92.18 124.41 36.24 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.388 -0.823 . . . . 0.0 110.447 -179.958 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -126.48 120.26 23.29 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 116.451 -0.341 . . . . 0.0 110.874 -179.864 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 62.5 Cg_endo -73.41 -28.65 11.99 Favored 'Trans proline' 0 C--N 1.346 0.425 0 C-N-CA 122.465 2.11 . . . . 0.0 112.16 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -173.07 -169.38 0.54 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.959 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 1.9 mp -80.36 -5.56 56.59 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.556 -179.909 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 2.2 ptm85 -102.76 27.28 7.12 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.861 0.362 . . . . 0.0 111.153 -179.807 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 4.3 m-85 -138.37 81.53 1.86 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.914 179.858 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -60.97 161.85 7.78 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.98 -179.847 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 1.064 HD23 HG21 ' A' ' 86' ' ' ILE . 0.5 OUTLIER -79.99 -65.31 1.02 Allowed 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.674 179.897 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 114.34 58.33 0.38 Allowed Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.916 179.512 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . 0.564 ' HD2' HG23 ' A' ' 104' ' ' ILE . 14.2 p90 -165.33 128.49 2.22 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.916 0.389 . . . . 0.0 111.106 179.698 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 6.4 t -71.98 144.09 48.99 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.832 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.941 HG11 ' HB ' ' A' ' 140' ' ' ILE . 48.9 t -111.9 136.9 46.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 121.032 0.444 . . . . 0.0 111.648 -179.705 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 4.1 mm-40 -135.72 88.06 2.37 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.722 -0.672 . . . . 0.0 109.507 178.563 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 85.6 m-20 53.57 21.65 2.63 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.985 -178.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . 0.404 ' N ' ' CD1' ' A' ' 140' ' ' ILE . . . 121.88 -32.83 4.46 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.922 -0.656 . . . . 0.0 112.374 179.902 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.623 HG12 ' HB2' ' A' ' 158' ' ' ALA . 31.2 mt -77.49 128.65 38.01 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 121.003 0.43 . . . . 0.0 111.781 -179.649 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.848 HD11 ' CD1' ' A' ' 124' ' ' ILE . 3.6 mp -84.42 144.81 9.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.146 179.296 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' CYS . . . . . 0.551 ' O ' HG13 ' A' ' 120' ' ' VAL . 55.9 m -126.51 -80.64 0.61 Allowed 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 112.009 0.374 . . . . 0.0 112.009 -179.205 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 40.3 m -79.17 66.18 4.55 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 112.027 0.38 . . . . 0.0 112.027 -178.797 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.803 ' HB3' HG22 ' A' ' 120' ' ' VAL . 14.0 tp -89.12 100.58 13.33 Favored 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 178.859 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 2.0 ptm -81.33 140.51 34.74 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.317 -179.472 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.51 166.74 9.9 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.596 179.697 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 92.79 -41.97 2.69 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.533 -0.842 . . . . 0.0 112.23 -179.732 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -58.21 168.76 5.25 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.227 179.751 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.415 ' CG2' ' HG3' ' A' ' 87' ' ' ARG . 0.9 OUTLIER -78.35 -16.23 13.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.733 0.301 . . . . 0.0 111.768 -179.797 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 113' ' ' ALA . . . . . 0.482 ' HA ' HG12 ' A' ' 86' ' ' ILE . . . -57.52 -30.34 65.07 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 121.015 0.436 . . . . 0.0 110.78 179.853 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 15.3 pt-20 -60.15 -46.69 88.79 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.904 179.56 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 16.2 mtm180 -64.7 -46.38 82.62 Favored 'General case' 0 N--CA 1.453 -0.314 0 CA-C-N 116.009 -0.541 . . . . 0.0 111.127 -179.316 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -50.55 -73.41 0.37 Allowed Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.431 -0.89 . . . . 0.0 112.686 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . 0.576 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 171.78 -21.27 0.07 OUTLIER Glycine 0 CA--C 1.519 0.284 0 C-N-CA 121.048 -0.596 . . . . 0.0 112.663 -179.971 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.771 HG23 HG11 ' A' ' 84' ' ' VAL . 1.2 t -37.95 135.9 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.261 0 CA-C-O 120.98 0.419 . . . . 0.0 111.638 -179.783 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 5.3 mtm180 -136.64 132.18 34.66 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.553 179.64 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 120' ' ' VAL . . . . . 0.803 HG22 ' HB3' ' A' ' 107' ' ' LEU . 15.4 t -57.11 89.45 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.852 0.358 . . . . 0.0 110.999 -179.866 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 131.98 -3.32 5.25 Favored Glycine 0 CA--C 1.52 0.375 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.861 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 1.6 m-70 -90.16 127.51 36.12 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-O 120.888 0.375 . . . . 0.0 110.73 179.899 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . 0.914 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 20.8 ttm180 -82.62 92.35 7.12 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.926 -179.373 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . 0.848 ' CD1' HD11 ' A' ' 104' ' ' ILE . 10.0 mt -50.39 157.56 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.05 178.544 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 125' ' ' ILE . . . . . 0.793 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.6 OUTLIER -150.77 -85.66 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 N-CA-C 112.38 0.511 . . . . 0.0 112.38 -179.349 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -75.29 85.12 2.46 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 112.067 0.395 . . . . 0.0 112.067 -178.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.801 HG23 ' HB3' ' A' ' 153' ' ' MET . 1.3 mt -92.61 102.6 13.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 120.951 0.405 . . . . 0.0 111.312 179.47 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 1.3 m-20 61.83 15.52 7.15 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.596 179.745 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 119.88 -16.95 10.15 Favored Glycine 0 C--N 1.333 0.368 0 C-N-CA 120.401 -0.904 . . . . 0.0 113.338 179.634 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 8.2 pt20 -101.94 123.08 45.24 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 117.091 0.445 . . . . 0.0 111.104 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 48.1 t -81.05 101.68 9.73 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.347 -179.68 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . 0.784 HG21 HD11 ' A' ' 127' ' ' ILE . 27.2 m -81.68 2.7 2.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.68 179.691 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.793 ' HB ' HG22 ' A' ' 125' ' ' ILE . 8.0 p -44.7 -45.18 2.64 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.133 0 CA-C-O 120.853 0.358 . . . . 0.0 111.697 -179.674 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 134' ' ' ALA . . . . . 0.484 ' N ' HG13 ' A' ' 133' ' ' VAL . . . -112.46 30.22 7.27 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.869 179.73 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . 0.514 HG22 ' HB3' ' A' ' 139' ' ' LYS . 86.2 m -109.28 142.47 25.68 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.942 -179.788 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 136' ' ' PRO . . . . . 0.472 ' HD2' HG23 ' A' ' 135' ' ' THR . 71.2 Cg_exo -50.73 164.01 0.64 Allowed 'Trans proline' 0 C--N 1.348 0.535 0 C-N-CA 122.583 2.189 . . . . 0.0 112.431 179.864 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 28.1 p-80 -72.02 -51.22 22.84 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.161 -179.814 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -55.25 -30.96 61.1 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.986 -179.899 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 139' ' ' LYS . . . . . 0.726 ' O ' HD12 ' A' ' 143' ' ' ILE . 0.2 OUTLIER -64.62 -48.65 74.07 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.94 179.998 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . 0.941 ' HB ' HG11 ' A' ' 99' ' ' VAL . 5.4 mt -58.76 -45.01 91.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-O 121.048 0.452 . . . . 0.0 110.438 179.973 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 48.4 t -61.21 -32.43 52.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.417 179.24 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 1.6 m-70 -62.19 -53.09 60.32 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.723 179.79 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . 0.726 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.2 mp -53.28 -56.27 8.97 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.44 0 CA-C-O 121.207 0.527 . . . . 0.0 110.222 179.157 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.785 ' HB3' HD11 ' A' ' 95' ' ' LEU . 2.9 mt -62.95 -30.36 71.5 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.466 179.741 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 2.8 m -67.22 -29.9 69.69 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.17 -0.468 . . . . 0.0 109.743 178.738 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 4.4 m-80 -131.13 38.28 3.67 Favored 'General case' 0 C--N 1.333 -0.135 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.625 179.596 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 147' ' ' ALA . . . . . 1.079 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -90.15 -51.91 5.21 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.246 0.546 . . . . 0.0 111.258 -179.545 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.505 HG23 ' C ' ' A' ' 147' ' ' ALA . 0.2 OUTLIER 57.01 164.61 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-N 115.292 -0.867 . . . . 0.0 111.078 -179.932 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 73.18 -133.41 18.26 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.524 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 -114.39 99.71 7.78 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.788 0.328 . . . . 0.0 110.92 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . 1.079 HD11 ' HB3' ' A' ' 147' ' ' ALA . 0.6 OUTLIER -68.1 111.9 2.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.987 179.982 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . 0.547 ' CD2' HD12 ' A' ' 85' ' ' LEU . 0.7 OUTLIER -108.31 115.75 30.69 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.251 179.455 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 153' ' ' MET . . . . . 0.801 ' HB3' HG23 ' A' ' 127' ' ' ILE . 0.0 OUTLIER -143.62 176.05 9.5 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.208 0.528 . . . . 0.0 111.846 -179.356 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 9.7 mttp -122.76 151.99 41.07 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.416 -0.811 . . . . 0.0 109.487 178.919 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . 0.466 HG22 ' CG1' ' A' ' 124' ' ' ILE . 6.6 p -141.57 141.39 33.5 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.031 0.443 . . . . 0.0 111.598 -179.345 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 156' ' ' MET . . . . . . . . . . . . . 9.6 mtp -125.8 133.52 24.98 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.588 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 82.5 Cg_exo -44.68 120.19 2.66 Favored 'Trans proline' 0 C--N 1.345 0.344 0 C-N-CA 122.558 2.172 . . . . 0.0 112.752 -179.888 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 158' ' ' ALA . . . . . 0.914 ' HB2' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.249 1.061 0 CA-C-O 118.181 -0.914 . . . . 0.0 111.061 179.87 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 39.0 t . . . . . 0 C--O 1.232 0.142 0 CA-C-O 120.794 0.331 . . . . 0.0 110.9 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.0 m -123.18 140.93 52.51 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.01 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 20.0 m -97.34 111.37 23.65 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.059 179.134 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.814 HG22 ' N ' ' A' ' 118' ' ' VAL . 78.9 t -88.98 105.73 16.15 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.42 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.792 -179.239 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.487 ' O ' ' HA2' ' A' ' 116' ' ' GLY . 0.5 OUTLIER -103.21 83.87 2.26 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 178.395 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 1.067 HG21 HD23 ' A' ' 95' ' ' LEU . 19.8 mt -80.85 132.51 31.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 121.405 0.621 . . . . 0.0 111.862 -178.306 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.865 ' O ' HG21 ' A' ' 112' ' ' ILE . 2.9 mmt180 -79.38 149.01 31.8 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 114.957 -1.02 . . . . 0.0 111.137 -179.477 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.534 ' HB3' ' HA ' ' A' ' 148' ' ' VAL . 2.7 mtt-85 -164.57 97.81 0.89 Allowed Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.846 179.689 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 70.3 Cg_endo -89.26 25.77 0.59 Allowed 'Trans proline' 0 N--CA 1.46 -0.483 0 C-N-CA 122.893 2.396 . . . . 0.0 113.414 -179.296 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . 0.729 ' O ' HG12 ' A' ' 148' ' ' VAL . 5.6 p-10 -179.03 177.74 0.79 Allowed 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.039 0.447 . . . . 0.0 111.741 179.922 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 0.822 ' HG ' HG11 ' A' ' 148' ' ' VAL . 6.0 mt -98.42 6.68 47.05 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.692 -0.686 . . . . 0.0 111.486 -179.89 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 8.6 ptt180 -129.18 42.06 3.37 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.853 0.359 . . . . 0.0 111.035 -179.78 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -120.52 126.04 49.37 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.748 179.828 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -86.02 136.6 33.18 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.963 -179.844 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 1.067 HD23 HG21 ' A' ' 86' ' ' ILE . 2.2 mp -77.24 -28.28 53.59 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.804 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 75.08 73.17 0.98 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.835 -0.697 . . . . 0.0 112.782 179.622 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . 0.71 ' CZ ' HD12 ' A' ' 144' ' ' LEU . 0.3 OUTLIER -176.14 156.75 1.72 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.806 0.336 . . . . 0.0 111.168 179.766 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.466 ' O ' ' HA ' ' A' ' 104' ' ' ILE . 3.3 t -106.15 133.81 50.27 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.422 179.559 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.529 HG21 HG21 ' A' ' 140' ' ' ILE . 9.7 p -118.49 134.84 60.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 121.026 0.441 . . . . 0.0 111.459 -179.581 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -131.75 89.24 2.67 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.23 179.405 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 12.1 m120 57.78 18.28 4.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.134 -179.468 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 128.18 -39.83 1.83 Allowed Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.531 179.858 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.529 HG12 ' HB2' ' A' ' 158' ' ' ALA . 26.6 mt -77.3 138.66 20.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 121.006 0.432 . . . . 0.0 111.531 -179.57 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.888 HD11 ' CD1' ' A' ' 124' ' ' ILE . 4.5 mp -99.07 137.83 25.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.911 179.917 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 43.4 t -105.0 -77.98 0.58 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.983 -179.781 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 77.0 p -90.63 119.24 30.71 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.707 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 25.7 tp -112.91 119.3 37.47 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.841 -179.938 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 9.3 mtp -68.13 98.26 0.77 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.975 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -60.86 117.59 5.61 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.826 -179.95 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 97.44 32.5 6.3 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.407 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . 0.513 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -118.61 -160.74 11.56 Favored Glycine 0 N--CA 1.453 -0.216 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.968 -179.789 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.865 HG21 ' O ' ' A' ' 87' ' ' ARG . 7.9 mt -80.62 -39.9 18.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-O 121.094 0.473 . . . . 0.0 111.506 -179.924 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 113' ' ' ALA . . . . . 0.595 ' HB1' HG11 ' A' ' 118' ' ' VAL . . . -57.67 -39.29 76.72 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.12 -179.481 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 114' ' ' GLU . . . . . 0.513 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 15.3 pt-20 -62.83 -37.83 88.33 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.503 179.499 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.497 ' N ' ' HG3' ' A' ' 114' ' ' GLU . 54.8 mtt85 -59.2 -46.71 87.71 Favored 'General case' 0 N--CA 1.452 -0.361 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.644 -179.866 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.487 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -56.33 -71.14 0.78 Allowed Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.343 -0.932 . . . . 0.0 112.501 179.719 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . 0.47 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 175.04 -22.74 0.06 OUTLIER Glycine 0 CA--C 1.52 0.39 0 C-N-CA 120.788 -0.72 . . . . 0.0 113.064 -179.902 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.814 ' N ' HG22 ' A' ' 84' ' ' VAL . 6.0 p -34.27 146.36 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 N-CA-C 112.128 0.418 . . . . 0.0 112.128 -179.604 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -140.95 153.84 45.81 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.917 -179.925 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 22.0 t -74.7 88.44 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.972 179.9 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 124.01 41.0 0.42 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.921 -0.657 . . . . 0.0 112.295 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 1.2 m170 -135.08 122.68 22.09 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.858 0.361 . . . . 0.0 110.764 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . 0.958 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 34.9 ttp180 -79.74 93.6 5.6 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.538 -179.731 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . 0.888 ' CD1' HD11 ' A' ' 104' ' ' ILE . 9.2 mt -49.98 158.21 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 178.715 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 125' ' ' ILE . . . . . 0.789 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.6 OUTLIER -148.99 -82.7 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 N-CA-C 112.446 0.535 . . . . 0.0 112.446 -179.49 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 -74.64 80.72 2.01 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 112.361 0.504 . . . . 0.0 112.361 -178.758 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.991 HG23 ' CG ' ' A' ' 153' ' ' MET . 2.7 mt -84.55 92.04 3.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 121.05 0.452 . . . . 0.0 111.01 179.259 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . 0.414 ' N ' ' O ' ' A' ' 152' ' ' HIS . 56.9 m-80 58.65 25.26 13.06 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.995 -179.81 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 113.36 -16.96 21.81 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.716 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 6.0 tt0 -94.4 111.15 22.89 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.809 0.338 . . . . 0.0 110.814 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -75.98 93.29 3.24 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.084 -179.822 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . 0.73 HG11 HD12 ' A' ' 127' ' ' ILE . 30.6 m -76.39 -1.58 3.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.881 179.835 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.789 ' HB ' HG22 ' A' ' 125' ' ' ILE . 8.7 p -42.94 -44.23 1.22 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.121 0 CA-C-O 120.825 0.345 . . . . 0.0 111.611 -179.653 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 134' ' ' ALA . . . . . 0.474 ' N ' HG13 ' A' ' 133' ' ' VAL . . . -117.24 29.75 7.71 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.772 179.714 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . 0.485 HG22 ' HB3' ' A' ' 139' ' ' LYS . 52.3 m -108.71 142.17 24.87 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.057 -0.519 . . . . 0.0 111.161 -179.844 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 136' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -52.37 164.11 1.45 Allowed 'Trans proline' 0 C--N 1.346 0.442 0 C-N-CA 122.56 2.173 . . . . 0.0 112.284 179.677 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 31.9 p-80 -70.95 -49.81 41.44 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.368 -179.855 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 5.8 tp10 -54.36 -34.79 61.88 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.332 -0.394 . . . . 0.0 111.393 -179.695 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 139' ' ' LYS . . . . . 0.724 ' O ' HD12 ' A' ' 143' ' ' ILE . 3.3 tttp -62.76 -47.34 83.94 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.881 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . 0.529 HG21 HG21 ' A' ' 99' ' ' VAL . 15.1 mt -58.59 -45.45 90.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.603 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . 0.417 ' CG2' ' CG1' ' A' ' 99' ' ' VAL . 87.9 t -60.27 -32.5 50.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.326 178.987 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 1.8 t-80 -62.06 -53.56 53.77 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.012 179.774 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . 0.724 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.1 mp -52.94 -56.8 6.11 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.463 0 CA-C-O 121.227 0.537 . . . . 0.0 110.265 179.44 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.728 HD13 HD22 ' A' ' 95' ' ' LEU . 1.9 mt -62.44 -30.33 71.16 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.313 -0.858 . . . . 0.0 110.397 179.674 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 27.5 t -67.67 -27.8 67.15 Favored 'General case' 0 N--CA 1.453 -0.29 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.085 178.884 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 7.8 m-80 -133.81 37.34 3.26 Favored 'General case' 0 CA--C 1.529 0.163 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.164 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 147' ' ' ALA . . . . . 0.944 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -101.46 -37.66 8.34 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.118 0.485 . . . . 0.0 111.301 -179.861 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.822 HG11 ' HG ' ' A' ' 91' ' ' LEU . 32.0 m 44.56 -172.67 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.37 -0.832 . . . . 0.0 112.036 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 58.38 -135.14 52.13 Favored Glycine 0 C--N 1.332 0.309 0 C-N-CA 121.035 -0.602 . . . . 0.0 112.704 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.429 ' OE1' HD21 ' A' ' 85' ' ' LEU . 62.2 mm-40 -110.09 91.28 3.59 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.851 0.357 . . . . 0.0 110.449 179.836 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . 0.944 HD11 ' HB3' ' A' ' 147' ' ' ALA . 0.7 OUTLIER -61.03 111.62 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.49 -179.448 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . 0.414 ' O ' ' N ' ' A' ' 128' ' ' ASN . 4.2 t60 -90.03 115.78 27.57 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 109.168 -0.679 . . . . 0.0 109.168 178.573 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 153' ' ' MET . . . . . 0.991 ' CG ' HG23 ' A' ' 127' ' ' ILE . 26.9 mtp -133.62 162.14 32.73 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.422 0.629 . . . . 0.0 112.452 -178.431 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 17.7 mttt -134.04 140.39 46.64 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 114.881 -1.054 . . . . 0.0 108.905 178.673 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . 0.61 HG22 ' CG1' ' A' ' 124' ' ' ILE . 1.6 p -140.32 149.44 42.76 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.241 0.543 . . . . 0.0 112.046 -178.871 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 156' ' ' MET . . . . . . . . . . . . . 4.8 ptp -132.23 156.38 80.17 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 115.207 -0.906 . . . . 0.0 110.139 179.146 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_endo -57.4 120.41 8.31 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.366 2.044 . . . . 0.0 112.639 -179.726 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 158' ' ' ALA . . . . . 0.958 ' HB2' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.249 1.029 0 CA-C-O 118.289 -0.862 . . . . 0.0 111.114 179.876 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 20.2 t . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.741 0.305 . . . . 0.0 111.01 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 1.9 m -115.2 139.03 50.28 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.951 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 8.4 m -95.79 111.31 23.31 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.014 179.091 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.766 HG22 ' N ' ' A' ' 118' ' ' VAL . 67.3 t -90.63 105.76 16.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.757 -179.166 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.462 ' O ' ' HA2' ' A' ' 116' ' ' GLY . 6.2 tt -103.0 84.36 2.35 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 178.633 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.977 HG21 HD23 ' A' ' 95' ' ' LEU . 3.6 mt -80.94 128.64 38.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 121.27 0.557 . . . . 0.0 111.864 -178.526 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.829 ' O ' HG21 ' A' ' 112' ' ' ILE . 0.2 OUTLIER -74.81 153.01 38.94 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.459 179.962 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.401 ' HB3' ' N ' ' A' ' 149' ' ' GLY . 0.2 OUTLIER -148.33 100.1 3.61 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.109 179.845 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' PRO . . . . . 0.424 ' HG2' ' CD2' ' A' ' 93' ' ' TYR . 57.8 Cg_endo -71.21 -39.85 3.64 Favored 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.423 2.082 . . . . 0.0 112.497 -179.855 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -145.69 -169.24 3.18 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.167 -179.887 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 0.584 HD12 HG11 ' A' ' 148' ' ' VAL . 0.4 OUTLIER -88.78 -53.27 4.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.057 -179.967 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.2 mpp_? -57.93 -20.06 34.65 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.522 -179.528 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . 0.424 ' CD2' ' HG2' ' A' ' 89' ' ' PRO . 12.7 m-85 -77.21 133.39 38.91 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.799 179.896 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 4.5 mp0 -89.58 177.48 6.53 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.986 -179.925 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 0.977 HD23 HG21 ' A' ' 86' ' ' ILE . 2.3 mp -93.61 -67.62 0.85 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.858 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 134.8 52.53 0.07 OUTLIER Glycine 0 CA--C 1.519 0.332 0 C-N-CA 120.465 -0.874 . . . . 0.0 113.026 179.584 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . 0.598 ' HD2' HG21 ' A' ' 118' ' ' VAL . 0.0 OUTLIER 179.96 177.41 0.65 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.839 0.352 . . . . 0.0 111.402 179.663 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 71.0 m -125.73 137.09 53.8 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.762 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.758 HG21 HG21 ' A' ' 140' ' ' ILE . 7.1 p -109.74 135.26 49.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.453 -179.687 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 4.6 tt0 -131.58 89.4 2.7 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.068 179.359 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 61.05 15.85 6.55 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.016 -179.215 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 125.37 -37.01 2.64 Favored Glycine 0 N--CA 1.447 -0.569 0 C-N-CA 120.987 -0.625 . . . . 0.0 112.065 -179.924 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.828 HG23 ' O ' ' A' ' 122' ' ' HIS . 44.8 mt -77.43 140.93 16.28 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-O 121.016 0.436 . . . . 0.0 111.574 -179.815 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.838 HD11 ' CD1' ' A' ' 124' ' ' ILE . 3.7 mp -98.53 141.21 16.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.985 -179.824 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 22.0 m -119.82 -48.45 2.36 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.936 -0.574 . . . . 0.0 111.003 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -96.81 151.66 19.44 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.871 -179.972 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.725 HD11 HG13 ' A' ' 118' ' ' VAL . 0.4 OUTLIER -167.25 116.46 0.83 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.871 179.988 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 5.0 tmm? -85.49 116.31 23.72 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.939 -179.939 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -60.78 125.6 24.29 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.921 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 88.11 26.99 27.1 Favored Glycine 0 N--CA 1.453 -0.217 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.552 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . 0.496 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -108.36 -161.61 20.55 Favored Glycine 0 CA--C 1.518 0.249 0 C-N-CA 120.782 -0.723 . . . . 0.0 113.031 -179.704 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.829 HG21 ' O ' ' A' ' 87' ' ' ARG . 7.6 mt -80.46 -42.68 21.32 Favored 'Isoleucine or valine' 0 C--O 1.237 0.434 0 CA-C-O 121.181 0.515 . . . . 0.0 111.41 -179.829 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 113' ' ' ALA . . . . . 0.787 ' O ' HG12 ' A' ' 118' ' ' VAL . . . -57.76 -34.72 69.85 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.283 -179.251 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 114' ' ' GLU . . . . . 0.518 ' HG3' ' N ' ' A' ' 115' ' ' ARG . 7.3 pt-20 -67.9 -35.72 78.97 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.725 179.568 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.518 ' N ' ' HG3' ' A' ' 114' ' ' GLU . 36.1 mmt180 -61.71 -47.35 85.7 Favored 'General case' 0 N--CA 1.452 -0.368 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.885 -179.626 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.462 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -55.09 -72.58 0.53 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.225 -0.988 . . . . 0.0 112.615 179.894 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . 0.406 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 175.49 -22.15 0.06 OUTLIER Glycine 0 CA--C 1.52 0.393 0 C-N-CA 120.936 -0.65 . . . . 0.0 112.857 -179.881 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.787 HG12 ' O ' ' A' ' 113' ' ' ALA . 9.1 p -30.76 147.24 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 N-CA-C 112.637 0.606 . . . . 0.0 112.637 -179.723 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -142.79 130.47 21.42 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.653 179.748 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 120' ' ' VAL . . . . . 0.439 HG22 ' HB2' ' A' ' 107' ' ' LEU . 26.0 t -62.0 95.75 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.209 -179.809 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 123.38 40.41 0.47 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.688 179.859 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . 0.828 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -125.32 -165.98 1.48 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.656 0.265 . . . . 0.0 110.851 -179.982 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . 0.642 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 0.1 OUTLIER -145.76 90.75 2.02 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.376 -0.375 . . . . 0.0 110.813 179.952 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . 0.838 ' CD1' HD11 ' A' ' 104' ' ' ILE . 8.0 mt -53.36 157.04 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.582 179.496 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 125' ' ' ILE . . . . . 0.8 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.6 OUTLIER -150.31 -84.48 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 N-CA-C 112.209 0.448 . . . . 0.0 112.209 -179.474 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 21.9 mt-10 -79.75 85.84 5.39 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 112.176 0.436 . . . . 0.0 112.176 -178.964 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.797 HG23 ' HB3' ' A' ' 153' ' ' MET . 1.9 mt -89.83 108.3 19.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 116.396 -0.365 . . . . 0.0 111.377 179.475 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . 0.51 HD22 HG22 ' A' ' 127' ' ' ILE . 55.2 m-80 54.42 24.88 5.54 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.128 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 105.26 -10.22 46.76 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.665 -0.779 . . . . 0.0 112.794 -179.85 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 130' ' ' GLN . . . . . 0.492 HE22 HD11 ' A' ' 143' ' ' ILE . 21.4 tt0 -98.85 112.19 24.36 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.85 0.357 . . . . 0.0 110.756 179.855 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 1.5 m -74.49 91.09 2.24 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.286 -179.595 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . 0.691 HG11 HD12 ' A' ' 127' ' ' ILE . 29.6 m -71.54 -5.6 6.18 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.312 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.547 179.43 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.8 ' HB ' HG22 ' A' ' 125' ' ' ILE . 10.3 p -48.63 121.63 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.254 0 CA-C-O 120.893 0.378 . . . . 0.0 111.133 -179.916 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 134' ' ' ALA . . . . . 0.414 ' HB3' ' O ' ' A' ' 133' ' ' VAL . . . 68.15 22.38 8.3 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.034 -179.395 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . 0.449 ' HB ' ' O ' ' A' ' 132' ' ' VAL . 50.8 m -106.16 141.53 22.94 Favored Pre-proline 0 C--N 1.326 -0.438 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.698 179.559 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 136' ' ' PRO . . . . . 0.418 ' HD2' HG23 ' A' ' 135' ' ' THR . 80.2 Cg_exo -45.38 146.92 2.84 Favored 'Trans proline' 0 C--N 1.345 0.359 0 C-N-CA 122.609 2.206 . . . . 0.0 112.565 -179.922 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 137' ' ' HIS . . . . . 0.416 ' CE1' ' HG2' ' A' ' 138' ' ' GLU . 7.0 p80 -65.21 -41.74 94.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.019 -179.929 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . 0.416 ' HG2' ' CE1' ' A' ' 137' ' ' HIS . 4.7 mm-40 -56.25 -37.21 69.44 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.947 -179.899 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 139' ' ' LYS . . . . . 0.795 ' O ' HD12 ' A' ' 143' ' ' ILE . 27.9 tttt -63.66 -48.96 75.09 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.903 179.942 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . 0.758 HG21 HG21 ' A' ' 99' ' ' VAL . 16.1 mt -58.62 -42.15 84.07 Favored 'Isoleucine or valine' 0 C--O 1.236 0.364 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.628 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . 0.45 HG22 HG12 ' A' ' 99' ' ' VAL . 89.2 t -62.49 -33.03 57.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.194 178.972 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -61.85 -51.74 66.99 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.64 179.736 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . 0.795 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.4 mp -53.24 -57.18 5.3 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.433 0 CA-C-O 121.079 0.466 . . . . 0.0 110.316 179.167 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.595 HD13 HD22 ' A' ' 95' ' ' LEU . 2.9 mt -61.71 -30.24 70.63 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.25 179.597 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 2.1 m -69.27 -25.96 64.52 Favored 'General case' 0 N--CA 1.453 -0.317 0 CA-C-N 116.097 -0.501 . . . . 0.0 109.965 178.529 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 4.9 m-80 -130.15 33.91 4.29 Favored 'General case' 0 CA--C 1.529 0.149 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.213 179.861 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 147' ' ' ALA . . . . . 0.573 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -117.89 54.88 0.89 Allowed 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.192 179.908 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.584 HG11 HD12 ' A' ' 91' ' ' LEU . 8.1 m -50.78 177.61 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.447 -179.972 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . 0.401 ' N ' ' HB3' ' A' ' 88' ' ' ARG . . . 81.75 -111.62 3.35 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.458 -179.948 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 58.9 mt-10 -138.4 105.64 5.49 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.877 0.37 . . . . 0.0 110.715 179.841 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . 0.574 HG12 HD22 ' A' ' 144' ' ' LEU . 1.1 mt -73.01 111.36 7.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.069 -179.802 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . 0.403 ' CE1' ' HA ' ' A' ' 128' ' ' ASN . 8.3 p80 -106.34 115.58 30.46 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 178.918 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 153' ' ' MET . . . . . 0.797 ' HB3' HG23 ' A' ' 127' ' ' ILE . 1.5 ptt? -140.35 176.13 9.03 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.324 0.583 . . . . 0.0 112.085 -178.663 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 17.6 mttm -126.94 147.69 50.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.194 -0.912 . . . . 0.0 109.812 179.153 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . 0.554 HG22 ' CG1' ' A' ' 124' ' ' ILE . 4.7 p -142.73 145.27 33.16 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.977 0.418 . . . . 0.0 111.163 -179.515 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 156' ' ' MET . . . . . 0.424 ' O ' ' N ' ' A' ' 123' ' ' ARG . 6.6 ptp -133.12 156.65 79.75 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.631 179.647 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_exo -49.46 126.18 15.42 Favored 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.508 2.139 . . . . 0.0 112.623 -179.887 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 158' ' ' ALA . . . . . 0.646 ' HB2' HG12 ' A' ' 103' ' ' ILE . . . . . . . . 0 C--O 1.249 1.034 0 CA-C-O 118.26 -0.876 . . . . 0.0 111.016 179.823 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 21.5 t . . . . . 0 C--O 1.23 0.051 0 CA-C-O 120.811 0.338 . . . . 0.0 111.011 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.2 m -101.8 134.91 44.23 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.786 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 20.2 m -95.71 111.78 23.65 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.186 179.235 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.762 HG22 ' N ' ' A' ' 118' ' ' VAL . 62.2 t -85.63 105.37 14.29 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.41 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.401 -179.408 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.48 HD21 ' HB3' ' A' ' 150' ' ' GLU . 1.0 OUTLIER -103.17 83.68 2.23 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.058 -0.519 . . . . 0.0 109.652 178.893 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.845 HG21 ' CD2' ' A' ' 95' ' ' LEU . 12.6 mt -81.77 123.72 38.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-O 121.368 0.604 . . . . 0.0 111.717 -178.756 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.474 ' HB2' HG21 ' A' ' 112' ' ' ILE . 0.0 OUTLIER -71.98 132.5 44.39 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.776 -179.901 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.442 ' HG3' HD12 ' A' ' 151' ' ' ILE . 0.0 OUTLIER -130.14 90.43 42.11 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.705 179.969 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' PRO . . . . . 0.456 ' HG2' ' CD2' ' A' ' 93' ' ' TYR . 48.7 Cg_endo -68.87 -25.28 33.07 Favored 'Trans proline' 0 C--N 1.345 0.376 0 C-N-CA 122.552 2.168 . . . . 0.0 112.569 -179.912 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . 0.572 ' O ' HG23 ' A' ' 148' ' ' VAL . 0.6 OUTLIER -155.02 -169.57 3.23 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.978 0.418 . . . . 0.0 111.238 -179.856 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -97.44 -46.65 5.98 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.121 -179.82 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -57.01 -20.5 24.42 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.906 -0.588 . . . . 0.0 111.538 -179.631 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . 0.456 ' CD2' ' HG2' ' A' ' 89' ' ' PRO . 8.2 m-85 -60.3 -177.44 0.07 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.688 179.765 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -151.28 161.46 42.67 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.173 -179.941 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 0.845 ' CD2' HG21 ' A' ' 86' ' ' ILE . 1.4 mt -96.89 -50.34 4.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.698 179.898 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 88.78 72.0 1.27 Allowed Glycine 0 N--CA 1.452 -0.249 0 C-N-CA 120.797 -0.716 . . . . 0.0 113.096 179.456 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . 0.593 ' HE1' HD13 ' A' ' 95' ' ' LEU . 15.9 p90 -175.66 158.33 2.17 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.827 0.346 . . . . 0.0 111.174 179.57 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -105.17 146.64 28.96 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.681 179.924 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.436 ' CG2' HD12 ' A' ' 140' ' ' ILE . 7.3 p -130.63 134.02 62.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.307 -179.688 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -127.04 89.41 2.97 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.351 179.493 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 6.5 m120 57.11 18.74 4.27 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.052 -179.432 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 129.79 -41.44 1.54 Allowed Glycine 0 N--CA 1.448 -0.506 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.515 179.871 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.52 HG12 ' CB ' ' A' ' 158' ' ' ALA . 22.7 mt -77.57 129.5 37.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 121.077 0.465 . . . . 0.0 111.576 -179.344 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.872 HD11 ' CD1' ' A' ' 124' ' ' ILE . 3.6 mp -85.75 140.84 15.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.771 179.684 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 64.6 m -106.44 -69.89 0.81 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.826 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -100.86 141.25 34.01 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.788 179.859 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.405 ' CB ' HG22 ' A' ' 120' ' ' VAL . 5.7 tp -143.6 113.72 7.29 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.695 179.93 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 21.9 mmm -76.28 116.7 17.23 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.86 -179.839 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.05 78.88 0.05 OUTLIER 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.675 179.809 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 173.91 -34.24 0.11 Allowed Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.937 -0.649 . . . . 0.0 112.207 -179.811 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . 0.412 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -57.85 174.63 2.31 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.258 179.853 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.474 HG21 ' HB2' ' A' ' 87' ' ' ARG . 0.9 OUTLIER -78.53 -16.98 13.65 Favored 'Isoleucine or valine' 0 C--O 1.236 0.395 0 CA-C-O 120.91 0.386 . . . . 0.0 111.611 -179.886 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 113' ' ' ALA . . . . . 0.623 ' O ' HG12 ' A' ' 118' ' ' VAL . . . -57.81 -30.68 65.91 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.997 0.427 . . . . 0.0 110.875 179.908 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 114' ' ' GLU . . . . . 0.412 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 17.0 pt-20 -63.96 -46.85 82.84 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.856 179.828 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.4 ' N ' ' CG ' ' A' ' 114' ' ' GLU . 8.8 mtt180 -58.91 -47.33 85.39 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.087 -179.557 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.429 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -50.1 -72.67 0.45 Allowed Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.368 -0.92 . . . . 0.0 112.689 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . 0.521 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 172.34 -21.69 0.07 OUTLIER Glycine 0 CA--C 1.519 0.293 0 C-N-CA 120.972 -0.632 . . . . 0.0 112.674 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.762 ' N ' HG22 ' A' ' 84' ' ' VAL . 3.8 p -30.34 144.58 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.29 0 N-CA-C 112.327 0.492 . . . . 0.0 112.327 -179.78 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.425 ' HB3' ' CD2' ' A' ' 122' ' ' HIS . 0.0 OUTLIER -136.64 126.65 26.02 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.643 -179.992 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 120' ' ' VAL . . . . . 0.405 HG22 ' CB ' ' A' ' 107' ' ' LEU . 19.5 t -56.05 90.79 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.184 179.899 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 121.25 11.21 6.29 Favored Glycine 0 CA--C 1.52 0.379 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.8 -179.904 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . 0.425 ' CD2' ' HB3' ' A' ' 119' ' ' ARG . 6.9 m170 -98.24 132.21 43.94 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.891 0.377 . . . . 0.0 110.739 179.889 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . 0.871 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 0.0 OUTLIER -79.41 90.78 5.04 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.586 -179.622 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . 0.872 ' CD1' HD11 ' A' ' 104' ' ' ILE . 7.7 mt -54.13 143.15 6.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 N-CA-C 109.709 -0.478 . . . . 0.0 109.709 178.577 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 125' ' ' ILE . . . . . 0.796 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.5 OUTLIER -137.97 -82.84 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 N-CA-C 112.365 0.506 . . . . 0.0 112.365 -179.35 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 11.6 mt-10 -73.92 81.35 1.66 Allowed 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 112.538 0.57 . . . . 0.0 112.538 -178.776 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.97 HG23 ' CG ' ' A' ' 153' ' ' MET . 3.0 mt -82.61 92.44 2.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.95 179.045 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . 0.406 ' N ' ' O ' ' A' ' 152' ' ' HIS . 1.6 t-20 58.9 21.11 8.78 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.014 -179.915 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 119.08 -18.5 10.37 Favored Glycine 0 C--N 1.332 0.349 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.787 -179.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -94.72 112.02 23.77 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.837 0.351 . . . . 0.0 110.922 -179.842 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 3.6 p -76.22 96.4 3.91 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.0 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . 0.699 HG11 HD12 ' A' ' 127' ' ' ILE . 27.4 m -81.04 2.64 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.323 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.86 179.983 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.796 ' HB ' HG22 ' A' ' 125' ' ' ILE . 9.0 p -44.43 -42.57 2.14 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.178 0 CA-C-O 120.922 0.392 . . . . 0.0 111.661 -179.761 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 134' ' ' ALA . . . . . 0.429 ' N ' HG13 ' A' ' 133' ' ' VAL . . . -116.55 29.73 7.77 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.843 179.587 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . 0.478 HG23 ' HD2' ' A' ' 136' ' ' PRO . 85.4 m -111.92 140.17 23.11 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.089 -179.834 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 136' ' ' PRO . . . . . 0.478 ' HD2' HG23 ' A' ' 135' ' ' THR . 10.6 Cg_endo -54.44 164.23 3.08 Favored 'Trans proline' 0 C--N 1.347 0.455 0 C-N-CA 122.646 2.23 . . . . 0.0 112.333 179.895 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 15.2 p80 -67.44 -46.65 72.47 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.603 -179.593 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -53.68 -35.21 60.83 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.387 -0.369 . . . . 0.0 111.468 -179.445 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 139' ' ' LYS . . . . . 0.783 ' O ' HD12 ' A' ' 143' ' ' ILE . 0.1 OUTLIER -65.36 -48.94 71.2 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.85 0.357 . . . . 0.0 111.079 -179.8 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . 0.836 HG23 ' CD1' ' A' ' 127' ' ' ILE . 10.1 mt -58.58 -46.19 90.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.529 -179.925 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . 0.405 ' CG2' ' CG1' ' A' ' 99' ' ' VAL . 86.8 t -60.41 -32.29 50.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.058 178.797 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 1.9 t60 -60.65 -52.94 63.01 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.664 179.585 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . 0.783 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.2 mp -53.25 -57.03 5.59 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.456 0 CA-C-O 121.151 0.5 . . . . 0.0 110.178 179.364 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.686 HD22 HG12 ' A' ' 151' ' ' ILE . 4.5 mt -60.96 -30.23 70.12 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.279 179.699 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 1.3 m -68.56 -27.0 65.69 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.13 -0.486 . . . . 0.0 109.887 178.572 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 9.0 m120 -127.82 32.59 4.93 Favored 'General case' 0 CA--C 1.528 0.109 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.124 179.813 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 147' ' ' ALA . . . . . 0.512 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -119.26 63.45 0.79 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.375 -0.375 . . . . 0.0 111.223 179.915 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.694 HG22 ' H ' ' A' ' 149' ' ' GLY . 1.6 p -60.11 -157.28 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.983 -179.869 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . 0.694 ' H ' HG22 ' A' ' 148' ' ' VAL . . . 58.0 -109.94 2.15 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.867 -0.683 . . . . 0.0 112.438 -179.961 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.48 ' HB3' HD21 ' A' ' 85' ' ' LEU . 3.9 mm-40 -131.18 100.13 5.1 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.739 0.304 . . . . 0.0 110.526 179.791 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . 0.686 HG12 HD22 ' A' ' 144' ' ' LEU . 0.3 OUTLIER -63.04 111.73 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.982 0.42 . . . . 0.0 111.213 -179.751 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . 0.406 ' O ' ' N ' ' A' ' 128' ' ' ASN . 1.2 t-80 -95.56 121.32 37.13 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 178.943 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 153' ' ' MET . . . . . 0.97 ' CG ' HG23 ' A' ' 127' ' ' ILE . 29.3 mtp -137.74 166.43 23.98 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.386 0.612 . . . . 0.0 112.368 -178.525 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 154' ' ' LYS . . . . . 0.405 ' O ' HG13 ' A' ' 125' ' ' ILE . 0.9 OUTLIER -143.34 132.19 22.74 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 114.852 -1.067 . . . . 0.0 108.811 178.762 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . 0.441 HG22 HG12 ' A' ' 124' ' ' ILE . 1.3 p -138.57 161.25 37.56 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.333 0.587 . . . . 0.0 112.176 -178.53 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 156' ' ' MET . . . . . 0.42 ' O ' ' N ' ' A' ' 123' ' ' ARG . 5.1 ptp -135.58 160.03 69.28 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 115.133 -0.94 . . . . 0.0 109.953 179.174 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 21.6 Cg_endo -61.67 118.36 5.23 Favored 'Trans proline' 0 C--N 1.343 0.274 0 C-N-CA 122.366 2.044 . . . . 0.0 112.544 -179.675 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 158' ' ' ALA . . . . . 0.871 ' HB2' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.25 1.092 0 CA-C-O 118.211 -0.9 . . . . 0.0 111.037 179.749 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 10.3 p . . . . . 0 C--O 1.231 0.1 0 CA-C-O 120.718 0.294 . . . . 0.0 110.864 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.8 m -121.35 142.94 49.49 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.013 -179.842 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 5.4 m -101.37 111.15 23.3 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.135 179.2 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 1.018 HG11 HG23 ' A' ' 118' ' ' VAL . 41.4 t -82.85 105.95 13.18 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.562 0 CA-C-N 115.949 -0.569 . . . . 0.0 112.184 -179.215 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.456 ' O ' HD23 ' A' ' 85' ' ' LEU . 7.1 tt -99.96 79.81 2.24 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 178.069 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.892 HG13 HG12 ' A' ' 84' ' ' VAL . 3.3 mt -82.66 104.95 11.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.767 -178.413 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.785 ' O ' HG21 ' A' ' 112' ' ' ILE . 0.0 OUTLIER -74.93 108.31 7.57 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.428 179.21 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.494 ' HG3' HD12 ' A' ' 151' ' ' ILE . 10.4 mtp180 -92.32 111.45 50.52 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.184 -179.646 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_exo -62.26 -63.9 0.09 OUTLIER 'Trans proline' 0 C--N 1.346 0.445 0 C-N-CA 122.572 2.181 . . . . 0.0 112.407 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 3.1 t0 -121.44 -173.36 2.61 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.919 0.39 . . . . 0.0 111.165 -179.71 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 0.552 ' HG ' HG13 ' A' ' 148' ' ' VAL . 0.0 OUTLIER -94.82 -21.2 18.86 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.281 -179.905 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -96.7 23.28 7.14 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.81 0.338 . . . . 0.0 111.14 -179.877 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 2.0 m-85 -102.23 178.41 4.6 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.824 179.827 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -135.71 143.61 45.46 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.017 -179.918 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 0.778 ' CD2' HD13 ' A' ' 86' ' ' ILE . 8.3 mp -72.57 -31.06 64.94 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.798 179.872 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 82.96 55.16 3.01 Favored Glycine 0 C--N 1.33 0.242 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.968 179.626 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -173.17 156.82 3.29 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.836 0.351 . . . . 0.0 111.144 179.82 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.2 m -99.28 155.92 17.25 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.677 179.804 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.43 ' CG1' ' CG2' ' A' ' 141' ' ' VAL . 8.5 p -133.0 132.15 58.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.927 0.394 . . . . 0.0 111.336 -179.86 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -128.97 89.27 2.85 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.27 179.509 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 3.3 m-80 58.25 17.25 4.52 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.126 -179.637 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 129.81 -40.09 1.73 Allowed Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.261 179.905 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.524 HG12 ' CB ' ' A' ' 158' ' ' ALA . 30.1 mt -77.24 130.19 36.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 121.098 0.475 . . . . 0.0 111.522 -179.677 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.807 HD11 ' CD1' ' A' ' 124' ' ' ILE . 3.8 mp -83.96 139.67 17.28 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.793 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -84.62 -75.62 0.34 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.328 -179.479 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -132.37 121.75 23.96 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.917 0.389 . . . . 0.0 111.114 -179.74 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.408 HD12 ' N ' ' A' ' 108' ' ' MET . 7.8 tp -105.57 116.2 31.53 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.463 179.761 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 108' ' ' MET . . . . . 0.408 ' N ' HD12 ' A' ' 107' ' ' LEU . 36.2 mtm -69.27 132.94 47.26 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.056 -179.807 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -67.18 76.14 0.14 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.549 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 174.63 -34.22 0.1 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.285 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . 0.439 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -56.54 176.26 1.05 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.438 179.774 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.785 HG21 ' O ' ' A' ' 87' ' ' ARG . 1.8 mt -78.61 -22.04 13.09 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-O 120.782 0.325 . . . . 0.0 111.615 -179.846 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 113' ' ' ALA . . . . . . . . . . . . . . . -57.82 -30.31 65.63 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.008 0.432 . . . . 0.0 110.702 179.828 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 114' ' ' GLU . . . . . 0.439 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 19.6 pt-20 -60.63 -47.19 87.32 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.89 -0.595 . . . . 0.0 111.197 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 3.8 mtm180 -66.59 -41.33 88.67 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.241 -179.294 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -56.19 -72.63 0.54 Allowed Glycine 0 N--CA 1.448 -0.539 0 C-N-CA 120.398 -0.906 . . . . 0.0 112.669 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . 0.428 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 161.09 -10.67 0.13 Allowed Glycine 0 CA--C 1.522 0.47 0 C-N-CA 121.219 -0.515 . . . . 0.0 112.851 -179.879 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 1.018 HG23 HG11 ' A' ' 84' ' ' VAL . 2.2 t -29.75 -71.46 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 C-N-CA 123.11 0.564 . . . . 0.0 112.306 -179.677 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.654 ' N ' HG12 ' A' ' 118' ' ' VAL . 0.0 OUTLIER 64.32 136.12 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.467 -179.486 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 120' ' ' VAL . . . . . 0.403 ' CG2' ' HB3' ' A' ' 107' ' ' LEU . 20.2 t -69.73 116.98 11.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.447 -0.342 . . . . 0.0 111.427 -179.69 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 112.55 33.25 2.12 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.799 179.644 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 1.5 m-70 -135.71 132.96 37.55 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.831 0.348 . . . . 0.0 110.991 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . 0.977 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 72.3 ttt180 -88.76 95.29 10.22 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.65 -179.686 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . 0.807 ' CD1' HD11 ' A' ' 104' ' ' ILE . 11.7 mt -49.68 146.63 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 178.657 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 125' ' ' ILE . . . . . 0.924 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.6 OUTLIER -137.11 -84.8 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 N-CA-C 112.772 0.656 . . . . 0.0 112.772 -178.924 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 19.5 mt-10 -80.8 90.86 5.87 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 112.454 0.538 . . . . 0.0 112.454 -178.383 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.823 HG23 ' HB3' ' A' ' 153' ' ' MET . 1.8 mt -92.15 100.79 11.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.288 179.284 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . 0.488 HD22 HG22 ' A' ' 127' ' ' ILE . 52.7 m-80 57.82 17.87 4.52 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.622 179.815 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 121.69 -20.69 8.18 Favored Glycine 0 C--N 1.333 0.39 0 C-N-CA 120.348 -0.929 . . . . 0.0 113.381 179.406 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -98.22 120.96 39.53 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 117.256 0.528 . . . . 0.0 111.038 -179.727 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 67.4 p -79.25 94.62 5.47 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.362 -179.838 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . 0.782 HG21 HD11 ' A' ' 127' ' ' ILE . 31.0 m -74.62 -4.87 6.17 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.304 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.594 179.679 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.924 ' HB ' HG22 ' A' ' 125' ' ' ILE . 6.6 p -46.5 -37.69 3.32 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.141 0 CA-C-O 120.895 0.379 . . . . 0.0 111.526 -179.683 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -116.99 29.66 7.79 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.719 179.602 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . 0.526 HG23 ' HD2' ' A' ' 136' ' ' PRO . 87.9 m -117.24 141.94 29.37 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-N 115.881 -0.6 . . . . 0.0 111.033 -179.759 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 136' ' ' PRO . . . . . 0.526 ' HD2' HG23 ' A' ' 135' ' ' THR . 7.6 Cg_endo -49.65 164.04 0.41 Allowed 'Trans proline' 0 C--N 1.347 0.477 0 C-N-CA 122.77 2.313 . . . . 0.0 112.23 179.685 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 11.3 p80 -73.38 -45.95 51.84 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.539 -179.655 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -53.78 -36.94 62.95 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.373 -179.55 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 139' ' ' LYS . . . . . 0.728 ' O ' HD12 ' A' ' 143' ' ' ILE . 0.1 OUTLIER -63.26 -47.34 82.78 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.895 -179.857 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 8.6 mt -58.74 -41.79 83.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.965 0.412 . . . . 0.0 110.646 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . 0.43 ' CG2' ' CG1' ' A' ' 99' ' ' VAL . 90.1 t -63.51 -32.68 57.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.28 179.139 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 56.7 t60 -62.33 -54.57 38.54 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.828 179.943 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . 0.728 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.3 mp -53.23 -56.83 6.36 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.395 0 CA-C-O 121.112 0.482 . . . . 0.0 110.138 179.373 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.721 HD13 ' CD2' ' A' ' 95' ' ' LEU . 5.1 mt -60.63 -30.28 69.77 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.47 -0.786 . . . . 0.0 110.313 179.409 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 2.3 m -67.65 -27.08 66.56 Favored 'General case' 0 N--CA 1.453 -0.323 0 CA-C-N 116.164 -0.471 . . . . 0.0 109.981 178.471 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 4.6 m-80 -130.28 34.73 4.16 Favored 'General case' 0 CA--C 1.527 0.087 0 CA-C-N 116.013 -0.54 . . . . 0.0 111.215 179.796 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 147' ' ' ALA . . . . . 0.569 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -118.65 55.26 0.92 Allowed 'General case' 0 C--O 1.232 0.149 0 CA-C-O 120.864 0.364 . . . . 0.0 111.451 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.552 HG13 ' HG ' ' A' ' 91' ' ' LEU . 2.8 m -55.84 174.89 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.181 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 88.64 -101.69 2.77 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.813 -0.708 . . . . 0.0 112.606 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 29.8 mt-10 -148.95 94.49 2.26 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.786 0.327 . . . . 0.0 110.989 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . 0.569 HD11 ' HB3' ' A' ' 147' ' ' ALA . 1.2 mt -61.75 112.2 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.995 179.939 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . 0.404 ' O ' ' N ' ' A' ' 128' ' ' ASN . 0.3 OUTLIER -102.68 115.53 30.77 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.076 179.144 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 153' ' ' MET . . . . . 0.823 ' HB3' HG23 ' A' ' 127' ' ' ILE . 1.8 ptm -147.59 166.68 26.62 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.129 0.49 . . . . 0.0 111.875 -179.111 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 35.4 mttp -112.58 155.99 23.43 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.889 179.146 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . 0.436 HG23 HG23 ' A' ' 84' ' ' VAL . 13.8 p -141.2 144.13 34.58 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.226 0.536 . . . . 0.0 111.915 -179.451 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 156' ' ' MET . . . . . 0.597 ' CE ' HD13 ' A' ' 125' ' ' ILE . 1.5 mtm -110.86 179.94 0.74 Allowed Pre-proline 0 C--N 1.33 -0.241 0 CA-C-N 115.257 -0.883 . . . . 0.0 110.072 179.593 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 157' ' ' PRO . . . . . 0.418 ' CD ' ' CB ' ' A' ' 156' ' ' MET . 90.2 Cg_endo -92.68 106.98 0.2 Allowed 'Trans proline' 0 N--CA 1.456 -0.725 0 C-N-CA 122.757 2.305 . . . . 0.0 112.511 -179.919 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 158' ' ' ALA . . . . . 0.977 ' HB2' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.249 1.039 0 CA-C-O 118.186 -0.912 . . . . 0.0 111.036 179.801 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.498 HG22 ' HE3' ' A' ' 156' ' ' MET . 44.7 t . . . . . 0 C--O 1.232 0.144 0 CA-C-O 120.819 0.342 . . . . 0.0 110.922 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.7 m -131.31 140.04 49.68 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.02 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 6.8 m -100.29 111.3 23.57 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.149 179.284 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.829 HG12 HG13 ' A' ' 86' ' ' ILE . 49.5 t -83.68 106.57 14.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.929 -179.339 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.474 HD23 ' C ' ' A' ' 85' ' ' LEU . 7.0 tt -105.88 81.57 1.67 Allowed 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 178.317 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.829 HG13 HG12 ' A' ' 84' ' ' VAL . 12.7 mt -81.52 152.26 4.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.549 -178.498 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.404 ' CG ' ' CG2' ' A' ' 112' ' ' ILE . 0.0 OUTLIER -111.68 141.39 45.35 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.797 -179.426 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 11.5 mtp85 -140.27 84.32 14.65 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.85 179.812 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 63.7 Cg_exo -51.66 -35.44 57.34 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.656 2.238 . . . . 0.0 112.516 -179.817 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . 0.621 ' O ' HG12 ' A' ' 148' ' ' VAL . 0.3 OUTLIER -136.06 -169.64 2.47 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.942 0.401 . . . . 0.0 111.134 -179.777 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 0.787 ' HG ' HG11 ' A' ' 148' ' ' VAL . 3.9 mt -93.63 -43.17 8.8 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.783 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 2.3 mpp_? -63.27 -14.79 53.39 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.84 -0.618 . . . . 0.0 111.703 -179.595 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 7.5 m-85 -56.69 174.72 0.14 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.866 0.365 . . . . 0.0 110.915 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.491 ' O ' HD12 ' A' ' 112' ' ' ILE . 9.0 mp0 -138.6 166.13 25.14 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.027 -179.943 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 0.67 HD11 ' HB3' ' A' ' 144' ' ' LEU . 1.1 mt -97.66 -49.07 4.99 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.877 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 91.62 50.92 2.61 Favored Glycine 0 C--N 1.331 0.298 0 C-N-CA 120.728 -0.748 . . . . 0.0 113.108 179.5 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . 0.519 ' HE1' HD13 ' A' ' 95' ' ' LEU . 0.5 OUTLIER -168.95 162.97 11.39 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.795 0.331 . . . . 0.0 111.039 179.64 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -110.55 133.95 52.83 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.726 179.907 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.629 HG21 HG21 ' A' ' 140' ' ' ILE . 11.4 p -110.46 132.13 59.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.378 -179.813 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 3.6 mt-30 -129.08 89.51 2.88 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.222 179.485 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 2.4 m120 59.67 18.04 6.8 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.037 -0.528 . . . . 0.0 111.0 -179.406 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 124.9 -37.29 2.61 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.441 179.887 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.56 HG12 ' CB ' ' A' ' 158' ' ' ALA . 28.3 mt -77.28 140.29 17.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.97 0.414 . . . . 0.0 111.598 -179.603 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.875 HD11 ' CD1' ' A' ' 124' ' ' ILE . 4.5 mp -100.23 137.13 28.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.818 179.732 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -114.93 -64.31 1.33 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.876 -179.898 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 5.1 m -86.16 145.15 27.13 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.862 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 3.9 tt -162.26 116.54 1.83 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.705 179.81 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 3.6 tmm? -94.44 128.86 41.27 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.991 -179.774 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -65.44 79.5 0.06 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.64 179.744 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 176.89 -35.22 0.09 OUTLIER Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 120.927 -0.654 . . . . 0.0 111.956 -179.843 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . 0.402 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -59.18 167.86 7.16 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.017 179.613 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.491 HD12 ' O ' ' A' ' 94' ' ' GLN . 1.0 OUTLIER -78.36 -16.54 13.79 Favored 'Isoleucine or valine' 0 C--O 1.235 0.313 0 CA-C-O 120.872 0.367 . . . . 0.0 111.6 -179.837 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 113' ' ' ALA . . . . . 0.4 ' HA ' HG12 ' A' ' 86' ' ' ILE . . . -57.97 -30.44 66.02 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.969 0.414 . . . . 0.0 110.556 179.797 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 114' ' ' GLU . . . . . 0.402 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 16.4 pt-20 -60.42 -47.02 87.91 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.859 179.665 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -63.16 -47.32 83.16 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.049 -179.52 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.401 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -49.64 -73.8 0.33 Allowed Glycine 0 CA--C 1.52 0.379 0 C-N-CA 120.414 -0.898 . . . . 0.0 112.6 -179.862 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . 0.555 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 169.8 -19.79 0.07 OUTLIER Glycine 0 CA--C 1.519 0.296 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.719 -179.937 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.764 ' N ' HG22 ' A' ' 84' ' ' VAL . 1.2 t -40.46 108.21 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.529 0.149 0 CA-C-O 120.999 0.428 . . . . 0.0 111.494 -179.791 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 6.1 mtp180 -102.75 128.34 49.52 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.612 179.751 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 22.2 t -54.06 92.61 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 121.017 0.437 . . . . 0.0 111.1 -179.815 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 128.58 -0.08 6.28 Favored Glycine 0 CA--C 1.519 0.297 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.999 -179.944 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 1.4 m170 -93.82 133.1 37.57 Favored 'General case' 0 C--O 1.232 0.156 0 CA-C-O 120.876 0.37 . . . . 0.0 110.865 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . 0.941 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 0.2 OUTLIER -83.27 91.62 7.32 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.009 -0.541 . . . . 0.0 111.791 -179.509 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . 0.875 ' CD1' HD11 ' A' ' 104' ' ' ILE . 14.9 mt -51.03 142.93 3.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 N-CA-C 109.638 -0.504 . . . . 0.0 109.638 178.572 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 125' ' ' ILE . . . . . 0.815 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.6 OUTLIER -136.65 -83.98 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 N-CA-C 112.995 0.739 . . . . 0.0 112.995 -178.581 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -78.5 85.82 4.56 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 112.733 0.642 . . . . 0.0 112.733 -178.28 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.858 HG23 ' HB3' ' A' ' 153' ' ' MET . 1.4 mt -90.61 104.32 15.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-O 121.071 0.462 . . . . 0.0 110.897 178.872 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 59.1 m-20 53.19 24.35 3.62 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.202 -179.93 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 111.47 -16.42 26.7 Favored Glycine 0 CA--C 1.519 0.33 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.944 179.879 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 10.4 tt0 -94.09 113.12 25.02 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.865 0.365 . . . . 0.0 111.04 -179.855 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -77.52 93.96 4.24 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.087 -179.974 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . 0.617 HG11 ' CD1' ' A' ' 127' ' ' ILE . 28.2 m -75.88 -3.31 4.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.183 -0.462 . . . . 0.0 112.038 -179.977 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.815 ' HB ' HG22 ' A' ' 125' ' ' ILE . 7.2 p -45.16 -38.26 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 CA-C-O 120.856 0.36 . . . . 0.0 111.616 -179.596 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -121.14 28.16 8.0 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.765 179.508 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . 0.565 HG22 ' HB3' ' A' ' 139' ' ' LYS . 43.3 m -109.48 140.52 22.18 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.999 -179.88 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 136' ' ' PRO . . . . . 0.46 ' HD2' HG23 ' A' ' 135' ' ' THR . 11.1 Cg_endo -54.26 151.02 30.54 Favored 'Trans proline' 0 C--N 1.346 0.403 0 C-N-CA 122.654 2.236 . . . . 0.0 112.1 179.694 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 3.8 p-80 -60.41 -33.69 72.86 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.51 -179.727 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -62.53 -39.3 93.14 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.815 0.34 . . . . 0.0 111.227 -179.661 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 139' ' ' LYS . . . . . 0.677 ' O ' HD12 ' A' ' 143' ' ' ILE . 1.7 tptp -62.84 -46.17 89.18 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.025 -179.72 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . 0.629 HG21 HG21 ' A' ' 99' ' ' VAL . 7.5 mt -58.97 -46.13 91.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.697 -179.819 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . 0.413 ' CG2' ' CG1' ' A' ' 99' ' ' VAL . 89.1 t -60.87 -32.46 52.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.22 179.235 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -61.56 -54.95 36.26 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.966 179.888 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . 0.677 HD12 ' O ' ' A' ' 139' ' ' LYS . 3.9 mp -53.18 -57.42 4.8 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.476 0 CA-C-O 121.185 0.517 . . . . 0.0 110.229 179.463 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.743 HD22 HG12 ' A' ' 151' ' ' ILE . 2.6 mt -60.36 -30.06 69.31 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.219 -0.9 . . . . 0.0 110.445 179.571 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 2.2 m -67.23 -27.99 67.69 Favored 'General case' 0 N--CA 1.454 -0.251 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.024 178.825 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 10.8 m120 -134.35 37.73 3.14 Favored 'General case' 0 CA--C 1.527 0.095 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.192 179.83 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 147' ' ' ALA . . . . . 0.616 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -111.62 40.17 2.18 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.484 -0.326 . . . . 0.0 111.43 -179.848 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.787 HG11 ' HG ' ' A' ' 91' ' ' LEU . 4.3 m -48.27 143.52 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.818 0.342 . . . . 0.0 111.412 179.884 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 118.65 -109.55 1.77 Allowed Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.443 -179.829 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.405 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 70.4 mt-10 -137.86 90.17 2.47 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.758 0.313 . . . . 0.0 110.77 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . 0.743 HG12 HD22 ' A' ' 144' ' ' LEU . 1.2 mp -65.54 111.82 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-O 121.012 0.434 . . . . 0.0 110.804 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 4.0 t60 -109.64 115.8 30.56 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.358 179.559 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 153' ' ' MET . . . . . 0.858 ' HB3' HG23 ' A' ' 127' ' ' ILE . 0.0 OUTLIER -144.37 166.23 25.69 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.194 0.521 . . . . 0.0 112.033 -179.258 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 154' ' ' LYS . . . . . 0.406 ' HG2' ' CG1' ' A' ' 81' ' ' VAL . 0.0 OUTLIER -109.74 151.81 26.45 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.526 -0.761 . . . . 0.0 109.346 178.665 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . 0.453 HG22 HG12 ' A' ' 124' ' ' ILE . 16.1 p -139.84 138.61 35.89 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.054 0.454 . . . . 0.0 111.697 -179.453 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 156' ' ' MET . . . . . 0.498 ' HE3' HG22 ' A' ' 81' ' ' VAL . 0.0 OUTLIER -101.72 178.68 1.16 Allowed Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 115.474 -0.784 . . . . 0.0 110.31 179.732 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 157' ' ' PRO . . . . . 0.42 ' HD2' ' HB3' ' A' ' 156' ' ' MET . 94.7 Cg_endo -91.99 96.19 0.19 Allowed 'Trans proline' 0 N--CA 1.456 -0.722 0 C-N-CA 122.765 2.31 . . . . 0.0 112.505 -179.773 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 158' ' ' ALA . . . . . 0.941 ' HB2' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.201 -0.904 . . . . 0.0 111.051 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 40.6 t . . . . . 0 C--O 1.23 0.049 0 CA-C-O 120.846 0.355 . . . . 0.0 110.932 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 1.8 m -124.62 142.65 51.21 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.931 179.842 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 4.1 m -101.73 111.44 23.69 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.22 179.267 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.76 HG22 ' N ' ' A' ' 118' ' ' VAL . 60.9 t -87.71 106.08 15.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.439 -179.461 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.424 ' O ' ' HA2' ' A' ' 116' ' ' GLY . 2.5 tt -104.33 85.55 2.38 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.094 -0.503 . . . . 0.0 109.827 178.778 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 1.054 HG21 HD23 ' A' ' 95' ' ' LEU . 3.5 mt -81.35 138.59 19.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 121.008 0.433 . . . . 0.0 111.306 -179.064 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.489 ' HG2' HG22 ' A' ' 112' ' ' ILE . 0.1 OUTLIER -98.77 108.83 21.61 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.507 -179.723 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 8.5 mmt180 -103.39 103.37 35.04 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.016 -179.84 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' PRO . . . . . 0.454 ' HG2' ' CG ' ' A' ' 93' ' ' TYR . 56.3 Cg_endo -70.49 -28.33 21.88 Favored 'Trans proline' 0 C--N 1.347 0.472 0 C-N-CA 122.385 2.056 . . . . 0.0 112.332 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . 0.442 ' HB2' ' CD1' ' A' ' 93' ' ' TYR . 2.9 m-20 -164.4 -175.49 3.93 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.876 0.37 . . . . 0.0 111.131 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 1.5 mp -80.32 -31.56 38.06 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.984 -179.884 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -73.84 -6.26 46.03 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.693 -179.708 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . 0.454 ' CG ' ' HG2' ' A' ' 89' ' ' PRO . 28.5 m-85 -104.7 110.37 22.66 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.803 0.335 . . . . 0.0 110.866 179.932 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 2.0 mp0 -80.29 179.34 7.72 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.981 -179.927 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 1.054 HD23 HG21 ' A' ' 86' ' ' ILE . 0.6 OUTLIER -91.42 -66.67 0.91 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.749 179.902 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 118.83 63.51 0.29 Allowed Glycine 0 C--N 1.33 0.224 0 C-N-CA 120.566 -0.825 . . . . 0.0 112.959 179.57 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 19.5 p90 -176.82 161.64 2.04 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.807 0.337 . . . . 0.0 110.967 179.664 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 14.5 m -102.64 145.49 29.58 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.768 179.792 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.683 HG21 HG21 ' A' ' 140' ' ' ILE . 10.1 p -126.08 130.56 72.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.332 -179.809 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 4.3 mt-30 -129.83 89.5 2.83 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.253 179.625 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 85.7 m-20 60.22 18.22 7.68 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.858 -179.343 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 123.23 -36.95 2.91 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 120.934 -0.651 . . . . 0.0 112.409 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.695 HG12 ' HB2' ' A' ' 158' ' ' ALA . 26.6 mt -77.24 130.77 35.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 121.018 0.437 . . . . 0.0 111.506 -179.619 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.732 HD11 ' CD1' ' A' ' 124' ' ' ILE . 3.7 mp -82.32 139.52 17.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.87 179.787 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -100.52 -78.79 0.51 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.104 -179.793 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 18.4 m -108.43 135.57 49.51 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.91 -179.826 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.618 HD11 HG13 ' A' ' 118' ' ' VAL . 0.9 OUTLIER -110.75 108.73 18.69 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.823 179.89 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 41.1 mtm -73.01 100.39 2.97 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.965 -179.929 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 25.0 mmt85 -56.97 122.09 11.48 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.78 179.888 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 129.44 -31.29 3.45 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.85 -0.691 . . . . 0.0 112.024 -179.683 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . 0.424 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -66.68 175.81 21.46 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.716 -0.755 . . . . 0.0 112.273 179.688 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.489 HG22 ' HG2' ' A' ' 87' ' ' ARG . 0.8 OUTLIER -78.63 -18.18 13.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-O 120.88 0.372 . . . . 0.0 111.62 -179.842 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 113' ' ' ALA . . . . . 0.533 ' HB1' HG11 ' A' ' 118' ' ' VAL . . . -58.31 -30.25 66.51 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.95 0.405 . . . . 0.0 110.611 179.817 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 114' ' ' GLU . . . . . 0.424 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 15.2 pt-20 -59.87 -45.65 91.79 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.731 179.503 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -64.69 -46.96 80.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.2 -179.433 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.424 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -51.05 -74.03 0.32 Allowed Glycine 0 CA--C 1.518 0.262 0 C-N-CA 120.355 -0.926 . . . . 0.0 112.59 -179.908 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . 0.443 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 175.5 -20.91 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.938 -0.649 . . . . 0.0 112.808 -179.958 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.76 ' N ' HG22 ' A' ' 84' ' ' VAL . 0.3 OUTLIER -34.7 128.07 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.23 0 CA-C-O 120.912 0.387 . . . . 0.0 112.026 -179.801 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -136.66 144.85 44.21 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.847 -179.822 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 120' ' ' VAL . . . . . 0.519 HG22 ' HB2' ' A' ' 107' ' ' LEU . 22.7 t -70.43 102.47 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.208 -179.981 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 119.7 49.11 0.32 Allowed Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.61 -0.805 . . . . 0.0 112.681 179.869 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 5.4 m170 -154.29 132.65 11.95 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.834 0.35 . . . . 0.0 110.857 179.849 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . 0.919 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 2.8 ttt180 -87.85 95.71 10.2 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.664 -179.532 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . 0.732 ' CD1' HD11 ' A' ' 104' ' ' ILE . 9.1 mt -49.71 159.14 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 178.771 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 125' ' ' ILE . . . . . 0.813 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.6 OUTLIER -148.79 -82.23 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 N-CA-C 112.567 0.58 . . . . 0.0 112.567 -179.579 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . 0.41 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 13.7 mt-10 -76.88 80.84 3.45 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 112.44 0.533 . . . . 0.0 112.44 -178.69 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.954 HG23 ' CG ' ' A' ' 153' ' ' MET . 2.8 mt -82.99 90.8 2.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 121.05 0.452 . . . . 0.0 111.153 179.117 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . 0.452 ' N ' ' O ' ' A' ' 152' ' ' HIS . 1.2 m-20 56.99 29.84 17.11 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.9 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 109.34 -15.11 32.93 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.774 -0.726 . . . . 0.0 112.686 -179.892 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 20.7 tt0 -95.04 106.03 17.99 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.895 0.379 . . . . 0.0 110.846 -179.921 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 11.7 p -73.5 90.3 1.72 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.851 179.971 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . 0.747 HG11 HD12 ' A' ' 127' ' ' ILE . 27.2 m -75.2 -2.86 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.29 0 CA-C-N 116.31 -0.405 . . . . 0.0 112.013 -179.828 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.813 ' HB ' HG22 ' A' ' 125' ' ' ILE . 10.4 p -44.77 -42.1 2.29 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.148 0 CA-C-O 120.862 0.363 . . . . 0.0 111.558 -179.731 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 134' ' ' ALA . . . . . 0.439 ' N ' HG13 ' A' ' 133' ' ' VAL . . . -116.2 29.54 7.9 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.891 179.578 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . 0.479 HG22 ' HB3' ' A' ' 139' ' ' LYS . 38.1 m -114.73 140.06 24.9 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.175 -179.839 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 136' ' ' PRO . . . . . 0.447 ' HD2' HG23 ' A' ' 135' ' ' THR . 11.5 Cg_endo -55.32 164.06 4.23 Favored 'Trans proline' 0 C--N 1.348 0.512 0 C-N-CA 122.652 2.235 . . . . 0.0 112.121 179.766 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 18.8 p-80 -66.43 -45.79 78.67 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.749 -179.557 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -53.71 -39.78 65.49 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.562 -179.341 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 139' ' ' LYS . . . . . 0.725 ' O ' HD12 ' A' ' 143' ' ' ILE . 8.7 tttt -62.7 -46.71 86.89 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.467 -0.333 . . . . 0.0 111.131 -179.7 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . 0.683 HG21 HG21 ' A' ' 99' ' ' VAL . 9.0 mt -58.32 -45.92 89.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.735 -179.836 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . 0.411 ' CG2' ' CG1' ' A' ' 99' ' ' VAL . 82.6 t -60.87 -32.64 52.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.334 179.244 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -62.02 -55.19 31.76 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.012 179.908 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . 0.725 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.2 mp -52.83 -56.9 5.54 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.489 0 CA-C-O 121.321 0.581 . . . . 0.0 110.248 179.459 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.794 ' HB3' HD11 ' A' ' 95' ' ' LEU . 3.0 mt -61.2 -30.11 70.22 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.305 -0.861 . . . . 0.0 110.398 179.579 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 3.0 m -68.78 -26.74 65.36 Favored 'General case' 0 N--CA 1.454 -0.226 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.022 178.691 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 3.6 m-80 -129.92 33.92 4.34 Favored 'General case' 0 CA--C 1.527 0.093 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.182 179.894 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 147' ' ' ALA . . . . . 0.806 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -112.28 45.73 1.25 Allowed 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.887 0.375 . . . . 0.0 111.242 179.992 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 3.1 m -50.48 152.33 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.592 -179.929 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 108.74 -104.42 1.97 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.539 -179.944 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 53.2 mt-10 -141.63 98.39 3.34 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.81 0.338 . . . . 0.0 110.558 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . 0.806 HD11 ' HB3' ' A' ' 147' ' ' ALA . 1.2 mt -73.41 111.79 8.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.353 -179.65 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . 0.452 ' O ' ' N ' ' A' ' 128' ' ' ASN . 0.0 OUTLIER -98.17 115.47 28.39 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 178.436 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 153' ' ' MET . . . . . 0.954 ' CG ' HG23 ' A' ' 127' ' ' ILE . 24.4 mtp -128.63 168.17 16.14 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.614 0.721 . . . . 0.0 112.677 -178.311 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 154' ' ' LYS . . . . . 0.416 ' O ' HG13 ' A' ' 125' ' ' ILE . 17.1 mttm -134.6 140.15 45.87 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 114.723 -1.126 . . . . 0.0 108.759 178.502 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . 0.698 HG22 ' CG1' ' A' ' 124' ' ' ILE . 3.1 p -136.66 140.31 42.66 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.137 0.494 . . . . 0.0 111.909 -178.79 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 156' ' ' MET . . . . . . . . . . . . . 3.8 ptp -132.37 145.75 58.62 Favored Pre-proline 0 C--N 1.328 -0.362 0 CA-C-N 115.318 -0.855 . . . . 0.0 110.44 179.291 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_exo -44.43 122.7 4.02 Favored 'Trans proline' 0 C--N 1.345 0.35 0 C-N-CA 122.597 2.198 . . . . 0.0 112.879 -179.704 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 158' ' ' ALA . . . . . 0.919 ' HB2' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.25 1.081 0 CA-C-O 118.259 -0.877 . . . . 0.0 111.051 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_endo . . . . . 0 N--CA 1.49 1.286 0 CA-C-O 120.798 0.249 . . . . 0.0 111.763 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo -78.4 55.67 5.52 Favored 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.684 2.256 . . . . 0.0 112.527 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.417 HG13 ' O ' ' A' ' 81' ' ' VAL . 14.4 p -90.88 126.31 43.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.179 179.934 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.3 m -103.66 141.49 35.97 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.8 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 5.1 m -105.63 111.3 23.93 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.149 179.191 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.738 HG11 HG23 ' A' ' 118' ' ' VAL . 48.5 t -82.66 106.14 13.2 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.65 -179.418 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.404 ' HA ' ' O ' ' A' ' 151' ' ' ILE . 0.8 OUTLIER -105.55 84.04 2.03 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 178.456 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.7 HG13 HG12 ' A' ' 84' ' ' VAL . 4.0 mt -81.53 151.28 4.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.582 -178.671 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.462 ' CB ' HG21 ' A' ' 112' ' ' ILE . 0.0 OUTLIER -110.07 114.85 28.7 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.712 -0.677 . . . . 0.0 110.451 -179.789 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.439 ' HD2' HD11 ' A' ' 95' ' ' LEU . 0.0 OUTLIER -120.56 100.91 46.63 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.058 -179.728 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . 0.437 ' HG2' ' CD2' ' A' ' 93' ' ' TYR . 71.5 Cg_endo -74.54 -26.73 11.61 Favored 'Trans proline' 0 C--N 1.346 0.414 0 C-N-CA 122.585 2.19 . . . . 0.0 112.448 179.874 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -141.39 -166.01 2.1 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.087 -179.866 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.507 ' CD2' HG13 ' A' ' 148' ' ' VAL . 2.6 mt -102.59 -19.74 14.72 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.43 -179.823 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -95.08 21.81 7.35 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.48 -0.327 . . . . 0.0 111.291 -179.775 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . 0.437 ' CD2' ' HG2' ' A' ' 89' ' ' PRO . 7.4 m-85 -112.31 98.67 7.45 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.768 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 1.2 pm0 -57.97 146.76 31.35 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.136 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 0.866 ' CD2' HD13 ' A' ' 144' ' ' LEU . 6.7 mp -71.78 -52.5 17.31 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.758 -179.919 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 124.85 36.82 0.57 Allowed Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.579 -0.82 . . . . 0.0 113.023 179.576 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . 0.71 ' CZ ' HG21 ' A' ' 118' ' ' VAL . 31.8 p90 -177.36 169.24 2.24 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.839 0.352 . . . . 0.0 111.197 179.787 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -120.66 148.2 44.24 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.745 179.735 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.829 HG21 HG21 ' A' ' 140' ' ' ILE . 8.6 p -115.3 142.82 26.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.427 -179.878 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . 0.407 ' O ' ' N ' ' A' ' 102' ' ' GLY . 22.8 tt0 -132.14 88.42 2.55 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.905 -0.588 . . . . 0.0 110.233 179.049 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' ASN . . . . . 0.699 ' O ' HD11 ' A' ' 140' ' ' ILE . 2.2 t-20 65.36 -68.51 0.11 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.151 -179.838 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.444 ' O ' ' HA ' ' A' ' 123' ' ' ARG . . . -142.9 -2.24 1.05 Allowed Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.387 -0.911 . . . . 0.0 113.4 -179.758 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.609 HD12 ' CB ' ' A' ' 158' ' ' ALA . 42.2 mm -122.86 151.36 26.99 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.128 0 CA-C-N 117.13 0.465 . . . . 0.0 111.529 -179.716 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.646 ' N ' HD12 ' A' ' 104' ' ' ILE . 2.8 mp -86.46 158.33 3.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.499 179.605 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' CYS . . . . . 0.482 ' N ' HG22 ' A' ' 104' ' ' ILE . 1.6 m -109.59 -71.68 0.75 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.475 -179.595 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 8.3 m -125.23 173.56 8.7 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.93 0.395 . . . . 0.0 111.17 -179.543 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.813 HD11 HG12 ' A' ' 118' ' ' VAL . 0.3 OUTLIER -148.48 140.63 24.05 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.779 179.901 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 2.0 mtm -106.22 114.21 28.2 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.868 -179.883 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -63.58 82.74 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.708 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 167.02 -31.36 0.19 Allowed Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.938 -0.648 . . . . 0.0 112.002 -179.858 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -64.34 172.48 17.46 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.132 179.651 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.462 HG21 ' CB ' ' A' ' 87' ' ' ARG . 0.5 OUTLIER -78.65 -16.66 13.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 120.744 0.306 . . . . 0.0 111.474 -179.952 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' ALA . . . . . 0.485 ' HA ' HG12 ' A' ' 86' ' ' ILE . . . -58.0 -30.35 66.0 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.002 0.429 . . . . 0.0 110.671 179.744 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 19.7 pt-20 -60.03 -46.63 88.86 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.876 179.67 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 23.3 mtt180 -65.0 -46.19 82.45 Favored 'General case' 0 N--CA 1.453 -0.301 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.21 -179.572 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -51.1 -73.57 0.37 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.557 -0.83 . . . . 0.0 112.641 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . 0.572 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 170.54 -20.11 0.07 OUTLIER Glycine 0 CA--C 1.518 0.271 0 C-N-CA 121.032 -0.604 . . . . 0.0 112.662 -179.773 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.813 HG12 HD11 ' A' ' 107' ' ' LEU . 0.9 OUTLIER -37.59 114.92 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.323 0 CA-C-O 120.937 0.399 . . . . 0.0 111.652 -179.819 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -117.46 100.95 8.0 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.577 179.799 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . 0.621 ' O ' HG13 ' A' ' 120' ' ' VAL . 10.1 p -48.11 101.76 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 121.057 0.456 . . . . 0.0 111.106 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 133.38 -10.19 5.01 Favored Glycine 0 N--CA 1.451 -0.36 0 CA-C-N 115.831 -0.622 . . . . 0.0 112.231 -179.318 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . 0.421 ' O ' HG23 ' A' ' 103' ' ' ILE . 35.7 m170 -86.1 -161.62 0.66 Allowed 'General case' 0 C--N 1.331 -0.231 0 N-CA-C 110.322 -0.251 . . . . 0.0 110.322 179.802 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.749 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 10.1 ttm-85 -139.35 90.4 2.41 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.679 0.276 . . . . 0.0 110.802 -179.866 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . 0.581 ' CG1' HG22 ' A' ' 155' ' ' THR . 15.4 mt -55.99 157.13 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.251 179.225 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' ILE . . . . . 0.853 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.7 OUTLIER -151.54 -84.51 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.451 -0.383 0 N-CA-C 112.374 0.509 . . . . 0.0 112.374 -179.538 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . 0.42 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 13.5 mt-10 -79.99 88.24 5.36 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 112.498 0.555 . . . . 0.0 112.498 -178.793 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.878 HG23 ' HB3' ' A' ' 153' ' ' MET . 1.3 mt -92.44 103.05 14.22 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.185 0 CA-C-O 121.101 0.477 . . . . 0.0 111.344 179.281 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . 0.496 ' ND2' HG22 ' A' ' 127' ' ' ILE . 20.2 m-80 59.84 18.64 7.57 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.857 -0.61 . . . . 0.0 111.369 179.847 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 116.6 -17.18 13.88 Favored Glycine 0 C--N 1.333 0.372 0 C-N-CA 120.517 -0.849 . . . . 0.0 113.179 179.627 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' GLN . . . . . 0.556 HE22 HD13 ' A' ' 143' ' ' ILE . 1.2 pt20 -97.88 119.56 36.71 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 117.029 0.414 . . . . 0.0 110.963 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 2.5 m -79.06 93.15 5.09 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.119 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . 0.698 HG21 HD11 ' A' ' 127' ' ' ILE . 27.2 m -72.56 -5.38 6.22 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.298 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.978 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.853 ' HB ' HG22 ' A' ' 125' ' ' ILE . 8.3 p -45.36 -38.46 2.22 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.135 0 CA-C-O 120.818 0.342 . . . . 0.0 111.487 -179.807 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -120.08 28.22 8.2 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.748 179.465 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . 0.416 ' CG2' ' HD2' ' A' ' 136' ' ' PRO . 36.0 m -110.73 143.15 27.63 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.181 -179.929 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' PRO . . . . . 0.416 ' HD2' ' CG2' ' A' ' 135' ' ' THR . 50.1 Cg_exo -53.41 164.21 2.14 Favored 'Trans proline' 0 C--N 1.347 0.456 0 C-N-CA 122.526 2.151 . . . . 0.0 112.119 179.704 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' HIS . . . . . 0.522 ' HA ' HD12 ' A' ' 140' ' ' ILE . 9.3 p80 -74.05 -46.95 40.04 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.224 -179.798 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -54.16 -35.14 61.95 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.173 -179.786 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 139' ' ' LYS . . . . . 0.764 ' O ' HD12 ' A' ' 143' ' ' ILE . 0.0 OUTLIER -65.96 -48.87 69.86 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.943 -179.931 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . 0.829 HG21 HG21 ' A' ' 99' ' ' VAL . 8.7 mt -59.47 -46.41 92.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 121.033 0.444 . . . . 0.0 110.319 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . 0.411 HG23 ' CG1' ' A' ' 99' ' ' VAL . 55.6 t -59.54 -32.53 49.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 115.711 -0.677 . . . . 0.0 109.93 179.074 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -61.47 -54.22 46.27 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.009 -0.542 . . . . 0.0 110.835 179.808 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . 0.764 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.3 mp -53.39 -57.86 4.23 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.424 0 CA-C-O 121.015 0.436 . . . . 0.0 110.135 179.487 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.866 HD13 ' CD2' ' A' ' 95' ' ' LEU . 15.1 mt -60.39 -30.14 69.4 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.408 179.402 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 23.4 t -69.38 -28.55 66.28 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.219 -0.446 . . . . 0.0 109.934 178.811 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 4.9 m-80 -128.17 34.48 4.57 Favored 'General case' 0 C--N 1.333 -0.112 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.908 179.666 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 147' ' ' ALA . . . . . 0.844 ' CB ' HD11 ' A' ' 151' ' ' ILE . . . -103.62 79.21 1.65 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.207 -179.929 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.507 HG13 ' CD2' ' A' ' 91' ' ' LEU . 5.7 m -77.32 146.18 8.92 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.338 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.149 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 105.43 -104.68 2.35 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.525 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 53.4 mt-10 -145.58 114.73 7.03 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.79 0.328 . . . . 0.0 110.847 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . 0.844 HD11 ' CB ' ' A' ' 147' ' ' ALA . 1.8 mp -81.93 128.13 39.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 121.047 0.451 . . . . 0.0 110.628 179.854 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . 0.414 ' CD2' ' HA ' ' A' ' 128' ' ' ASN . 21.6 p-80 -125.47 115.77 20.77 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.361 179.819 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 153' ' ' MET . . . . . 0.878 ' HB3' HG23 ' A' ' 127' ' ' ILE . 0.0 OUTLIER -141.21 174.99 10.01 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.164 0.507 . . . . 0.0 111.619 -179.379 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -121.41 147.83 45.2 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.589 -0.732 . . . . 0.0 109.912 179.22 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . 0.581 HG22 ' CG1' ' A' ' 124' ' ' ILE . 12.1 p -140.7 140.49 34.92 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.04 0.448 . . . . 0.0 111.175 -179.665 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 156' ' ' MET . . . . . 0.459 ' O ' ' N ' ' A' ' 123' ' ' ARG . 0.0 OUTLIER -108.7 178.86 0.95 Allowed Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 115.791 -0.64 . . . . 0.0 110.56 179.854 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . 0.413 ' CD ' ' CB ' ' A' ' 156' ' ' MET . 94.6 Cg_endo -89.85 111.01 0.46 Allowed 'Trans proline' 0 N--CA 1.458 -0.559 0 C-N-CA 122.532 2.154 . . . . 0.0 112.504 -179.776 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 158' ' ' ALA . . . . . 0.749 ' HB2' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.283 -0.865 . . . . 0.0 110.962 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_endo . . . . . 0 N--CA 1.489 1.24 0 CA-C-O 120.67 0.196 . . . . 0.0 111.736 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -72.3 99.52 1.03 Allowed 'Trans proline' 0 C--N 1.345 0.351 0 C-N-CA 122.524 2.15 . . . . 0.0 112.396 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 10.2 p -81.4 140.58 16.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.015 179.933 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.9 m -126.52 140.99 52.03 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.984 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 6.6 m -99.86 111.18 23.51 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.147 179.272 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.918 HG11 HG23 ' A' ' 118' ' ' VAL . 47.2 t -82.66 108.57 15.64 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 CA-C-N 116.015 -0.539 . . . . 0.0 112.268 -179.112 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 6.7 tt -103.12 85.01 2.43 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.876 -0.602 . . . . 0.0 109.436 178.345 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.821 HG21 ' CD2' ' A' ' 95' ' ' LEU . 5.6 mt -82.81 118.81 31.17 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.251 0 CA-C-O 121.293 0.568 . . . . 0.0 111.893 -178.715 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.446 ' HB2' HG21 ' A' ' 112' ' ' ILE . 0.2 OUTLIER -73.13 153.06 40.92 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.089 -0.959 . . . . 0.0 109.99 179.21 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.438 ' HD2' HD11 ' A' ' 95' ' ' LEU . 0.0 OUTLIER -152.92 124.32 3.68 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 120.618 0.247 . . . . 0.0 111.11 -179.979 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 92.0 Cg_endo -83.47 -42.45 0.08 OUTLIER 'Trans proline' 0 C--N 1.347 0.465 0 C-N-CA 122.613 2.209 . . . . 0.0 112.584 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 57.4 p30 -156.78 -167.54 2.4 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.203 -179.781 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 7.3 mt -96.19 30.87 2.33 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.43 -179.519 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -138.9 32.06 2.21 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.886 0.374 . . . . 0.0 110.982 179.914 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 2.1 m-85 -136.84 104.06 5.37 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.832 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 3.0 mp0 -65.51 145.07 56.56 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.03 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 0.821 ' CD2' HG21 ' A' ' 86' ' ' ILE . 8.3 mp -78.49 -24.62 45.77 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.94 179.93 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 72.27 68.81 1.51 Allowed Glycine 0 C--N 1.331 0.257 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.868 179.709 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . 0.763 ' CZ ' HD12 ' A' ' 144' ' ' LEU . 1.8 p90 -161.37 -171.83 3.15 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.918 0.39 . . . . 0.0 111.212 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.419 ' O ' ' HA ' ' A' ' 104' ' ' ILE . 1.2 t -149.67 126.24 10.95 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.408 179.71 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.654 HG21 HG21 ' A' ' 140' ' ' ILE . 11.8 p -111.97 140.16 32.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 121.163 0.506 . . . . 0.0 111.764 -179.284 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 3.6 mp0 -133.03 89.75 2.66 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.598 -0.728 . . . . 0.0 109.847 179.156 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 9.8 t-20 60.35 15.64 5.59 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.756 -178.921 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 127.31 -39.3 1.97 Allowed Glycine 0 N--CA 1.449 -0.474 0 C-N-CA 121.012 -0.613 . . . . 0.0 112.228 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.81 HG23 ' O ' ' A' ' 122' ' ' HIS . 31.5 mt -77.27 138.67 20.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 121.007 0.432 . . . . 0.0 111.575 -179.587 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.832 HD11 ' CD1' ' A' ' 124' ' ' ILE . 4.1 mp -96.36 138.25 22.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.991 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -108.0 -65.62 1.1 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.653 179.878 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 9.5 p -94.22 155.06 17.23 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.614 179.724 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.478 ' HB3' HG22 ' A' ' 120' ' ' VAL . 0.6 OUTLIER -163.92 121.71 1.81 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.942 -179.855 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 20.2 ttp -82.36 120.94 26.06 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.881 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -67.97 71.92 0.16 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.143 0.497 . . . . 0.0 110.602 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 175.36 -33.85 0.1 OUTLIER Glycine 0 N--CA 1.45 -0.39 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.966 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . 0.429 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -55.26 176.33 0.6 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.781 -0.724 . . . . 0.0 112.275 179.788 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.446 HG21 ' HB2' ' A' ' 87' ' ' ARG . 1.1 mp -78.7 -18.57 13.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 N-CA-C 111.848 0.314 . . . . 0.0 111.848 -179.734 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' ALA . . . . . . . . . . . . . . . -58.01 -30.54 66.19 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.895 0.378 . . . . 0.0 110.757 179.855 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' GLU . . . . . 0.429 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 13.2 pt-20 -61.64 -47.42 85.48 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.871 179.8 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 43.4 mtm180 -62.27 -41.98 98.93 Favored 'General case' 0 N--CA 1.453 -0.31 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.832 -179.631 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -53.79 -73.83 0.37 Allowed Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.296 -0.954 . . . . 0.0 112.394 179.854 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . 0.55 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 164.57 -18.13 0.11 Allowed Glycine 0 CA--C 1.523 0.538 0 C-N-CA 121.249 -0.5 . . . . 0.0 112.74 -179.889 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.918 HG23 HG11 ' A' ' 84' ' ' VAL . 2.0 t -29.58 -64.26 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 C-N-CA 123.212 0.605 . . . . 0.0 112.569 -179.54 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.576 ' N ' HG12 ' A' ' 118' ' ' VAL . 30.0 mmt180 61.71 178.7 0.12 Allowed 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.303 -0.408 . . . . 0.0 109.941 -178.872 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . 0.478 HG22 ' HB3' ' A' ' 107' ' ' LEU . 11.8 t -111.18 101.12 12.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-O 120.917 0.389 . . . . 0.0 111.341 -179.86 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 126.17 42.34 0.3 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.894 -0.669 . . . . 0.0 112.417 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . 0.81 ' O ' HG23 ' A' ' 103' ' ' ILE . 15.3 m170 -129.87 -171.52 2.54 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.767 0.317 . . . . 0.0 110.963 -179.822 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.799 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 5.7 ttm-85 -142.08 89.39 2.17 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.874 -179.756 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . 0.832 ' CD1' HD11 ' A' ' 104' ' ' ILE . 14.6 mt -51.67 142.5 4.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.547 -0.297 . . . . 0.0 110.285 179.375 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' ILE . . . . . 0.859 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.6 OUTLIER -137.18 -84.46 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 N-CA-C 112.668 0.618 . . . . 0.0 112.668 -179.05 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . 0.421 ' CD ' HD12 ' A' ' 125' ' ' ILE . 1.0 OUTLIER -80.52 83.73 6.26 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 112.421 0.526 . . . . 0.0 112.421 -178.538 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.862 HG23 ' HB3' ' A' ' 153' ' ' MET . 1.9 mt -86.26 104.37 13.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 120.97 0.414 . . . . 0.0 111.175 179.086 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 11.3 m-20 56.15 23.05 6.56 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.777 -0.647 . . . . 0.0 111.402 179.804 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 112.68 -14.21 24.71 Favored Glycine 0 C--N 1.332 0.318 0 C-N-CA 120.554 -0.831 . . . . 0.0 112.961 179.746 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' GLN . . . . . 0.4 ' O ' ' CG ' ' A' ' 130' ' ' GLN . 5.0 pt20 -96.16 122.07 38.61 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.742 0.306 . . . . 0.0 110.484 -179.888 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 21.3 p -83.75 90.02 7.26 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.892 0.377 . . . . 0.0 110.826 179.921 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . 0.624 HG21 HD11 ' A' ' 127' ' ' ILE . 35.0 m -72.69 -3.81 4.45 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.351 0 CA-C-N 116.013 -0.54 . . . . 0.0 112.04 -179.845 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.859 ' HB ' HG22 ' A' ' 125' ' ' ILE . 7.9 p -47.27 -35.13 3.41 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.158 0 CA-C-O 120.894 0.378 . . . . 0.0 111.228 -179.889 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -121.01 27.84 8.24 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.684 179.4 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . 0.419 HG23 ' HD2' ' A' ' 136' ' ' PRO . 25.8 m -114.08 140.64 25.16 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 115.664 -0.698 . . . . 0.0 111.02 -179.8 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 136' ' ' PRO . . . . . 0.419 ' HD2' HG23 ' A' ' 135' ' ' THR . 8.3 Cg_endo -50.11 163.97 0.52 Allowed 'Trans proline' 0 C--N 1.347 0.458 0 C-N-CA 122.676 2.251 . . . . 0.0 112.181 179.64 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 137' ' ' HIS . . . . . 0.404 ' CD2' ' N ' ' A' ' 138' ' ' GLU . 22.9 p-80 -74.45 -41.85 60.11 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.284 -0.417 . . . . 0.0 111.439 -179.642 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . 0.404 ' N ' ' CD2' ' A' ' 137' ' ' HIS . 53.8 mt-10 -54.15 -38.04 65.06 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.753 0.311 . . . . 0.0 111.42 -179.516 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 139' ' ' LYS . . . . . 0.76 ' O ' HD12 ' A' ' 143' ' ' ILE . 6.9 tttp -64.67 -48.86 73.2 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.11 -179.728 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . 0.654 HG21 HG21 ' A' ' 99' ' ' VAL . 13.8 mt -59.26 -43.27 89.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.624 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . 0.574 HG22 HG12 ' A' ' 99' ' ' VAL . 86.6 t -62.29 -33.13 57.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.389 179.291 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -61.93 -56.46 18.98 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.07 -0.514 . . . . 0.0 111.104 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . 0.76 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.3 mp -52.9 -57.17 4.92 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.49 0 CA-C-O 121.095 0.474 . . . . 0.0 110.192 179.559 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.763 HD12 ' CZ ' ' A' ' 97' ' ' PHE . 6.3 mt -59.83 -29.91 68.58 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.575 179.409 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 14.0 t -73.18 -28.25 62.1 Favored 'General case' 0 N--CA 1.456 -0.141 0 CA-C-N 116.361 -0.382 . . . . 0.0 110.219 178.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 3.1 m-80 -125.11 31.58 5.58 Favored 'General case' 0 C--O 1.232 0.152 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.189 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 147' ' ' ALA . . . . . 0.784 ' CB ' HD11 ' A' ' 151' ' ' ILE . . . -107.02 97.06 6.88 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.243 179.942 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 6.3 m -79.96 179.86 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.357 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.983 -179.744 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 67.94 -116.04 7.38 Favored Glycine 0 N--CA 1.453 -0.223 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.599 179.924 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.403 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 11.5 mt-10 -134.97 110.7 9.27 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.606 0.241 . . . . 0.0 110.984 -179.815 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . 0.784 HD11 ' CB ' ' A' ' 147' ' ' ALA . 1.7 mp -68.16 124.02 22.77 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-O 120.915 0.388 . . . . 0.0 110.778 179.776 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -113.51 115.56 28.18 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.801 -0.636 . . . . 0.0 109.964 179.192 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 153' ' ' MET . . . . . 0.862 ' HB3' HG23 ' A' ' 127' ' ' ILE . 1.4 ptt? -147.2 164.77 32.1 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.217 0.532 . . . . 0.0 111.732 -178.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 2.2 mttm -110.9 152.33 26.86 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.524 -0.762 . . . . 0.0 109.851 179.182 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 37.4 p -136.88 142.59 42.78 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.163 0.506 . . . . 0.0 111.604 -179.547 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 156' ' ' MET . . . . . 0.504 ' O ' ' N ' ' A' ' 123' ' ' ARG . 0.0 OUTLIER -111.82 179.0 0.86 Allowed Pre-proline 0 C--N 1.327 -0.392 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.39 179.755 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . 0.412 ' CD ' ' CB ' ' A' ' 156' ' ' MET . 80.2 Cg_endo -92.96 103.41 0.17 Allowed 'Trans proline' 0 N--CA 1.456 -0.688 0 C-N-CA 122.786 2.324 . . . . 0.0 112.543 -179.752 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 158' ' ' ALA . . . . . 0.799 ' HB2' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.25 1.085 0 CA-C-O 118.169 -0.92 . . . . 0.0 111.09 179.788 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . 0.474 ' CB ' ' CD ' ' A' ' 80' ' ' PRO . 2.0 Cg_endo . . . . . 0 N--CA 1.484 0.944 0 CA-C-O 120.522 0.134 . . . . 0.0 112.155 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . 0.474 ' CD ' ' CB ' ' A' ' 79' ' ' PRO . 42.4 Cg_endo -67.93 165.58 27.57 Favored 'Trans proline' 0 C--N 1.343 0.284 0 C-N-CA 122.51 2.14 . . . . 0.0 112.355 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.561 HG13 ' O ' ' A' ' 155' ' ' THR . 47.0 t -81.16 140.93 15.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.04 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.7 m -118.61 134.25 55.25 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.848 179.849 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 6.9 m -95.25 111.52 23.36 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.178 179.324 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.759 HG12 HG13 ' A' ' 86' ' ' ILE . 58.3 t -82.56 105.73 12.7 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.547 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.742 -179.33 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.45 ' CD1' ' CD2' ' A' ' 152' ' ' HIS . 4.6 tp -107.73 80.1 1.35 Allowed 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 178.348 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.759 HG13 HG12 ' A' ' 84' ' ' VAL . 1.2 mt -81.67 130.95 34.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 121.173 0.511 . . . . 0.0 111.729 -178.272 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.431 ' H ' HG22 ' A' ' 112' ' ' ILE . 0.0 OUTLIER -84.19 142.87 30.0 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.443 -0.799 . . . . 0.0 110.256 179.929 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 3.7 ttt180 -144.88 114.16 5.01 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.964 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -75.32 -45.24 0.27 Allowed 'Trans proline' 0 C--N 1.347 0.466 0 C-N-CA 122.463 2.109 . . . . 0.0 112.616 -179.895 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -135.1 -173.97 3.47 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.196 -179.753 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.456 ' HG ' HG13 ' A' ' 148' ' ' VAL . 0.8 OUTLIER -86.96 -34.04 19.44 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.976 -179.928 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 3.2 ptm180 -73.07 -7.97 53.65 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.608 -179.842 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 10.9 m-85 -85.08 128.57 34.7 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.797 0.332 . . . . 0.0 110.876 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 4.0 mp0 -89.51 160.49 16.7 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.899 -179.895 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 0.797 ' CD1' HD13 ' A' ' 144' ' ' LEU . 59.3 mt -81.42 -69.21 0.63 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.903 179.917 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 135.9 40.96 0.13 Allowed Glycine 0 CA--C 1.518 0.277 0 C-N-CA 120.484 -0.865 . . . . 0.0 113.192 179.631 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . 0.455 ' CE1' HG21 ' A' ' 118' ' ' VAL . 33.1 p90 -175.12 174.67 2.4 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.879 0.371 . . . . 0.0 111.09 179.62 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -124.74 143.86 50.55 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.961 -179.814 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.673 HG21 HG21 ' A' ' 140' ' ' ILE . 10.6 p -111.54 139.48 35.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.026 179.907 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . 0.413 ' O ' ' N ' ' A' ' 102' ' ' GLY . 0.5 OUTLIER -130.53 89.01 2.71 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.806 179.758 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' ASN . . . . . 0.65 ' O ' HD11 ' A' ' 140' ' ' ILE . 7.3 m-80 64.34 -68.19 0.1 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.903 -0.59 . . . . 0.0 111.51 179.569 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.432 ' O ' HD13 ' A' ' 103' ' ' ILE . . . -143.83 1.1 1.27 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.238 -0.982 . . . . 0.0 113.414 -179.731 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.732 HD12 ' CB ' ' A' ' 158' ' ' ALA . 44.2 mm -126.46 155.08 36.64 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 117.232 0.516 . . . . 0.0 111.209 -179.886 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.658 ' N ' HD12 ' A' ' 104' ' ' ILE . 3.2 mp -97.26 145.11 9.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.735 179.817 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 1.6 m -106.46 -79.48 0.57 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.171 -179.704 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 1.5 m -90.91 168.83 11.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.375 -0.375 . . . . 0.0 111.141 -179.7 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.586 HD23 HG23 ' A' ' 120' ' ' VAL . 62.1 tp -174.16 101.86 0.1 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.698 179.897 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 8.0 mtp -73.93 122.05 21.94 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.081 -179.819 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.03 78.2 0.09 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.692 179.775 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 174.25 -33.62 0.11 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.986 -0.626 . . . . 0.0 112.04 -179.837 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . 0.413 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -57.46 174.62 2.0 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.142 179.741 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.431 HG22 ' H ' ' A' ' 87' ' ' ARG . 0.9 OUTLIER -78.5 -17.46 13.59 Favored 'Isoleucine or valine' 0 C--O 1.236 0.36 0 CA-C-O 120.829 0.347 . . . . 0.0 111.522 -179.845 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' ALA . . . . . 0.534 ' HB1' HG21 ' A' ' 118' ' ' VAL . . . -58.11 -30.62 66.43 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.911 0.386 . . . . 0.0 110.703 179.863 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' GLU . . . . . 0.413 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 17.4 pt-20 -60.48 -47.21 87.15 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.969 -0.559 . . . . 0.0 110.766 179.634 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 2.4 mmt85 -62.32 -44.78 95.71 Favored 'General case' 0 N--CA 1.452 -0.337 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.892 -179.556 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -53.25 -74.01 0.35 Allowed Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.245 -0.979 . . . . 0.0 112.519 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . 0.56 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 172.45 -24.94 0.08 OUTLIER Glycine 0 CA--C 1.518 0.249 0 C-N-CA 121.065 -0.588 . . . . 0.0 112.701 -179.951 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.718 ' N ' HG22 ' A' ' 84' ' ' VAL . 18.0 t -15.11 -83.31 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.627 0 C-N-CA 123.235 0.614 . . . . 0.0 112.489 -179.835 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.651 ' N ' HG12 ' A' ' 118' ' ' VAL . 0.0 OUTLIER 62.56 143.19 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.725 -179.649 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . 0.586 HG23 HD23 ' A' ' 107' ' ' LEU . 11.4 t -81.97 132.06 32.37 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 116.439 -0.346 . . . . 0.0 111.198 -179.704 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 101.63 24.63 8.6 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.886 -0.673 . . . . 0.0 112.57 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 10.4 m170 -112.72 -174.42 2.45 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.656 0.265 . . . . 0.0 110.706 179.869 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.714 ' CD ' HD11 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -140.58 90.14 2.33 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.819 -179.783 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . 0.62 ' O ' HG23 ' A' ' 125' ' ' ILE . 5.9 mt -50.82 154.95 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.811 179.484 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' ILE . . . . . 0.844 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.8 OUTLIER -157.79 -86.66 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 N-CA-C 112.481 0.549 . . . . 0.0 112.481 -179.88 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . 0.428 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 15.6 mt-10 -81.82 92.79 6.74 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 112.321 0.489 . . . . 0.0 112.321 -178.637 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.922 HD11 HG21 ' A' ' 132' ' ' VAL . 1.5 mt -91.3 99.16 9.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.126 179.297 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 52.8 m-20 63.96 15.92 9.52 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.451 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 121.19 -18.94 8.82 Favored Glycine 0 C--N 1.332 0.31 0 C-N-CA 120.452 -0.88 . . . . 0.0 113.117 179.629 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 1.8 pt20 -98.63 117.1 32.32 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.93 0.395 . . . . 0.0 110.948 -179.916 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 1.4 m -77.18 93.41 3.93 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.182 -179.787 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . 0.922 HG21 HD11 ' A' ' 127' ' ' ILE . 35.6 m -77.08 0.31 2.64 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.324 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.801 179.67 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.844 ' HB ' HG22 ' A' ' 125' ' ' ILE . 8.5 p -46.82 -40.23 4.72 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.14 0 CA-C-O 120.805 0.336 . . . . 0.0 111.261 -179.826 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -113.13 29.54 7.9 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.687 179.452 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . 0.549 HG23 ' HD2' ' A' ' 136' ' ' PRO . 91.0 m -116.97 143.03 30.8 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.852 -179.805 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 136' ' ' PRO . . . . . 0.549 ' HD2' HG23 ' A' ' 135' ' ' THR . 6.1 Cg_endo -47.92 164.09 0.18 Allowed 'Trans proline' 0 C--N 1.347 0.451 0 C-N-CA 122.805 2.337 . . . . 0.0 112.281 179.795 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 45.1 p-80 -76.11 -44.55 38.02 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.301 -179.606 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -54.08 -33.53 57.79 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.362 -179.607 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 139' ' ' LYS . . . . . 0.823 ' O ' HD12 ' A' ' 143' ' ' ILE . 0.0 OUTLIER -66.41 -50.12 64.49 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.873 0.368 . . . . 0.0 111.033 -179.923 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . 0.786 HG23 ' CD1' ' A' ' 127' ' ' ILE . 8.5 mt -59.1 -46.18 92.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.421 179.827 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . 0.567 HG22 HG12 ' A' ' 99' ' ' VAL . 69.0 t -59.86 -32.38 49.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.906 -0.588 . . . . 0.0 109.885 178.73 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 2.1 t-160 -60.57 -52.97 62.89 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.492 179.604 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . 0.823 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.5 mp -53.29 -57.78 4.28 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.394 0 CA-C-O 121.035 0.445 . . . . 0.0 110.108 179.202 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.797 HD13 ' CD1' ' A' ' 95' ' ' LEU . 9.7 mt -60.05 -30.19 69.04 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.627 -0.715 . . . . 0.0 110.231 179.389 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 38.9 t -70.81 -27.79 64.15 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.075 -0.511 . . . . 0.0 109.878 178.745 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 2.8 m-80 -124.85 31.47 5.65 Favored 'General case' 0 C--O 1.232 0.151 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.83 179.799 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 147' ' ' ALA . . . . . 0.784 ' CB ' HD11 ' A' ' 151' ' ' ILE . . . -113.14 101.06 9.08 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.952 179.789 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.456 HG13 ' HG ' ' A' ' 91' ' ' LEU . 3.4 m -101.59 158.62 4.24 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.433 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.321 -179.79 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 95.0 -95.89 1.94 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.564 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 14.4 mt-10 -146.81 104.93 3.76 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.716 0.294 . . . . 0.0 110.715 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . 0.784 HD11 ' CB ' ' A' ' 147' ' ' ALA . 1.5 mp -72.41 117.52 16.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 121.149 0.5 . . . . 0.0 111.204 -179.756 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . 0.45 ' CD2' ' CD1' ' A' ' 85' ' ' LEU . 0.2 OUTLIER -101.37 121.84 42.64 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.585 -0.734 . . . . 0.0 109.295 178.724 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 153' ' ' MET . . . . . 0.8 ' HB2' HG23 ' A' ' 127' ' ' ILE . 8.6 tmm? -153.41 155.16 35.84 Favored 'General case' 0 C--N 1.327 -0.385 0 C-N-CA 120.754 -0.378 . . . . 0.0 111.678 -178.436 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . 0.41 ' CG ' ' CG1' ' A' ' 81' ' ' VAL . 0.0 OUTLIER -109.23 152.27 25.41 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.605 179.893 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . 0.561 ' O ' HG13 ' A' ' 81' ' ' VAL . 30.3 p -142.13 150.05 40.61 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 121.159 0.504 . . . . 0.0 111.644 -179.919 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 156' ' ' MET . . . . . 0.503 ' O ' ' N ' ' A' ' 123' ' ' ARG . 10.7 mmm -115.82 178.93 0.87 Allowed Pre-proline 0 C--N 1.328 -0.369 0 CA-C-N 115.556 -0.747 . . . . 0.0 110.302 179.413 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . 0.443 ' CD ' ' HB3' ' A' ' 156' ' ' MET . 88.5 Cg_endo -91.33 114.82 0.4 Allowed 'Trans proline' 0 N--CA 1.457 -0.632 0 C-N-CA 122.61 2.207 . . . . 0.0 112.546 -179.685 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 158' ' ' ALA . . . . . 0.732 ' CB ' HD12 ' A' ' 103' ' ' ILE . . . . . . . . 0 C--O 1.249 1.035 0 CA-C-O 118.285 -0.864 . . . . 0.0 111.071 179.727 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo . . . . . 0 N--CA 1.488 1.175 0 CA-C-O 120.671 0.196 . . . . 0.0 111.706 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -75.48 129.57 12.04 Favored 'Trans proline' 0 C--N 1.345 0.354 0 C-N-CA 122.616 2.211 . . . . 0.0 112.592 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.588 HG13 ' CE ' ' A' ' 156' ' ' MET . 56.5 t -87.95 142.39 13.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.884 179.843 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . 0.429 HG21 ' O ' ' A' ' 117' ' ' GLY . 1.8 m -120.5 143.01 48.78 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.868 179.75 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 35.9 m -107.09 111.33 23.73 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.267 179.289 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.668 HG12 ' CD1' ' A' ' 86' ' ' ILE . 53.6 t -86.21 106.33 15.49 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.423 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.107 -179.759 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.413 ' O ' ' HA2' ' A' ' 116' ' ' GLY . 1.4 tt -110.09 81.93 1.51 Allowed 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.157 -0.474 . . . . 0.0 109.729 179.107 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.668 ' CD1' HG12 ' A' ' 84' ' ' VAL . 1.8 mp -81.83 134.17 27.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 121.106 0.479 . . . . 0.0 111.732 -178.965 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.51 ' O ' HG21 ' A' ' 112' ' ' ILE . 0.0 OUTLIER -91.36 108.69 20.06 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.99 179.813 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.537 ' HE ' HD13 ' A' ' 112' ' ' ILE . 1.0 OUTLIER -113.14 87.11 10.24 Favored Pre-proline 0 C--N 1.328 -0.365 0 CA-C-O 120.878 0.371 . . . . 0.0 111.676 -179.209 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . 0.405 ' HD2' ' NH2' ' A' ' 88' ' ' ARG . 96.4 Cg_endo -78.96 1.91 8.73 Favored 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.598 2.199 . . . . 0.0 112.952 179.776 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . 0.783 ' O ' HG12 ' A' ' 148' ' ' VAL . 1.0 OUTLIER -154.5 -162.29 1.37 Allowed 'General case' 0 C--N 1.332 -0.17 0 CA-C-O 120.743 0.306 . . . . 0.0 111.36 -179.884 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.609 HD12 HG11 ' A' ' 148' ' ' VAL . 0.1 OUTLIER -128.18 -40.58 1.64 Allowed 'General case' 0 C--N 1.332 -0.153 0 CA-C-O 120.925 0.393 . . . . 0.0 111.389 -179.622 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -53.44 -23.3 9.6 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.536 -179.524 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . 0.463 ' HB2' ' NH2' ' A' ' 88' ' ' ARG . 77.4 m-85 -95.65 148.89 22.06 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.828 179.824 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -97.03 175.6 6.26 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.155 -179.842 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 0.613 ' HG ' HD13 ' A' ' 144' ' ' LEU . 2.7 mm? -72.49 -51.68 19.06 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.661 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 121.74 31.74 1.09 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.9 179.784 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 47.8 p90 -175.55 145.14 0.71 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.832 0.349 . . . . 0.0 111.058 179.818 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.432 ' O ' ' HA ' ' A' ' 104' ' ' ILE . 14.8 m -91.76 148.44 22.24 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.747 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.78 HG21 HG21 ' A' ' 140' ' ' ILE . 5.1 p -118.82 137.02 54.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.366 -179.686 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -129.89 89.85 2.88 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.866 -0.607 . . . . 0.0 109.959 179.424 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 63.9 t30 60.6 17.38 7.39 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.627 -179.038 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.411 ' HA2' ' HB ' ' A' ' 124' ' ' ILE . . . 124.58 -39.31 2.15 Favored Glycine 0 N--CA 1.448 -0.566 0 C-N-CA 120.957 -0.639 . . . . 0.0 112.031 -179.808 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.483 HG12 ' HB2' ' A' ' 158' ' ' ALA . 23.2 mt -78.35 131.41 34.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-O 120.989 0.423 . . . . 0.0 111.432 -179.693 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.766 HD11 ' CD1' ' A' ' 124' ' ' ILE . 3.6 mp -85.54 139.34 17.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.841 179.743 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 12.0 t -94.97 -67.35 0.86 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.047 -179.648 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 3.3 m -112.64 146.92 37.8 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.79 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.889 HD11 HG13 ' A' ' 118' ' ' VAL . 0.5 OUTLIER -133.24 100.89 4.99 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.662 179.979 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 2.7 tmm? -60.01 141.34 55.82 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.907 -179.888 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -93.4 44.14 1.13 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.09 0.471 . . . . 0.0 110.703 179.798 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -162.78 23.98 0.2 Allowed Glycine 0 N--CA 1.45 -0.375 0 CA-C-N 115.691 -0.686 . . . . 0.0 112.282 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . 0.489 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -112.77 175.46 16.8 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.851 -0.69 . . . . 0.0 111.952 179.798 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.537 HD13 ' HE ' ' A' ' 88' ' ' ARG . 0.5 OUTLIER -79.27 -23.55 12.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-O 120.933 0.397 . . . . 0.0 111.578 -179.772 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' ALA . . . . . 0.529 ' O ' HG12 ' A' ' 118' ' ' VAL . . . -57.92 -30.41 65.91 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.968 0.413 . . . . 0.0 110.604 -179.93 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' GLU . . . . . 0.489 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 8.6 pt-20 -59.92 -45.2 93.33 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.722 179.467 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 88.5 mtt180 -64.78 -46.26 82.83 Favored 'General case' 0 N--CA 1.452 -0.358 0 CA-C-N 115.96 -0.564 . . . . 0.0 111.087 -179.441 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.413 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -49.75 -74.65 0.25 Allowed Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.413 -0.899 . . . . 0.0 112.591 179.918 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . 0.429 ' O ' HG21 ' A' ' 82' ' ' THR . . . 175.21 -16.49 0.04 OUTLIER Glycine 0 CA--C 1.52 0.386 0 C-N-CA 120.77 -0.729 . . . . 0.0 113.112 179.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.889 HG13 HD11 ' A' ' 107' ' ' LEU . 5.0 p -34.13 148.8 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 N-CA-C 112.156 0.428 . . . . 0.0 112.156 -179.659 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 1.1 ttp85 -151.83 113.01 4.28 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.823 179.907 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . 0.55 ' O ' HG13 ' A' ' 120' ' ' VAL . 14.9 p -52.48 114.89 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.316 -179.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 113.5 19.12 6.74 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.433 -179.809 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 3.2 m170 -120.86 139.79 52.69 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.803 0.335 . . . . 0.0 110.773 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.673 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 10.7 ttt180 -83.65 90.65 7.31 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.384 -179.673 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . 0.784 HG23 ' SD ' ' A' ' 153' ' ' MET . 71.4 mt -48.75 134.33 6.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 178.784 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' ILE . . . . . 0.867 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.8 OUTLIER -128.29 -84.46 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 N-CA-C 113.175 0.806 . . . . 0.0 113.175 -178.398 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . 0.435 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 4.3 mt-10 -80.88 92.16 6.08 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 112.922 0.712 . . . . 0.0 112.922 -178.236 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.702 HG23 ' HB2' ' A' ' 153' ' ' MET . 1.3 mt -94.34 94.87 4.74 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.668 178.722 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . 0.454 ' N ' ' O ' ' A' ' 152' ' ' HIS . 55.5 m-80 62.3 26.35 15.77 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.882 -179.813 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 108.91 -19.37 30.44 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.733 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 5.5 tt0 -90.77 110.39 21.59 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.785 0.326 . . . . 0.0 110.878 179.903 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 1.4 m -76.2 93.32 3.36 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.077 -179.822 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . 0.635 HG21 HD11 ' A' ' 127' ' ' ILE . 25.9 m -73.48 -5.15 6.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.877 179.859 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.867 ' HB ' HG22 ' A' ' 125' ' ' ILE . 11.4 p -47.26 -36.65 4.1 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-O 120.857 0.361 . . . . 0.0 111.41 -179.713 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -117.28 28.65 8.35 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.628 179.501 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . 0.476 HG23 ' HD2' ' A' ' 136' ' ' PRO . 67.4 m -116.37 140.81 27.0 Favored Pre-proline 0 C--N 1.328 -0.363 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.343 -179.734 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 136' ' ' PRO . . . . . 0.476 ' HD2' HG23 ' A' ' 135' ' ' THR . 8.9 Cg_endo -50.99 164.36 0.63 Allowed 'Trans proline' 0 C--N 1.347 0.493 0 C-N-CA 122.759 2.306 . . . . 0.0 112.347 179.765 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 137' ' ' HIS . . . . . 0.405 ' CE1' ' HG3' ' A' ' 138' ' ' GLU . 20.9 p80 -70.91 -50.09 38.63 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.739 -179.42 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . 0.405 ' HG3' ' CE1' ' A' ' 137' ' ' HIS . 3.7 mt-10 -53.91 -33.79 57.66 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.607 -179.355 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 139' ' ' LYS . . . . . 0.745 ' O ' HD12 ' A' ' 143' ' ' ILE . 8.6 tptt -64.02 -48.05 77.86 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.369 -0.378 . . . . 0.0 111.098 -179.828 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . 0.78 HG21 HG21 ' A' ' 99' ' ' VAL . 13.9 mt -58.38 -46.15 89.38 Favored 'Isoleucine or valine' 0 C--O 1.235 0.318 0 CA-C-O 121.013 0.435 . . . . 0.0 110.669 -179.898 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . 0.535 HG22 HG12 ' A' ' 99' ' ' VAL . 58.9 t -60.05 -32.82 51.16 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.353 179.166 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 57.2 t-80 -62.77 -54.15 43.4 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.304 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . 0.745 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.2 mp -52.96 -57.21 4.9 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.451 0 CA-C-O 121.018 0.437 . . . . 0.0 110.375 179.647 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.613 HD13 ' HG ' ' A' ' 95' ' ' LEU . 1.4 mt -62.41 -30.04 70.93 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.55 -0.75 . . . . 0.0 110.381 179.581 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 3.4 m -66.63 -26.57 67.14 Favored 'General case' 0 N--CA 1.452 -0.347 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 178.448 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 4.3 m-80 -132.86 35.86 3.53 Favored 'General case' 0 CA--C 1.529 0.145 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.377 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 147' ' ' ALA . . . . . 0.638 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -118.06 52.59 1.0 Allowed 'General case' 0 C--N 1.332 -0.178 0 CA-C-O 120.776 0.322 . . . . 0.0 111.464 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.783 HG12 ' O ' ' A' ' 90' ' ' ASP . 15.6 m -53.5 -178.48 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 120.877 0.37 . . . . 0.0 111.035 179.91 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 83.96 -108.47 3.08 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.424 -179.834 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 20.2 mt-10 -138.27 101.6 4.43 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.878 0.37 . . . . 0.0 110.454 179.787 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . 0.638 HD11 ' HB3' ' A' ' 147' ' ' ALA . 1.1 mt -76.15 111.72 13.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 121.051 0.453 . . . . 0.0 111.487 -179.516 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . 0.454 ' O ' ' N ' ' A' ' 128' ' ' ASN . 0.2 OUTLIER -99.72 124.23 44.76 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 178.356 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 153' ' ' MET . . . . . 0.784 ' SD ' HG23 ' A' ' 124' ' ' ILE . 11.5 tmm? -150.68 155.08 38.63 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.139 0.495 . . . . 0.0 112.25 -177.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -113.45 148.17 36.43 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.59 -0.732 . . . . 0.0 109.669 178.977 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . 0.587 HG22 ' SD ' ' A' ' 153' ' ' MET . 16.3 p -130.7 141.02 50.39 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.28 0.562 . . . . 0.0 111.836 -179.266 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 156' ' ' MET . . . . . 0.59 ' HE3' HD11 ' A' ' 125' ' ' ILE . 0.0 OUTLIER -123.28 119.45 27.49 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 115.109 -0.951 . . . . 0.0 110.053 179.475 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 88.9 Cg_exo -42.24 110.63 0.16 Allowed 'Trans proline' 0 C--N 1.346 0.402 0 C-N-CA 122.56 2.173 . . . . 0.0 112.935 -179.756 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 158' ' ' ALA . . . . . 0.673 ' HB2' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.249 1.05 0 CA-C-O 118.23 -0.89 . . . . 0.0 111.043 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_endo . . . . . 0 N--CA 1.488 1.196 0 CA-C-O 120.604 0.168 . . . . 0.0 111.753 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 55.1 Cg_exo -52.05 88.87 0.03 OUTLIER 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 122.519 2.146 . . . . 0.0 112.377 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 12.5 p -86.16 141.43 14.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.035 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 3.0 m -115.49 132.05 56.74 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.993 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 26.6 m -92.26 111.65 23.29 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.032 179.235 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.783 HG12 HG13 ' A' ' 86' ' ' ILE . 94.5 t -83.89 105.41 13.34 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.566 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.68 -179.093 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.443 HD23 ' C ' ' A' ' 85' ' ' LEU . 5.2 tt -105.2 80.07 1.56 Allowed 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 109.176 -0.676 . . . . 0.0 109.176 178.466 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.813 HG21 HD22 ' A' ' 95' ' ' LEU . 4.5 mt -82.04 125.33 39.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 121.236 0.541 . . . . 0.0 111.874 -178.354 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.465 ' HB2' HG21 ' A' ' 112' ' ' ILE . 0.1 OUTLIER -76.94 147.86 36.7 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.289 -0.869 . . . . 0.0 110.061 179.467 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 6.0 mtp85 -141.84 96.13 6.81 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 120.686 0.279 . . . . 0.0 111.089 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_exo -56.38 -60.28 0.51 Allowed 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 122.562 2.175 . . . . 0.0 112.447 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -127.5 -169.17 2.0 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 121.03 0.443 . . . . 0.0 111.033 -179.692 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -89.11 -43.16 11.26 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.988 -0.551 . . . . 0.0 111.04 -179.942 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 16.5 mtt-85 -64.81 -13.66 56.44 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.639 -179.689 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 24.1 m-85 -88.68 117.57 27.75 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.456 -0.338 . . . . 0.0 110.976 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -85.21 169.42 13.84 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.999 -179.918 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 0.813 HD22 HG21 ' A' ' 86' ' ' ILE . 76.9 mt -76.21 -69.4 0.51 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.779 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 128.23 54.13 0.12 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.457 -0.877 . . . . 0.0 113.1 179.531 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . 0.617 ' CE2' ' HB2' ' A' ' 113' ' ' ALA . 42.5 p90 -177.83 174.25 1.47 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.817 0.342 . . . . 0.0 111.053 179.635 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -116.52 150.3 38.17 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.866 179.869 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.625 HG21 HG21 ' A' ' 140' ' ' ILE . 9.3 p -125.6 136.36 61.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.314 -179.894 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . 0.409 ' HG3' ' HB ' ' A' ' 103' ' ' ILE . 1.6 pt20 -130.37 91.64 3.13 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.215 179.464 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER 60.74 13.83 4.64 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.175 -179.343 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 129.67 -38.4 2.0 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.872 -0.68 . . . . 0.0 112.366 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.848 HG23 ' O ' ' A' ' 122' ' ' HIS . 36.2 mt -77.13 136.86 23.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-O 121.105 0.479 . . . . 0.0 111.684 -179.559 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.726 HG12 HG13 ' A' ' 118' ' ' VAL . 4.0 mp -90.98 138.37 19.73 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.54 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 7.7 m -94.29 -84.28 0.32 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.509 -179.298 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 46.3 t -109.88 113.53 26.33 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.926 0.393 . . . . 0.0 111.203 -179.6 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.713 HD13 ' O ' ' A' ' 107' ' ' LEU . 1.4 tm? -105.74 110.06 22.23 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.45 179.645 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 9.0 ttp -58.08 116.84 3.79 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.024 -179.762 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 7.1 mtt85 -63.89 80.79 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.001 0.429 . . . . 0.0 110.671 179.789 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 166.74 -30.88 0.2 Allowed Glycine 0 N--CA 1.45 -0.399 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.894 -179.754 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . 0.441 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -59.1 176.18 2.7 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.131 179.625 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.465 HG21 ' HB2' ' A' ' 87' ' ' ARG . 1.2 mt -79.06 -19.53 12.88 Favored 'Isoleucine or valine' 0 C--O 1.236 0.343 0 CA-C-O 120.892 0.377 . . . . 0.0 111.729 -179.69 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' ALA . . . . . 0.617 ' HB2' ' CE2' ' A' ' 97' ' ' PHE . . . -57.77 -30.61 65.78 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.981 0.42 . . . . 0.0 110.74 179.909 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' GLU . . . . . 0.441 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 10.5 pt-20 -60.92 -46.46 90.59 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.746 179.703 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -62.23 -45.76 91.89 Favored 'General case' 0 N--CA 1.453 -0.304 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.946 -179.444 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.401 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -51.19 -74.35 0.3 Allowed Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.297 -0.954 . . . . 0.0 112.532 179.872 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . 0.562 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 174.29 -26.22 0.08 OUTLIER Glycine 0 CA--C 1.518 0.276 0 C-N-CA 121.116 -0.564 . . . . 0.0 112.61 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.736 ' N ' HG22 ' A' ' 84' ' ' VAL . 13.5 t -15.72 -81.98 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.471 0.594 0 C-N-CA 123.259 0.624 . . . . 0.0 112.632 -179.824 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.653 ' N ' HG12 ' A' ' 118' ' ' VAL . 0.8 OUTLIER 63.84 129.05 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.748 0.309 . . . . 0.0 110.454 -179.43 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 22.2 t -63.29 130.88 28.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.314 -179.799 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 97.41 34.22 5.65 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.685 179.756 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . 0.848 ' O ' HG23 ' A' ' 103' ' ' ILE . 5.1 m170 -122.65 -174.54 2.94 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.933 0.396 . . . . 0.0 110.878 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.81 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 8.7 ttm-85 -144.23 89.43 2.02 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.87 -179.803 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . 0.653 HG13 HD11 ' A' ' 104' ' ' ILE . 78.3 mt -50.4 150.16 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 N-CA-C 110.208 -0.293 . . . . 0.0 110.208 179.246 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' ILE . . . . . 0.863 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.6 OUTLIER -146.07 -84.5 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 N-CA-C 112.87 0.693 . . . . 0.0 112.87 -178.892 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . 0.404 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 40.0 mt-10 -83.2 89.12 6.92 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 112.532 0.568 . . . . 0.0 112.532 -178.499 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.818 HG23 ' HB3' ' A' ' 153' ' ' MET . 1.8 mt -89.03 102.0 12.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.005 179.221 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 22.6 m-20 53.75 24.85 4.64 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.121 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 111.83 -16.51 25.76 Favored Glycine 0 CA--C 1.519 0.317 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.725 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -93.16 108.94 20.45 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.782 0.325 . . . . 0.0 110.889 -179.88 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 83.1 p -74.83 89.47 2.33 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.096 -179.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . 0.784 HG21 HD11 ' A' ' 127' ' ' ILE . 27.7 m -74.99 -4.08 5.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.832 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.863 ' HB ' HG22 ' A' ' 125' ' ' ILE . 12.1 p -46.37 -40.95 4.35 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-O 120.928 0.394 . . . . 0.0 111.343 -179.854 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . 0.411 ' N ' HG13 ' A' ' 133' ' ' VAL . . . -113.91 29.48 7.97 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.673 179.395 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . 0.464 HG23 ' HD2' ' A' ' 136' ' ' PRO . 84.0 m -114.04 143.26 29.32 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.047 -179.746 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 136' ' ' PRO . . . . . 0.464 ' HD2' HG23 ' A' ' 135' ' ' THR . 74.8 Cg_exo -49.72 156.97 2.73 Favored 'Trans proline' 0 C--N 1.347 0.494 0 C-N-CA 122.45 2.1 . . . . 0.0 112.245 179.851 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 137' ' ' HIS . . . . . 0.426 ' CE1' ' HG3' ' A' ' 138' ' ' GLU . 7.6 p80 -68.08 -46.47 70.93 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.266 -179.762 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . 0.426 ' HG3' ' CE1' ' A' ' 137' ' ' HIS . 18.1 mt-10 -55.56 -35.75 66.07 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.299 -179.791 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 139' ' ' LYS . . . . . 0.758 ' O ' HD12 ' A' ' 143' ' ' ILE . 5.4 tptt -62.78 -47.5 83.2 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.885 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . 0.625 HG21 HG21 ' A' ' 99' ' ' VAL . 16.4 mt -58.8 -43.04 87.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.584 179.951 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . 0.469 HG22 HG12 ' A' ' 99' ' ' VAL . 92.8 t -62.16 -32.72 55.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.177 179.051 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 2.0 t-80 -62.19 -54.48 40.36 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.907 179.901 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . 0.758 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.4 mp -53.09 -56.94 5.67 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.408 0 CA-C-O 121.207 0.527 . . . . 0.0 110.214 179.391 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.74 HD13 ' CD1' ' A' ' 95' ' ' LEU . 4.5 mt -60.94 -30.12 70.04 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.327 -0.852 . . . . 0.0 110.288 179.619 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 28.5 t -69.37 -26.45 64.67 Favored 'General case' 0 N--CA 1.452 -0.356 0 CA-C-N 116.183 -0.462 . . . . 0.0 109.929 178.672 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -128.9 33.42 4.62 Favored 'General case' 0 C--O 1.232 0.138 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.104 179.85 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 147' ' ' ALA . . . . . 0.652 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -115.81 46.17 1.58 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.859 0.361 . . . . 0.0 111.462 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 11.2 m -50.69 157.36 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.389 -179.864 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 102.68 -106.39 2.91 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.504 -179.966 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.417 ' HB3' HD21 ' A' ' 85' ' ' LEU . 30.1 mt-10 -139.14 94.44 2.8 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.805 0.336 . . . . 0.0 110.768 179.93 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . 0.652 HD11 ' HB3' ' A' ' 147' ' ' ALA . 1.0 OUTLIER -64.71 111.96 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.037 -179.867 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . 0.41 ' CD2' ' HG ' ' A' ' 85' ' ' LEU . 0.2 OUTLIER -99.43 115.94 30.42 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.046 -0.524 . . . . 0.0 109.962 179.135 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 153' ' ' MET . . . . . 0.818 ' HB3' HG23 ' A' ' 127' ' ' ILE . 0.1 OUTLIER -147.82 177.42 9.33 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.406 0.622 . . . . 0.0 111.58 -179.216 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 12.9 mttt -126.7 160.27 31.26 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 114.938 -1.028 . . . . 0.0 109.866 179.562 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . 0.54 HG22 ' HA ' ' A' ' 124' ' ' ILE . 24.4 p -144.18 144.58 31.62 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.299 0.571 . . . . 0.0 111.814 -179.565 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 156' ' ' MET . . . . . 0.53 ' O ' ' N ' ' A' ' 123' ' ' ARG . 0.0 OUTLIER -115.87 177.51 1.19 Allowed Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 115.142 -0.936 . . . . 0.0 109.997 179.508 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . 0.401 ' HD2' ' HB3' ' A' ' 156' ' ' MET . 89.8 Cg_endo -92.4 102.07 0.19 Allowed 'Trans proline' 0 N--CA 1.455 -0.757 0 C-N-CA 122.585 2.19 . . . . 0.0 112.627 -179.684 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 158' ' ' ALA . . . . . 0.81 ' HB2' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.248 1.025 0 CA-C-O 118.168 -0.92 . . . . 0.0 111.054 179.739 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_endo . . . . . 0 N--CA 1.489 1.25 0 CA-C-O 120.652 0.188 . . . . 0.0 111.772 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -72.08 65.46 3.4 Favored 'Trans proline' 0 C--N 1.343 0.248 0 C-N-CA 122.575 2.183 . . . . 0.0 112.37 -179.878 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.644 HG13 ' CE ' ' A' ' 156' ' ' MET . 37.1 t -108.02 121.6 61.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.061 179.796 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.5 m -98.69 139.24 34.69 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.869 179.912 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 10.3 m -109.29 111.46 23.06 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.106 -0.497 . . . . 0.0 109.93 179.015 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.723 HG11 HG23 ' A' ' 118' ' ' VAL . 66.2 t -81.72 106.38 12.68 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.638 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.506 -179.475 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.514 HD13 ' CD2' ' A' ' 152' ' ' HIS . 16.8 tp -104.91 87.06 2.57 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.592 178.859 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.678 HG21 HD22 ' A' ' 95' ' ' LEU . 3.7 mt -81.56 146.82 6.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.229 -179.088 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.485 ' CB ' HG21 ' A' ' 112' ' ' ILE . 0.0 OUTLIER -115.7 108.97 17.06 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.486 -179.602 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 53.5 ttt180 -104.02 108.28 59.49 Favored Pre-proline 0 C--N 1.33 -0.257 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.847 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -68.45 -27.56 33.4 Favored 'Trans proline' 0 C--N 1.347 0.487 0 C-N-CA 122.36 2.04 . . . . 0.0 112.402 -179.942 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . 0.417 ' HB2' ' CD1' ' A' ' 93' ' ' TYR . 1.1 m-20 -165.22 168.98 16.52 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.993 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -66.86 -36.87 83.3 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.067 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.21 -14.15 59.96 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.086 -0.507 . . . . 0.0 111.492 -179.769 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . 0.417 ' CD1' ' HB2' ' A' ' 90' ' ' ASP . 46.6 m-85 -99.39 113.11 25.26 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.42 -0.355 . . . . 0.0 110.889 179.881 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -73.98 165.93 24.27 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.007 -179.926 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 0.8 HD11 ' HB3' ' A' ' 144' ' ' LEU . 26.0 mt -77.44 -67.43 0.72 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.835 179.965 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.573 ' O ' HD23 ' A' ' 107' ' ' LEU . . . 132.51 40.6 0.2 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.566 -0.826 . . . . 0.0 112.956 179.624 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 35.3 p90 -177.05 159.55 1.67 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.796 0.331 . . . . 0.0 110.968 179.68 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -112.94 144.67 42.12 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.963 -179.92 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.83 HG21 HG21 ' A' ' 140' ' ' ILE . 12.7 p -111.47 138.0 41.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.591 -179.861 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . 0.422 ' O ' ' N ' ' A' ' 102' ' ' GLY . 5.2 mm-40 -130.04 88.58 2.68 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.007 179.013 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' ASN . . . . . 0.673 ' O ' HD11 ' A' ' 140' ' ' ILE . 3.7 t30 64.69 -70.66 0.08 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.951 -179.662 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.508 ' O ' HD13 ' A' ' 103' ' ' ILE . . . -141.86 -1.19 1.4 Allowed Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 120.445 -0.883 . . . . 0.0 113.024 179.928 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.823 HD12 ' HB2' ' A' ' 158' ' ' ALA . 25.5 mm -119.55 159.2 20.68 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.166 0 CA-C-O 120.969 0.414 . . . . 0.0 111.304 -179.712 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.559 ' N ' HD12 ' A' ' 104' ' ' ILE . 3.3 mp -102.19 141.46 18.36 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.912 -179.762 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -83.51 -69.43 0.64 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.936 -179.845 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -142.9 168.98 18.42 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.941 -179.882 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.801 HD11 ' O ' ' A' ' 118' ' ' VAL . 0.6 OUTLIER -123.1 167.46 13.63 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.912 179.926 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 4.5 ttt -122.62 97.76 5.6 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.648 179.705 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -55.21 91.0 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.86 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 152.94 -29.38 0.82 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.947 -0.644 . . . . 0.0 112.029 -179.69 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -70.88 176.82 35.88 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.278 179.753 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.485 HG21 ' CB ' ' A' ' 87' ' ' ARG . 0.6 OUTLIER -78.74 -16.6 13.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 120.711 0.291 . . . . 0.0 111.664 -179.769 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' ALA . . . . . 0.495 ' HA ' HG12 ' A' ' 86' ' ' ILE . . . -57.75 -30.53 65.66 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.013 0.435 . . . . 0.0 110.726 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -60.34 -46.91 88.24 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.662 179.632 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -62.49 -47.8 82.39 Favored 'General case' 0 N--CA 1.452 -0.352 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.125 -179.684 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -49.91 -74.14 0.3 Allowed Glycine 0 CA--C 1.519 0.325 0 C-N-CA 120.454 -0.879 . . . . 0.0 112.452 179.866 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . 0.587 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 173.99 -25.16 0.07 OUTLIER Glycine 0 CA--C 1.519 0.299 0 C-N-CA 121.141 -0.552 . . . . 0.0 112.366 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.801 ' O ' HD11 ' A' ' 107' ' ' LEU . 1.1 t -40.24 113.76 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.256 0 CA-C-O 120.981 0.419 . . . . 0.0 111.802 -179.709 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 2.3 ttt180 -132.3 110.26 10.47 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.117 179.462 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . 0.726 ' H ' HD12 ' A' ' 107' ' ' LEU . 85.1 t -43.6 118.12 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.688 -179.451 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 118.5 28.13 2.21 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.845 -0.693 . . . . 0.0 112.932 179.73 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . 0.505 ' CE1' HD13 ' A' ' 104' ' ' ILE . 20.2 p-80 -137.3 -170.29 2.7 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.619 0.247 . . . . 0.0 111.07 179.752 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.541 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 55.6 ttp85 -133.92 114.39 13.23 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-N 116.574 -0.285 . . . . 0.0 111.711 -179.555 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . 0.653 ' HA ' HG22 ' A' ' 155' ' ' THR . 34.7 mt -73.16 158.58 6.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 178.59 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' ILE . . . . . 0.573 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.8 OUTLIER -147.14 -83.02 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 N-CA-C 112.867 0.691 . . . . 0.0 112.867 -179.624 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . 0.47 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 5.4 mt-10 -87.41 87.7 7.48 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 112.44 0.533 . . . . 0.0 112.44 -178.477 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.855 HG23 ' HB3' ' A' ' 153' ' ' MET . 2.4 mt -87.06 103.83 13.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.29 179.197 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 7.5 m-20 53.01 25.32 3.96 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.905 -0.588 . . . . 0.0 111.193 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 110.08 -13.57 31.45 Favored Glycine 0 CA--C 1.519 0.3 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.846 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 11.6 tt0 -95.72 110.88 22.95 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.787 0.327 . . . . 0.0 110.772 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' SER . . . . . 0.415 ' HA ' ' O ' ' A' ' 125' ' ' ILE . 1.1 m -74.84 87.24 2.25 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.042 -179.901 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . 0.696 HG21 HD11 ' A' ' 127' ' ' ILE . 31.9 m -73.9 -5.3 6.53 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.369 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.956 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.573 ' HB ' HG22 ' A' ' 125' ' ' ILE . 9.8 p -46.31 -31.56 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-O 120.888 0.375 . . . . 0.0 111.566 -179.695 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -127.95 27.41 5.7 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.617 179.409 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . 0.434 ' CG2' ' HD2' ' A' ' 136' ' ' PRO . 32.5 m -110.65 143.79 28.93 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 115.833 -0.621 . . . . 0.0 111.214 -179.736 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 136' ' ' PRO . . . . . 0.434 ' HD2' ' CG2' ' A' ' 135' ' ' THR . 50.5 Cg_exo -53.78 164.27 2.45 Favored 'Trans proline' 0 C--N 1.347 0.495 0 C-N-CA 122.545 2.163 . . . . 0.0 112.048 179.512 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 137' ' ' HIS . . . . . 0.615 ' HA ' HD12 ' A' ' 140' ' ' ILE . 6.8 p80 -72.6 -46.83 52.27 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.517 -179.607 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . 0.405 ' N ' ' CG ' ' A' ' 137' ' ' HIS . 1.7 mm-40 -54.01 -39.13 65.85 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.472 -179.513 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 139' ' ' LYS . . . . . 0.785 ' O ' HD12 ' A' ' 143' ' ' ILE . 7.0 tttp -63.53 -45.97 88.18 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.225 -179.701 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . 0.83 HG21 HG21 ' A' ' 99' ' ' VAL . 9.7 mt -59.36 -46.08 92.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.983 0.421 . . . . 0.0 110.431 179.956 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . 0.483 HG23 ' CG1' ' A' ' 99' ' ' VAL . 55.4 t -60.08 -32.37 50.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.039 179.034 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 4.6 t60 -61.08 -53.68 54.06 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.679 179.579 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . 0.785 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.3 mp -53.16 -56.9 5.98 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.379 0 CA-C-O 121.276 0.56 . . . . 0.0 110.263 179.209 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.8 ' HB3' HD11 ' A' ' 95' ' ' LEU . 3.9 mt -61.24 -30.32 70.38 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.254 -0.884 . . . . 0.0 110.275 179.453 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 30.9 t -69.31 -26.38 64.69 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.123 -0.489 . . . . 0.0 109.925 178.676 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -127.43 32.2 5.06 Favored 'General case' 0 C--O 1.231 0.099 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.985 179.697 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 147' ' ' ALA . . . . . 0.795 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -114.03 41.62 2.21 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.352 -0.386 . . . . 0.0 111.296 -179.966 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 18.5 m -51.72 138.76 8.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.447 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 120.88 -103.46 0.9 Allowed Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.442 -179.914 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 4.7 mt-10 -139.28 100.65 4.06 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.79 0.328 . . . . 0.0 110.877 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . 0.795 HD11 ' HB3' ' A' ' 147' ' ' ALA . 1.3 mt -78.86 111.78 16.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.942 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . 0.514 ' CD2' HD13 ' A' ' 85' ' ' LEU . 0.5 OUTLIER -106.97 115.55 30.37 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.141 179.325 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 153' ' ' MET . . . . . 0.855 ' HB3' HG23 ' A' ' 127' ' ' ILE . 1.7 ptm -136.64 161.98 34.43 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.071 0.463 . . . . 0.0 111.729 -179.318 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . 0.551 ' HB3' HD11 ' A' ' 125' ' ' ILE . 3.5 mttt -104.53 150.3 24.73 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.712 -0.676 . . . . 0.0 109.778 179.121 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . 0.653 HG22 ' HA ' ' A' ' 124' ' ' ILE . 21.8 p -146.14 150.44 35.89 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.295 0.569 . . . . 0.0 112.076 -179.086 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 156' ' ' MET . . . . . 0.644 ' CE ' HG13 ' A' ' 81' ' ' VAL . 0.0 OUTLIER -144.76 145.33 27.58 Favored Pre-proline 0 C--N 1.327 -0.406 0 CA-C-N 115.226 -0.897 . . . . 0.0 110.346 179.102 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_exo -50.92 109.38 0.3 Allowed 'Trans proline' 0 C--N 1.343 0.263 0 C-N-CA 122.512 2.141 . . . . 0.0 112.628 -179.759 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 158' ' ' ALA . . . . . 0.823 ' HB2' HD12 ' A' ' 103' ' ' ILE . . . . . . . . 0 C--O 1.25 1.084 0 CA-C-O 118.266 -0.873 . . . . 0.0 111.343 179.863 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_exo . . . . . 0 N--CA 1.489 1.252 0 CA-C-O 120.716 0.215 . . . . 0.0 111.733 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -70.22 115.36 4.12 Favored 'Trans proline' 0 C--N 1.343 0.265 0 C-N-CA 122.515 2.143 . . . . 0.0 112.372 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 18.3 t -93.17 139.42 18.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.104 179.945 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.1 m -114.42 132.14 56.35 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.926 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.545 HG23 ' HE2' ' A' ' 154' ' ' LYS . 56.5 m -95.58 111.19 23.16 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.947 179.119 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.794 HG22 ' N ' ' A' ' 118' ' ' VAL . 86.3 t -88.39 105.38 15.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.58 -179.206 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.457 ' O ' ' HA2' ' A' ' 116' ' ' GLY . 2.7 tp -100.01 84.27 2.84 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 178.588 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.748 HG13 HG12 ' A' ' 84' ' ' VAL . 22.0 mt -81.27 127.31 39.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-O 121.4 0.619 . . . . 0.0 111.928 -178.501 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.803 ' O ' HG21 ' A' ' 112' ' ' ILE . 0.0 OUTLIER -74.49 153.34 39.16 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.136 -0.938 . . . . 0.0 110.407 179.856 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.471 ' HD2' HD21 ' A' ' 95' ' ' LEU . 5.5 ttt-85 -152.15 91.71 3.62 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 120.682 0.277 . . . . 0.0 111.161 -179.931 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -58.53 -63.48 0.14 Allowed 'Trans proline' 0 C--N 1.345 0.346 0 C-N-CA 122.583 2.189 . . . . 0.0 112.23 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 4.9 t0 -117.14 -173.68 2.45 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.169 -179.859 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.847 HD12 HG11 ' A' ' 148' ' ' VAL . 0.1 OUTLIER -91.79 -21.95 20.41 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.311 -179.864 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -95.76 22.7 6.97 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.469 -0.332 . . . . 0.0 111.219 -179.779 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 17.7 m-85 -121.04 117.97 28.59 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.801 0.334 . . . . 0.0 110.835 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 3.4 mp0 -64.57 177.93 0.83 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.874 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 0.83 ' CD1' HD13 ' A' ' 144' ' ' LEU . 42.5 mt -96.98 -61.35 1.42 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.932 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 132.05 53.91 0.09 OUTLIER Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.718 179.912 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . 0.514 ' HZ ' HD12 ' A' ' 144' ' ' LEU . 0.2 OUTLIER -176.68 -171.96 0.41 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.904 0.383 . . . . 0.0 110.991 179.9 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 8.3 t -137.44 130.35 30.36 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.793 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 1.058 HG21 HG21 ' A' ' 140' ' ' ILE . 10.4 p -109.97 114.35 46.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.06 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . 0.421 ' O ' ' N ' ' A' ' 102' ' ' GLY . 1.2 tt0 -110.31 89.0 2.9 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.817 0.341 . . . . 0.0 110.908 -180.0 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' ASN . . . . . 0.717 ' O ' HD11 ' A' ' 140' ' ' ILE . 1.6 t30 65.18 -64.64 0.17 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.51 179.702 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.421 ' N ' ' O ' ' A' ' 100' ' ' GLN . . . -146.88 -4.49 0.42 Allowed Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.336 -0.935 . . . . 0.0 113.661 -179.623 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.727 HD12 ' CB ' ' A' ' 158' ' ' ALA . 31.5 mm -125.09 142.64 41.35 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 117.389 0.594 . . . . 0.0 111.307 -179.543 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.678 HD11 HG13 ' A' ' 124' ' ' ILE . 3.9 mp -84.44 142.58 13.16 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.788 179.712 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -105.42 -77.73 0.58 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.991 -179.829 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 62.6 p -90.64 146.98 23.6 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.944 0.402 . . . . 0.0 110.9 -179.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.728 ' HB2' HG22 ' A' ' 120' ' ' VAL . 0.2 OUTLIER -136.72 123.92 21.77 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.883 179.993 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 4.1 mtt -77.06 120.37 22.05 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.882 -179.949 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -81.33 105.59 12.63 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.765 179.893 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 101.66 26.63 7.52 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.394 -179.917 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . 0.5 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -111.76 -158.25 14.53 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.701 -0.762 . . . . 0.0 113.209 -179.761 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.803 HG21 ' O ' ' A' ' 87' ' ' ARG . 16.3 mt -80.16 -41.92 21.35 Favored 'Isoleucine or valine' 0 C--O 1.238 0.463 0 CA-C-O 121.076 0.465 . . . . 0.0 111.766 -179.588 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' ALA . . . . . 0.804 ' O ' HG12 ' A' ' 118' ' ' VAL . . . -57.7 -36.21 71.67 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.193 -179.394 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' GLU . . . . . 0.53 ' HG3' ' N ' ' A' ' 115' ' ' ARG . 8.3 pt-20 -66.9 -36.26 81.87 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.484 179.561 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.53 ' N ' ' HG3' ' A' ' 114' ' ' GLU . 0.0 OUTLIER -59.39 -46.55 88.35 Favored 'General case' 0 N--CA 1.452 -0.359 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.559 -179.905 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.457 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -56.05 -71.31 0.75 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.205 -0.998 . . . . 0.0 112.539 179.635 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . 0.481 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 174.32 -22.76 0.06 OUTLIER Glycine 0 CA--C 1.519 0.282 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.824 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.804 HG12 ' O ' ' A' ' 113' ' ' ALA . 7.3 p -31.75 145.72 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 N-CA-C 112.265 0.469 . . . . 0.0 112.265 -179.621 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.441 ' HB3' ' CD2' ' A' ' 122' ' ' HIS . 0.1 OUTLIER -147.83 134.43 19.85 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.734 179.899 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . 0.728 HG22 ' HB2' ' A' ' 107' ' ' LEU . 22.0 t -59.48 111.26 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.036 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 109.72 18.49 8.91 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.602 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . 0.566 ' O ' HG23 ' A' ' 103' ' ' ILE . 1.7 m-70 -102.22 -173.02 2.24 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.682 0.277 . . . . 0.0 110.693 179.909 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.626 ' HD2' HD11 ' A' ' 103' ' ' ILE . 40.4 ttt180 -142.76 90.71 2.24 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.363 -0.38 . . . . 0.0 111.335 -179.647 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . 0.678 HG13 HD11 ' A' ' 104' ' ' ILE . 25.2 mt -51.48 157.07 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.307 179.112 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' ILE . . . . . 0.771 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.6 OUTLIER -149.38 -82.99 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 N-CA-C 112.576 0.584 . . . . 0.0 112.576 -179.389 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . 0.411 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 72.7 mt-10 -89.29 89.4 7.89 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 112.353 0.501 . . . . 0.0 112.353 -178.62 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.831 HG23 ' HB3' ' A' ' 153' ' ' MET . 2.1 mt -88.89 106.87 17.24 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.181 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.573 179.43 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . 0.429 ' HA ' ' CE1' ' A' ' 152' ' ' HIS . 3.1 t-20 53.45 31.69 12.64 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.899 -0.591 . . . . 0.0 111.066 179.726 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 98.23 -7.26 62.06 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.754 -179.74 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 2.9 tt0 -99.92 106.23 18.02 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.836 0.351 . . . . 0.0 110.756 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 1.6 m -71.12 84.26 0.72 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.157 -179.773 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . 0.706 HG11 HD12 ' A' ' 127' ' ' ILE . 34.1 m -67.73 -10.03 11.67 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.759 179.867 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.771 ' HB ' HG22 ' A' ' 125' ' ' ILE . 9.3 p -51.06 117.85 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.925 0.393 . . . . 0.0 110.961 179.969 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . 0.521 ' HB3' ' O ' ' A' ' 133' ' ' VAL . . . 75.1 21.2 1.98 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.754 -178.997 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . 0.47 ' CG2' ' HD2' ' A' ' 136' ' ' PRO . 29.3 m -103.5 142.52 24.74 Favored Pre-proline 0 C--N 1.327 -0.402 0 CA-C-N 115.648 -0.706 . . . . 0.0 110.802 179.828 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 136' ' ' PRO . . . . . 0.47 ' HD2' ' CG2' ' A' ' 135' ' ' THR . 94.9 Cg_exo -42.77 164.2 0.04 OUTLIER 'Trans proline' 0 C--N 1.348 0.533 0 C-N-CA 122.849 2.366 . . . . 0.0 112.9 -179.869 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 137' ' ' HIS . . . . . 0.447 ' CE1' ' O ' ' A' ' 99' ' ' VAL . 3.1 t-160 -74.17 -59.35 2.76 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.558 -179.525 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -53.67 -27.17 26.07 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.901 -179.135 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 139' ' ' LYS . . . . . 0.762 ' O ' HD12 ' A' ' 143' ' ' ILE . 0.9 OUTLIER -67.52 -51.44 50.85 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.651 0.262 . . . . 0.0 111.172 -179.535 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . 1.058 HG21 HG21 ' A' ' 99' ' ' VAL . 17.4 mt -59.54 -46.35 93.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 121.026 0.441 . . . . 0.0 110.751 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . 0.437 HG22 HG12 ' A' ' 99' ' ' VAL . 93.5 t -60.11 -32.44 50.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.227 179.237 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -61.75 -54.88 36.48 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.971 179.723 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . 0.762 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.1 mp -52.88 -56.9 5.62 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.391 0 CA-C-O 121.232 0.539 . . . . 0.0 110.267 179.569 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.83 HD13 ' CD1' ' A' ' 95' ' ' LEU . 1.6 mt -61.75 -29.97 70.48 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.394 179.582 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 25.8 t -69.25 -26.56 64.84 Favored 'General case' 0 C--N 1.33 -0.242 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 178.523 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -126.91 31.61 5.26 Favored 'General case' 0 CA--C 1.53 0.181 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.093 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 147' ' ' ALA . . . . . 0.772 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -116.98 58.19 0.78 Allowed 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.356 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.847 HG11 HD12 ' A' ' 91' ' ' LEU . 3.9 m -53.28 173.7 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.346 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . 0.409 ' N ' ' HB3' ' A' ' 88' ' ' ARG . . . 87.9 -113.38 4.01 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.468 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 -139.76 102.84 4.53 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.835 0.35 . . . . 0.0 110.778 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . 0.772 HD11 ' HB3' ' A' ' 147' ' ' ALA . 1.3 mt -73.99 111.67 9.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.098 -179.905 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . 0.429 ' CE1' ' HA ' ' A' ' 128' ' ' ASN . 8.7 p80 -104.58 115.58 30.59 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.136 -0.484 . . . . 0.0 109.733 178.84 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 153' ' ' MET . . . . . 0.831 ' HB3' HG23 ' A' ' 127' ' ' ILE . 0.8 OUTLIER -136.72 174.66 10.37 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.193 0.52 . . . . 0.0 111.874 -178.737 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . 0.685 ' HB3' HD11 ' A' ' 125' ' ' ILE . 0.0 OUTLIER -118.56 151.62 37.55 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.77 179.268 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . 0.419 HG22 ' HA ' ' A' ' 124' ' ' ILE . 44.4 p -139.65 143.22 37.07 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.027 0.441 . . . . 0.0 111.479 -179.551 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 156' ' ' MET . . . . . 0.45 ' O ' ' N ' ' A' ' 123' ' ' ARG . 0.0 OUTLIER -110.77 176.63 1.45 Allowed Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 115.538 -0.755 . . . . 0.0 110.545 179.764 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 96.3 Cg_endo -90.12 118.75 0.74 Allowed 'Trans proline' 0 N--CA 1.457 -0.619 0 C-N-CA 122.735 2.29 . . . . 0.0 112.546 -179.856 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 158' ' ' ALA . . . . . 0.727 ' CB ' HD12 ' A' ' 103' ' ' ILE . . . . . . . . 0 C--O 1.249 1.071 0 CA-C-O 118.242 -0.885 . . . . 0.0 111.019 179.781 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_exo . . . . . 0 N--CA 1.488 1.178 0 N-CA-C 111.656 -0.171 . . . . 0.0 111.656 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_exo -66.64 62.57 0.56 Allowed 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.79 2.327 . . . . 0.0 112.351 -179.79 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.4 HG23 ' O ' ' A' ' 155' ' ' THR . 9.4 p -87.33 146.57 6.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.048 179.92 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.6 m -111.1 121.28 44.92 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.871 179.764 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.433 ' HA ' ' O ' ' A' ' 153' ' ' MET . 8.9 m -92.65 110.82 22.26 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.039 179.046 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.858 HG11 HG23 ' A' ' 118' ' ' VAL . 76.2 t -83.31 106.0 13.54 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.597 0 CA-C-N 116.298 -0.41 . . . . 0.0 112.059 -179.17 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.418 HD12 ' NE2' ' A' ' 152' ' ' HIS . 3.9 tt -102.97 81.11 1.94 Allowed 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 177.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.842 HG13 HG12 ' A' ' 84' ' ' VAL . 4.4 mt -81.49 123.88 38.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 121.281 0.562 . . . . 0.0 111.769 -178.328 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.565 ' HB2' HG21 ' A' ' 112' ' ' ILE . 0.1 OUTLIER -70.43 142.62 51.98 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.307 -0.86 . . . . 0.0 110.496 179.761 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.511 ' HG3' HD12 ' A' ' 151' ' ' ILE . 10.2 mtp180 -141.93 98.73 6.22 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.891 179.993 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . 0.447 ' HG2' ' CG ' ' A' ' 93' ' ' TYR . 64.1 Cg_endo -73.61 -41.62 1.09 Allowed 'Trans proline' 0 C--N 1.346 0.403 0 C-N-CA 122.552 2.168 . . . . 0.0 112.561 -179.877 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -137.05 -168.09 2.22 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.149 -179.824 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.607 ' HG ' HG11 ' A' ' 148' ' ' VAL . 3.9 mt -95.08 -22.74 17.69 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.204 -179.861 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 4.5 ptt-85 -96.23 22.84 7.2 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.144 -179.834 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . 0.447 ' CG ' ' HG2' ' A' ' 89' ' ' PRO . 12.9 m-85 -106.05 96.63 6.61 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.922 0.391 . . . . 0.0 110.894 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 1.3 pp0? -50.58 159.21 0.54 Allowed 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.276 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 0.83 HD23 HD13 ' A' ' 86' ' ' ILE . 2.1 mp -88.05 -66.8 0.88 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.861 179.872 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 130.49 37.77 0.32 Allowed Glycine 0 CA--C 1.519 0.29 0 C-N-CA 120.562 -0.828 . . . . 0.0 112.885 179.661 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . 0.439 ' CD1' ' HB2' ' A' ' 113' ' ' ALA . 50.2 p90 -176.93 178.06 1.21 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.707 0.289 . . . . 0.0 110.936 179.775 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.6 t -128.36 146.1 50.88 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.97 0.414 . . . . 0.0 111.06 -179.787 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 1.086 HG21 HG21 ' A' ' 140' ' ' ILE . 5.5 p -113.09 124.33 69.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.832 179.9 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . 0.417 ' O ' ' N ' ' A' ' 102' ' ' GLY . 1.9 tt0 -115.55 88.77 2.95 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.803 179.766 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' ASN . . . . . 0.65 ' O ' HD11 ' A' ' 140' ' ' ILE . 1.2 m-80 64.94 -67.16 0.12 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.87 -0.605 . . . . 0.0 111.424 179.685 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.423 ' O ' ' HA ' ' A' ' 123' ' ' ARG . . . -144.52 -3.7 0.7 Allowed Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.29 -0.957 . . . . 0.0 113.41 -179.629 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.653 HD12 ' HB2' ' A' ' 158' ' ' ALA . 39.2 mm -122.99 148.57 26.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 117.315 0.557 . . . . 0.0 111.406 -179.574 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.638 HD11 ' CD1' ' A' ' 124' ' ' ILE . 2.8 mp -85.08 141.91 13.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.507 179.594 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 94.1 m -97.81 -80.11 0.45 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.125 -179.677 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 1.4 m -109.13 145.63 35.41 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.981 -179.872 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.874 HD12 HG12 ' A' ' 118' ' ' VAL . 1.2 tt -143.2 113.2 7.14 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.808 179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -74.83 142.55 44.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.719 179.852 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.87 47.52 1.42 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.974 0.416 . . . . 0.0 110.808 -179.904 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -161.35 25.83 0.26 Allowed Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.39 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . 0.454 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -121.05 -174.63 14.98 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.331 179.867 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.565 HG21 ' HB2' ' A' ' 87' ' ' ARG . 1.2 mp -78.92 -22.56 12.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 120.785 0.326 . . . . 0.0 111.463 -179.876 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' ALA . . . . . 0.439 ' HB2' ' CD1' ' A' ' 97' ' ' PHE . . . -58.2 -30.57 66.56 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.894 0.378 . . . . 0.0 110.723 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' GLU . . . . . 0.454 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 12.4 pt-20 -61.26 -46.42 90.42 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.796 179.734 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 3.5 mtp85 -63.38 -44.13 95.62 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.908 -179.617 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -53.73 -73.97 0.35 Allowed Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.386 -0.911 . . . . 0.0 112.504 179.885 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . 0.564 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 174.98 -27.01 0.08 OUTLIER Glycine 0 CA--C 1.519 0.331 0 C-N-CA 120.922 -0.656 . . . . 0.0 112.65 -179.824 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.874 HG12 HD12 ' A' ' 107' ' ' LEU . 94.3 t -31.87 116.56 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 CA-C-O 121.026 0.441 . . . . 0.0 111.709 -179.82 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 11.7 mtt-85 -128.62 112.64 14.49 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.294 179.583 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . 0.567 HG22 ' HB2' ' A' ' 107' ' ' LEU . 32.2 t -46.99 108.42 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.239 -179.768 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 120.36 16.28 4.76 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 121.009 -0.615 . . . . 0.0 112.54 -179.721 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . 0.464 ' O ' HG23 ' A' ' 103' ' ' ILE . 3.9 m170 -110.35 -172.39 2.03 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.597 0.237 . . . . 0.0 110.562 179.923 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.74 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 4.1 ttt180 -139.88 92.87 2.59 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.682 0.277 . . . . 0.0 111.418 -179.657 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . 0.638 ' CD1' HD11 ' A' ' 104' ' ' ILE . 7.2 mt -52.76 147.65 1.91 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.077 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' ILE . . . . . 0.905 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.6 OUTLIER -141.42 -84.79 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 N-CA-C 112.393 0.516 . . . . 0.0 112.393 -179.335 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 8.5 mm-40 -86.39 90.06 8.08 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 112.316 0.488 . . . . 0.0 112.316 -178.719 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.889 HG23 ' HB3' ' A' ' 153' ' ' MET . 2.3 mt -85.45 105.72 14.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 121.24 0.543 . . . . 0.0 111.473 179.307 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . 0.44 ' N ' ' O ' ' A' ' 152' ' ' HIS . 0.6 OUTLIER 56.61 20.81 5.23 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.694 -0.684 . . . . 0.0 111.512 179.667 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 115.14 -12.8 19.54 Favored Glycine 0 C--N 1.331 0.301 0 C-N-CA 120.519 -0.848 . . . . 0.0 113.434 179.665 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 1.1 pt20 -103.17 117.54 34.78 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-O 120.958 0.408 . . . . 0.0 110.834 179.957 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 95.9 p -74.85 85.8 2.22 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.31 -179.643 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . 0.596 HG11 HD12 ' A' ' 127' ' ' ILE . 33.8 m -66.61 -10.89 12.39 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.315 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.535 179.537 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.905 ' HB ' HG22 ' A' ' 125' ' ' ILE . 8.9 p -49.69 117.73 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 120.915 0.388 . . . . 0.0 110.964 -179.952 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . 0.529 ' HB3' ' O ' ' A' ' 133' ' ' VAL . . . 76.15 20.77 1.58 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.789 -179.141 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . 0.471 HG23 ' HD2' ' A' ' 136' ' ' PRO . 36.9 m -104.21 143.21 26.2 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.691 179.637 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 136' ' ' PRO . . . . . 0.471 ' HD2' HG23 ' A' ' 135' ' ' THR . 1.9 Cg_endo -41.51 141.19 1.47 Allowed 'Trans proline' 0 C--N 1.347 0.499 0 C-N-CA 123.113 2.542 . . . . 0.0 112.631 179.898 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 38.0 p-80 -63.95 -48.49 76.3 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.024 -0.534 . . . . 0.0 111.464 -179.62 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -54.73 -36.58 64.92 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.301 -179.625 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 139' ' ' LYS . . . . . 0.808 ' O ' HD12 ' A' ' 143' ' ' ILE . 19.2 tttm -63.34 -48.81 76.41 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.83 -179.933 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . 1.086 HG21 HG21 ' A' ' 99' ' ' VAL . 21.6 mt -58.47 -46.12 89.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.722 -179.861 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . 0.485 HG22 HG12 ' A' ' 99' ' ' VAL . 99.3 t -59.34 -32.5 48.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.014 178.869 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 1.7 t60 -61.78 -52.01 65.96 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.71 179.628 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . 0.808 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.3 mp -53.19 -57.23 5.14 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.414 0 CA-C-O 121.024 0.44 . . . . 0.0 110.222 179.416 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.749 HD13 ' CD2' ' A' ' 95' ' ' LEU . 3.4 mt -60.53 -30.15 69.57 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.562 -0.745 . . . . 0.0 110.23 179.574 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 1.1 m -69.33 -26.91 64.94 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-N 116.062 -0.517 . . . . 0.0 109.895 178.557 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 3.6 m-80 -129.82 34.61 4.27 Favored 'General case' 0 CA--C 1.528 0.114 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.216 179.837 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 147' ' ' ALA . . . . . 0.586 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -116.82 56.39 0.8 Allowed 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.835 0.35 . . . . 0.0 111.325 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.607 HG11 ' HG ' ' A' ' 91' ' ' LEU . 27.7 m -54.21 -177.96 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.403 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 81.67 -100.96 2.11 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.552 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 13.0 mt-10 -152.9 98.2 2.29 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.813 0.34 . . . . 0.0 110.707 -179.898 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . 0.586 HD11 ' HB3' ' A' ' 147' ' ' ALA . 1.2 mt -63.09 111.56 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.185 -179.718 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . 0.44 ' O ' ' N ' ' A' ' 128' ' ' ASN . 1.5 t-160 -107.1 115.64 30.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.983 -0.553 . . . . 0.0 109.805 179.121 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 153' ' ' MET . . . . . 0.889 ' HB3' HG23 ' A' ' 127' ' ' ILE . 1.0 OUTLIER -141.96 176.17 9.15 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.041 0.448 . . . . 0.0 111.82 -178.893 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 53.1 mttt -124.23 148.9 46.99 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.064 179.401 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . 0.4 ' O ' HG23 ' A' ' 81' ' ' VAL . 20.0 p -137.1 132.17 33.7 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.942 0.401 . . . . 0.0 111.466 -179.57 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 156' ' ' MET . . . . . 0.476 ' O ' ' N ' ' A' ' 123' ' ' ARG . 0.0 OUTLIER -104.78 154.43 38.58 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.266 179.51 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 17.1 Cg_exo -66.77 118.78 5.82 Favored 'Trans proline' 0 C--N 1.342 0.228 0 C-N-CA 122.359 2.04 . . . . 0.0 112.136 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 158' ' ' ALA . . . . . 0.74 ' HB2' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.249 1.058 0 CA-C-O 118.262 -0.875 . . . . 0.0 111.107 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_exo . . . . . 0 N--CA 1.488 1.18 0 CA-C-O 120.772 0.238 . . . . 0.0 111.804 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 62.5 Cg_endo -73.81 -172.98 1.22 Allowed 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.507 2.138 . . . . 0.0 112.292 -179.835 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.589 HG13 ' O ' ' A' ' 155' ' ' THR . 41.7 t -87.65 141.19 14.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.094 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.5 m -117.09 143.4 45.83 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.913 179.854 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 17.7 m -105.67 111.56 24.3 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.247 179.279 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.74 HG11 HG23 ' A' ' 118' ' ' VAL . 43.4 t -82.34 105.94 12.73 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.552 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.78 -179.359 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.49 HD23 ' C ' ' A' ' 85' ' ' LEU . 6.3 tt -108.14 82.3 1.61 Allowed 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 109.122 -0.696 . . . . 0.0 109.122 178.574 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.992 HG21 HD22 ' A' ' 95' ' ' LEU . 5.1 mt -81.36 145.21 9.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.009 -0.541 . . . . 0.0 111.807 -178.165 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.418 ' HG2' ' CG2' ' A' ' 112' ' ' ILE . 0.1 OUTLIER -97.71 114.71 26.75 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.518 -179.831 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.472 ' HD2' HD12 ' A' ' 151' ' ' ILE . 2.3 ttt-85 -112.26 103.09 55.15 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.136 -179.714 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . 0.429 ' HB2' ' CD2' ' A' ' 93' ' ' TYR . 34.8 Cg_exo -57.63 -53.6 4.37 Favored 'Trans proline' 0 C--N 1.347 0.475 0 C-N-CA 122.498 2.132 . . . . 0.0 112.369 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -140.41 -167.07 2.25 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.986 -179.921 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.423 ' HG ' HG11 ' A' ' 148' ' ' VAL . 8.2 mt -84.01 -20.1 33.37 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.313 -179.868 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -96.41 23.33 6.86 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.095 -179.808 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . 0.429 ' CD2' ' HB2' ' A' ' 89' ' ' PRO . 15.9 m-85 -115.04 122.04 44.96 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.951 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -79.58 162.11 25.53 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.818 -179.979 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 0.992 HD22 HG21 ' A' ' 86' ' ' ILE . 53.9 mt -89.5 -69.94 0.69 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.837 179.964 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.407 ' O ' HD12 ' A' ' 107' ' ' LEU . . . 138.54 43.66 0.08 OUTLIER Glycine 0 CA--C 1.518 0.234 0 C-N-CA 120.42 -0.895 . . . . 0.0 113.011 179.724 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 35.4 p90 -176.74 161.97 2.12 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.849 0.357 . . . . 0.0 111.07 179.65 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -115.63 139.16 50.37 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.761 179.876 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.785 HG21 HG21 ' A' ' 140' ' ' ILE . 12.3 p -109.88 131.7 60.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.487 -179.818 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . 0.412 ' O ' ' N ' ' A' ' 102' ' ' GLY . 10.0 mt-30 -122.58 88.57 2.95 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.13 179.224 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' ASN . . . . . 0.649 ' O ' HD11 ' A' ' 140' ' ' ILE . 2.0 m120 63.89 -73.94 0.05 OUTLIER 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.971 -179.725 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.526 ' O ' HD13 ' A' ' 103' ' ' ILE . . . -137.82 0.67 2.74 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.299 -0.953 . . . . 0.0 113.05 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.813 HD12 ' HB2' ' A' ' 158' ' ' ALA . 38.1 mm -124.17 151.88 29.51 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.127 0 CA-C-O 121.014 0.435 . . . . 0.0 111.435 -179.617 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.765 HD11 HG13 ' A' ' 124' ' ' ILE . 3.2 mp -93.32 152.15 3.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.739 179.858 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 96.3 m -105.59 -67.54 0.92 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.107 -179.8 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 78.8 p -123.98 154.24 40.1 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.387 -0.369 . . . . 0.0 111.167 -179.853 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.407 HD12 ' O ' ' A' ' 96' ' ' GLY . 27.1 tp -139.55 103.42 4.69 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.619 179.861 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 6.8 ttm -60.89 110.91 1.46 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.006 -179.861 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 2.2 tmt_? -68.7 72.21 0.23 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.768 179.747 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 174.34 -34.12 0.11 Allowed Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.973 -0.632 . . . . 0.0 112.149 -179.853 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . 0.402 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -60.0 -176.73 1.31 Allowed Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.21 179.697 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.482 ' H ' HD12 ' A' ' 112' ' ' ILE . 0.8 OUTLIER -78.7 -17.09 13.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-O 120.822 0.344 . . . . 0.0 111.625 -179.89 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' ALA . . . . . 0.446 ' HA ' HG12 ' A' ' 86' ' ' ILE . . . -58.08 -30.46 66.25 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.937 0.398 . . . . 0.0 110.827 179.961 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' GLU . . . . . 0.402 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 14.5 pt-20 -61.56 -46.84 88.21 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.74 179.687 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 27.9 mtm-85 -62.1 -44.59 96.33 Favored 'General case' 0 N--CA 1.451 -0.406 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.082 -179.64 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.415 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -52.92 -73.75 0.37 Allowed Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.36 -0.924 . . . . 0.0 112.536 179.975 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . 0.567 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 167.33 -19.31 0.09 OUTLIER Glycine 0 CA--C 1.52 0.377 0 C-N-CA 121.0 -0.619 . . . . 0.0 112.75 -179.702 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.74 HG23 HG11 ' A' ' 84' ' ' VAL . 0.9 OUTLIER -38.5 129.47 0.36 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.244 0 CA-C-O 121.007 0.432 . . . . 0.0 111.607 -179.862 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -127.63 101.94 6.62 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.603 179.752 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . 0.513 ' O ' HG13 ' A' ' 120' ' ' VAL . 12.5 p -49.86 117.81 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.013 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 115.91 -14.56 16.77 Favored Glycine 0 CA--C 1.518 0.228 0 C-N-CA 120.854 -0.689 . . . . 0.0 112.333 -179.488 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -84.65 -165.6 1.23 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.64 0.257 . . . . 0.0 110.54 179.872 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.595 ' HA ' HD13 ' A' ' 103' ' ' ILE . 51.6 ttt85 -130.39 102.2 6.07 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.881 0.372 . . . . 0.0 111.445 -179.718 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . 0.842 ' HA ' HG22 ' A' ' 155' ' ' THR . 9.1 mt -60.63 157.95 2.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.092 178.86 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' ILE . . . . . 0.839 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.7 OUTLIER -154.79 -85.04 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 N-CA-C 113.086 0.773 . . . . 0.0 113.086 -179.708 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . 0.401 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 3.3 mt-10 -84.28 91.21 7.7 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 112.932 0.716 . . . . 0.0 112.932 -178.117 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.875 HD11 HG21 ' A' ' 132' ' ' VAL . 1.7 mt -90.88 98.79 8.76 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.146 0 CA-C-N 116.374 -0.376 . . . . 0.0 110.878 178.628 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . 0.422 ' N ' ' O ' ' A' ' 152' ' ' HIS . 45.8 m-20 60.84 26.13 16.0 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.703 -179.848 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 106.98 -16.14 39.55 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.556 -179.841 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -92.35 108.17 19.76 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.909 0.385 . . . . 0.0 110.715 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 27.4 m -74.59 90.9 2.28 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.125 -179.772 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . 0.875 HG21 HD11 ' A' ' 127' ' ' ILE . 35.0 m -81.62 4.39 2.02 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.341 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.967 179.904 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.839 ' HB ' HG22 ' A' ' 125' ' ' ILE . 9.8 p -47.81 -32.42 3.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 120.914 0.388 . . . . 0.0 111.253 -179.857 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -124.68 27.69 6.78 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.601 179.313 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . 0.523 HG23 ' HD2' ' A' ' 136' ' ' PRO . 90.6 m -109.5 143.69 28.31 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.982 -179.841 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 136' ' ' PRO . . . . . 0.523 ' HD2' HG23 ' A' ' 135' ' ' THR . 80.3 Cg_exo -48.27 164.16 0.21 Allowed 'Trans proline' 0 C--N 1.349 0.565 0 C-N-CA 122.496 2.13 . . . . 0.0 112.483 179.909 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 137' ' ' HIS . . . . . 0.557 ' HA ' HD12 ' A' ' 140' ' ' ILE . 57.1 p-80 -76.23 -48.45 20.29 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.492 -179.606 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -55.53 -34.66 64.87 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.939 0.4 . . . . 0.0 111.197 -179.636 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 139' ' ' LYS . . . . . 0.791 ' O ' HD12 ' A' ' 143' ' ' ILE . 0.8 OUTLIER -64.43 -47.47 78.98 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.021 -179.831 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . 0.785 HG21 HG21 ' A' ' 99' ' ' VAL . 8.7 mt -59.18 -46.5 92.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 121.155 0.503 . . . . 0.0 110.553 -179.868 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . 0.486 HG23 ' CG1' ' A' ' 99' ' ' VAL . 54.1 t -59.68 -32.45 49.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.057 179.013 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 5.6 t-160 -61.58 -53.44 56.31 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.909 179.738 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . 0.791 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.2 mp -53.06 -56.95 5.62 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.468 0 CA-C-O 121.203 0.525 . . . . 0.0 110.455 179.494 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.651 HD22 HG12 ' A' ' 151' ' ' ILE . 1.6 mt -63.3 -29.82 71.07 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.414 -0.812 . . . . 0.0 110.455 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 4.0 m -69.66 -28.47 65.9 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 178.773 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 4.6 m-80 -129.67 35.42 4.19 Favored 'General case' 0 CA--C 1.528 0.128 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.227 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 147' ' ' ALA . . . . . 0.949 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -101.05 -33.27 10.22 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.945 0.402 . . . . 0.0 111.28 -179.917 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.438 HG22 ' O ' ' A' ' 147' ' ' ALA . 35.5 m 44.44 -173.63 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.527 -0.76 . . . . 0.0 111.849 -179.877 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 50.78 -148.67 7.42 Favored Glycine 0 C--N 1.332 0.341 0 C-N-CA 120.854 -0.689 . . . . 0.0 112.772 -179.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.443 ' HB3' HD21 ' A' ' 85' ' ' LEU . 7.9 mt-10 -89.41 105.33 17.73 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.72 0.295 . . . . 0.0 110.845 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . 0.949 HD11 ' HB3' ' A' ' 147' ' ' ALA . 0.6 OUTLIER -78.25 111.58 15.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.387 -0.37 . . . . 0.0 111.12 -179.917 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . 0.422 ' O ' ' N ' ' A' ' 128' ' ' ASN . 0.0 OUTLIER -93.29 124.79 37.51 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 178.889 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 153' ' ' MET . . . . . 0.745 ' HG3' HG23 ' A' ' 127' ' ' ILE . 5.2 tmm? -147.92 151.89 36.62 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.873 0.368 . . . . 0.0 111.79 -178.721 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . 0.401 ' HG2' HG11 ' A' ' 81' ' ' VAL . 0.0 OUTLIER -111.86 148.14 34.27 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.476 179.644 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . 0.842 HG22 ' HA ' ' A' ' 124' ' ' ILE . 37.6 p -145.23 151.32 38.21 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.086 0.47 . . . . 0.0 111.702 -179.755 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 156' ' ' MET . . . . . 0.435 ' O ' ' N ' ' A' ' 123' ' ' ARG . 5.0 ptp -139.43 156.3 71.65 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.295 179.061 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 12.7 Cg_endo -56.43 120.44 8.31 Favored 'Trans proline' 0 C--N 1.342 0.229 0 C-N-CA 122.5 2.133 . . . . 0.0 112.609 -179.714 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 158' ' ' ALA . . . . . 0.813 ' HB2' HD12 ' A' ' 103' ' ' ILE . . . . . . . . 0 C--O 1.249 1.051 0 CA-C-O 118.308 -0.853 . . . . 0.0 110.995 179.845 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_endo . . . . . 0 N--CA 1.489 1.252 0 CA-C-O 120.831 0.263 . . . . 0.0 111.7 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -70.13 126.67 13.32 Favored 'Trans proline' 0 C--N 1.345 0.348 0 C-N-CA 122.566 2.178 . . . . 0.0 112.351 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.703 HG23 ' O ' ' A' ' 155' ' ' THR . 11.6 p -83.89 140.48 16.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.969 179.857 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 1.4 m -82.2 146.03 29.75 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.87 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 8.8 m -108.3 111.16 22.96 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.188 179.13 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.652 HG12 ' CD1' ' A' ' 86' ' ' ILE . 49.9 t -90.29 106.13 16.97 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.448 0 CA-C-N 116.024 -0.534 . . . . 0.0 111.078 -179.708 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.409 ' O ' ' HA2' ' A' ' 116' ' ' GLY . 0.9 OUTLIER -107.01 81.55 1.56 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.02 179.134 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.652 ' CD1' HG12 ' A' ' 84' ' ' VAL . 1.7 mp -81.59 149.09 4.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 121.067 0.46 . . . . 0.0 111.047 -179.235 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.452 ' CB ' HG21 ' A' ' 112' ' ' ILE . 0.3 OUTLIER -109.43 108.8 19.45 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.761 -179.354 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -102.82 104.75 41.12 Favored Pre-proline 0 C--N 1.33 -0.257 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.812 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . 0.445 ' HG2' ' CG ' ' A' ' 93' ' ' TYR . 37.9 Cg_endo -66.46 -49.21 1.88 Allowed 'Trans proline' 0 C--N 1.347 0.479 0 C-N-CA 122.341 2.027 . . . . 0.0 112.546 -179.814 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -136.2 178.95 6.66 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.157 -179.86 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 25.5 mt -77.64 -19.89 54.74 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.194 -179.897 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 2.9 ptt180 -96.85 23.26 7.29 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.48 -0.327 . . . . 0.0 111.158 -179.895 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . 0.445 ' CG ' ' HG2' ' A' ' 89' ' ' PRO . 16.8 m-85 -120.15 92.3 3.74 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.942 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -59.49 165.92 2.63 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.049 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 0.542 ' HG ' HG21 ' A' ' 86' ' ' ILE . 2.4 mp -82.63 -37.46 24.91 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.709 179.836 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 96.11 50.85 1.84 Allowed Glycine 0 C--N 1.33 0.229 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.84 179.653 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 1.3 p90 -160.58 -172.92 3.72 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.905 0.383 . . . . 0.0 111.077 179.873 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.428 ' O ' ' HA ' ' A' ' 104' ' ' ILE . 6.4 t -135.71 128.64 31.34 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.458 179.757 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.431 ' CG1' HG23 ' A' ' 141' ' ' VAL . 9.9 p -109.79 131.59 60.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.918 0.389 . . . . 0.0 111.675 -179.525 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 13.0 mt-30 -123.33 88.32 2.9 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.908 -0.587 . . . . 0.0 109.527 178.842 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 4.6 m120 56.59 18.97 3.9 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.932 -178.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 128.68 -41.43 1.57 Allowed Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.854 -0.688 . . . . 0.0 112.572 179.835 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.53 HG12 ' CB ' ' A' ' 158' ' ' ALA . 21.0 mt -77.42 133.38 30.8 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-O 121.061 0.457 . . . . 0.0 111.678 -179.361 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.885 HD11 ' CD1' ' A' ' 124' ' ' ILE . 4.5 mp -93.14 137.57 22.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.609 179.487 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 53.5 t -108.89 -75.39 0.63 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.094 -179.576 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 2.7 m -90.6 124.3 34.93 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.052 -179.826 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.612 HD11 ' CG1' ' A' ' 118' ' ' VAL . 1.1 tt -130.91 110.06 11.0 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.646 179.857 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -64.63 150.12 47.62 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.786 -179.905 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -91.96 45.53 1.22 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.164 0.507 . . . . 0.0 110.619 179.79 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -153.2 -33.81 0.03 OUTLIER Glycine 0 N--CA 1.45 -0.419 0 CA-C-N 115.617 -0.72 . . . . 0.0 112.283 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . 0.438 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -49.39 166.53 0.31 Allowed Glycine 0 C--N 1.333 0.411 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.431 179.812 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.455 ' H ' HD12 ' A' ' 112' ' ' ILE . 0.8 OUTLIER -78.86 -19.44 13.04 Favored 'Isoleucine or valine' 0 C--O 1.237 0.404 0 CA-C-O 120.822 0.344 . . . . 0.0 111.835 -179.652 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' ALA . . . . . 0.613 ' O ' HG12 ' A' ' 118' ' ' VAL . . . -58.12 -30.38 66.26 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.939 0.399 . . . . 0.0 110.529 179.796 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' GLU . . . . . 0.438 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 20.2 pt-20 -59.34 -44.98 92.58 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.682 179.525 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 7.9 mtm180 -64.55 -47.48 78.6 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.151 -179.48 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.409 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -49.04 -74.5 0.26 Allowed Glycine 0 CA--C 1.519 0.297 0 C-N-CA 120.296 -0.954 . . . . 0.0 112.744 -179.933 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 175.45 -14.97 0.04 OUTLIER Glycine 0 CA--C 1.52 0.398 0 C-N-CA 120.863 -0.684 . . . . 0.0 113.116 -179.876 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.628 ' N ' HG22 ' A' ' 84' ' ' VAL . 7.6 p -35.49 153.19 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.275 0 N-CA-C 112.132 0.419 . . . . 0.0 112.132 -179.727 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 9.5 mmt180 -139.73 138.86 36.29 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.881 179.924 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 19.4 t -71.22 81.5 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.154 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 132.1 41.02 0.2 Allowed Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.664 179.902 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 12.9 m170 -131.64 132.0 43.66 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.843 0.354 . . . . 0.0 110.766 179.856 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.978 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 0.2 OUTLIER -81.3 92.39 6.37 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.391 -179.768 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . 0.885 ' CD1' HD11 ' A' ' 104' ' ' ILE . 9.0 mt -46.16 156.7 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.164 178.753 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' ILE . . . . . 0.786 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.6 OUTLIER -153.89 -86.06 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 N-CA-C 112.48 0.548 . . . . 0.0 112.48 -179.497 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 13.5 mt-10 -77.01 92.64 3.73 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 112.131 0.419 . . . . 0.0 112.131 -178.707 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.754 HG23 ' CG ' ' A' ' 153' ' ' MET . 1.2 mt -91.52 98.77 8.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 121.008 0.432 . . . . 0.0 110.991 179.194 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . 0.423 ' N ' ' O ' ' A' ' 152' ' ' HIS . 19.3 p30 48.18 26.51 1.06 Allowed 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.651 -0.704 . . . . 0.0 112.133 179.752 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 125.2 -26.22 5.59 Favored Glycine 0 C--N 1.332 0.357 0 C-N-CA 120.239 -0.981 . . . . 0.0 113.878 178.905 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -100.03 114.02 27.02 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 117.27 0.535 . . . . 0.0 111.428 -179.497 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 12.0 t -78.33 101.99 7.48 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.047 179.847 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . 0.634 HG21 HD11 ' A' ' 127' ' ' ILE . 21.5 m -83.08 6.94 1.57 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.282 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.825 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.786 ' HB ' HG22 ' A' ' 125' ' ' ILE . 11.1 p -51.91 119.7 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.18 0 CA-C-O 120.958 0.409 . . . . 0.0 110.82 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . 0.408 ' HB3' ' O ' ' A' ' 133' ' ' VAL . . . 68.45 22.84 7.67 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.751 -179.101 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . 0.443 HG21 ' HD2' ' A' ' 139' ' ' LYS . 28.8 m -99.47 142.05 23.92 Favored Pre-proline 0 C--N 1.328 -0.364 0 CA-C-N 115.669 -0.696 . . . . 0.0 110.702 179.864 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 136' ' ' PRO . . . . . 0.425 ' HD2' ' CG2' ' A' ' 135' ' ' THR . 87.1 Cg_exo -44.97 142.65 5.15 Favored 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 122.628 2.219 . . . . 0.0 112.549 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 6.8 p80 -62.86 -48.05 80.71 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.468 -179.599 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 1.4 tt0 -55.23 -33.44 63.11 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.244 -179.726 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 139' ' ' LYS . . . . . 0.752 ' O ' HD12 ' A' ' 143' ' ' ILE . 1.6 tmtp? -66.14 -49.44 67.44 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.933 -179.928 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 8.0 mt -58.82 -45.14 91.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 121.102 0.477 . . . . 0.0 110.405 179.888 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . 0.431 HG23 ' CG1' ' A' ' 99' ' ' VAL . 93.3 t -60.78 -32.67 52.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.06 178.794 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 3.8 t-160 -59.9 -52.57 64.87 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.538 179.586 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . 0.752 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.1 mp -53.15 -56.85 6.15 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.433 0 CA-C-O 121.197 0.522 . . . . 0.0 110.282 179.253 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.594 HD22 HG12 ' A' ' 151' ' ' ILE . 1.2 mt -61.9 -29.97 70.56 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.315 -0.857 . . . . 0.0 110.45 179.625 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 1.5 m -68.84 -26.73 65.3 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.124 -0.489 . . . . 0.0 109.939 178.549 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 3.8 m-80 -127.41 32.07 5.09 Favored 'General case' 0 C--O 1.232 0.152 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.173 179.796 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 147' ' ' ALA . . . . . 0.718 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -117.62 59.52 0.78 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.819 0.343 . . . . 0.0 111.16 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 28.1 m -54.74 175.7 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.37 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 79.3 -118.62 4.82 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.779 -0.725 . . . . 0.0 112.393 179.912 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -123.8 117.15 24.23 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.714 0.293 . . . . 0.0 110.582 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . 0.718 HD11 ' HB3' ' A' ' 147' ' ' ALA . 0.9 OUTLIER -89.32 111.87 23.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.365 -179.679 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . 0.423 ' O ' ' N ' ' A' ' 128' ' ' ASN . 6.4 m-70 -94.83 120.02 34.36 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 178.357 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 153' ' ' MET . . . . . 0.754 ' CG ' HG23 ' A' ' 127' ' ' ILE . 27.4 ttp -139.86 162.93 33.97 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 112.44 0.533 . . . . 0.0 112.44 -178.106 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 6.1 mttp -129.96 141.3 50.79 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.226 -0.897 . . . . 0.0 109.831 179.276 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . 0.703 ' O ' HG23 ' A' ' 81' ' ' VAL . 4.7 p -139.61 147.4 41.05 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.948 0.404 . . . . 0.0 111.726 -179.174 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 156' ' ' MET . . . . . 0.448 ' CB ' ' CD ' ' A' ' 157' ' ' PRO . 1.0 OUTLIER -113.75 -179.78 0.67 Allowed Pre-proline 0 C--N 1.328 -0.368 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.24 179.59 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . 0.448 ' CD ' ' CB ' ' A' ' 156' ' ' MET . 89.3 Cg_endo -85.11 112.09 1.41 Allowed 'Trans proline' 0 N--CA 1.462 -0.375 0 C-N-CA 122.493 2.128 . . . . 0.0 112.558 -179.883 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 158' ' ' ALA . . . . . 0.978 ' HB2' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.249 1.074 0 CA-C-O 118.141 -0.933 . . . . 0.0 111.092 179.864 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_exo . . . . . 0 N--CA 1.488 1.194 0 CA-C-O 120.689 0.204 . . . . 0.0 111.671 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -74.55 94.76 0.93 Allowed 'Trans proline' 0 C--N 1.344 0.315 0 C-N-CA 122.64 2.227 . . . . 0.0 112.343 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 29.6 t -107.79 126.85 64.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.062 179.938 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 1.6 m -104.64 145.79 29.84 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.994 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 91.7 m -107.05 111.09 23.39 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.049 -0.523 . . . . 0.0 109.917 178.92 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.742 HG13 ' H ' ' A' ' 118' ' ' VAL . 33.5 t -93.15 105.94 17.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.696 -179.415 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.475 HD21 ' OE1' ' A' ' 150' ' ' GLU . 4.2 tt -102.77 83.28 2.23 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.21 -0.45 . . . . 0.0 109.823 179.047 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.8 HD13 HD12 ' A' ' 95' ' ' LEU . 2.0 mt -81.7 132.46 31.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-O 121.096 0.474 . . . . 0.0 111.389 -178.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.441 ' O ' HG21 ' A' ' 112' ' ' ILE . 0.0 OUTLIER -89.45 114.01 25.44 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.692 -0.685 . . . . 0.0 110.531 -179.917 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.534 ' HG3' HD12 ' A' ' 151' ' ' ILE . 5.9 mmm180 -104.91 104.4 46.28 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.451 -0.341 . . . . 0.0 111.133 -179.733 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . 0.425 ' HG2' ' CE2' ' A' ' 93' ' ' TYR . 29.7 Cg_exo -61.96 -39.81 48.07 Favored 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.581 2.187 . . . . 0.0 112.427 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -153.61 -171.26 3.84 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.939 0.399 . . . . 0.0 111.303 -179.87 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.541 ' HG ' HG11 ' A' ' 148' ' ' VAL . 6.0 mt -86.14 -19.23 30.43 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.491 -179.757 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -93.97 21.58 6.55 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.707 0.289 . . . . 0.0 111.344 -179.585 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . 0.425 ' CE2' ' HG2' ' A' ' 89' ' ' PRO . 15.8 m-85 -104.25 175.56 5.45 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.654 179.547 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -128.35 149.71 50.41 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.897 0.38 . . . . 0.0 111.131 -179.876 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 0.8 HD12 HD13 ' A' ' 86' ' ' ILE . 4.6 mm? -67.59 -56.55 9.01 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.662 179.799 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 118.1 29.63 1.94 Allowed Glycine 0 C--N 1.333 0.401 0 C-N-CA 120.637 -0.792 . . . . 0.0 112.995 179.424 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . 0.432 ' CE2' ' HB3' ' A' ' 95' ' ' LEU . 47.8 p90 -166.81 165.23 16.36 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.852 0.358 . . . . 0.0 111.374 179.843 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -101.16 138.18 38.54 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.626 179.843 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.58 HG21 HG21 ' A' ' 140' ' ' ILE . 9.7 p -115.36 132.75 63.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.923 0.392 . . . . 0.0 111.591 -179.716 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 24.6 mt-30 -131.11 89.25 2.71 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.1 179.387 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 44.7 m-80 60.61 16.25 6.4 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.004 -179.436 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.419 ' O ' ' HB ' ' A' ' 124' ' ' ILE . . . 124.87 -36.25 2.9 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.969 -0.634 . . . . 0.0 112.293 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.701 HG23 ' O ' ' A' ' 122' ' ' HIS . 36.7 mt -77.77 134.97 27.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-O 121.067 0.461 . . . . 0.0 111.738 -179.639 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.769 HD11 ' CD1' ' A' ' 124' ' ' ILE . 4.4 mp -90.29 135.48 26.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.519 179.666 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -106.15 -72.18 0.72 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.208 -179.591 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 1.5 m -101.87 142.26 33.45 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.145 -179.691 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.627 HD11 HG11 ' A' ' 118' ' ' VAL . 1.2 tt -144.68 124.54 13.44 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.646 179.695 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 19.8 mtp -82.09 149.76 27.86 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.03 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 4.6 mtm-85 -93.25 44.47 1.14 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.213 0.53 . . . . 0.0 110.367 179.649 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -161.03 22.43 0.23 Allowed Glycine 0 N--CA 1.449 -0.447 0 CA-C-N 115.617 -0.72 . . . . 0.0 112.284 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . 0.514 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -110.35 174.2 17.17 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 120.934 -0.651 . . . . 0.0 111.901 179.743 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.441 HG21 ' O ' ' A' ' 87' ' ' ARG . 0.6 OUTLIER -79.22 -21.94 12.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-O 120.854 0.359 . . . . 0.0 111.585 -179.713 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' ALA . . . . . 0.735 ' O ' HG12 ' A' ' 118' ' ' VAL . . . -58.35 -30.76 66.99 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.934 0.397 . . . . 0.0 110.549 179.775 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' GLU . . . . . 0.514 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 9.0 pt-20 -59.76 -44.59 93.79 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.753 179.672 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 85.1 mtt180 -65.36 -46.74 78.99 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.32 -179.468 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.404 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -48.94 -74.43 0.27 Allowed Glycine 0 CA--C 1.519 0.316 0 C-N-CA 120.302 -0.951 . . . . 0.0 112.709 -179.903 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . 0.433 ' O ' ' C ' ' A' ' 118' ' ' VAL . . . 175.59 -20.46 0.05 OUTLIER Glycine 0 CA--C 1.519 0.283 0 C-N-CA 121.013 -0.613 . . . . 0.0 112.72 -179.902 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.742 ' H ' HG13 ' A' ' 84' ' ' VAL . 11.0 p -24.91 136.87 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.399 0 N-CA-C 112.575 0.583 . . . . 0.0 112.575 -179.847 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 3.3 ttt180 -134.33 110.69 9.64 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.855 179.902 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . 0.489 HG22 ' HB2' ' A' ' 107' ' ' LEU . 21.0 t -57.11 100.21 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.083 -179.88 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 124.02 40.67 0.44 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.39 -179.83 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . 0.701 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.1 OUTLIER -134.91 -167.22 1.95 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.664 0.269 . . . . 0.0 110.657 -179.917 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.718 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 13.8 ttt180 -137.26 90.44 2.52 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.883 179.976 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . 0.769 ' CD1' HD11 ' A' ' 104' ' ' ILE . 9.4 mt -50.06 156.08 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 N-CA-C 110.158 -0.312 . . . . 0.0 110.158 179.199 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 125' ' ' ILE . . . . . 0.848 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.6 OUTLIER -148.59 -84.71 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 N-CA-C 112.171 0.434 . . . . 0.0 112.171 -179.577 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . 0.404 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 12.2 mt-10 -80.34 86.16 5.74 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 112.164 0.431 . . . . 0.0 112.164 -178.999 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.845 HD11 HG21 ' A' ' 132' ' ' VAL . 1.4 mt -89.53 102.43 13.1 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 CA-C-O 120.899 0.381 . . . . 0.0 110.839 179.117 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . 0.461 ' HA ' ' CD2' ' A' ' 152' ' ' HIS . 0.9 OUTLIER 59.97 24.83 13.98 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.077 -0.511 . . . . 0.0 111.109 179.902 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 107.29 -13.43 40.07 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.919 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -97.62 113.07 24.72 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.789 0.328 . . . . 0.0 111.025 -179.878 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 1.2 p -77.44 94.68 4.3 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.019 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . 0.845 HG21 HD11 ' A' ' 127' ' ' ILE . 27.1 m -80.14 1.38 2.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.883 -179.879 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.848 ' HB ' HG22 ' A' ' 125' ' ' ILE . 9.2 p -46.79 -38.11 3.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-O 120.907 0.384 . . . . 0.0 111.619 -179.65 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -115.97 28.89 8.32 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.747 179.554 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . 0.506 HG23 ' HD2' ' A' ' 136' ' ' PRO . 97.9 m -116.32 144.61 33.36 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 115.912 -0.585 . . . . 0.0 111.172 -179.834 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 136' ' ' PRO . . . . . 0.506 ' HD2' HG23 ' A' ' 135' ' ' THR . 48.9 Cg_exo -55.75 164.29 4.66 Favored 'Trans proline' 0 C--N 1.348 0.516 0 C-N-CA 122.528 2.152 . . . . 0.0 112.245 179.842 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 41.7 p-80 -67.18 -48.9 66.56 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.299 -179.837 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 6.0 tp10 -54.47 -36.66 64.36 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.388 -179.692 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 139' ' ' LYS . . . . . 0.796 ' O ' HD12 ' A' ' 143' ' ' ILE . 4.1 mmmt -61.63 -46.54 89.35 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.723 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . 0.825 HG23 ' CD1' ' A' ' 127' ' ' ILE . 16.8 mt -58.86 -46.03 91.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.581 -179.909 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . 0.411 ' CG2' ' CG1' ' A' ' 99' ' ' VAL . 93.7 t -59.8 -32.42 49.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.089 179.086 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -61.77 -54.0 48.33 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.834 179.764 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . 0.796 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.3 mp -52.88 -56.44 7.56 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.454 0 CA-C-O 121.194 0.521 . . . . 0.0 110.312 179.413 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.732 HD22 HG12 ' A' ' 151' ' ' ILE . 2.2 mt -63.0 -29.92 71.2 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.294 -0.866 . . . . 0.0 110.361 179.83 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 15.5 t -69.83 -30.14 67.58 Favored 'General case' 0 N--CA 1.453 -0.289 0 CA-C-N 116.302 -0.408 . . . . 0.0 109.933 178.676 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 3.0 m-80 -125.65 34.66 4.86 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.864 179.722 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 147' ' ' ALA . . . . . 1.06 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -100.3 -39.33 8.07 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.036 0.446 . . . . 0.0 111.585 -179.68 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.541 HG11 ' HG ' ' A' ' 91' ' ' LEU . 24.8 m 44.86 -171.38 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.488 -0.778 . . . . 0.0 111.662 -179.88 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 55.76 -135.35 48.88 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.569 -179.813 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.475 ' OE1' HD21 ' A' ' 85' ' ' LEU . 27.9 mt-10 -107.69 101.24 10.56 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.839 0.352 . . . . 0.0 110.761 179.884 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . 1.06 HD11 ' HB3' ' A' ' 147' ' ' ALA . 0.5 OUTLIER -76.07 111.76 12.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.189 -179.768 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . 0.461 ' CD2' ' HA ' ' A' ' 128' ' ' ASN . 0.8 OUTLIER -98.94 115.13 28.2 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 178.241 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 153' ' ' MET . . . . . 0.68 ' CG ' HG23 ' A' ' 127' ' ' ILE . 13.1 ttp -123.17 163.3 20.86 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.318 0.58 . . . . 0.0 112.139 -178.064 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -128.97 139.39 52.12 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.118 -0.946 . . . . 0.0 109.454 179.077 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . 0.665 HG22 ' CG1' ' A' ' 124' ' ' ILE . 10.4 p -136.0 143.48 44.81 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.125 0.488 . . . . 0.0 111.738 -179.253 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 156' ' ' MET . . . . . 0.465 ' O ' ' CB ' ' A' ' 123' ' ' ARG . 8.9 mtp -132.64 149.66 73.65 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 115.28 -0.873 . . . . 0.0 110.298 179.646 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 77.2 Cg_exo -47.96 116.8 2.11 Favored 'Trans proline' 0 C--N 1.343 0.286 0 C-N-CA 122.37 2.047 . . . . 0.0 112.713 -179.834 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 158' ' ' ALA . . . . . 0.718 ' HB2' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.248 1.019 0 CA-C-O 118.317 -0.849 . . . . 0.0 110.958 179.837 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_endo . . . . . 0 N--CA 1.488 1.154 0 CA-C-O 120.805 0.252 . . . . 0.0 111.792 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.54 169.41 18.69 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.444 2.096 . . . . 0.0 112.351 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.573 HG13 ' O ' ' A' ' 155' ' ' THR . 35.0 t -80.88 142.02 14.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.936 -179.995 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.8 m -117.3 134.56 54.67 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.867 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 3.5 m -94.58 111.27 23.03 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.128 179.314 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.838 HG11 HG23 ' A' ' 118' ' ' VAL . 63.7 t -82.77 106.2 13.35 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.938 -179.249 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.408 ' O ' ' HA2' ' A' ' 116' ' ' GLY . 0.9 OUTLIER -106.83 80.81 1.48 Allowed 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 178.491 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.777 HG13 HG12 ' A' ' 84' ' ' VAL . 3.3 mt -81.53 136.02 23.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-O 121.252 0.549 . . . . 0.0 111.945 -178.195 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.426 ' H ' HG22 ' A' ' 112' ' ' ILE . 0.0 OUTLIER -90.45 148.44 22.77 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.368 -0.833 . . . . 0.0 110.194 179.685 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -155.05 102.91 2.27 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.595 -0.275 . . . . 0.0 110.96 -179.819 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 67.3 Cg_endo -74.06 -24.59 14.78 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.514 2.143 . . . . 0.0 112.494 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -149.59 -166.94 2.69 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.914 0.388 . . . . 0.0 111.236 -179.786 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.56 ' HG ' HG11 ' A' ' 148' ' ' VAL . 4.2 mt -96.54 -44.4 7.18 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.349 -179.598 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -58.06 -18.77 26.77 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.96 -0.564 . . . . 0.0 111.634 -179.436 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 38.4 m-85 -88.2 87.71 7.4 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.805 179.833 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -66.42 -177.83 0.6 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.079 -179.948 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 0.771 ' CD2' HD13 ' A' ' 86' ' ' ILE . 6.5 mp -94.74 -56.18 2.86 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.771 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 98.06 71.07 1.01 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.848 179.745 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . 0.665 ' CZ ' HD12 ' A' ' 144' ' ' LEU . 14.0 p90 -166.27 162.4 17.34 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.918 0.389 . . . . 0.0 111.01 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.42 ' O ' ' HA ' ' A' ' 104' ' ' ILE . 1.5 m -106.18 120.49 41.96 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.607 179.724 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.427 ' CG1' ' CG2' ' A' ' 141' ' ' VAL . 8.4 p -109.78 139.05 34.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.448 -179.697 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -135.87 89.15 2.46 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.309 179.491 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' ASN . . . . . 0.406 ' ND2' ' HA ' ' A' ' 136' ' ' PRO . 27.2 m120 58.26 18.91 5.78 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.174 -179.529 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 126.73 -38.16 2.25 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.575 179.884 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.49 HG12 ' CB ' ' A' ' 158' ' ' ALA . 31.8 mt -76.88 141.9 15.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 121.034 0.445 . . . . 0.0 111.452 -179.611 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.904 HD11 ' CD1' ' A' ' 124' ' ' ILE . 5.2 mp -109.54 130.01 63.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.863 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 1.8 m -123.52 28.97 6.78 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.969 -179.872 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . 0.433 ' H ' HG22 ' A' ' 104' ' ' ILE . 0.3 OUTLIER -178.19 141.24 0.24 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.772 179.988 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -159.09 107.63 1.86 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.844 -179.826 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 2.8 ttp -68.13 113.14 5.53 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.74 179.918 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 26.1 mtt180 -58.81 86.49 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.798 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 163.79 -33.97 0.29 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.913 -0.66 . . . . 0.0 112.012 -179.818 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . 0.405 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -61.13 171.43 7.8 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.193 179.693 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.426 HG22 ' H ' ' A' ' 87' ' ' ARG . 0.8 OUTLIER -78.64 -16.93 13.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 120.777 0.323 . . . . 0.0 111.477 -179.789 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' ALA . . . . . 0.47 ' HA ' HG12 ' A' ' 86' ' ' ILE . . . -58.12 -30.5 66.35 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.056 0.455 . . . . 0.0 110.707 179.882 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' GLU . . . . . 0.405 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 21.7 pt-20 -62.0 -46.51 88.9 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.768 -0.651 . . . . 0.0 111.105 179.823 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.4 ' N ' ' CG ' ' A' ' 114' ' ' GLU . 25.2 mtt-85 -62.75 -46.16 89.33 Favored 'General case' 0 N--CA 1.452 -0.347 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.142 -179.378 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.408 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -50.29 -74.05 0.31 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.338 -0.934 . . . . 0.0 112.578 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . 0.572 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 175.97 -27.4 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.736 -179.782 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.838 HG23 HG11 ' A' ' 84' ' ' VAL . 12.0 t -31.25 102.04 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 CA-C-O 120.993 0.425 . . . . 0.0 111.8 -179.722 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -104.13 123.89 48.09 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.643 179.765 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 21.4 t -53.76 99.99 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.188 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 120.7 14.67 5.15 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.934 -0.651 . . . . 0.0 112.79 -179.879 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 14.0 m170 -115.61 132.89 56.49 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.744 0.307 . . . . 0.0 110.626 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.858 ' HB3' ' HB2' ' A' ' 158' ' ' ALA . 13.1 ptt180 -84.55 91.85 7.97 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.677 -179.734 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . 0.904 ' CD1' HD11 ' A' ' 104' ' ' ILE . 19.1 mt -48.09 157.85 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.333 -0.133 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 178.72 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 125' ' ' ILE . . . . . 0.845 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.6 OUTLIER -150.73 -83.37 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 N-CA-C 113.064 0.765 . . . . 0.0 113.064 -179.008 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -75.62 81.85 2.62 Favored 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 112.695 0.628 . . . . 0.0 112.695 -178.247 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.743 HG23 ' HB3' ' A' ' 153' ' ' MET . 1.7 mt -91.02 95.25 5.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.931 0.395 . . . . 0.0 111.062 179.015 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . 0.442 ' N ' ' O ' ' A' ' 152' ' ' HIS . 33.0 m-20 57.76 39.93 26.72 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.934 179.966 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 91.51 -4.18 79.56 Favored Glycine 0 CA--C 1.519 0.329 0 C-N-CA 120.632 -0.794 . . . . 0.0 112.813 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 2.9 tt0 -104.08 107.51 18.44 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.824 0.345 . . . . 0.0 110.836 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 26.0 p -75.6 92.01 2.9 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.093 -179.824 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . 0.734 HG21 HD11 ' A' ' 127' ' ' ILE . 31.4 m -74.74 -3.67 4.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.724 179.838 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.845 ' HB ' HG22 ' A' ' 125' ' ' ILE . 9.0 p -43.79 -44.6 1.87 Allowed 'Isoleucine or valine' 0 C--O 1.231 0.111 0 CA-C-O 120.806 0.336 . . . . 0.0 111.804 -179.775 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . 0.474 ' N ' HG13 ' A' ' 133' ' ' VAL . . . -113.37 30.24 7.36 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.958 179.906 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . 0.499 HG21 ' HD2' ' A' ' 139' ' ' LYS . 91.6 m -115.15 140.47 25.71 Favored Pre-proline 0 C--N 1.33 -0.244 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.015 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 136' ' ' PRO . . . . . 0.481 ' HD2' HG23 ' A' ' 135' ' ' THR . 7.6 Cg_endo -50.33 164.18 0.53 Allowed 'Trans proline' 0 C--N 1.347 0.494 0 C-N-CA 122.64 2.226 . . . . 0.0 112.244 179.841 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 137' ' ' HIS . . . . . 0.439 ' CD2' ' N ' ' A' ' 138' ' ' GLU . 32.9 p-80 -72.77 -46.69 52.03 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.606 -179.5 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . 0.439 ' N ' ' CD2' ' A' ' 137' ' ' HIS . 16.7 mt-10 -53.69 -36.69 62.46 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.396 -179.59 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 139' ' ' LYS . . . . . 0.821 ' O ' HD12 ' A' ' 143' ' ' ILE . 6.7 tmtm? -62.93 -47.02 85.04 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.927 -179.816 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 8.6 mt -58.41 -44.71 89.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.523 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . 0.427 ' CG2' ' CG1' ' A' ' 99' ' ' VAL . 93.1 t -60.78 -32.46 52.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.107 178.856 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -61.46 -52.32 65.01 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.641 179.558 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . 0.821 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.4 mp -53.23 -56.67 7.1 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.395 0 CA-C-O 121.098 0.475 . . . . 0.0 110.205 179.422 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.718 HD13 ' CD2' ' A' ' 95' ' ' LEU . 4.9 mt -62.31 -30.31 71.06 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.518 -0.764 . . . . 0.0 110.326 179.506 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 34.5 t -70.09 -28.31 65.31 Favored 'General case' 0 N--CA 1.453 -0.283 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.117 178.901 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 10.3 m120 -131.71 37.4 3.65 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.082 179.808 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 147' ' ' ALA . . . . . 0.635 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -99.79 -44.71 5.99 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.094 0.473 . . . . 0.0 111.512 -179.68 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.56 HG11 ' HG ' ' A' ' 91' ' ' LEU . 32.4 m 45.96 -174.68 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 115.321 -0.854 . . . . 0.0 111.788 -179.684 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 59.64 -108.07 1.54 Allowed Glycine 0 N--CA 1.453 -0.214 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.361 -179.819 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 46.1 mt-10 -136.81 114.1 10.8 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.778 0.323 . . . . 0.0 110.856 179.892 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . 0.635 HD11 ' HB3' ' A' ' 147' ' ' ALA . 1.5 mt -82.84 112.0 19.96 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.139 -179.912 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . 0.442 ' O ' ' N ' ' A' ' 128' ' ' ASN . 0.1 OUTLIER -99.09 115.88 30.01 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.978 -0.556 . . . . 0.0 109.82 179.04 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 153' ' ' MET . . . . . 0.743 ' HB3' HG23 ' A' ' 127' ' ' ILE . 0.0 OUTLIER -144.64 177.83 8.41 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.548 0.69 . . . . 0.0 111.751 -179.048 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 14.4 mttp -139.43 152.66 47.23 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 114.633 -1.167 . . . . 0.0 109.977 179.546 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . 0.693 HG22 HG12 ' A' ' 124' ' ' ILE . 2.0 p -142.99 150.4 39.59 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.195 0.522 . . . . 0.0 111.888 -179.488 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 156' ' ' MET . . . . . 0.423 ' CB ' ' CD ' ' A' ' 157' ' ' PRO . 2.3 mtp -118.69 178.93 0.94 Allowed Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 115.235 -0.893 . . . . 0.0 109.898 179.343 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . 0.423 ' CD ' ' CB ' ' A' ' 156' ' ' MET . 89.9 Cg_endo -86.45 106.16 0.75 Allowed 'Trans proline' 0 N--CA 1.459 -0.555 0 C-N-CA 122.44 2.094 . . . . 0.0 112.493 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 158' ' ' ALA . . . . . 0.858 ' HB2' ' HB3' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.249 1.057 0 CA-C-O 118.253 -0.879 . . . . 0.0 111.052 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 6.6 Cg_endo . . . . . 0 N--CA 1.49 1.319 0 CA-C-O 120.722 0.218 . . . . 0.0 111.744 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_exo -61.18 113.38 1.73 Allowed 'Trans proline' 0 C--N 1.346 0.412 0 C-N-CA 122.582 2.188 . . . . 0.0 112.295 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.516 HG23 ' O ' ' A' ' 155' ' ' THR . 11.2 p -81.4 145.49 8.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.77 179.816 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.5 m -104.26 146.09 29.29 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.925 0.393 . . . . 0.0 111.203 -179.709 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 11.6 m -110.17 111.09 22.21 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.002 178.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.769 HG22 ' N ' ' A' ' 118' ' ' VAL . 72.6 t -86.23 106.5 15.66 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.896 -179.164 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.423 ' O ' ' HA2' ' A' ' 116' ' ' GLY . 4.2 tt -106.34 81.34 1.6 Allowed 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 178.497 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.866 HG21 ' CD1' ' A' ' 95' ' ' LEU . 1.2 mt -81.46 140.19 16.9 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 121.167 0.508 . . . . 0.0 111.674 -178.777 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.439 ' HG3' ' CG2' ' A' ' 112' ' ' ILE . 0.0 OUTLIER -99.01 145.9 26.6 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.551 -0.749 . . . . 0.0 110.27 179.873 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 3.8 mtt-85 -139.09 102.26 7.53 Favored Pre-proline 0 C--N 1.331 -0.232 0 CA-C-N 116.463 -0.335 . . . . 0.0 110.982 -179.782 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . 0.434 ' HB2' ' CE1' ' A' ' 93' ' ' TYR . 52.5 Cg_exo -55.09 -57.04 1.88 Allowed 'Trans proline' 0 C--N 1.347 0.478 0 C-N-CA 122.465 2.11 . . . . 0.0 112.35 -179.858 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.7 t0 -139.83 -168.67 2.55 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.869 0.366 . . . . 0.0 111.174 -179.86 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.424 ' CD1' HG11 ' A' ' 148' ' ' VAL . 0.2 OUTLIER -83.32 -30.82 27.21 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.04 -179.924 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -68.13 -11.02 58.4 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.62 -179.694 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . 0.434 ' CE1' ' HB2' ' A' ' 89' ' ' PRO . 25.2 m-85 -82.88 178.17 8.3 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.507 -0.315 . . . . 0.0 110.784 179.839 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 8.3 mp0 -136.57 164.8 27.35 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.068 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 0.866 ' CD1' HG21 ' A' ' 86' ' ' ILE . 0.7 OUTLIER -72.51 -60.21 2.34 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.781 179.847 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 121.4 14.0 5.06 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.657 -0.783 . . . . 0.0 113.174 179.797 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . 0.62 ' HD2' HG23 ' A' ' 104' ' ' ILE . 30.5 p90 -160.45 175.12 13.12 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.958 0.408 . . . . 0.0 111.197 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -118.42 141.19 48.79 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.009 -0.542 . . . . 0.0 110.771 179.86 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.719 HG21 HG21 ' A' ' 140' ' ' ILE . 6.3 p -109.98 136.0 47.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 121.1 0.476 . . . . 0.0 111.427 -179.858 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -126.92 89.78 3.04 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.048 179.457 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 2.5 m-20 62.27 12.2 5.01 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.814 -179.083 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 129.7 -37.65 2.13 Favored Glycine 0 N--CA 1.445 -0.716 0 C-N-CA 121.095 -0.574 . . . . 0.0 112.007 -179.871 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.55 HG12 ' HB2' ' A' ' 158' ' ' ALA . 41.8 mt -79.2 135.67 25.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-O 121.093 0.473 . . . . 0.0 111.801 -179.469 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.843 HD11 ' CD1' ' A' ' 124' ' ' ILE . 3.8 mp -91.54 141.27 14.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.825 179.799 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' CYS . . . . . 0.413 ' O ' HG13 ' A' ' 120' ' ' VAL . 36.9 m -116.82 -81.1 0.61 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.285 -179.556 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 4.6 m -77.13 139.16 39.88 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.991 -179.78 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.475 ' HB3' HG22 ' A' ' 120' ' ' VAL . 9.5 tt -156.38 120.75 4.5 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.636 179.867 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 19.2 mtm -90.75 129.0 36.87 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.985 -179.889 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 2.3 mpt_? -66.13 76.71 0.09 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.644 179.82 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 178.23 -34.8 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.927 -0.654 . . . . 0.0 112.126 -179.843 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -55.31 171.54 1.46 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.286 179.697 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.439 ' CG2' ' HG3' ' A' ' 87' ' ' ARG . 0.5 OUTLIER -78.66 -17.59 13.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-O 120.82 0.343 . . . . 0.0 111.505 -179.778 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' ALA . . . . . 0.563 ' HA ' HG12 ' A' ' 86' ' ' ILE . . . -58.4 -30.78 67.1 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.87 0.367 . . . . 0.0 110.633 179.804 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -60.02 -45.72 91.88 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.691 179.579 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 1.6 mmm180 -62.93 -49.08 76.18 Favored 'General case' 0 N--CA 1.452 -0.359 0 CA-C-N 115.843 -0.617 . . . . 0.0 111.132 -179.473 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.423 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -49.52 -74.33 0.28 Allowed Glycine 0 CA--C 1.519 0.318 0 C-N-CA 120.224 -0.989 . . . . 0.0 112.532 179.936 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . 0.555 ' C ' HG22 ' A' ' 84' ' ' VAL . . . -179.81 -30.67 0.06 OUTLIER Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 121.124 -0.56 . . . . 0.0 112.181 179.864 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.769 ' N ' HG22 ' A' ' 84' ' ' VAL . 73.6 t -26.43 123.7 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.384 0 C-N-CA 122.956 0.503 . . . . 0.0 112.283 -179.771 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 14.1 mtt-85 -123.29 118.42 27.52 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.54 179.779 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . 0.475 HG22 ' HB3' ' A' ' 107' ' ' LEU . 21.5 t -52.2 93.23 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.239 -179.919 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 122.78 37.9 0.6 Allowed Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.933 -0.651 . . . . 0.0 112.332 -179.861 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . 0.436 ' O ' HG23 ' A' ' 103' ' ' ILE . 10.3 m170 -138.77 169.25 18.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.753 0.311 . . . . 0.0 110.805 179.933 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.742 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 1.4 ttm180 -108.42 143.89 36.75 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.201 -179.877 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . 0.843 ' CD1' HD11 ' A' ' 104' ' ' ILE . 26.8 mt -101.29 155.36 4.6 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 178.465 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 125' ' ' ILE . . . . . 0.868 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.7 OUTLIER -147.45 -84.31 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 N-CA-C 113.208 0.818 . . . . 0.0 113.208 -178.561 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . 0.42 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 6.1 mt-10 -79.87 85.34 5.53 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 112.626 0.602 . . . . 0.0 112.626 -178.093 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.8 HD11 HG21 ' A' ' 132' ' ' VAL . 1.7 mt -91.18 103.35 14.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 121.025 0.441 . . . . 0.0 111.17 179.094 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . 0.547 ' ND2' HG22 ' A' ' 127' ' ' ILE . 33.4 m-80 55.65 25.4 8.08 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.106 -179.969 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 107.65 -13.91 38.69 Favored Glycine 0 CA--C 1.518 0.273 0 C-N-CA 120.624 -0.798 . . . . 0.0 112.775 179.895 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 22.3 tt0 -95.95 113.94 25.61 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.849 0.357 . . . . 0.0 110.875 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -77.54 91.4 3.95 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.141 -179.902 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . 0.8 HG21 HD11 ' A' ' 127' ' ' ILE . 32.4 m -75.41 -2.57 4.11 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.257 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.818 179.891 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.868 ' HB ' HG22 ' A' ' 125' ' ' ILE . 8.2 p -46.24 -38.3 3.22 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.142 0 CA-C-O 120.858 0.361 . . . . 0.0 111.445 -179.758 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -117.6 28.57 8.36 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.787 179.401 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . 0.505 HG23 ' HD2' ' A' ' 136' ' ' PRO . 86.0 m -111.48 141.88 25.41 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 115.777 -0.647 . . . . 0.0 111.105 -179.772 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 136' ' ' PRO . . . . . 0.505 ' HD2' HG23 ' A' ' 135' ' ' THR . 9.5 Cg_endo -51.87 164.23 1.13 Allowed 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.8 2.333 . . . . 0.0 112.215 179.742 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 137' ' ' HIS . . . . . 0.403 ' O ' HG23 ' A' ' 141' ' ' VAL . 12.4 p80 -70.47 -47.64 59.6 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.376 -179.785 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -55.6 -32.74 63.33 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.249 -179.707 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 139' ' ' LYS . . . . . 0.761 ' O ' HD12 ' A' ' 143' ' ' ILE . 0.4 OUTLIER -65.08 -50.27 66.78 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.833 -179.917 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . 0.719 HG21 HG21 ' A' ' 99' ' ' VAL . 8.8 mt -58.68 -43.46 87.68 Favored 'Isoleucine or valine' 0 C--O 1.235 0.311 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.577 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . 0.569 HG22 HG12 ' A' ' 99' ' ' VAL . 61.8 t -61.42 -32.93 54.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.292 179.189 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 0.5 OUTLIER -62.66 -53.47 54.05 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.968 179.924 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . 0.761 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.3 mp -53.04 -57.23 4.96 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.393 0 CA-C-O 121.162 0.506 . . . . 0.0 110.371 179.558 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.565 HD22 HG12 ' A' ' 151' ' ' ILE . 1.8 mt -62.16 -30.04 70.77 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.417 -0.81 . . . . 0.0 110.42 179.557 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 9.2 t -68.16 -26.7 65.89 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.179 -0.464 . . . . 0.0 109.872 178.567 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 4.1 m-80 -131.19 35.01 3.95 Favored 'General case' 0 CA--C 1.528 0.107 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.199 179.918 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 147' ' ' ALA . . . . . 0.67 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -114.29 48.75 1.07 Allowed 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.855 0.36 . . . . 0.0 111.304 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.424 HG11 ' CD1' ' A' ' 91' ' ' LEU . 29.8 m -54.09 150.35 1.76 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.285 -179.953 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 108.68 -107.72 2.51 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.445 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 40.9 mt-10 -138.05 104.32 5.2 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.711 0.291 . . . . 0.0 110.889 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . 0.67 HD11 ' HB3' ' A' ' 147' ' ' ALA . 1.2 mt -78.64 111.7 15.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.065 -179.91 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . 0.42 ' CD2' ' HG ' ' A' ' 85' ' ' LEU . 0.6 OUTLIER -103.82 115.66 30.88 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.999 -0.546 . . . . 0.0 109.828 179.129 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 153' ' ' MET . . . . . 0.772 ' HB3' HG23 ' A' ' 127' ' ' ILE . 1.9 ptt? -145.91 167.08 24.15 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.089 0.471 . . . . 0.0 111.876 -179.077 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -115.06 153.28 30.99 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.625 -0.716 . . . . 0.0 109.899 179.234 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . 0.707 HG22 ' HA ' ' A' ' 124' ' ' ILE . 51.8 p -142.69 140.29 31.48 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.235 0.54 . . . . 0.0 111.829 -179.302 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 156' ' ' MET . . . . . 0.41 ' N ' ' O ' ' A' ' 123' ' ' ARG . 0.2 OUTLIER -126.46 152.45 74.23 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 115.329 -0.85 . . . . 0.0 109.947 179.309 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 12.6 Cg_endo -56.16 115.8 2.72 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.497 2.131 . . . . 0.0 112.496 -179.784 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 158' ' ' ALA . . . . . 0.742 ' HB2' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.248 0.992 0 CA-C-O 118.234 -0.889 . . . . 0.0 110.943 179.733 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_endo . . . . . 0 N--CA 1.489 1.235 0 CA-C-O 120.703 0.21 . . . . 0.0 111.838 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 12.6 Cg_exo -69.76 85.77 0.6 Allowed 'Trans proline' 0 C--N 1.345 0.346 0 C-N-CA 122.734 2.289 . . . . 0.0 112.301 -179.853 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 37.0 t -102.09 122.79 54.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.995 179.859 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.3 m -111.12 138.4 47.6 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.85 179.934 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 9.5 m -98.63 111.14 23.6 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.166 179.266 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.771 HG11 HG23 ' A' ' 118' ' ' VAL . 62.0 t -84.95 106.2 14.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.731 -179.432 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.608 ' O ' HD23 ' A' ' 85' ' ' LEU . 10.2 tt -104.36 83.8 2.11 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 178.431 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 1.064 HG21 HD23 ' A' ' 95' ' ' LEU . 7.3 mt -81.84 130.89 35.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.92 -178.342 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.415 ' HG3' ' CG2' ' A' ' 112' ' ' ILE . 0.0 OUTLIER -92.18 124.41 36.24 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.388 -0.823 . . . . 0.0 110.447 -179.958 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -126.48 120.26 23.29 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 116.451 -0.341 . . . . 0.0 110.874 -179.864 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 62.5 Cg_endo -73.41 -28.65 11.99 Favored 'Trans proline' 0 C--N 1.346 0.425 0 C-N-CA 122.465 2.11 . . . . 0.0 112.16 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -173.07 -169.38 0.54 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.959 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 1.9 mp -80.36 -5.56 56.59 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.556 -179.909 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 2.2 ptm85 -102.76 27.28 7.12 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.861 0.362 . . . . 0.0 111.153 -179.807 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 4.3 m-85 -138.37 81.53 1.86 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.914 179.858 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -60.97 161.85 7.78 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.98 -179.847 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 1.064 HD23 HG21 ' A' ' 86' ' ' ILE . 0.5 OUTLIER -79.99 -65.31 1.02 Allowed 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.674 179.897 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 114.34 58.33 0.38 Allowed Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.916 179.512 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . 0.564 ' HD2' HG23 ' A' ' 104' ' ' ILE . 14.2 p90 -165.33 128.49 2.22 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.916 0.389 . . . . 0.0 111.106 179.698 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 6.4 t -71.98 144.09 48.99 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.832 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.941 HG11 ' HB ' ' A' ' 140' ' ' ILE . 48.9 t -111.9 136.9 46.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 121.032 0.444 . . . . 0.0 111.648 -179.705 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 4.1 mm-40 -135.72 88.06 2.37 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.722 -0.672 . . . . 0.0 109.507 178.563 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 85.6 m-20 53.57 21.65 2.63 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.985 -178.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.404 ' N ' ' CD1' ' A' ' 140' ' ' ILE . . . 121.88 -32.83 4.46 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.922 -0.656 . . . . 0.0 112.374 179.902 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.623 HG12 ' HB2' ' A' ' 158' ' ' ALA . 31.2 mt -77.49 128.65 38.01 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 121.003 0.43 . . . . 0.0 111.781 -179.649 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.848 HD11 ' CD1' ' A' ' 124' ' ' ILE . 3.6 mp -84.42 144.81 9.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.146 179.296 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' CYS . . . . . 0.551 ' O ' HG13 ' A' ' 120' ' ' VAL . 55.9 m -126.51 -80.64 0.61 Allowed 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 112.009 0.374 . . . . 0.0 112.009 -179.205 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 40.3 m -79.17 66.18 4.55 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 112.027 0.38 . . . . 0.0 112.027 -178.797 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.803 ' HB3' HG22 ' A' ' 120' ' ' VAL . 14.0 tp -89.12 100.58 13.33 Favored 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 178.859 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 2.0 ptm -81.33 140.51 34.74 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.317 -179.472 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.51 166.74 9.9 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.596 179.697 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 92.79 -41.97 2.69 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.533 -0.842 . . . . 0.0 112.23 -179.732 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -58.21 168.76 5.25 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.227 179.751 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.415 ' CG2' ' HG3' ' A' ' 87' ' ' ARG . 0.9 OUTLIER -78.35 -16.23 13.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.733 0.301 . . . . 0.0 111.768 -179.797 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' ALA . . . . . 0.482 ' HA ' HG12 ' A' ' 86' ' ' ILE . . . -57.52 -30.34 65.07 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 121.015 0.436 . . . . 0.0 110.78 179.853 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 15.3 pt-20 -60.15 -46.69 88.79 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.904 179.56 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 16.2 mtm180 -64.7 -46.38 82.62 Favored 'General case' 0 N--CA 1.453 -0.314 0 CA-C-N 116.009 -0.541 . . . . 0.0 111.127 -179.316 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -50.55 -73.41 0.37 Allowed Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.431 -0.89 . . . . 0.0 112.686 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . 0.576 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 171.78 -21.27 0.07 OUTLIER Glycine 0 CA--C 1.519 0.284 0 C-N-CA 121.048 -0.596 . . . . 0.0 112.663 -179.971 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.771 HG23 HG11 ' A' ' 84' ' ' VAL . 1.2 t -37.95 135.9 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.261 0 CA-C-O 120.98 0.419 . . . . 0.0 111.638 -179.783 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 5.3 mtm180 -136.64 132.18 34.66 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.553 179.64 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . 0.803 HG22 ' HB3' ' A' ' 107' ' ' LEU . 15.4 t -57.11 89.45 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.852 0.358 . . . . 0.0 110.999 -179.866 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 131.98 -3.32 5.25 Favored Glycine 0 CA--C 1.52 0.375 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.861 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 1.6 m-70 -90.16 127.51 36.12 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-O 120.888 0.375 . . . . 0.0 110.73 179.899 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.914 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 20.8 ttm180 -82.62 92.35 7.12 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.926 -179.373 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . 0.848 ' CD1' HD11 ' A' ' 104' ' ' ILE . 10.0 mt -50.39 157.56 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.05 178.544 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 125' ' ' ILE . . . . . 0.793 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.6 OUTLIER -150.77 -85.66 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 N-CA-C 112.38 0.511 . . . . 0.0 112.38 -179.349 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -75.29 85.12 2.46 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 112.067 0.395 . . . . 0.0 112.067 -178.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.801 HG23 ' HB3' ' A' ' 153' ' ' MET . 1.3 mt -92.61 102.6 13.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 120.951 0.405 . . . . 0.0 111.312 179.47 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 1.3 m-20 61.83 15.52 7.15 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.596 179.745 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 119.88 -16.95 10.15 Favored Glycine 0 C--N 1.333 0.368 0 C-N-CA 120.401 -0.904 . . . . 0.0 113.338 179.634 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 8.2 pt20 -101.94 123.08 45.24 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 117.091 0.445 . . . . 0.0 111.104 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 48.1 t -81.05 101.68 9.73 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.347 -179.68 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . 0.784 HG21 HD11 ' A' ' 127' ' ' ILE . 27.2 m -81.68 2.7 2.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.68 179.691 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.793 ' HB ' HG22 ' A' ' 125' ' ' ILE . 8.0 p -44.7 -45.18 2.64 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.133 0 CA-C-O 120.853 0.358 . . . . 0.0 111.697 -179.674 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . 0.484 ' N ' HG13 ' A' ' 133' ' ' VAL . . . -112.46 30.22 7.27 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.869 179.73 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . 0.514 HG22 ' HB3' ' A' ' 139' ' ' LYS . 86.2 m -109.28 142.47 25.68 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.942 -179.788 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 136' ' ' PRO . . . . . 0.472 ' HD2' HG23 ' A' ' 135' ' ' THR . 71.2 Cg_exo -50.73 164.01 0.64 Allowed 'Trans proline' 0 C--N 1.348 0.535 0 C-N-CA 122.583 2.189 . . . . 0.0 112.431 179.864 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 28.1 p-80 -72.02 -51.22 22.84 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.161 -179.814 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -55.25 -30.96 61.1 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.986 -179.899 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 139' ' ' LYS . . . . . 0.726 ' O ' HD12 ' A' ' 143' ' ' ILE . 0.2 OUTLIER -64.62 -48.65 74.07 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.94 179.998 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . 0.941 ' HB ' HG11 ' A' ' 99' ' ' VAL . 5.4 mt -58.76 -45.01 91.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-O 121.048 0.452 . . . . 0.0 110.438 179.973 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 48.4 t -61.21 -32.43 52.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.417 179.24 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 1.6 m-70 -62.19 -53.09 60.32 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.723 179.79 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . 0.726 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.2 mp -53.28 -56.27 8.97 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.44 0 CA-C-O 121.207 0.527 . . . . 0.0 110.222 179.157 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.785 ' HB3' HD11 ' A' ' 95' ' ' LEU . 2.9 mt -62.95 -30.36 71.5 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.466 179.741 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 2.8 m -67.22 -29.9 69.69 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.17 -0.468 . . . . 0.0 109.743 178.738 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 4.4 m-80 -131.13 38.28 3.67 Favored 'General case' 0 C--N 1.333 -0.135 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.625 179.596 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 147' ' ' ALA . . . . . 1.079 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -90.15 -51.91 5.21 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.246 0.546 . . . . 0.0 111.258 -179.545 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.505 HG23 ' C ' ' A' ' 147' ' ' ALA . 0.2 OUTLIER 57.01 164.61 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-N 115.292 -0.867 . . . . 0.0 111.078 -179.932 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 73.18 -133.41 18.26 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.524 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 -114.39 99.71 7.78 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.788 0.328 . . . . 0.0 110.92 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . 1.079 HD11 ' HB3' ' A' ' 147' ' ' ALA . 0.6 OUTLIER -68.1 111.9 2.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.987 179.982 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . 0.547 ' CD2' HD12 ' A' ' 85' ' ' LEU . 0.7 OUTLIER -108.31 115.75 30.69 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.251 179.455 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 153' ' ' MET . . . . . 0.801 ' HB3' HG23 ' A' ' 127' ' ' ILE . 0.0 OUTLIER -143.62 176.05 9.5 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.208 0.528 . . . . 0.0 111.846 -179.356 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 9.7 mttp -122.76 151.99 41.07 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.416 -0.811 . . . . 0.0 109.487 178.919 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . 0.466 HG22 ' CG1' ' A' ' 124' ' ' ILE . 6.6 p -141.57 141.39 33.5 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.031 0.443 . . . . 0.0 111.598 -179.345 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 156' ' ' MET . . . . . . . . . . . . . 9.6 mtp -125.8 133.52 24.98 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.588 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 82.5 Cg_exo -44.68 120.19 2.66 Favored 'Trans proline' 0 C--N 1.345 0.344 0 C-N-CA 122.558 2.172 . . . . 0.0 112.752 -179.888 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 158' ' ' ALA . . . . . 0.914 ' HB2' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.249 1.061 0 CA-C-O 118.181 -0.914 . . . . 0.0 111.061 179.87 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo . . . . . 0 N--CA 1.489 1.212 0 CA-C-O 120.88 0.283 . . . . 0.0 111.632 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 68.2 Cg_endo -74.14 94.49 0.89 Allowed 'Trans proline' 0 C--N 1.343 0.284 0 C-N-CA 122.531 2.154 . . . . 0.0 112.466 -179.918 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 39.0 t -117.84 142.04 34.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.9 179.835 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.0 m -123.18 140.93 52.51 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.01 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 20.0 m -97.34 111.37 23.65 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.059 179.134 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.814 HG22 ' N ' ' A' ' 118' ' ' VAL . 78.9 t -88.98 105.73 16.15 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.42 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.792 -179.239 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.487 ' O ' ' HA2' ' A' ' 116' ' ' GLY . 0.5 OUTLIER -103.21 83.87 2.26 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 178.395 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 1.067 HG21 HD23 ' A' ' 95' ' ' LEU . 19.8 mt -80.85 132.51 31.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 121.405 0.621 . . . . 0.0 111.862 -178.306 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.865 ' O ' HG21 ' A' ' 112' ' ' ILE . 2.9 mmt180 -79.38 149.01 31.8 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 114.957 -1.02 . . . . 0.0 111.137 -179.477 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.534 ' HB3' ' HA ' ' A' ' 148' ' ' VAL . 2.7 mtt-85 -164.57 97.81 0.89 Allowed Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.846 179.689 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 70.3 Cg_endo -89.26 25.77 0.59 Allowed 'Trans proline' 0 N--CA 1.46 -0.483 0 C-N-CA 122.893 2.396 . . . . 0.0 113.414 -179.296 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . 0.729 ' O ' HG12 ' A' ' 148' ' ' VAL . 5.6 p-10 -179.03 177.74 0.79 Allowed 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.039 0.447 . . . . 0.0 111.741 179.922 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.822 ' HG ' HG11 ' A' ' 148' ' ' VAL . 6.0 mt -98.42 6.68 47.05 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.692 -0.686 . . . . 0.0 111.486 -179.89 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 8.6 ptt180 -129.18 42.06 3.37 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.853 0.359 . . . . 0.0 111.035 -179.78 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -120.52 126.04 49.37 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.748 179.828 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -86.02 136.6 33.18 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.963 -179.844 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 1.067 HD23 HG21 ' A' ' 86' ' ' ILE . 2.2 mp -77.24 -28.28 53.59 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.804 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 75.08 73.17 0.98 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.835 -0.697 . . . . 0.0 112.782 179.622 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . 0.71 ' CZ ' HD12 ' A' ' 144' ' ' LEU . 0.3 OUTLIER -176.14 156.75 1.72 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.806 0.336 . . . . 0.0 111.168 179.766 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.466 ' O ' ' HA ' ' A' ' 104' ' ' ILE . 3.3 t -106.15 133.81 50.27 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.422 179.559 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.529 HG21 HG21 ' A' ' 140' ' ' ILE . 9.7 p -118.49 134.84 60.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 121.026 0.441 . . . . 0.0 111.459 -179.581 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -131.75 89.24 2.67 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.23 179.405 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 12.1 m120 57.78 18.28 4.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.134 -179.468 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 128.18 -39.83 1.83 Allowed Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.531 179.858 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.529 HG12 ' HB2' ' A' ' 158' ' ' ALA . 26.6 mt -77.3 138.66 20.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 121.006 0.432 . . . . 0.0 111.531 -179.57 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.888 HD11 ' CD1' ' A' ' 124' ' ' ILE . 4.5 mp -99.07 137.83 25.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.911 179.917 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 43.4 t -105.0 -77.98 0.58 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.983 -179.781 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 77.0 p -90.63 119.24 30.71 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.707 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 25.7 tp -112.91 119.3 37.47 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.841 -179.938 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 9.3 mtp -68.13 98.26 0.77 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.975 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -60.86 117.59 5.61 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.826 -179.95 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 97.44 32.5 6.3 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.407 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . 0.513 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -118.61 -160.74 11.56 Favored Glycine 0 N--CA 1.453 -0.216 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.968 -179.789 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.865 HG21 ' O ' ' A' ' 87' ' ' ARG . 7.9 mt -80.62 -39.9 18.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-O 121.094 0.473 . . . . 0.0 111.506 -179.924 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' ALA . . . . . 0.595 ' HB1' HG11 ' A' ' 118' ' ' VAL . . . -57.67 -39.29 76.72 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.12 -179.481 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' GLU . . . . . 0.513 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 15.3 pt-20 -62.83 -37.83 88.33 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.503 179.499 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.497 ' N ' ' HG3' ' A' ' 114' ' ' GLU . 54.8 mtt85 -59.2 -46.71 87.71 Favored 'General case' 0 N--CA 1.452 -0.361 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.644 -179.866 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.487 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -56.33 -71.14 0.78 Allowed Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.343 -0.932 . . . . 0.0 112.501 179.719 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . 0.47 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 175.04 -22.74 0.06 OUTLIER Glycine 0 CA--C 1.52 0.39 0 C-N-CA 120.788 -0.72 . . . . 0.0 113.064 -179.902 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.814 ' N ' HG22 ' A' ' 84' ' ' VAL . 6.0 p -34.27 146.36 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 N-CA-C 112.128 0.418 . . . . 0.0 112.128 -179.604 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -140.95 153.84 45.81 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.917 -179.925 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 22.0 t -74.7 88.44 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.972 179.9 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 124.01 41.0 0.42 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.921 -0.657 . . . . 0.0 112.295 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 1.2 m170 -135.08 122.68 22.09 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.858 0.361 . . . . 0.0 110.764 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.958 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 34.9 ttp180 -79.74 93.6 5.6 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.538 -179.731 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . 0.888 ' CD1' HD11 ' A' ' 104' ' ' ILE . 9.2 mt -49.98 158.21 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 178.715 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 125' ' ' ILE . . . . . 0.789 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.6 OUTLIER -148.99 -82.7 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 N-CA-C 112.446 0.535 . . . . 0.0 112.446 -179.49 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 -74.64 80.72 2.01 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 112.361 0.504 . . . . 0.0 112.361 -178.758 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.991 HG23 ' CG ' ' A' ' 153' ' ' MET . 2.7 mt -84.55 92.04 3.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 121.05 0.452 . . . . 0.0 111.01 179.259 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . 0.414 ' N ' ' O ' ' A' ' 152' ' ' HIS . 56.9 m-80 58.65 25.26 13.06 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.995 -179.81 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 113.36 -16.96 21.81 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.716 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 6.0 tt0 -94.4 111.15 22.89 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.809 0.338 . . . . 0.0 110.814 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -75.98 93.29 3.24 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.084 -179.822 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . 0.73 HG11 HD12 ' A' ' 127' ' ' ILE . 30.6 m -76.39 -1.58 3.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.881 179.835 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.789 ' HB ' HG22 ' A' ' 125' ' ' ILE . 8.7 p -42.94 -44.23 1.22 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.121 0 CA-C-O 120.825 0.345 . . . . 0.0 111.611 -179.653 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . 0.474 ' N ' HG13 ' A' ' 133' ' ' VAL . . . -117.24 29.75 7.71 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.772 179.714 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . 0.485 HG22 ' HB3' ' A' ' 139' ' ' LYS . 52.3 m -108.71 142.17 24.87 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.057 -0.519 . . . . 0.0 111.161 -179.844 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 136' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -52.37 164.11 1.45 Allowed 'Trans proline' 0 C--N 1.346 0.442 0 C-N-CA 122.56 2.173 . . . . 0.0 112.284 179.677 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 31.9 p-80 -70.95 -49.81 41.44 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.368 -179.855 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 5.8 tp10 -54.36 -34.79 61.88 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.332 -0.394 . . . . 0.0 111.393 -179.695 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 139' ' ' LYS . . . . . 0.724 ' O ' HD12 ' A' ' 143' ' ' ILE . 3.3 tttp -62.76 -47.34 83.94 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.881 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . 0.529 HG21 HG21 ' A' ' 99' ' ' VAL . 15.1 mt -58.59 -45.45 90.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.603 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . 0.417 ' CG2' ' CG1' ' A' ' 99' ' ' VAL . 87.9 t -60.27 -32.5 50.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.326 178.987 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 1.8 t-80 -62.06 -53.56 53.77 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.012 179.774 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . 0.724 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.1 mp -52.94 -56.8 6.11 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.463 0 CA-C-O 121.227 0.537 . . . . 0.0 110.265 179.44 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.728 HD13 HD22 ' A' ' 95' ' ' LEU . 1.9 mt -62.44 -30.33 71.16 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.313 -0.858 . . . . 0.0 110.397 179.674 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 27.5 t -67.67 -27.8 67.15 Favored 'General case' 0 N--CA 1.453 -0.29 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.085 178.884 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 7.8 m-80 -133.81 37.34 3.26 Favored 'General case' 0 CA--C 1.529 0.163 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.164 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 147' ' ' ALA . . . . . 0.944 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -101.46 -37.66 8.34 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.118 0.485 . . . . 0.0 111.301 -179.861 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.822 HG11 ' HG ' ' A' ' 91' ' ' LEU . 32.0 m 44.56 -172.67 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.37 -0.832 . . . . 0.0 112.036 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 58.38 -135.14 52.13 Favored Glycine 0 C--N 1.332 0.309 0 C-N-CA 121.035 -0.602 . . . . 0.0 112.704 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.429 ' OE1' HD21 ' A' ' 85' ' ' LEU . 62.2 mm-40 -110.09 91.28 3.59 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.851 0.357 . . . . 0.0 110.449 179.836 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . 0.944 HD11 ' HB3' ' A' ' 147' ' ' ALA . 0.7 OUTLIER -61.03 111.62 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.49 -179.448 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . 0.414 ' O ' ' N ' ' A' ' 128' ' ' ASN . 4.2 t60 -90.03 115.78 27.57 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 109.168 -0.679 . . . . 0.0 109.168 178.573 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 153' ' ' MET . . . . . 0.991 ' CG ' HG23 ' A' ' 127' ' ' ILE . 26.9 mtp -133.62 162.14 32.73 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.422 0.629 . . . . 0.0 112.452 -178.431 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 17.7 mttt -134.04 140.39 46.64 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 114.881 -1.054 . . . . 0.0 108.905 178.673 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . 0.61 HG22 ' CG1' ' A' ' 124' ' ' ILE . 1.6 p -140.32 149.44 42.76 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.241 0.543 . . . . 0.0 112.046 -178.871 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 156' ' ' MET . . . . . . . . . . . . . 4.8 ptp -132.23 156.38 80.17 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 115.207 -0.906 . . . . 0.0 110.139 179.146 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_endo -57.4 120.41 8.31 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.366 2.044 . . . . 0.0 112.639 -179.726 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 158' ' ' ALA . . . . . 0.958 ' HB2' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.249 1.029 0 CA-C-O 118.289 -0.862 . . . . 0.0 111.114 179.876 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . 0.526 ' HB2' HG23 ' A' ' 81' ' ' VAL . 2.8 Cg_exo . . . . . 0 N--CA 1.488 1.18 0 CA-C-O 120.734 0.223 . . . . 0.0 111.673 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -74.42 60.05 4.86 Favored 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.536 2.157 . . . . 0.0 112.44 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.526 HG23 ' HB2' ' A' ' 79' ' ' PRO . 20.2 t -96.24 137.36 24.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.01 179.93 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 1.9 m -115.2 139.03 50.28 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.951 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 8.4 m -95.79 111.31 23.31 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.014 179.091 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.766 HG22 ' N ' ' A' ' 118' ' ' VAL . 67.3 t -90.63 105.76 16.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.757 -179.166 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.462 ' O ' ' HA2' ' A' ' 116' ' ' GLY . 6.2 tt -103.0 84.36 2.35 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 178.633 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.977 HG21 HD23 ' A' ' 95' ' ' LEU . 3.6 mt -80.94 128.64 38.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 121.27 0.557 . . . . 0.0 111.864 -178.526 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.829 ' O ' HG21 ' A' ' 112' ' ' ILE . 0.2 OUTLIER -74.81 153.01 38.94 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.459 179.962 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.401 ' HB3' ' N ' ' A' ' 149' ' ' GLY . 0.2 OUTLIER -148.33 100.1 3.61 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.109 179.845 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . 0.424 ' HG2' ' CD2' ' A' ' 93' ' ' TYR . 57.8 Cg_endo -71.21 -39.85 3.64 Favored 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.423 2.082 . . . . 0.0 112.497 -179.855 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -145.69 -169.24 3.18 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.167 -179.887 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.584 HD12 HG11 ' A' ' 148' ' ' VAL . 0.4 OUTLIER -88.78 -53.27 4.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.057 -179.967 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.2 mpp_? -57.93 -20.06 34.65 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.522 -179.528 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . 0.424 ' CD2' ' HG2' ' A' ' 89' ' ' PRO . 12.7 m-85 -77.21 133.39 38.91 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.799 179.896 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 4.5 mp0 -89.58 177.48 6.53 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.986 -179.925 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 0.977 HD23 HG21 ' A' ' 86' ' ' ILE . 2.3 mp -93.61 -67.62 0.85 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.858 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 134.8 52.53 0.07 OUTLIER Glycine 0 CA--C 1.519 0.332 0 C-N-CA 120.465 -0.874 . . . . 0.0 113.026 179.584 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . 0.598 ' HD2' HG21 ' A' ' 118' ' ' VAL . 0.0 OUTLIER 179.96 177.41 0.65 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.839 0.352 . . . . 0.0 111.402 179.663 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 71.0 m -125.73 137.09 53.8 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.762 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.758 HG21 HG21 ' A' ' 140' ' ' ILE . 7.1 p -109.74 135.26 49.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.453 -179.687 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 4.6 tt0 -131.58 89.4 2.7 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.068 179.359 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 61.05 15.85 6.55 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.016 -179.215 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 125.37 -37.01 2.64 Favored Glycine 0 N--CA 1.447 -0.569 0 C-N-CA 120.987 -0.625 . . . . 0.0 112.065 -179.924 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.828 HG23 ' O ' ' A' ' 122' ' ' HIS . 44.8 mt -77.43 140.93 16.28 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-O 121.016 0.436 . . . . 0.0 111.574 -179.815 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.838 HD11 ' CD1' ' A' ' 124' ' ' ILE . 3.7 mp -98.53 141.21 16.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.985 -179.824 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 22.0 m -119.82 -48.45 2.36 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.936 -0.574 . . . . 0.0 111.003 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -96.81 151.66 19.44 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.871 -179.972 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.725 HD11 HG13 ' A' ' 118' ' ' VAL . 0.4 OUTLIER -167.25 116.46 0.83 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.871 179.988 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 5.0 tmm? -85.49 116.31 23.72 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.939 -179.939 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -60.78 125.6 24.29 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.921 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 88.11 26.99 27.1 Favored Glycine 0 N--CA 1.453 -0.217 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.552 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . 0.496 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -108.36 -161.61 20.55 Favored Glycine 0 CA--C 1.518 0.249 0 C-N-CA 120.782 -0.723 . . . . 0.0 113.031 -179.704 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.829 HG21 ' O ' ' A' ' 87' ' ' ARG . 7.6 mt -80.46 -42.68 21.32 Favored 'Isoleucine or valine' 0 C--O 1.237 0.434 0 CA-C-O 121.181 0.515 . . . . 0.0 111.41 -179.829 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' ALA . . . . . 0.787 ' O ' HG12 ' A' ' 118' ' ' VAL . . . -57.76 -34.72 69.85 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.283 -179.251 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' GLU . . . . . 0.518 ' HG3' ' N ' ' A' ' 115' ' ' ARG . 7.3 pt-20 -67.9 -35.72 78.97 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.725 179.568 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.518 ' N ' ' HG3' ' A' ' 114' ' ' GLU . 36.1 mmt180 -61.71 -47.35 85.7 Favored 'General case' 0 N--CA 1.452 -0.368 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.885 -179.626 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.462 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -55.09 -72.58 0.53 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.225 -0.988 . . . . 0.0 112.615 179.894 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . 0.406 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 175.49 -22.15 0.06 OUTLIER Glycine 0 CA--C 1.52 0.393 0 C-N-CA 120.936 -0.65 . . . . 0.0 112.857 -179.881 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.787 HG12 ' O ' ' A' ' 113' ' ' ALA . 9.1 p -30.76 147.24 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 N-CA-C 112.637 0.606 . . . . 0.0 112.637 -179.723 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -142.79 130.47 21.42 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.653 179.748 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . 0.439 HG22 ' HB2' ' A' ' 107' ' ' LEU . 26.0 t -62.0 95.75 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.209 -179.809 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 123.38 40.41 0.47 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.688 179.859 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . 0.828 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -125.32 -165.98 1.48 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.656 0.265 . . . . 0.0 110.851 -179.982 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.642 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 0.1 OUTLIER -145.76 90.75 2.02 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.376 -0.375 . . . . 0.0 110.813 179.952 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . 0.838 ' CD1' HD11 ' A' ' 104' ' ' ILE . 8.0 mt -53.36 157.04 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.582 179.496 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 125' ' ' ILE . . . . . 0.8 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.6 OUTLIER -150.31 -84.48 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 N-CA-C 112.209 0.448 . . . . 0.0 112.209 -179.474 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 21.9 mt-10 -79.75 85.84 5.39 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 112.176 0.436 . . . . 0.0 112.176 -178.964 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.797 HG23 ' HB3' ' A' ' 153' ' ' MET . 1.9 mt -89.83 108.3 19.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 116.396 -0.365 . . . . 0.0 111.377 179.475 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . 0.51 HD22 HG22 ' A' ' 127' ' ' ILE . 55.2 m-80 54.42 24.88 5.54 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.128 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 105.26 -10.22 46.76 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.665 -0.779 . . . . 0.0 112.794 -179.85 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 130' ' ' GLN . . . . . 0.492 HE22 HD11 ' A' ' 143' ' ' ILE . 21.4 tt0 -98.85 112.19 24.36 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.85 0.357 . . . . 0.0 110.756 179.855 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 1.5 m -74.49 91.09 2.24 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.286 -179.595 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . 0.691 HG11 HD12 ' A' ' 127' ' ' ILE . 29.6 m -71.54 -5.6 6.18 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.312 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.547 179.43 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.8 ' HB ' HG22 ' A' ' 125' ' ' ILE . 10.3 p -48.63 121.63 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.254 0 CA-C-O 120.893 0.378 . . . . 0.0 111.133 -179.916 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . 0.414 ' HB3' ' O ' ' A' ' 133' ' ' VAL . . . 68.15 22.38 8.3 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.034 -179.395 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . 0.449 ' HB ' ' O ' ' A' ' 132' ' ' VAL . 50.8 m -106.16 141.53 22.94 Favored Pre-proline 0 C--N 1.326 -0.438 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.698 179.559 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 136' ' ' PRO . . . . . 0.418 ' HD2' HG23 ' A' ' 135' ' ' THR . 80.2 Cg_exo -45.38 146.92 2.84 Favored 'Trans proline' 0 C--N 1.345 0.359 0 C-N-CA 122.609 2.206 . . . . 0.0 112.565 -179.922 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 137' ' ' HIS . . . . . 0.416 ' CE1' ' HG2' ' A' ' 138' ' ' GLU . 7.0 p80 -65.21 -41.74 94.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.019 -179.929 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . 0.416 ' HG2' ' CE1' ' A' ' 137' ' ' HIS . 4.7 mm-40 -56.25 -37.21 69.44 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.947 -179.899 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 139' ' ' LYS . . . . . 0.795 ' O ' HD12 ' A' ' 143' ' ' ILE . 27.9 tttt -63.66 -48.96 75.09 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.903 179.942 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . 0.758 HG21 HG21 ' A' ' 99' ' ' VAL . 16.1 mt -58.62 -42.15 84.07 Favored 'Isoleucine or valine' 0 C--O 1.236 0.364 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.628 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . 0.45 HG22 HG12 ' A' ' 99' ' ' VAL . 89.2 t -62.49 -33.03 57.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.194 178.972 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -61.85 -51.74 66.99 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.64 179.736 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . 0.795 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.4 mp -53.24 -57.18 5.3 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.433 0 CA-C-O 121.079 0.466 . . . . 0.0 110.316 179.167 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.595 HD13 HD22 ' A' ' 95' ' ' LEU . 2.9 mt -61.71 -30.24 70.63 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.25 179.597 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 2.1 m -69.27 -25.96 64.52 Favored 'General case' 0 N--CA 1.453 -0.317 0 CA-C-N 116.097 -0.501 . . . . 0.0 109.965 178.529 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 4.9 m-80 -130.15 33.91 4.29 Favored 'General case' 0 CA--C 1.529 0.149 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.213 179.861 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 147' ' ' ALA . . . . . 0.573 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -117.89 54.88 0.89 Allowed 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.192 179.908 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.584 HG11 HD12 ' A' ' 91' ' ' LEU . 8.1 m -50.78 177.61 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.447 -179.972 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . 0.401 ' N ' ' HB3' ' A' ' 88' ' ' ARG . . . 81.75 -111.62 3.35 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.458 -179.948 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 58.9 mt-10 -138.4 105.64 5.49 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.877 0.37 . . . . 0.0 110.715 179.841 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . 0.574 HG12 HD22 ' A' ' 144' ' ' LEU . 1.1 mt -73.01 111.36 7.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.069 -179.802 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . 0.403 ' CE1' ' HA ' ' A' ' 128' ' ' ASN . 8.3 p80 -106.34 115.58 30.46 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 178.918 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 153' ' ' MET . . . . . 0.797 ' HB3' HG23 ' A' ' 127' ' ' ILE . 1.5 ptt? -140.35 176.13 9.03 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.324 0.583 . . . . 0.0 112.085 -178.663 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 17.6 mttm -126.94 147.69 50.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.194 -0.912 . . . . 0.0 109.812 179.153 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . 0.554 HG22 ' CG1' ' A' ' 124' ' ' ILE . 4.7 p -142.73 145.27 33.16 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.977 0.418 . . . . 0.0 111.163 -179.515 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 156' ' ' MET . . . . . 0.424 ' O ' ' N ' ' A' ' 123' ' ' ARG . 6.6 ptp -133.12 156.65 79.75 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.631 179.647 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_exo -49.46 126.18 15.42 Favored 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.508 2.139 . . . . 0.0 112.623 -179.887 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 158' ' ' ALA . . . . . 0.646 ' HB2' HG12 ' A' ' 103' ' ' ILE . . . . . . . . 0 C--O 1.249 1.034 0 CA-C-O 118.26 -0.876 . . . . 0.0 111.016 179.823 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_endo . . . . . 0 N--CA 1.488 1.204 0 CA-C-O 120.691 0.204 . . . . 0.0 111.807 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -70.21 99.65 0.81 Allowed 'Trans proline' 0 C--N 1.344 0.309 0 C-N-CA 122.659 2.239 . . . . 0.0 112.29 -179.936 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 21.5 t -103.68 130.73 53.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.011 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.2 m -101.8 134.91 44.23 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.786 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 20.2 m -95.71 111.78 23.65 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.186 179.235 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.762 HG22 ' N ' ' A' ' 118' ' ' VAL . 62.2 t -85.63 105.37 14.29 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.41 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.401 -179.408 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.48 HD21 ' HB3' ' A' ' 150' ' ' GLU . 1.0 OUTLIER -103.17 83.68 2.23 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.058 -0.519 . . . . 0.0 109.652 178.893 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.845 HG21 ' CD2' ' A' ' 95' ' ' LEU . 12.6 mt -81.77 123.72 38.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-O 121.368 0.604 . . . . 0.0 111.717 -178.756 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.474 ' HB2' HG21 ' A' ' 112' ' ' ILE . 0.0 OUTLIER -71.98 132.5 44.39 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.776 -179.901 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.442 ' HG3' HD12 ' A' ' 151' ' ' ILE . 0.0 OUTLIER -130.14 90.43 42.11 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.705 179.969 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . 0.456 ' HG2' ' CD2' ' A' ' 93' ' ' TYR . 48.7 Cg_endo -68.87 -25.28 33.07 Favored 'Trans proline' 0 C--N 1.345 0.376 0 C-N-CA 122.552 2.168 . . . . 0.0 112.569 -179.912 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . 0.572 ' O ' HG23 ' A' ' 148' ' ' VAL . 0.6 OUTLIER -155.02 -169.57 3.23 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.978 0.418 . . . . 0.0 111.238 -179.856 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -97.44 -46.65 5.98 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.121 -179.82 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -57.01 -20.5 24.42 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.906 -0.588 . . . . 0.0 111.538 -179.631 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . 0.456 ' CD2' ' HG2' ' A' ' 89' ' ' PRO . 8.2 m-85 -60.3 -177.44 0.07 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.688 179.765 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -151.28 161.46 42.67 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.173 -179.941 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 0.845 ' CD2' HG21 ' A' ' 86' ' ' ILE . 1.4 mt -96.89 -50.34 4.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.698 179.898 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 88.78 72.0 1.27 Allowed Glycine 0 N--CA 1.452 -0.249 0 C-N-CA 120.797 -0.716 . . . . 0.0 113.096 179.456 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . 0.593 ' HE1' HD13 ' A' ' 95' ' ' LEU . 15.9 p90 -175.66 158.33 2.17 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.827 0.346 . . . . 0.0 111.174 179.57 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -105.17 146.64 28.96 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.681 179.924 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.436 ' CG2' HD12 ' A' ' 140' ' ' ILE . 7.3 p -130.63 134.02 62.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.307 -179.688 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -127.04 89.41 2.97 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.351 179.493 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 6.5 m120 57.11 18.74 4.27 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.052 -179.432 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 129.79 -41.44 1.54 Allowed Glycine 0 N--CA 1.448 -0.506 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.515 179.871 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.52 HG12 ' CB ' ' A' ' 158' ' ' ALA . 22.7 mt -77.57 129.5 37.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 121.077 0.465 . . . . 0.0 111.576 -179.344 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.872 HD11 ' CD1' ' A' ' 124' ' ' ILE . 3.6 mp -85.75 140.84 15.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.771 179.684 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 64.6 m -106.44 -69.89 0.81 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.826 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -100.86 141.25 34.01 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.788 179.859 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.405 ' CB ' HG22 ' A' ' 120' ' ' VAL . 5.7 tp -143.6 113.72 7.29 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.695 179.93 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 21.9 mmm -76.28 116.7 17.23 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.86 -179.839 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.05 78.88 0.05 OUTLIER 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.675 179.809 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 173.91 -34.24 0.11 Allowed Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.937 -0.649 . . . . 0.0 112.207 -179.811 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . 0.412 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -57.85 174.63 2.31 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.258 179.853 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.474 HG21 ' HB2' ' A' ' 87' ' ' ARG . 0.9 OUTLIER -78.53 -16.98 13.65 Favored 'Isoleucine or valine' 0 C--O 1.236 0.395 0 CA-C-O 120.91 0.386 . . . . 0.0 111.611 -179.886 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' ALA . . . . . 0.623 ' O ' HG12 ' A' ' 118' ' ' VAL . . . -57.81 -30.68 65.91 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.997 0.427 . . . . 0.0 110.875 179.908 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 114' ' ' GLU . . . . . 0.412 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 17.0 pt-20 -63.96 -46.85 82.84 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.856 179.828 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.4 ' N ' ' CG ' ' A' ' 114' ' ' GLU . 8.8 mtt180 -58.91 -47.33 85.39 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.087 -179.557 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.429 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -50.1 -72.67 0.45 Allowed Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.368 -0.92 . . . . 0.0 112.689 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . 0.521 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 172.34 -21.69 0.07 OUTLIER Glycine 0 CA--C 1.519 0.293 0 C-N-CA 120.972 -0.632 . . . . 0.0 112.674 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.762 ' N ' HG22 ' A' ' 84' ' ' VAL . 3.8 p -30.34 144.58 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.29 0 N-CA-C 112.327 0.492 . . . . 0.0 112.327 -179.78 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.425 ' HB3' ' CD2' ' A' ' 122' ' ' HIS . 0.0 OUTLIER -136.64 126.65 26.02 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.643 -179.992 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . 0.405 HG22 ' CB ' ' A' ' 107' ' ' LEU . 19.5 t -56.05 90.79 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.184 179.899 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 121.25 11.21 6.29 Favored Glycine 0 CA--C 1.52 0.379 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.8 -179.904 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . 0.425 ' CD2' ' HB3' ' A' ' 119' ' ' ARG . 6.9 m170 -98.24 132.21 43.94 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.891 0.377 . . . . 0.0 110.739 179.889 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.871 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 0.0 OUTLIER -79.41 90.78 5.04 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.586 -179.622 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . 0.872 ' CD1' HD11 ' A' ' 104' ' ' ILE . 7.7 mt -54.13 143.15 6.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 N-CA-C 109.709 -0.478 . . . . 0.0 109.709 178.577 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 125' ' ' ILE . . . . . 0.796 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.5 OUTLIER -137.97 -82.84 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 N-CA-C 112.365 0.506 . . . . 0.0 112.365 -179.35 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 11.6 mt-10 -73.92 81.35 1.66 Allowed 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 112.538 0.57 . . . . 0.0 112.538 -178.776 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.97 HG23 ' CG ' ' A' ' 153' ' ' MET . 3.0 mt -82.61 92.44 2.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.95 179.045 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . 0.406 ' N ' ' O ' ' A' ' 152' ' ' HIS . 1.6 t-20 58.9 21.11 8.78 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.014 -179.915 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 119.08 -18.5 10.37 Favored Glycine 0 C--N 1.332 0.349 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.787 -179.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -94.72 112.02 23.77 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.837 0.351 . . . . 0.0 110.922 -179.842 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 3.6 p -76.22 96.4 3.91 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.0 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . 0.699 HG11 HD12 ' A' ' 127' ' ' ILE . 27.4 m -81.04 2.64 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.323 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.86 179.983 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.796 ' HB ' HG22 ' A' ' 125' ' ' ILE . 9.0 p -44.43 -42.57 2.14 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.178 0 CA-C-O 120.922 0.392 . . . . 0.0 111.661 -179.761 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . 0.429 ' N ' HG13 ' A' ' 133' ' ' VAL . . . -116.55 29.73 7.77 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.843 179.587 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . 0.478 HG23 ' HD2' ' A' ' 136' ' ' PRO . 85.4 m -111.92 140.17 23.11 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.089 -179.834 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 136' ' ' PRO . . . . . 0.478 ' HD2' HG23 ' A' ' 135' ' ' THR . 10.6 Cg_endo -54.44 164.23 3.08 Favored 'Trans proline' 0 C--N 1.347 0.455 0 C-N-CA 122.646 2.23 . . . . 0.0 112.333 179.895 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 15.2 p80 -67.44 -46.65 72.47 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.603 -179.593 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -53.68 -35.21 60.83 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.387 -0.369 . . . . 0.0 111.468 -179.445 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 139' ' ' LYS . . . . . 0.783 ' O ' HD12 ' A' ' 143' ' ' ILE . 0.1 OUTLIER -65.36 -48.94 71.2 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.85 0.357 . . . . 0.0 111.079 -179.8 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . 0.836 HG23 ' CD1' ' A' ' 127' ' ' ILE . 10.1 mt -58.58 -46.19 90.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.529 -179.925 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . 0.405 ' CG2' ' CG1' ' A' ' 99' ' ' VAL . 86.8 t -60.41 -32.29 50.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.058 178.797 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 1.9 t60 -60.65 -52.94 63.01 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.664 179.585 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . 0.783 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.2 mp -53.25 -57.03 5.59 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.456 0 CA-C-O 121.151 0.5 . . . . 0.0 110.178 179.364 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.686 HD22 HG12 ' A' ' 151' ' ' ILE . 4.5 mt -60.96 -30.23 70.12 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.279 179.699 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 1.3 m -68.56 -27.0 65.69 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.13 -0.486 . . . . 0.0 109.887 178.572 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 9.0 m120 -127.82 32.59 4.93 Favored 'General case' 0 CA--C 1.528 0.109 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.124 179.813 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 147' ' ' ALA . . . . . 0.512 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -119.26 63.45 0.79 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.375 -0.375 . . . . 0.0 111.223 179.915 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.694 HG22 ' H ' ' A' ' 149' ' ' GLY . 1.6 p -60.11 -157.28 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.983 -179.869 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . 0.694 ' H ' HG22 ' A' ' 148' ' ' VAL . . . 58.0 -109.94 2.15 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.867 -0.683 . . . . 0.0 112.438 -179.961 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.48 ' HB3' HD21 ' A' ' 85' ' ' LEU . 3.9 mm-40 -131.18 100.13 5.1 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.739 0.304 . . . . 0.0 110.526 179.791 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . 0.686 HG12 HD22 ' A' ' 144' ' ' LEU . 0.3 OUTLIER -63.04 111.73 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.982 0.42 . . . . 0.0 111.213 -179.751 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . 0.406 ' O ' ' N ' ' A' ' 128' ' ' ASN . 1.2 t-80 -95.56 121.32 37.13 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 178.943 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 153' ' ' MET . . . . . 0.97 ' CG ' HG23 ' A' ' 127' ' ' ILE . 29.3 mtp -137.74 166.43 23.98 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.386 0.612 . . . . 0.0 112.368 -178.525 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . 0.405 ' O ' HG13 ' A' ' 125' ' ' ILE . 0.9 OUTLIER -143.34 132.19 22.74 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 114.852 -1.067 . . . . 0.0 108.811 178.762 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . 0.441 HG22 HG12 ' A' ' 124' ' ' ILE . 1.3 p -138.57 161.25 37.56 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.333 0.587 . . . . 0.0 112.176 -178.53 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 156' ' ' MET . . . . . 0.42 ' O ' ' N ' ' A' ' 123' ' ' ARG . 5.1 ptp -135.58 160.03 69.28 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 115.133 -0.94 . . . . 0.0 109.953 179.174 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 21.6 Cg_endo -61.67 118.36 5.23 Favored 'Trans proline' 0 C--N 1.343 0.274 0 C-N-CA 122.366 2.044 . . . . 0.0 112.544 -179.675 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 158' ' ' ALA . . . . . 0.871 ' HB2' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.25 1.092 0 CA-C-O 118.211 -0.9 . . . . 0.0 111.037 179.749 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_endo . . . . . 0 N--CA 1.488 1.183 0 CA-C-O 120.701 0.209 . . . . 0.0 111.717 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -71.2 99.52 0.91 Allowed 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.498 2.132 . . . . 0.0 112.364 179.916 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 10.3 p -80.83 130.35 36.03 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.864 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.8 m -121.35 142.94 49.49 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.013 -179.842 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 5.4 m -101.37 111.15 23.3 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.135 179.2 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 1.018 HG11 HG23 ' A' ' 118' ' ' VAL . 41.4 t -82.85 105.95 13.18 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.562 0 CA-C-N 115.949 -0.569 . . . . 0.0 112.184 -179.215 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.456 ' O ' HD23 ' A' ' 85' ' ' LEU . 7.1 tt -99.96 79.81 2.24 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 178.069 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.892 HG13 HG12 ' A' ' 84' ' ' VAL . 3.3 mt -82.66 104.95 11.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.767 -178.413 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.785 ' O ' HG21 ' A' ' 112' ' ' ILE . 0.0 OUTLIER -74.93 108.31 7.57 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.428 179.21 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.494 ' HG3' HD12 ' A' ' 151' ' ' ILE . 10.4 mtp180 -92.32 111.45 50.52 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.184 -179.646 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_exo -62.26 -63.9 0.09 OUTLIER 'Trans proline' 0 C--N 1.346 0.445 0 C-N-CA 122.572 2.181 . . . . 0.0 112.407 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 3.1 t0 -121.44 -173.36 2.61 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.919 0.39 . . . . 0.0 111.165 -179.71 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.552 ' HG ' HG13 ' A' ' 148' ' ' VAL . 0.0 OUTLIER -94.82 -21.2 18.86 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.281 -179.905 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -96.7 23.28 7.14 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.81 0.338 . . . . 0.0 111.14 -179.877 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 2.0 m-85 -102.23 178.41 4.6 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.824 179.827 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -135.71 143.61 45.46 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.017 -179.918 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 0.778 ' CD2' HD13 ' A' ' 86' ' ' ILE . 8.3 mp -72.57 -31.06 64.94 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.798 179.872 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 82.96 55.16 3.01 Favored Glycine 0 C--N 1.33 0.242 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.968 179.626 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -173.17 156.82 3.29 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.836 0.351 . . . . 0.0 111.144 179.82 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.2 m -99.28 155.92 17.25 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.677 179.804 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.43 ' CG1' ' CG2' ' A' ' 141' ' ' VAL . 8.5 p -133.0 132.15 58.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.927 0.394 . . . . 0.0 111.336 -179.86 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -128.97 89.27 2.85 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.27 179.509 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 3.3 m-80 58.25 17.25 4.52 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.126 -179.637 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 129.81 -40.09 1.73 Allowed Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.261 179.905 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.524 HG12 ' CB ' ' A' ' 158' ' ' ALA . 30.1 mt -77.24 130.19 36.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 121.098 0.475 . . . . 0.0 111.522 -179.677 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.807 HD11 ' CD1' ' A' ' 124' ' ' ILE . 3.8 mp -83.96 139.67 17.28 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.793 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -84.62 -75.62 0.34 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.328 -179.479 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -132.37 121.75 23.96 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.917 0.389 . . . . 0.0 111.114 -179.74 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.408 HD12 ' N ' ' A' ' 108' ' ' MET . 7.8 tp -105.57 116.2 31.53 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.463 179.761 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' MET . . . . . 0.408 ' N ' HD12 ' A' ' 107' ' ' LEU . 36.2 mtm -69.27 132.94 47.26 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.056 -179.807 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -67.18 76.14 0.14 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.549 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 174.63 -34.22 0.1 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.285 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . 0.439 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -56.54 176.26 1.05 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.438 179.774 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.785 HG21 ' O ' ' A' ' 87' ' ' ARG . 1.8 mt -78.61 -22.04 13.09 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-O 120.782 0.325 . . . . 0.0 111.615 -179.846 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' ALA . . . . . . . . . . . . . . . -57.82 -30.31 65.63 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.008 0.432 . . . . 0.0 110.702 179.828 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 114' ' ' GLU . . . . . 0.439 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 19.6 pt-20 -60.63 -47.19 87.32 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.89 -0.595 . . . . 0.0 111.197 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 3.8 mtm180 -66.59 -41.33 88.67 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.241 -179.294 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -56.19 -72.63 0.54 Allowed Glycine 0 N--CA 1.448 -0.539 0 C-N-CA 120.398 -0.906 . . . . 0.0 112.669 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . 0.428 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 161.09 -10.67 0.13 Allowed Glycine 0 CA--C 1.522 0.47 0 C-N-CA 121.219 -0.515 . . . . 0.0 112.851 -179.879 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 1.018 HG23 HG11 ' A' ' 84' ' ' VAL . 2.2 t -29.75 -71.46 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 C-N-CA 123.11 0.564 . . . . 0.0 112.306 -179.677 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.654 ' N ' HG12 ' A' ' 118' ' ' VAL . 0.0 OUTLIER 64.32 136.12 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.467 -179.486 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . 0.403 ' CG2' ' HB3' ' A' ' 107' ' ' LEU . 20.2 t -69.73 116.98 11.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.447 -0.342 . . . . 0.0 111.427 -179.69 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 112.55 33.25 2.12 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.799 179.644 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 1.5 m-70 -135.71 132.96 37.55 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.831 0.348 . . . . 0.0 110.991 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.977 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 72.3 ttt180 -88.76 95.29 10.22 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.65 -179.686 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . 0.807 ' CD1' HD11 ' A' ' 104' ' ' ILE . 11.7 mt -49.68 146.63 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 178.657 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 125' ' ' ILE . . . . . 0.924 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.6 OUTLIER -137.11 -84.8 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 N-CA-C 112.772 0.656 . . . . 0.0 112.772 -178.924 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 19.5 mt-10 -80.8 90.86 5.87 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 112.454 0.538 . . . . 0.0 112.454 -178.383 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.823 HG23 ' HB3' ' A' ' 153' ' ' MET . 1.8 mt -92.15 100.79 11.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.288 179.284 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . 0.488 HD22 HG22 ' A' ' 127' ' ' ILE . 52.7 m-80 57.82 17.87 4.52 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.622 179.815 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 121.69 -20.69 8.18 Favored Glycine 0 C--N 1.333 0.39 0 C-N-CA 120.348 -0.929 . . . . 0.0 113.381 179.406 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -98.22 120.96 39.53 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 117.256 0.528 . . . . 0.0 111.038 -179.727 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 67.4 p -79.25 94.62 5.47 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.362 -179.838 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . 0.782 HG21 HD11 ' A' ' 127' ' ' ILE . 31.0 m -74.62 -4.87 6.17 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.304 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.594 179.679 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.924 ' HB ' HG22 ' A' ' 125' ' ' ILE . 6.6 p -46.5 -37.69 3.32 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.141 0 CA-C-O 120.895 0.379 . . . . 0.0 111.526 -179.683 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -116.99 29.66 7.79 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.719 179.602 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . 0.526 HG23 ' HD2' ' A' ' 136' ' ' PRO . 87.9 m -117.24 141.94 29.37 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-N 115.881 -0.6 . . . . 0.0 111.033 -179.759 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 136' ' ' PRO . . . . . 0.526 ' HD2' HG23 ' A' ' 135' ' ' THR . 7.6 Cg_endo -49.65 164.04 0.41 Allowed 'Trans proline' 0 C--N 1.347 0.477 0 C-N-CA 122.77 2.313 . . . . 0.0 112.23 179.685 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 11.3 p80 -73.38 -45.95 51.84 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.539 -179.655 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -53.78 -36.94 62.95 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.373 -179.55 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 139' ' ' LYS . . . . . 0.728 ' O ' HD12 ' A' ' 143' ' ' ILE . 0.1 OUTLIER -63.26 -47.34 82.78 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.895 -179.857 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 8.6 mt -58.74 -41.79 83.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.965 0.412 . . . . 0.0 110.646 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . 0.43 ' CG2' ' CG1' ' A' ' 99' ' ' VAL . 90.1 t -63.51 -32.68 57.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.28 179.139 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 56.7 t60 -62.33 -54.57 38.54 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.828 179.943 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . 0.728 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.3 mp -53.23 -56.83 6.36 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.395 0 CA-C-O 121.112 0.482 . . . . 0.0 110.138 179.373 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.721 HD13 ' CD2' ' A' ' 95' ' ' LEU . 5.1 mt -60.63 -30.28 69.77 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.47 -0.786 . . . . 0.0 110.313 179.409 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 2.3 m -67.65 -27.08 66.56 Favored 'General case' 0 N--CA 1.453 -0.323 0 CA-C-N 116.164 -0.471 . . . . 0.0 109.981 178.471 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 4.6 m-80 -130.28 34.73 4.16 Favored 'General case' 0 CA--C 1.527 0.087 0 CA-C-N 116.013 -0.54 . . . . 0.0 111.215 179.796 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 147' ' ' ALA . . . . . 0.569 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -118.65 55.26 0.92 Allowed 'General case' 0 C--O 1.232 0.149 0 CA-C-O 120.864 0.364 . . . . 0.0 111.451 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.552 HG13 ' HG ' ' A' ' 91' ' ' LEU . 2.8 m -55.84 174.89 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.181 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 88.64 -101.69 2.77 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.813 -0.708 . . . . 0.0 112.606 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 29.8 mt-10 -148.95 94.49 2.26 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.786 0.327 . . . . 0.0 110.989 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . 0.569 HD11 ' HB3' ' A' ' 147' ' ' ALA . 1.2 mt -61.75 112.2 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.995 179.939 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . 0.404 ' O ' ' N ' ' A' ' 128' ' ' ASN . 0.3 OUTLIER -102.68 115.53 30.77 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.076 179.144 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 153' ' ' MET . . . . . 0.823 ' HB3' HG23 ' A' ' 127' ' ' ILE . 1.8 ptm -147.59 166.68 26.62 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.129 0.49 . . . . 0.0 111.875 -179.111 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 35.4 mttp -112.58 155.99 23.43 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.889 179.146 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . 0.436 HG23 HG23 ' A' ' 84' ' ' VAL . 13.8 p -141.2 144.13 34.58 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.226 0.536 . . . . 0.0 111.915 -179.451 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 156' ' ' MET . . . . . 0.597 ' CE ' HD13 ' A' ' 125' ' ' ILE . 1.5 mtm -110.86 179.94 0.74 Allowed Pre-proline 0 C--N 1.33 -0.241 0 CA-C-N 115.257 -0.883 . . . . 0.0 110.072 179.593 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . 0.418 ' CD ' ' CB ' ' A' ' 156' ' ' MET . 90.2 Cg_endo -92.68 106.98 0.2 Allowed 'Trans proline' 0 N--CA 1.456 -0.725 0 C-N-CA 122.757 2.305 . . . . 0.0 112.511 -179.919 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 158' ' ' ALA . . . . . 0.977 ' HB2' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.249 1.039 0 CA-C-O 118.186 -0.912 . . . . 0.0 111.036 179.801 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo . . . . . 0 N--CA 1.487 1.139 0 CA-C-O 120.725 0.219 . . . . 0.0 111.756 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -72.61 97.6 0.9 Allowed 'Trans proline' 0 C--N 1.344 0.313 0 C-N-CA 122.59 2.193 . . . . 0.0 112.376 -179.925 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.498 HG22 ' HE3' ' A' ' 156' ' ' MET . 44.7 t -93.54 143.91 10.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.922 179.836 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 2.7 m -131.31 140.04 49.68 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.02 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 6.8 m -100.29 111.3 23.57 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.149 179.284 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.829 HG12 HG13 ' A' ' 86' ' ' ILE . 49.5 t -83.68 106.57 14.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.929 -179.339 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.474 HD23 ' C ' ' A' ' 85' ' ' LEU . 7.0 tt -105.88 81.57 1.67 Allowed 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 178.317 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.829 HG13 HG12 ' A' ' 84' ' ' VAL . 12.7 mt -81.52 152.26 4.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.549 -178.498 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.404 ' CG ' ' CG2' ' A' ' 112' ' ' ILE . 0.0 OUTLIER -111.68 141.39 45.35 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.797 -179.426 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 11.5 mtp85 -140.27 84.32 14.65 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.85 179.812 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 63.7 Cg_exo -51.66 -35.44 57.34 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.656 2.238 . . . . 0.0 112.516 -179.817 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . 0.621 ' O ' HG12 ' A' ' 148' ' ' VAL . 0.3 OUTLIER -136.06 -169.64 2.47 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.942 0.401 . . . . 0.0 111.134 -179.777 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.787 ' HG ' HG11 ' A' ' 148' ' ' VAL . 3.9 mt -93.63 -43.17 8.8 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.783 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 2.3 mpp_? -63.27 -14.79 53.39 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.84 -0.618 . . . . 0.0 111.703 -179.595 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 7.5 m-85 -56.69 174.72 0.14 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.866 0.365 . . . . 0.0 110.915 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.491 ' O ' HD12 ' A' ' 112' ' ' ILE . 9.0 mp0 -138.6 166.13 25.14 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.027 -179.943 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 0.67 HD11 ' HB3' ' A' ' 144' ' ' LEU . 1.1 mt -97.66 -49.07 4.99 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.877 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 91.62 50.92 2.61 Favored Glycine 0 C--N 1.331 0.298 0 C-N-CA 120.728 -0.748 . . . . 0.0 113.108 179.5 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . 0.519 ' HE1' HD13 ' A' ' 95' ' ' LEU . 0.5 OUTLIER -168.95 162.97 11.39 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.795 0.331 . . . . 0.0 111.039 179.64 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -110.55 133.95 52.83 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.726 179.907 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.629 HG21 HG21 ' A' ' 140' ' ' ILE . 11.4 p -110.46 132.13 59.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.378 -179.813 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 3.6 mt-30 -129.08 89.51 2.88 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.222 179.485 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 2.4 m120 59.67 18.04 6.8 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.037 -0.528 . . . . 0.0 111.0 -179.406 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 124.9 -37.29 2.61 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.441 179.887 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.56 HG12 ' CB ' ' A' ' 158' ' ' ALA . 28.3 mt -77.28 140.29 17.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.97 0.414 . . . . 0.0 111.598 -179.603 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.875 HD11 ' CD1' ' A' ' 124' ' ' ILE . 4.5 mp -100.23 137.13 28.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.818 179.732 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -114.93 -64.31 1.33 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.876 -179.898 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 5.1 m -86.16 145.15 27.13 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.862 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 3.9 tt -162.26 116.54 1.83 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.705 179.81 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 3.6 tmm? -94.44 128.86 41.27 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.991 -179.774 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -65.44 79.5 0.06 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.64 179.744 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 176.89 -35.22 0.09 OUTLIER Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 120.927 -0.654 . . . . 0.0 111.956 -179.843 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . 0.402 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -59.18 167.86 7.16 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.017 179.613 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.491 HD12 ' O ' ' A' ' 94' ' ' GLN . 1.0 OUTLIER -78.36 -16.54 13.79 Favored 'Isoleucine or valine' 0 C--O 1.235 0.313 0 CA-C-O 120.872 0.367 . . . . 0.0 111.6 -179.837 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' ALA . . . . . 0.4 ' HA ' HG12 ' A' ' 86' ' ' ILE . . . -57.97 -30.44 66.02 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.969 0.414 . . . . 0.0 110.556 179.797 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 114' ' ' GLU . . . . . 0.402 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 16.4 pt-20 -60.42 -47.02 87.91 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.859 179.665 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -63.16 -47.32 83.16 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.049 -179.52 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.401 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -49.64 -73.8 0.33 Allowed Glycine 0 CA--C 1.52 0.379 0 C-N-CA 120.414 -0.898 . . . . 0.0 112.6 -179.862 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . 0.555 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 169.8 -19.79 0.07 OUTLIER Glycine 0 CA--C 1.519 0.296 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.719 -179.937 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.764 ' N ' HG22 ' A' ' 84' ' ' VAL . 1.2 t -40.46 108.21 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.529 0.149 0 CA-C-O 120.999 0.428 . . . . 0.0 111.494 -179.791 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 6.1 mtp180 -102.75 128.34 49.52 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.612 179.751 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 22.2 t -54.06 92.61 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 121.017 0.437 . . . . 0.0 111.1 -179.815 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 128.58 -0.08 6.28 Favored Glycine 0 CA--C 1.519 0.297 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.999 -179.944 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 1.4 m170 -93.82 133.1 37.57 Favored 'General case' 0 C--O 1.232 0.156 0 CA-C-O 120.876 0.37 . . . . 0.0 110.865 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.941 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 0.2 OUTLIER -83.27 91.62 7.32 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.009 -0.541 . . . . 0.0 111.791 -179.509 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . 0.875 ' CD1' HD11 ' A' ' 104' ' ' ILE . 14.9 mt -51.03 142.93 3.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 N-CA-C 109.638 -0.504 . . . . 0.0 109.638 178.572 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 125' ' ' ILE . . . . . 0.815 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.6 OUTLIER -136.65 -83.98 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 N-CA-C 112.995 0.739 . . . . 0.0 112.995 -178.581 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -78.5 85.82 4.56 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 112.733 0.642 . . . . 0.0 112.733 -178.28 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.858 HG23 ' HB3' ' A' ' 153' ' ' MET . 1.4 mt -90.61 104.32 15.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-O 121.071 0.462 . . . . 0.0 110.897 178.872 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 59.1 m-20 53.19 24.35 3.62 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.202 -179.93 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 111.47 -16.42 26.7 Favored Glycine 0 CA--C 1.519 0.33 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.944 179.879 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 10.4 tt0 -94.09 113.12 25.02 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.865 0.365 . . . . 0.0 111.04 -179.855 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -77.52 93.96 4.24 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.087 -179.974 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . 0.617 HG11 ' CD1' ' A' ' 127' ' ' ILE . 28.2 m -75.88 -3.31 4.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.183 -0.462 . . . . 0.0 112.038 -179.977 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.815 ' HB ' HG22 ' A' ' 125' ' ' ILE . 7.2 p -45.16 -38.26 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 CA-C-O 120.856 0.36 . . . . 0.0 111.616 -179.596 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -121.14 28.16 8.0 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.765 179.508 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . 0.565 HG22 ' HB3' ' A' ' 139' ' ' LYS . 43.3 m -109.48 140.52 22.18 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.999 -179.88 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 136' ' ' PRO . . . . . 0.46 ' HD2' HG23 ' A' ' 135' ' ' THR . 11.1 Cg_endo -54.26 151.02 30.54 Favored 'Trans proline' 0 C--N 1.346 0.403 0 C-N-CA 122.654 2.236 . . . . 0.0 112.1 179.694 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 3.8 p-80 -60.41 -33.69 72.86 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.51 -179.727 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -62.53 -39.3 93.14 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.815 0.34 . . . . 0.0 111.227 -179.661 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 139' ' ' LYS . . . . . 0.677 ' O ' HD12 ' A' ' 143' ' ' ILE . 1.7 tptp -62.84 -46.17 89.18 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.025 -179.72 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . 0.629 HG21 HG21 ' A' ' 99' ' ' VAL . 7.5 mt -58.97 -46.13 91.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.697 -179.819 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . 0.413 ' CG2' ' CG1' ' A' ' 99' ' ' VAL . 89.1 t -60.87 -32.46 52.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.22 179.235 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -61.56 -54.95 36.26 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.966 179.888 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . 0.677 HD12 ' O ' ' A' ' 139' ' ' LYS . 3.9 mp -53.18 -57.42 4.8 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.476 0 CA-C-O 121.185 0.517 . . . . 0.0 110.229 179.463 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.743 HD22 HG12 ' A' ' 151' ' ' ILE . 2.6 mt -60.36 -30.06 69.31 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.219 -0.9 . . . . 0.0 110.445 179.571 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 2.2 m -67.23 -27.99 67.69 Favored 'General case' 0 N--CA 1.454 -0.251 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.024 178.825 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 10.8 m120 -134.35 37.73 3.14 Favored 'General case' 0 CA--C 1.527 0.095 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.192 179.83 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 147' ' ' ALA . . . . . 0.616 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -111.62 40.17 2.18 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.484 -0.326 . . . . 0.0 111.43 -179.848 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.787 HG11 ' HG ' ' A' ' 91' ' ' LEU . 4.3 m -48.27 143.52 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.818 0.342 . . . . 0.0 111.412 179.884 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 118.65 -109.55 1.77 Allowed Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.443 -179.829 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.405 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 70.4 mt-10 -137.86 90.17 2.47 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.758 0.313 . . . . 0.0 110.77 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . 0.743 HG12 HD22 ' A' ' 144' ' ' LEU . 1.2 mp -65.54 111.82 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-O 121.012 0.434 . . . . 0.0 110.804 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 4.0 t60 -109.64 115.8 30.56 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.358 179.559 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 153' ' ' MET . . . . . 0.858 ' HB3' HG23 ' A' ' 127' ' ' ILE . 0.0 OUTLIER -144.37 166.23 25.69 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.194 0.521 . . . . 0.0 112.033 -179.258 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . 0.406 ' HG2' ' CG1' ' A' ' 81' ' ' VAL . 0.0 OUTLIER -109.74 151.81 26.45 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.526 -0.761 . . . . 0.0 109.346 178.665 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . 0.453 HG22 HG12 ' A' ' 124' ' ' ILE . 16.1 p -139.84 138.61 35.89 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.054 0.454 . . . . 0.0 111.697 -179.453 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 156' ' ' MET . . . . . 0.498 ' HE3' HG22 ' A' ' 81' ' ' VAL . 0.0 OUTLIER -101.72 178.68 1.16 Allowed Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 115.474 -0.784 . . . . 0.0 110.31 179.732 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . 0.42 ' HD2' ' HB3' ' A' ' 156' ' ' MET . 94.7 Cg_endo -91.99 96.19 0.19 Allowed 'Trans proline' 0 N--CA 1.456 -0.722 0 C-N-CA 122.765 2.31 . . . . 0.0 112.505 -179.773 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 158' ' ' ALA . . . . . 0.941 ' HB2' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.201 -0.904 . . . . 0.0 111.051 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . 0.673 ' O ' HG23 ' A' ' 81' ' ' VAL . 4.8 Cg_endo . . . . . 0 N--CA 1.488 1.192 0 CA-C-O 120.634 0.181 . . . . 0.0 111.798 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_exo -51.73 90.03 0.03 OUTLIER 'Trans proline' 0 C--N 1.345 0.366 0 C-N-CA 122.608 2.205 . . . . 0.0 112.382 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.673 HG23 ' O ' ' A' ' 79' ' ' PRO . 40.6 t -88.54 140.36 15.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.932 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 1.8 m -124.62 142.65 51.21 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.931 179.842 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 4.1 m -101.73 111.44 23.69 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.22 179.267 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.76 HG22 ' N ' ' A' ' 118' ' ' VAL . 60.9 t -87.71 106.08 15.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.439 -179.461 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.424 ' O ' ' HA2' ' A' ' 116' ' ' GLY . 2.5 tt -104.33 85.55 2.38 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.094 -0.503 . . . . 0.0 109.827 178.778 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 1.054 HG21 HD23 ' A' ' 95' ' ' LEU . 3.5 mt -81.35 138.59 19.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 121.008 0.433 . . . . 0.0 111.306 -179.064 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.489 ' HG2' HG22 ' A' ' 112' ' ' ILE . 0.1 OUTLIER -98.77 108.83 21.61 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.507 -179.723 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 8.5 mmt180 -103.39 103.37 35.04 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.016 -179.84 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . 0.454 ' HG2' ' CG ' ' A' ' 93' ' ' TYR . 56.3 Cg_endo -70.49 -28.33 21.88 Favored 'Trans proline' 0 C--N 1.347 0.472 0 C-N-CA 122.385 2.056 . . . . 0.0 112.332 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . 0.442 ' HB2' ' CD1' ' A' ' 93' ' ' TYR . 2.9 m-20 -164.4 -175.49 3.93 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.876 0.37 . . . . 0.0 111.131 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 1.5 mp -80.32 -31.56 38.06 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.984 -179.884 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -73.84 -6.26 46.03 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.693 -179.708 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . 0.454 ' CG ' ' HG2' ' A' ' 89' ' ' PRO . 28.5 m-85 -104.7 110.37 22.66 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.803 0.335 . . . . 0.0 110.866 179.932 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . . . . . . . . . 2.0 mp0 -80.29 179.34 7.72 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.981 -179.927 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 1.054 HD23 HG21 ' A' ' 86' ' ' ILE . 0.6 OUTLIER -91.42 -66.67 0.91 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.749 179.902 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 118.83 63.51 0.29 Allowed Glycine 0 C--N 1.33 0.224 0 C-N-CA 120.566 -0.825 . . . . 0.0 112.959 179.57 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 19.5 p90 -176.82 161.64 2.04 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.807 0.337 . . . . 0.0 110.967 179.664 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 14.5 m -102.64 145.49 29.58 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.768 179.792 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.683 HG21 HG21 ' A' ' 140' ' ' ILE . 10.1 p -126.08 130.56 72.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.332 -179.809 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 4.3 mt-30 -129.83 89.5 2.83 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.253 179.625 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 85.7 m-20 60.22 18.22 7.68 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.858 -179.343 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 123.23 -36.95 2.91 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 120.934 -0.651 . . . . 0.0 112.409 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.695 HG12 ' HB2' ' A' ' 158' ' ' ALA . 26.6 mt -77.24 130.77 35.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 121.018 0.437 . . . . 0.0 111.506 -179.619 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.732 HD11 ' CD1' ' A' ' 124' ' ' ILE . 3.7 mp -82.32 139.52 17.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.87 179.787 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -100.52 -78.79 0.51 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.104 -179.793 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 18.4 m -108.43 135.57 49.51 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.91 -179.826 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.618 HD11 HG13 ' A' ' 118' ' ' VAL . 0.9 OUTLIER -110.75 108.73 18.69 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.823 179.89 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 41.1 mtm -73.01 100.39 2.97 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.965 -179.929 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 25.0 mmt85 -56.97 122.09 11.48 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.78 179.888 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 129.44 -31.29 3.45 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.85 -0.691 . . . . 0.0 112.024 -179.683 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . 0.424 ' O ' ' HG2' ' A' ' 114' ' ' GLU . . . -66.68 175.81 21.46 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.716 -0.755 . . . . 0.0 112.273 179.688 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.489 HG22 ' HG2' ' A' ' 87' ' ' ARG . 0.8 OUTLIER -78.63 -18.18 13.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-O 120.88 0.372 . . . . 0.0 111.62 -179.842 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 113' ' ' ALA . . . . . 0.533 ' HB1' HG11 ' A' ' 118' ' ' VAL . . . -58.31 -30.25 66.51 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.95 0.405 . . . . 0.0 110.611 179.817 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 114' ' ' GLU . . . . . 0.424 ' HG2' ' O ' ' A' ' 111' ' ' GLY . 15.2 pt-20 -59.87 -45.65 91.79 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.731 179.503 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -64.69 -46.96 80.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.2 -179.433 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.424 ' HA2' ' O ' ' A' ' 85' ' ' LEU . . . -51.05 -74.03 0.32 Allowed Glycine 0 CA--C 1.518 0.262 0 C-N-CA 120.355 -0.926 . . . . 0.0 112.59 -179.908 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . 0.443 ' C ' HG22 ' A' ' 84' ' ' VAL . . . 175.5 -20.91 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.938 -0.649 . . . . 0.0 112.808 -179.958 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.76 ' N ' HG22 ' A' ' 84' ' ' VAL . 0.3 OUTLIER -34.7 128.07 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.23 0 CA-C-O 120.912 0.387 . . . . 0.0 112.026 -179.801 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -136.66 144.85 44.21 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.847 -179.822 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . 0.519 HG22 ' HB2' ' A' ' 107' ' ' LEU . 22.7 t -70.43 102.47 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.208 -179.981 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 119.7 49.11 0.32 Allowed Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.61 -0.805 . . . . 0.0 112.681 179.869 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 5.4 m170 -154.29 132.65 11.95 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.834 0.35 . . . . 0.0 110.857 179.849 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.919 ' HB2' ' HB2' ' A' ' 158' ' ' ALA . 2.8 ttt180 -87.85 95.71 10.2 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.664 -179.532 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . 0.732 ' CD1' HD11 ' A' ' 104' ' ' ILE . 9.1 mt -49.71 159.14 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 178.771 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 125' ' ' ILE . . . . . 0.813 HG22 ' HB ' ' A' ' 133' ' ' VAL . 0.6 OUTLIER -148.79 -82.23 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 N-CA-C 112.567 0.58 . . . . 0.0 112.567 -179.579 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . 0.41 ' H ' ' CG1' ' A' ' 125' ' ' ILE . 13.7 mt-10 -76.88 80.84 3.45 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 112.44 0.533 . . . . 0.0 112.44 -178.69 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.954 HG23 ' CG ' ' A' ' 153' ' ' MET . 2.8 mt -82.99 90.8 2.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 121.05 0.452 . . . . 0.0 111.153 179.117 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . 0.452 ' N ' ' O ' ' A' ' 152' ' ' HIS . 1.2 m-20 56.99 29.84 17.11 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.9 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 109.34 -15.11 32.93 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.774 -0.726 . . . . 0.0 112.686 -179.892 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 130' ' ' GLN . . . . . . . . . . . . . 20.7 tt0 -95.04 106.03 17.99 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.895 0.379 . . . . 0.0 110.846 -179.921 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 11.7 p -73.5 90.3 1.72 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.851 179.971 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . 0.747 HG11 HD12 ' A' ' 127' ' ' ILE . 27.2 m -75.2 -2.86 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.29 0 CA-C-N 116.31 -0.405 . . . . 0.0 112.013 -179.828 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.813 ' HB ' HG22 ' A' ' 125' ' ' ILE . 10.4 p -44.77 -42.1 2.29 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.148 0 CA-C-O 120.862 0.363 . . . . 0.0 111.558 -179.731 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . 0.439 ' N ' HG13 ' A' ' 133' ' ' VAL . . . -116.2 29.54 7.9 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.891 179.578 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . 0.479 HG22 ' HB3' ' A' ' 139' ' ' LYS . 38.1 m -114.73 140.06 24.9 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.175 -179.839 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 136' ' ' PRO . . . . . 0.447 ' HD2' HG23 ' A' ' 135' ' ' THR . 11.5 Cg_endo -55.32 164.06 4.23 Favored 'Trans proline' 0 C--N 1.348 0.512 0 C-N-CA 122.652 2.235 . . . . 0.0 112.121 179.766 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 18.8 p-80 -66.43 -45.79 78.67 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.749 -179.557 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -53.71 -39.78 65.49 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.562 -179.341 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 139' ' ' LYS . . . . . 0.725 ' O ' HD12 ' A' ' 143' ' ' ILE . 8.7 tttt -62.7 -46.71 86.89 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.467 -0.333 . . . . 0.0 111.131 -179.7 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . 0.683 HG21 HG21 ' A' ' 99' ' ' VAL . 9.0 mt -58.32 -45.92 89.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.735 -179.836 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . 0.411 ' CG2' ' CG1' ' A' ' 99' ' ' VAL . 82.6 t -60.87 -32.64 52.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.334 179.244 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 142' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -62.02 -55.19 31.76 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.012 179.908 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . 0.725 HD12 ' O ' ' A' ' 139' ' ' LYS . 4.2 mp -52.83 -56.9 5.54 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.489 0 CA-C-O 121.321 0.581 . . . . 0.0 110.248 179.459 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.794 ' HB3' HD11 ' A' ' 95' ' ' LEU . 3.0 mt -61.2 -30.11 70.22 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.305 -0.861 . . . . 0.0 110.398 179.579 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 3.0 m -68.78 -26.74 65.36 Favored 'General case' 0 N--CA 1.454 -0.226 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.022 178.691 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 3.6 m-80 -129.92 33.92 4.34 Favored 'General case' 0 CA--C 1.527 0.093 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.182 179.894 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 147' ' ' ALA . . . . . 0.806 ' HB3' HD11 ' A' ' 151' ' ' ILE . . . -112.28 45.73 1.25 Allowed 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.887 0.375 . . . . 0.0 111.242 179.992 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 3.1 m -50.48 152.33 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.592 -179.929 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 108.74 -104.42 1.97 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.539 -179.944 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 53.2 mt-10 -141.63 98.39 3.34 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.81 0.338 . . . . 0.0 110.558 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . 0.806 HD11 ' HB3' ' A' ' 147' ' ' ALA . 1.2 mt -73.41 111.79 8.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.353 -179.65 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . 0.452 ' O ' ' N ' ' A' ' 128' ' ' ASN . 0.0 OUTLIER -98.17 115.47 28.39 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 178.436 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 153' ' ' MET . . . . . 0.954 ' CG ' HG23 ' A' ' 127' ' ' ILE . 24.4 mtp -128.63 168.17 16.14 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.614 0.721 . . . . 0.0 112.677 -178.311 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . 0.416 ' O ' HG13 ' A' ' 125' ' ' ILE . 17.1 mttm -134.6 140.15 45.87 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 114.723 -1.126 . . . . 0.0 108.759 178.502 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . 0.698 HG22 ' CG1' ' A' ' 124' ' ' ILE . 3.1 p -136.66 140.31 42.66 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.137 0.494 . . . . 0.0 111.909 -178.79 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 156' ' ' MET . . . . . . . . . . . . . 3.8 ptp -132.37 145.75 58.62 Favored Pre-proline 0 C--N 1.328 -0.362 0 CA-C-N 115.318 -0.855 . . . . 0.0 110.44 179.291 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_exo -44.43 122.7 4.02 Favored 'Trans proline' 0 C--N 1.345 0.35 0 C-N-CA 122.597 2.198 . . . . 0.0 112.879 -179.704 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 158' ' ' ALA . . . . . 0.919 ' HB2' ' HB2' ' A' ' 123' ' ' ARG . . . . . . . . 0 C--O 1.25 1.081 0 CA-C-O 118.259 -0.877 . . . . 0.0 111.051 179.894 . . . . . . . . 1 1 . 1 stop_ save_